data_5wpx_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5wpx _Structure_validation_residue.Date_analyzed 2018-02-02 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.2 29.48 0.5 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.337 -0.852 . . . . 0.0 109.04 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.09 -32.97 72.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.311 -0.868 . . . . 0.0 109.883 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -61.01 -35.72 77.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.058 -1.026 . . . . 0.0 109.58 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -67.29 -38.41 80.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.028 179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.2 mt -61.73 -50.45 80.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.1 -45.52 88.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.197 -0.939 . . . . 0.0 109.096 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.99 -44.32 89.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.477 -0.764 . . . . 0.0 109.266 179.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.671 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -65.15 -46.97 78.72 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.648 -0.658 . . . . 0.0 109.915 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 75.7 t -67.65 -47.31 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.378 -0.826 . . . . 0.0 110.124 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.3 t -65.84 -34.47 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.364 -0.835 . . . . 0.0 110.613 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.53 -36.61 55.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.117 -0.99 . . . . 0.0 110.013 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.15 -34.07 76.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 110.662 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -94.83 -64.24 1.09 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.927 -1.108 . . . . 0.0 110.784 -178.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.1 mp . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.31 -0.869 . . . . 0.0 110.155 -179.073 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -65.28 -30.01 54.57 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.637 1.558 . . . . 0.0 111.869 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.98 61.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.182 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -87.96 6.35 36.22 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.341 -0.849 . . . . 0.0 109.387 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -100.64 137.53 27.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.394 -0.816 . . . . 0.0 108.824 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.52 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -62.69 88.07 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.185 -0.947 . . . . 0.0 109.434 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.1 m -62.15 0.08 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.397 -0.814 . . . . 0.0 109.281 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.52 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -90.88 6.82 42.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.295 -0.878 . . . . 0.0 108.949 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 tp -94.29 137.04 33.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.53 -0.731 . . . . 0.0 109.499 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -60.94 121.77 13.22 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -73.16 4.57 4.28 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.192 -0.943 . . . . 0.0 109.959 -179.021 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.4 p -51.17 -38.61 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.08 -1.012 . . . . 0.0 108.423 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.442 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.12 -35.43 69.44 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.7 m-20 -84.45 17.03 2.79 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -43.22 -14.04 0.02 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.05 -35.94 15.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.261 -1.141 . . . . 0.0 108.971 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.573 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.5 tt -70.01 -23.31 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.356 -0.84 . . . . 0.0 109.889 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.595 ' OD2' ' CD1' ' A' ' 66' ' ' PHE . 77.0 m-20 -56.33 -34.17 66.32 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.384 -0.823 . . . . 0.0 110.622 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -112.57 -64.45 1.3 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 111.092 -178.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 50.9 tp -64.25 -51.96 61.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.71 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.38 -36.5 69.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.1 tt -58.37 -41.82 85.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.224 -1.163 . . . . 0.0 109.685 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.8 mt -67.08 -44.14 80.81 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.137 -0.977 . . . . 0.0 109.391 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.5 mttm -67.09 -41.65 85.96 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.26 -0.9 . . . . 0.0 109.843 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 88.6 t -66.68 -43.2 90.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.307 -0.871 . . . . 0.0 109.956 -179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -59.73 -50.53 79.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.263 -0.898 . . . . 0.0 109.569 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.6 -38.46 87.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.182 -0.949 . . . . 0.0 109.413 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.671 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -68.48 -41.43 80.11 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.302 -0.874 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 13.8 tp -56.97 -47.42 80.81 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.403 -0.811 . . . . 0.0 109.644 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.514 ' OE2' ' O ' ' A' ' 54' ' ' ILE . 28.0 tp10 -69.26 -35.71 76.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.182 -0.949 . . . . 0.0 109.287 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -63.98 -46.07 86.21 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.077 -1.014 . . . . 0.0 110.552 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 22.4 ttm180 -88.15 -58.22 2.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 111.926 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -79.38 -24.4 42.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.0 -1.062 . . . . 0.0 111.751 -177.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.26 32.82 41.96 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.187 -1.483 . . . . 0.0 109.417 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.514 ' O ' ' OE2' ' A' ' 49' ' ' GLU . 68.8 mt -104.44 143.94 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.274 -1.133 . . . . 0.0 109.189 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.53 146.92 43.25 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.155 -0.966 . . . . 0.0 109.478 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.39 -0.819 . . . . 0.0 109.604 -179.391 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -54.13 -28.47 51.36 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.549 2.166 . . . . 0.0 111.953 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -68.39 -15.9 63.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.413 -0.805 . . . . 0.0 109.482 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 7.4 t-160 -66.7 -25.39 66.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.536 -0.727 . . . . 0.0 110.143 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.595 ' CD1' ' OD2' ' A' ' 37' ' ' ASP . 62.3 m-85 -87.68 2.91 49.78 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.019 -1.051 . . . . 0.0 109.99 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -57.25 -39.82 76.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.944 -1.097 . . . . 0.0 110.293 -179.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.508 ' HG ' ' H ' ' A' ' 71' ' ' SER . 86.0 p -143.31 153.21 42.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.834 -1.166 . . . . 0.0 110.264 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -65.96 -36.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.456 -0.778 . . . . 0.0 109.67 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.2 mtm180 -60.94 -37.18 81.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.789 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.508 ' H ' ' HG ' ' A' ' 68' ' ' SER . 19.6 m -59.36 -41.98 90.51 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.068 -1.02 . . . . 0.0 109.083 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.62 -38.18 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.321 -0.862 . . . . 0.0 109.431 179.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -57.06 -39.61 75.24 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.342 -0.849 . . . . 0.0 109.704 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.91 -39.11 90.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.247 -0.908 . . . . 0.0 109.904 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.25 -47.51 85.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.743 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.3 t -65.37 -41.06 90.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.149 -0.969 . . . . 0.0 109.777 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.7 t -61.51 -44.6 98.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.204 -0.935 . . . . 0.0 109.936 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -65.14 -40.54 96.93 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.81 -49.67 12.59 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.147 -1.207 . . . . 0.0 109.766 -179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.471 ' O ' ' O ' ' A' ' 76' ' ' VAL . 19.3 p -130.46 156.89 44.02 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.504 0 O-C-N 121.171 -0.955 . . . . 0.0 109.78 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.2 0.524 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -139.52 6.47 2.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.271 -0.893 . . . . 0.0 109.762 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.472 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.26 -33.87 71.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.075 -1.016 . . . . 0.0 109.761 -179.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.22 -45.01 92.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.067 -1.021 . . . . 0.0 109.59 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.9 -36.59 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.268 -0.895 . . . . 0.0 108.656 179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 91.8 mt -66.75 -42.16 89.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.433 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.24 -50.39 70.38 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.047 -1.033 . . . . 0.0 110.241 -179.021 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.642 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.31 -42.97 71.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.291 179.749 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.642 ' N ' HE21 ' A' ' 9' ' ' GLN . 67.9 t80 -62.56 -48.72 78.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.366 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 64.4 t -65.49 -45.07 93.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 0.0 109.333 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.441 ' O ' ' N ' ' A' ' 16' ' ' LEU . 69.4 t -65.85 -37.12 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.439 -0.788 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -52.86 -30.78 35.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.38 -0.825 . . . . 0.0 109.811 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.54 -31.26 72.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.66 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.551 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 34.4 p90 -143.93 44.24 1.46 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.185 -0.947 . . . . 0.0 109.601 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.559 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.155 -0.966 . . . . 0.0 110.305 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -49.38 -29.66 18.42 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 121.881 1.721 . . . . 0.0 111.813 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.6 -25.99 68.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.315 -0.866 . . . . 0.0 109.528 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -95.38 6.42 49.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.319 -0.863 . . . . 0.0 109.209 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.3 t -104.07 136.37 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.573 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.4 m-20 -69.7 88.89 0.54 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.202 -0.936 . . . . 0.0 109.529 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.2 m -59.91 0.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.196 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.573 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.91 9.97 33.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 108.884 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -90.34 137.37 32.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.533 -0.729 . . . . 0.0 109.507 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.495 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.89 121.82 14.43 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.12 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.62 10.86 0.31 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.144 -0.972 . . . . 0.0 109.932 -178.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.495 ' H ' ' C ' ' A' ' 29' ' ' ASP . 75.7 t -54.68 -44.22 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.002 -1.061 . . . . 0.0 108.627 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.72 -36.64 67.44 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 179.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.5 m-20 -86.21 18.24 3.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 178.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.92 -14.99 0.02 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.9 t -52.05 -37.13 21.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.117 -1.225 . . . . 0.0 108.677 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.4 tt -70.59 -22.5 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.533 -0.73 . . . . 0.0 110.323 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -54.14 -32.62 55.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.313 -0.867 . . . . 0.0 111.284 -178.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.34 -64.23 1.33 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.912 -1.117 . . . . 0.0 111.165 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.3 -52.5 63.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.9 -1.125 . . . . 0.0 110.343 -178.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.53 -37.1 62.34 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 36' ' ' ILE . 16.2 tp -58.51 -43.53 89.16 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.38 -1.07 . . . . 0.0 109.931 -178.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.9 mt -65.6 -43.56 89.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.556 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -63.08 -34.43 77.57 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.259 -0.9 . . . . 0.0 109.366 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 68.4 t -60.52 -41.43 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.914 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.428 HG23 HD13 ' A' ' 45' ' ' ILE . 35.8 mm -58.94 -50.16 80.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.983 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.24 -35.6 79.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.801 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.513 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 44.2 t90 -66.49 -41.74 88.48 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.269 -0.894 . . . . 0.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -61.24 -43.35 99.01 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 109.918 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -67.51 -37.16 82.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.98 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -60.3 -44.79 95.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.049 -1.032 . . . . 0.0 110.555 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -87.49 -53.02 5.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.136 -0.977 . . . . 0.0 111.585 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -80.16 -24.75 40.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.041 -1.037 . . . . 0.0 111.59 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.67 31.05 51.29 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.6 mt -103.41 147.51 9.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.393 -1.063 . . . . 0.0 109.556 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.04 157.6 15.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.188 -0.945 . . . . 0.0 109.309 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.456 0 O-C-N 121.24 -0.912 . . . . 0.0 109.773 -179.156 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.79 -27.05 84.04 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.618 2.212 . . . . 0.0 111.886 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.56 -24.49 67.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.403 -0.81 . . . . 0.0 109.945 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.5 ' O ' ' OG ' ' A' ' 71' ' ' SER . 51.3 t-80 -67.13 -26.61 66.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.155 -0.965 . . . . 0.0 110.234 -179.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -97.71 6.68 47.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.074 -1.016 . . . . 0.0 109.001 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 -56.49 -37.8 70.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.452 -0.78 . . . . 0.0 109.977 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.8 p -137.03 153.25 50.68 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.096 -1.003 . . . . 0.0 110.121 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.6 mt -64.59 -36.45 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.478 -0.763 . . . . 0.0 110.251 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -60.87 -37.02 80.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.133 -0.979 . . . . 0.0 110.217 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 92.6 p -61.59 -36.15 79.87 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.014 -1.054 . . . . 0.0 109.66 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -64.93 -40.63 89.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.232 -0.918 . . . . 0.0 109.453 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.472 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 53.9 t0 -59.12 -36.93 76.04 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.305 -0.872 . . . . 0.0 109.634 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.88 -40.71 94.04 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.326 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.413 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 66.6 t80 -64.16 -48.7 75.0 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.305 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.5 t -64.89 -43.45 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.317 -0.864 . . . . 0.0 109.671 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.7 t -59.87 -41.06 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.225 -0.922 . . . . 0.0 109.627 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.33 -31.83 70.82 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.1 -50.63 3.32 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.021 -1.282 . . . . 0.0 110.844 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 21.8 p -131.28 159.43 37.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.225 -0.922 . . . . 0.0 109.854 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.389 0 O-C-N 121.189 -0.944 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.8 mt-30 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.4 m80 47.46 38.44 7.71 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.118 -0.988 . . . . 0.0 109.298 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.12 -34.26 73.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.288 -0.883 . . . . 0.0 109.629 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -59.14 -36.64 75.59 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 109.618 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.8 t -62.88 -40.96 90.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.287 -0.883 . . . . 0.0 109.516 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.498 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 85.5 mt -59.69 -43.95 92.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.356 -0.84 . . . . 0.0 109.839 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.4 77.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.429 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.42 ' C ' ' CD ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.08 -33.66 73.89 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.414 -0.804 . . . . 0.0 109.624 179.826 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 63.1 t80 -62.64 -52.08 64.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.001 . . . . 0.0 109.977 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.5 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 6.3 p -74.91 -44.32 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.357 -0.839 . . . . 0.0 110.855 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.5 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 76.9 t -65.32 -40.09 87.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.183 -0.948 . . . . 0.0 111.031 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -58.22 -28.69 65.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.045 -1.034 . . . . 0.0 109.791 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.8 -38.69 89.64 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.276 -0.89 . . . . 0.0 110.425 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -96.68 -45.11 6.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.04 -1.038 . . . . 0.0 110.489 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.5 mt . . . . . 0 N--CA 1.493 1.719 0 O-C-N 121.284 -0.885 . . . . 0.0 110.273 -179.147 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -64.69 -30.36 59.79 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 C-N-CA 121.585 1.524 . . . . 0.0 111.966 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.86 -19.05 63.46 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.064 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -89.18 1.74 55.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.361 -0.837 . . . . 0.0 108.99 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.1 t -102.28 139.0 24.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.2 t0 -67.97 94.14 0.46 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 109.438 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -59.99 0.56 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.429 -0.794 . . . . 0.0 109.229 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.1 m-20 -88.16 9.8 21.55 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.019 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.4 tp -86.33 134.17 33.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.541 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -62.94 122.07 15.1 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.48 ' O ' ' N ' ' A' ' 33' ' ' ASN . 74.1 mt -59.72 -12.14 6.48 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.3 p -49.97 -37.28 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 119.32 -0.952 . . . . 0.0 108.647 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.13 -36.01 70.18 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.3 m-20 -86.13 21.07 2.1 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.3 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.48 -40.32 24.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 120.979 -1.307 . . . . 0.0 108.54 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.637 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.2 tt -71.77 -24.41 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.509 -0.744 . . . . 0.0 110.418 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 91.9 m-20 -59.25 -28.13 66.42 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.931 -1.105 . . . . 0.0 110.962 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 m -113.3 -64.32 1.32 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.026 -1.046 . . . . 0.0 111.167 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.2 mp -68.88 -51.31 41.58 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.904 -1.123 . . . . 0.0 110.472 -178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.02 -35.89 72.12 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.637 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.0 tt -57.99 -45.24 87.11 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.421 -1.046 . . . . 0.0 110.145 -179.083 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.8 mt -61.83 -44.18 97.37 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.001 -1.062 . . . . 0.0 109.191 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -71.64 -35.54 70.44 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.351 -0.843 . . . . 0.0 110.303 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 66.0 t -64.56 -49.41 80.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.284 -0.885 . . . . 0.0 111.277 -178.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.2 mm -58.78 -49.46 82.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 120.566 -1.334 . . . . 0.0 109.644 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.34 -35.6 79.73 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.012 -1.055 . . . . 0.0 109.68 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.476 ' CE3' ' CD2' ' A' ' 48' ' ' LEU . 19.2 t90 -76.84 -51.07 11.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.272 -0.892 . . . . 0.0 111.398 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.476 ' CD2' ' CE3' ' A' ' 47' ' ' TRP . 3.8 mm? -65.72 -39.32 91.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.062 -1.024 . . . . 0.0 110.616 -179.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 17.8 pt-20 -65.73 -35.01 79.53 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.979 -1.076 . . . . 0.0 109.596 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -65.45 -43.52 90.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.173 -0.954 . . . . 0.0 110.051 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -67.68 -43.13 80.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.252 -0.905 . . . . 0.0 111.165 -179.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -98.34 -12.73 21.19 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.9 -1.125 . . . . 0.0 110.47 -178.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.05 42.16 96.82 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.5 mt -104.79 129.21 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 109.531 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.95 144.39 57.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 109.451 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.271 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -49.95 -36.12 42.92 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 121.814 1.676 . . . . 0.0 112.107 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.92 -27.73 66.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.257 -0.902 . . . . 0.0 109.677 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.556 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 36.6 t-80 -68.22 -27.13 66.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 110.211 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -100.72 9.14 42.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.485 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 35.9 tpt85 -55.52 -36.21 66.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.479 -0.763 . . . . 0.0 109.369 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.1 p -143.56 158.34 43.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.18 -0.95 . . . . 0.0 110.017 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.7 mt -64.15 -36.54 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.387 -0.821 . . . . 0.0 110.35 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.6 mtm180 -60.72 -38.82 86.4 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.098 -1.001 . . . . 0.0 110.068 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.0 t -61.45 -44.09 97.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.042 -1.036 . . . . 0.0 109.539 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 84.3 mt -67.72 -40.08 83.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.288 -0.882 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 59.8 t0 -58.99 -41.59 88.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.867 . . . . 0.0 110.391 -179.256 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.39 -43.78 84.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.034 -1.041 . . . . 0.0 110.248 -179.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.556 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 66.4 t80 -62.67 -47.27 84.39 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.748 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.92 -44.36 96.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.1 t -61.06 -39.74 83.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.11 -0.994 . . . . 0.0 109.459 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.85 -33.17 67.46 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.02 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.054 -1.263 . . . . 0.0 110.489 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 8.3 t -158.41 152.69 24.19 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.064 -1.023 . . . . 0.0 110.204 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 108.937 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 120.905 0.383 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -149.0 3.45 0.61 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.965 -1.085 . . . . 0.0 110.603 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.586 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -63.34 -32.4 73.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.778 -1.201 . . . . 0.0 109.866 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.7 p -59.04 -35.3 73.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.069 -1.02 . . . . 0.0 109.372 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.34 -37.74 80.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.264 -0.898 . . . . 0.0 109.2 179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 30.8 mm -62.16 -47.12 94.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.419 -0.8 . . . . 0.0 110.176 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.81 -49.74 71.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.206 -0.933 . . . . 0.0 110.445 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.466 ' NE2' ' CA ' ' A' ' 10' ' ' PHE . 4.2 pp0? -69.71 -42.75 73.62 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.154 -0.967 . . . . 0.0 109.858 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CA ' ' NE2' ' A' ' 9' ' ' GLN . 69.9 t80 -61.63 -46.66 88.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.147 -0.971 . . . . 0.0 109.512 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 91.4 t -67.5 -47.61 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.375 -0.828 . . . . 0.0 109.966 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 78.7 t -66.44 -34.74 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.416 -0.802 . . . . 0.0 110.423 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.77 -36.46 58.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -0.93 . . . . 0.0 109.897 -179.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.76 -35.12 78.14 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.273 -0.892 . . . . 0.0 110.708 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -92.91 -63.47 1.22 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.919 -1.113 . . . . 0.0 110.767 -178.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.7 mp . . . . . 0 N--CA 1.495 1.794 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.018 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -64.62 -23.91 63.28 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 121.628 1.552 . . . . 0.0 111.828 -179.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.49 -14.89 62.27 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.446 -0.784 . . . . 0.0 109.272 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -82.9 3.24 30.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.383 -0.823 . . . . 0.0 109.158 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.54 136.97 30.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.487 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.12 88.13 0.07 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.136 -0.977 . . . . 0.0 109.271 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -63.61 0.04 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.273 -0.892 . . . . 0.0 109.309 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.487 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -93.44 4.65 53.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 108.969 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.8 tt -98.36 137.65 36.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.461 -0.775 . . . . 0.0 109.541 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.496 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.4 m-20 -60.56 121.57 12.48 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.231 -0.918 . . . . 0.0 108.625 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.426 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.6 OUTLIER -64.94 6.08 0.27 Allowed 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.255 -0.903 . . . . 0.0 110.047 -178.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.496 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.0 p -51.55 -38.23 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.053 -1.029 . . . . 0.0 108.634 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.83 -35.68 71.21 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.641 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.4 m-20 -86.18 20.14 2.44 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.84 -14.69 0.02 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.641 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.52 -35.62 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.264 -1.139 . . . . 0.0 108.802 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.561 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -69.99 -22.16 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.567 -0.708 . . . . 0.0 110.067 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -55.02 -32.51 61.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.302 -0.874 . . . . 0.0 110.845 -178.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.7 m -118.0 -63.79 1.38 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.22 -0.925 . . . . 0.0 111.168 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.5 tp -62.01 -52.55 63.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.961 -1.087 . . . . 0.0 110.276 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.8 -38.17 66.1 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.561 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -59.57 -40.66 88.11 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.419 -1.048 . . . . 0.0 109.15 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.99 -44.12 97.4 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.217 -0.927 . . . . 0.0 108.947 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.4 mttm -65.73 -37.42 86.33 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.316 -0.865 . . . . 0.0 109.483 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.5 t -62.84 -39.97 87.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.399 -0.813 . . . . 0.0 109.875 -179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -59.87 -51.41 73.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.11 -0.994 . . . . 0.0 109.664 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.59 -39.28 84.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -0.908 . . . . 0.0 109.627 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.676 ' HE1' ' CZ ' ' A' ' 51' ' ' ARG . 76.2 t90 -68.89 -43.04 76.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.41 -0.806 . . . . 0.0 109.962 -179.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.0 tp -63.15 -46.83 85.38 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.353 -0.842 . . . . 0.0 109.962 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -68.23 -36.0 78.81 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.88 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.56 -45.48 93.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.066 -1.022 . . . . 0.0 110.68 -179.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.676 ' CZ ' ' HE1' ' A' ' 47' ' ' TRP . 85.0 mtt180 -87.2 -50.25 6.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.078 -1.013 . . . . 0.0 111.45 -178.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -80.1 -24.78 40.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.0 -1.062 . . . . 0.0 111.271 -178.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.21 30.07 57.59 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -105.95 144.13 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.288 -1.125 . . . . 0.0 109.478 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.89 152.1 28.35 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.2 -0.938 . . . . 0.0 109.479 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.417 -0.802 . . . . 0.0 109.704 -179.295 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.06 0.457 . . . . 0.0 109.874 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.48 -29.96 90.2 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.704 2.269 . . . . 0.0 111.931 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.54 -26.77 68.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.393 -0.817 . . . . 0.0 109.614 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 12.5 t-80 -67.81 -25.89 65.8 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 110.691 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -88.69 7.52 33.22 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.031 -1.043 . . . . 0.0 110.606 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.3 mmt85 -59.73 -36.93 77.57 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.985 -1.072 . . . . 0.0 110.547 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.484 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 93.5 p -132.94 150.53 52.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.995 -1.066 . . . . 0.0 110.345 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.9 mt -65.9 -37.67 80.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 O-C-N 121.49 -0.756 . . . . 0.0 109.854 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 93.8 mtm-85 -61.2 -38.29 86.03 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.091 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.484 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 22.2 m -60.07 -40.7 90.44 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.137 -0.977 . . . . 0.0 109.404 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -65.66 -42.33 92.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.267 -0.895 . . . . 0.0 109.836 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.586 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 53.2 t0 -60.05 -38.74 83.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.335 -0.853 . . . . 0.0 110.062 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.12 -40.64 98.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.182 -0.949 . . . . 0.0 109.747 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -62.7 -46.94 85.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -64.44 -44.02 97.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.24 -0.913 . . . . 0.0 109.757 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 58.2 t -60.54 -40.66 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.34 -0.85 . . . . 0.0 109.625 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.46 -31.97 71.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.73 -50.44 3.41 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.113 -1.228 . . . . 0.0 110.807 -179.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.0 p -131.43 157.62 42.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 109.805 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.408 0 O-C-N 121.213 -0.93 . . . . 0.0 109.255 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.272 0.558 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.486 ' CD2' ' CG2' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -155.18 28.44 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.129 -0.982 . . . . 0.0 109.541 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.63 -33.39 73.85 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.57 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 84.8 p -61.59 -36.56 81.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.197 -0.939 . . . . 0.0 109.497 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.486 ' CG2' ' CD2' ' A' ' 3' ' ' HIS . 69.8 t -67.83 -37.85 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.209 -0.932 . . . . 0.0 109.0 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 84.4 mt -60.47 -50.92 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.268 -0.895 . . . . 0.0 109.219 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.68 -47.53 78.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.303 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -44.4 96.02 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.486 -0.759 . . . . 0.0 109.19 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.57 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.7 t80 -65.05 -46.48 81.04 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.538 0.685 . . . . 0.0 109.607 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.7 t -69.73 -47.42 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.529 -0.732 . . . . 0.0 110.293 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.8 t -64.57 -34.81 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.397 -0.814 . . . . 0.0 110.729 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.68 -36.11 56.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.072 -1.018 . . . . 0.0 109.982 -179.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.71 -35.06 78.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 110.676 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -92.82 -63.79 1.18 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.932 -1.105 . . . . 0.0 110.682 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.4 mt . . . . . 0 N--CA 1.494 1.742 0 O-C-N 121.334 -0.854 . . . . 0.0 110.196 -178.98 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.308 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.88 -25.63 59.92 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 C-N-CA 121.586 1.524 . . . . 0.0 111.877 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.47 -14.95 62.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -0.862 . . . . 0.0 109.136 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -84.05 2.99 36.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.313 -0.867 . . . . 0.0 109.024 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.66 136.64 32.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.453 ' C ' ' H ' ' A' ' 27' ' ' ASP . 87.4 m-20 -68.05 87.96 0.27 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.148 -0.97 . . . . 0.0 109.478 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -64.06 -0.15 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.34 -0.85 . . . . 0.0 109.594 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.473 ' C ' ' OD2' ' A' ' 27' ' ' ASP . 49.3 p30 -88.83 7.57 33.49 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.203 -0.936 . . . . 0.0 108.954 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -97.15 141.75 29.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.618 -0.676 . . . . 0.0 109.486 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.422 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.0 m-20 -60.52 121.76 12.96 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.4 pp -68.77 4.92 1.24 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.166 -0.959 . . . . 0.0 109.975 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.445 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.87 -38.34 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.034 -1.041 . . . . 0.0 108.53 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -58.44 -35.7 72.52 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 66.9 m-80 -84.55 16.33 3.24 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.042 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.03 -14.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.7 t -51.3 -36.61 17.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.119 -1.224 . . . . 0.0 108.891 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.3 tt -70.56 -21.84 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 110.091 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -55.22 -31.88 61.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 111.083 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.15 -64.59 1.29 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.066 -1.021 . . . . 0.0 111.518 -178.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.2 tp -65.12 -52.08 57.45 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.814 -1.179 . . . . 0.0 110.581 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -68.9 -35.69 79.92 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.0 tp -58.14 -41.59 84.04 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -1.138 . . . . 0.0 109.282 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 87.6 mt -62.61 -44.07 97.23 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.138 -0.976 . . . . 0.0 108.823 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.2 mttp -63.56 -36.71 84.7 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.8 t -64.12 -38.31 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.774 -0.579 . . . . 0.0 109.749 179.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -56.91 -51.03 73.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 109.958 -179.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.42 -39.15 85.48 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.055 -1.028 . . . . 0.0 109.7 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.57 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 52.4 t90 -67.51 -44.39 78.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.301 -0.874 . . . . 0.0 111.08 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.13 -49.1 77.21 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.133 -0.979 . . . . 0.0 109.978 -178.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -68.83 -39.22 80.1 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.957 -1.089 . . . . 0.0 109.391 179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -64.65 -42.62 95.29 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.119 -0.988 . . . . 0.0 111.135 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.692 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 54.7 ttt-85 -72.2 -48.23 44.66 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.216 -0.927 . . . . 0.0 112.036 -177.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.692 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 90.9 m-85 -104.23 -6.21 21.15 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 111.733 -178.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.56 30.79 66.09 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 59.9 mt -106.04 142.27 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.255 -1.144 . . . . 0.0 109.34 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.18 122.66 15.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.955 -1.091 . . . . 0.0 108.958 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.46 -0.775 . . . . 0.0 110.142 -179.456 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -57.7 -31.93 93.31 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.675 2.25 . . . . 0.0 111.962 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.88 -24.8 66.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 179.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.9 t60 -67.28 -26.4 66.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.287 -0.883 . . . . 0.0 109.955 -179.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -95.05 6.23 49.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.107 -0.995 . . . . 0.0 109.426 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -56.33 -39.6 73.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.917 . . . . 0.0 109.7 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.402 ' HG ' ' H ' ' A' ' 71' ' ' SER . 96.8 p -135.25 153.5 51.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.094 -1.004 . . . . 0.0 109.924 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.6 mt -63.88 -36.31 76.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 O-C-N 121.4 -0.813 . . . . 0.0 109.818 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.5 mtm180 -60.73 -37.68 82.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.823 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.402 ' H ' ' HG ' ' A' ' 68' ' ' SER . 21.7 t -59.76 -43.94 94.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.064 -1.023 . . . . 0.0 109.346 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.3 mt -64.39 -38.54 82.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.28 -0.888 . . . . 0.0 109.455 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -56.16 -38.14 70.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.351 -0.843 . . . . 0.0 109.511 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.16 95.31 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.305 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -64.05 -46.69 83.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.493 179.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 58.3 t -64.18 -41.63 93.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.439 -0.788 . . . . 0.0 109.708 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.8 t -62.82 -43.5 98.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.216 -0.928 . . . . 0.0 109.96 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.82 -37.92 95.12 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -88.78 -49.64 6.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.111 -1.229 . . . . 0.0 110.185 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 28.0 m -128.86 138.75 52.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.441 -0.787 . . . . 0.0 109.566 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.583 ' CD2' ' OD2' ' A' ' 73' ' ' ASP . 5.4 p80 -160.33 23.14 0.16 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.372 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.4 -38.64 87.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.91 -34.12 77.25 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.357 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.68 -38.1 80.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.285 -0.885 . . . . 0.0 109.356 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 88.4 mt -60.43 -50.39 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.526 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.47 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.0 -44.09 93.7 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.301 -0.874 . . . . 0.0 109.024 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.47 -40.8 89.54 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.529 -0.732 . . . . 0.0 109.647 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -66.39 -49.47 66.73 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.535 -0.728 . . . . 0.0 111.272 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.4 p -69.95 -44.81 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.126 -0.984 . . . . 0.0 111.258 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.47 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 15.9 m -67.48 -33.87 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.026 -1.046 . . . . 0.0 110.733 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -52.2 -36.34 51.68 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.107 -0.996 . . . . 0.0 109.832 -178.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -33.36 75.41 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.176 -0.952 . . . . 0.0 110.568 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -95.94 -63.72 1.12 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.016 -1.053 . . . . 0.0 110.98 -178.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.1 mp . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 110.62 -178.69 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.362 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -65.24 -28.82 55.57 Favored 'Trans proline' 0 N--CA 1.49 1.271 0 C-N-CA 121.596 1.531 . . . . 0.0 112.041 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.71 -14.85 61.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.377 -0.827 . . . . 0.0 109.297 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -90.68 8.17 35.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.364 -0.835 . . . . 0.0 109.34 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.2 t -98.3 137.15 26.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.352 -0.842 . . . . 0.0 108.79 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -65.57 85.01 0.07 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.168 -0.958 . . . . 0.0 109.466 -179.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -59.89 -0.06 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.312 -0.868 . . . . 0.0 109.266 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.45 7.14 44.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 108.954 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -94.23 136.01 35.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.6 m-20 -63.51 121.71 14.52 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.78 5.24 1.15 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.87 -178.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.1 p -52.81 -38.87 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.03 -1.044 . . . . 0.0 108.547 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.446 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.9 t0 -57.77 -35.47 70.81 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.8 m-20 -86.06 19.52 2.6 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -14.51 0.01 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.4 t -51.44 -36.35 17.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 108.558 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.549 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.3 OUTLIER -69.98 -20.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.455 -0.778 . . . . 0.0 110.054 179.967 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -51.35 -35.57 38.94 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.216 -0.928 . . . . 0.0 110.98 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -119.1 -61.9 1.58 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.131 -0.981 . . . . 0.0 111.51 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.9 -52.39 64.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.925 -1.11 . . . . 0.0 110.14 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.35 -41.1 59.58 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.8 -41.86 87.75 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.386 -1.067 . . . . 0.0 109.491 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -59.32 -44.31 92.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.184 -0.947 . . . . 0.0 108.949 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -65.35 -34.64 78.8 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.272 -0.892 . . . . 0.0 109.007 179.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.2 t -62.67 -41.59 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.784 . . . . 0.0 110.424 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.2 mm -59.32 -49.59 82.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 120.931 -1.106 . . . . 0.0 109.635 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -65.84 -40.98 92.28 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -0.97 . . . . 0.0 109.338 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 69.3 t90 -66.89 -41.63 86.88 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.446 -0.784 . . . . 0.0 109.289 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.8 tp -60.07 -46.91 88.01 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.421 -0.8 . . . . 0.0 109.168 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.401 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -67.89 -34.18 76.15 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.314 -0.866 . . . . 0.0 109.207 178.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 92.4 m-20 -59.19 -46.62 87.94 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.233 -0.917 . . . . 0.0 110.291 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 42.2 mtp180 -88.46 -51.77 5.54 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.075 -1.016 . . . . 0.0 111.616 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -80.23 -25.3 39.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.984 -1.072 . . . . 0.0 111.633 -177.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.34 31.16 52.52 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.248 -1.453 . . . . 0.0 109.712 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.401 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.9 mt -97.86 145.3 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.276 -1.132 . . . . 0.0 109.409 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.17 145.52 50.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.09 -1.006 . . . . 0.0 109.71 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.463 -0.773 . . . . 0.0 109.933 -179.594 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -56.41 -27.41 67.84 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.664 2.243 . . . . 0.0 111.955 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.54 -27.46 69.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.249 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 33.5 t-80 -67.14 -26.25 66.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.434 -0.791 . . . . 0.0 109.697 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 0.9 OUTLIER -91.64 7.77 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.2 -0.937 . . . . 0.0 109.188 -179.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.6 tpt180 -55.63 -39.44 70.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.971 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 91.6 p -137.25 152.57 49.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.047 -1.033 . . . . 0.0 110.214 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.5 mt -65.25 -36.67 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.308 -0.87 . . . . 0.0 110.027 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.1 ptt85 -61.2 -40.5 94.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 110.07 -179.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -59.21 -40.51 86.02 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.108 -0.995 . . . . 0.0 109.402 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -65.97 -39.74 85.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.338 -0.851 . . . . 0.0 109.728 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.583 ' OD2' ' CD2' ' A' ' 3' ' ' HIS . 60.7 t0 -58.51 -38.64 78.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.315 -0.866 . . . . 0.0 109.918 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.52 -42.17 95.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 109.92 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -63.58 -48.53 77.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.07 -1.019 . . . . 0.0 109.606 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -65.49 -41.6 91.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.295 -0.878 . . . . 0.0 109.761 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.6 t -61.33 -41.39 89.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.311 -0.868 . . . . 0.0 109.788 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.86 -31.72 76.96 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.49 -50.26 3.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.042 -1.27 . . . . 0.0 110.618 -178.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.1 p -129.86 157.52 42.01 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.399 -0.813 . . . . 0.0 109.613 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.385 0 O-C-N 121.206 -0.933 . . . . 0.0 109.393 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.609 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 81.9 m-70 -139.61 28.35 2.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.456 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -60.62 -34.35 74.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.281 -0.887 . . . . 0.0 110.151 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m -58.87 -40.16 83.5 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.018 -1.051 . . . . 0.0 109.666 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -64.5 -36.59 77.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.88 . . . . 0.0 109.066 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.424 HG21 HD11 ' A' ' 7' ' ' ILE . 27.7 mm -64.76 -44.31 96.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.433 -0.792 . . . . 0.0 110.323 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.529 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.73 -50.44 69.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.113 -0.992 . . . . 0.0 110.734 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.506 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.86 -39.49 76.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.016 -1.052 . . . . 0.0 109.566 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 68.3 t80 -65.75 -51.29 60.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.346 -0.846 . . . . 0.0 109.94 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -67.93 -40.76 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 109.763 -179.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.529 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 71.1 t -65.93 -40.55 87.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.216 -0.927 . . . . 0.0 109.571 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -52.74 -30.54 33.15 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.438 -0.789 . . . . 0.0 109.827 -179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -65.37 -30.46 71.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.939 . . . . 0.0 109.412 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.9 p90 -145.41 44.12 1.3 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.4 pt? . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.054 -1.029 . . . . 0.0 110.082 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -49.04 -31.54 21.1 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.817 1.678 . . . . 0.0 111.993 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.96 -22.28 66.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.419 -0.8 . . . . 0.0 109.446 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -95.88 2.06 53.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.429 -0.795 . . . . 0.0 108.928 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.6 t -104.88 136.46 38.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.5 t0 -71.19 97.03 1.46 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.051 -1.031 . . . . 0.0 109.312 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.6 m -59.5 0.14 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.195 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -91.96 7.82 40.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.325 -0.859 . . . . 0.0 108.779 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.8 tp -91.22 133.83 35.06 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.478 -0.764 . . . . 0.0 109.376 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -66.33 121.31 14.96 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -74.74 9.6 1.77 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.219 -0.925 . . . . 0.0 109.825 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.5 p -52.25 -38.91 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.156 -0.965 . . . . 0.0 108.642 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.454 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.1 m-20 -57.33 -35.73 70.25 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 178.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.2 m-20 -84.94 18.25 2.54 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.011 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.92 -13.69 0.01 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -50.72 -35.24 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.072 -1.251 . . . . 0.0 108.945 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.578 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -70.01 -23.48 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.418 ' OD2' ' CG ' ' A' ' 66' ' ' PHE . 84.2 m-20 -54.93 -32.42 61.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 110.714 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.51 -64.09 1.36 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.149 -0.969 . . . . 0.0 111.174 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 15.5 mt -62.67 -52.52 62.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.002 -1.061 . . . . 0.0 110.2 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.48 -37.19 69.18 Favored Glycine 0 N--CA 1.486 1.97 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.578 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.86 -41.46 87.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.266 -1.138 . . . . 0.0 109.149 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -61.51 -44.22 97.45 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.348 -0.845 . . . . 0.0 108.894 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -67.92 -40.79 83.32 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.301 -0.875 . . . . 0.0 110.007 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.8 t -65.68 -42.86 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.277 -0.889 . . . . 0.0 110.131 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -58.87 -50.47 79.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.186 -0.946 . . . . 0.0 109.65 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.72 -37.18 85.7 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.94 . . . . 0.0 109.436 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.517 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -69.32 -43.7 73.2 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.281 -0.887 . . . . 0.0 109.715 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.1 tp -57.34 -48.0 80.12 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.323 -0.86 . . . . 0.0 109.402 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -68.73 -37.71 79.66 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.301 -0.874 . . . . 0.0 109.122 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.5 t0 -63.77 -41.73 97.91 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.297 -0.877 . . . . 0.0 110.593 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.7 ttt180 -87.1 -55.26 3.9 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.231 -0.918 . . . . 0.0 111.454 -178.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -79.49 -22.34 44.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.987 -1.071 . . . . 0.0 111.383 -178.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 25.84 60.69 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.1 mt -106.07 144.91 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.471 -1.017 . . . . 0.0 109.416 -179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 152.41 29.01 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.283 -0.886 . . . . 0.0 109.54 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.368 -0.833 . . . . 0.0 109.688 -179.571 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.449 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.218 0.532 . . . . 0.0 110.228 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -58.08 -25.99 73.49 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 C-N-CA 122.578 2.186 . . . . 0.0 111.664 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.72 -23.54 65.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.56 -0.713 . . . . 0.0 110.198 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -67.76 -26.63 66.22 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.59 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.418 ' CG ' ' OD2' ' A' ' 37' ' ' ASP . 68.4 m-85 -80.17 -3.67 49.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.883 -1.136 . . . . 0.0 110.144 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 83.1 mmt-85 -60.47 -36.18 77.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.892 -1.13 . . . . 0.0 109.745 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.7 p -139.92 150.94 45.17 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.014 -1.054 . . . . 0.0 109.749 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 80.2 mt -65.13 -36.65 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -60.63 -38.41 84.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 110.197 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 24.6 m -57.81 -40.63 80.4 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.018 -1.051 . . . . 0.0 109.53 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.0 mm -65.36 -38.97 83.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.154 -0.966 . . . . 0.0 109.17 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.456 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 54.4 t0 -57.23 -38.35 73.65 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.288 -0.882 . . . . 0.0 109.594 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.44 99.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.307 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -63.75 -46.56 84.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.357 -0.839 . . . . 0.0 109.432 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.8 t -64.68 -41.63 92.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.333 -0.854 . . . . 0.0 109.663 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 52.9 t -61.59 -40.94 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.269 -0.894 . . . . 0.0 109.634 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.17 76.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.28 -50.01 5.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.096 -1.237 . . . . 0.0 109.961 -179.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.4 t -144.97 153.21 41.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.55 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.609 ' HG1' ' HE2' ' A' ' 3' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.213 -0.929 . . . . 0.0 109.552 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.682 ' HD1' ' HG1' ' A' ' 81' ' ' THR . 45.2 m80 -152.92 28.89 0.52 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.417 -0.802 . . . . 0.0 109.19 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.27 -33.02 71.73 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.412 -0.805 . . . . 0.0 109.658 -179.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -58.97 -38.95 80.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.173 -0.954 . . . . 0.0 109.613 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -65.14 -39.06 84.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.15 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.1 mt -60.58 -50.62 79.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.276 -0.89 . . . . 0.0 109.459 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.538 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.96 -44.62 92.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 109.064 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.37 -44.17 88.48 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.74 0.781 . . . . 0.0 109.227 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -61.61 -47.79 83.86 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.525 -0.735 . . . . 0.0 109.331 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 96.6 t -73.16 -41.49 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.446 -0.784 . . . . 0.0 110.139 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.538 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 78.4 t -63.96 -41.27 91.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -0.882 . . . . 0.0 111.022 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -57.01 -28.25 62.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 109.907 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.44 -30.09 70.84 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.21 -0.931 . . . . 0.0 109.359 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.603 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.8 p90 -146.8 45.68 1.19 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.161 -0.962 . . . . 0.0 109.775 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.565 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 120.965 -1.084 . . . . 0.0 110.369 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -49.25 -33.8 29.46 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.878 1.719 . . . . 0.0 111.697 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.03 -21.87 65.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.489 -0.757 . . . . 0.0 109.331 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.4 5.21 50.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.55 -0.719 . . . . 0.0 109.17 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.4 t -102.54 136.49 34.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' C ' ' H ' ' A' ' 27' ' ' ASP . 84.5 m-20 -67.42 94.35 0.39 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.137 -0.977 . . . . 0.0 109.418 -179.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.5 m -59.24 0.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.39 -0.819 . . . . 0.0 109.423 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 25' ' ' ASP . 48.2 p30 -84.26 9.79 12.08 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.227 -0.921 . . . . 0.0 109.078 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.8 tp -86.34 134.95 33.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.6 -0.687 . . . . 0.0 109.366 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -65.43 121.83 15.78 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 108.733 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.427 ' O ' ' N ' ' A' ' 33' ' ' ASN . 82.3 mt -56.87 -16.66 7.14 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 108.931 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' A' ' 34' ' ' GLY . 41.7 t -50.64 -40.94 19.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.237 -0.914 . . . . 0.0 108.914 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.67 -36.17 66.81 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 178.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' A' ' 35' ' ' VAL . 9.7 m120 -85.02 20.44 1.88 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.11 -15.35 0.02 OUTLIER Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.346 -1.101 . . . . 0.0 110.346 -179.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.597 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.4 t -51.91 -40.17 27.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.604 -1.527 . . . . 0.0 108.585 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.4 tt -71.91 -22.25 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.577 -0.702 . . . . 0.0 110.883 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.401 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 93.0 m-20 -52.51 -34.8 51.36 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.154 -0.966 . . . . 0.0 111.784 -177.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.02 -60.59 1.74 Allowed 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.957 -1.09 . . . . 0.0 111.224 -178.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.96 -52.18 65.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.145 . . . . 0.0 109.598 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.91 -36.98 65.29 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.7 tt -58.02 -41.02 82.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.358 -1.083 . . . . 0.0 109.294 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 30.4 mt -60.31 -44.43 95.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 108.667 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -67.75 -38.74 83.89 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.406 -0.809 . . . . 0.0 109.576 179.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 79.5 t -65.09 -39.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.448 -0.783 . . . . 0.0 110.351 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -58.11 -50.6 77.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.033 -1.042 . . . . 0.0 109.642 -179.262 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.16 -39.14 86.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.089 -1.007 . . . . 0.0 109.702 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.5 t90 -70.38 -42.14 72.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.131 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.7 tp -61.43 -47.2 86.81 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.383 -0.823 . . . . 0.0 110.029 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.584 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -64.72 -43.7 92.59 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.116 -0.99 . . . . 0.0 108.613 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -66.45 -39.93 89.15 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.335 -0.853 . . . . 0.0 110.232 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 27.2 tpt85 -63.02 -45.06 94.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.499 -0.751 . . . . 0.0 111.547 -178.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 54.8 m-85 -126.24 2.27 7.1 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.912 -1.118 . . . . 0.0 111.858 -178.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.7 33.79 54.91 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.6 mt -95.85 135.87 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.183 -1.186 . . . . 0.0 109.146 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.54 140.7 58.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.087 -1.008 . . . . 0.0 109.678 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.452 0 O-C-N 121.468 -0.77 . . . . 0.0 109.786 -179.756 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -59.39 -35.13 97.22 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.511 2.141 . . . . 0.0 112.184 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.91 -28.73 68.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.398 -0.814 . . . . 0.0 109.796 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.677 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 51.3 t-80 -67.81 -27.03 66.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.289 -0.882 . . . . 0.0 110.231 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -101.68 13.84 33.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.133 -0.98 . . . . 0.0 110.06 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -53.03 -32.96 49.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.094 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.7 t -151.29 151.76 32.25 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 109.973 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.8 mt -60.97 -36.87 75.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 O-C-N 121.262 -0.898 . . . . 0.0 110.11 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -60.63 -40.82 93.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.224 -0.922 . . . . 0.0 110.214 -179.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.2 m -60.66 -41.8 95.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.037 -1.04 . . . . 0.0 109.936 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.3 mt -66.95 -40.83 86.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.245 -0.909 . . . . 0.0 110.156 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 52.1 t0 -59.12 -40.72 86.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 110.405 -179.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.17 -41.9 89.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.124 -0.985 . . . . 0.0 110.09 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.677 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 66.7 t80 -62.06 -49.65 75.15 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.164 -0.96 . . . . 0.0 109.482 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.539 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.6 t -65.55 -47.05 87.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.219 -0.926 . . . . 0.0 109.562 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 45.8 t -58.93 -38.84 75.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.112 -0.992 . . . . 0.0 109.455 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.73 -33.06 66.6 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.46 -51.24 3.14 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -1.224 . . . . 0.0 110.397 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.2 t -153.87 152.41 30.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.728 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.682 ' HG1' ' HD1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.469 0 O-C-N 121.236 -0.915 . . . . 0.0 109.22 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.406 ' HD1' ' CG2' ' A' ' 6' ' ' VAL . 2.9 m-70 -137.03 18.69 3.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.352 -0.843 . . . . 0.0 109.702 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -57.64 -38.98 75.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.166 -0.959 . . . . 0.0 109.599 -179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.522 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 85.6 p -65.24 -37.29 86.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.098 -1.001 . . . . 0.0 109.624 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.522 ' N ' ' HG ' ' A' ' 5' ' ' SER . 76.2 t -68.13 -37.81 78.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.287 -0.883 . . . . 0.0 109.261 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 97.2 mt -60.02 -49.79 82.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.71 -47.17 82.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.184 -0.947 . . . . 0.0 109.098 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -44.16 94.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.445 -0.785 . . . . 0.0 109.252 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.696 ' CZ ' ' CZ3' ' A' ' 47' ' ' TRP . 70.2 t80 -68.39 -48.32 65.01 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.512 0.673 . . . . 0.0 109.48 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.5 t -68.67 -44.22 82.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.667 -0.645 . . . . 0.0 110.014 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 96.9 t -64.22 -36.71 77.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -52.37 -32.8 40.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.316 -0.865 . . . . 0.0 109.729 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.594 ' OE1' ' CZ3' ' A' ' 47' ' ' TRP . 76.8 mm-40 -66.0 -31.79 72.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.206 -0.934 . . . . 0.0 109.804 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.548 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 34.4 p90 -140.06 42.94 1.94 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.103 -0.998 . . . . 0.0 109.835 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.569 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.05 -1.031 . . . . 0.0 110.015 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -49.76 -31.45 25.92 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 121.842 1.695 . . . . 0.0 111.924 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.38 -22.77 66.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.537 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -92.77 4.29 54.06 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.448 -0.782 . . . . 0.0 109.225 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -105.35 136.48 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.566 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -69.23 91.24 0.52 Allowed 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -59.83 0.08 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.349 -0.844 . . . . 0.0 109.186 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.566 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -93.44 8.19 41.57 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.339 -0.851 . . . . 0.0 108.886 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.7 tp -92.34 136.86 32.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.432 -0.793 . . . . 0.0 109.519 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.58 ' C ' ' H ' ' A' ' 31' ' ' VAL . 33.6 p30 -62.61 114.4 3.55 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.141 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -63.74 8.7 0.08 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.112 -0.993 . . . . 0.0 109.926 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.58 ' H ' ' C ' ' A' ' 29' ' ' ASP . 6.3 p -54.98 -38.25 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.059 -1.025 . . . . 0.0 109.172 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.433 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.3 t0 -56.85 -37.21 70.98 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.596 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.5 m-80 -87.3 16.92 4.76 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.43 -17.4 0.03 OUTLIER Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.749 -1.341 . . . . 0.0 109.749 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.596 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.13 -34.19 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 O-C-N 120.969 -1.312 . . . . 0.0 108.453 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.593 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.9 OUTLIER -71.08 -21.32 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.512 -0.743 . . . . 0.0 110.042 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -55.06 -33.6 62.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.29 -0.881 . . . . 0.0 111.388 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 31.6 m -114.02 -64.52 1.3 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.055 -1.028 . . . . 0.0 111.522 -178.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.7 mp -65.45 -51.68 58.45 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.0 -1.062 . . . . 0.0 110.573 -178.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.5 -37.64 69.08 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 120.016 -1.088 . . . . 0.0 110.426 -179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.593 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.9 tt -58.75 -41.49 86.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.176 -1.191 . . . . 0.0 109.796 -179.193 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.9 tp -66.76 -44.66 80.85 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.299 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -67.89 -37.95 82.39 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.1 t -63.59 -40.94 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.412 -0.805 . . . . 0.0 110.303 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.4 HD13 ' N ' ' A' ' 45' ' ' ILE . 1.3 mp -58.88 -51.09 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.113 -0.992 . . . . 0.0 109.832 -179.189 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -37.46 83.84 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.11 -0.994 . . . . 0.0 109.217 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.696 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 25.9 t90 -66.25 -39.61 89.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.445 -0.784 . . . . 0.0 109.538 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.53 -41.92 91.09 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.511 -0.743 . . . . 0.0 109.84 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.461 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 4.1 tm-20 -65.77 -39.11 90.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.183 -0.948 . . . . 0.0 109.925 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -60.09 -39.09 84.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.617 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.6 mtp85 -86.02 -54.18 4.64 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 111.247 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -80.4 -22.89 40.79 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.054 -1.028 . . . . 0.0 110.984 -178.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 78.25 27.47 57.76 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.461 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 68.3 mt -104.85 148.7 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.343 -1.092 . . . . 0.0 109.424 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.38 155.21 22.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.33 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.325 -0.859 . . . . 0.0 109.809 -179.261 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -60.93 -27.12 84.3 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.649 2.232 . . . . 0.0 112.096 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.69 -25.45 67.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.384 -0.823 . . . . 0.0 109.947 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.405 ' HE2' ' HB2' ' A' ' 75' ' ' PHE . 52.6 t-80 -67.16 -26.64 66.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.173 -0.955 . . . . 0.0 110.202 -179.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -96.78 3.14 52.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.095 -1.003 . . . . 0.0 109.387 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -56.67 -41.01 76.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.806 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -130.26 147.2 51.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.224 -0.922 . . . . 0.0 109.926 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.8 mt -63.12 -35.85 73.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 O-C-N 121.372 -0.83 . . . . 0.0 109.977 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.5 mtm180 -60.35 -37.35 80.4 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.202 -0.936 . . . . 0.0 110.108 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.3 t -58.67 -39.77 81.62 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.035 -1.041 . . . . 0.0 108.821 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.5 mt -62.65 -38.19 80.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.4 -0.812 . . . . 0.0 108.985 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -54.31 -38.73 66.29 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.409 -0.807 . . . . 0.0 109.275 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.15 93.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.927 . . . . 0.0 109.246 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.405 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 71.2 t80 -65.4 -46.35 80.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.244 -0.91 . . . . 0.0 109.374 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.2 t -65.38 -41.99 92.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.383 -0.823 . . . . 0.0 110.123 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.4 t -62.8 -42.92 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.085 -1.009 . . . . 0.0 109.864 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.95 -36.41 92.13 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.47 -49.79 5.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 110.532 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 37.9 m -129.22 139.68 51.77 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.835 . . . . 0.0 109.95 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.38 -0.825 . . . . 0.0 109.284 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 68.1 tp60 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.229 0.538 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.571 ' NE2' ' OG1' ' A' ' 81' ' ' THR . 95.9 m-70 -139.98 8.82 2.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.182 -0.949 . . . . 0.0 109.78 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.449 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.83 -37.49 79.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.163 -0.961 . . . . 0.0 109.394 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -59.76 -36.53 76.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.216 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 82.5 t -64.91 -37.25 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.388 -0.82 . . . . 0.0 109.45 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.6 mt -59.54 -48.53 86.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.567 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.453 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.25 -45.25 92.4 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.092 -1.005 . . . . 0.0 108.628 179.288 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -38.22 88.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.512 0.672 . . . . 0.0 109.398 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.433 ' N ' ' O ' ' A' ' 6' ' ' VAL . 68.6 t80 -64.51 -51.69 61.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.567 -0.708 . . . . 0.0 110.003 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 16.2 m -74.42 -41.53 49.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 110.457 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.453 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 73.9 t -62.85 -36.22 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.16 -0.963 . . . . 0.0 110.403 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -57.36 -36.91 71.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -67.38 -36.85 82.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 110.504 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -90.58 -61.61 1.64 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.028 -1.045 . . . . 0.0 110.721 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.1 mt . . . . . 0 N--CA 1.493 1.691 0 O-C-N 121.304 -0.873 . . . . 0.0 110.134 -179.118 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.87 -27.51 59.05 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.528 1.485 . . . . 0.0 111.808 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.28 -17.07 63.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.198 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -82.95 -1.26 51.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.385 -0.822 . . . . 0.0 108.787 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -102.5 138.65 25.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.552 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.4 t0 -67.93 94.36 0.47 Allowed 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.125 -0.984 . . . . 0.0 109.4 -179.399 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.5 m -60.87 0.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.363 -0.835 . . . . 0.0 109.319 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.552 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.1 m-20 -87.57 9.58 20.68 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.007 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -87.38 134.59 33.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.47 -0.769 . . . . 0.0 109.516 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.481 ' OD1' ' O ' ' A' ' 67' ' ' ARG . 86.1 m-20 -62.27 122.29 15.26 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 108.776 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.3 mt -58.13 -10.82 2.1 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.176 -0.952 . . . . 0.0 109.311 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 89.0 t -50.55 -45.35 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.116 -0.99 . . . . 0.0 108.691 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -55.94 -36.54 67.88 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.2 m-20 -90.13 22.91 3.05 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.13 -15.13 0.01 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -52.61 -37.2 23.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.308 . . . . 0.0 108.542 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.517 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.8 tt -70.48 -19.42 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.514 -0.741 . . . . 0.0 110.167 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.589 ' OD1' ' CE1' ' A' ' 66' ' ' PHE . 77.2 m-20 -56.71 -35.57 68.66 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.234 -0.916 . . . . 0.0 111.461 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.08 -64.56 1.29 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.086 -1.009 . . . . 0.0 111.268 -178.322 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.41 -48.93 77.52 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.066 -1.021 . . . . 0.0 110.02 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.08 -43.52 56.6 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -58.8 -39.66 81.76 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -1.097 . . . . 0.0 109.371 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.77 -44.24 93.96 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.171 -0.956 . . . . 0.0 108.772 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -68.42 -39.95 81.41 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.323 -0.861 . . . . 0.0 109.602 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.4 t -65.84 -44.09 92.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.4 -0.812 . . . . 0.0 110.123 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.63 -50.5 80.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.127 -0.983 . . . . 0.0 109.481 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.85 -38.25 86.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.311 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 44.7 t90 -68.97 -43.57 74.68 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.328 -0.858 . . . . 0.0 109.6 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -60.2 -43.68 95.76 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.434 -0.792 . . . . 0.0 109.485 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -67.71 -36.3 80.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.298 -0.876 . . . . 0.0 109.874 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -59.42 -39.24 82.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.838 -1.164 . . . . 0.0 110.119 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 36.3 mtp180 -87.04 -58.22 2.67 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.184 -0.947 . . . . 0.0 111.522 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -80.58 -23.16 40.06 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.951 -1.093 . . . . 0.0 111.733 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.71 35.01 33.15 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.319 -1.42 . . . . 0.0 109.709 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.2 mt -97.63 138.5 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.247 -1.149 . . . . 0.0 108.878 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.93 142.72 56.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.891 -1.131 . . . . 0.0 109.487 -179.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.356 -0.84 . . . . 0.0 109.335 -179.715 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_exo -51.67 -23.55 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.283 1.989 . . . . 0.0 111.971 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.5 -20.87 61.51 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 109.564 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -67.43 -26.94 66.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.309 -0.869 . . . . 0.0 110.383 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.589 ' CE1' ' OD1' ' A' ' 37' ' ' ASP . 51.7 m-85 -72.91 -14.14 61.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.009 -1.057 . . . . 0.0 109.555 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.481 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 25.1 mmt180 -56.79 -35.94 69.3 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.299 -0.875 . . . . 0.0 110.194 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.66 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 61.9 p -157.52 143.77 17.75 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.86 -1.15 . . . . 0.0 110.463 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.9 mt -66.99 -36.6 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 O-C-N 121.562 -0.711 . . . . 0.0 110.172 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -60.27 -41.89 94.25 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -0.829 . . . . 0.0 110.629 -178.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.66 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 19.6 m -57.49 -42.12 82.06 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.134 -0.978 . . . . 0.0 109.774 -179.281 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.14 -38.66 80.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.133 -0.979 . . . . 0.0 109.928 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.449 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 40.4 t0 -57.72 -40.54 79.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 -179.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.9 85.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.142 -0.974 . . . . 0.0 109.745 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -62.97 -48.88 76.95 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.228 -0.92 . . . . 0.0 109.398 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.55 -45.47 88.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.242 -0.911 . . . . 0.0 109.725 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 49.2 t -60.91 -41.84 90.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 O-C-N 121.069 -1.02 . . . . 0.0 109.592 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.96 -28.42 63.56 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.32 -50.67 3.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.139 -1.212 . . . . 0.0 110.678 -179.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.1 t -149.17 156.58 42.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.068 -1.02 . . . . 0.0 109.997 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.571 ' OG1' ' NE2' ' A' ' 3' ' ' HIS . 0.2 OUTLIER . . . . . 0 C--N 1.302 -1.466 0 O-C-N 121.454 -0.779 . . . . 0.0 108.918 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.594 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 93.4 mt-30 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.594 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 22.0 p-80 40.28 24.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.412 -0.805 . . . . 0.0 109.164 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.553 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -61.53 -37.58 84.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.488 -0.757 . . . . 0.0 109.652 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 m -59.56 -38.1 80.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -0.943 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' CB ' ' A' ' 10' ' ' PHE . 71.6 t -64.28 -37.53 80.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.255 -0.903 . . . . 0.0 109.07 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.9 mt -64.19 -46.82 92.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.283 -0.886 . . . . 0.0 109.961 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.538 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.21 -49.98 69.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.293 -0.879 . . . . 0.0 110.593 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.715 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.72 -40.93 75.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.014 -1.054 . . . . 0.0 109.866 -179.661 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.715 ' N ' HE21 ' A' ' 9' ' ' GLN . 74.4 t80 -63.69 -51.32 65.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -0.973 . . . . 0.0 110.159 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 5.0 p -68.51 -40.38 81.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.703 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.538 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 72.4 t -66.95 -37.8 80.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.311 -0.868 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -52.41 -29.67 25.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.378 -0.827 . . . . 0.0 109.992 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.51 -30.42 71.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.222 -0.924 . . . . 0.0 109.679 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.574 ' CE1' ' OD1' ' A' ' 33' ' ' ASN . 38.6 p90 -142.56 38.52 1.52 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.068 -1.02 . . . . 0.0 109.963 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.565 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.459 0 O-C-N 120.827 -1.17 . . . . 0.0 110.053 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_exo -50.02 -31.09 26.51 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 C-N-CA 121.943 1.762 . . . . 0.0 112.104 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.3 -25.44 68.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.64 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -96.74 8.62 43.86 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.237 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.46 137.18 28.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.356 -0.84 . . . . 0.0 108.818 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.56 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.87 85.89 0.33 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.216 -0.927 . . . . 0.0 109.642 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.8 m -59.97 0.08 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.387 -0.82 . . . . 0.0 109.086 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.56 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.64 7.69 40.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.345 -0.847 . . . . 0.0 108.87 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.9 tp -90.81 138.0 31.92 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.45 -0.781 . . . . 0.0 109.454 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.36 121.54 15.07 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.416 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -72.53 3.34 5.0 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.944 -178.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.2 p -52.46 -39.22 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.007 -1.058 . . . . 0.0 108.635 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -58.11 -34.74 70.53 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.721 ' N ' HD21 ' A' ' 33' ' ' ASN . 0.9 OUTLIER -84.42 16.97 2.81 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 179.093 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.17 -17.37 0.03 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.295 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.79 -35.81 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.038 -1.272 . . . . 0.0 108.51 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.4 tt -70.22 -16.07 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.571 -0.706 . . . . 0.0 109.768 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -55.87 -32.94 64.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 111.392 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 73.9 m -119.43 -64.69 1.24 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.008 -1.057 . . . . 0.0 111.601 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.401 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.5 mp -62.51 -48.14 80.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 110.612 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.8 -42.56 60.99 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.5 mt -62.39 -38.92 91.5 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.272 -1.134 . . . . 0.0 109.675 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.8 tp -59.12 -44.03 91.99 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.143 -0.973 . . . . 0.0 108.676 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -66.16 -38.25 87.62 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.291 -0.881 . . . . 0.0 109.017 178.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.93 -39.6 86.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.527 -0.733 . . . . 0.0 110.054 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.4 mp -58.1 -50.27 78.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.221 -0.925 . . . . 0.0 109.679 -179.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.54 -38.16 90.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.14 -0.975 . . . . 0.0 109.171 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.715 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 51.6 t90 -66.84 -40.15 87.86 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.392 -0.817 . . . . 0.0 109.474 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 tp -61.01 -43.53 98.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.462 -0.774 . . . . 0.0 109.735 -179.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -66.3 -36.4 82.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 110.001 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -62.3 -46.24 89.65 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.045 -1.034 . . . . 0.0 110.837 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.715 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt180 -87.4 -51.14 6.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.074 -1.016 . . . . 0.0 111.798 -178.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -79.88 -24.1 41.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.966 -1.084 . . . . 0.0 111.13 -178.084 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.47 31.54 45.55 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.44 -1.362 . . . . 0.0 109.739 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 68.1 mt -100.21 136.31 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.167 -1.196 . . . . 0.0 108.656 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.925 -1.11 . . . . 0.0 109.765 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.522 -0.736 . . . . 0.0 109.405 179.934 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -57.69 -30.67 89.75 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.757 2.304 . . . . 0.0 112.11 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.54 -31.83 73.21 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.264 -0.897 . . . . 0.0 109.509 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.5 ' O ' ' OG ' ' A' ' 71' ' ' SER . 83.7 t60 -68.59 -26.19 65.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 110.653 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -88.79 7.35 34.5 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.996 -1.065 . . . . 0.0 110.489 -178.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 24.0 mmt85 -58.07 -36.33 72.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.07 -1.019 . . . . 0.0 109.968 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.509 ' HG ' ' H ' ' A' ' 71' ' ' SER . 90.9 p -133.68 150.04 51.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.208 -0.932 . . . . 0.0 109.834 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.9 mt -66.05 -36.45 77.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.313 -0.867 . . . . 0.0 109.875 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -60.93 -37.61 82.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.171 -0.955 . . . . 0.0 109.916 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.509 ' H ' ' HG ' ' A' ' 68' ' ' SER . 88.4 p -61.37 -35.73 78.25 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.07 -1.019 . . . . 0.0 109.274 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.406 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 81.3 mt -61.41 -39.06 81.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.25 -0.907 . . . . 0.0 109.015 179.412 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.4 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 51.3 t0 -59.24 -37.32 77.27 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.515 -0.741 . . . . 0.0 109.68 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.19 -46.67 82.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.188 -0.945 . . . . 0.0 109.872 -179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -66.12 -44.85 83.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.053 -1.029 . . . . 0.0 109.079 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -62.63 -41.83 93.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.471 -0.768 . . . . 0.0 109.549 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.4 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 53.6 t -61.92 -41.73 91.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 O-C-N 121.264 -0.898 . . . . 0.0 109.661 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.65 -36.33 85.29 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -90.57 -49.82 6.28 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.11 -1.23 . . . . 0.0 110.079 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 76' ' ' VAL . 12.4 t -145.1 153.35 41.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -0.888 . . . . 0.0 109.577 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.667 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.1 mt-30 . . . . . 0 N--CA 1.488 1.447 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.4 m80 61.79 20.09 11.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -0.988 . . . . 0.0 109.139 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -63.43 -38.24 90.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.6 m -60.79 -39.12 87.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.97 . . . . 0.0 110.065 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.5 t -64.81 -38.09 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.103 -0.998 . . . . 0.0 109.554 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 83.2 mt -59.81 -50.8 78.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.25 -0.906 . . . . 0.0 109.631 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.542 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.21 -46.36 84.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 109.139 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.36 -39.98 94.95 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.4 -0.813 . . . . 0.0 109.648 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.64 -51.21 61.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.431 -0.793 . . . . 0.0 110.493 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.9 m -73.74 -39.28 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.24 -0.913 . . . . 0.0 110.367 -179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.542 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 99.3 t -65.13 -39.03 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.065 -1.022 . . . . 0.0 109.773 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -53.12 -35.87 60.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 109.8 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.62 -31.88 72.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.27 -0.894 . . . . 0.0 109.918 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.88 39.86 3.12 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 110.047 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.569 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.93 -1.106 . . . . 0.0 110.024 -179.73 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -49.52 -30.28 20.91 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.929 1.753 . . . . 0.0 112.052 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.04 -22.86 67.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.307 -0.87 . . . . 0.0 109.643 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -96.11 7.13 47.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.333 -0.854 . . . . 0.0 109.132 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.58 136.52 34.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.1 89.61 0.44 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.175 -0.953 . . . . 0.0 109.605 -179.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -59.63 0.11 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.261 -0.899 . . . . 0.0 109.146 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -92.21 8.22 39.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.352 -0.842 . . . . 0.0 108.786 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.0 tp -90.96 139.06 31.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.427 -0.796 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.453 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.9 m-20 -60.82 121.58 12.69 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -69.86 7.13 0.97 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.254 -0.904 . . . . 0.0 109.847 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.453 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.4 p -53.46 -38.61 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.113 -0.992 . . . . 0.0 109.123 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.92 -36.45 72.5 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.15 19.55 3.09 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -15.01 0.02 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.63 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -53.43 -36.49 27.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.125 -1.221 . . . . 0.0 108.862 179.53 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.5 tt -70.38 -22.48 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.538 -0.726 . . . . 0.0 110.245 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.3 m-20 -55.42 -33.22 63.36 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 110.932 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -116.17 -63.75 1.41 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.123 -0.985 . . . . 0.0 111.24 -178.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.529 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.4 mm? -62.41 -52.18 64.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.047 -1.033 . . . . 0.0 110.096 -178.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.79 -40.19 64.87 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.7 tt -58.7 -41.04 85.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -1.094 . . . . 0.0 109.552 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 24.9 tp -62.76 -44.4 96.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.935 . . . . 0.0 109.024 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -66.24 -35.12 79.6 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.349 -0.844 . . . . 0.0 109.592 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 64.2 t -60.86 -42.99 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 110.24 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -59.64 -50.54 79.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.105 -0.997 . . . . 0.0 109.632 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.91 -36.65 82.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 34.3 t90 -67.79 -43.33 79.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 109.633 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.01 -46.3 85.48 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.477 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -67.84 -38.05 82.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.35 -0.844 . . . . 0.0 109.067 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.8 t0 -65.47 -41.48 93.32 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 110.64 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 74.5 ttt-85 -87.12 -58.14 2.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.171 -0.956 . . . . 0.0 111.662 -178.385 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -79.73 -19.47 48.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.02 -1.05 . . . . 0.0 111.559 -177.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 28.19 56.26 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -104.47 142.58 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.405 -1.056 . . . . 0.0 109.348 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.47 154.73 23.69 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.237 -0.914 . . . . 0.0 109.143 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.494 0 O-C-N 121.259 -0.901 . . . . 0.0 109.405 -179.354 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.19 -21.47 59.91 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.892 2.395 . . . . 0.0 111.866 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.43 -32.32 70.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.402 -0.811 . . . . 0.0 110.091 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.484 ' O ' ' OG ' ' A' ' 71' ' ' SER . 44.9 t-80 -70.23 -26.27 63.77 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.319 -0.863 . . . . 0.0 111.404 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -95.11 8.0 44.37 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.799 -1.188 . . . . 0.0 110.817 -178.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -60.91 -38.44 85.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.998 -1.064 . . . . 0.0 110.671 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.4 m -126.66 147.58 49.91 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.222 -0.924 . . . . 0.0 110.483 -179.149 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.2 -36.09 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 O-C-N 121.434 -0.791 . . . . 0.0 109.802 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -60.42 -37.7 81.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 110.157 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.484 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 97.6 p -61.44 -36.85 81.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.08 -1.013 . . . . 0.0 109.282 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.6 -38.62 82.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.373 -0.83 . . . . 0.0 109.117 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 53.5 t0 -56.52 -38.74 72.24 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.43 -0.794 . . . . 0.0 109.655 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.84 -42.04 97.7 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.132 -0.98 . . . . 0.0 109.405 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -64.35 -45.66 86.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.863 . . . . 0.0 109.563 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.6 t -65.0 -42.42 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.348 -0.845 . . . . 0.0 110.05 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.2 t -63.18 -42.37 96.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.155 -0.966 . . . . 0.0 109.892 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.9 -30.07 72.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -97.69 -49.54 4.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.958 -1.319 . . . . 0.0 110.307 -179.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 76' ' ' VAL . 11.0 t -139.19 155.54 47.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.554 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.467 0 O-C-N 121.448 -0.783 . . . . 0.0 109.514 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.335 0.588 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.458 ' CD2' ' CG2' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -163.88 25.0 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.155 -0.966 . . . . 0.0 109.385 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.87 -34.83 76.71 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.231 -0.918 . . . . 0.0 109.563 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 t -59.11 -39.6 82.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.159 -0.963 . . . . 0.0 109.543 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.458 ' CG2' ' CD2' ' A' ' 3' ' ' HIS . 78.3 t -65.13 -39.29 85.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.2 179.63 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.401 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 88.1 mt -59.86 -48.0 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.444 -0.785 . . . . 0.0 109.657 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.66 -46.37 85.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.318 -0.864 . . . . 0.0 109.656 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.443 ' HG3' ' N ' ' A' ' 10' ' ' PHE . 0.9 OUTLIER -69.52 -36.54 76.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.547 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.3 t80 -68.57 -48.23 64.76 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.389 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 73.7 t -69.12 -46.3 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 110.104 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 76.6 t -63.53 -35.2 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.39 -0.819 . . . . 0.0 110.676 -179.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.95 -36.8 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.125 -0.985 . . . . 0.0 109.86 -179.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.72 -35.39 78.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 110.685 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -91.99 -63.6 1.22 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.022 -1.049 . . . . 0.0 110.731 -178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.9 mt . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.255 -0.903 . . . . 0.0 110.19 -179.024 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.403 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.0 -28.6 57.6 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.574 1.516 . . . . 0.0 111.813 -179.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.62 -14.75 62.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.391 -0.818 . . . . 0.0 109.174 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -82.94 -0.16 47.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.377 -0.827 . . . . 0.0 108.917 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -98.94 137.74 25.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.551 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -67.41 92.75 0.3 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.087 -1.008 . . . . 0.0 109.437 -179.277 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 m -59.77 0.01 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.421 -0.799 . . . . 0.0 109.206 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.551 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -88.98 5.69 43.05 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.8 tp -92.67 136.42 33.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.612 -0.68 . . . . 0.0 109.399 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.497 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.2 m-20 -60.93 121.58 12.74 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.1 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -67.02 6.53 0.51 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.126 -0.983 . . . . 0.0 109.72 -178.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.1 p -54.78 -37.57 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 108.933 179.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.432 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.25 -36.31 70.8 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.1 m-20 -84.96 17.92 2.69 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.44 ' O ' ' CG ' ' A' ' 37' ' ' ASP . . . -42.87 -14.26 0.01 OUTLIER Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.6 t -51.34 -37.93 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 108.855 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -70.9 -11.82 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.47 -0.769 . . . . 0.0 109.757 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.44 ' CG ' ' O ' ' A' ' 34' ' ' GLY . 85.3 m-20 -51.64 -42.31 61.96 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 111.376 -177.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -120.91 -58.66 1.8 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.109 -0.995 . . . . 0.0 111.975 -178.381 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.6 mp -61.27 -52.15 65.95 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.825 -1.172 . . . . 0.0 110.135 -178.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.56 -36.06 68.08 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.98 -43.23 86.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -1.083 . . . . 0.0 109.548 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.65 -43.91 95.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.076 -1.015 . . . . 0.0 109.205 179.577 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -65.27 -38.05 89.1 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 80.0 t -65.31 -39.93 86.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.381 -0.825 . . . . 0.0 110.067 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -58.45 -50.1 79.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.155 -0.966 . . . . 0.0 109.905 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.98 -36.7 80.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.971 -1.081 . . . . 0.0 109.94 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.547 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -76.58 -41.92 44.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.143 -0.973 . . . . 0.0 110.126 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.7 tt -60.84 -43.12 98.74 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.411 -0.805 . . . . 0.0 110.801 -178.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.58 ' O ' ' N ' ' A' ' 53' ' ' GLY . 54.8 mt-10 -65.78 -39.64 91.2 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.946 -1.096 . . . . 0.0 109.217 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -67.84 -49.21 63.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.419 -0.8 . . . . 0.0 110.932 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.615 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 67.4 ttt-85 -62.07 -41.3 98.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 97.5 m-85 -101.58 -9.62 20.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.953 -1.092 . . . . 0.0 110.559 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.58 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.21 35.78 88.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -105.88 143.94 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.302 -1.117 . . . . 0.0 109.869 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.76 152.85 34.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.365 -0.835 . . . . 0.0 109.082 179.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.546 ' CB ' ' OE1' ' A' ' 49' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 110.206 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.43 -28.06 77.78 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.532 2.154 . . . . 0.0 111.943 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -60.95 -28.3 68.88 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.418 -0.801 . . . . 0.0 109.993 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -67.78 -26.54 66.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.15 -0.969 . . . . 0.0 110.188 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -100.75 8.12 43.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.767 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.5 tpt180 -54.86 -40.06 69.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.356 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -127.69 148.6 50.4 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.319 -0.863 . . . . 0.0 109.69 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.3 mt -60.72 -36.59 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.299 -0.876 . . . . 0.0 109.891 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -60.55 -39.26 87.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.271 -0.893 . . . . 0.0 110.25 -179.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 m -58.25 -41.25 83.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.983 -1.073 . . . . 0.0 109.521 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.2 -38.62 83.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.521 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 91.9 m-20 -56.31 -38.14 70.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.461 -0.774 . . . . 0.0 109.609 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.88 -45.99 86.92 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -65.69 -46.67 78.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.181 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.3 t -64.35 -40.73 90.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.422 -0.799 . . . . 0.0 109.681 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.521 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 55.1 t -60.33 -43.34 93.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.16 -0.963 . . . . 0.0 109.91 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.46 -37.38 94.71 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -87.62 -50.15 6.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.999 -1.295 . . . . 0.0 110.331 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.9 p -130.8 156.24 45.34 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.409 -0.807 . . . . 0.0 109.199 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.302 -1.474 0 O-C-N 121.219 -0.926 . . . . 0.0 109.609 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -152.04 57.42 0.84 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.905 . . . . 0.0 109.107 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.36 -35.41 75.61 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.265 -0.897 . . . . 0.0 109.97 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -59.46 -40.8 88.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.055 -1.028 . . . . 0.0 109.545 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.2 t -67.01 -37.85 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.239 -0.913 . . . . 0.0 109.182 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.494 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 87.8 mt -59.73 -40.03 81.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.496 -0.753 . . . . 0.0 110.101 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.18 -50.0 72.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.023 -1.048 . . . . 0.0 109.294 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.488 ' OE1' ' OE1' ' A' ' 13' ' ' GLU . 1.2 pp0? -69.94 -33.94 72.79 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.338 -0.851 . . . . 0.0 109.439 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.424 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 65.0 t80 -66.35 -51.96 51.84 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.043 -1.035 . . . . 0.0 109.942 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 5.5 p -70.57 -38.7 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.233 -0.917 . . . . 0.0 110.111 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 88.6 t -65.25 -42.1 93.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.211 -0.93 . . . . 0.0 110.639 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' OE1' ' OE1' ' A' ' 9' ' ' GLN . 76.6 mt-10 -55.18 -27.38 45.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.021 -1.049 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -65.38 -27.75 68.79 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 109.101 179.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.586 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.0 p90 -149.83 41.64 0.85 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.219 -0.926 . . . . 0.0 109.852 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.568 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 O-C-N 120.948 -1.095 . . . . 0.0 110.196 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -49.94 -32.55 30.85 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.936 1.757 . . . . 0.0 111.938 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.33 -24.84 67.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.453 -0.779 . . . . 0.0 109.64 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -98.47 7.12 46.58 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -0.863 . . . . 0.0 109.453 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.4 t -103.8 135.16 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.315 -0.866 . . . . 0.0 108.879 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.471 ' C ' ' H ' ' A' ' 27' ' ' ASP . 88.0 m-20 -72.17 86.06 1.06 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.219 -0.925 . . . . 0.0 109.315 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.7 m -63.11 -0.3 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.233 -0.917 . . . . 0.0 109.627 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.475 ' OD1' ' C ' ' A' ' 27' ' ' ASP . 48.0 p30 -90.7 8.52 34.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.141 -0.974 . . . . 0.0 108.787 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 18.8 tp -93.93 136.37 34.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 109.447 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -60.95 122.48 15.02 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.6 mt -66.89 -0.86 3.35 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.258 -0.901 . . . . 0.0 109.87 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.9 t -52.61 -42.47 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.089 -1.007 . . . . 0.0 108.911 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.46 -36.33 66.46 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.619 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.8 m-80 -86.55 20.29 2.53 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.46 -15.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.619 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -53.33 -38.81 32.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.884 -1.363 . . . . 0.0 108.277 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.585 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.4 tt -70.87 -24.2 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.599 -0.688 . . . . 0.0 109.95 179.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -62.54 -22.51 66.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.181 -0.949 . . . . 0.0 110.697 -178.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -117.47 -64.87 1.24 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.081 -1.012 . . . . 0.0 111.013 -178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.2 mp -67.41 -50.2 60.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.034 -1.041 . . . . 0.0 110.171 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.74 -41.24 64.13 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tt -61.1 -40.05 92.26 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.494 -1.003 . . . . 0.0 109.617 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.6 tp -58.63 -44.31 89.96 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.189 -0.944 . . . . 0.0 108.569 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.0 mtpt -65.06 -34.2 77.86 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.49 -39.77 86.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.495 -0.753 . . . . 0.0 110.511 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.419 HG22 HD11 ' A' ' 45' ' ' ILE . 27.9 mm -59.22 -50.74 78.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.637 -1.29 . . . . 0.0 109.525 -179.488 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.87 -41.31 83.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.292 -0.88 . . . . 0.0 109.793 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 16.8 t90 -69.77 -42.81 73.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 110.233 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 33.2 tp -59.36 -41.93 90.43 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.329 -0.857 . . . . 0.0 109.712 -179.384 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.569 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.5 tt0 -64.06 -38.12 89.92 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.238 -0.914 . . . . 0.0 109.753 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -60.07 -37.08 78.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.951 -1.093 . . . . 0.0 110.064 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -75.09 -48.68 22.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.245 -0.91 . . . . 0.0 111.958 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -114.66 -3.12 12.91 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.012 -1.055 . . . . 0.0 111.855 -178.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 30.48 61.22 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.874 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 75.8 mt -78.19 138.78 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -1.217 . . . . 0.0 108.977 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 131.21 49.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.827 -1.17 . . . . 0.0 109.736 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.448 -0.782 . . . . 0.0 109.258 179.848 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -50.7 -31.45 32.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.222 1.948 . . . . 0.0 111.69 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.05 -30.72 71.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.423 -0.798 . . . . 0.0 109.074 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.563 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 46.7 t-80 -67.65 -26.55 66.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.474 -0.767 . . . . 0.0 109.802 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -91.9 10.22 29.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.181 -0.949 . . . . 0.0 109.449 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -53.61 -36.55 62.11 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.294 -0.879 . . . . 0.0 109.463 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.9 t -150.3 152.61 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.273 -0.892 . . . . 0.0 109.846 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -64.31 -36.16 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -60.7 -38.07 83.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.111 -0.993 . . . . 0.0 110.107 -179.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.01 -37.03 85.55 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.073 -1.017 . . . . 0.0 109.16 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.5 mt -66.36 -38.43 81.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.329 -0.857 . . . . 0.0 109.29 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.494 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 53.1 t0 -56.25 -41.05 75.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.491 -0.756 . . . . 0.0 109.88 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.63 -45.33 79.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.205 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.563 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 65.6 t80 -63.08 -48.61 77.88 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -0.966 . . . . 0.0 109.751 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.9 t -66.48 -42.83 90.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.251 -0.906 . . . . 0.0 109.836 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 44.5 t -61.96 -40.55 87.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 120.969 -1.082 . . . . 0.0 109.693 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.84 -34.36 71.06 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.36 -50.65 3.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.133 -1.216 . . . . 0.0 110.79 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.504 ' O ' ' O ' ' A' ' 76' ' ' VAL . 56.0 m -153.96 140.41 18.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.995 -1.066 . . . . 0.0 110.267 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.282 -0.886 . . . . 0.0 109.239 179.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.552 ' NE2' ' CG1' ' A' ' 6' ' ' VAL . 57.1 t-80 -148.33 8.06 0.8 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.34 -0.85 . . . . 0.0 109.724 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.63 -39.81 95.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.055 -1.028 . . . . 0.0 109.769 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.3 t -61.52 -40.08 93.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.924 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.552 ' CG1' ' NE2' ' A' ' 3' ' ' HIS . 78.1 t -63.27 -39.71 86.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.257 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 92.0 mt -62.4 -46.45 96.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.346 -0.846 . . . . 0.0 110.01 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.88 -49.93 70.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 110.411 -179.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.436 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 4.2 pp0? -69.91 -42.07 73.83 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.182 -0.949 . . . . 0.0 109.894 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 9' ' ' GLN . 71.4 t80 -60.49 -46.47 90.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 67.2 t -69.63 -47.01 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.44 -0.787 . . . . 0.0 109.92 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.5 t -65.51 -35.18 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.404 -0.81 . . . . 0.0 110.453 -179.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -53.52 -36.66 62.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.214 -0.928 . . . . 0.0 109.992 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.96 -35.57 78.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 110.771 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -91.74 -63.6 1.23 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.963 -1.085 . . . . 0.0 110.657 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.2 mp . . . . . 0 N--CA 1.493 1.718 0 O-C-N 121.331 -0.855 . . . . 0.0 110.119 -179.056 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.354 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.9 -25.57 59.81 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.524 1.483 . . . . 0.0 111.723 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.49 -14.87 62.7 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.31 -0.869 . . . . 0.0 109.232 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -82.87 2.91 31.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.255 -0.903 . . . . 0.0 108.929 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.13 137.27 32.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.509 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.4 89.17 0.14 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.147 -0.971 . . . . 0.0 109.377 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.7 m -62.31 -0.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.307 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.509 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -93.85 7.07 46.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 108.979 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.9 tp -95.7 137.87 34.15 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.483 -0.761 . . . . 0.0 109.6 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.407 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.8 m-20 -61.71 121.81 13.75 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.453 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.5 OUTLIER -67.97 2.87 1.79 Allowed 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.266 -0.896 . . . . 0.0 109.932 -178.811 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.456 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -51.28 -39.19 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.08 -1.012 . . . . 0.0 108.395 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.42 -35.78 70.5 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.7 m-20 -87.09 22.14 2.14 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.009 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -14.27 0.01 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -51.26 -35.31 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.104 -1.233 . . . . 0.0 108.612 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.577 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -70.07 -19.94 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.517 -0.739 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.418 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -55.53 -33.18 63.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -0.87 . . . . 0.0 111.046 -178.51 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -116.78 -64.13 1.35 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.115 -0.991 . . . . 0.0 111.356 -178.571 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.5 mp -62.88 -52.08 64.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.99 -1.068 . . . . 0.0 110.093 -178.661 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.67 -38.92 67.39 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.577 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.2 tt -58.45 -43.08 88.7 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.401 -1.058 . . . . 0.0 109.725 -179.75 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 tp -60.23 -44.32 95.31 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 108.956 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -69.72 -40.1 76.46 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.373 -0.829 . . . . 0.0 109.967 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.8 t -66.03 -45.01 91.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 110.391 -179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -59.45 -50.24 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.084 -1.01 . . . . 0.0 109.513 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.62 -32.2 73.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 29.6 t90 -74.46 -45.83 43.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.878 . . . . 0.0 110.246 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -57.41 -45.31 84.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.362 -0.836 . . . . 0.0 110.009 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.414 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 8.4 pt-20 -71.23 -36.42 71.82 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.098 -1.001 . . . . 0.0 109.056 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.9 t0 -64.78 -41.45 95.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.322 -0.861 . . . . 0.0 110.639 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.4 ttt180 -83.78 -51.56 7.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 110.95 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -79.85 -24.55 41.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.05 -1.031 . . . . 0.0 110.842 -178.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.41 31.44 54.54 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 53.9 mt -109.4 134.28 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -1.085 . . . . 0.0 109.582 -179.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.93 143.39 57.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.352 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 -179.84 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.89 -26.88 74.53 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.481 2.121 . . . . 0.0 112.281 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -57.65 -27.42 62.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.843 . . . . 0.0 109.654 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.436 ' O ' ' CG1' ' A' ' 72' ' ' ILE . 85.9 t60 -67.13 -26.92 66.91 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.941 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -101.1 4.25 42.01 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.028 -1.045 . . . . 0.0 110.373 -179.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -58.86 -40.94 85.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.887 -1.133 . . . . 0.0 109.86 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.1 p -150.06 154.89 38.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.903 -1.123 . . . . 0.0 110.019 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 87.6 mt -65.33 -37.36 79.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.343 -0.848 . . . . 0.0 109.857 179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.7 ttp180 -60.93 -40.43 93.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 110.164 -179.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -59.58 -41.85 91.19 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.999 -1.063 . . . . 0.0 109.695 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.436 ' CG1' ' O ' ' A' ' 65' ' ' HIS . 87.2 mt -67.43 -39.96 83.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.258 -0.901 . . . . 0.0 110.005 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -59.16 -40.79 86.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 110.188 -179.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.53 -42.71 98.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.129 -0.982 . . . . 0.0 109.586 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.0 t80 -63.74 -45.34 90.34 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.247 -0.908 . . . . 0.0 109.336 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.7 t -63.75 -45.36 97.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.355 -0.841 . . . . 0.0 109.915 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.0 t -60.97 -40.09 84.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 O-C-N 121.125 -0.984 . . . . 0.0 109.637 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.76 -32.25 65.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.15 -50.17 3.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.084 -1.245 . . . . 0.0 110.403 -179.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 76' ' ' VAL . 8.4 t -146.22 155.61 42.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.171 -0.956 . . . . 0.0 110.021 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.317 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.39 11.84 3.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.334 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.75 -33.24 71.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.347 -0.846 . . . . 0.0 109.918 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.35 -35.3 77.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.097 -1.002 . . . . 0.0 109.552 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.26 -37.83 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.184 -0.947 . . . . 0.0 109.167 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.3 mt -63.55 -43.27 98.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.067 -1.021 . . . . 0.0 110.089 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.47 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.22 -50.67 67.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.789 -179.178 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.5 -36.93 74.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.958 -1.088 . . . . 0.0 110.065 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -59.4 -51.3 70.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.844 -1.16 . . . . 0.0 110.082 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.4 ' O ' ' CD1' ' A' ' 15' ' ' PHE . 20.4 m -74.3 -40.64 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.142 -0.973 . . . . 0.0 110.32 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.47 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 79.7 t -62.49 -39.38 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.257 -0.902 . . . . 0.0 110.502 -179.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -61.86 -32.56 72.92 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.128 -0.982 . . . . 0.0 110.02 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.37 -33.24 75.28 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.869 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 11' ' ' VAL . 62.3 m-85 -93.1 -63.86 1.16 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.162 -0.961 . . . . 0.0 110.451 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.289 -0.882 . . . . 0.0 110.594 -178.707 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.4 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -64.84 -27.61 59.24 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 121.54 1.493 . . . . 0.0 111.924 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.56 -14.84 62.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.443 -0.786 . . . . 0.0 109.213 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -83.3 4.13 28.48 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.42 -0.8 . . . . 0.0 109.18 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.5 t -102.09 136.88 32.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.45 -0.781 . . . . 0.0 108.906 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 27' ' ' ASP . 47.6 p30 -67.48 84.36 0.17 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.225 -0.922 . . . . 0.0 109.734 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -60.4 0.23 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.263 179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -88.25 3.75 48.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 108.87 179.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.92 139.82 30.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.524 -0.735 . . . . 0.0 109.45 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.415 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.9 m-20 -60.93 121.73 13.11 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 179.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -66.23 1.41 1.56 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.146 -0.971 . . . . 0.0 109.927 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.7 -39.16 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.038 -1.038 . . . . 0.0 108.29 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.458 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.93 -34.94 72.3 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.107 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.702 ' N ' HD21 ' A' ' 33' ' ' ASN . 1.0 OUTLIER -84.11 16.5 2.9 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.54 -15.12 0.02 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.01 -36.44 15.89 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.922 -1.34 . . . . 0.0 108.769 179.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.588 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.0 tt -70.54 -19.53 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.469 -0.769 . . . . 0.0 109.774 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -55.94 -31.73 63.19 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.324 -0.86 . . . . 0.0 111.228 -178.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.9 m -118.89 -64.71 1.25 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.099 -1.0 . . . . 0.0 111.334 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -61.68 -52.18 65.39 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.76 -1.213 . . . . 0.0 109.891 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.44 -38.27 62.27 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.588 ' N ' ' O ' ' A' ' 36' ' ' ILE . 30.5 tp -58.54 -44.2 89.52 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.343 -1.093 . . . . 0.0 109.979 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 86.1 mt -61.71 -43.82 98.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.117 -0.989 . . . . 0.0 109.287 179.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -62.65 -34.91 78.03 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.239 -0.913 . . . . 0.0 108.916 179.206 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.0 t -62.74 -39.8 86.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.529 -0.732 . . . . 0.0 110.136 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.7 mm -58.6 -50.3 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.008 -1.057 . . . . 0.0 109.734 -179.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.15 -37.64 84.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.722 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.0 t90 -70.48 -44.6 67.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.962 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.3 tp -58.34 -47.12 84.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 109.63 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -66.82 -37.39 84.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -0.929 . . . . 0.0 109.11 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.13 -42.13 84.95 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 110.668 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.3 ttt-85 -87.37 -58.48 2.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.257 -0.902 . . . . 0.0 111.809 -178.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -79.85 -19.46 48.29 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 111.599 -177.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 33.05 41.11 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.1 mt -102.8 141.87 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.375 -1.074 . . . . 0.0 109.374 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.88 145.01 54.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.254 -0.904 . . . . 0.0 109.854 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.538 -0.726 . . . . 0.0 109.876 -179.799 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.74 -25.64 74.95 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.68 2.253 . . . . 0.0 112.235 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.36 -31.46 71.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 109.727 -179.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.432 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 48.6 t-80 -68.63 -25.93 65.09 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.446 -0.784 . . . . 0.0 111.127 -179.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -95.6 5.86 50.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.743 -1.223 . . . . 0.0 110.92 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 -60.21 -37.53 80.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.895 -1.128 . . . . 0.0 110.353 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.3 p -133.38 147.44 51.79 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.076 -1.015 . . . . 0.0 110.07 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 78.1 mt -66.38 -36.71 78.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 O-C-N 121.432 -0.793 . . . . 0.0 109.797 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 92.3 mtm-85 -60.97 -37.97 84.28 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.346 -0.846 . . . . 0.0 110.099 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.3 p -61.72 -35.92 79.45 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.107 -0.996 . . . . 0.0 109.458 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 61.8 mt -66.71 -39.02 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.238 -0.914 . . . . 0.0 109.174 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -59.1 -39.44 82.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.333 -0.855 . . . . 0.0 109.779 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.27 -44.2 92.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.1 -1.0 . . . . 0.0 109.654 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.432 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 69.4 t80 -63.42 -46.17 87.57 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.242 -0.911 . . . . 0.0 109.387 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -64.43 -43.36 96.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.346 -0.846 . . . . 0.0 109.739 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 51.1 t -60.35 -40.83 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 O-C-N 121.24 -0.913 . . . . 0.0 109.659 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.31 -32.56 72.57 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.88 -50.41 3.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.063 -1.257 . . . . 0.0 110.719 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.4 p -131.79 157.9 42.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.283 -0.885 . . . . 0.0 109.827 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.408 0 O-C-N 121.182 -0.949 . . . . 0.0 109.434 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.494 ' OE1' ' OD1' ' A' ' 73' ' ' ASP . 96.0 mt-30 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.352 -0.611 . . . . 0.0 109.352 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 30.9 m80 60.94 43.42 11.69 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -55.68 -34.86 65.41 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.471 -0.768 . . . . 0.0 109.658 -179.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -58.89 -39.35 81.18 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.229 -0.919 . . . . 0.0 109.01 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' N ' ' A' ' 10' ' ' PHE . 66.0 t -67.78 -39.25 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.401 -0.812 . . . . 0.0 109.004 179.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 90.9 mt -58.95 -50.05 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.479 -0.763 . . . . 0.0 109.634 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.538 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.62 -45.75 88.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.353 -0.842 . . . . 0.0 109.668 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.43 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.03 -33.75 74.12 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.365 -0.834 . . . . 0.0 109.694 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.565 ' CE1' ' CZ2' ' A' ' 47' ' ' TRP . 61.7 t80 -64.96 -51.49 61.5 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.091 -1.005 . . . . 0.0 109.694 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.401 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 15.8 m -74.49 -40.39 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.308 -0.87 . . . . 0.0 110.098 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.538 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 77.4 t -62.05 -37.8 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.203 -0.936 . . . . 0.0 110.122 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -56.75 -36.7 70.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.33 -0.856 . . . . 0.0 109.752 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -68.16 -35.87 78.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 110.681 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -89.78 -63.01 1.34 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.025 -1.047 . . . . 0.0 110.618 -178.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mt . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.302 -0.874 . . . . 0.0 110.113 -179.285 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.73 -30.5 59.36 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.612 1.541 . . . . 0.0 112.052 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.75 -14.73 62.55 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.374 -0.829 . . . . 0.0 109.001 179.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -86.53 4.73 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.547 -0.72 . . . . 0.0 109.116 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -98.74 135.59 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.481 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -70.37 83.26 0.56 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.19 -0.944 . . . . 0.0 109.651 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -63.47 -0.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 109.117 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.481 ' H ' ' C ' ' A' ' 25' ' ' ASP . 50.6 p30 -100.39 9.83 42.08 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.248 -0.907 . . . . 0.0 109.195 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.7 tp -92.02 145.39 24.57 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.481 -0.762 . . . . 0.0 109.434 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -60.02 121.4 11.75 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 67' ' ' ARG . 76.4 mt -61.81 -11.73 13.89 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.436 -0.79 . . . . 0.0 109.97 -178.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.8 t -50.53 -45.33 26.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.801 -1.187 . . . . 0.0 108.678 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -57.61 -35.34 70.33 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.602 ' O ' ' N ' ' A' ' 35' ' ' VAL . 10.6 m120 -86.9 19.04 3.17 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.05 -18.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.602 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.5 t -52.8 -38.85 29.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.234 -1.157 . . . . 0.0 108.505 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -70.4 -24.05 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.555 -0.716 . . . . 0.0 109.375 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -56.3 -33.01 65.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.513 -0.742 . . . . 0.0 110.919 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -113.78 -64.47 1.31 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.159 -0.963 . . . . 0.0 111.098 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.6 mp -64.01 -50.44 68.5 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.955 -1.091 . . . . 0.0 110.188 -178.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.53 -40.55 67.39 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.73 -40.55 84.1 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.45 -1.029 . . . . 0.0 109.505 -179.552 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.3 tp -65.92 -44.24 85.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -65.22 -37.47 87.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.263 -0.898 . . . . 0.0 110.005 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 73.4 t -62.28 -43.26 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.351 -0.843 . . . . 0.0 110.073 -179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -62.87 -50.42 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.244 -0.91 . . . . 0.0 109.911 -179.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.01 -34.91 78.76 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.267 -0.895 . . . . 0.0 110.16 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.565 ' CZ2' ' CE1' ' A' ' 10' ' ' PHE . 3.8 t90 -66.99 -44.39 80.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 0.0 109.946 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.7 tp -57.51 -43.98 84.67 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.406 -0.809 . . . . 0.0 109.716 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -66.31 -38.54 87.96 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.221 -0.924 . . . . 0.0 109.401 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.86 -41.06 95.98 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.147 -0.97 . . . . 0.0 110.648 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -87.17 -58.37 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.104 -0.998 . . . . 0.0 111.644 -178.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -79.73 -19.99 47.49 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.1 -1.0 . . . . 0.0 111.587 -177.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 30.23 50.97 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -179.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.43 142.39 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.412 -1.052 . . . . 0.0 109.421 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.36 154.03 25.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.189 -0.944 . . . . 0.0 109.217 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.449 0 O-C-N 121.233 -0.917 . . . . 0.0 109.542 -179.328 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.155 0.503 . . . . 0.0 109.739 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -60.17 -22.98 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.926 2.417 . . . . 0.0 112.168 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.5 -31.14 71.84 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 110.028 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -67.76 -26.71 66.26 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.47 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 28.2 m-85 -97.07 2.66 51.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.193 -0.942 . . . . 0.0 109.281 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 30' ' ' LEU . 56.0 ttp180 -56.15 -39.62 72.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.476 -0.765 . . . . 0.0 110.524 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 91.2 p -119.66 148.91 42.8 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.415 -0.803 . . . . 0.0 110.463 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.7 mt -65.89 -36.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.679 -0.638 . . . . 0.0 109.981 179.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -61.5 -39.21 90.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 110.231 -179.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 19.7 m -60.74 -44.14 97.05 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.018 -1.051 . . . . 0.0 109.529 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -67.13 -39.61 83.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.338 -0.852 . . . . 0.0 109.237 179.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.539 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 38.6 t0 -57.5 -38.18 74.18 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.541 -0.724 . . . . 0.0 109.617 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.72 -46.24 89.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.954 -1.091 . . . . 0.0 109.434 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -67.06 -47.47 71.2 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.159 -0.963 . . . . 0.0 108.861 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.1 t -63.17 -40.11 87.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.539 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 38.0 t -55.63 -42.42 68.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 O-C-N 121.292 -0.88 . . . . 0.0 108.876 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.54 69.14 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.79 -1.724 . . . . 0.0 108.79 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.9 -47.55 68.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -1.098 . . . . 0.0 110.213 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 172.49 2.59 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.045 -1.034 . . . . 0.0 111.328 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.486 ' H ' ' HG1' ' A' ' 81' ' ' THR . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.665 -1.272 . . . . 0.0 108.439 179.638 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.451 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.9 mt-30 . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.451 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.9 m170 42.86 38.7 1.46 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.185 -0.947 . . . . 0.0 109.014 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.94 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 109.722 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.7 p -61.42 -37.52 83.8 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.065 -1.022 . . . . 0.0 109.325 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.5 t -68.5 -38.71 79.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.19 -0.944 . . . . 0.0 108.83 179.104 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 86.4 mt -60.27 -51.72 69.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.35 -0.844 . . . . 0.0 109.274 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -65.33 -47.16 77.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.38 -0.825 . . . . 0.0 109.591 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.7 -44.2 94.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.572 -0.705 . . . . 0.0 109.451 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.401 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.9 t80 -62.15 -48.24 80.98 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.53 -0.731 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 85.3 t -69.71 -44.5 79.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.461 -0.774 . . . . 0.0 109.696 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 84.2 t -66.86 -39.5 83.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.428 -0.795 . . . . 0.0 110.183 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -53.68 -28.92 36.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.184 -0.947 . . . . 0.0 109.957 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.24 -30.43 71.31 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.533 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.575 ' CD2' ' O ' ' A' ' 15' ' ' PHE . 33.5 p90 -146.73 44.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.558 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.078 -1.014 . . . . 0.0 109.978 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -49.66 -31.91 26.67 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 121.911 1.741 . . . . 0.0 112.042 179.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.6 -23.91 66.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.345 -0.847 . . . . 0.0 109.714 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.28 8.53 44.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.351 -0.843 . . . . 0.0 109.32 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -88.86 142.52 12.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.327 -0.858 . . . . 0.0 108.814 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.451 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -70.09 84.83 0.53 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.168 -0.958 . . . . 0.0 109.487 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.6 m -64.5 -0.26 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.258 -0.901 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.451 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -98.45 11.17 39.03 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.34 -0.85 . . . . 0.0 108.969 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -88.08 136.5 32.94 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.475 -0.766 . . . . 0.0 109.562 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -61.93 122.02 14.41 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.5 mt -56.21 -16.1 4.82 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.423 -0.798 . . . . 0.0 109.542 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.2 t -50.9 -43.05 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.064 -1.023 . . . . 0.0 109.125 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.24 -37.97 70.46 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.4 m-20 -91.18 22.33 3.85 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.72 -15.5 0.02 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.5 p -53.89 -33.81 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.013 -1.286 . . . . 0.0 108.891 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.591 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.9 tt -70.99 -19.04 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.51 -0.744 . . . . 0.0 109.673 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 82.1 m-20 -58.05 -31.32 66.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.434 -0.791 . . . . 0.0 111.451 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.7 m -116.39 -64.91 1.25 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.985 -1.072 . . . . 0.0 111.327 -178.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -64.0 -50.72 67.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 110.06 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.85 -40.1 64.37 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.591 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.8 tp -58.77 -40.88 85.24 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.469 -1.018 . . . . 0.0 109.671 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.91 -44.31 96.44 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.75 -40.22 88.2 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.273 -0.892 . . . . 0.0 109.981 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 79.9 t -65.1 -42.01 93.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.345 -0.847 . . . . 0.0 110.199 -179.377 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.402 ' N ' HD13 ' A' ' 45' ' ' ILE . 1.1 mp -60.79 -50.61 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.219 -0.926 . . . . 0.0 109.837 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.52 -30.83 71.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.188 -0.945 . . . . 0.0 109.365 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.7 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 55.4 t90 -73.13 -47.09 47.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.395 -0.815 . . . . 0.0 110.118 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.83 -45.29 94.44 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -67.13 -36.62 82.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.272 -0.892 . . . . 0.0 109.803 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -62.12 -44.08 97.42 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.703 -179.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.7 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 82.1 mtt180 -87.04 -51.43 6.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.05 -1.031 . . . . 0.0 111.52 -178.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -80.11 -24.58 40.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.005 -1.059 . . . . 0.0 111.223 -178.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.09 26.71 59.52 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.7 mt -104.87 143.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -1.121 . . . . 0.0 109.354 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.98 156.54 17.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.185 -0.947 . . . . 0.0 109.692 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.4 -0.813 . . . . 0.0 109.526 -179.488 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.226 0.536 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.1 -25.25 79.34 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.942 2.428 . . . . 0.0 112.237 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.43 -31.45 72.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -67.92 -26.21 65.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -0.842 . . . . 0.0 109.939 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -94.16 16.45 14.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.365 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 tpt180 -53.41 -39.16 64.1 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.334 -0.854 . . . . 0.0 110.018 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.0 p -150.85 165.9 32.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.923 -1.111 . . . . 0.0 110.271 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 95.0 mt -59.31 -36.51 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.378 -0.826 . . . . 0.0 110.078 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.6 mtm180 -60.49 -39.2 86.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 110.077 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.3 m -61.43 -42.89 99.45 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.994 -1.066 . . . . 0.0 109.428 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.415 HG22 HD13 ' A' ' 72' ' ' ILE . 78.4 mt -64.91 -38.41 82.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.249 -0.907 . . . . 0.0 109.32 179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.433 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 92.4 m-20 -56.06 -37.45 69.29 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.286 -0.884 . . . . 0.0 109.219 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.15 -43.73 98.19 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.26 -0.9 . . . . 0.0 109.061 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -63.91 -47.5 80.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.154 179.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.7 t -64.4 -40.44 89.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.389 -0.82 . . . . 0.0 109.288 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.433 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 55.4 t -58.32 -44.02 87.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.333 -0.854 . . . . 0.0 109.615 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -64.77 -41.49 97.57 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.52 -49.53 16.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.135 -1.215 . . . . 0.0 109.645 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 22.1 p -128.32 157.31 41.31 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.302 -1.472 0 O-C-N 121.058 -1.026 . . . . 0.0 110.261 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 50.49 36.09 12.7 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.142 -0.974 . . . . 0.0 109.027 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.56 -35.58 76.39 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.39 -0.819 . . . . 0.0 109.78 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 t -59.53 -40.57 87.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.722 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.42 ' O ' ' N ' ' A' ' 10' ' ' PHE . 55.1 t -64.39 -40.02 87.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 0.0 109.165 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.469 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 91.8 mt -59.66 -50.15 81.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.36 -0.837 . . . . 0.0 109.512 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.539 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.91 -45.19 90.43 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 108.904 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.4 -39.65 92.44 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.533 -0.729 . . . . 0.0 109.651 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 61.0 t80 -60.66 -52.04 66.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.446 -0.784 . . . . 0.0 110.029 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.474 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.8 p -74.08 -40.56 51.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.902 . . . . 0.0 109.844 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.539 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 94.2 t -66.69 -40.0 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.395 -0.816 . . . . 0.0 110.315 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -56.17 -27.63 55.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.228 -0.92 . . . . 0.0 109.574 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -65.04 -32.09 73.64 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.342 -0.849 . . . . 0.0 109.724 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -144.2 44.46 1.43 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.066 -1.021 . . . . 0.0 109.92 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.563 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.085 -1.009 . . . . 0.0 110.048 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -48.49 -32.12 19.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.969 1.78 . . . . 0.0 111.814 179.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.78 -25.97 67.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.419 -0.801 . . . . 0.0 109.447 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -97.69 4.75 49.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.361 -0.837 . . . . 0.0 109.386 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -103.55 137.41 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.551 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -63.78 95.9 0.12 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.404 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.3 m -59.57 0.48 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.168 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.551 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.6 m-20 -87.99 11.24 16.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.362 -0.836 . . . . 0.0 108.939 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 35.2 tp -82.59 134.12 35.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 109.395 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -67.07 121.85 16.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.342 -0.849 . . . . 0.0 108.871 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.445 ' O ' ' N ' ' A' ' 33' ' ' ASN . 82.6 mt -59.28 -14.1 10.14 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.303 -0.873 . . . . 0.0 109.198 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.412 ' O ' ' N ' ' A' ' 34' ' ' GLY . 42.1 t -50.44 -42.34 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 O-C-N 121.179 -0.951 . . . . 0.0 108.89 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.62 -35.32 65.74 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 178.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.608 ' O ' ' N ' ' A' ' 35' ' ' VAL . 8.5 m120 -86.27 21.55 2.03 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.0 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.162 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.608 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.0 t -53.05 -40.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.766 -1.432 . . . . 0.0 108.228 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.653 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.2 tt -71.15 -24.11 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.575 -0.703 . . . . 0.0 109.924 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -62.11 -27.54 69.0 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.957 -1.09 . . . . 0.0 110.975 -178.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.18 -65.73 1.05 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.801 -1.187 . . . . 0.0 111.055 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -73.73 -51.24 17.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.951 -1.093 . . . . 0.0 110.61 -178.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.75 -36.32 92.11 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.1 tt -57.95 -43.14 86.2 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.208 -1.172 . . . . 0.0 109.2 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.9 mt -60.96 -44.1 97.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.094 -1.004 . . . . 0.0 108.694 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -69.97 -35.45 74.46 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.423 -0.798 . . . . 0.0 109.84 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.1 t -64.78 -49.85 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.339 -0.851 . . . . 0.0 110.849 -178.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -60.41 -47.82 90.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 120.944 -1.097 . . . . 0.0 109.51 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.46 -32.95 74.64 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.179 -0.951 . . . . 0.0 109.232 179.7 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 39.4 t90 -71.67 -47.46 54.09 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.24 -0.912 . . . . 0.0 109.927 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 26.5 tp -59.81 -44.98 93.72 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.318 -0.864 . . . . 0.0 109.687 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.47 ' O ' ' N ' ' A' ' 53' ' ' GLY . 80.3 tt0 -68.62 -34.88 76.51 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 110.057 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.21 -38.49 80.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.008 -1.058 . . . . 0.0 110.028 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.536 ' NE ' ' CZ2' ' A' ' 47' ' ' TRP . 34.2 mtm105 -86.39 -48.52 8.38 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.149 -0.969 . . . . 0.0 111.497 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -90.9 -24.44 20.2 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.8 -1.187 . . . . 0.0 111.219 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 79.35 50.03 5.95 Favored Glycine 0 N--CA 1.496 2.689 0 C-N-CA 119.588 -1.292 . . . . 0.0 110.525 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.426 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 65.2 mt -108.04 140.94 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.199 -1.177 . . . . 0.0 109.21 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.53 141.11 57.95 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.937 -1.102 . . . . 0.0 109.334 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.574 -179.704 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.0 p . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -53.37 -34.31 70.39 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.346 2.031 . . . . 0.0 111.61 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -68.08 -14.32 62.89 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.525 -0.735 . . . . 0.0 109.148 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.426 ' HE2' ' HB2' ' A' ' 75' ' ' PHE . 21.7 t-80 -66.2 -26.32 67.34 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.432 -0.792 . . . . 0.0 110.062 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -92.45 9.05 35.98 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.006 -1.058 . . . . 0.0 109.597 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.4 tpt180 -54.7 -35.98 64.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.8 p -150.82 149.39 29.65 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.215 -0.928 . . . . 0.0 110.023 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.6 mt -66.56 -39.33 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.425 -0.797 . . . . 0.0 110.264 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.4 HH22 ' HA ' ' A' ' 27' ' ' ASP . 93.0 mtm-85 -61.35 -39.99 92.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -0.906 . . . . 0.0 110.373 -178.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 t -60.63 -45.91 92.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.985 -1.072 . . . . 0.0 109.425 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -63.91 -38.74 83.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.85 . . . . 0.0 109.709 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.469 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 55.9 t0 -57.54 -42.28 82.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 110.256 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.76 -46.09 76.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 110.502 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.426 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 58.4 m-85 -63.36 -45.1 92.71 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.099 -1.0 . . . . 0.0 109.496 -179.785 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.1 t -68.18 -47.6 77.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.219 -0.926 . . . . 0.0 110.159 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 45.4 t -68.28 -44.22 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.051 -1.031 . . . . 0.0 110.023 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.02 -27.0 68.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.27 -50.12 3.55 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.199 -1.177 . . . . 0.0 111.143 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.529 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.2 m -134.91 140.1 45.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.107 -0.995 . . . . 0.0 110.864 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.545 ' CE1' ' CG2' ' A' ' 6' ' ' VAL . 73.6 t60 -116.13 8.94 14.58 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.478 -0.764 . . . . 0.0 109.478 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.58 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -61.09 -35.61 77.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.212 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 m -58.8 -40.28 83.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.053 -1.03 . . . . 0.0 109.395 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.545 ' CG2' ' CE1' ' A' ' 3' ' ' HIS . 72.3 t -66.53 -36.56 77.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.007 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.428 ' O ' ' CG2' ' A' ' 11' ' ' VAL . 81.8 mt -63.59 -44.18 98.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.397 -0.814 . . . . 0.0 110.31 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.0 -50.63 67.78 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.175 -0.953 . . . . 0.0 110.521 -178.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.418 ' HG3' ' H ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.22 -44.3 68.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.122 -0.986 . . . . 0.0 109.673 -179.844 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.568 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 75.1 t80 -59.52 -45.89 90.44 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.993 -1.067 . . . . 0.0 109.282 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.428 ' CG2' ' O ' ' A' ' 7' ' ' ILE . 99.7 t -70.03 -46.52 72.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 74.9 t -66.51 -37.23 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.337 -0.852 . . . . 0.0 111.086 -179.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -60.93 -31.72 71.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.771 -179.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -66.16 -32.51 73.99 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.938 -1.102 . . . . 0.0 110.137 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -96.63 -61.11 1.47 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.104 -0.997 . . . . 0.0 110.6 -179.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 3.7 mp . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.29 -0.881 . . . . 0.0 110.663 -178.897 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.334 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -64.98 -26.75 58.43 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 C-N-CA 121.619 1.546 . . . . 0.0 111.854 -179.176 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.92 -13.88 60.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.421 -0.799 . . . . 0.0 109.326 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -85.58 8.03 20.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 109.853 -179.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -107.58 144.41 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.372 -0.83 . . . . 0.0 109.034 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.535 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.6 m-20 -69.05 86.18 0.36 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.006 -1.059 . . . . 0.0 109.177 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.9 0.06 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.34 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.535 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.03 6.04 47.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.321 -0.862 . . . . 0.0 108.77 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -93.58 136.82 33.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.599 -0.688 . . . . 0.0 109.364 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -61.16 121.53 12.75 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.5 pp -68.84 0.25 4.61 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.285 -0.885 . . . . 0.0 109.796 -179.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 34' ' ' GLY . 72.7 t -56.16 -35.17 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.21 -0.931 . . . . 0.0 108.946 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.44 ' C ' ' H ' ' A' ' 34' ' ' GLY . 92.3 m-20 -53.94 -34.83 60.78 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -83.53 21.89 1.14 Allowed 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.028 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -41.73 -13.99 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.93 -1.268 . . . . 0.0 109.93 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 3.4 p -51.94 -31.12 13.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.085 -1.244 . . . . 0.0 108.479 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.424 ' HA ' ' H ' ' A' ' 40' ' ' GLY . 32.6 pt -73.56 -7.14 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.522 -0.736 . . . . 0.0 109.965 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.44 ' CG ' ' O ' ' A' ' 34' ' ' GLY . 92.7 m-20 -48.88 -39.95 27.88 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.342 -0.849 . . . . 0.0 110.205 -178.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -122.56 -48.24 2.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 111.348 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.2 mp -74.71 -52.79 10.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.944 -1.097 . . . . 0.0 111.63 -178.077 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 36' ' ' ILE . . . -70.49 -43.21 62.12 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 120.079 -1.058 . . . . 0.0 110.77 -178.665 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.2 mt -63.42 -40.66 97.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.065 -1.256 . . . . 0.0 110.482 -179.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.63 -44.17 96.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.322 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttt -66.96 -41.58 86.64 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.244 -0.91 . . . . 0.0 109.465 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.1 t -66.95 -41.06 86.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.446 -0.784 . . . . 0.0 109.879 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.4 mp -58.94 -49.03 84.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.245 -0.91 . . . . 0.0 109.65 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.94 -32.29 72.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.604 ' CZ2' ' NH1' ' A' ' 51' ' ' ARG . 9.3 t90 -68.51 -44.81 73.84 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.37 -0.831 . . . . 0.0 109.508 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -62.53 -44.98 95.02 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 109.605 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 53' ' ' GLY . 81.6 tt0 -67.2 -34.51 77.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.909 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -58.75 -39.3 80.54 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.89 -1.131 . . . . 0.0 109.759 -179.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.604 ' NH1' ' CZ2' ' A' ' 47' ' ' TRP . 51.7 mtm180 -86.97 -53.86 4.66 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.135 -0.978 . . . . 0.0 110.931 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.42 -25.02 39.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 111.367 -178.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 76.46 39.2 31.11 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.334 -1.412 . . . . 0.0 109.627 -179.676 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -103.03 138.73 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.197 -1.178 . . . . 0.0 109.331 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.05 141.08 57.66 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.737 -1.227 . . . . 0.0 109.303 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.338 -179.55 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 -27.54 69.48 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.862 1.708 . . . . 0.0 112.324 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.88 -28.12 69.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.892 . . . . 0.0 109.711 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.553 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 11.6 t-160 -67.8 -26.74 66.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.296 -0.878 . . . . 0.0 110.02 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -102.27 13.65 34.06 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.955 . . . . 0.0 109.97 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 25.6 tpt180 -53.19 -36.88 61.42 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 108.959 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t -143.46 146.91 33.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -0.887 . . . . 0.0 109.479 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.78 -38.44 76.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.285 -0.885 . . . . 0.0 109.91 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 ptt85 -61.81 -40.23 94.51 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.8 p -61.69 -36.68 81.58 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.097 -1.002 . . . . 0.0 110.043 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.1 mt -65.12 -40.81 90.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 121.095 -1.003 . . . . 0.0 109.807 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 55.6 t0 -58.75 -38.05 77.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.713 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.85 -41.69 99.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.178 -0.951 . . . . 0.0 109.598 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.553 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 65.6 t80 -63.8 -47.44 80.88 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.283 -0.886 . . . . 0.0 109.366 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.5 t -64.15 -42.72 96.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.288 -0.882 . . . . 0.0 109.551 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 46.6 t -58.98 -41.07 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.288 -0.883 . . . . 0.0 109.532 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.18 -32.56 76.71 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.85 -50.45 3.53 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.026 -1.279 . . . . 0.0 110.746 -179.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 76' ' ' VAL . 16.6 p -129.14 156.65 43.57 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.333 -0.854 . . . . 0.0 109.519 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.39 0 O-C-N 121.184 -0.947 . . . . 0.0 109.499 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.48 ' H3 ' ' CB ' ' A' ' 4' ' ' ALA . 63.8 mtt . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -58.93 -36.18 74.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.166 -0.959 . . . . 0.0 109.388 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -153.2 29.48 0.5 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.337 -0.852 . . . . 0.0 109.04 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.48 ' CB ' ' H3 ' ' A' ' 1' ' ' MET . . . -61.09 -32.97 72.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.311 -0.868 . . . . 0.0 109.883 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -61.01 -35.72 77.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.058 -1.026 . . . . 0.0 109.58 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -67.29 -38.41 80.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.028 179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.2 mt -61.73 -50.45 80.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.1 -45.52 88.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.197 -0.939 . . . . 0.0 109.096 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.99 -44.32 89.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.477 -0.764 . . . . 0.0 109.266 179.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.671 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -65.15 -46.97 78.72 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.648 -0.658 . . . . 0.0 109.915 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 75.7 t -67.65 -47.31 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.378 -0.826 . . . . 0.0 110.124 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.3 t -65.84 -34.47 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.364 -0.835 . . . . 0.0 110.613 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.53 -36.61 55.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.117 -0.99 . . . . 0.0 110.013 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.15 -34.07 76.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 110.662 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -94.83 -64.24 1.09 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.927 -1.108 . . . . 0.0 110.784 -178.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.1 mp -123.64 83.04 53.86 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.31 -0.869 . . . . 0.0 110.155 -179.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -83.48 -21.73 4.19 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.973 2.449 . . . . 0.0 112.168 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -76.84 -4.09 41.86 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.239 -0.913 . . . . 0.0 109.19 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -113.32 140.76 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.84 117.74 31.76 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.971 -1.081 . . . . 0.0 108.61 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -65.28 -30.01 54.57 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.637 1.558 . . . . 0.0 111.869 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.98 61.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.182 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -87.96 6.35 36.22 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.341 -0.849 . . . . 0.0 109.387 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -100.64 137.53 27.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.394 -0.816 . . . . 0.0 108.824 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.52 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -62.69 88.07 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.185 -0.947 . . . . 0.0 109.434 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.1 m -62.15 0.08 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.397 -0.814 . . . . 0.0 109.281 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.52 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -90.88 6.82 42.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.295 -0.878 . . . . 0.0 108.949 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 tp -94.29 137.04 33.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.53 -0.731 . . . . 0.0 109.499 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -60.94 121.77 13.22 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -73.16 4.57 4.28 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.192 -0.943 . . . . 0.0 109.959 -179.021 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.4 p -51.17 -38.61 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.08 -1.012 . . . . 0.0 108.423 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.442 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.12 -35.43 69.44 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.7 m-20 -84.45 17.03 2.79 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -43.22 -14.04 0.02 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.05 -35.94 15.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.261 -1.141 . . . . 0.0 108.971 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.573 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.5 tt -70.01 -23.31 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.356 -0.84 . . . . 0.0 109.889 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.595 ' OD2' ' CD1' ' A' ' 66' ' ' PHE . 77.0 m-20 -56.33 -34.17 66.32 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.384 -0.823 . . . . 0.0 110.622 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.552 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.6 OUTLIER -112.57 -64.45 1.3 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 111.092 -178.522 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 50.9 tp -64.25 -51.96 61.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.71 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.38 -36.5 69.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.1 tt -58.37 -41.82 85.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.224 -1.163 . . . . 0.0 109.685 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.8 mt -67.08 -44.14 80.81 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.137 -0.977 . . . . 0.0 109.391 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.5 mttm -67.09 -41.65 85.96 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.26 -0.9 . . . . 0.0 109.843 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.524 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 88.6 t -66.68 -43.2 90.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.307 -0.871 . . . . 0.0 109.956 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -59.73 -50.53 79.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.263 -0.898 . . . . 0.0 109.569 -179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.6 -38.46 87.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.182 -0.949 . . . . 0.0 109.413 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.671 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -68.48 -41.43 80.11 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.302 -0.874 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 13.8 tp -56.97 -47.42 80.81 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.403 -0.811 . . . . 0.0 109.644 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.514 ' OE2' ' O ' ' A' ' 54' ' ' ILE . 28.0 tp10 -69.26 -35.71 76.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.182 -0.949 . . . . 0.0 109.287 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -63.98 -46.07 86.21 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.077 -1.014 . . . . 0.0 110.552 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 22.4 ttm180 -88.15 -58.22 2.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 111.926 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -79.38 -24.4 42.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.0 -1.062 . . . . 0.0 111.751 -177.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.26 32.82 41.96 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.187 -1.483 . . . . 0.0 109.417 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.514 ' O ' ' OE2' ' A' ' 49' ' ' GLU . 68.8 mt -104.44 143.94 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.274 -1.133 . . . . 0.0 109.189 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.53 146.92 43.25 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.155 -0.966 . . . . 0.0 109.478 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.82 -33.69 68.87 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.39 -0.819 . . . . 0.0 109.604 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 54.11 44.22 29.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.326 -0.859 . . . . 0.0 109.532 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.444 ' OD1' ' C ' ' A' ' 58' ' ' ASP . 53.2 p30 -95.09 12.21 29.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.641 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.63 -43.04 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.119 -0.988 . . . . 0.0 109.736 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -115.95 135.05 54.34 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.508 -0.745 . . . . 0.0 109.53 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 20.7 mt -108.25 140.09 42.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.379 -0.825 . . . . 0.0 109.301 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -130.72 84.18 59.47 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.355 -0.84 . . . . 0.0 109.7 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -54.13 -28.47 51.36 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.549 2.166 . . . . 0.0 111.953 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -68.39 -15.9 63.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.413 -0.805 . . . . 0.0 109.482 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 7.4 t-160 -66.7 -25.39 66.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.536 -0.727 . . . . 0.0 110.143 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.595 ' CD1' ' OD2' ' A' ' 37' ' ' ASP . 62.3 m-85 -87.68 2.91 49.78 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.019 -1.051 . . . . 0.0 109.99 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -57.25 -39.82 76.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.944 -1.097 . . . . 0.0 110.293 -179.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.508 ' HG ' ' H ' ' A' ' 71' ' ' SER . 86.0 p -143.31 153.21 42.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.834 -1.166 . . . . 0.0 110.264 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -65.96 -36.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.456 -0.778 . . . . 0.0 109.67 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.2 mtm180 -60.94 -37.18 81.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.789 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.508 ' H ' ' HG ' ' A' ' 68' ' ' SER . 19.6 m -59.36 -41.98 90.51 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.068 -1.02 . . . . 0.0 109.083 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.62 -38.18 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.321 -0.862 . . . . 0.0 109.431 179.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -57.06 -39.61 75.24 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.342 -0.849 . . . . 0.0 109.704 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.91 -39.11 90.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.247 -0.908 . . . . 0.0 109.904 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.25 -47.51 85.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.743 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.3 t -65.37 -41.06 90.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.149 -0.969 . . . . 0.0 109.777 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.7 t -61.51 -44.6 98.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.204 -0.935 . . . . 0.0 109.936 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -65.14 -40.54 96.93 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.81 -49.67 12.59 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.147 -1.207 . . . . 0.0 109.766 -179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.471 ' O ' ' O ' ' A' ' 76' ' ' VAL . 19.3 p -130.46 156.89 44.02 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -140.09 87.55 12.3 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.171 -0.955 . . . . 0.0 109.78 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.444 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.1 Cg_exo -66.03 -175.91 0.56 Allowed 'Trans proline' 0 N--CA 1.493 1.496 0 C-N-CA 122.83 2.353 . . . . 0.0 111.865 179.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 24.2 Cg_exo -60.37 150.94 77.84 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.483 2.122 . . . . 0.0 111.52 179.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 13.0 p -92.12 127.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.133 -0.979 . . . . 0.0 109.833 -179.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -134.31 158.53 43.54 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.429 -0.794 . . . . 0.0 109.079 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.62 123.26 25.22 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 109.247 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -59.89 -37.14 78.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.508 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.6 tp -98.77 130.58 45.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.477 -179.99 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.552 ' O2P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.597 ' H2 ' ' CB ' ' A' ' 4' ' ' ALA . 84.4 mtp . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.17 -38.21 82.52 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.91 . . . . 0.0 109.631 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.585 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 40.1 m80 -139.52 6.47 2.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.271 -0.893 . . . . 0.0 109.762 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.597 ' CB ' ' H2 ' ' A' ' 1' ' ' MET . . . -59.26 -33.87 71.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.075 -1.016 . . . . 0.0 109.761 -179.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.689 ' HG ' ' HZ1' ' A' ' 87' ' ' LYS . 22.2 t -59.22 -45.01 92.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.067 -1.021 . . . . 0.0 109.59 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.9 -36.59 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.268 -0.895 . . . . 0.0 108.656 179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 91.8 mt -66.75 -42.16 89.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.433 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.24 -50.39 70.38 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.047 -1.033 . . . . 0.0 110.241 -179.021 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.642 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.31 -42.97 71.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.291 179.749 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.642 ' N ' HE21 ' A' ' 9' ' ' GLN . 67.9 t80 -62.56 -48.72 78.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.366 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 64.4 t -65.49 -45.07 93.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 0.0 109.333 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.441 ' O ' ' N ' ' A' ' 16' ' ' LEU . 69.4 t -65.85 -37.12 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.439 -0.788 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -52.86 -30.78 35.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.38 -0.825 . . . . 0.0 109.811 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.54 -31.26 72.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.66 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.551 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 34.4 p90 -143.93 44.24 1.46 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.185 -0.947 . . . . 0.0 109.601 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.559 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.68 130.47 64.21 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.155 -0.966 . . . . 0.0 110.305 -179.822 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.419 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.3 Cg_endo -77.79 -151.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 122.111 1.874 . . . . 0.0 110.542 178.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -79.44 17.27 0.87 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.898 -1.126 . . . . 0.0 108.965 179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.419 ' H ' ' C ' ' A' ' 17' ' ' PRO . 40.2 t -113.2 135.77 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.402 -0.811 . . . . 0.0 109.81 -179.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.4 141.71 80.6 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.164 -0.96 . . . . 0.0 109.243 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -49.38 -29.66 18.42 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 121.881 1.721 . . . . 0.0 111.813 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.6 -25.99 68.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.315 -0.866 . . . . 0.0 109.528 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -95.38 6.42 49.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.319 -0.863 . . . . 0.0 109.209 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.3 t -104.07 136.37 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.573 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.4 m-20 -69.7 88.89 0.54 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.202 -0.936 . . . . 0.0 109.529 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.2 m -59.91 0.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.196 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.573 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.91 9.97 33.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 108.884 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -90.34 137.37 32.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.533 -0.729 . . . . 0.0 109.507 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.495 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.89 121.82 14.43 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.12 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.62 10.86 0.31 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.144 -0.972 . . . . 0.0 109.932 -178.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.495 ' H ' ' C ' ' A' ' 29' ' ' ASP . 75.7 t -54.68 -44.22 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.002 -1.061 . . . . 0.0 108.627 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.72 -36.64 67.44 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 179.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.5 m-20 -86.21 18.24 3.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 178.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.92 -14.99 0.02 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.9 t -52.05 -37.13 21.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.117 -1.225 . . . . 0.0 108.677 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.4 tt -70.59 -22.5 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.533 -0.73 . . . . 0.0 110.323 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.407 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 88.1 m-20 -54.14 -32.62 55.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.313 -0.867 . . . . 0.0 111.284 -178.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.534 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.4 OUTLIER -117.34 -64.23 1.33 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.912 -1.117 . . . . 0.0 111.165 -178.782 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.3 -52.5 63.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.9 -1.125 . . . . 0.0 110.343 -178.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.53 -37.1 62.34 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 36' ' ' ILE . 16.2 tp -58.51 -43.53 89.16 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.38 -1.07 . . . . 0.0 109.931 -178.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.9 mt -65.6 -43.56 89.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.556 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -63.08 -34.43 77.57 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.259 -0.9 . . . . 0.0 109.366 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.549 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 68.4 t -60.52 -41.43 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.914 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.428 HG23 HD13 ' A' ' 45' ' ' ILE . 35.8 mm -58.94 -50.16 80.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.983 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.24 -35.6 79.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.801 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.513 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 44.2 t90 -66.49 -41.74 88.48 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.269 -0.894 . . . . 0.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -61.24 -43.35 99.01 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 109.918 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 -67.51 -37.16 82.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.98 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -60.3 -44.79 95.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.049 -1.032 . . . . 0.0 110.555 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -87.49 -53.02 5.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.136 -0.977 . . . . 0.0 111.585 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -80.16 -24.75 40.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.041 -1.037 . . . . 0.0 111.59 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.67 31.05 51.29 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.6 mt -103.41 147.51 9.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.393 -1.063 . . . . 0.0 109.556 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.04 157.6 15.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.188 -0.945 . . . . 0.0 109.309 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -52.95 -39.16 62.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.24 -0.912 . . . . 0.0 109.773 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 51.89 50.69 18.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.114 -0.991 . . . . 0.0 109.092 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -71.19 116.98 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.929 -179.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 29.5 m -130.24 162.17 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -89.28 122.62 32.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.998 -1.064 . . . . 0.0 110.085 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.414 ' H ' ' H17' ' A' ' 101' ' ' 7V9 . 30.8 mt -115.97 144.81 43.57 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.25 153.13 95.43 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.166 -0.959 . . . . 0.0 109.276 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.79 -27.05 84.04 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.618 2.212 . . . . 0.0 111.886 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.56 -24.49 67.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.403 -0.81 . . . . 0.0 109.945 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.5 ' O ' ' OG ' ' A' ' 71' ' ' SER . 51.3 t-80 -67.13 -26.61 66.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.155 -0.965 . . . . 0.0 110.234 -179.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -97.71 6.68 47.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.074 -1.016 . . . . 0.0 109.001 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 -56.49 -37.8 70.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.452 -0.78 . . . . 0.0 109.977 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.8 p -137.03 153.25 50.68 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.096 -1.003 . . . . 0.0 110.121 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.6 mt -64.59 -36.45 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.478 -0.763 . . . . 0.0 110.251 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -60.87 -37.02 80.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.133 -0.979 . . . . 0.0 110.217 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 92.6 p -61.59 -36.15 79.87 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.014 -1.054 . . . . 0.0 109.66 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -64.93 -40.63 89.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.232 -0.918 . . . . 0.0 109.453 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.472 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 53.9 t0 -59.12 -36.93 76.04 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.305 -0.872 . . . . 0.0 109.634 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.88 -40.71 94.04 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.326 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.413 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 66.6 t80 -64.16 -48.7 75.0 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.305 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.5 t -64.89 -43.45 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.317 -0.864 . . . . 0.0 109.671 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.7 t -59.87 -41.06 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.225 -0.922 . . . . 0.0 109.627 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.33 -31.83 70.82 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.1 -50.63 3.32 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.021 -1.282 . . . . 0.0 110.844 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 21.8 p -131.28 159.43 37.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.225 -0.922 . . . . 0.0 109.854 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.96 88.17 15.96 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.189 -0.944 . . . . 0.0 109.449 179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.585 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 10.7 Cg_exo -66.38 -178.01 1.04 Allowed 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.551 2.167 . . . . 0.0 112.146 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.417 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.0 Cg_exo -61.34 150.26 85.72 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.423 2.082 . . . . 0.0 111.779 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.5 t -109.32 129.69 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.562 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -137.71 155.45 49.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.382 -0.824 . . . . 0.0 109.459 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -102.59 140.21 37.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.34 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.689 ' HZ1' ' HG ' ' A' ' 5' ' ' SER . 30.4 mttm -59.23 -34.77 72.59 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.152 -0.967 . . . . 0.0 109.539 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.8 tp -99.62 130.31 45.84 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.337 -0.852 . . . . 0.0 109.462 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.442 -179.923 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.549 ' C18' ' CG1' ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 83.3 mmm . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.8 mt-30 -108.5 138.05 45.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.328 -0.857 . . . . 0.0 109.153 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.4 m80 47.46 38.44 7.71 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.118 -0.988 . . . . 0.0 109.298 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.12 -34.26 73.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.288 -0.883 . . . . 0.0 109.629 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -59.14 -36.64 75.59 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 109.618 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.402 HG11 ' H ' ' A' ' 84' ' ' VAL . 57.8 t -62.88 -40.96 90.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.287 -0.883 . . . . 0.0 109.516 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.498 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 85.5 mt -59.69 -43.95 92.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.356 -0.84 . . . . 0.0 109.839 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.4 77.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.429 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.42 ' C ' ' CD ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.08 -33.66 73.89 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.414 -0.804 . . . . 0.0 109.624 179.826 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.413 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 63.1 t80 -62.64 -52.08 64.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.001 . . . . 0.0 109.977 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.5 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 6.3 p -74.91 -44.32 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.357 -0.839 . . . . 0.0 110.855 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.5 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 76.9 t -65.32 -40.09 87.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.183 -0.948 . . . . 0.0 111.031 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -58.22 -28.69 65.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.045 -1.034 . . . . 0.0 109.791 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.8 -38.69 89.64 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.276 -0.89 . . . . 0.0 110.425 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -96.68 -45.11 6.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.04 -1.038 . . . . 0.0 110.489 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.5 mt -126.93 82.46 67.85 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.284 -0.885 . . . . 0.0 110.273 -179.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -83.01 -24.81 3.07 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.104 2.536 . . . . 0.0 112.149 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -81.01 -3.73 52.73 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.195 -0.94 . . . . 0.0 109.622 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.48 141.07 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.87 117.92 33.58 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.026 -1.046 . . . . 0.0 108.669 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -64.69 -30.36 59.79 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 C-N-CA 121.585 1.524 . . . . 0.0 111.966 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.86 -19.05 63.46 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.064 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -89.18 1.74 55.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.361 -0.837 . . . . 0.0 108.99 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.1 t -102.28 139.0 24.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.2 t0 -67.97 94.14 0.46 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 109.438 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -59.99 0.56 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.429 -0.794 . . . . 0.0 109.229 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.1 m-20 -88.16 9.8 21.55 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.019 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.4 tp -86.33 134.17 33.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.541 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -62.94 122.07 15.1 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.48 ' O ' ' N ' ' A' ' 33' ' ' ASN . 74.1 mt -59.72 -12.14 6.48 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.3 p -49.97 -37.28 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 119.32 -0.952 . . . . 0.0 108.647 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.13 -36.01 70.18 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.3 m-20 -86.13 21.07 2.1 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.3 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.48 -40.32 24.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 120.979 -1.307 . . . . 0.0 108.54 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.637 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.2 tt -71.77 -24.41 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.509 -0.744 . . . . 0.0 110.418 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 91.9 m-20 -59.25 -28.13 66.42 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.931 -1.105 . . . . 0.0 110.962 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.562 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 1.3 m -113.3 -64.32 1.32 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.026 -1.046 . . . . 0.0 111.167 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.2 mp -68.88 -51.31 41.58 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.904 -1.123 . . . . 0.0 110.472 -178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.02 -35.89 72.12 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.637 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.0 tt -57.99 -45.24 87.11 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.421 -1.046 . . . . 0.0 110.145 -179.083 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.8 mt -61.83 -44.18 97.37 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.001 -1.062 . . . . 0.0 109.191 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -71.64 -35.54 70.44 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.351 -0.843 . . . . 0.0 110.303 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 66.0 t -64.56 -49.41 80.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.284 -0.885 . . . . 0.0 111.277 -178.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.2 mm -58.78 -49.46 82.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 120.566 -1.334 . . . . 0.0 109.644 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.34 -35.6 79.73 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.012 -1.055 . . . . 0.0 109.68 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.511 ' CZ3' ' NZ ' ' A' ' 87' ' ' LYS . 19.2 t90 -76.84 -51.07 11.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.272 -0.892 . . . . 0.0 111.398 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.476 ' CD2' ' CE3' ' A' ' 47' ' ' TRP . 3.8 mm? -65.72 -39.32 91.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.062 -1.024 . . . . 0.0 110.616 -179.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 17.8 pt-20 -65.73 -35.01 79.53 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.979 -1.076 . . . . 0.0 109.596 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -65.45 -43.52 90.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.173 -0.954 . . . . 0.0 110.051 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -67.68 -43.13 80.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.252 -0.905 . . . . 0.0 111.165 -179.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -98.34 -12.73 21.19 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.9 -1.125 . . . . 0.0 110.47 -178.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.05 42.16 96.82 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.5 mt -104.79 129.21 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 109.531 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.95 144.39 57.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 109.451 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.2 -33.76 75.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.271 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -58.08 -34.09 69.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.408 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.48 -33.33 44.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.241 -0.912 . . . . 0.0 109.745 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.06 151.57 24.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.417 -0.802 . . . . 0.0 109.652 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -111.9 148.8 32.92 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.451 -0.781 . . . . 0.0 109.524 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.8 mt -84.22 140.52 31.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.48 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.0 OUTLIER -155.98 109.25 2.12 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.301 -0.874 . . . . 0.0 109.174 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -49.95 -36.12 42.92 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 121.814 1.676 . . . . 0.0 112.107 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.92 -27.73 66.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.257 -0.902 . . . . 0.0 109.677 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.556 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 36.6 t-80 -68.22 -27.13 66.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 110.211 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.653 ' CE2' ' C8 ' ' A' ' 101' ' ' 7V9 . 88.7 m-85 -100.72 9.14 42.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.485 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 35.9 tpt85 -55.52 -36.21 66.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.479 -0.763 . . . . 0.0 109.369 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.1 p -143.56 158.34 43.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.18 -0.95 . . . . 0.0 110.017 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.7 mt -64.15 -36.54 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.387 -0.821 . . . . 0.0 110.35 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.6 mtm180 -60.72 -38.82 86.4 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.098 -1.001 . . . . 0.0 110.068 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.0 t -61.45 -44.09 97.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.042 -1.036 . . . . 0.0 109.539 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 84.3 mt -67.72 -40.08 83.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.288 -0.882 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 59.8 t0 -58.99 -41.59 88.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.867 . . . . 0.0 110.391 -179.256 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.39 -43.78 84.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.034 -1.041 . . . . 0.0 110.248 -179.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.556 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 66.4 t80 -62.67 -47.27 84.39 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.748 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.92 -44.36 96.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.1 t -61.06 -39.74 83.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.11 -0.994 . . . . 0.0 109.459 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.85 -33.17 67.46 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.02 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.054 -1.263 . . . . 0.0 110.489 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 8.3 t -158.41 152.69 24.19 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.064 -1.023 . . . . 0.0 110.204 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -130.09 88.66 47.69 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 108.937 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -93.91 107.05 0.15 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.345 2.697 . . . . 0.0 113.132 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -80.65 138.85 12.23 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 C-N-CA 122.307 2.004 . . . . 0.0 111.996 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.402 ' H ' HG11 ' A' ' 6' ' ' VAL . 10.9 p -134.13 140.97 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.155 -0.966 . . . . 0.0 109.422 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.54 -35.2 79.69 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.588 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -149.23 155.92 41.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.511 ' NZ ' ' CZ3' ' A' ' 47' ' ' TRP . 19.8 tttm -57.75 -36.98 72.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.482 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.1 mt -92.17 142.06 27.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.441 -179.962 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.653 ' C8 ' ' CE2' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.483 ' SD ' ' N ' ' A' ' 5' ' ' SER . 11.9 ptp . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.348 0.594 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 -60.16 -42.76 95.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.385 -0.822 . . . . 0.0 110.247 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 90.6 m-70 -149.0 3.45 0.61 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.965 -1.085 . . . . 0.0 110.603 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.586 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -63.34 -32.4 73.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.778 -1.201 . . . . 0.0 109.866 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.508 ' OG ' ' CG2' ' A' ' 84' ' ' VAL . 83.7 p -59.04 -35.3 73.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.069 -1.02 . . . . 0.0 109.372 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.34 -37.74 80.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.264 -0.898 . . . . 0.0 109.2 179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 30.8 mm -62.16 -47.12 94.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.419 -0.8 . . . . 0.0 110.176 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.81 -49.74 71.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.206 -0.933 . . . . 0.0 110.445 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.466 ' NE2' ' CA ' ' A' ' 10' ' ' PHE . 4.2 pp0? -69.71 -42.75 73.62 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.154 -0.967 . . . . 0.0 109.858 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CA ' ' NE2' ' A' ' 9' ' ' GLN . 69.9 t80 -61.63 -46.66 88.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.147 -0.971 . . . . 0.0 109.512 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 91.4 t -67.5 -47.61 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.375 -0.828 . . . . 0.0 109.966 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 78.7 t -66.44 -34.74 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.416 -0.802 . . . . 0.0 110.423 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.77 -36.46 58.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -0.93 . . . . 0.0 109.897 -179.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.76 -35.12 78.14 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.273 -0.892 . . . . 0.0 110.708 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -92.91 -63.47 1.22 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.919 -1.113 . . . . 0.0 110.767 -178.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.7 mp -125.19 83.05 61.3 Favored Pre-proline 0 N--CA 1.495 1.794 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -82.6 -21.39 5.15 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.845 2.363 . . . . 0.0 112.11 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.91 -3.8 40.55 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.238 -0.914 . . . . 0.0 109.127 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.8 t -113.26 142.05 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.68 118.96 43.09 Favored Pre-proline 0 C--N 1.304 -1.4 0 O-C-N 120.909 -1.119 . . . . 0.0 108.785 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -64.62 -23.91 63.28 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 121.628 1.552 . . . . 0.0 111.828 -179.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.49 -14.89 62.27 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.446 -0.784 . . . . 0.0 109.272 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -82.9 3.24 30.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.383 -0.823 . . . . 0.0 109.158 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.54 136.97 30.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.487 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.12 88.13 0.07 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.136 -0.977 . . . . 0.0 109.271 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -63.61 0.04 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.273 -0.892 . . . . 0.0 109.309 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.487 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -93.44 4.65 53.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 108.969 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.8 tt -98.36 137.65 36.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.461 -0.775 . . . . 0.0 109.541 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.496 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.4 m-20 -60.56 121.57 12.48 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.231 -0.918 . . . . 0.0 108.625 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.426 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.6 OUTLIER -64.94 6.08 0.27 Allowed 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.255 -0.903 . . . . 0.0 110.047 -178.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.496 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.0 p -51.55 -38.23 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.053 -1.029 . . . . 0.0 108.634 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.83 -35.68 71.21 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.641 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.4 m-20 -86.18 20.14 2.44 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.84 -14.69 0.02 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.641 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.52 -35.62 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.264 -1.139 . . . . 0.0 108.802 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.561 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -69.99 -22.16 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.567 -0.708 . . . . 0.0 110.067 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -55.02 -32.51 61.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.302 -0.874 . . . . 0.0 110.845 -178.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.7 m -118.0 -63.79 1.38 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.22 -0.925 . . . . 0.0 111.168 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.5 tp -62.01 -52.55 63.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.961 -1.087 . . . . 0.0 110.276 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.8 -38.17 66.1 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.561 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -59.57 -40.66 88.11 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.419 -1.048 . . . . 0.0 109.15 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.99 -44.12 97.4 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.217 -0.927 . . . . 0.0 108.947 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.4 mttm -65.73 -37.42 86.33 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.316 -0.865 . . . . 0.0 109.483 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.441 ' CG1' ' C19' ' A' ' 101' ' ' 7V9 . 72.5 t -62.84 -39.97 87.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.399 -0.813 . . . . 0.0 109.875 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -59.87 -51.41 73.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.11 -0.994 . . . . 0.0 109.664 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.59 -39.28 84.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -0.908 . . . . 0.0 109.627 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.676 ' HE1' ' CZ ' ' A' ' 51' ' ' ARG . 76.2 t90 -68.89 -43.04 76.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.41 -0.806 . . . . 0.0 109.962 -179.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.0 tp -63.15 -46.83 85.38 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.353 -0.842 . . . . 0.0 109.962 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -68.23 -36.0 78.81 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.88 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.56 -45.48 93.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.066 -1.022 . . . . 0.0 110.68 -179.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.676 ' CZ ' ' HE1' ' A' ' 47' ' ' TRP . 85.0 mtt180 -87.2 -50.25 6.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.078 -1.013 . . . . 0.0 111.45 -178.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -80.1 -24.78 40.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.0 -1.062 . . . . 0.0 111.271 -178.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.21 30.07 57.59 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -105.95 144.13 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.288 -1.125 . . . . 0.0 109.478 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.89 152.1 28.35 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.2 -0.938 . . . . 0.0 109.479 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.31 -33.15 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.417 -0.802 . . . . 0.0 109.704 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 54.28 46.19 25.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.192 -0.943 . . . . 0.0 109.402 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.53 11.34 24.45 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.328 -0.858 . . . . 0.0 109.76 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 78.2 t -56.9 -41.5 76.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.541 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -116.07 138.34 51.32 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.505 -0.747 . . . . 0.0 109.197 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -106.54 138.02 43.48 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.369 -0.832 . . . . 0.0 109.255 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p -132.83 73.92 75.14 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.874 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.48 -29.96 90.2 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.704 2.269 . . . . 0.0 111.931 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.54 -26.77 68.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.393 -0.817 . . . . 0.0 109.614 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 12.5 t-80 -67.81 -25.89 65.8 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 110.691 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -88.69 7.52 33.22 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.031 -1.043 . . . . 0.0 110.606 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.3 mmt85 -59.73 -36.93 77.57 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.985 -1.072 . . . . 0.0 110.547 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.484 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 93.5 p -132.94 150.53 52.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.995 -1.066 . . . . 0.0 110.345 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 88.9 mt -65.9 -37.67 80.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 O-C-N 121.49 -0.756 . . . . 0.0 109.854 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 93.8 mtm-85 -61.2 -38.29 86.03 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.091 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.484 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 22.2 m -60.07 -40.7 90.44 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.137 -0.977 . . . . 0.0 109.404 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -65.66 -42.33 92.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.267 -0.895 . . . . 0.0 109.836 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.586 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 53.2 t0 -60.05 -38.74 83.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.335 -0.853 . . . . 0.0 110.062 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.12 -40.64 98.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.182 -0.949 . . . . 0.0 109.747 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -62.7 -46.94 85.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -64.44 -44.02 97.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.24 -0.913 . . . . 0.0 109.757 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 58.2 t -60.54 -40.66 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.34 -0.85 . . . . 0.0 109.625 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.46 -31.97 71.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.73 -50.44 3.41 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.113 -1.228 . . . . 0.0 110.807 -179.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.0 p -131.43 157.62 42.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 109.805 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.24 88.43 17.31 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.213 -0.93 . . . . 0.0 109.255 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 72.9 Cg_endo -82.94 160.28 15.89 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.758 2.305 . . . . 0.0 112.561 -179.721 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.94 150.88 84.49 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.91 2.407 . . . . 0.0 111.962 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.508 ' CG2' ' OG ' ' A' ' 5' ' ' SER . 14.5 p -126.77 139.17 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.39 -0.819 . . . . 0.0 109.71 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -116.79 141.86 47.67 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.92 137.47 58.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.114 -0.991 . . . . 0.0 109.298 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 26.9 mttp -59.99 -34.74 73.72 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.338 -0.851 . . . . 0.0 109.482 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.1 tp -57.16 -37.6 72.34 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.457 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.482 179.952 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.472 ' N16' ' CG2' ' A' ' 76' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.9 mmm . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -60.12 -35.89 76.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.35 -0.844 . . . . 0.0 109.703 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.486 ' CD2' ' CG2' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -155.18 28.44 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.129 -0.982 . . . . 0.0 109.541 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.63 -33.39 73.85 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.57 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 84.8 p -61.59 -36.56 81.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.197 -0.939 . . . . 0.0 109.497 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.486 ' CG2' ' CD2' ' A' ' 3' ' ' HIS . 69.8 t -67.83 -37.85 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.209 -0.932 . . . . 0.0 109.0 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 84.4 mt -60.47 -50.92 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.268 -0.895 . . . . 0.0 109.219 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.68 -47.53 78.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.303 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -44.4 96.02 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.486 -0.759 . . . . 0.0 109.19 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.57 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.7 t80 -65.05 -46.48 81.04 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.538 0.685 . . . . 0.0 109.607 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.7 t -69.73 -47.42 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.529 -0.732 . . . . 0.0 110.293 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.8 t -64.57 -34.81 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.397 -0.814 . . . . 0.0 110.729 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.68 -36.11 56.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.072 -1.018 . . . . 0.0 109.982 -179.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.71 -35.06 78.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 110.676 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -92.82 -63.79 1.18 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.932 -1.105 . . . . 0.0 110.682 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.4 mt -124.86 83.03 60.04 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.334 -0.854 . . . . 0.0 110.196 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -82.83 -21.29 4.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.928 2.419 . . . . 0.0 112.21 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.94 -4.2 42.7 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.152 -0.968 . . . . 0.0 109.263 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.7 t -113.32 141.64 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.9 117.82 32.7 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 120.933 -1.104 . . . . 0.0 108.574 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.88 -25.63 59.92 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 C-N-CA 121.586 1.524 . . . . 0.0 111.877 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.47 -14.95 62.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -0.862 . . . . 0.0 109.136 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -84.05 2.99 36.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.313 -0.867 . . . . 0.0 109.024 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.66 136.64 32.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.453 ' C ' ' H ' ' A' ' 27' ' ' ASP . 87.4 m-20 -68.05 87.96 0.27 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.148 -0.97 . . . . 0.0 109.478 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -64.06 -0.15 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.34 -0.85 . . . . 0.0 109.594 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.473 ' C ' ' OD2' ' A' ' 27' ' ' ASP . 49.3 p30 -88.83 7.57 33.49 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.203 -0.936 . . . . 0.0 108.954 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -97.15 141.75 29.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.618 -0.676 . . . . 0.0 109.486 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.422 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.0 m-20 -60.52 121.76 12.96 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.4 pp -68.77 4.92 1.24 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.166 -0.959 . . . . 0.0 109.975 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.445 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.87 -38.34 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.034 -1.041 . . . . 0.0 108.53 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -58.44 -35.7 72.52 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 66.9 m-80 -84.55 16.33 3.24 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.042 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.03 -14.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.7 t -51.3 -36.61 17.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.119 -1.224 . . . . 0.0 108.891 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.3 tt -70.56 -21.84 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 110.091 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -55.22 -31.88 61.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 111.083 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.15 -64.59 1.29 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.066 -1.021 . . . . 0.0 111.518 -178.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.2 tp -65.12 -52.08 57.45 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.814 -1.179 . . . . 0.0 110.581 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -68.9 -35.69 79.92 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.0 tp -58.14 -41.59 84.04 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -1.138 . . . . 0.0 109.282 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 87.6 mt -62.61 -44.07 97.23 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.138 -0.976 . . . . 0.0 108.823 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.2 mttp -63.56 -36.71 84.7 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.503 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 61.8 t -64.12 -38.31 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.774 -0.579 . . . . 0.0 109.749 179.58 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -56.91 -51.03 73.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 109.958 -179.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.42 -39.15 85.48 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.055 -1.028 . . . . 0.0 109.7 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.57 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 52.4 t90 -67.51 -44.39 78.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.301 -0.874 . . . . 0.0 111.08 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.13 -49.1 77.21 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.133 -0.979 . . . . 0.0 109.978 -178.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -68.83 -39.22 80.1 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.957 -1.089 . . . . 0.0 109.391 179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -64.65 -42.62 95.29 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.119 -0.988 . . . . 0.0 111.135 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.692 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 54.7 ttt-85 -72.2 -48.23 44.66 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.216 -0.927 . . . . 0.0 112.036 -177.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.692 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 90.9 m-85 -104.23 -6.21 21.15 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 111.733 -178.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.56 30.79 66.09 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 59.9 mt -106.04 142.27 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.255 -1.144 . . . . 0.0 109.34 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.18 122.66 15.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.955 -1.091 . . . . 0.0 108.958 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.87 -32.74 73.46 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.46 -0.775 . . . . 0.0 110.142 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -92.26 8.65 37.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.35 -0.844 . . . . 0.0 110.284 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -54.08 -40.34 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.996 -1.065 . . . . 0.0 109.308 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.7 p -138.89 143.88 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.352 -0.843 . . . . 0.0 109.363 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -100.91 138.11 38.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.104 -0.998 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.8 mt -104.67 143.48 33.02 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.409 -0.807 . . . . 0.0 109.713 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -83.96 159.22 60.56 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.217 -0.927 . . . . 0.0 109.251 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -57.7 -31.93 93.31 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.675 2.25 . . . . 0.0 111.962 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.88 -24.8 66.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 179.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.9 t60 -67.28 -26.4 66.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.287 -0.883 . . . . 0.0 109.955 -179.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -95.05 6.23 49.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.107 -0.995 . . . . 0.0 109.426 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -56.33 -39.6 73.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.917 . . . . 0.0 109.7 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.402 ' HG ' ' H ' ' A' ' 71' ' ' SER . 96.8 p -135.25 153.5 51.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.094 -1.004 . . . . 0.0 109.924 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.6 mt -63.88 -36.31 76.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 O-C-N 121.4 -0.813 . . . . 0.0 109.818 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.5 mtm180 -60.73 -37.68 82.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.823 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.402 ' H ' ' HG ' ' A' ' 68' ' ' SER . 21.7 t -59.76 -43.94 94.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.064 -1.023 . . . . 0.0 109.346 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.3 mt -64.39 -38.54 82.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.28 -0.888 . . . . 0.0 109.455 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -56.16 -38.14 70.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.351 -0.843 . . . . 0.0 109.511 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.16 95.31 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.305 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -64.05 -46.69 83.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.493 179.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 58.3 t -64.18 -41.63 93.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.439 -0.788 . . . . 0.0 109.708 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.8 t -62.82 -43.5 98.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.216 -0.928 . . . . 0.0 109.96 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.82 -37.92 95.12 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -88.78 -49.64 6.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.111 -1.229 . . . . 0.0 110.185 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 28.0 m -128.86 138.75 52.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.68 88.41 51.98 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.441 -0.787 . . . . 0.0 109.566 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -66.08 160.33 45.14 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.533 2.155 . . . . 0.0 111.872 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -61.23 150.31 85.21 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.705 2.27 . . . . 0.0 111.949 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.5 t -107.99 135.2 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.389 -0.819 . . . . 0.0 109.504 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -151.84 -18.81 0.19 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -140.35 158.46 43.98 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.248 -0.907 . . . . 0.0 109.62 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 32.7 tttm 60.91 54.6 3.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.4 -0.812 . . . . 0.0 109.361 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.6 tp -99.0 130.45 45.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.189 -0.945 . . . . 0.0 109.357 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.484 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.503 ' C18' ' CG1' ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.404 ' H3 ' ' CB ' ' A' ' 4' ' ' ALA . 91.9 mmm . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -58.85 -34.94 72.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.919 . . . . 0.0 109.384 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.583 ' CD2' ' OD2' ' A' ' 73' ' ' ASP . 5.4 p80 -160.33 23.14 0.16 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.372 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.404 ' CB ' ' H3 ' ' A' ' 1' ' ' MET . . . -61.4 -38.64 87.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.91 -34.12 77.25 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.357 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.68 -38.1 80.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.285 -0.885 . . . . 0.0 109.356 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 88.4 mt -60.43 -50.39 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.526 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.47 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.0 -44.09 93.7 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.301 -0.874 . . . . 0.0 109.024 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.47 -40.8 89.54 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.529 -0.732 . . . . 0.0 109.647 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -66.39 -49.47 66.73 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.535 -0.728 . . . . 0.0 111.272 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.4 p -69.95 -44.81 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.126 -0.984 . . . . 0.0 111.258 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.47 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 15.9 m -67.48 -33.87 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.026 -1.046 . . . . 0.0 110.733 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -52.2 -36.34 51.68 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.107 -0.996 . . . . 0.0 109.832 -178.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -33.36 75.41 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.176 -0.952 . . . . 0.0 110.568 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -95.94 -63.72 1.12 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.016 -1.053 . . . . 0.0 110.98 -178.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.32 83.09 57.27 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 110.62 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -84.12 -18.27 5.26 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.024 2.482 . . . . 0.0 112.048 179.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.97 -3.4 38.73 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.279 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.3 t -109.09 144.21 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.17 117.59 27.87 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 120.864 -1.148 . . . . 0.0 108.465 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -65.24 -28.82 55.57 Favored 'Trans proline' 0 N--CA 1.49 1.271 0 C-N-CA 121.596 1.531 . . . . 0.0 112.041 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.71 -14.85 61.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.377 -0.827 . . . . 0.0 109.297 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -90.68 8.17 35.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.364 -0.835 . . . . 0.0 109.34 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.2 t -98.3 137.15 26.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.352 -0.842 . . . . 0.0 108.79 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -65.57 85.01 0.07 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.168 -0.958 . . . . 0.0 109.466 -179.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -59.89 -0.06 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.312 -0.868 . . . . 0.0 109.266 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.45 7.14 44.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 108.954 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -94.23 136.01 35.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.6 m-20 -63.51 121.71 14.52 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.78 5.24 1.15 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.87 -178.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.1 p -52.81 -38.87 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.03 -1.044 . . . . 0.0 108.547 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.446 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.9 t0 -57.77 -35.47 70.81 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.8 m-20 -86.06 19.52 2.6 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -14.51 0.01 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.4 t -51.44 -36.35 17.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 108.558 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.549 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.3 OUTLIER -69.98 -20.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.455 -0.778 . . . . 0.0 110.054 179.967 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -51.35 -35.57 38.94 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.216 -0.928 . . . . 0.0 110.98 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -119.1 -61.9 1.58 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.131 -0.981 . . . . 0.0 111.51 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.9 -52.39 64.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.925 -1.11 . . . . 0.0 110.14 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.35 -41.1 59.58 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.8 -41.86 87.75 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.386 -1.067 . . . . 0.0 109.491 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -59.32 -44.31 92.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.184 -0.947 . . . . 0.0 108.949 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -65.35 -34.64 78.8 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.272 -0.892 . . . . 0.0 109.007 179.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.442 ' CG1' ' C19' ' A' ' 101' ' ' 7V9 . 70.2 t -62.67 -41.59 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.784 . . . . 0.0 110.424 -179.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.2 mm -59.32 -49.59 82.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 120.931 -1.106 . . . . 0.0 109.635 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -65.84 -40.98 92.28 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -0.97 . . . . 0.0 109.338 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 69.3 t90 -66.89 -41.63 86.88 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.446 -0.784 . . . . 0.0 109.289 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.8 tp -60.07 -46.91 88.01 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.421 -0.8 . . . . 0.0 109.168 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.401 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -67.89 -34.18 76.15 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.314 -0.866 . . . . 0.0 109.207 178.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 92.4 m-20 -59.19 -46.62 87.94 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.233 -0.917 . . . . 0.0 110.291 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 42.2 mtp180 -88.46 -51.77 5.54 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.075 -1.016 . . . . 0.0 111.616 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -80.23 -25.3 39.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.984 -1.072 . . . . 0.0 111.633 -177.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.34 31.16 52.52 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.248 -1.453 . . . . 0.0 109.712 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.401 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.9 mt -97.86 145.3 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.276 -1.132 . . . . 0.0 109.409 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.17 145.52 50.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.09 -1.006 . . . . 0.0 109.71 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.49 -36.47 80.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.463 -0.773 . . . . 0.0 109.933 -179.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -97.81 8.54 44.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.273 -0.892 . . . . 0.0 109.964 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -55.79 -40.54 72.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.71 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -135.15 153.58 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 109.666 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -134.98 118.25 16.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.264 -0.898 . . . . 0.0 109.296 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.631 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 1.4 mm? -110.33 139.31 45.66 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.83 . . . . 0.0 109.704 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -77.91 162.07 68.9 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.257 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -56.41 -27.41 67.84 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.664 2.243 . . . . 0.0 111.955 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.54 -27.46 69.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.249 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 33.5 t-80 -67.14 -26.25 66.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.434 -0.791 . . . . 0.0 109.697 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 0.9 OUTLIER -91.64 7.77 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.2 -0.937 . . . . 0.0 109.188 -179.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.6 tpt180 -55.63 -39.44 70.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.971 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 91.6 p -137.25 152.57 49.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.047 -1.033 . . . . 0.0 110.214 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.5 mt -65.25 -36.67 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.308 -0.87 . . . . 0.0 110.027 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.1 ptt85 -61.2 -40.5 94.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 110.07 -179.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -59.21 -40.51 86.02 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.108 -0.995 . . . . 0.0 109.402 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -65.97 -39.74 85.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.338 -0.851 . . . . 0.0 109.728 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.583 ' OD2' ' CD2' ' A' ' 3' ' ' HIS . 60.7 t0 -58.51 -38.64 78.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.315 -0.866 . . . . 0.0 109.918 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.52 -42.17 95.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 109.92 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -63.58 -48.53 77.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.07 -1.019 . . . . 0.0 109.606 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -65.49 -41.6 91.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.295 -0.878 . . . . 0.0 109.761 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.6 t -61.33 -41.39 89.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.311 -0.868 . . . . 0.0 109.788 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.86 -31.72 76.96 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.49 -50.26 3.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.042 -1.27 . . . . 0.0 110.618 -178.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.1 p -129.86 157.52 42.01 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.399 -0.813 . . . . 0.0 109.613 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.31 88.36 17.24 Favored Pre-proline 0 C--N 1.304 -1.385 0 O-C-N 121.206 -0.933 . . . . 0.0 109.393 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.458 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.5 Cg_exo -63.13 -176.23 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.688 2.259 . . . . 0.0 112.178 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.458 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.6 Cg_exo -60.84 151.07 79.89 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.674 2.249 . . . . 0.0 111.907 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.0 t -99.39 129.41 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -136.0 158.86 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.317 -0.864 . . . . 0.0 109.366 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -98.55 137.91 36.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 17.9 mttp -59.15 -35.38 73.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.46 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.2 tp -101.46 129.84 47.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 117.982 -1.008 . . . . 0.0 109.448 179.995 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.516 ' O8 ' ' N ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.2 mtm . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -59.38 -37.43 77.94 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.541 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.609 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 81.9 m-70 -139.61 28.35 2.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.456 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -60.62 -34.35 74.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.281 -0.887 . . . . 0.0 110.151 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m -58.87 -40.16 83.5 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.018 -1.051 . . . . 0.0 109.666 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -64.5 -36.59 77.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.88 . . . . 0.0 109.066 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.424 HG21 HD11 ' A' ' 7' ' ' ILE . 27.7 mm -64.76 -44.31 96.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.433 -0.792 . . . . 0.0 110.323 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.529 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.73 -50.44 69.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.113 -0.992 . . . . 0.0 110.734 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.506 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.86 -39.49 76.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.016 -1.052 . . . . 0.0 109.566 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 68.3 t80 -65.75 -51.29 60.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.346 -0.846 . . . . 0.0 109.94 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -67.93 -40.76 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 109.763 -179.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.529 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 71.1 t -65.93 -40.55 87.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.216 -0.927 . . . . 0.0 109.571 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -52.74 -30.54 33.15 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.438 -0.789 . . . . 0.0 109.827 -179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -65.37 -30.46 71.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.939 . . . . 0.0 109.412 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.9 p90 -145.41 44.12 1.3 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.4 pt? -80.63 130.79 63.12 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.054 -1.029 . . . . 0.0 110.082 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.436 ' C ' ' H ' ' A' ' 19' ' ' VAL . 68.6 Cg_endo -76.62 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.362 0 C-N-CA 121.83 1.687 . . . . 0.0 110.625 178.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.63 16.62 0.81 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.958 -1.089 . . . . 0.0 108.916 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.436 ' H ' ' C ' ' A' ' 17' ' ' PRO . 41.0 t -113.57 135.62 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.416 -0.802 . . . . 0.0 109.786 -179.517 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.61 141.43 76.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -49.04 -31.54 21.1 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.817 1.678 . . . . 0.0 111.993 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.96 -22.28 66.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.419 -0.8 . . . . 0.0 109.446 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -95.88 2.06 53.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.429 -0.795 . . . . 0.0 108.928 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.6 t -104.88 136.46 38.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.5 t0 -71.19 97.03 1.46 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.051 -1.031 . . . . 0.0 109.312 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.6 m -59.5 0.14 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.195 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -91.96 7.82 40.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.325 -0.859 . . . . 0.0 108.779 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.8 tp -91.22 133.83 35.06 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.478 -0.764 . . . . 0.0 109.376 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -66.33 121.31 14.96 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -74.74 9.6 1.77 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.219 -0.925 . . . . 0.0 109.825 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.5 p -52.25 -38.91 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.156 -0.965 . . . . 0.0 108.642 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.454 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.1 m-20 -57.33 -35.73 70.25 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 178.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.2 m-20 -84.94 18.25 2.54 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.011 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.92 -13.69 0.01 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -50.72 -35.24 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.072 -1.251 . . . . 0.0 108.945 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.578 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -70.01 -23.48 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.418 ' OD2' ' CG ' ' A' ' 66' ' ' PHE . 84.2 m-20 -54.93 -32.42 61.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 110.714 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.51 -64.09 1.36 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.149 -0.969 . . . . 0.0 111.174 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 15.5 mt -62.67 -52.52 62.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.002 -1.061 . . . . 0.0 110.2 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.48 -37.19 69.18 Favored Glycine 0 N--CA 1.486 1.97 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.578 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.86 -41.46 87.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.266 -1.138 . . . . 0.0 109.149 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -61.51 -44.22 97.45 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.348 -0.845 . . . . 0.0 108.894 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -67.92 -40.79 83.32 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.301 -0.875 . . . . 0.0 110.007 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.524 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 74.8 t -65.68 -42.86 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.277 -0.889 . . . . 0.0 110.131 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.1 mp -58.87 -50.47 79.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.186 -0.946 . . . . 0.0 109.65 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.72 -37.18 85.7 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.94 . . . . 0.0 109.436 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.517 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -69.32 -43.7 73.2 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.281 -0.887 . . . . 0.0 109.715 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.1 tp -57.34 -48.0 80.12 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.323 -0.86 . . . . 0.0 109.402 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -68.73 -37.71 79.66 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.301 -0.874 . . . . 0.0 109.122 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.5 t0 -63.77 -41.73 97.91 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.297 -0.877 . . . . 0.0 110.593 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.7 ttt180 -87.1 -55.26 3.9 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.231 -0.918 . . . . 0.0 111.454 -178.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -79.49 -22.34 44.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.987 -1.071 . . . . 0.0 111.383 -178.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 25.84 60.69 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.1 mt -106.07 144.91 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.471 -1.017 . . . . 0.0 109.416 -179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 152.41 29.01 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.283 -0.886 . . . . 0.0 109.54 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.78 -28.56 61.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.368 -0.833 . . . . 0.0 109.688 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 54.86 46.23 24.89 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.262 -0.899 . . . . 0.0 109.278 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.447 ' OD2' ' C ' ' A' ' 58' ' ' ASP . 53.3 p30 -88.42 13.11 12.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.39 -0.819 . . . . 0.0 109.621 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 55.8 t -53.85 -42.52 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.238 -0.914 . . . . 0.0 109.607 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -121.68 136.34 54.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.464 -0.772 . . . . 0.0 109.75 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 20.1 mt -104.84 140.47 38.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.32 -0.863 . . . . 0.0 108.975 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.449 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.8 OUTLIER -130.27 80.57 70.37 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.197 -0.939 . . . . 0.0 110.228 -179.516 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -58.08 -25.99 73.49 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 C-N-CA 122.578 2.186 . . . . 0.0 111.664 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.72 -23.54 65.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.56 -0.713 . . . . 0.0 110.198 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -67.76 -26.63 66.22 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.59 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.418 ' CG ' ' OD2' ' A' ' 37' ' ' ASP . 68.4 m-85 -80.17 -3.67 49.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.883 -1.136 . . . . 0.0 110.144 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 83.1 mmt-85 -60.47 -36.18 77.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.892 -1.13 . . . . 0.0 109.745 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 93.7 p -139.92 150.94 45.17 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.014 -1.054 . . . . 0.0 109.749 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 80.2 mt -65.13 -36.65 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -60.63 -38.41 84.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 110.197 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 24.6 m -57.81 -40.63 80.4 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.018 -1.051 . . . . 0.0 109.53 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.0 mm -65.36 -38.97 83.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.154 -0.966 . . . . 0.0 109.17 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.456 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 54.4 t0 -57.23 -38.35 73.65 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.288 -0.882 . . . . 0.0 109.594 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.44 99.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.307 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -63.75 -46.56 84.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.357 -0.839 . . . . 0.0 109.432 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.8 t -64.68 -41.63 92.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.333 -0.854 . . . . 0.0 109.663 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 52.9 t -61.59 -40.94 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.269 -0.894 . . . . 0.0 109.634 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.17 76.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.28 -50.01 5.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.096 -1.237 . . . . 0.0 109.961 -179.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.4 t -144.97 153.21 41.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.55 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.609 ' HG1' ' HE2' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -133.11 89.07 34.54 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.213 -0.929 . . . . 0.0 109.552 -179.901 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.5 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 61.4 Cg_endo -82.51 161.38 17.0 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.715 2.277 . . . . 0.0 112.494 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.39 150.83 83.26 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.868 2.379 . . . . 0.0 112.022 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.408 ' HB ' ' HD1' ' A' ' 3' ' ' HIS . 13.4 p -128.13 141.03 47.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.38 -0.825 . . . . 0.0 109.859 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.16 151.5 39.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.565 -0.71 . . . . 0.0 109.096 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.54 142.54 58.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -0.901 . . . . 0.0 109.432 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 61.4 mttp -58.88 -36.39 74.57 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.356 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.9 tp -104.38 130.12 52.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.901 . . . . 0.0 109.435 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.489 1.517 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.451 -179.957 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.524 ' C18' ' CG1' ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.8 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.387 0.613 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -55.39 -38.92 69.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.191 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.682 ' HD1' ' HG1' ' A' ' 81' ' ' THR . 45.2 m80 -152.92 28.89 0.52 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.417 -0.802 . . . . 0.0 109.19 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.27 -33.02 71.73 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.412 -0.805 . . . . 0.0 109.658 -179.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -58.97 -38.95 80.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.173 -0.954 . . . . 0.0 109.613 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -65.14 -39.06 84.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.15 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.1 mt -60.58 -50.62 79.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.276 -0.89 . . . . 0.0 109.459 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.538 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.96 -44.62 92.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 109.064 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.37 -44.17 88.48 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.74 0.781 . . . . 0.0 109.227 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -61.61 -47.79 83.86 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.525 -0.735 . . . . 0.0 109.331 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 96.6 t -73.16 -41.49 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.446 -0.784 . . . . 0.0 110.139 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.538 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 78.4 t -63.96 -41.27 91.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -0.882 . . . . 0.0 111.022 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -57.01 -28.25 62.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 109.907 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.44 -30.09 70.84 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.21 -0.931 . . . . 0.0 109.359 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.603 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.8 p90 -146.8 45.68 1.19 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.161 -0.962 . . . . 0.0 109.775 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.565 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.93 63.18 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.965 -1.084 . . . . 0.0 110.369 -179.725 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.405 ' HB2' ' H ' ' A' ' 18' ' ' ASP . 72.3 Cg_endo -77.55 -149.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 122.021 1.814 . . . . 0.0 110.311 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.452 ' OD1' ' C ' ' A' ' 18' ' ' ASP . 53.6 p30 -80.73 15.77 1.63 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.764 -1.21 . . . . 0.0 109.146 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.4 t -113.33 136.05 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.443 -0.786 . . . . 0.0 109.778 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.55 142.06 85.95 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.212 -0.93 . . . . 0.0 109.386 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -49.25 -33.8 29.46 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.878 1.719 . . . . 0.0 111.697 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.03 -21.87 65.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.489 -0.757 . . . . 0.0 109.331 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.4 5.21 50.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.55 -0.719 . . . . 0.0 109.17 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.4 t -102.54 136.49 34.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' C ' ' H ' ' A' ' 27' ' ' ASP . 84.5 m-20 -67.42 94.35 0.39 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.137 -0.977 . . . . 0.0 109.418 -179.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.5 m -59.24 0.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.39 -0.819 . . . . 0.0 109.423 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 25' ' ' ASP . 48.2 p30 -84.26 9.79 12.08 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.227 -0.921 . . . . 0.0 109.078 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.8 tp -86.34 134.95 33.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.6 -0.687 . . . . 0.0 109.366 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -65.43 121.83 15.78 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 108.733 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.427 ' O ' ' N ' ' A' ' 33' ' ' ASN . 82.3 mt -56.87 -16.66 7.14 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 108.931 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' A' ' 34' ' ' GLY . 41.7 t -50.64 -40.94 19.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.237 -0.914 . . . . 0.0 108.914 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.67 -36.17 66.81 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 178.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' A' ' 35' ' ' VAL . 9.7 m120 -85.02 20.44 1.88 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.11 -15.35 0.02 OUTLIER Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.346 -1.101 . . . . 0.0 110.346 -179.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.597 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.4 t -51.91 -40.17 27.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.604 -1.527 . . . . 0.0 108.585 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.4 tt -71.91 -22.25 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.577 -0.702 . . . . 0.0 110.883 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.408 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 93.0 m-20 -52.51 -34.8 51.36 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.154 -0.966 . . . . 0.0 111.784 -177.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.554 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.5 OUTLIER -119.02 -60.59 1.74 Allowed 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.957 -1.09 . . . . 0.0 111.224 -178.692 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.96 -52.18 65.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.145 . . . . 0.0 109.598 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.91 -36.98 65.29 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.7 tt -58.02 -41.02 82.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.358 -1.083 . . . . 0.0 109.294 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 30.4 mt -60.31 -44.43 95.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 108.667 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -67.75 -38.74 83.89 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.406 -0.809 . . . . 0.0 109.576 179.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 79.5 t -65.09 -39.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.448 -0.783 . . . . 0.0 110.351 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -58.11 -50.6 77.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.033 -1.042 . . . . 0.0 109.642 -179.262 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.16 -39.14 86.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.089 -1.007 . . . . 0.0 109.702 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.5 t90 -70.38 -42.14 72.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.131 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.7 tp -61.43 -47.2 86.81 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.383 -0.823 . . . . 0.0 110.029 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.584 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -64.72 -43.7 92.59 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.116 -0.99 . . . . 0.0 108.613 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -66.45 -39.93 89.15 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.335 -0.853 . . . . 0.0 110.232 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 27.2 tpt85 -63.02 -45.06 94.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.499 -0.751 . . . . 0.0 111.547 -178.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.405 ' CZ ' ' CB ' ' A' ' 82' ' ' PRO . 54.8 m-85 -126.24 2.27 7.1 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.912 -1.118 . . . . 0.0 111.858 -178.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.7 33.79 54.91 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.5 ' CG2' ' OD1' ' A' ' 58' ' ' ASP . 70.6 mt -95.85 135.87 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.183 -1.186 . . . . 0.0 109.146 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.54 140.7 58.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.087 -1.008 . . . . 0.0 109.678 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.89 -35.74 81.65 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.468 -0.77 . . . . 0.0 109.786 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -99.75 14.3 30.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.331 -0.856 . . . . 0.0 110.118 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.577 ' OD2' ' N ' ' A' ' 59' ' ' VAL . 28.5 p-10 -57.68 -35.51 70.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.096 -1.003 . . . . 0.0 109.458 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.577 ' N ' ' OD2' ' A' ' 58' ' ' ASP . 21.7 m -130.98 158.67 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.472 -0.767 . . . . 0.0 109.436 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -95.19 137.67 33.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.177 -0.952 . . . . 0.0 109.241 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.604 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 4.1 mp -106.34 139.02 41.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.861 -179.742 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.61 155.54 75.17 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.349 -0.844 . . . . 0.0 108.967 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -59.39 -35.13 97.22 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.511 2.141 . . . . 0.0 112.184 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.91 -28.73 68.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.398 -0.814 . . . . 0.0 109.796 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.677 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 51.3 t-80 -67.81 -27.03 66.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.289 -0.882 . . . . 0.0 110.231 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.603 ' CD1' ' O8 ' ' A' ' 101' ' ' 7V9 . 56.0 m-85 -101.68 13.84 33.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.133 -0.98 . . . . 0.0 110.06 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -53.03 -32.96 49.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.094 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.7 t -151.29 151.76 32.25 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 109.973 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.8 mt -60.97 -36.87 75.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 O-C-N 121.262 -0.898 . . . . 0.0 110.11 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -60.63 -40.82 93.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.224 -0.922 . . . . 0.0 110.214 -179.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.2 m -60.66 -41.8 95.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.037 -1.04 . . . . 0.0 109.936 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.3 mt -66.95 -40.83 86.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.245 -0.909 . . . . 0.0 110.156 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 52.1 t0 -59.12 -40.72 86.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 110.405 -179.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.17 -41.9 89.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.124 -0.985 . . . . 0.0 110.09 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.677 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 66.7 t80 -62.06 -49.65 75.15 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.164 -0.96 . . . . 0.0 109.482 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.539 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.6 t -65.55 -47.05 87.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.219 -0.926 . . . . 0.0 109.562 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 45.8 t -58.93 -38.84 75.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.112 -0.992 . . . . 0.0 109.455 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.73 -33.06 66.6 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.46 -51.24 3.14 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -1.224 . . . . 0.0 110.397 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.539 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.2 t -153.87 152.41 30.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.728 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.682 ' HG1' ' HD1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -123.7 88.66 51.89 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.236 -0.915 . . . . 0.0 109.22 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.405 ' CB ' ' CZ ' ' A' ' 52' ' ' PHE . 97.2 Cg_endo -92.57 108.44 0.22 Allowed 'Trans proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.184 2.59 . . . . 0.0 112.973 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -80.11 136.1 11.38 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.103 1.869 . . . . 0.0 111.698 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.1 t -124.15 129.14 74.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.359 -0.838 . . . . 0.0 109.647 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.99 -37.31 81.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.928 . . . . 0.0 109.471 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -155.29 153.01 29.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.282 -0.886 . . . . 0.0 109.542 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -58.54 -37.72 76.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.191 -0.943 . . . . 0.0 109.461 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.0 mt -59.52 -35.27 73.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.222 -0.924 . . . . 0.0 109.513 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.517 179.988 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.603 ' O8 ' ' CD1' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.312 0.577 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -59.49 -36.63 76.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.874 . . . . 0.0 109.458 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 83' ' ' PRO . 2.9 m-70 -137.03 18.69 3.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.352 -0.843 . . . . 0.0 109.702 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -57.64 -38.98 75.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.166 -0.959 . . . . 0.0 109.599 -179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.522 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 85.6 p -65.24 -37.29 86.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.098 -1.001 . . . . 0.0 109.624 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.522 ' N ' ' HG ' ' A' ' 5' ' ' SER . 76.2 t -68.13 -37.81 78.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.287 -0.883 . . . . 0.0 109.261 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 97.2 mt -60.02 -49.79 82.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.71 -47.17 82.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.184 -0.947 . . . . 0.0 109.098 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -44.16 94.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.445 -0.785 . . . . 0.0 109.252 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.696 ' CZ ' ' CZ3' ' A' ' 47' ' ' TRP . 70.2 t80 -68.39 -48.32 65.01 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.512 0.673 . . . . 0.0 109.48 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.5 t -68.67 -44.22 82.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.667 -0.645 . . . . 0.0 110.014 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 96.9 t -64.22 -36.71 77.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -52.37 -32.8 40.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.316 -0.865 . . . . 0.0 109.729 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.594 ' OE1' ' CZ3' ' A' ' 47' ' ' TRP . 76.8 mm-40 -66.0 -31.79 72.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.206 -0.934 . . . . 0.0 109.804 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.548 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 34.4 p90 -140.06 42.94 1.94 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.103 -0.998 . . . . 0.0 109.835 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.569 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.63 130.56 64.02 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.05 -1.031 . . . . 0.0 110.015 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.44 ' C ' ' H ' ' A' ' 19' ' ' VAL . 73.4 Cg_endo -76.86 -152.18 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 121.962 1.774 . . . . 0.0 110.667 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.55 15.53 0.79 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.934 -1.104 . . . . 0.0 108.966 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.44 ' H ' ' C ' ' A' ' 17' ' ' PRO . 42.8 t -113.42 135.22 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.516 -0.74 . . . . 0.0 109.736 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.22 140.91 80.26 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.208 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.544 ' C ' ' HZ3' ' A' ' 87' ' ' LYS . 35.1 Cg_exo -49.76 -31.45 25.92 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 121.842 1.695 . . . . 0.0 111.924 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.38 -22.77 66.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.537 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -92.77 4.29 54.06 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.448 -0.782 . . . . 0.0 109.225 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -105.35 136.48 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.566 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -69.23 91.24 0.52 Allowed 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -59.83 0.08 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.349 -0.844 . . . . 0.0 109.186 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.566 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -93.44 8.19 41.57 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.339 -0.851 . . . . 0.0 108.886 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.7 tp -92.34 136.86 32.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.432 -0.793 . . . . 0.0 109.519 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.58 ' C ' ' H ' ' A' ' 31' ' ' VAL . 33.6 p30 -62.61 114.4 3.55 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.141 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -63.74 8.7 0.08 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.112 -0.993 . . . . 0.0 109.926 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.58 ' H ' ' C ' ' A' ' 29' ' ' ASP . 6.3 p -54.98 -38.25 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.059 -1.025 . . . . 0.0 109.172 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.433 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.3 t0 -56.85 -37.21 70.98 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.596 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.5 m-80 -87.3 16.92 4.76 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.43 -17.4 0.03 OUTLIER Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.749 -1.341 . . . . 0.0 109.749 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.596 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.13 -34.19 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 O-C-N 120.969 -1.312 . . . . 0.0 108.453 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.593 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.9 OUTLIER -71.08 -21.32 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.512 -0.743 . . . . 0.0 110.042 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -55.06 -33.6 62.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.29 -0.881 . . . . 0.0 111.388 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 31.6 m -114.02 -64.52 1.3 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.055 -1.028 . . . . 0.0 111.522 -178.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.7 mp -65.45 -51.68 58.45 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.0 -1.062 . . . . 0.0 110.573 -178.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.5 -37.64 69.08 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 120.016 -1.088 . . . . 0.0 110.426 -179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.593 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.9 tt -58.75 -41.49 86.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.176 -1.191 . . . . 0.0 109.796 -179.193 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.9 tp -66.76 -44.66 80.85 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.299 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -67.89 -37.95 82.39 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.1 t -63.59 -40.94 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.412 -0.805 . . . . 0.0 110.303 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.4 HD13 ' N ' ' A' ' 45' ' ' ILE . 1.3 mp -58.88 -51.09 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.113 -0.992 . . . . 0.0 109.832 -179.189 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -37.46 83.84 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.11 -0.994 . . . . 0.0 109.217 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.696 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 25.9 t90 -66.25 -39.61 89.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.445 -0.784 . . . . 0.0 109.538 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.53 -41.92 91.09 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.511 -0.743 . . . . 0.0 109.84 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.461 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 4.1 tm-20 -65.77 -39.11 90.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.183 -0.948 . . . . 0.0 109.925 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -60.09 -39.09 84.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.617 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.6 mtp85 -86.02 -54.18 4.64 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 111.247 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -80.4 -22.89 40.79 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.054 -1.028 . . . . 0.0 110.984 -178.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 78.25 27.47 57.76 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.461 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 68.3 mt -104.85 148.7 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.343 -1.092 . . . . 0.0 109.424 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.38 155.21 22.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.33 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.25 -37.98 67.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.325 -0.859 . . . . 0.0 109.809 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 51.92 50.52 18.42 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.057 -1.027 . . . . 0.0 108.9 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -71.86 116.36 12.15 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 110.055 -179.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.454 ' O ' ' O8 ' ' A' ' 101' ' ' 7V9 . 22.8 m -130.36 161.59 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -88.17 117.16 26.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.904 -1.122 . . . . 0.0 110.233 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.466 ' H ' ' C6 ' ' A' ' 101' ' ' 7V9 . 32.8 mt -116.03 145.15 43.22 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -68.16 153.84 94.86 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.149 -0.97 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -60.93 -27.12 84.3 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.649 2.232 . . . . 0.0 112.096 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.69 -25.45 67.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.384 -0.823 . . . . 0.0 109.947 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.405 ' HE2' ' HB2' ' A' ' 75' ' ' PHE . 52.6 t-80 -67.16 -26.64 66.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.173 -0.955 . . . . 0.0 110.202 -179.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -96.78 3.14 52.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.095 -1.003 . . . . 0.0 109.387 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -56.67 -41.01 76.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.806 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -130.26 147.2 51.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.224 -0.922 . . . . 0.0 109.926 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.8 mt -63.12 -35.85 73.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 O-C-N 121.372 -0.83 . . . . 0.0 109.977 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.5 mtm180 -60.35 -37.35 80.4 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.202 -0.936 . . . . 0.0 110.108 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.3 t -58.67 -39.77 81.62 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.035 -1.041 . . . . 0.0 108.821 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.5 mt -62.65 -38.19 80.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.4 -0.812 . . . . 0.0 108.985 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -54.31 -38.73 66.29 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.409 -0.807 . . . . 0.0 109.275 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.15 93.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.927 . . . . 0.0 109.246 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.405 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 71.2 t80 -65.4 -46.35 80.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.244 -0.91 . . . . 0.0 109.374 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.2 t -65.38 -41.99 92.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.383 -0.823 . . . . 0.0 110.123 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.4 t -62.8 -42.92 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.085 -1.009 . . . . 0.0 109.864 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.95 -36.41 92.13 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.47 -49.79 5.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 110.532 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 37.9 m -129.22 139.68 51.77 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.835 . . . . 0.0 109.95 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.19 88.0 55.18 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.38 -0.825 . . . . 0.0 109.284 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.543 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 56.7 Cg_endo -82.07 161.34 18.11 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.666 2.244 . . . . 0.0 112.452 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 18.7 Cg_endo -61.39 148.91 91.73 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.817 2.345 . . . . 0.0 111.7 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.2 t -98.08 131.52 44.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.115 -0.991 . . . . 0.0 109.97 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.12 163.5 23.68 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.24 141.41 35.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.186 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.544 ' HZ3' ' C ' ' A' ' 21' ' ' PRO . 43.7 tttm -58.7 -36.19 73.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.266 -0.896 . . . . 0.0 109.518 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.5 mt -58.7 -35.35 72.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.438 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.436 -179.996 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.466 ' C6 ' ' H ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.618 ' H2 ' ' CB ' ' A' ' 4' ' ' ALA . 93.3 mmm . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 68.1 tp60 -56.98 -41.36 78.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.233 -0.917 . . . . 0.0 109.643 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.571 ' NE2' ' OG1' ' A' ' 81' ' ' THR . 95.9 m-70 -139.98 8.82 2.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.182 -0.949 . . . . 0.0 109.78 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.618 ' CB ' ' H2 ' ' A' ' 1' ' ' MET . . . -59.83 -37.49 79.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.163 -0.961 . . . . 0.0 109.394 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -59.76 -36.53 76.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.216 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 82.5 t -64.91 -37.25 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.388 -0.82 . . . . 0.0 109.45 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.6 mt -59.54 -48.53 86.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.567 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.453 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.25 -45.25 92.4 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.092 -1.005 . . . . 0.0 108.628 179.288 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.445 ' NE2' ' O ' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -65.65 -38.22 88.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.512 0.672 . . . . 0.0 109.398 179.276 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.594 ' CE2' ' NZ ' ' A' ' 87' ' ' LYS . 68.6 t80 -64.51 -51.69 61.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.567 -0.708 . . . . 0.0 110.003 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 16.2 m -74.42 -41.53 49.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 110.457 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.453 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 73.9 t -62.85 -36.22 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.16 -0.963 . . . . 0.0 110.403 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -57.36 -36.91 71.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -67.38 -36.85 82.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 110.504 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -90.58 -61.61 1.64 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.028 -1.045 . . . . 0.0 110.721 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.1 mt -125.7 82.83 63.23 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.304 -0.873 . . . . 0.0 110.134 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -83.02 -20.58 5.14 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.819 2.346 . . . . 0.0 112.204 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.88 -4.31 43.07 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.184 -0.948 . . . . 0.0 108.905 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.3 t -113.56 140.09 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.83 118.52 39.37 Favored Pre-proline 0 C--N 1.303 -1.431 0 O-C-N 120.96 -1.088 . . . . 0.0 108.726 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.87 -27.51 59.05 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.528 1.485 . . . . 0.0 111.808 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.28 -17.07 63.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.198 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -82.95 -1.26 51.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.385 -0.822 . . . . 0.0 108.787 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -102.5 138.65 25.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.552 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.4 t0 -67.93 94.36 0.47 Allowed 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.125 -0.984 . . . . 0.0 109.4 -179.399 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.5 m -60.87 0.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.363 -0.835 . . . . 0.0 109.319 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.552 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.1 m-20 -87.57 9.58 20.68 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.007 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -87.38 134.59 33.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.47 -0.769 . . . . 0.0 109.516 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.481 ' OD1' ' O ' ' A' ' 67' ' ' ARG . 86.1 m-20 -62.27 122.29 15.26 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 108.776 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.3 mt -58.13 -10.82 2.1 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.176 -0.952 . . . . 0.0 109.311 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 89.0 t -50.55 -45.35 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.116 -0.99 . . . . 0.0 108.691 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -55.94 -36.54 67.88 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.2 m-20 -90.13 22.91 3.05 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.13 -15.13 0.01 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -52.61 -37.2 23.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.308 . . . . 0.0 108.542 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.517 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.8 tt -70.48 -19.42 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.514 -0.741 . . . . 0.0 110.167 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.589 ' OD1' ' CE1' ' A' ' 66' ' ' PHE . 77.2 m-20 -56.71 -35.57 68.66 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.234 -0.916 . . . . 0.0 111.461 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.533 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.6 OUTLIER -113.08 -64.56 1.29 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.086 -1.009 . . . . 0.0 111.268 -178.322 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.41 -48.93 77.52 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.066 -1.021 . . . . 0.0 110.02 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.08 -43.52 56.6 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -58.8 -39.66 81.76 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -1.097 . . . . 0.0 109.371 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.77 -44.24 93.96 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.171 -0.956 . . . . 0.0 108.772 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -68.42 -39.95 81.41 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.323 -0.861 . . . . 0.0 109.602 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.439 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 70.4 t -65.84 -44.09 92.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.4 -0.812 . . . . 0.0 110.123 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.63 -50.5 80.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.127 -0.983 . . . . 0.0 109.481 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.85 -38.25 86.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.311 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 44.7 t90 -68.97 -43.57 74.68 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.328 -0.858 . . . . 0.0 109.6 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -60.2 -43.68 95.76 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.434 -0.792 . . . . 0.0 109.485 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -67.71 -36.3 80.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.298 -0.876 . . . . 0.0 109.874 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -59.42 -39.24 82.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.838 -1.164 . . . . 0.0 110.119 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 36.3 mtp180 -87.04 -58.22 2.67 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.184 -0.947 . . . . 0.0 111.522 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -80.58 -23.16 40.06 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.951 -1.093 . . . . 0.0 111.733 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.71 35.01 33.15 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.319 -1.42 . . . . 0.0 109.709 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.401 ' CG2' ' OD2' ' A' ' 58' ' ' ASP . 69.2 mt -97.63 138.5 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.247 -1.149 . . . . 0.0 108.878 179.636 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.93 142.72 56.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.891 -1.131 . . . . 0.0 109.487 -179.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.05 -34.42 73.39 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.356 -0.84 . . . . 0.0 109.335 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -94.58 11.07 32.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.87 . . . . 0.0 109.419 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.401 ' OD2' ' CG2' ' A' ' 54' ' ' ILE . 53.9 t0 -52.91 -33.33 49.88 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.318 -0.864 . . . . 0.0 109.847 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.1 m -124.59 159.67 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.393 -0.817 . . . . 0.0 109.745 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -83.56 152.72 24.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.836 . . . . 0.0 109.449 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 36.6 mt -72.52 136.28 45.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 109.398 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.84 87.45 19.73 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.621 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_exo -51.67 -23.55 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.283 1.989 . . . . 0.0 111.971 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.5 -20.87 61.51 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 109.564 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -67.43 -26.94 66.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.309 -0.869 . . . . 0.0 110.383 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.589 ' CE1' ' OD1' ' A' ' 37' ' ' ASP . 51.7 m-85 -72.91 -14.14 61.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.009 -1.057 . . . . 0.0 109.555 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.481 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 25.1 mmt180 -56.79 -35.94 69.3 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.299 -0.875 . . . . 0.0 110.194 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.66 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 61.9 p -157.52 143.77 17.75 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.86 -1.15 . . . . 0.0 110.463 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.9 mt -66.99 -36.6 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 O-C-N 121.562 -0.711 . . . . 0.0 110.172 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -60.27 -41.89 94.25 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -0.829 . . . . 0.0 110.629 -178.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.66 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 19.6 m -57.49 -42.12 82.06 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.134 -0.978 . . . . 0.0 109.774 -179.281 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.14 -38.66 80.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.133 -0.979 . . . . 0.0 109.928 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.449 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 40.4 t0 -57.72 -40.54 79.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 -179.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.9 85.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.142 -0.974 . . . . 0.0 109.745 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -62.97 -48.88 76.95 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.228 -0.92 . . . . 0.0 109.398 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.55 -45.47 88.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.242 -0.911 . . . . 0.0 109.725 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 49.2 t -60.91 -41.84 90.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 O-C-N 121.069 -1.02 . . . . 0.0 109.592 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.96 -28.42 63.56 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.32 -50.67 3.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.139 -1.212 . . . . 0.0 110.678 -179.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.1 t -149.17 156.58 42.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.068 -1.02 . . . . 0.0 109.997 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.571 ' OG1' ' NE2' ' A' ' 3' ' ' HIS . 0.2 OUTLIER -129.07 89.19 49.21 Favored Pre-proline 0 C--N 1.302 -1.466 0 O-C-N 121.454 -0.779 . . . . 0.0 108.918 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -60.86 157.04 40.14 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.665 2.243 . . . . 0.0 112.891 -178.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.42 151.92 83.56 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 123.034 2.489 . . . . 0.0 112.153 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.2 p -89.57 130.22 39.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.172 -0.955 . . . . 0.0 109.458 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.445 ' O ' ' NE2' ' A' ' 9' ' ' GLN . 73.6 tt0 -171.47 -119.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.32 -0.862 . . . . 0.0 109.187 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -159.26 165.24 33.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 109.581 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.594 ' NZ ' ' CE2' ' A' ' 10' ' ' PHE . 26.2 mttm -71.29 143.72 50.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.921 . . . . 0.0 109.302 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 70.0 mt -59.3 -35.09 73.15 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.911 . . . . 0.0 109.435 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.496 -179.967 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.533 ' O2P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.8 mtt . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.315 0.579 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.594 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 93.4 mt-30 -104.93 140.34 38.31 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.594 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 22.0 p-80 40.28 24.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.412 -0.805 . . . . 0.0 109.164 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.553 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -61.53 -37.58 84.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.488 -0.757 . . . . 0.0 109.652 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 m -59.56 -38.1 80.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -0.943 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' CB ' ' A' ' 10' ' ' PHE . 71.6 t -64.28 -37.53 80.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.255 -0.903 . . . . 0.0 109.07 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.9 mt -64.19 -46.82 92.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.283 -0.886 . . . . 0.0 109.961 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.538 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.21 -49.98 69.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.293 -0.879 . . . . 0.0 110.593 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.715 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.72 -40.93 75.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.014 -1.054 . . . . 0.0 109.866 -179.661 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.715 ' N ' HE21 ' A' ' 9' ' ' GLN . 74.4 t80 -63.69 -51.32 65.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -0.973 . . . . 0.0 110.159 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 5.0 p -68.51 -40.38 81.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.703 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.538 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 72.4 t -66.95 -37.8 80.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.311 -0.868 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -52.41 -29.67 25.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.378 -0.827 . . . . 0.0 109.992 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.51 -30.42 71.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.222 -0.924 . . . . 0.0 109.679 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.574 ' CE1' ' OD1' ' A' ' 33' ' ' ASN . 38.6 p90 -142.56 38.52 1.52 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.068 -1.02 . . . . 0.0 109.963 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.565 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.66 130.92 62.5 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.827 -1.17 . . . . 0.0 110.053 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.436 ' C ' ' H ' ' A' ' 19' ' ' VAL . 67.7 Cg_endo -76.07 -152.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 122.015 1.81 . . . . 0.0 110.784 179.017 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -77.75 16.26 0.71 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.98 -1.075 . . . . 0.0 109.117 179.531 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.436 ' H ' ' C ' ' A' ' 17' ' ' PRO . 43.4 t -113.19 136.29 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 109.674 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.6 141.9 93.5 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.511 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_exo -50.02 -31.09 26.51 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 C-N-CA 121.943 1.762 . . . . 0.0 112.104 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.3 -25.44 68.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.64 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -96.74 8.62 43.86 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.237 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.46 137.18 28.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.356 -0.84 . . . . 0.0 108.818 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.56 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.87 85.89 0.33 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.216 -0.927 . . . . 0.0 109.642 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.8 m -59.97 0.08 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.387 -0.82 . . . . 0.0 109.086 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.56 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.64 7.69 40.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.345 -0.847 . . . . 0.0 108.87 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.9 tp -90.81 138.0 31.92 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.45 -0.781 . . . . 0.0 109.454 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.36 121.54 15.07 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.416 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -72.53 3.34 5.0 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.944 -178.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.2 p -52.46 -39.22 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.007 -1.058 . . . . 0.0 108.635 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -58.11 -34.74 70.53 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.721 ' N ' HD21 ' A' ' 33' ' ' ASN . 0.9 OUTLIER -84.42 16.97 2.81 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 179.093 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.17 -17.37 0.03 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.295 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.79 -35.81 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.038 -1.272 . . . . 0.0 108.51 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.4 tt -70.22 -16.07 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.571 -0.706 . . . . 0.0 109.768 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -55.87 -32.94 64.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 111.392 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 73.9 m -119.43 -64.69 1.24 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.008 -1.057 . . . . 0.0 111.601 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.401 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.5 mp -62.51 -48.14 80.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 110.612 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.8 -42.56 60.99 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.5 mt -62.39 -38.92 91.5 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.272 -1.134 . . . . 0.0 109.675 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.8 tp -59.12 -44.03 91.99 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.143 -0.973 . . . . 0.0 108.676 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -66.16 -38.25 87.62 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.291 -0.881 . . . . 0.0 109.017 178.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.93 -39.6 86.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.527 -0.733 . . . . 0.0 110.054 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.4 mp -58.1 -50.27 78.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.221 -0.925 . . . . 0.0 109.679 -179.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.54 -38.16 90.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.14 -0.975 . . . . 0.0 109.171 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.715 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 51.6 t90 -66.84 -40.15 87.86 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.392 -0.817 . . . . 0.0 109.474 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 tp -61.01 -43.53 98.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.462 -0.774 . . . . 0.0 109.735 -179.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -66.3 -36.4 82.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 110.001 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -62.3 -46.24 89.65 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.045 -1.034 . . . . 0.0 110.837 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.715 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt180 -87.4 -51.14 6.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.074 -1.016 . . . . 0.0 111.798 -178.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -79.88 -24.1 41.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.966 -1.084 . . . . 0.0 111.13 -178.084 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.47 31.54 45.55 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.44 -1.362 . . . . 0.0 109.739 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 68.1 mt -100.21 136.31 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.167 -1.196 . . . . 0.0 108.656 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.925 -1.11 . . . . 0.0 109.765 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.79 -32.57 74.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.522 -0.736 . . . . 0.0 109.405 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -58.91 -33.45 70.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.453 -0.78 . . . . 0.0 110.463 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -73.68 109.45 7.19 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.017 -1.052 . . . . 0.0 109.996 -179.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 m -133.94 157.77 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.44 -0.788 . . . . 0.0 109.242 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 63.1 tt0 -169.44 23.29 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.127 -0.983 . . . . 0.0 109.021 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.568 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 5.8 mp -104.65 143.34 33.21 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.168 -0.958 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.74 162.34 21.07 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.479 -0.763 . . . . 0.0 109.316 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -57.69 -30.67 89.75 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.757 2.304 . . . . 0.0 112.11 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.54 -31.83 73.21 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.264 -0.897 . . . . 0.0 109.509 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.5 ' O ' ' OG ' ' A' ' 71' ' ' SER . 83.7 t60 -68.59 -26.19 65.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 110.653 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -88.79 7.35 34.5 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.996 -1.065 . . . . 0.0 110.489 -178.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 24.0 mmt85 -58.07 -36.33 72.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.07 -1.019 . . . . 0.0 109.968 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.509 ' HG ' ' H ' ' A' ' 71' ' ' SER . 90.9 p -133.68 150.04 51.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.208 -0.932 . . . . 0.0 109.834 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.9 mt -66.05 -36.45 77.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.313 -0.867 . . . . 0.0 109.875 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -60.93 -37.61 82.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.171 -0.955 . . . . 0.0 109.916 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.509 ' H ' ' HG ' ' A' ' 68' ' ' SER . 88.4 p -61.37 -35.73 78.25 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.07 -1.019 . . . . 0.0 109.274 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.406 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 81.3 mt -61.41 -39.06 81.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.25 -0.907 . . . . 0.0 109.015 179.412 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.4 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 51.3 t0 -59.24 -37.32 77.27 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.515 -0.741 . . . . 0.0 109.68 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.19 -46.67 82.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.188 -0.945 . . . . 0.0 109.872 -179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -66.12 -44.85 83.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.053 -1.029 . . . . 0.0 109.079 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -62.63 -41.83 93.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.471 -0.768 . . . . 0.0 109.549 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.4 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 53.6 t -61.92 -41.73 91.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 O-C-N 121.264 -0.898 . . . . 0.0 109.661 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.65 -36.33 85.29 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -90.57 -49.82 6.28 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.11 -1.23 . . . . 0.0 110.079 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 76' ' ' VAL . 12.4 t -145.1 153.35 41.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -0.888 . . . . 0.0 109.577 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -134.69 88.5 28.24 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.667 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.44 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.0 Cg_exo -65.27 -176.47 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.655 2.237 . . . . 0.0 111.985 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.44 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.5 Cg_exo -60.59 150.9 79.4 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.574 2.182 . . . . 0.0 111.714 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 43.7 t -100.43 131.82 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 109.735 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -125.42 157.7 36.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.498 -0.751 . . . . 0.0 109.364 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -103.47 149.79 24.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.447 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -78.72 146.6 33.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.949 . . . . 0.0 109.373 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.0 mt -58.79 -34.99 72.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.901 . . . . 0.0 109.412 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.451 179.983 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.492 ' CE2' ' N5 ' ' A' ' 101' ' ' 7V9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.542 ' SD ' ' CD ' ' A' ' 70' ' ' ARG . 67.0 mtm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.444 0.64 . . . . 0.0 109.943 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.1 mt-30 -100.75 127.01 47.34 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.403 -0.811 . . . . 0.0 108.87 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.594 ' CD2' ' O ' ' A' ' 82' ' ' PRO . 6.4 m80 61.79 20.09 11.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -0.988 . . . . 0.0 109.139 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -63.43 -38.24 90.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.6 m -60.79 -39.12 87.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.97 . . . . 0.0 110.065 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.5 t -64.81 -38.09 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.103 -0.998 . . . . 0.0 109.554 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 83.2 mt -59.81 -50.8 78.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.25 -0.906 . . . . 0.0 109.631 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.542 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.21 -46.36 84.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 109.139 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.36 -39.98 94.95 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.4 -0.813 . . . . 0.0 109.648 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.64 -51.21 61.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.431 -0.793 . . . . 0.0 110.493 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.9 m -73.74 -39.28 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.24 -0.913 . . . . 0.0 110.367 -179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.542 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 99.3 t -65.13 -39.03 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.065 -1.022 . . . . 0.0 109.773 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -53.12 -35.87 60.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 109.8 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.62 -31.88 72.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.27 -0.894 . . . . 0.0 109.918 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.88 39.86 3.12 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 110.047 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.569 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.54 130.39 64.97 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 120.93 -1.106 . . . . 0.0 110.024 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.422 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.3 Cg_endo -77.84 -149.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 122.01 1.807 . . . . 0.0 110.346 178.516 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.45 ' OD2' ' C ' ' A' ' 18' ' ' ASP . 53.5 p30 -77.91 13.3 1.42 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.719 -1.238 . . . . 0.0 108.871 179.167 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.422 ' H ' ' C ' ' A' ' 17' ' ' PRO . 42.3 t -113.51 136.13 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.575 -0.703 . . . . 0.0 109.62 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.93 141.49 81.84 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.311 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -49.52 -30.28 20.91 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.929 1.753 . . . . 0.0 112.052 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.04 -22.86 67.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.307 -0.87 . . . . 0.0 109.643 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -96.11 7.13 47.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.333 -0.854 . . . . 0.0 109.132 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.58 136.52 34.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.1 89.61 0.44 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.175 -0.953 . . . . 0.0 109.605 -179.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -59.63 0.11 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.261 -0.899 . . . . 0.0 109.146 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -92.21 8.22 39.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.352 -0.842 . . . . 0.0 108.786 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.0 tp -90.96 139.06 31.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.427 -0.796 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.453 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.9 m-20 -60.82 121.58 12.69 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -69.86 7.13 0.97 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.254 -0.904 . . . . 0.0 109.847 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.453 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.4 p -53.46 -38.61 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.113 -0.992 . . . . 0.0 109.123 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.92 -36.45 72.5 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.15 19.55 3.09 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -15.01 0.02 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.63 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -53.43 -36.49 27.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.125 -1.221 . . . . 0.0 108.862 179.53 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.5 tt -70.38 -22.48 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.538 -0.726 . . . . 0.0 110.245 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.3 m-20 -55.42 -33.22 63.36 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 110.932 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -116.17 -63.75 1.41 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.123 -0.985 . . . . 0.0 111.24 -178.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.529 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.4 mm? -62.41 -52.18 64.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.047 -1.033 . . . . 0.0 110.096 -178.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.79 -40.19 64.87 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.7 tt -58.7 -41.04 85.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -1.094 . . . . 0.0 109.552 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 24.9 tp -62.76 -44.4 96.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.935 . . . . 0.0 109.024 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -66.24 -35.12 79.6 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.349 -0.844 . . . . 0.0 109.592 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 64.2 t -60.86 -42.99 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 110.24 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -59.64 -50.54 79.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.105 -0.997 . . . . 0.0 109.632 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.91 -36.65 82.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 34.3 t90 -67.79 -43.33 79.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 109.633 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.01 -46.3 85.48 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.477 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -67.84 -38.05 82.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.35 -0.844 . . . . 0.0 109.067 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.8 t0 -65.47 -41.48 93.32 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 110.64 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 74.5 ttt-85 -87.12 -58.14 2.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.171 -0.956 . . . . 0.0 111.662 -178.385 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -79.73 -19.47 48.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.02 -1.05 . . . . 0.0 111.559 -177.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 28.19 56.26 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -104.47 142.58 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.405 -1.056 . . . . 0.0 109.348 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.47 154.73 23.69 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.237 -0.914 . . . . 0.0 109.143 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -53.12 -39.34 63.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.259 -0.901 . . . . 0.0 109.405 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 52.0 48.19 23.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.193 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.84 133.61 56.25 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.252 -0.905 . . . . 0.0 109.747 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 31.3 m -132.23 160.9 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.492 -0.755 . . . . 0.0 109.203 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -91.99 120.64 32.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.059 -1.026 . . . . 0.0 109.81 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -134.31 -166.98 1.89 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 109.091 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.77 160.95 64.07 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.476 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.19 -21.47 59.91 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.892 2.395 . . . . 0.0 111.866 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.43 -32.32 70.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.402 -0.811 . . . . 0.0 110.091 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.484 ' O ' ' OG ' ' A' ' 71' ' ' SER . 44.9 t-80 -70.23 -26.27 63.77 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.319 -0.863 . . . . 0.0 111.404 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -95.11 8.0 44.37 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.799 -1.188 . . . . 0.0 110.817 -178.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -60.91 -38.44 85.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.998 -1.064 . . . . 0.0 110.671 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.4 m -126.66 147.58 49.91 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.222 -0.924 . . . . 0.0 110.483 -179.149 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.2 -36.09 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 O-C-N 121.434 -0.791 . . . . 0.0 109.802 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.542 ' CD ' ' SD ' ' A' ' 1' ' ' MET . 80.5 mtm180 -60.42 -37.7 81.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 110.157 -178.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.484 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 97.6 p -61.44 -36.85 81.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.08 -1.013 . . . . 0.0 109.282 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.6 -38.62 82.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.373 -0.83 . . . . 0.0 109.117 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 53.5 t0 -56.52 -38.74 72.24 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.43 -0.794 . . . . 0.0 109.655 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.84 -42.04 97.7 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.132 -0.98 . . . . 0.0 109.405 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -64.35 -45.66 86.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.863 . . . . 0.0 109.563 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.6 t -65.0 -42.42 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.348 -0.845 . . . . 0.0 110.05 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.2 t -63.18 -42.37 96.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.155 -0.966 . . . . 0.0 109.892 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.9 -30.07 72.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -97.69 -49.54 4.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.958 -1.319 . . . . 0.0 110.307 -179.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 76' ' ' VAL . 11.0 t -139.19 155.54 47.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.554 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 89.48 32.76 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.448 -0.783 . . . . 0.0 109.514 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.594 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 55.1 Cg_endo -79.86 162.22 23.92 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.737 2.291 . . . . 0.0 112.519 -179.512 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -61.26 150.81 83.0 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.785 2.323 . . . . 0.0 112.04 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 17.1 m -89.69 131.72 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.708 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.82 143.39 51.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.512 -0.743 . . . . 0.0 109.236 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.05 144.66 42.9 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -0.963 . . . . 0.0 109.498 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 47.3 mttp -58.06 -33.51 69.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.948 . . . . 0.0 109.274 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 50.7 mt -90.21 142.46 27.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 50.4 tt0 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.888 -1.053 . . . . 0.0 109.515 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.8 mmm . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' O ' ' O ' ' A' ' 83' ' ' PRO . 94.4 mt-30 -58.71 -35.17 72.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.458 ' CD2' ' CG2' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -163.88 25.0 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.155 -0.966 . . . . 0.0 109.385 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.87 -34.83 76.71 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.231 -0.918 . . . . 0.0 109.563 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 t -59.11 -39.6 82.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.159 -0.963 . . . . 0.0 109.543 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.458 ' CG2' ' CD2' ' A' ' 3' ' ' HIS . 78.3 t -65.13 -39.29 85.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.2 179.63 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.401 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 88.1 mt -59.86 -48.0 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.444 -0.785 . . . . 0.0 109.657 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.66 -46.37 85.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.318 -0.864 . . . . 0.0 109.656 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.443 ' HG3' ' N ' ' A' ' 10' ' ' PHE . 0.9 OUTLIER -69.52 -36.54 76.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.547 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.3 t80 -68.57 -48.23 64.76 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.389 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 73.7 t -69.12 -46.3 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 110.104 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 76.6 t -63.53 -35.2 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.39 -0.819 . . . . 0.0 110.676 -179.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.95 -36.8 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.125 -0.985 . . . . 0.0 109.86 -179.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.72 -35.39 78.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 110.685 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -91.99 -63.6 1.22 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.022 -1.049 . . . . 0.0 110.731 -178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.9 mt -125.66 83.03 62.79 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.255 -0.903 . . . . 0.0 110.19 -179.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -82.78 -19.53 5.98 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.299 179.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.45 ' OD1' ' C ' ' A' ' 18' ' ' ASP . 54.3 p30 -78.15 -3.41 42.33 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.176 -0.953 . . . . 0.0 109.216 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 57.7 t -113.81 140.33 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.91 117.82 32.74 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.936 -1.103 . . . . 0.0 108.552 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.0 -28.6 57.6 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.574 1.516 . . . . 0.0 111.813 -179.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.62 -14.75 62.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.391 -0.818 . . . . 0.0 109.174 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -82.94 -0.16 47.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.377 -0.827 . . . . 0.0 108.917 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -98.94 137.74 25.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.551 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -67.41 92.75 0.3 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.087 -1.008 . . . . 0.0 109.437 -179.277 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 m -59.77 0.01 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.421 -0.799 . . . . 0.0 109.206 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.551 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -88.98 5.69 43.05 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.8 tp -92.67 136.42 33.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.612 -0.68 . . . . 0.0 109.399 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.497 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.2 m-20 -60.93 121.58 12.74 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.1 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -67.02 6.53 0.51 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.126 -0.983 . . . . 0.0 109.72 -178.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.1 p -54.78 -37.57 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 108.933 179.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.432 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.25 -36.31 70.8 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.1 m-20 -84.96 17.92 2.69 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.44 ' O ' ' CG ' ' A' ' 37' ' ' ASP . . . -42.87 -14.26 0.01 OUTLIER Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.6 t -51.34 -37.93 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 108.855 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -70.9 -11.82 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.47 -0.769 . . . . 0.0 109.757 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.44 ' CG ' ' O ' ' A' ' 34' ' ' GLY . 85.3 m-20 -51.64 -42.31 61.96 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 111.376 -177.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.47 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.4 OUTLIER -120.91 -58.66 1.8 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.109 -0.995 . . . . 0.0 111.975 -178.381 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.6 mp -61.27 -52.15 65.95 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.825 -1.172 . . . . 0.0 110.135 -178.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.56 -36.06 68.08 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.98 -43.23 86.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -1.083 . . . . 0.0 109.548 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.65 -43.91 95.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.076 -1.015 . . . . 0.0 109.205 179.577 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -65.27 -38.05 89.1 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 80.0 t -65.31 -39.93 86.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.381 -0.825 . . . . 0.0 110.067 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -58.45 -50.1 79.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.155 -0.966 . . . . 0.0 109.905 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.98 -36.7 80.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.971 -1.081 . . . . 0.0 109.94 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.547 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -76.58 -41.92 44.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.143 -0.973 . . . . 0.0 110.126 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.7 tt -60.84 -43.12 98.74 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.411 -0.805 . . . . 0.0 110.801 -178.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.58 ' O ' ' N ' ' A' ' 53' ' ' GLY . 54.8 mt-10 -65.78 -39.64 91.2 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.946 -1.096 . . . . 0.0 109.217 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -67.84 -49.21 63.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.419 -0.8 . . . . 0.0 110.932 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.615 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 67.4 ttt-85 -62.07 -41.3 98.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 97.5 m-85 -101.58 -9.62 20.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.953 -1.092 . . . . 0.0 110.559 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.58 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.21 35.78 88.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -105.88 143.94 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.302 -1.117 . . . . 0.0 109.869 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.76 152.85 34.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.365 -0.835 . . . . 0.0 109.082 179.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.546 ' CB ' ' OE1' ' A' ' 49' ' ' GLU . . . -58.98 -38.78 79.92 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 110.206 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.446 ' O ' ' C ' ' A' ' 58' ' ' ASP . 85.4 m-20 52.92 48.8 21.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.052 -1.03 . . . . 0.0 108.495 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.446 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.3 m-20 -39.49 110.72 0.15 Allowed 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 121.563 0.697 . . . . 0.0 110.336 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 33.8 m -132.97 160.14 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -96.41 117.05 30.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.011 -1.056 . . . . 0.0 109.753 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.618 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 1.6 mm? -108.98 140.92 41.83 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.467 -0.77 . . . . 0.0 109.224 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.51 150.51 70.37 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.333 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.43 -28.06 77.78 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.532 2.154 . . . . 0.0 111.943 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -60.95 -28.3 68.88 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.418 -0.801 . . . . 0.0 109.993 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -67.78 -26.54 66.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.15 -0.969 . . . . 0.0 110.188 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.694 ' CD1' ' N9 ' ' A' ' 101' ' ' 7V9 . 71.5 m-85 -100.75 8.12 43.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.767 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.5 tpt180 -54.86 -40.06 69.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.356 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -127.69 148.6 50.4 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.319 -0.863 . . . . 0.0 109.69 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.3 mt -60.72 -36.59 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.299 -0.876 . . . . 0.0 109.891 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -60.55 -39.26 87.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.271 -0.893 . . . . 0.0 110.25 -179.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 m -58.25 -41.25 83.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.983 -1.073 . . . . 0.0 109.521 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.2 -38.62 83.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.521 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 91.9 m-20 -56.31 -38.14 70.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.461 -0.774 . . . . 0.0 109.609 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.88 -45.99 86.92 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -65.69 -46.67 78.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.181 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.3 t -64.35 -40.73 90.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.422 -0.799 . . . . 0.0 109.681 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.521 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 55.1 t -60.33 -43.34 93.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.16 -0.963 . . . . 0.0 109.91 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.46 -37.38 94.71 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -87.62 -50.15 6.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.999 -1.295 . . . . 0.0 110.331 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.9 p -130.8 156.24 45.34 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.409 -0.807 . . . . 0.0 109.199 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.23 88.53 11.42 Favored Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.219 -0.926 . . . . 0.0 109.609 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.425 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.0 Cg_exo -63.94 -177.68 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.528 2.152 . . . . 0.0 111.911 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 2' ' ' GLN . 22.1 Cg_exo -60.73 150.55 82.04 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.463 2.108 . . . . 0.0 111.819 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 42.3 t -105.56 129.13 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.294 -0.879 . . . . 0.0 109.718 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -138.88 156.0 47.64 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.366 -0.834 . . . . 0.0 109.218 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.88 140.74 58.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.068 -1.02 . . . . 0.0 109.188 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 48.0 tttm -88.73 143.11 27.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.434 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.1 mt -56.91 -32.15 65.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.306 -0.871 . . . . 0.0 109.879 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 92.3 mm-40 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.944 -1.026 . . . . 0.0 109.384 -179.667 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.694 ' N9 ' ' CD1' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.343 0.592 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -58.98 -35.91 74.0 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.35 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -152.04 57.42 0.84 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.905 . . . . 0.0 109.107 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.36 -35.41 75.61 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.265 -0.897 . . . . 0.0 109.97 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -59.46 -40.8 88.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.055 -1.028 . . . . 0.0 109.545 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.2 t -67.01 -37.85 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.239 -0.913 . . . . 0.0 109.182 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.494 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 87.8 mt -59.73 -40.03 81.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.496 -0.753 . . . . 0.0 110.101 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.18 -50.0 72.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.023 -1.048 . . . . 0.0 109.294 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.488 ' OE1' ' OE1' ' A' ' 13' ' ' GLU . 1.2 pp0? -69.94 -33.94 72.79 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.338 -0.851 . . . . 0.0 109.439 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.595 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 65.0 t80 -66.35 -51.96 51.84 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.043 -1.035 . . . . 0.0 109.942 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 5.5 p -70.57 -38.7 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.233 -0.917 . . . . 0.0 110.111 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 88.6 t -65.25 -42.1 93.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.211 -0.93 . . . . 0.0 110.639 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' OE1' ' OE1' ' A' ' 9' ' ' GLN . 76.6 mt-10 -55.18 -27.38 45.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.021 -1.049 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -65.38 -27.75 68.79 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 109.101 179.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.586 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.0 p90 -149.83 41.64 0.85 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.219 -0.926 . . . . 0.0 109.852 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.568 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.67 131.21 61.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 120.948 -1.095 . . . . 0.0 110.196 -179.817 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.405 ' C ' ' H ' ' A' ' 19' ' ' VAL . 67.0 Cg_endo -75.94 -151.31 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 C-N-CA 122.061 1.841 . . . . 0.0 110.671 178.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -79.3 17.01 0.87 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.86 -1.15 . . . . 0.0 109.345 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 17' ' ' PRO . 40.6 t -113.37 136.83 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.368 -0.832 . . . . 0.0 109.586 -179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.06 142.17 97.02 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.192 -0.942 . . . . 0.0 109.496 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -49.94 -32.55 30.85 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.936 1.757 . . . . 0.0 111.938 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.33 -24.84 67.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.453 -0.779 . . . . 0.0 109.64 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -98.47 7.12 46.58 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -0.863 . . . . 0.0 109.453 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.4 t -103.8 135.16 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.315 -0.866 . . . . 0.0 108.879 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.471 ' C ' ' H ' ' A' ' 27' ' ' ASP . 88.0 m-20 -72.17 86.06 1.06 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.219 -0.925 . . . . 0.0 109.315 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.7 m -63.11 -0.3 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.233 -0.917 . . . . 0.0 109.627 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.475 ' OD1' ' C ' ' A' ' 27' ' ' ASP . 48.0 p30 -90.7 8.52 34.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.141 -0.974 . . . . 0.0 108.787 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 18.8 tp -93.93 136.37 34.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 109.447 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -60.95 122.48 15.02 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.6 mt -66.89 -0.86 3.35 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.258 -0.901 . . . . 0.0 109.87 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.9 t -52.61 -42.47 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.089 -1.007 . . . . 0.0 108.911 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.46 -36.33 66.46 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.619 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.8 m-80 -86.55 20.29 2.53 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.46 -15.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.619 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -53.33 -38.81 32.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.884 -1.363 . . . . 0.0 108.277 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.585 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.4 tt -70.87 -24.2 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.599 -0.688 . . . . 0.0 109.95 179.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -62.54 -22.51 66.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.181 -0.949 . . . . 0.0 110.697 -178.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -117.47 -64.87 1.24 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.081 -1.012 . . . . 0.0 111.013 -178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.2 mp -67.41 -50.2 60.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.034 -1.041 . . . . 0.0 110.171 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.74 -41.24 64.13 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tt -61.1 -40.05 92.26 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.494 -1.003 . . . . 0.0 109.617 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.6 tp -58.63 -44.31 89.96 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.189 -0.944 . . . . 0.0 108.569 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.0 mtpt -65.06 -34.2 77.86 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.49 -39.77 86.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.495 -0.753 . . . . 0.0 110.511 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.419 HG22 HD11 ' A' ' 45' ' ' ILE . 27.9 mm -59.22 -50.74 78.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.637 -1.29 . . . . 0.0 109.525 -179.488 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.87 -41.31 83.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.292 -0.88 . . . . 0.0 109.793 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 16.8 t90 -69.77 -42.81 73.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 110.233 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 33.2 tp -59.36 -41.93 90.43 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.329 -0.857 . . . . 0.0 109.712 -179.384 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.569 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.5 tt0 -64.06 -38.12 89.92 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.238 -0.914 . . . . 0.0 109.753 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -60.07 -37.08 78.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.951 -1.093 . . . . 0.0 110.064 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -75.09 -48.68 22.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.245 -0.91 . . . . 0.0 111.958 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -114.66 -3.12 12.91 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.012 -1.055 . . . . 0.0 111.855 -178.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 30.48 61.22 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.874 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 75.8 mt -78.19 138.78 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -1.217 . . . . 0.0 108.977 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 131.21 49.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.827 -1.17 . . . . 0.0 109.736 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.82 -28.5 68.41 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.448 -0.782 . . . . 0.0 109.258 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.81 -31.96 63.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.444 -0.785 . . . . 0.0 110.247 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -49.04 139.15 10.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.062 -1.024 . . . . 0.0 109.758 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.536 ' O ' ' CG2' ' A' ' 59' ' ' VAL . 7.7 p -157.8 29.02 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.417 -0.802 . . . . 0.0 109.207 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.03 -26.75 68.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.346 -0.847 . . . . 0.0 109.719 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.494 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 5.6 mp -75.97 146.07 39.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.289 -0.882 . . . . 0.0 109.725 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 173.17 6.16 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.465 -0.772 . . . . 0.0 109.226 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -50.7 -31.45 32.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.222 1.948 . . . . 0.0 111.69 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.05 -30.72 71.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.423 -0.798 . . . . 0.0 109.074 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.563 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 46.7 t-80 -67.65 -26.55 66.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.474 -0.767 . . . . 0.0 109.802 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -91.9 10.22 29.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.181 -0.949 . . . . 0.0 109.449 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -53.61 -36.55 62.11 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.294 -0.879 . . . . 0.0 109.463 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.9 t -150.3 152.61 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.273 -0.892 . . . . 0.0 109.846 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -64.31 -36.16 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -60.7 -38.07 83.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.111 -0.993 . . . . 0.0 110.107 -179.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.01 -37.03 85.55 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.073 -1.017 . . . . 0.0 109.16 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.5 mt -66.36 -38.43 81.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.329 -0.857 . . . . 0.0 109.29 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.494 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 53.1 t0 -56.25 -41.05 75.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.491 -0.756 . . . . 0.0 109.88 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.63 -45.33 79.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.205 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.563 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 65.6 t80 -63.08 -48.61 77.88 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -0.966 . . . . 0.0 109.751 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.9 t -66.48 -42.83 90.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.251 -0.906 . . . . 0.0 109.836 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 44.5 t -61.96 -40.55 87.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 120.969 -1.082 . . . . 0.0 109.693 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.84 -34.36 71.06 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.36 -50.65 3.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.133 -1.216 . . . . 0.0 110.79 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.504 ' O ' ' O ' ' A' ' 76' ' ' VAL . 56.0 m -153.96 140.41 18.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.995 -1.066 . . . . 0.0 110.267 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.99 87.77 50.89 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.282 -0.886 . . . . 0.0 109.239 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -95.87 105.69 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 123.542 2.828 . . . . 0.0 112.894 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -80.36 128.36 7.06 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.098 1.865 . . . . 0.0 111.953 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.04 132.4 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.617 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.23 -38.86 92.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.266 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -162.46 150.89 14.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.304 -0.873 . . . . 0.0 109.419 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.595 ' NZ ' ' O ' ' A' ' 10' ' ' PHE . 16.6 mttm -59.76 -33.76 72.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.121 -0.987 . . . . 0.0 109.627 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 33.4 tp -95.85 130.28 42.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.474 -179.964 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.6 mtt . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -60.04 -37.49 79.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.935 . . . . 0.0 109.266 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.552 ' NE2' ' CG1' ' A' ' 6' ' ' VAL . 57.1 t-80 -148.33 8.06 0.8 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.34 -0.85 . . . . 0.0 109.724 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.63 -39.81 95.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.055 -1.028 . . . . 0.0 109.769 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.3 t -61.52 -40.08 93.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.924 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.552 ' CG1' ' NE2' ' A' ' 3' ' ' HIS . 78.1 t -63.27 -39.71 86.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.257 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 92.0 mt -62.4 -46.45 96.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.346 -0.846 . . . . 0.0 110.01 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.88 -49.93 70.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 110.411 -179.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.436 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 4.2 pp0? -69.91 -42.07 73.83 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.182 -0.949 . . . . 0.0 109.894 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 9' ' ' GLN . 71.4 t80 -60.49 -46.47 90.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 67.2 t -69.63 -47.01 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.44 -0.787 . . . . 0.0 109.92 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.5 t -65.51 -35.18 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.404 -0.81 . . . . 0.0 110.453 -179.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -53.52 -36.66 62.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.214 -0.928 . . . . 0.0 109.992 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.96 -35.57 78.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 110.771 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -91.74 -63.6 1.23 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.963 -1.085 . . . . 0.0 110.657 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.2 mp -125.66 83.06 62.76 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.331 -0.855 . . . . 0.0 110.119 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.64 -18.96 7.76 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.853 2.369 . . . . 0.0 112.202 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.451 ' OD2' ' C ' ' A' ' 18' ' ' ASP . 54.4 p30 -80.11 -1.25 39.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.211 -0.931 . . . . 0.0 109.119 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.4 t -113.59 142.09 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.72 117.44 28.35 Favored Pre-proline 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 108.531 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.567 ' C ' ' HZ1' ' A' ' 87' ' ' LYS . 17.9 Cg_endo -64.9 -25.57 59.81 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.524 1.483 . . . . 0.0 111.723 -179.268 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.645 ' CA ' ' HZ3' ' A' ' 87' ' ' LYS . . . -70.49 -14.87 62.7 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.31 -0.869 . . . . 0.0 109.232 179.419 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -82.87 2.91 31.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.255 -0.903 . . . . 0.0 108.929 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.13 137.27 32.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.509 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.4 89.17 0.14 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.147 -0.971 . . . . 0.0 109.377 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.7 m -62.31 -0.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.307 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.509 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -93.85 7.07 46.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 108.979 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.9 tp -95.7 137.87 34.15 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.483 -0.761 . . . . 0.0 109.6 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.407 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.8 m-20 -61.71 121.81 13.75 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.453 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.5 OUTLIER -67.97 2.87 1.79 Allowed 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.266 -0.896 . . . . 0.0 109.932 -178.811 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.456 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -51.28 -39.19 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.08 -1.012 . . . . 0.0 108.395 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.42 -35.78 70.5 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.7 m-20 -87.09 22.14 2.14 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.009 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -14.27 0.01 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -51.26 -35.31 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.104 -1.233 . . . . 0.0 108.612 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.577 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -70.07 -19.94 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.517 -0.739 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.418 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -55.53 -33.18 63.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -0.87 . . . . 0.0 111.046 -178.51 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.486 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.5 OUTLIER -116.78 -64.13 1.35 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.115 -0.991 . . . . 0.0 111.356 -178.571 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.5 mp -62.88 -52.08 64.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.99 -1.068 . . . . 0.0 110.093 -178.661 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.67 -38.92 67.39 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.577 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.2 tt -58.45 -43.08 88.7 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.401 -1.058 . . . . 0.0 109.725 -179.75 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 tp -60.23 -44.32 95.31 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 108.956 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -69.72 -40.1 76.46 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.373 -0.829 . . . . 0.0 109.967 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.8 t -66.03 -45.01 91.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 110.391 -179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -59.45 -50.24 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.084 -1.01 . . . . 0.0 109.513 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.62 -32.2 73.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 29.6 t90 -74.46 -45.83 43.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.878 . . . . 0.0 110.246 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -57.41 -45.31 84.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.362 -0.836 . . . . 0.0 110.009 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.414 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 8.4 pt-20 -71.23 -36.42 71.82 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.098 -1.001 . . . . 0.0 109.056 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.9 t0 -64.78 -41.45 95.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.322 -0.861 . . . . 0.0 110.639 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.4 ttt180 -83.78 -51.56 7.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 110.95 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -79.85 -24.55 41.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.05 -1.031 . . . . 0.0 110.842 -178.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.41 31.44 54.54 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 53.9 mt -109.4 134.28 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -1.085 . . . . 0.0 109.582 -179.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.93 143.39 57.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.352 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.79 73.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -56.96 -35.52 69.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.252 -0.905 . . . . 0.0 109.74 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -53.84 -33.74 57.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.767 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.6 t -97.49 137.32 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.144 -0.973 . . . . 0.0 109.758 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -78.66 142.83 36.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.573 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 33.0 mt -95.08 137.36 34.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.399 -0.813 . . . . 0.0 109.654 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.411 ' H ' ' H16' ' A' ' 101' ' ' 7V9 . 0.0 OUTLIER 178.56 145.66 0.34 Allowed Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.973 . . . . 0.0 109.665 179.514 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.89 -26.88 74.53 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.481 2.121 . . . . 0.0 112.281 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -57.65 -27.42 62.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.843 . . . . 0.0 109.654 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.436 ' O ' ' CG1' ' A' ' 72' ' ' ILE . 85.9 t60 -67.13 -26.92 66.91 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.941 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -101.1 4.25 42.01 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.028 -1.045 . . . . 0.0 110.373 -179.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -58.86 -40.94 85.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.887 -1.133 . . . . 0.0 109.86 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.1 p -150.06 154.89 38.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.903 -1.123 . . . . 0.0 110.019 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 87.6 mt -65.33 -37.36 79.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.343 -0.848 . . . . 0.0 109.857 179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.7 ttp180 -60.93 -40.43 93.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 110.164 -179.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -59.58 -41.85 91.19 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.999 -1.063 . . . . 0.0 109.695 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.436 ' CG1' ' O ' ' A' ' 65' ' ' HIS . 87.2 mt -67.43 -39.96 83.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.258 -0.901 . . . . 0.0 110.005 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -59.16 -40.79 86.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 110.188 -179.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.53 -42.71 98.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.129 -0.982 . . . . 0.0 109.586 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.0 t80 -63.74 -45.34 90.34 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.247 -0.908 . . . . 0.0 109.336 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.7 t -63.75 -45.36 97.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.355 -0.841 . . . . 0.0 109.915 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.0 t -60.97 -40.09 84.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 O-C-N 121.125 -0.984 . . . . 0.0 109.637 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.76 -32.25 65.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.15 -50.17 3.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.084 -1.245 . . . . 0.0 110.403 -179.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 76' ' ' VAL . 8.4 t -146.22 155.61 42.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.171 -0.956 . . . . 0.0 110.021 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -133.21 88.55 35.54 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.317 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -67.18 159.4 52.32 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.588 2.192 . . . . 0.0 112.239 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.76 150.82 84.28 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.915 2.41 . . . . 0.0 112.165 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.1 141.05 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.382 -0.824 . . . . 0.0 109.427 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -173.59 -7.54 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.335 -0.853 . . . . 0.0 109.105 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.71 -39.18 80.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.015 -1.053 . . . . 0.0 109.815 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.645 ' HZ3' ' CA ' ' A' ' 22' ' ' ALA . 49.3 mttm -106.65 146.74 30.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 109.41 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.462 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 69.7 mt -59.43 -35.8 74.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.238 -0.914 . . . . 0.0 109.822 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.566 HE21 ' CB ' ' A' ' 87' ' ' LYS . 99.3 mm-40 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.465 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.486 ' O2P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtt . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.313 0.578 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -59.43 -38.34 80.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.381 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.583 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 49.4 m80 -136.39 11.84 3.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.334 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.75 -33.24 71.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.347 -0.846 . . . . 0.0 109.918 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.35 -35.3 77.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.097 -1.002 . . . . 0.0 109.552 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.26 -37.83 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.184 -0.947 . . . . 0.0 109.167 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.3 mt -63.55 -43.27 98.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.067 -1.021 . . . . 0.0 110.089 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.47 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.22 -50.67 67.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.789 -179.178 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.5 -36.93 74.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.958 -1.088 . . . . 0.0 110.065 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -59.4 -51.3 70.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.844 -1.16 . . . . 0.0 110.082 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.4 ' O ' ' CD1' ' A' ' 15' ' ' PHE . 20.4 m -74.3 -40.64 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.142 -0.973 . . . . 0.0 110.32 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.47 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 79.7 t -62.49 -39.38 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.257 -0.902 . . . . 0.0 110.502 -179.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -61.86 -32.56 72.92 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.128 -0.982 . . . . 0.0 110.02 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.37 -33.24 75.28 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.869 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 11' ' ' VAL . 62.3 m-85 -93.1 -63.86 1.16 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.162 -0.961 . . . . 0.0 110.451 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.8 mt -129.52 83.47 64.74 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.289 -0.882 . . . . 0.0 110.594 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.22 -13.88 13.6 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.613 2.209 . . . . 0.0 112.169 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.69 -4.46 43.32 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.136 -0.978 . . . . 0.0 108.869 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.89 141.02 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.81 119.69 50.16 Favored Pre-proline 0 C--N 1.304 -1.404 0 O-C-N 120.905 -1.122 . . . . 0.0 108.74 -179.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -64.84 -27.61 59.24 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 121.54 1.493 . . . . 0.0 111.924 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . . . -70.56 -14.84 62.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.443 -0.786 . . . . 0.0 109.213 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -83.3 4.13 28.48 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.42 -0.8 . . . . 0.0 109.18 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.5 t -102.09 136.88 32.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.45 -0.781 . . . . 0.0 108.906 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 27' ' ' ASP . 47.6 p30 -67.48 84.36 0.17 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.225 -0.922 . . . . 0.0 109.734 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -60.4 0.23 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.263 179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -88.25 3.75 48.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 108.87 179.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.92 139.82 30.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.524 -0.735 . . . . 0.0 109.45 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.415 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.9 m-20 -60.93 121.73 13.11 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 179.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -66.23 1.41 1.56 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.146 -0.971 . . . . 0.0 109.927 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.7 -39.16 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.038 -1.038 . . . . 0.0 108.29 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.458 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.93 -34.94 72.3 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.107 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.702 ' N ' HD21 ' A' ' 33' ' ' ASN . 1.0 OUTLIER -84.11 16.5 2.9 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.54 -15.12 0.02 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.01 -36.44 15.89 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.922 -1.34 . . . . 0.0 108.769 179.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.588 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.0 tt -70.54 -19.53 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.469 -0.769 . . . . 0.0 109.774 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -55.94 -31.73 63.19 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.324 -0.86 . . . . 0.0 111.228 -178.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.9 m -118.89 -64.71 1.25 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.099 -1.0 . . . . 0.0 111.334 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -61.68 -52.18 65.39 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.76 -1.213 . . . . 0.0 109.891 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.44 -38.27 62.27 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.588 ' N ' ' O ' ' A' ' 36' ' ' ILE . 30.5 tp -58.54 -44.2 89.52 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.343 -1.093 . . . . 0.0 109.979 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 86.1 mt -61.71 -43.82 98.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.117 -0.989 . . . . 0.0 109.287 179.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -62.65 -34.91 78.03 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.239 -0.913 . . . . 0.0 108.916 179.206 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.585 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 78.0 t -62.74 -39.8 86.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.529 -0.732 . . . . 0.0 110.136 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.7 mm -58.6 -50.3 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.008 -1.057 . . . . 0.0 109.734 -179.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.15 -37.64 84.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.722 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.0 t90 -70.48 -44.6 67.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.962 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.3 tp -58.34 -47.12 84.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 109.63 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -66.82 -37.39 84.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -0.929 . . . . 0.0 109.11 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.13 -42.13 84.95 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 110.668 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.3 ttt-85 -87.37 -58.48 2.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.257 -0.902 . . . . 0.0 111.809 -178.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -79.85 -19.46 48.29 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 111.599 -177.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 33.05 41.11 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.1 mt -102.8 141.87 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.375 -1.074 . . . . 0.0 109.374 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.88 145.01 54.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.254 -0.904 . . . . 0.0 109.854 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.9 -19.27 65.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.538 -0.726 . . . . 0.0 109.876 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.485 ' O ' ' O ' ' A' ' 58' ' ' ASP . 92.2 m-20 -52.85 -37.27 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.17 -0.956 . . . . 0.0 109.371 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.485 ' O ' ' O ' ' A' ' 57' ' ' ASP . 94.1 m-20 52.42 172.44 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.274 -0.891 . . . . 0.0 109.231 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.1 p -136.67 142.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.266 -0.896 . . . . 0.0 110.161 -179.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 52.92 77.52 0.16 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.43 -0.794 . . . . 0.0 110.187 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.628 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -104.23 127.13 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.302 -0.874 . . . . 0.0 109.168 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.17 148.01 17.23 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 120.962 -1.086 . . . . 0.0 109.712 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.74 -25.64 74.95 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.68 2.253 . . . . 0.0 112.235 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.36 -31.46 71.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 109.727 -179.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.432 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 48.6 t-80 -68.63 -25.93 65.09 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.446 -0.784 . . . . 0.0 111.127 -179.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -95.6 5.86 50.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.743 -1.223 . . . . 0.0 110.92 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 -60.21 -37.53 80.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.895 -1.128 . . . . 0.0 110.353 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.3 p -133.38 147.44 51.79 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.076 -1.015 . . . . 0.0 110.07 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 78.1 mt -66.38 -36.71 78.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 O-C-N 121.432 -0.793 . . . . 0.0 109.797 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 92.3 mtm-85 -60.97 -37.97 84.28 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.346 -0.846 . . . . 0.0 110.099 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.3 p -61.72 -35.92 79.45 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.107 -0.996 . . . . 0.0 109.458 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 61.8 mt -66.71 -39.02 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.238 -0.914 . . . . 0.0 109.174 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -59.1 -39.44 82.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.333 -0.855 . . . . 0.0 109.779 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.27 -44.2 92.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.1 -1.0 . . . . 0.0 109.654 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.432 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 69.4 t80 -63.42 -46.17 87.57 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.242 -0.911 . . . . 0.0 109.387 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -64.43 -43.36 96.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.346 -0.846 . . . . 0.0 109.739 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 51.1 t -60.35 -40.83 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 O-C-N 121.24 -0.913 . . . . 0.0 109.659 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.31 -32.56 72.57 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.88 -50.41 3.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.063 -1.257 . . . . 0.0 110.719 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.4 p -131.79 157.9 42.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.283 -0.885 . . . . 0.0 109.827 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.82 87.99 16.43 Favored Pre-proline 0 C--N 1.304 -1.408 0 O-C-N 121.182 -0.949 . . . . 0.0 109.434 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.583 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 14.4 Cg_exo -65.03 -177.96 0.69 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.553 2.169 . . . . 0.0 112.008 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.421 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.2 Cg_exo -61.1 148.57 92.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.499 2.133 . . . . 0.0 111.845 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 43.4 t -111.97 130.83 64.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.345 -0.847 . . . . 0.0 109.571 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.41 156.78 47.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.453 -0.779 . . . . 0.0 109.364 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.8 144.61 54.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -0.934 . . . . 0.0 109.303 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.421 ' NZ ' ' O ' ' A' ' 22' ' ' ALA . 63.8 tttm -57.95 -37.19 73.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.47 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.3 mt -93.89 141.82 28.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.457 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.585 ' C18' ' CG1' ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.68 ' N ' ' SD ' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.579 ' NE2' ' CG1' ' A' ' 84' ' ' VAL . 96.0 mt-30 -83.71 21.79 1.2 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 109.352 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 30.9 m80 60.94 43.42 11.69 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -55.68 -34.86 65.41 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.471 -0.768 . . . . 0.0 109.658 -179.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -58.89 -39.35 81.18 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.229 -0.919 . . . . 0.0 109.01 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' N ' ' A' ' 10' ' ' PHE . 66.0 t -67.78 -39.25 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.401 -0.812 . . . . 0.0 109.004 179.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 90.9 mt -58.95 -50.05 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.479 -0.763 . . . . 0.0 109.634 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.538 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.62 -45.75 88.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.353 -0.842 . . . . 0.0 109.668 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.43 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.03 -33.75 74.12 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.365 -0.834 . . . . 0.0 109.694 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.565 ' CE1' ' CZ2' ' A' ' 47' ' ' TRP . 61.7 t80 -64.96 -51.49 61.5 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.091 -1.005 . . . . 0.0 109.694 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.401 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 15.8 m -74.49 -40.39 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.308 -0.87 . . . . 0.0 110.098 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.538 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 77.4 t -62.05 -37.8 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.203 -0.936 . . . . 0.0 110.122 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -56.75 -36.7 70.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.33 -0.856 . . . . 0.0 109.752 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -68.16 -35.87 78.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 110.681 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -89.78 -63.01 1.34 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.025 -1.047 . . . . 0.0 110.618 -178.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mt -127.36 82.91 67.35 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.302 -0.874 . . . . 0.0 110.113 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -81.01 -18.7 8.72 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.699 2.266 . . . . 0.0 112.125 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.83 -4.14 42.05 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.226 -0.921 . . . . 0.0 109.017 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.57 141.6 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.71 119.1 44.48 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.0 -1.063 . . . . 0.0 108.599 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.73 -30.5 59.36 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.612 1.541 . . . . 0.0 112.052 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.75 -14.73 62.55 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.374 -0.829 . . . . 0.0 109.001 179.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -86.53 4.73 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.547 -0.72 . . . . 0.0 109.116 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -98.74 135.59 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.481 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -70.37 83.26 0.56 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.19 -0.944 . . . . 0.0 109.651 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -63.47 -0.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 109.117 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.481 ' H ' ' C ' ' A' ' 25' ' ' ASP . 50.6 p30 -100.39 9.83 42.08 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.248 -0.907 . . . . 0.0 109.195 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.7 tp -92.02 145.39 24.57 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.481 -0.762 . . . . 0.0 109.434 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -60.02 121.4 11.75 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 67' ' ' ARG . 76.4 mt -61.81 -11.73 13.89 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.436 -0.79 . . . . 0.0 109.97 -178.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.8 t -50.53 -45.33 26.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.801 -1.187 . . . . 0.0 108.678 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -57.61 -35.34 70.33 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.602 ' O ' ' N ' ' A' ' 35' ' ' VAL . 10.6 m120 -86.9 19.04 3.17 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.05 -18.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.602 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.5 t -52.8 -38.85 29.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.234 -1.157 . . . . 0.0 108.505 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -70.4 -24.05 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.555 -0.716 . . . . 0.0 109.375 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -56.3 -33.01 65.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.513 -0.742 . . . . 0.0 110.919 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -113.78 -64.47 1.31 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.159 -0.963 . . . . 0.0 111.098 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.6 mp -64.01 -50.44 68.5 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.955 -1.091 . . . . 0.0 110.188 -178.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.53 -40.55 67.39 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.73 -40.55 84.1 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.45 -1.029 . . . . 0.0 109.505 -179.552 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.3 tp -65.92 -44.24 85.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -65.22 -37.47 87.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.263 -0.898 . . . . 0.0 110.005 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 73.4 t -62.28 -43.26 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.351 -0.843 . . . . 0.0 110.073 -179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -62.87 -50.42 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.244 -0.91 . . . . 0.0 109.911 -179.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.01 -34.91 78.76 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.267 -0.895 . . . . 0.0 110.16 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.565 ' CZ2' ' CE1' ' A' ' 10' ' ' PHE . 3.8 t90 -66.99 -44.39 80.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 0.0 109.946 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.7 tp -57.51 -43.98 84.67 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.406 -0.809 . . . . 0.0 109.716 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -66.31 -38.54 87.96 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.221 -0.924 . . . . 0.0 109.401 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.86 -41.06 95.98 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.147 -0.97 . . . . 0.0 110.648 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -87.17 -58.37 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.104 -0.998 . . . . 0.0 111.644 -178.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -79.73 -19.99 47.49 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.1 -1.0 . . . . 0.0 111.587 -177.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 30.23 50.97 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -179.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.43 142.39 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.412 -1.052 . . . . 0.0 109.421 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.36 154.03 25.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.189 -0.944 . . . . 0.0 109.217 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.12 -40.15 67.08 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.233 -0.917 . . . . 0.0 109.542 -179.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 51.45 47.84 24.06 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.173 -0.955 . . . . 0.0 109.311 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -59.87 133.78 56.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.202 -0.936 . . . . 0.0 109.717 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 39.2 t -126.85 139.81 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.52 -0.737 . . . . 0.0 109.279 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -68.29 88.59 0.31 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.976 . . . . 0.0 109.74 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.404 ' H ' ' H15' ' A' ' 101' ' ' 7V9 . 25.6 mt -111.98 142.28 44.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.535 -0.728 . . . . 0.0 109.43 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.15 159.24 80.77 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.302 -0.874 . . . . 0.0 109.739 -179.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -60.17 -22.98 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.926 2.417 . . . . 0.0 112.168 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.5 -31.14 71.84 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 110.028 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -67.76 -26.71 66.26 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.47 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 28.2 m-85 -97.07 2.66 51.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.193 -0.942 . . . . 0.0 109.281 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 30' ' ' LEU . 56.0 ttp180 -56.15 -39.62 72.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.476 -0.765 . . . . 0.0 110.524 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 91.2 p -119.66 148.91 42.8 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.415 -0.803 . . . . 0.0 110.463 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.7 mt -65.89 -36.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.679 -0.638 . . . . 0.0 109.981 179.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -61.5 -39.21 90.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 110.231 -179.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.579 ' HG ' ' HZ1' ' A' ' 87' ' ' LYS . 19.7 m -60.74 -44.14 97.05 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.018 -1.051 . . . . 0.0 109.529 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -67.13 -39.61 83.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.338 -0.852 . . . . 0.0 109.237 179.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.539 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 38.6 t0 -57.5 -38.18 74.18 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.541 -0.724 . . . . 0.0 109.617 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.72 -46.24 89.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.954 -1.091 . . . . 0.0 109.434 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -67.06 -47.47 71.2 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.159 -0.963 . . . . 0.0 108.861 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.1 t -63.17 -40.11 87.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.539 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 38.0 t -55.63 -42.42 68.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 O-C-N 121.292 -0.88 . . . . 0.0 108.876 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.54 69.14 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.79 -1.724 . . . . 0.0 108.79 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.9 -47.55 68.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -1.098 . . . . 0.0 110.213 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 172.49 2.59 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.045 -1.034 . . . . 0.0 111.328 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.486 ' H ' ' HG1' ' A' ' 81' ' ' THR . 0.1 OUTLIER -75.04 142.88 76.61 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 120.665 -1.272 . . . . 0.0 108.439 179.638 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.459 ' C ' ' O ' ' A' ' 81' ' ' THR . 89.3 Cg_exo -26.65 125.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.318 -1.078 0 C-N-CA 123.024 2.483 . . . . 0.0 112.802 -178.793 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -76.43 150.64 32.43 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 122.572 2.182 . . . . 0.0 113.312 -179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.579 ' CG1' ' NE2' ' A' ' 2' ' ' GLN . 12.7 p -133.35 142.03 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.448 -0.782 . . . . 0.0 109.139 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -58.8 -36.02 73.78 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -0.945 . . . . 0.0 109.669 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -153.0 153.38 32.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.063 -1.023 . . . . 0.0 109.72 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.579 ' HZ1' ' HG ' ' A' ' 71' ' ' SER . 87.3 tttt -58.74 -38.28 78.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.862 . . . . 0.0 109.392 179.75 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.432 ' O ' ' C ' ' A' ' 89' ' ' GLN . 54.0 mt -96.74 142.2 29.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.399 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.432 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.426 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.404 ' H15' ' H ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ptp . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.416 -0.586 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.562 ' N ' ' O ' ' A' ' 83' ' ' PRO . 91.9 mt-30 55.92 43.31 27.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.367 -0.833 . . . . 0.0 109.437 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.451 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.9 m170 42.86 38.7 1.46 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.185 -0.947 . . . . 0.0 109.014 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.94 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 109.722 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.7 p -61.42 -37.52 83.8 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.065 -1.022 . . . . 0.0 109.325 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.5 t -68.5 -38.71 79.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.19 -0.944 . . . . 0.0 108.83 179.104 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 86.4 mt -60.27 -51.72 69.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.35 -0.844 . . . . 0.0 109.274 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -65.33 -47.16 77.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.38 -0.825 . . . . 0.0 109.591 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.7 -44.2 94.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.572 -0.705 . . . . 0.0 109.451 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.401 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.9 t80 -62.15 -48.24 80.98 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.53 -0.731 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 85.3 t -69.71 -44.5 79.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.461 -0.774 . . . . 0.0 109.696 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 84.2 t -66.86 -39.5 83.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.428 -0.795 . . . . 0.0 110.183 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -53.68 -28.92 36.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.184 -0.947 . . . . 0.0 109.957 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.24 -30.43 71.31 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.533 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.575 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.5 p90 -146.73 44.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.558 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.67 130.78 63.04 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.078 -1.014 . . . . 0.0 109.978 -179.94 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.435 ' C ' ' H ' ' A' ' 19' ' ' VAL . 70.7 Cg_endo -76.66 -152.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 121.975 1.783 . . . . 0.0 110.626 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -78.37 16.99 0.7 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.924 -1.11 . . . . 0.0 108.997 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.435 ' H ' ' C ' ' A' ' 17' ' ' PRO . 42.5 t -113.27 137.0 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.493 -0.755 . . . . 0.0 109.755 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.63 141.53 95.29 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.435 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -49.66 -31.91 26.67 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 121.911 1.741 . . . . 0.0 112.042 179.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.6 -23.91 66.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.345 -0.847 . . . . 0.0 109.714 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.28 8.53 44.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.351 -0.843 . . . . 0.0 109.32 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -88.86 142.52 12.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.327 -0.858 . . . . 0.0 108.814 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.451 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -70.09 84.83 0.53 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.168 -0.958 . . . . 0.0 109.487 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.6 m -64.5 -0.26 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.258 -0.901 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.451 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -98.45 11.17 39.03 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.34 -0.85 . . . . 0.0 108.969 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -88.08 136.5 32.94 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.475 -0.766 . . . . 0.0 109.562 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -61.93 122.02 14.41 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.5 mt -56.21 -16.1 4.82 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.423 -0.798 . . . . 0.0 109.542 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.2 t -50.9 -43.05 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.064 -1.023 . . . . 0.0 109.125 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.24 -37.97 70.46 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.4 m-20 -91.18 22.33 3.85 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.72 -15.5 0.02 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.5 p -53.89 -33.81 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.013 -1.286 . . . . 0.0 108.891 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.591 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.9 tt -70.99 -19.04 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.51 -0.744 . . . . 0.0 109.673 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 82.1 m-20 -58.05 -31.32 66.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.434 -0.791 . . . . 0.0 111.451 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.7 m -116.39 -64.91 1.25 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.985 -1.072 . . . . 0.0 111.327 -178.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -64.0 -50.72 67.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 110.06 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.85 -40.1 64.37 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.591 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.8 tp -58.77 -40.88 85.24 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.469 -1.018 . . . . 0.0 109.671 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.91 -44.31 96.44 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.75 -40.22 88.2 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.273 -0.892 . . . . 0.0 109.981 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 79.9 t -65.1 -42.01 93.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.345 -0.847 . . . . 0.0 110.199 -179.377 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.402 ' N ' HD13 ' A' ' 45' ' ' ILE . 1.1 mp -60.79 -50.61 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.219 -0.926 . . . . 0.0 109.837 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.52 -30.83 71.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.188 -0.945 . . . . 0.0 109.365 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.7 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 55.4 t90 -73.13 -47.09 47.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.395 -0.815 . . . . 0.0 110.118 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.83 -45.29 94.44 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -67.13 -36.62 82.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.272 -0.892 . . . . 0.0 109.803 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -62.12 -44.08 97.42 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.703 -179.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.7 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 82.1 mtt180 -87.04 -51.43 6.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.05 -1.031 . . . . 0.0 111.52 -178.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -80.11 -24.58 40.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.005 -1.059 . . . . 0.0 111.223 -178.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.09 26.71 59.52 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.7 mt -104.87 143.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -1.121 . . . . 0.0 109.354 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.98 156.54 17.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.185 -0.947 . . . . 0.0 109.692 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.14 -20.14 6.2 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.4 -0.813 . . . . 0.0 109.526 -179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 56.9 46.56 19.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.491 -0.756 . . . . 0.0 109.91 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.433 ' CG ' ' O8 ' ' A' ' 101' ' ' 7V9 . 88.1 m-20 -96.96 19.4 12.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -0.803 . . . . 0.0 109.088 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.9 t -55.35 -41.56 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 110.613 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -159.08 64.08 0.4 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.858 -1.151 . . . . 0.0 110.219 -179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.483 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 3.5 mm? -104.04 141.46 36.17 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.097 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.84 162.25 50.69 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.384 -0.823 . . . . 0.0 109.81 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.1 -25.25 79.34 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.942 2.428 . . . . 0.0 112.237 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.43 -31.45 72.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -67.92 -26.21 65.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -0.842 . . . . 0.0 109.939 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -94.16 16.45 14.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.365 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 tpt180 -53.41 -39.16 64.1 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.334 -0.854 . . . . 0.0 110.018 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.0 p -150.85 165.9 32.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.923 -1.111 . . . . 0.0 110.271 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 95.0 mt -59.31 -36.51 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.378 -0.826 . . . . 0.0 110.078 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.6 mtm180 -60.49 -39.2 86.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 110.077 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.3 m -61.43 -42.89 99.45 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.994 -1.066 . . . . 0.0 109.428 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.415 HG22 HD13 ' A' ' 72' ' ' ILE . 78.4 mt -64.91 -38.41 82.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.249 -0.907 . . . . 0.0 109.32 179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.433 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 92.4 m-20 -56.06 -37.45 69.29 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.286 -0.884 . . . . 0.0 109.219 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.15 -43.73 98.19 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.26 -0.9 . . . . 0.0 109.061 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -63.91 -47.5 80.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.154 179.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.7 t -64.4 -40.44 89.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.389 -0.82 . . . . 0.0 109.288 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.433 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 55.4 t -58.32 -44.02 87.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.333 -0.854 . . . . 0.0 109.615 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -64.77 -41.49 97.57 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.52 -49.53 16.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.135 -1.215 . . . . 0.0 109.645 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 22.1 p -128.32 157.31 41.31 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.33 87.84 11.73 Favored Pre-proline 0 C--N 1.302 -1.472 0 O-C-N 121.058 -1.026 . . . . 0.0 110.261 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -68.72 -178.2 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.486 2.124 . . . . 0.0 111.26 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.562 ' O ' ' N ' ' A' ' 2' ' ' GLN . 23.2 Cg_exo -60.19 148.49 89.55 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.2 1.933 . . . . 0.0 111.429 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.7 m -125.16 141.72 44.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.262 -0.899 . . . . 0.0 109.921 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.537 ' O ' ' CB ' ' A' ' 86' ' ' ALA . 78.1 mm-40 -142.23 -40.41 0.35 Allowed 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.353 -0.842 . . . . 0.0 109.201 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 85' ' ' GLU . . . 160.28 95.23 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.423 -0.798 . . . . 0.0 109.368 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -57.72 -38.39 75.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.121 -0.987 . . . . 0.0 109.358 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 31.0 tp -102.92 130.34 49.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.387 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.496 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.452 ' H18' ' CB ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.481 0.657 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.58 119.09 36.7 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.48 -0.763 . . . . 0.0 108.985 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 50.49 36.09 12.7 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.142 -0.974 . . . . 0.0 109.027 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.56 -35.58 76.39 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.39 -0.819 . . . . 0.0 109.78 -179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 t -59.53 -40.57 87.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.722 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.42 ' O ' ' N ' ' A' ' 10' ' ' PHE . 55.1 t -64.39 -40.02 87.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 0.0 109.165 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.469 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 91.8 mt -59.66 -50.15 81.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.36 -0.837 . . . . 0.0 109.512 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.539 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.91 -45.19 90.43 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 108.904 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.4 -39.65 92.44 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.533 -0.729 . . . . 0.0 109.651 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 61.0 t80 -60.66 -52.04 66.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.446 -0.784 . . . . 0.0 110.029 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.474 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.8 p -74.08 -40.56 51.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.902 . . . . 0.0 109.844 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.539 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 94.2 t -66.69 -40.0 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.395 -0.816 . . . . 0.0 110.315 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -56.17 -27.63 55.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.228 -0.92 . . . . 0.0 109.574 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -65.04 -32.09 73.64 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.342 -0.849 . . . . 0.0 109.724 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -144.2 44.46 1.43 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.066 -1.021 . . . . 0.0 109.92 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.563 ' O ' ' CD2' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.46 131.46 61.54 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.085 -1.009 . . . . 0.0 110.048 -179.981 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.46 -150.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.314 -1.277 0 C-N-CA 121.954 1.769 . . . . 0.0 110.655 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.441 ' OD1' ' C ' ' A' ' 18' ' ' ASP . 53.6 p30 -78.36 13.04 1.67 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.133 . . . . 0.0 109.324 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.2 t -113.53 135.48 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.483 -0.761 . . . . 0.0 109.612 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.09 142.43 87.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.312 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -48.49 -32.12 19.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.969 1.78 . . . . 0.0 111.814 179.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.78 -25.97 67.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.419 -0.801 . . . . 0.0 109.447 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -97.69 4.75 49.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.361 -0.837 . . . . 0.0 109.386 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -103.55 137.41 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.551 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -63.78 95.9 0.12 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.404 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.3 m -59.57 0.48 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.168 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.551 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.6 m-20 -87.99 11.24 16.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.362 -0.836 . . . . 0.0 108.939 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 35.2 tp -82.59 134.12 35.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 109.395 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -67.07 121.85 16.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.342 -0.849 . . . . 0.0 108.871 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.445 ' O ' ' N ' ' A' ' 33' ' ' ASN . 82.6 mt -59.28 -14.1 10.14 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.303 -0.873 . . . . 0.0 109.198 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.412 ' O ' ' N ' ' A' ' 34' ' ' GLY . 42.1 t -50.44 -42.34 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 O-C-N 121.179 -0.951 . . . . 0.0 108.89 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.62 -35.32 65.74 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 178.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.608 ' O ' ' N ' ' A' ' 35' ' ' VAL . 8.5 m120 -86.27 21.55 2.03 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.0 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.162 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.608 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.0 t -53.05 -40.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.766 -1.432 . . . . 0.0 108.228 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.653 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.2 tt -71.15 -24.11 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.575 -0.703 . . . . 0.0 109.924 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 83.5 m-20 -62.11 -27.54 69.0 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.957 -1.09 . . . . 0.0 110.975 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.546 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.3 OUTLIER -106.18 -65.73 1.05 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.801 -1.187 . . . . 0.0 111.055 -178.766 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -73.73 -51.24 17.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.951 -1.093 . . . . 0.0 110.61 -178.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.75 -36.32 92.11 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.1 tt -57.95 -43.14 86.2 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.208 -1.172 . . . . 0.0 109.2 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.9 mt -60.96 -44.1 97.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.094 -1.004 . . . . 0.0 108.694 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -69.97 -35.45 74.46 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.423 -0.798 . . . . 0.0 109.84 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 81.1 t -64.78 -49.85 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.339 -0.851 . . . . 0.0 110.849 -178.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -60.41 -47.82 90.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 120.944 -1.097 . . . . 0.0 109.51 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.46 -32.95 74.64 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.179 -0.951 . . . . 0.0 109.232 179.7 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 39.4 t90 -71.67 -47.46 54.09 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.24 -0.912 . . . . 0.0 109.927 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 26.5 tp -59.81 -44.98 93.72 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.318 -0.864 . . . . 0.0 109.687 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.47 ' O ' ' N ' ' A' ' 53' ' ' GLY . 80.3 tt0 -68.62 -34.88 76.51 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 110.057 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.21 -38.49 80.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.008 -1.058 . . . . 0.0 110.028 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.536 ' NE ' ' CZ2' ' A' ' 47' ' ' TRP . 34.2 mtm105 -86.39 -48.52 8.38 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.149 -0.969 . . . . 0.0 111.497 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -90.9 -24.44 20.2 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.8 -1.187 . . . . 0.0 111.219 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 79.35 50.03 5.95 Favored Glycine 0 N--CA 1.496 2.689 0 C-N-CA 119.588 -1.292 . . . . 0.0 110.525 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.426 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 65.2 mt -108.04 140.94 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.199 -1.177 . . . . 0.0 109.21 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.53 141.11 57.95 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.937 -1.102 . . . . 0.0 109.334 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.51 -29.25 70.42 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.574 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -82.89 1.02 41.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.339 -0.85 . . . . 0.0 109.826 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.2 -31.53 61.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.615 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.5 m -122.47 159.73 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.502 -0.749 . . . . 0.0 109.403 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -99.12 169.4 9.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.399 -0.813 . . . . 0.0 109.954 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.652 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -76.83 125.56 29.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.455 -0.778 . . . . 0.0 109.222 -179.499 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.663 ' H ' ' C8 ' ' A' ' 101' ' ' 7V9 . 4.0 p -142.77 87.34 9.04 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.16 -0.963 . . . . 0.0 109.955 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -53.37 -34.31 70.39 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.346 2.031 . . . . 0.0 111.61 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -68.08 -14.32 62.89 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.525 -0.735 . . . . 0.0 109.148 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.426 ' HE2' ' HB2' ' A' ' 75' ' ' PHE . 21.7 t-80 -66.2 -26.32 67.34 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.432 -0.792 . . . . 0.0 110.062 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -92.45 9.05 35.98 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.006 -1.058 . . . . 0.0 109.597 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.4 tpt180 -54.7 -35.98 64.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.8 p -150.82 149.39 29.65 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.215 -0.928 . . . . 0.0 110.023 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.6 mt -66.56 -39.33 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.425 -0.797 . . . . 0.0 110.264 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.4 HH22 ' HA ' ' A' ' 27' ' ' ASP . 93.0 mtm-85 -61.35 -39.99 92.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -0.906 . . . . 0.0 110.373 -178.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 t -60.63 -45.91 92.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.985 -1.072 . . . . 0.0 109.425 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -63.91 -38.74 83.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.85 . . . . 0.0 109.709 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.469 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 55.9 t0 -57.54 -42.28 82.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 110.256 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.76 -46.09 76.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 110.502 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.426 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 58.4 m-85 -63.36 -45.1 92.71 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.099 -1.0 . . . . 0.0 109.496 -179.785 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.1 t -68.18 -47.6 77.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.219 -0.926 . . . . 0.0 110.159 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 45.4 t -68.28 -44.22 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.051 -1.031 . . . . 0.0 110.023 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.02 -27.0 68.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.27 -50.12 3.55 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.199 -1.177 . . . . 0.0 111.143 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.529 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.2 m -134.91 140.1 45.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.107 -0.995 . . . . 0.0 110.864 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.34 88.4 53.07 Favored Pre-proline 0 N--CA 1.488 1.445 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -81.97 159.97 18.36 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.714 2.276 . . . . 0.0 113.344 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -64.56 152.42 81.82 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.27 2.647 . . . . 0.0 111.767 179.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.6 t -89.04 127.38 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.081 -1.012 . . . . 0.0 109.565 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -143.18 152.45 41.78 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.439 -0.788 . . . . 0.0 109.238 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.76 143.89 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.17 -0.956 . . . . 0.0 109.375 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.6 tttm -77.95 134.71 37.81 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.9 mt -58.89 -35.52 73.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.527 179.93 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . 0.663 ' C8 ' ' H ' ' A' ' 62' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.9 mtm . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.372 0.606 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -60.11 -37.03 78.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 109.494 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.545 ' CE1' ' CG2' ' A' ' 6' ' ' VAL . 73.6 t60 -116.13 8.94 14.58 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.478 -0.764 . . . . 0.0 109.478 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.58 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -61.09 -35.61 77.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.212 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 m -58.8 -40.28 83.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.053 -1.03 . . . . 0.0 109.395 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.545 ' CG2' ' CE1' ' A' ' 3' ' ' HIS . 72.3 t -66.53 -36.56 77.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.007 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.428 ' O ' ' CG2' ' A' ' 11' ' ' VAL . 81.8 mt -63.59 -44.18 98.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.397 -0.814 . . . . 0.0 110.31 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.0 -50.63 67.78 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.175 -0.953 . . . . 0.0 110.521 -178.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.418 ' HG3' ' H ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.22 -44.3 68.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.122 -0.986 . . . . 0.0 109.673 -179.844 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.568 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 75.1 t80 -59.52 -45.89 90.44 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.993 -1.067 . . . . 0.0 109.282 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.428 ' CG2' ' O ' ' A' ' 7' ' ' ILE . 99.7 t -70.03 -46.52 72.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 74.9 t -66.51 -37.23 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.337 -0.852 . . . . 0.0 111.086 -179.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -60.93 -31.72 71.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.771 -179.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -66.16 -32.51 73.99 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.938 -1.102 . . . . 0.0 110.137 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -96.63 -61.11 1.47 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.104 -0.997 . . . . 0.0 110.6 -179.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 3.7 mp -129.16 83.24 66.4 Favored Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 121.29 -0.881 . . . . 0.0 110.663 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -80.75 -13.29 11.88 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.841 2.361 . . . . 0.0 112.102 178.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.56 -4.3 42.08 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.138 -0.976 . . . . 0.0 108.974 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.59 140.62 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.86 117.87 33.04 Favored Pre-proline 0 C--N 1.305 -1.353 0 O-C-N 120.882 -1.136 . . . . 0.0 108.779 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -64.98 -26.75 58.43 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 C-N-CA 121.619 1.546 . . . . 0.0 111.854 -179.176 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.92 -13.88 60.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.421 -0.799 . . . . 0.0 109.326 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -85.58 8.03 20.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 109.853 -179.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -107.58 144.41 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.372 -0.83 . . . . 0.0 109.034 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.535 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.6 m-20 -69.05 86.18 0.36 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.006 -1.059 . . . . 0.0 109.177 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.9 0.06 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.34 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.535 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.03 6.04 47.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.321 -0.862 . . . . 0.0 108.77 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -93.58 136.82 33.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.599 -0.688 . . . . 0.0 109.364 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -61.16 121.53 12.75 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.5 pp -68.84 0.25 4.61 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.285 -0.885 . . . . 0.0 109.796 -179.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 34' ' ' GLY . 72.7 t -56.16 -35.17 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.21 -0.931 . . . . 0.0 108.946 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.44 ' C ' ' H ' ' A' ' 34' ' ' GLY . 92.3 m-20 -53.94 -34.83 60.78 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -83.53 21.89 1.14 Allowed 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.028 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -41.73 -13.99 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.93 -1.268 . . . . 0.0 109.93 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 3.4 p -51.94 -31.12 13.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.085 -1.244 . . . . 0.0 108.479 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.424 ' HA ' ' H ' ' A' ' 40' ' ' GLY . 32.6 pt -73.56 -7.14 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.522 -0.736 . . . . 0.0 109.965 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.44 ' CG ' ' O ' ' A' ' 34' ' ' GLY . 92.7 m-20 -48.88 -39.95 27.88 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.342 -0.849 . . . . 0.0 110.205 -178.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -122.56 -48.24 2.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 111.348 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.2 mp -74.71 -52.79 10.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.944 -1.097 . . . . 0.0 111.63 -178.077 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 36' ' ' ILE . . . -70.49 -43.21 62.12 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 120.079 -1.058 . . . . 0.0 110.77 -178.665 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.2 mt -63.42 -40.66 97.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.065 -1.256 . . . . 0.0 110.482 -179.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.63 -44.17 96.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.322 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttt -66.96 -41.58 86.64 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.244 -0.91 . . . . 0.0 109.465 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 90.1 t -66.95 -41.06 86.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.446 -0.784 . . . . 0.0 109.879 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.4 mp -58.94 -49.03 84.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.245 -0.91 . . . . 0.0 109.65 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.94 -32.29 72.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.604 ' CZ2' ' NH1' ' A' ' 51' ' ' ARG . 9.3 t90 -68.51 -44.81 73.84 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.37 -0.831 . . . . 0.0 109.508 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -62.53 -44.98 95.02 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 109.605 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 53' ' ' GLY . 81.6 tt0 -67.2 -34.51 77.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.909 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -58.75 -39.3 80.54 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.89 -1.131 . . . . 0.0 109.759 -179.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.604 ' NH1' ' CZ2' ' A' ' 47' ' ' TRP . 51.7 mtm180 -86.97 -53.86 4.66 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.135 -0.978 . . . . 0.0 110.931 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.42 -25.02 39.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 111.367 -178.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 76.46 39.2 31.11 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.334 -1.412 . . . . 0.0 109.627 -179.676 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -103.03 138.73 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.197 -1.178 . . . . 0.0 109.331 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.05 141.08 57.66 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.737 -1.227 . . . . 0.0 109.303 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.48 -34.1 73.55 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.338 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -95.98 12.41 30.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.405 -0.809 . . . . 0.0 109.468 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -52.32 -34.66 48.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.923 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.3 m -126.45 158.84 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.356 -0.84 . . . . 0.0 109.668 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -68.73 143.64 54.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.343 -0.848 . . . . 0.0 109.448 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 12.9 mt -92.4 139.97 30.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.25 -0.906 . . . . 0.0 109.144 -179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -154.41 129.8 5.18 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.973 -1.079 . . . . 0.0 109.41 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 -27.54 69.48 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.862 1.708 . . . . 0.0 112.324 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.88 -28.12 69.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.892 . . . . 0.0 109.711 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.553 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 11.6 t-160 -67.8 -26.74 66.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.296 -0.878 . . . . 0.0 110.02 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -102.27 13.65 34.06 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.955 . . . . 0.0 109.97 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 25.6 tpt180 -53.19 -36.88 61.42 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 108.959 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t -143.46 146.91 33.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -0.887 . . . . 0.0 109.479 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.78 -38.44 76.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.285 -0.885 . . . . 0.0 109.91 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 ptt85 -61.81 -40.23 94.51 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.8 p -61.69 -36.68 81.58 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.097 -1.002 . . . . 0.0 110.043 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.1 mt -65.12 -40.81 90.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 121.095 -1.003 . . . . 0.0 109.807 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 55.6 t0 -58.75 -38.05 77.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.713 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.85 -41.69 99.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.178 -0.951 . . . . 0.0 109.598 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.553 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 65.6 t80 -63.8 -47.44 80.88 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.283 -0.886 . . . . 0.0 109.366 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.5 t -64.15 -42.72 96.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.288 -0.882 . . . . 0.0 109.551 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 46.6 t -58.98 -41.07 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.288 -0.883 . . . . 0.0 109.532 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.18 -32.56 76.71 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.85 -50.45 3.53 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.026 -1.279 . . . . 0.0 110.746 -179.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 76' ' ' VAL . 16.6 p -129.14 156.65 43.57 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.333 -0.854 . . . . 0.0 109.519 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.01 88.77 21.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 O-C-N 121.184 -0.947 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -81.32 159.65 20.02 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.539 2.159 . . . . 0.0 112.365 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.84 148.57 92.8 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.755 2.303 . . . . 0.0 111.98 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 13.8 p -130.09 141.31 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.403 -0.81 . . . . 0.0 109.669 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -110.04 164.04 13.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.514 -0.741 . . . . 0.0 109.177 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -51.03 141.74 13.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.296 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -58.61 -37.07 75.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.263 -0.898 . . . . 0.0 109.469 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.5 tp -100.6 130.55 46.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 109.507 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 60.7 tp60 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.433 -179.974 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' 7V9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.792 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -153.2 29.48 0.5 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.337 -0.852 . . . . 0.0 109.04 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.09 -32.97 72.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.311 -0.868 . . . . 0.0 109.883 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -61.01 -35.72 77.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.058 -1.026 . . . . 0.0 109.58 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.792 HG21 ' CE1' ' A' ' 3' ' ' HIS . 72.4 t -67.29 -38.41 80.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.028 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.456 ' O ' HG23 ' A' ' 11' ' ' VAL . 89.2 mt -61.73 -50.45 80.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.1 -45.52 88.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.197 -0.939 . . . . 0.0 109.096 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.99 -44.32 89.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.477 -0.764 . . . . 0.0 109.266 179.636 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.671 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -65.15 -46.97 78.72 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.648 -0.658 . . . . 0.0 109.915 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.683 HG13 HD12 ' A' ' 36' ' ' ILE . 75.7 t -67.65 -47.31 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.378 -0.826 . . . . 0.0 110.124 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.3 t -65.84 -34.47 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.364 -0.835 . . . . 0.0 110.613 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.53 -36.61 55.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.117 -0.99 . . . . 0.0 110.013 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.15 -34.07 76.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 110.662 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.615 ' O ' HD12 ' A' ' 16' ' ' LEU . 66.5 m-85 -94.83 -64.24 1.09 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.927 -1.108 . . . . 0.0 110.784 -178.68 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.615 HD12 ' O ' ' A' ' 15' ' ' PHE . 6.1 mp . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.31 -0.869 . . . . 0.0 110.155 -179.073 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -65.28 -30.01 54.57 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.637 1.558 . . . . 0.0 111.869 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.98 61.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.182 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.0 m-20 -87.96 6.35 36.22 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.341 -0.849 . . . . 0.0 109.387 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -100.64 137.53 27.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.394 -0.816 . . . . 0.0 108.824 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -62.69 88.07 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.185 -0.947 . . . . 0.0 109.434 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.1 m -62.15 0.08 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.397 -0.814 . . . . 0.0 109.281 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -90.88 6.82 42.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.295 -0.878 . . . . 0.0 108.949 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 tp -94.29 137.04 33.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.53 -0.731 . . . . 0.0 109.499 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -60.94 121.77 13.22 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.188 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -73.16 4.57 4.28 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.192 -0.943 . . . . 0.0 109.959 -179.021 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.4 p -51.17 -38.61 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.08 -1.012 . . . . 0.0 108.423 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.442 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.12 -35.43 69.44 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.379 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.7 m-20 -84.45 17.03 2.79 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -43.22 -14.04 0.02 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.05 -35.94 15.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.261 -1.141 . . . . 0.0 108.971 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.683 HD12 HG13 ' A' ' 11' ' ' VAL . 1.5 tt -70.01 -23.31 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.356 -0.84 . . . . 0.0 109.889 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.595 ' OD2' ' CD1' ' A' ' 66' ' ' PHE . 77.0 m-20 -56.33 -34.17 66.32 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.384 -0.823 . . . . 0.0 110.622 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -112.57 -64.45 1.3 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 111.092 -178.522 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 50.9 tp -64.25 -51.96 61.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.71 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -36.5 69.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.1 tt -58.37 -41.82 85.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.224 -1.163 . . . . 0.0 109.685 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 42' ' ' LEU . 92.8 mt -67.08 -44.14 80.81 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.137 -0.977 . . . . 0.0 109.391 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.5 mttm -67.09 -41.65 85.96 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.26 -0.9 . . . . 0.0 109.843 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 40' ' ' GLY . 88.6 t -66.68 -43.2 90.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.307 -0.871 . . . . 0.0 109.956 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.446 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.73 -50.53 79.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.263 -0.898 . . . . 0.0 109.569 -179.689 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.446 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -66.6 -38.46 87.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.182 -0.949 . . . . 0.0 109.413 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.671 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -68.48 -41.43 80.11 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.302 -0.874 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 13.8 tp -56.97 -47.42 80.81 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.403 -0.811 . . . . 0.0 109.644 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.514 ' OE2' ' O ' ' A' ' 54' ' ' ILE . 28.0 tp10 -69.26 -35.71 76.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.182 -0.949 . . . . 0.0 109.287 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -63.98 -46.07 86.21 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.077 -1.014 . . . . 0.0 110.552 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 22.4 ttm180 -88.15 -58.22 2.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 111.926 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -79.38 -24.4 42.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.0 -1.062 . . . . 0.0 111.751 -177.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.26 32.82 41.96 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.187 -1.483 . . . . 0.0 109.417 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.514 ' O ' ' OE2' ' A' ' 49' ' ' GLU . 68.8 mt -104.44 143.94 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.274 -1.133 . . . . 0.0 109.189 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.53 146.92 43.25 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.155 -0.966 . . . . 0.0 109.478 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.39 -0.819 . . . . 0.0 109.604 -179.391 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -54.13 -28.47 51.36 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.549 2.166 . . . . 0.0 111.953 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -68.39 -15.9 63.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.413 -0.805 . . . . 0.0 109.482 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 7.4 t-160 -66.7 -25.39 66.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.536 -0.727 . . . . 0.0 110.143 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.595 ' CD1' ' OD2' ' A' ' 37' ' ' ASP . 62.3 m-85 -87.68 2.91 49.78 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.019 -1.051 . . . . 0.0 109.99 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -57.25 -39.82 76.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.944 -1.097 . . . . 0.0 110.293 -179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.422 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 86.0 p -143.31 153.21 42.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.834 -1.166 . . . . 0.0 110.264 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -65.96 -36.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.456 -0.778 . . . . 0.0 109.67 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.2 mtm180 -60.94 -37.18 81.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.789 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.422 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 19.6 m -59.36 -41.98 90.51 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.068 -1.02 . . . . 0.0 109.083 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.62 -38.18 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.321 -0.862 . . . . 0.0 109.431 179.502 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.484 ' O ' HG23 ' A' ' 77' ' ' VAL . 74.5 m-20 -57.06 -39.61 75.24 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.342 -0.849 . . . . 0.0 109.704 -179.591 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.91 -39.11 90.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.247 -0.908 . . . . 0.0 109.904 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.25 -47.51 85.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.743 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.3 t -65.37 -41.06 90.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.149 -0.969 . . . . 0.0 109.777 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.7 t -61.51 -44.6 98.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.204 -0.935 . . . . 0.0 109.936 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -65.14 -40.54 96.93 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.81 -49.67 12.59 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.147 -1.207 . . . . 0.0 109.766 -179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.471 ' O ' ' O ' ' A' ' 76' ' ' VAL . 19.3 p -130.46 156.89 44.02 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.504 0 O-C-N 121.171 -0.955 . . . . 0.0 109.78 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.2 0.524 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -139.52 6.47 2.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.271 -0.893 . . . . 0.0 109.762 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.496 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.26 -33.87 71.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.075 -1.016 . . . . 0.0 109.761 -179.482 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.22 -45.01 92.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.067 -1.021 . . . . 0.0 109.59 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.9 -36.59 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.268 -0.895 . . . . 0.0 108.656 179.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.496 HD12 ' HA ' ' A' ' 4' ' ' ALA . 91.8 mt -66.75 -42.16 89.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.609 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.24 -50.39 70.38 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.047 -1.033 . . . . 0.0 110.241 -179.021 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.31 -42.97 71.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.291 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.513 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.9 t80 -62.56 -48.72 78.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.366 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.797 HG13 HD12 ' A' ' 36' ' ' ILE . 64.4 t -65.49 -45.07 93.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 0.0 109.333 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.609 HG23 ' O ' ' A' ' 8' ' ' ALA . 69.4 t -65.85 -37.12 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.439 -0.788 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -52.86 -30.78 35.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.38 -0.825 . . . . 0.0 109.811 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.54 -31.26 72.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.66 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.551 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 34.4 p90 -143.93 44.24 1.46 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.185 -0.947 . . . . 0.0 109.601 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.797 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.155 -0.966 . . . . 0.0 110.305 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -49.38 -29.66 18.42 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 121.881 1.721 . . . . 0.0 111.813 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.6 -25.99 68.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.315 -0.866 . . . . 0.0 109.528 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -95.38 6.42 49.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.319 -0.863 . . . . 0.0 109.209 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.3 t -104.07 136.37 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.528 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.4 m-20 -69.7 88.89 0.54 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.202 -0.936 . . . . 0.0 109.529 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.2 m -59.91 0.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.196 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.528 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.91 9.97 33.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 108.884 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -90.34 137.37 32.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.533 -0.729 . . . . 0.0 109.507 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.455 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.89 121.82 14.43 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.12 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.441 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -69.62 10.86 0.31 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.144 -0.972 . . . . 0.0 109.932 -178.977 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.455 ' H ' ' C ' ' A' ' 29' ' ' ASP . 75.7 t -54.68 -44.22 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.002 -1.061 . . . . 0.0 108.627 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.72 -36.64 67.44 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 179.055 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.5 m-20 -86.21 18.24 3.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 178.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.92 -14.99 0.02 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.9 t -52.05 -37.13 21.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.117 -1.225 . . . . 0.0 108.677 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.797 HD12 HG13 ' A' ' 11' ' ' VAL . 1.4 tt -70.59 -22.5 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.533 -0.73 . . . . 0.0 110.323 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -54.14 -32.62 55.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.313 -0.867 . . . . 0.0 111.284 -178.128 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.34 -64.23 1.33 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.912 -1.117 . . . . 0.0 111.165 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.3 -52.5 63.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.9 -1.125 . . . . 0.0 110.343 -178.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.664 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.53 -37.1 62.34 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 36' ' ' ILE . 16.2 tp -58.51 -43.53 89.16 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.38 -1.07 . . . . 0.0 109.931 -178.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HA ' HD23 ' A' ' 42' ' ' LEU . 92.9 mt -65.6 -43.56 89.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.556 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -63.08 -34.43 77.57 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.259 -0.9 . . . . 0.0 109.366 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 40' ' ' GLY . 68.4 t -60.52 -41.43 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.914 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.505 HG21 ' HB1' ' A' ' 56' ' ' ALA . 35.8 mm -58.94 -50.16 80.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.983 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.24 -35.6 79.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.801 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.513 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 44.2 t90 -66.49 -41.74 88.48 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.269 -0.894 . . . . 0.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -61.24 -43.35 99.01 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 109.918 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.412 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 87.5 tt0 -67.51 -37.16 82.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -60.3 -44.79 95.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.049 -1.032 . . . . 0.0 110.555 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -87.49 -53.02 5.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.136 -0.977 . . . . 0.0 111.585 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -80.16 -24.75 40.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.041 -1.037 . . . . 0.0 111.59 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.67 31.05 51.29 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.412 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.6 mt -103.41 147.51 9.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.393 -1.063 . . . . 0.0 109.556 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.04 157.6 15.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.188 -0.945 . . . . 0.0 109.309 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.505 ' HB1' HG21 ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.456 0 O-C-N 121.24 -0.912 . . . . 0.0 109.773 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.79 -27.05 84.04 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.618 2.212 . . . . 0.0 111.886 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.56 -24.49 67.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.403 -0.81 . . . . 0.0 109.945 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -67.13 -26.61 66.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.155 -0.965 . . . . 0.0 110.234 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -97.71 6.68 47.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.074 -1.016 . . . . 0.0 109.001 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 -56.49 -37.8 70.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.452 -0.78 . . . . 0.0 109.977 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.8 p -137.03 153.25 50.68 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.096 -1.003 . . . . 0.0 110.121 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.6 mt -64.59 -36.45 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.478 -0.763 . . . . 0.0 110.251 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -60.87 -37.02 80.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.133 -0.979 . . . . 0.0 110.217 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 92.6 p -61.59 -36.15 79.87 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.014 -1.054 . . . . 0.0 109.66 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -64.93 -40.63 89.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.232 -0.918 . . . . 0.0 109.453 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.552 ' OD2' HG23 ' A' ' 77' ' ' VAL . 53.9 t0 -59.12 -36.93 76.04 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.305 -0.872 . . . . 0.0 109.634 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.88 -40.71 94.04 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.326 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -64.16 -48.7 75.0 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.305 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.5 t -64.89 -43.45 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.317 -0.864 . . . . 0.0 109.671 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.552 HG23 ' OD2' ' A' ' 73' ' ' ASP . 55.7 t -59.87 -41.06 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.225 -0.922 . . . . 0.0 109.627 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.33 -31.83 70.82 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.1 -50.63 3.32 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.021 -1.282 . . . . 0.0 110.844 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 21.8 p -131.28 159.43 37.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.225 -0.922 . . . . 0.0 109.854 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.389 0 O-C-N 121.189 -0.944 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.556 ' OE1' HG21 ' A' ' 81' ' ' THR . 91.8 mt-30 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.4 m80 47.46 38.44 7.71 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.118 -0.988 . . . . 0.0 109.298 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.12 -34.26 73.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.288 -0.883 . . . . 0.0 109.629 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -59.14 -36.64 75.59 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 109.618 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.8 t -62.88 -40.96 90.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.287 -0.883 . . . . 0.0 109.516 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.498 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 85.5 mt -59.69 -43.95 92.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.356 -0.84 . . . . 0.0 109.839 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.4 77.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.429 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.42 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.08 -33.66 73.89 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.414 -0.804 . . . . 0.0 109.624 179.826 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.407 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 63.1 t80 -62.64 -52.08 64.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.001 . . . . 0.0 109.977 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 12' ' ' VAL . 6.3 p -74.91 -44.32 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.357 -0.839 . . . . 0.0 110.855 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.538 ' N ' HG13 ' A' ' 11' ' ' VAL . 76.9 t -65.32 -40.09 87.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.183 -0.948 . . . . 0.0 111.031 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -58.22 -28.69 65.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.045 -1.034 . . . . 0.0 109.791 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.8 -38.69 89.64 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.276 -0.89 . . . . 0.0 110.425 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.498 ' HE1' HG22 ' A' ' 11' ' ' VAL . 5.4 m-85 -96.68 -45.11 6.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.04 -1.038 . . . . 0.0 110.489 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.5 mt . . . . . 0 N--CA 1.493 1.719 0 O-C-N 121.284 -0.885 . . . . 0.0 110.273 -179.147 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -64.69 -30.36 59.79 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 C-N-CA 121.585 1.524 . . . . 0.0 111.966 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.86 -19.05 63.46 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.064 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -89.18 1.74 55.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.361 -0.837 . . . . 0.0 108.99 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.1 t -102.28 139.0 24.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.515 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.2 t0 -67.97 94.14 0.46 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 109.438 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -59.99 0.56 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.429 -0.794 . . . . 0.0 109.229 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.1 m-20 -88.16 9.8 21.55 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.019 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.4 tp -86.33 134.17 33.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.541 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -62.94 122.07 15.1 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.742 HD11 HG12 ' A' ' 69' ' ' ILE . 74.1 mt -59.72 -12.14 6.48 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.3 p -49.97 -37.28 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 119.32 -0.952 . . . . 0.0 108.647 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.13 -36.01 70.18 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.3 m-20 -86.13 21.07 2.1 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.841 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.3 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.48 -40.32 24.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 120.979 -1.307 . . . . 0.0 108.54 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.637 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.2 tt -71.77 -24.41 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.509 -0.744 . . . . 0.0 110.418 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 91.9 m-20 -59.25 -28.13 66.42 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.931 -1.105 . . . . 0.0 110.962 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 m -113.3 -64.32 1.32 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.026 -1.046 . . . . 0.0 111.167 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.487 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.88 -51.31 41.58 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.904 -1.123 . . . . 0.0 110.472 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.02 -35.89 72.12 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.747 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.0 tt -57.99 -45.24 87.11 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.421 -1.046 . . . . 0.0 110.145 -179.083 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.8 mt -61.83 -44.18 97.37 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.001 -1.062 . . . . 0.0 109.191 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -71.64 -35.54 70.44 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.351 -0.843 . . . . 0.0 110.303 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 40' ' ' GLY . 66.0 t -64.56 -49.41 80.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.284 -0.885 . . . . 0.0 111.277 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.2 mm -58.78 -49.46 82.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 120.566 -1.334 . . . . 0.0 109.644 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.34 -35.6 79.73 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.012 -1.055 . . . . 0.0 109.68 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.476 ' CE3' ' CD2' ' A' ' 48' ' ' LEU . 19.2 t90 -76.84 -51.07 11.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.272 -0.892 . . . . 0.0 111.398 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.476 ' CD2' ' CE3' ' A' ' 47' ' ' TRP . 3.8 mm? -65.72 -39.32 91.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.062 -1.024 . . . . 0.0 110.616 -179.181 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 17.8 pt-20 -65.73 -35.01 79.53 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.979 -1.076 . . . . 0.0 109.596 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -65.45 -43.52 90.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.173 -0.954 . . . . 0.0 110.051 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -67.68 -43.13 80.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.252 -0.905 . . . . 0.0 111.165 -179.251 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -98.34 -12.73 21.19 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.9 -1.125 . . . . 0.0 110.47 -178.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.05 42.16 96.82 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.5 mt -104.79 129.21 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 109.531 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.95 144.39 57.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 109.451 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.271 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -49.95 -36.12 42.92 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 121.814 1.676 . . . . 0.0 112.107 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.92 -27.73 66.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.257 -0.902 . . . . 0.0 109.677 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 36.6 t-80 -68.22 -27.13 66.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 110.211 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -100.72 9.14 42.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.485 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 35.9 tpt85 -55.52 -36.21 66.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.479 -0.763 . . . . 0.0 109.369 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.1 p -143.56 158.34 43.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.18 -0.95 . . . . 0.0 110.017 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.742 HG12 HD11 ' A' ' 30' ' ' LEU . 75.7 mt -64.15 -36.54 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.387 -0.821 . . . . 0.0 110.35 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.6 mtm180 -60.72 -38.82 86.4 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.098 -1.001 . . . . 0.0 110.068 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.0 t -61.45 -44.09 97.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.042 -1.036 . . . . 0.0 109.539 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 84.3 mt -67.72 -40.08 83.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.288 -0.882 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 59.8 t0 -58.99 -41.59 88.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.867 . . . . 0.0 110.391 -179.256 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.39 -43.78 84.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.034 -1.041 . . . . 0.0 110.248 -179.265 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -62.67 -47.27 84.39 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.748 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.517 HG12 ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.92 -44.36 96.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 73' ' ' ASP . 48.1 t -61.06 -39.74 83.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.11 -0.994 . . . . 0.0 109.459 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.85 -33.17 67.46 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.02 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.054 -1.263 . . . . 0.0 110.489 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.517 ' O ' HG12 ' A' ' 76' ' ' VAL . 8.3 t -158.41 152.69 24.19 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.064 -1.023 . . . . 0.0 110.204 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.556 HG21 ' OE1' ' A' ' 2' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 108.937 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 120.905 0.383 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -149.0 3.45 0.61 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.965 -1.085 . . . . 0.0 110.603 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.586 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -63.34 -32.4 73.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.778 -1.201 . . . . 0.0 109.866 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.7 p -59.04 -35.3 73.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.069 -1.02 . . . . 0.0 109.372 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.34 -37.74 80.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.264 -0.898 . . . . 0.0 109.2 179.541 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.615 ' O ' HG23 ' A' ' 11' ' ' VAL . 30.8 mm -62.16 -47.12 94.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.419 -0.8 . . . . 0.0 110.176 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.81 -49.74 71.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.206 -0.933 . . . . 0.0 110.445 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.436 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.71 -42.75 73.62 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.154 -0.967 . . . . 0.0 109.858 -179.571 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 9' ' ' GLN . 69.9 t80 -61.63 -46.66 88.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.147 -0.971 . . . . 0.0 109.512 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.733 HG13 HD12 ' A' ' 36' ' ' ILE . 91.4 t -67.5 -47.61 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.375 -0.828 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 78.7 t -66.44 -34.74 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.416 -0.802 . . . . 0.0 110.423 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.77 -36.46 58.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -0.93 . . . . 0.0 109.897 -179.068 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.76 -35.12 78.14 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.273 -0.892 . . . . 0.0 110.708 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.619 ' O ' HD12 ' A' ' 16' ' ' LEU . 65.9 m-85 -92.91 -63.47 1.22 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.919 -1.113 . . . . 0.0 110.767 -178.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.619 HD12 ' O ' ' A' ' 15' ' ' PHE . 5.7 mp . . . . . 0 N--CA 1.495 1.794 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.418 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -64.62 -23.91 63.28 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 121.628 1.552 . . . . 0.0 111.828 -179.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.49 -14.89 62.27 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.446 -0.784 . . . . 0.0 109.272 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.418 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 90.5 m-20 -82.9 3.24 30.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.383 -0.823 . . . . 0.0 109.158 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.54 136.97 30.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.451 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.12 88.13 0.07 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.136 -0.977 . . . . 0.0 109.271 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -63.61 0.04 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.273 -0.892 . . . . 0.0 109.309 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.451 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -93.44 4.65 53.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 108.969 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.8 tt -98.36 137.65 36.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.461 -0.775 . . . . 0.0 109.541 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.63 ' O ' HD23 ' A' ' 28' ' ' LEU . 89.4 m-20 -60.56 121.57 12.48 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.231 -0.918 . . . . 0.0 108.625 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.426 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.6 OUTLIER -64.94 6.08 0.27 Allowed 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.255 -0.903 . . . . 0.0 110.047 -178.975 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.471 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.0 p -51.55 -38.23 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.053 -1.029 . . . . 0.0 108.634 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.83 -35.68 71.21 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.641 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.4 m-20 -86.18 20.14 2.44 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.176 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.84 -14.69 0.02 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.641 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.52 -35.62 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.264 -1.139 . . . . 0.0 108.802 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.733 HD12 HG13 ' A' ' 11' ' ' VAL . 1.1 tt -69.99 -22.16 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.567 -0.708 . . . . 0.0 110.067 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -55.02 -32.51 61.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.302 -0.874 . . . . 0.0 110.845 -178.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.7 m -118.0 -63.79 1.38 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.22 -0.925 . . . . 0.0 111.168 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.5 tp -62.01 -52.55 63.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.961 -1.087 . . . . 0.0 110.276 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -38.17 66.1 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.561 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -59.57 -40.66 88.11 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.419 -1.048 . . . . 0.0 109.15 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.99 -44.12 97.4 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.217 -0.927 . . . . 0.0 108.947 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.4 mttm -65.73 -37.42 86.33 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.316 -0.865 . . . . 0.0 109.483 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.5 t -62.84 -39.97 87.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.399 -0.813 . . . . 0.0 109.875 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.457 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.87 -51.41 73.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.11 -0.994 . . . . 0.0 109.664 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.59 -39.28 84.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -0.908 . . . . 0.0 109.627 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.706 ' HE1' ' CZ ' ' A' ' 51' ' ' ARG . 76.2 t90 -68.89 -43.04 76.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.41 -0.806 . . . . 0.0 109.962 -179.788 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.0 tp -63.15 -46.83 85.38 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.353 -0.842 . . . . 0.0 109.962 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -68.23 -36.0 78.81 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.88 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.56 -45.48 93.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.066 -1.022 . . . . 0.0 110.68 -179.293 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.706 ' CZ ' ' HE1' ' A' ' 47' ' ' TRP . 85.0 mtt180 -87.2 -50.25 6.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.078 -1.013 . . . . 0.0 111.45 -178.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -80.1 -24.78 40.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.0 -1.062 . . . . 0.0 111.271 -178.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.21 30.07 57.59 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -105.95 144.13 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.288 -1.125 . . . . 0.0 109.478 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.89 152.1 28.35 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.2 -0.938 . . . . 0.0 109.479 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.417 -0.802 . . . . 0.0 109.704 -179.295 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.06 0.457 . . . . 0.0 109.874 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.48 -29.96 90.2 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.704 2.269 . . . . 0.0 111.931 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.54 -26.77 68.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.393 -0.817 . . . . 0.0 109.614 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 12.5 t-80 -67.81 -25.89 65.8 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 110.691 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -88.69 7.52 33.22 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.031 -1.043 . . . . 0.0 110.606 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.3 mmt85 -59.73 -36.93 77.57 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.985 -1.072 . . . . 0.0 110.547 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.453 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 93.5 p -132.94 150.53 52.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.995 -1.066 . . . . 0.0 110.345 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.403 HG23 ' CG2' ' A' ' 7' ' ' ILE . 88.9 mt -65.9 -37.67 80.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 O-C-N 121.49 -0.756 . . . . 0.0 109.854 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 93.8 mtm-85 -61.2 -38.29 86.03 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.091 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.453 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 22.2 m -60.07 -40.7 90.44 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.137 -0.977 . . . . 0.0 109.404 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -65.66 -42.33 92.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.267 -0.895 . . . . 0.0 109.836 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.586 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 53.2 t0 -60.05 -38.74 83.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.335 -0.853 . . . . 0.0 110.062 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.12 -40.64 98.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.182 -0.949 . . . . 0.0 109.747 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -62.7 -46.94 85.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -64.44 -44.02 97.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.24 -0.913 . . . . 0.0 109.757 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 73' ' ' ASP . 58.2 t -60.54 -40.66 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.34 -0.85 . . . . 0.0 109.625 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.46 -31.97 71.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.73 -50.44 3.41 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.113 -1.228 . . . . 0.0 110.807 -179.116 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.0 p -131.43 157.62 42.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 109.805 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.408 0 O-C-N 121.213 -0.93 . . . . 0.0 109.255 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.272 0.558 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.822 ' NE2' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -155.18 28.44 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.129 -0.982 . . . . 0.0 109.541 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.43 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.63 -33.39 73.85 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.57 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 84.8 p -61.59 -36.56 81.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.197 -0.939 . . . . 0.0 109.497 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.822 HG21 ' NE2' ' A' ' 3' ' ' HIS . 69.8 t -67.83 -37.85 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.209 -0.932 . . . . 0.0 109.0 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.576 ' O ' HG23 ' A' ' 11' ' ' VAL . 84.4 mt -60.47 -50.92 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.268 -0.895 . . . . 0.0 109.219 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.68 -47.53 78.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.303 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -44.4 96.02 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.486 -0.759 . . . . 0.0 109.19 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.57 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.7 t80 -65.05 -46.48 81.04 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.538 0.685 . . . . 0.0 109.607 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.783 HG13 HD12 ' A' ' 36' ' ' ILE . 97.7 t -69.73 -47.42 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.529 -0.732 . . . . 0.0 110.293 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.8 t -64.57 -34.81 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.397 -0.814 . . . . 0.0 110.729 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.68 -36.11 56.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.072 -1.018 . . . . 0.0 109.982 -179.02 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.71 -35.06 78.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 110.676 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -92.82 -63.79 1.18 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.932 -1.105 . . . . 0.0 110.682 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.4 mt . . . . . 0 N--CA 1.494 1.742 0 O-C-N 121.334 -0.854 . . . . 0.0 110.196 -178.98 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.456 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.485 1.308 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.88 -25.63 59.92 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 C-N-CA 121.586 1.524 . . . . 0.0 111.877 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.47 -14.95 62.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -0.862 . . . . 0.0 109.136 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 91.3 m-20 -84.05 2.99 36.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.313 -0.867 . . . . 0.0 109.024 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.66 136.64 32.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 27' ' ' ASP . 87.4 m-20 -68.05 87.96 0.27 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.148 -0.97 . . . . 0.0 109.478 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -64.06 -0.15 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.34 -0.85 . . . . 0.0 109.594 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.473 ' OD2' ' C ' ' A' ' 27' ' ' ASP . 49.3 p30 -88.83 7.57 33.49 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.203 -0.936 . . . . 0.0 108.954 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -97.15 141.75 29.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.618 -0.676 . . . . 0.0 109.486 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.52 121.76 12.96 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.36 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.4 pp -68.77 4.92 1.24 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.166 -0.959 . . . . 0.0 109.975 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.445 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.87 -38.34 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.034 -1.041 . . . . 0.0 108.53 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -58.44 -35.7 72.52 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 34.8 m120 -84.55 16.33 3.24 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.042 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.03 -14.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.7 t -51.3 -36.61 17.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.119 -1.224 . . . . 0.0 108.891 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.783 HD12 HG13 ' A' ' 11' ' ' VAL . 1.3 tt -70.56 -21.84 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 110.091 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -55.22 -31.88 61.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 111.083 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.15 -64.59 1.29 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.066 -1.021 . . . . 0.0 111.518 -178.353 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.2 tp -65.12 -52.08 57.45 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.814 -1.179 . . . . 0.0 110.581 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.524 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.9 -35.69 79.92 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.0 tp -58.14 -41.59 84.04 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -1.138 . . . . 0.0 109.282 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 42' ' ' LEU . 87.6 mt -62.61 -44.07 97.23 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.138 -0.976 . . . . 0.0 108.823 179.223 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.2 mttp -63.56 -36.71 84.7 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.8 t -64.12 -38.31 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.774 -0.579 . . . . 0.0 109.749 179.58 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.532 HG13 ' HB1' ' A' ' 56' ' ' ALA . 1.3 mp -56.91 -51.03 73.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 109.958 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.459 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.42 -39.15 85.48 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.055 -1.028 . . . . 0.0 109.7 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.57 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 52.4 t90 -67.51 -44.39 78.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.301 -0.874 . . . . 0.0 111.08 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.593 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.4 OUTLIER -62.13 -49.1 77.21 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.133 -0.979 . . . . 0.0 109.978 -178.068 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -68.83 -39.22 80.1 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.957 -1.089 . . . . 0.0 109.391 179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -64.65 -42.62 95.29 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.119 -0.988 . . . . 0.0 111.135 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.692 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 54.7 ttt-85 -72.2 -48.23 44.66 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.216 -0.927 . . . . 0.0 112.036 -177.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.73 ' CE2' HG21 ' A' ' 80' ' ' THR . 90.9 m-85 -104.23 -6.21 21.15 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 111.733 -178.143 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.56 30.79 66.09 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 59.9 mt -106.04 142.27 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.255 -1.144 . . . . 0.0 109.34 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.18 122.66 15.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.955 -1.091 . . . . 0.0 108.958 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.532 ' HB1' HG13 ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.46 -0.775 . . . . 0.0 110.142 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -57.7 -31.93 93.31 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.675 2.25 . . . . 0.0 111.962 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.88 -24.8 66.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 179.623 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.9 t60 -67.28 -26.4 66.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.287 -0.883 . . . . 0.0 109.955 -179.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -95.05 6.23 49.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.107 -0.995 . . . . 0.0 109.426 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -56.33 -39.6 73.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.917 . . . . 0.0 109.7 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -135.25 153.5 51.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.094 -1.004 . . . . 0.0 109.924 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.4 ' N ' HD23 ' A' ' 30' ' ' LEU . 83.6 mt -63.88 -36.31 76.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 O-C-N 121.4 -0.813 . . . . 0.0 109.818 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.5 mtm180 -60.73 -37.68 82.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.823 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 t -59.76 -43.94 94.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.064 -1.023 . . . . 0.0 109.346 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.3 mt -64.39 -38.54 82.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.28 -0.888 . . . . 0.0 109.455 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.622 ' O ' HG23 ' A' ' 77' ' ' VAL . 21.8 t70 -56.16 -38.14 70.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.351 -0.843 . . . . 0.0 109.511 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.16 95.31 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.305 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -64.05 -46.69 83.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.493 179.407 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 58.3 t -64.18 -41.63 93.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.439 -0.788 . . . . 0.0 109.708 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.8 t -62.82 -43.5 98.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.216 -0.928 . . . . 0.0 109.96 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.82 -37.92 95.12 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -88.78 -49.64 6.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.111 -1.229 . . . . 0.0 110.185 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.73 HG21 ' CE2' ' A' ' 52' ' ' PHE . 28.0 m -128.86 138.75 52.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.441 -0.787 . . . . 0.0 109.566 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.604 ' OE1' HG13 ' A' ' 77' ' ' VAL . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.654 ' CE1' HD11 ' A' ' 7' ' ' ILE . 5.4 p80 -160.33 23.14 0.16 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.372 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.4 -38.64 87.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.91 -34.12 77.25 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.357 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.68 -38.1 80.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.285 -0.885 . . . . 0.0 109.356 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.875 ' O ' HG12 ' A' ' 11' ' ' VAL . 88.4 mt -60.43 -50.39 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.526 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.795 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -64.0 -44.09 93.7 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.301 -0.874 . . . . 0.0 109.024 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.47 -40.8 89.54 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.529 -0.732 . . . . 0.0 109.647 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -66.39 -49.47 66.73 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.535 -0.728 . . . . 0.0 111.272 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.875 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.4 p -69.95 -44.81 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.126 -0.984 . . . . 0.0 111.258 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.795 HG22 ' O ' ' A' ' 8' ' ' ALA . 15.9 m -67.48 -33.87 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.026 -1.046 . . . . 0.0 110.733 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.408 ' N ' HG23 ' A' ' 12' ' ' VAL . 82.8 tt0 -52.2 -36.34 51.68 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.107 -0.996 . . . . 0.0 109.832 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -33.36 75.41 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.176 -0.952 . . . . 0.0 110.568 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.67 ' O ' HD12 ' A' ' 16' ' ' LEU . 64.5 m-85 -95.94 -63.72 1.12 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.016 -1.053 . . . . 0.0 110.98 -178.749 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.67 HD12 ' O ' ' A' ' 15' ' ' PHE . 5.1 mp . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 110.62 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.362 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -65.24 -28.82 55.57 Favored 'Trans proline' 0 N--CA 1.49 1.271 0 C-N-CA 121.596 1.531 . . . . 0.0 112.041 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.71 -14.85 61.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.377 -0.827 . . . . 0.0 109.297 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -90.68 8.17 35.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.364 -0.835 . . . . 0.0 109.34 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.2 t -98.3 137.15 26.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.352 -0.842 . . . . 0.0 108.79 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.521 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -65.57 85.01 0.07 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.168 -0.958 . . . . 0.0 109.466 -179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -59.89 -0.06 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.312 -0.868 . . . . 0.0 109.266 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.45 7.14 44.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 108.954 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -94.23 136.01 35.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -63.51 121.71 14.52 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.128 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.468 HD11 ' O ' ' A' ' 66' ' ' PHE . 0.5 OUTLIER -68.78 5.24 1.15 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.87 -178.97 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.1 p -52.81 -38.87 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.03 -1.044 . . . . 0.0 108.547 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.446 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.9 t0 -57.77 -35.47 70.81 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.415 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.8 m-20 -86.06 19.52 2.6 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -14.51 0.01 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.4 t -51.44 -36.35 17.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 108.558 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.549 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.3 OUTLIER -69.98 -20.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.455 -0.778 . . . . 0.0 110.054 179.967 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -51.35 -35.57 38.94 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.216 -0.928 . . . . 0.0 110.98 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -119.1 -61.9 1.58 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.131 -0.981 . . . . 0.0 111.51 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.9 -52.39 64.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.925 -1.11 . . . . 0.0 110.14 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.583 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.35 -41.1 59.58 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.8 -41.86 87.75 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.386 -1.067 . . . . 0.0 109.491 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -59.32 -44.31 92.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.184 -0.947 . . . . 0.0 108.949 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -65.35 -34.64 78.8 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.272 -0.892 . . . . 0.0 109.007 179.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 40' ' ' GLY . 70.2 t -62.67 -41.59 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.784 . . . . 0.0 110.424 -179.373 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.2 mm -59.32 -49.59 82.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 120.931 -1.106 . . . . 0.0 109.635 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -65.84 -40.98 92.28 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -0.97 . . . . 0.0 109.338 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ2' ' HD3' ' A' ' 51' ' ' ARG . 69.3 t90 -66.89 -41.63 86.88 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.446 -0.784 . . . . 0.0 109.289 179.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.8 tp -60.07 -46.91 88.01 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.421 -0.8 . . . . 0.0 109.168 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.432 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -67.89 -34.18 76.15 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.314 -0.866 . . . . 0.0 109.207 178.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 92.4 m-20 -59.19 -46.62 87.94 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.233 -0.917 . . . . 0.0 110.291 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.401 ' HD3' ' CZ2' ' A' ' 47' ' ' TRP . 42.2 mtp180 -88.46 -51.77 5.54 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.075 -1.016 . . . . 0.0 111.616 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -80.23 -25.3 39.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.984 -1.072 . . . . 0.0 111.633 -177.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.34 31.16 52.52 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.248 -1.453 . . . . 0.0 109.712 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.432 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.9 mt -97.86 145.3 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.276 -1.132 . . . . 0.0 109.409 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.17 145.52 50.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.09 -1.006 . . . . 0.0 109.71 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.463 -0.773 . . . . 0.0 109.933 -179.594 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.406 ' HA ' ' CD1' ' A' ' 66' ' ' PHE . 10.0 Cg_endo -56.41 -27.41 67.84 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.664 2.243 . . . . 0.0 111.955 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.54 -27.46 69.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.249 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 33.5 t-80 -67.14 -26.25 66.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.434 -0.791 . . . . 0.0 109.697 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 0.9 OUTLIER -91.64 7.77 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.2 -0.937 . . . . 0.0 109.188 -179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.6 tpt180 -55.63 -39.44 70.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.971 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 91.6 p -137.25 152.57 49.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.047 -1.033 . . . . 0.0 110.214 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.479 HG23 ' CG2' ' A' ' 7' ' ' ILE . 89.5 mt -65.25 -36.67 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.308 -0.87 . . . . 0.0 110.027 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.1 ptt85 -61.2 -40.5 94.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 110.07 -179.219 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -59.21 -40.51 86.02 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.108 -0.995 . . . . 0.0 109.402 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -65.97 -39.74 85.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.338 -0.851 . . . . 0.0 109.728 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.691 ' O ' HG23 ' A' ' 77' ' ' VAL . 60.7 t0 -58.51 -38.64 78.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.315 -0.866 . . . . 0.0 109.918 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.52 -42.17 95.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 109.92 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -63.58 -48.53 77.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.07 -1.019 . . . . 0.0 109.606 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -65.49 -41.6 91.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.295 -0.878 . . . . 0.0 109.761 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.691 HG23 ' O ' ' A' ' 73' ' ' ASP . 62.6 t -61.33 -41.39 89.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.311 -0.868 . . . . 0.0 109.788 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.86 -31.72 76.96 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.49 -50.26 3.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.042 -1.27 . . . . 0.0 110.618 -178.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.1 p -129.86 157.52 42.01 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.399 -0.813 . . . . 0.0 109.613 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.385 0 O-C-N 121.206 -0.933 . . . . 0.0 109.393 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.606 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 81.9 m-70 -139.61 28.35 2.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.456 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -60.62 -34.35 74.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.281 -0.887 . . . . 0.0 110.151 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m -58.87 -40.16 83.5 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.018 -1.051 . . . . 0.0 109.666 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -64.5 -36.59 77.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.88 . . . . 0.0 109.066 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.44 ' O ' HG12 ' A' ' 11' ' ' VAL . 27.7 mm -64.76 -44.31 96.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.433 -0.792 . . . . 0.0 110.323 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.688 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.73 -50.44 69.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.113 -0.992 . . . . 0.0 110.734 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.86 -39.49 76.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.016 -1.052 . . . . 0.0 109.566 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 68.3 t80 -65.75 -51.29 60.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.346 -0.846 . . . . 0.0 109.94 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -67.93 -40.76 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 109.763 -179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.688 HG23 ' O ' ' A' ' 8' ' ' ALA . 71.1 t -65.93 -40.55 87.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.216 -0.927 . . . . 0.0 109.571 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -52.74 -30.54 33.15 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.438 -0.789 . . . . 0.0 109.827 -179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -65.37 -30.46 71.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.939 . . . . 0.0 109.412 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.9 p90 -145.41 44.12 1.3 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.4 pt? . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.054 -1.029 . . . . 0.0 110.082 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -49.04 -31.54 21.1 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.817 1.678 . . . . 0.0 111.993 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.96 -22.28 66.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.419 -0.8 . . . . 0.0 109.446 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -95.88 2.06 53.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.429 -0.795 . . . . 0.0 108.928 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.6 t -104.88 136.46 38.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.518 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.5 t0 -71.19 97.03 1.46 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.051 -1.031 . . . . 0.0 109.312 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.6 m -59.5 0.14 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.195 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.518 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -91.96 7.82 40.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.325 -0.859 . . . . 0.0 108.779 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.8 tp -91.22 133.83 35.06 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.478 -0.764 . . . . 0.0 109.376 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -66.33 121.31 14.96 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.049 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -74.74 9.6 1.77 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.219 -0.925 . . . . 0.0 109.825 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.5 p -52.25 -38.91 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.156 -0.965 . . . . 0.0 108.642 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.454 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.1 m-20 -57.33 -35.73 70.25 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 178.49 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.2 m-20 -84.94 18.25 2.54 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.011 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.92 -13.69 0.01 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -50.72 -35.24 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.072 -1.251 . . . . 0.0 108.945 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.578 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -70.01 -23.48 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.418 ' OD2' ' CG ' ' A' ' 66' ' ' PHE . 84.2 m-20 -54.93 -32.42 61.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 110.714 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.51 -64.09 1.36 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.149 -0.969 . . . . 0.0 111.174 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 15.5 mt -62.67 -52.52 62.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.002 -1.061 . . . . 0.0 110.2 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.48 -37.19 69.18 Favored Glycine 0 N--CA 1.486 1.97 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.73 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.4 tt -58.86 -41.46 87.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.266 -1.138 . . . . 0.0 109.149 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -61.51 -44.22 97.45 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.348 -0.845 . . . . 0.0 108.894 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -67.92 -40.79 83.32 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.301 -0.875 . . . . 0.0 110.007 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.8 t -65.68 -42.86 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.277 -0.889 . . . . 0.0 110.131 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -58.87 -50.47 79.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.186 -0.946 . . . . 0.0 109.65 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.424 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.72 -37.18 85.7 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.94 . . . . 0.0 109.436 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.517 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -69.32 -43.7 73.2 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.281 -0.887 . . . . 0.0 109.715 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.1 tp -57.34 -48.0 80.12 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.323 -0.86 . . . . 0.0 109.402 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -68.73 -37.71 79.66 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.301 -0.874 . . . . 0.0 109.122 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.5 t0 -63.77 -41.73 97.91 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.297 -0.877 . . . . 0.0 110.593 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.7 ttt180 -87.1 -55.26 3.9 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.231 -0.918 . . . . 0.0 111.454 -178.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -79.49 -22.34 44.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.987 -1.071 . . . . 0.0 111.383 -178.181 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 25.84 60.69 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.1 mt -106.07 144.91 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.471 -1.017 . . . . 0.0 109.416 -179.688 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 152.41 29.01 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.283 -0.886 . . . . 0.0 109.54 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.368 -0.833 . . . . 0.0 109.688 -179.571 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.449 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.218 0.532 . . . . 0.0 110.228 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -58.08 -25.99 73.49 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 C-N-CA 122.578 2.186 . . . . 0.0 111.664 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.72 -23.54 65.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.56 -0.713 . . . . 0.0 110.198 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.413 ' O ' HD11 ' A' ' 72' ' ' ILE . 0.2 OUTLIER -67.76 -26.63 66.22 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.59 -178.923 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.418 ' CG ' ' OD2' ' A' ' 37' ' ' ASP . 68.4 m-85 -80.17 -3.67 49.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.883 -1.136 . . . . 0.0 110.144 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 83.1 mmt-85 -60.47 -36.18 77.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.892 -1.13 . . . . 0.0 109.745 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.458 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 93.7 p -139.92 150.94 45.17 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.014 -1.054 . . . . 0.0 109.749 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 80.2 mt -65.13 -36.65 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -60.63 -38.41 84.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 110.197 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.458 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 24.6 m -57.81 -40.63 80.4 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.018 -1.051 . . . . 0.0 109.53 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.413 HD11 ' O ' ' A' ' 65' ' ' HIS . 17.0 mm -65.36 -38.97 83.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.154 -0.966 . . . . 0.0 109.17 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.536 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.4 t0 -57.23 -38.35 73.65 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.288 -0.882 . . . . 0.0 109.594 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.44 99.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.307 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -63.75 -46.56 84.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.357 -0.839 . . . . 0.0 109.432 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.8 t -64.68 -41.63 92.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.333 -0.854 . . . . 0.0 109.663 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 73' ' ' ASP . 52.9 t -61.59 -40.94 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.269 -0.894 . . . . 0.0 109.634 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.17 76.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.28 -50.01 5.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.096 -1.237 . . . . 0.0 109.961 -179.546 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.4 t -144.97 153.21 41.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.55 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.606 ' HG1' ' HE2' ' A' ' 3' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.213 -0.929 . . . . 0.0 109.552 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.468 ' OE1' HG13 ' A' ' 77' ' ' VAL . 61.4 tt0 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.587 ' ND1' ' OG1' ' A' ' 81' ' ' THR . 45.2 m80 -152.92 28.89 0.52 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.417 -0.802 . . . . 0.0 109.19 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.436 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.27 -33.02 71.73 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.412 -0.805 . . . . 0.0 109.658 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -58.97 -38.95 80.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.173 -0.954 . . . . 0.0 109.613 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -65.14 -39.06 84.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.15 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.436 HD12 ' HA ' ' A' ' 4' ' ' ALA . 89.1 mt -60.58 -50.62 79.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.276 -0.89 . . . . 0.0 109.459 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.737 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.96 -44.62 92.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 109.064 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.37 -44.17 88.48 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.74 0.781 . . . . 0.0 109.227 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -61.61 -47.79 83.86 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.525 -0.735 . . . . 0.0 109.331 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.476 HG12 ' HE1' ' A' ' 15' ' ' PHE . 96.6 t -73.16 -41.49 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.446 -0.784 . . . . 0.0 110.139 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 8' ' ' ALA . 78.4 t -63.96 -41.27 91.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -0.882 . . . . 0.0 111.022 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -57.01 -28.25 62.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 109.907 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.44 -30.09 70.84 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.21 -0.931 . . . . 0.0 109.359 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.603 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.8 p90 -146.8 45.68 1.19 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.161 -0.962 . . . . 0.0 109.775 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.819 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 120.965 -1.084 . . . . 0.0 110.369 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -49.25 -33.8 29.46 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.878 1.719 . . . . 0.0 111.697 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.03 -21.87 65.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.489 -0.757 . . . . 0.0 109.331 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.4 5.21 50.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.55 -0.719 . . . . 0.0 109.17 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.4 t -102.54 136.49 34.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.516 ' C ' ' H ' ' A' ' 27' ' ' ASP . 84.5 m-20 -67.42 94.35 0.39 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.137 -0.977 . . . . 0.0 109.418 -179.399 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.5 m -59.24 0.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.39 -0.819 . . . . 0.0 109.423 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.516 ' H ' ' C ' ' A' ' 25' ' ' ASP . 48.2 p30 -84.26 9.79 12.08 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.227 -0.921 . . . . 0.0 109.078 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.8 tp -86.34 134.95 33.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.6 -0.687 . . . . 0.0 109.366 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -65.43 121.83 15.78 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 108.733 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.694 HD11 HG12 ' A' ' 69' ' ' ILE . 82.3 mt -56.87 -16.66 7.14 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 108.931 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' A' ' 34' ' ' GLY . 41.7 t -50.64 -40.94 19.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.237 -0.914 . . . . 0.0 108.914 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.67 -36.17 66.81 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 178.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' A' ' 35' ' ' VAL . 9.7 m120 -85.02 20.44 1.88 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.11 -15.35 0.02 OUTLIER Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.346 -1.101 . . . . 0.0 110.346 -179.079 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.597 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.4 t -51.91 -40.17 27.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.604 -1.527 . . . . 0.0 108.585 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.4 tt -71.91 -22.25 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.577 -0.702 . . . . 0.0 110.883 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.401 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 93.0 m-20 -52.51 -34.8 51.36 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.154 -0.966 . . . . 0.0 111.784 -177.73 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.02 -60.59 1.74 Allowed 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.957 -1.09 . . . . 0.0 111.224 -178.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.96 -52.18 65.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.145 . . . . 0.0 109.598 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.441 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.91 -36.98 65.29 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.635 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.7 tt -58.02 -41.02 82.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.358 -1.083 . . . . 0.0 109.294 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 30.4 mt -60.31 -44.43 95.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 108.667 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -67.75 -38.74 83.89 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.406 -0.809 . . . . 0.0 109.576 179.281 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.5 t -65.09 -39.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.448 -0.783 . . . . 0.0 110.351 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -58.11 -50.6 77.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.033 -1.042 . . . . 0.0 109.642 -179.262 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.463 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.16 -39.14 86.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.089 -1.007 . . . . 0.0 109.702 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.5 t90 -70.38 -42.14 72.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.131 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.7 tp -61.43 -47.2 86.81 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.383 -0.823 . . . . 0.0 110.029 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.584 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -64.72 -43.7 92.59 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.116 -0.99 . . . . 0.0 108.613 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -66.45 -39.93 89.15 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.335 -0.853 . . . . 0.0 110.232 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 27.2 tpt85 -63.02 -45.06 94.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.499 -0.751 . . . . 0.0 111.547 -178.201 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 54.8 m-85 -126.24 2.27 7.1 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.912 -1.118 . . . . 0.0 111.858 -178.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.7 33.79 54.91 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.6 mt -95.85 135.87 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.183 -1.186 . . . . 0.0 109.146 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.54 140.7 58.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.087 -1.008 . . . . 0.0 109.678 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.452 0 O-C-N 121.468 -0.77 . . . . 0.0 109.786 -179.756 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -59.39 -35.13 97.22 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.511 2.141 . . . . 0.0 112.184 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.91 -28.73 68.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.398 -0.814 . . . . 0.0 109.796 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -67.81 -27.03 66.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.289 -0.882 . . . . 0.0 110.231 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.523 ' CD1' HD11 ' A' ' 72' ' ' ILE . 56.0 m-85 -101.68 13.84 33.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.133 -0.98 . . . . 0.0 110.06 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -53.03 -32.96 49.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.094 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.7 t -151.29 151.76 32.25 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 109.973 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.694 HG12 HD11 ' A' ' 30' ' ' LEU . 81.8 mt -60.97 -36.87 75.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 O-C-N 121.262 -0.898 . . . . 0.0 110.11 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -60.63 -40.82 93.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.224 -0.922 . . . . 0.0 110.214 -179.088 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.2 m -60.66 -41.8 95.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.037 -1.04 . . . . 0.0 109.936 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.523 HD11 ' CD1' ' A' ' 66' ' ' PHE . 77.3 mt -66.95 -40.83 86.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.245 -0.909 . . . . 0.0 110.156 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.407 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.1 t0 -59.12 -40.72 86.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 110.405 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.17 -41.9 89.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.124 -0.985 . . . . 0.0 110.09 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.7 t80 -62.06 -49.65 75.15 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.164 -0.96 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 80' ' ' THR . 53.6 t -65.55 -47.05 87.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.219 -0.926 . . . . 0.0 109.562 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.468 HG13 ' OE1' ' A' ' 2' ' ' GLN . 45.8 t -58.93 -38.84 75.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.112 -0.992 . . . . 0.0 109.455 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.73 -33.06 66.6 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.46 -51.24 3.14 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -1.224 . . . . 0.0 110.397 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.624 ' O ' HG12 ' A' ' 76' ' ' VAL . 7.2 t -153.87 152.41 30.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.728 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.587 ' OG1' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.469 0 O-C-N 121.236 -0.915 . . . . 0.0 109.22 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.434 ' ND1' HG21 ' A' ' 6' ' ' VAL . 2.9 m-70 -137.03 18.69 3.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.352 -0.843 . . . . 0.0 109.702 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.415 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -57.64 -38.98 75.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.166 -0.959 . . . . 0.0 109.599 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.6 p -65.24 -37.29 86.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.098 -1.001 . . . . 0.0 109.624 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.434 HG21 ' ND1' ' A' ' 3' ' ' HIS . 76.2 t -68.13 -37.81 78.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.287 -0.883 . . . . 0.0 109.261 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.554 HD11 ' HA ' ' A' ' 73' ' ' ASP . 97.2 mt -60.02 -49.79 82.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.75 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.71 -47.17 82.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.184 -0.947 . . . . 0.0 109.098 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -44.16 94.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.445 -0.785 . . . . 0.0 109.252 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.696 ' CZ ' ' CZ3' ' A' ' 47' ' ' TRP . 70.2 t80 -68.39 -48.32 65.01 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.512 0.673 . . . . 0.0 109.48 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.54 HG13 ' CD1' ' A' ' 36' ' ' ILE . 97.5 t -68.67 -44.22 82.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.667 -0.645 . . . . 0.0 110.014 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.728 HG23 ' O ' ' A' ' 8' ' ' ALA . 96.9 t -64.22 -36.71 77.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -52.37 -32.8 40.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.316 -0.865 . . . . 0.0 109.729 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.594 ' OE1' ' CZ3' ' A' ' 47' ' ' TRP . 76.8 mm-40 -66.0 -31.79 72.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.206 -0.934 . . . . 0.0 109.804 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.548 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 34.4 p90 -140.06 42.94 1.94 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.103 -0.998 . . . . 0.0 109.835 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.82 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.05 -1.031 . . . . 0.0 110.015 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -49.76 -31.45 25.92 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 121.842 1.695 . . . . 0.0 111.924 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.38 -22.77 66.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.537 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -92.77 4.29 54.06 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.448 -0.782 . . . . 0.0 109.225 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -105.35 136.48 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.522 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -69.23 91.24 0.52 Allowed 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -59.83 0.08 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.349 -0.844 . . . . 0.0 109.186 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.522 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -93.44 8.19 41.57 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.339 -0.851 . . . . 0.0 108.886 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.7 tp -92.34 136.86 32.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.432 -0.793 . . . . 0.0 109.519 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' A' ' 31' ' ' VAL . 33.6 p30 -62.61 114.4 3.55 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.141 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -63.74 8.7 0.08 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.112 -0.993 . . . . 0.0 109.926 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.539 ' H ' ' C ' ' A' ' 29' ' ' ASP . 6.3 p -54.98 -38.25 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.059 -1.025 . . . . 0.0 109.172 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.433 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.3 t0 -56.85 -37.21 70.98 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.596 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.5 m-80 -87.3 16.92 4.76 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.43 -17.4 0.03 OUTLIER Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.749 -1.341 . . . . 0.0 109.749 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.596 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.13 -34.19 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 O-C-N 120.969 -1.312 . . . . 0.0 108.453 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.593 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.9 OUTLIER -71.08 -21.32 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.512 -0.743 . . . . 0.0 110.042 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -55.06 -33.6 62.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.29 -0.881 . . . . 0.0 111.388 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 31.6 m -114.02 -64.52 1.3 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.055 -1.028 . . . . 0.0 111.522 -178.351 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.536 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.7 mp -65.45 -51.68 58.45 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.0 -1.062 . . . . 0.0 110.573 -178.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.613 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.5 -37.64 69.08 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 120.016 -1.088 . . . . 0.0 110.426 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.605 ' O ' HD13 ' A' ' 45' ' ' ILE . 6.9 tt -58.75 -41.49 86.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.176 -1.191 . . . . 0.0 109.796 -179.193 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.9 tp -66.76 -44.66 80.85 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.299 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -67.89 -37.95 82.39 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.1 t -63.59 -40.94 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.412 -0.805 . . . . 0.0 110.303 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.605 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.3 mp -58.88 -51.09 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.113 -0.992 . . . . 0.0 109.832 -179.189 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.441 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.14 -37.46 83.84 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.11 -0.994 . . . . 0.0 109.217 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.696 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 25.9 t90 -66.25 -39.61 89.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.445 -0.784 . . . . 0.0 109.538 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.53 -41.92 91.09 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.511 -0.743 . . . . 0.0 109.84 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.461 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 4.1 tm-20 -65.77 -39.11 90.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.183 -0.948 . . . . 0.0 109.925 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -60.09 -39.09 84.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.617 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.6 mtp85 -86.02 -54.18 4.64 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 111.247 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -80.4 -22.89 40.79 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.054 -1.028 . . . . 0.0 110.984 -178.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 27.47 57.76 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.461 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 68.3 mt -104.85 148.7 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.343 -1.092 . . . . 0.0 109.424 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.38 155.21 22.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.33 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.411 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.325 -0.859 . . . . 0.0 109.809 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -60.93 -27.12 84.3 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.649 2.232 . . . . 0.0 112.096 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.69 -25.45 67.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.384 -0.823 . . . . 0.0 109.947 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 52.6 t-80 -67.16 -26.64 66.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.173 -0.955 . . . . 0.0 110.202 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -96.78 3.14 52.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.095 -1.003 . . . . 0.0 109.387 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -56.67 -41.01 76.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.806 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -130.26 147.2 51.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.224 -0.922 . . . . 0.0 109.926 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.75 HD13 ' HB2' ' A' ' 8' ' ' ALA . 82.8 mt -63.12 -35.85 73.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 O-C-N 121.372 -0.83 . . . . 0.0 109.977 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.5 mtm180 -60.35 -37.35 80.4 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.202 -0.936 . . . . 0.0 110.108 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.3 t -58.67 -39.77 81.62 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.035 -1.041 . . . . 0.0 108.821 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.5 mt -62.65 -38.19 80.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.4 -0.812 . . . . 0.0 108.985 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.576 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.3 t0 -54.31 -38.73 66.29 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.409 -0.807 . . . . 0.0 109.275 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.15 93.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.927 . . . . 0.0 109.246 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -65.4 -46.35 80.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.244 -0.91 . . . . 0.0 109.374 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.2 t -65.38 -41.99 92.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.383 -0.823 . . . . 0.0 110.123 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.4 t -62.8 -42.92 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.085 -1.009 . . . . 0.0 109.864 -179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.95 -36.41 92.13 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.47 -49.79 5.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 110.532 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 37.9 m -129.22 139.68 51.77 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.835 . . . . 0.0 109.95 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.38 -0.825 . . . . 0.0 109.284 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 68.1 tp60 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.229 0.538 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.563 ' NE2' ' OG1' ' A' ' 81' ' ' THR . 95.9 m-70 -139.98 8.82 2.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.182 -0.949 . . . . 0.0 109.78 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.449 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.83 -37.49 79.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.163 -0.961 . . . . 0.0 109.394 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -59.76 -36.53 76.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.216 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 82.5 t -64.91 -37.25 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.388 -0.82 . . . . 0.0 109.45 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.54 ' CG2' HG23 ' A' ' 69' ' ' ILE . 89.6 mt -59.54 -48.53 86.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.567 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.612 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.25 -45.25 92.4 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.092 -1.005 . . . . 0.0 108.628 179.288 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -38.22 88.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.512 0.672 . . . . 0.0 109.398 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.433 ' N ' ' O ' ' A' ' 6' ' ' VAL . 68.6 t80 -64.51 -51.69 61.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.567 -0.708 . . . . 0.0 110.003 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.524 ' HB ' HD12 ' A' ' 36' ' ' ILE . 16.2 m -74.42 -41.53 49.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 110.457 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 8' ' ' ALA . 73.9 t -62.85 -36.22 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.16 -0.963 . . . . 0.0 110.403 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -57.36 -36.91 71.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -67.38 -36.85 82.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 110.504 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -90.58 -61.61 1.64 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.028 -1.045 . . . . 0.0 110.721 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.1 mt . . . . . 0 N--CA 1.493 1.691 0 O-C-N 121.304 -0.873 . . . . 0.0 110.134 -179.118 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.5 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.87 -27.51 59.05 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.528 1.485 . . . . 0.0 111.808 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.28 -17.07 63.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.198 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.5 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.9 m-20 -82.95 -1.26 51.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.385 -0.822 . . . . 0.0 108.787 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -102.5 138.65 25.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.505 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.4 t0 -67.93 94.36 0.47 Allowed 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.125 -0.984 . . . . 0.0 109.4 -179.399 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.5 m -60.87 0.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.363 -0.835 . . . . 0.0 109.319 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.505 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.1 m-20 -87.57 9.58 20.68 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.007 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -87.38 134.59 33.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.47 -0.769 . . . . 0.0 109.516 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.481 ' OD1' ' O ' ' A' ' 67' ' ' ARG . 86.1 m-20 -62.27 122.29 15.26 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 108.776 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.733 HD11 HG12 ' A' ' 69' ' ' ILE . 76.3 mt -58.13 -10.82 2.1 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.176 -0.952 . . . . 0.0 109.311 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 89.0 t -50.55 -45.35 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.116 -0.99 . . . . 0.0 108.691 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -55.94 -36.54 67.88 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.2 m-20 -90.13 22.91 3.05 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.13 -15.13 0.01 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.434 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -52.61 -37.2 23.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.308 . . . . 0.0 108.542 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.524 HD12 ' HB ' ' A' ' 11' ' ' VAL . 2.8 tt -70.48 -19.42 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.514 -0.741 . . . . 0.0 110.167 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.589 ' OD1' ' CE1' ' A' ' 66' ' ' PHE . 77.2 m-20 -56.71 -35.57 68.66 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.234 -0.916 . . . . 0.0 111.461 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.08 -64.56 1.29 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.086 -1.009 . . . . 0.0 111.268 -178.322 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.41 -48.93 77.52 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.066 -1.021 . . . . 0.0 110.02 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.08 -43.52 56.6 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -58.8 -39.66 81.76 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -1.097 . . . . 0.0 109.371 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.77 -44.24 93.96 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.171 -0.956 . . . . 0.0 108.772 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -68.42 -39.95 81.41 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.323 -0.861 . . . . 0.0 109.602 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.4 t -65.84 -44.09 92.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.4 -0.812 . . . . 0.0 110.123 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.413 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.2 mp -61.63 -50.5 80.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.127 -0.983 . . . . 0.0 109.481 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.413 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -66.85 -38.25 86.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.311 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 44.7 t90 -68.97 -43.57 74.68 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.328 -0.858 . . . . 0.0 109.6 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -60.2 -43.68 95.76 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.434 -0.792 . . . . 0.0 109.485 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.429 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 85.4 tt0 -67.71 -36.3 80.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.298 -0.876 . . . . 0.0 109.874 179.655 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -59.42 -39.24 82.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.838 -1.164 . . . . 0.0 110.119 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 36.3 mtp180 -87.04 -58.22 2.67 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.184 -0.947 . . . . 0.0 111.522 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -80.58 -23.16 40.06 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.951 -1.093 . . . . 0.0 111.733 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.71 35.01 33.15 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.319 -1.42 . . . . 0.0 109.709 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.429 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.2 mt -97.63 138.5 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.247 -1.149 . . . . 0.0 108.878 179.636 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.93 142.72 56.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.891 -1.131 . . . . 0.0 109.487 -179.403 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.356 -0.84 . . . . 0.0 109.335 -179.715 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_exo -51.67 -23.55 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.283 1.989 . . . . 0.0 111.971 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.5 -20.87 61.51 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 109.564 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -67.43 -26.94 66.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.309 -0.869 . . . . 0.0 110.383 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.589 ' CE1' ' OD1' ' A' ' 37' ' ' ASP . 51.7 m-85 -72.91 -14.14 61.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.009 -1.057 . . . . 0.0 109.555 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.481 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 25.1 mmt180 -56.79 -35.94 69.3 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.299 -0.875 . . . . 0.0 110.194 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.9 p -157.52 143.77 17.75 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.86 -1.15 . . . . 0.0 110.463 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.733 HG12 HD11 ' A' ' 30' ' ' LEU . 84.9 mt -66.99 -36.6 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 O-C-N 121.562 -0.711 . . . . 0.0 110.172 179.521 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -60.27 -41.89 94.25 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -0.829 . . . . 0.0 110.629 -178.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -57.49 -42.12 82.06 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.134 -0.978 . . . . 0.0 109.774 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.14 -38.66 80.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.133 -0.979 . . . . 0.0 109.928 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 77' ' ' VAL . 40.4 t0 -57.72 -40.54 79.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 -179.347 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.9 85.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.142 -0.974 . . . . 0.0 109.745 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -62.97 -48.88 76.95 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.228 -0.92 . . . . 0.0 109.398 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.55 -45.47 88.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.242 -0.911 . . . . 0.0 109.725 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 73' ' ' ASP . 49.2 t -60.91 -41.84 90.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 O-C-N 121.069 -1.02 . . . . 0.0 109.592 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.96 -28.42 63.56 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.32 -50.67 3.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.139 -1.212 . . . . 0.0 110.678 -179.163 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.1 t -149.17 156.58 42.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.068 -1.02 . . . . 0.0 109.997 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.563 ' OG1' ' NE2' ' A' ' 3' ' ' HIS . 0.2 OUTLIER . . . . . 0 C--N 1.302 -1.466 0 O-C-N 121.454 -0.779 . . . . 0.0 108.918 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.594 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 93.4 mt-30 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.594 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 22.0 p-80 40.28 24.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.412 -0.805 . . . . 0.0 109.164 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.553 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -61.53 -37.58 84.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.488 -0.757 . . . . 0.0 109.652 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 m -59.56 -38.1 80.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -0.943 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' CB ' ' A' ' 10' ' ' PHE . 71.6 t -64.28 -37.53 80.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.255 -0.903 . . . . 0.0 109.07 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.474 HD11 ' NE2' ' A' ' 3' ' ' HIS . 77.9 mt -64.19 -46.82 92.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.283 -0.886 . . . . 0.0 109.961 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.683 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.21 -49.98 69.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.293 -0.879 . . . . 0.0 110.593 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.72 -40.93 75.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.014 -1.054 . . . . 0.0 109.866 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.404 ' CB ' ' O ' ' A' ' 6' ' ' VAL . 74.4 t80 -63.69 -51.32 65.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -0.973 . . . . 0.0 110.159 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.47 HG12 ' O ' ' A' ' 7' ' ' ILE . 5.0 p -68.51 -40.38 81.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.703 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 8' ' ' ALA . 72.4 t -66.95 -37.8 80.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.311 -0.868 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -52.41 -29.67 25.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.378 -0.827 . . . . 0.0 109.992 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.51 -30.42 71.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.222 -0.924 . . . . 0.0 109.679 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.724 ' CE1' ' ND2' ' A' ' 33' ' ' ASN . 38.6 p90 -142.56 38.52 1.52 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.068 -1.02 . . . . 0.0 109.963 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.832 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.459 0 O-C-N 120.827 -1.17 . . . . 0.0 110.053 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.496 ' HD3' HD12 ' A' ' 16' ' ' LEU . 35.2 Cg_exo -50.02 -31.09 26.51 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 C-N-CA 121.943 1.762 . . . . 0.0 112.104 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.3 -25.44 68.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.64 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -96.74 8.62 43.86 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.237 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.46 137.18 28.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.356 -0.84 . . . . 0.0 108.818 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.53 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.87 85.89 0.33 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.216 -0.927 . . . . 0.0 109.642 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.8 m -59.97 0.08 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.387 -0.82 . . . . 0.0 109.086 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.53 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.64 7.69 40.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.345 -0.847 . . . . 0.0 108.87 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.9 tp -90.81 138.0 31.92 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.45 -0.781 . . . . 0.0 109.454 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.36 121.54 15.07 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.415 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -72.53 3.34 5.0 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.944 -178.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.2 p -52.46 -39.22 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.007 -1.058 . . . . 0.0 108.635 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -58.11 -34.74 70.53 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.397 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.724 ' ND2' ' CE1' ' A' ' 15' ' ' PHE . 4.4 m-20 -84.42 16.97 2.81 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 179.093 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.17 -17.37 0.03 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.295 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.79 -35.81 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.038 -1.272 . . . . 0.0 108.51 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.4 tt -70.22 -16.07 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.571 -0.706 . . . . 0.0 109.768 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -55.87 -32.94 64.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 111.392 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 73.9 m -119.43 -64.69 1.24 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.008 -1.057 . . . . 0.0 111.601 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.482 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.5 mp -62.51 -48.14 80.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 110.612 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -42.56 60.99 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.534 ' O ' HD13 ' A' ' 45' ' ' ILE . 2.5 mt -62.39 -38.92 91.5 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.272 -1.134 . . . . 0.0 109.675 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.8 tp -59.12 -44.03 91.99 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.143 -0.973 . . . . 0.0 108.676 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -66.16 -38.25 87.62 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.291 -0.881 . . . . 0.0 109.017 178.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.2 t -64.93 -39.6 86.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.527 -0.733 . . . . 0.0 110.054 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.534 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.4 mp -58.1 -50.27 78.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.221 -0.925 . . . . 0.0 109.679 -179.318 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.54 -38.16 90.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.14 -0.975 . . . . 0.0 109.171 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.741 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 51.6 t90 -66.84 -40.15 87.86 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.392 -0.817 . . . . 0.0 109.474 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 tp -61.01 -43.53 98.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.462 -0.774 . . . . 0.0 109.735 -179.694 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.403 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 85.4 tt0 -66.3 -36.4 82.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 110.001 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -62.3 -46.24 89.65 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.045 -1.034 . . . . 0.0 110.837 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.741 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt180 -87.4 -51.14 6.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.074 -1.016 . . . . 0.0 111.798 -178.529 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.785 ' CE2' HG21 ' A' ' 80' ' ' THR . 95.3 m-85 -79.88 -24.1 41.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.966 -1.084 . . . . 0.0 111.13 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.47 31.54 45.55 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.44 -1.362 . . . . 0.0 109.739 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.403 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 68.1 mt -100.21 136.31 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.167 -1.196 . . . . 0.0 108.656 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.925 -1.11 . . . . 0.0 109.765 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.462 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.522 -0.736 . . . . 0.0 109.405 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -57.69 -30.67 89.75 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.757 2.304 . . . . 0.0 112.11 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.54 -31.83 73.21 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.264 -0.897 . . . . 0.0 109.509 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.479 ' CE1' ' O ' ' A' ' 71' ' ' SER . 83.7 t60 -68.59 -26.19 65.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 110.653 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.491 ' CZ ' HD11 ' A' ' 41' ' ' LEU . 97.1 m-85 -88.79 7.35 34.5 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.996 -1.065 . . . . 0.0 110.489 -178.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 24.0 mmt85 -58.07 -36.33 72.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.07 -1.019 . . . . 0.0 109.968 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 90.9 p -133.68 150.04 51.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.208 -0.932 . . . . 0.0 109.834 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.9 mt -66.05 -36.45 77.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.313 -0.867 . . . . 0.0 109.875 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -60.93 -37.61 82.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.171 -0.955 . . . . 0.0 109.916 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.479 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 88.4 p -61.37 -35.73 78.25 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.07 -1.019 . . . . 0.0 109.274 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.3 mt -61.41 -39.06 81.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.25 -0.907 . . . . 0.0 109.015 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.725 ' O ' HG23 ' A' ' 77' ' ' VAL . 51.3 t0 -59.24 -37.32 77.27 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.515 -0.741 . . . . 0.0 109.68 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.19 -46.67 82.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.188 -0.945 . . . . 0.0 109.872 -179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.414 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 68.9 t80 -66.12 -44.85 83.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.053 -1.029 . . . . 0.0 109.079 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -62.63 -41.83 93.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.471 -0.768 . . . . 0.0 109.549 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.6 t -61.92 -41.73 91.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 O-C-N 121.264 -0.898 . . . . 0.0 109.661 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.65 -36.33 85.29 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -90.57 -49.82 6.28 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.11 -1.23 . . . . 0.0 110.079 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.785 HG21 ' CE2' ' A' ' 52' ' ' PHE . 12.4 t -145.1 153.35 41.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -0.888 . . . . 0.0 109.577 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.667 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.1 mt-30 . . . . . 0 N--CA 1.488 1.447 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.4 m80 61.79 20.09 11.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -0.988 . . . . 0.0 109.139 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -63.43 -38.24 90.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.6 m -60.79 -39.12 87.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.97 . . . . 0.0 110.065 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.5 t -64.81 -38.09 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.103 -0.998 . . . . 0.0 109.554 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.674 ' O ' HG22 ' A' ' 11' ' ' VAL . 83.2 mt -59.81 -50.8 78.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.25 -0.906 . . . . 0.0 109.631 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.718 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.21 -46.36 84.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 109.139 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.36 -39.98 94.95 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.4 -0.813 . . . . 0.0 109.648 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.64 -51.21 61.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.431 -0.793 . . . . 0.0 110.493 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.674 HG22 ' O ' ' A' ' 7' ' ' ILE . 22.9 m -73.74 -39.28 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.24 -0.913 . . . . 0.0 110.367 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.718 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.3 t -65.13 -39.03 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.065 -1.022 . . . . 0.0 109.773 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -53.12 -35.87 60.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 109.8 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.62 -31.88 72.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.27 -0.894 . . . . 0.0 109.918 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.88 39.86 3.12 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 110.047 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.834 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.93 -1.106 . . . . 0.0 110.024 -179.73 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -49.52 -30.28 20.91 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.929 1.753 . . . . 0.0 112.052 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.04 -22.86 67.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.307 -0.87 . . . . 0.0 109.643 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -96.11 7.13 47.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.333 -0.854 . . . . 0.0 109.132 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.58 136.52 34.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.535 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.1 89.61 0.44 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.175 -0.953 . . . . 0.0 109.605 -179.34 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -59.63 0.11 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.261 -0.899 . . . . 0.0 109.146 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.535 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -92.21 8.22 39.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.352 -0.842 . . . . 0.0 108.786 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.0 tp -90.96 139.06 31.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.427 -0.796 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.416 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.9 m-20 -60.82 121.58 12.69 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -69.86 7.13 0.97 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.254 -0.904 . . . . 0.0 109.847 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -53.46 -38.61 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.113 -0.992 . . . . 0.0 109.123 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.92 -36.45 72.5 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.15 19.55 3.09 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -15.01 0.02 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.63 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -53.43 -36.49 27.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.125 -1.221 . . . . 0.0 108.862 179.53 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.5 tt -70.38 -22.48 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.538 -0.726 . . . . 0.0 110.245 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.3 m-20 -55.42 -33.22 63.36 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 110.932 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -116.17 -63.75 1.41 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.123 -0.985 . . . . 0.0 111.24 -178.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.54 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.4 mm? -62.41 -52.18 64.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.047 -1.033 . . . . 0.0 110.096 -178.78 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.6 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.79 -40.19 64.87 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.7 tt -58.7 -41.04 85.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -1.094 . . . . 0.0 109.552 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 24.9 tp -62.76 -44.4 96.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.935 . . . . 0.0 109.024 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -66.24 -35.12 79.6 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.349 -0.844 . . . . 0.0 109.592 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 40' ' ' GLY . 64.2 t -60.86 -42.99 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 110.24 -179.366 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -59.64 -50.54 79.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.105 -0.997 . . . . 0.0 109.632 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.91 -36.65 82.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 34.3 t90 -67.79 -43.33 79.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 109.633 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.01 -46.3 85.48 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.477 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -67.84 -38.05 82.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.35 -0.844 . . . . 0.0 109.067 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.8 t0 -65.47 -41.48 93.32 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 110.64 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 74.5 ttt-85 -87.12 -58.14 2.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.171 -0.956 . . . . 0.0 111.662 -178.385 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -79.73 -19.47 48.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.02 -1.05 . . . . 0.0 111.559 -177.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 28.19 56.26 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -104.47 142.58 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.405 -1.056 . . . . 0.0 109.348 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.47 154.73 23.69 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.237 -0.914 . . . . 0.0 109.143 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.494 0 O-C-N 121.259 -0.901 . . . . 0.0 109.405 -179.354 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.19 -21.47 59.91 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.892 2.395 . . . . 0.0 111.866 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.43 -32.32 70.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.402 -0.811 . . . . 0.0 110.091 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.44 ' O ' ' OG ' ' A' ' 71' ' ' SER . 44.9 t-80 -70.23 -26.27 63.77 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.319 -0.863 . . . . 0.0 111.404 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -95.11 8.0 44.37 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.799 -1.188 . . . . 0.0 110.817 -178.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -60.91 -38.44 85.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.998 -1.064 . . . . 0.0 110.671 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.4 m -126.66 147.58 49.91 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.222 -0.924 . . . . 0.0 110.483 -179.149 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.2 -36.09 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 O-C-N 121.434 -0.791 . . . . 0.0 109.802 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -60.42 -37.7 81.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 110.157 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 97.6 p -61.44 -36.85 81.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.08 -1.013 . . . . 0.0 109.282 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.6 -38.62 82.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.373 -0.83 . . . . 0.0 109.117 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 53.5 t0 -56.52 -38.74 72.24 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.43 -0.794 . . . . 0.0 109.655 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.84 -42.04 97.7 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.132 -0.98 . . . . 0.0 109.405 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -64.35 -45.66 86.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.863 . . . . 0.0 109.563 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.6 t -65.0 -42.42 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.348 -0.845 . . . . 0.0 110.05 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.2 t -63.18 -42.37 96.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.155 -0.966 . . . . 0.0 109.892 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.9 -30.07 72.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -97.69 -49.54 4.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.958 -1.319 . . . . 0.0 110.307 -179.228 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 76' ' ' VAL . 11.0 t -139.19 155.54 47.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.554 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.467 0 O-C-N 121.448 -0.783 . . . . 0.0 109.514 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.335 0.588 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.726 ' CD2' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -163.88 25.0 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.155 -0.966 . . . . 0.0 109.385 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.641 ' HB2' ' OD1' ' A' ' 73' ' ' ASP . . . -61.87 -34.83 76.71 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.231 -0.918 . . . . 0.0 109.563 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 t -59.11 -39.6 82.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.159 -0.963 . . . . 0.0 109.543 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.726 HG21 ' CD2' ' A' ' 3' ' ' HIS . 78.3 t -65.13 -39.29 85.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.2 179.63 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.5 ' O ' HG23 ' A' ' 11' ' ' VAL . 88.1 mt -59.86 -48.0 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.444 -0.785 . . . . 0.0 109.657 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.487 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.66 -46.37 85.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.318 -0.864 . . . . 0.0 109.656 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.434 ' HG3' ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.52 -36.54 76.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.547 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.3 t80 -68.57 -48.23 64.76 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.389 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.527 HG13 HD12 ' A' ' 36' ' ' ILE . 73.7 t -69.12 -46.3 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 110.104 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 8' ' ' ALA . 76.6 t -63.53 -35.2 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.39 -0.819 . . . . 0.0 110.676 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.95 -36.8 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.125 -0.985 . . . . 0.0 109.86 -179.105 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.72 -35.39 78.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 110.685 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -91.99 -63.6 1.22 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.022 -1.049 . . . . 0.0 110.731 -178.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.9 mt . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.255 -0.903 . . . . 0.0 110.19 -179.024 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.652 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.487 1.403 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.0 -28.6 57.6 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.574 1.516 . . . . 0.0 111.813 -179.186 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.62 -14.75 62.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.391 -0.818 . . . . 0.0 109.174 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.652 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 90.0 m-20 -82.94 -0.16 47.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.377 -0.827 . . . . 0.0 108.917 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -98.94 137.74 25.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.525 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -67.41 92.75 0.3 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.087 -1.008 . . . . 0.0 109.437 -179.277 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 m -59.77 0.01 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.421 -0.799 . . . . 0.0 109.206 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -88.98 5.69 43.05 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.8 tp -92.67 136.42 33.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.612 -0.68 . . . . 0.0 109.399 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.45 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.2 m-20 -60.93 121.58 12.74 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.1 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.518 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -67.02 6.53 0.51 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.126 -0.983 . . . . 0.0 109.72 -178.938 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.513 HG21 ' NH2' ' A' ' 67' ' ' ARG . 5.1 p -54.78 -37.57 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 108.933 179.741 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.432 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.25 -36.31 70.8 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.1 m-20 -84.96 17.92 2.69 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.44 ' O ' ' CG ' ' A' ' 37' ' ' ASP . . . -42.87 -14.26 0.01 OUTLIER Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.6 t -51.34 -37.93 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 108.855 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.527 HD12 HG13 ' A' ' 11' ' ' VAL . 0.9 OUTLIER -70.9 -11.82 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.47 -0.769 . . . . 0.0 109.757 179.92 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.44 ' CG ' ' O ' ' A' ' 34' ' ' GLY . 85.3 m-20 -51.64 -42.31 61.96 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 111.376 -177.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -120.91 -58.66 1.8 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.109 -0.995 . . . . 0.0 111.975 -178.381 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.567 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.6 mp -61.27 -52.15 65.95 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.825 -1.172 . . . . 0.0 110.135 -178.313 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.625 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.56 -36.06 68.08 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.756 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.98 -43.23 86.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -1.083 . . . . 0.0 109.548 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.65 -43.91 95.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.076 -1.015 . . . . 0.0 109.205 179.577 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -65.27 -38.05 89.1 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 40' ' ' GLY . 80.0 t -65.31 -39.93 86.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.381 -0.825 . . . . 0.0 110.067 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.442 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -58.45 -50.1 79.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.155 -0.966 . . . . 0.0 109.905 -179.333 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.442 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -60.98 -36.7 80.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.971 -1.081 . . . . 0.0 109.94 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.547 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -76.58 -41.92 44.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.143 -0.973 . . . . 0.0 110.126 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.7 tt -60.84 -43.12 98.74 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.411 -0.805 . . . . 0.0 110.801 -178.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.714 ' OE1' ' HB2' ' A' ' 56' ' ' ALA . 54.8 mt-10 -65.78 -39.64 91.2 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.946 -1.096 . . . . 0.0 109.217 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -67.84 -49.21 63.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.419 -0.8 . . . . 0.0 110.932 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.615 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 67.4 ttt-85 -62.07 -41.3 98.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 97.5 m-85 -101.58 -9.62 20.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.953 -1.092 . . . . 0.0 110.559 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.21 35.78 88.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -105.88 143.94 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.302 -1.117 . . . . 0.0 109.869 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.76 152.85 34.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.365 -0.835 . . . . 0.0 109.082 179.523 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.714 ' HB2' ' OE1' ' A' ' 49' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 110.206 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.43 -28.06 77.78 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.532 2.154 . . . . 0.0 111.943 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -60.95 -28.3 68.88 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.418 -0.801 . . . . 0.0 109.993 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.402 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 78.4 t60 -67.78 -26.54 66.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.15 -0.969 . . . . 0.0 110.188 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -100.75 8.12 43.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.767 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.513 ' NH2' HG21 ' A' ' 31' ' ' VAL . 20.5 tpt180 -54.86 -40.06 69.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.356 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -127.69 148.6 50.4 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.319 -0.863 . . . . 0.0 109.69 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.3 mt -60.72 -36.59 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.299 -0.876 . . . . 0.0 109.891 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -60.55 -39.26 87.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.271 -0.893 . . . . 0.0 110.25 -179.195 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 m -58.25 -41.25 83.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.983 -1.073 . . . . 0.0 109.521 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.2 -38.62 83.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.839 ' O ' HG23 ' A' ' 77' ' ' VAL . 91.9 m-20 -56.31 -38.14 70.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.461 -0.774 . . . . 0.0 109.609 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.88 -45.99 86.92 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.402 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.6 t80 -65.69 -46.67 78.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.181 179.572 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.3 t -64.35 -40.73 90.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.422 -0.799 . . . . 0.0 109.681 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.839 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.1 t -60.33 -43.34 93.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.16 -0.963 . . . . 0.0 109.91 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.46 -37.38 94.71 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -87.62 -50.15 6.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.999 -1.295 . . . . 0.0 110.331 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.9 p -130.8 156.24 45.34 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.409 -0.807 . . . . 0.0 109.199 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.302 -1.474 0 O-C-N 121.219 -0.926 . . . . 0.0 109.609 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -152.04 57.42 0.84 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.905 . . . . 0.0 109.107 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.565 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.36 -35.41 75.61 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.265 -0.897 . . . . 0.0 109.97 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -59.46 -40.8 88.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.055 -1.028 . . . . 0.0 109.545 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.2 t -67.01 -37.85 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.239 -0.913 . . . . 0.0 109.182 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.565 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.8 mt -59.73 -40.03 81.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.496 -0.753 . . . . 0.0 110.101 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 1.018 ' HB1' HG11 ' A' ' 26' ' ' VAL . . . -63.18 -50.0 72.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.023 -1.048 . . . . 0.0 109.294 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.488 ' OE1' ' OE1' ' A' ' 13' ' ' GLU . 1.2 pp0? -69.94 -33.94 72.79 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.338 -0.851 . . . . 0.0 109.439 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.414 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 65.0 t80 -66.35 -51.96 51.84 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.043 -1.035 . . . . 0.0 109.942 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 5.5 p -70.57 -38.7 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.233 -0.917 . . . . 0.0 110.111 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.735 HG23 ' O ' ' A' ' 8' ' ' ALA . 88.6 t -65.25 -42.1 93.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.211 -0.93 . . . . 0.0 110.639 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' OE1' ' OE1' ' A' ' 9' ' ' GLN . 76.6 mt-10 -55.18 -27.38 45.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.021 -1.049 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.759 ' CD ' HD11 ' A' ' 36' ' ' ILE . 85.7 tt0 -65.38 -27.75 68.79 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 109.101 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.586 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.0 p90 -149.83 41.64 0.85 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.219 -0.926 . . . . 0.0 109.852 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 O-C-N 120.948 -1.095 . . . . 0.0 110.196 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.464 ' HD3' HD12 ' A' ' 16' ' ' LEU . 31.7 Cg_exo -49.94 -32.55 30.85 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.936 1.757 . . . . 0.0 111.938 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.33 -24.84 67.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.453 -0.779 . . . . 0.0 109.64 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -98.47 7.12 46.58 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -0.863 . . . . 0.0 109.453 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.4 t -103.8 135.16 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.315 -0.866 . . . . 0.0 108.879 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.429 ' C ' ' H ' ' A' ' 27' ' ' ASP . 88.0 m-20 -72.17 86.06 1.06 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.219 -0.925 . . . . 0.0 109.315 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.018 HG11 ' HB1' ' A' ' 8' ' ' ALA . 19.7 m -63.11 -0.3 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.233 -0.917 . . . . 0.0 109.627 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.475 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 48.0 p30 -90.7 8.52 34.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.141 -0.974 . . . . 0.0 108.787 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 18.8 tp -93.93 136.37 34.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 109.447 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -60.95 122.48 15.02 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.754 HD11 ' CG2' ' A' ' 69' ' ' ILE . 56.6 mt -66.89 -0.86 3.35 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.258 -0.901 . . . . 0.0 109.87 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.9 t -52.61 -42.47 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.089 -1.007 . . . . 0.0 108.911 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.46 -36.33 66.46 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.619 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.6 m120 -86.55 20.29 2.53 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.46 -15.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.619 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -53.33 -38.81 32.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.884 -1.363 . . . . 0.0 108.277 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.759 HD11 ' CD ' ' A' ' 14' ' ' GLU . 5.4 tt -70.87 -24.2 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.599 -0.688 . . . . 0.0 109.95 179.724 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -62.54 -22.51 66.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.181 -0.949 . . . . 0.0 110.697 -178.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -117.47 -64.87 1.24 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.081 -1.012 . . . . 0.0 111.013 -178.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.516 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -67.41 -50.2 60.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.034 -1.041 . . . . 0.0 110.171 -178.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.562 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.74 -41.24 64.13 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tt -61.1 -40.05 92.26 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.494 -1.003 . . . . 0.0 109.617 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.6 tp -58.63 -44.31 89.96 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.189 -0.944 . . . . 0.0 108.569 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.0 mtpt -65.06 -34.2 77.86 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.2 t -64.49 -39.77 86.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.495 -0.753 . . . . 0.0 110.511 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.9 mm -59.22 -50.74 78.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.637 -1.29 . . . . 0.0 109.525 -179.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.87 -41.31 83.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.292 -0.88 . . . . 0.0 109.793 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 16.8 t90 -69.77 -42.81 73.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 110.233 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 33.2 tp -59.36 -41.93 90.43 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.329 -0.857 . . . . 0.0 109.712 -179.384 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.567 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.5 tt0 -64.06 -38.12 89.92 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.238 -0.914 . . . . 0.0 109.753 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -60.07 -37.08 78.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.951 -1.093 . . . . 0.0 110.064 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -75.09 -48.68 22.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.245 -0.91 . . . . 0.0 111.958 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.509 ' CZ ' HG21 ' A' ' 80' ' ' THR . 24.7 m-85 -114.66 -3.12 12.91 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.012 -1.055 . . . . 0.0 111.855 -178.311 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 30.48 61.22 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.874 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.427 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.8 mt -78.19 138.78 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -1.217 . . . . 0.0 108.977 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 131.21 49.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.827 -1.17 . . . . 0.0 109.736 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.448 -0.782 . . . . 0.0 109.258 179.848 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -50.7 -31.45 32.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.222 1.948 . . . . 0.0 111.69 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.05 -30.72 71.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.423 -0.798 . . . . 0.0 109.074 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -67.65 -26.55 66.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.474 -0.767 . . . . 0.0 109.802 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -91.9 10.22 29.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.181 -0.949 . . . . 0.0 109.449 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -53.61 -36.55 62.11 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.294 -0.879 . . . . 0.0 109.463 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.9 t -150.3 152.61 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.273 -0.892 . . . . 0.0 109.846 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.754 ' CG2' HD11 ' A' ' 30' ' ' LEU . 0.9 OUTLIER -64.31 -36.16 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 179.854 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -60.7 -38.07 83.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.111 -0.993 . . . . 0.0 110.107 -179.241 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.01 -37.03 85.55 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.073 -1.017 . . . . 0.0 109.16 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.5 mt -66.36 -38.43 81.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.329 -0.857 . . . . 0.0 109.29 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.1 t0 -56.25 -41.05 75.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.491 -0.756 . . . . 0.0 109.88 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.63 -45.33 79.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.205 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.6 t80 -63.08 -48.61 77.88 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -0.966 . . . . 0.0 109.751 -179.753 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.637 HG12 ' O ' ' A' ' 80' ' ' THR . 71.9 t -66.48 -42.83 90.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.251 -0.906 . . . . 0.0 109.836 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' ' 73' ' ' ASP . 44.5 t -61.96 -40.55 87.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 120.969 -1.082 . . . . 0.0 109.693 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.84 -34.36 71.06 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.36 -50.65 3.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.133 -1.216 . . . . 0.0 110.79 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.637 ' O ' HG12 ' A' ' 76' ' ' VAL . 56.0 m -153.96 140.41 18.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.995 -1.066 . . . . 0.0 110.267 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.282 -0.886 . . . . 0.0 109.239 179.435 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.684 ' NE2' HG11 ' A' ' 6' ' ' VAL . 57.1 t-80 -148.33 8.06 0.8 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.34 -0.85 . . . . 0.0 109.724 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.63 -39.81 95.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.055 -1.028 . . . . 0.0 109.769 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.3 t -61.52 -40.08 93.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.924 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.684 HG11 ' NE2' ' A' ' 3' ' ' HIS . 78.1 t -63.27 -39.71 86.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.257 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.634 ' O ' HG23 ' A' ' 11' ' ' VAL . 92.0 mt -62.4 -46.45 96.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.346 -0.846 . . . . 0.0 110.01 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.45 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.88 -49.93 70.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 110.411 -179.327 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.436 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.91 -42.07 73.83 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.182 -0.949 . . . . 0.0 109.894 -179.677 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 9' ' ' GLN . 71.4 t80 -60.49 -46.47 90.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 7' ' ' ILE . 67.2 t -69.63 -47.01 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.44 -0.787 . . . . 0.0 109.92 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 8' ' ' ALA . 75.5 t -65.51 -35.18 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.404 -0.81 . . . . 0.0 110.453 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -53.52 -36.66 62.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.214 -0.928 . . . . 0.0 109.992 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.96 -35.57 78.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 110.771 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.662 ' O ' HD12 ' A' ' 16' ' ' LEU . 69.9 m-85 -91.74 -63.6 1.23 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.963 -1.085 . . . . 0.0 110.657 -178.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.662 HD12 ' O ' ' A' ' 15' ' ' PHE . 6.2 mp . . . . . 0 N--CA 1.493 1.718 0 O-C-N 121.331 -0.855 . . . . 0.0 110.119 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.544 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.486 1.354 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.9 -25.57 59.81 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.524 1.483 . . . . 0.0 111.723 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.49 -14.87 62.7 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.31 -0.869 . . . . 0.0 109.232 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.544 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -82.87 2.91 31.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.255 -0.903 . . . . 0.0 108.929 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.13 137.27 32.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.466 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.4 89.17 0.14 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.147 -0.971 . . . . 0.0 109.377 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.7 m -62.31 -0.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.307 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -93.85 7.07 46.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 108.979 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.9 tp -95.7 137.87 34.15 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.483 -0.761 . . . . 0.0 109.6 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -61.71 121.81 13.75 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.453 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.5 OUTLIER -67.97 2.87 1.79 Allowed 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.266 -0.896 . . . . 0.0 109.932 -178.811 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.456 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -51.28 -39.19 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.08 -1.012 . . . . 0.0 108.395 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.42 -35.78 70.5 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.7 m-20 -87.09 22.14 2.14 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.009 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -14.27 0.01 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -51.26 -35.31 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.104 -1.233 . . . . 0.0 108.612 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.624 HD12 HG13 ' A' ' 11' ' ' VAL . 1.1 tt -70.07 -19.94 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.517 -0.739 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.418 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -55.53 -33.18 63.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -0.87 . . . . 0.0 111.046 -178.51 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -116.78 -64.13 1.35 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.115 -0.991 . . . . 0.0 111.356 -178.571 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.531 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.5 mp -62.88 -52.08 64.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.99 -1.068 . . . . 0.0 110.093 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.67 -38.92 67.39 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.723 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.2 tt -58.45 -43.08 88.7 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.401 -1.058 . . . . 0.0 109.725 -179.75 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 tp -60.23 -44.32 95.31 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 108.956 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -69.72 -40.1 76.46 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.373 -0.829 . . . . 0.0 109.967 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.8 t -66.03 -45.01 91.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 110.391 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.2 mp -59.45 -50.24 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.084 -1.01 . . . . 0.0 109.513 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.401 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.62 -32.2 73.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 29.6 t90 -74.46 -45.83 43.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.878 . . . . 0.0 110.246 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -57.41 -45.31 84.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.362 -0.836 . . . . 0.0 110.009 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.414 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 8.4 pt-20 -71.23 -36.42 71.82 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.098 -1.001 . . . . 0.0 109.056 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.9 t0 -64.78 -41.45 95.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.322 -0.861 . . . . 0.0 110.639 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.4 ttt180 -83.78 -51.56 7.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 110.95 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.743 ' CE2' HG21 ' A' ' 80' ' ' THR . 92.7 m-85 -79.85 -24.55 41.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.05 -1.031 . . . . 0.0 110.842 -178.706 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.41 31.44 54.54 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.694 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 53.9 mt -109.4 134.28 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -1.085 . . . . 0.0 109.582 -179.559 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.93 143.39 57.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.352 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 -179.84 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.89 -26.88 74.53 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.481 2.121 . . . . 0.0 112.281 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -57.65 -27.42 62.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.843 . . . . 0.0 109.654 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.518 ' NE2' HG23 ' A' ' 72' ' ' ILE . 85.9 t60 -67.13 -26.92 66.91 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.941 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -101.1 4.25 42.01 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.028 -1.045 . . . . 0.0 110.373 -179.46 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -58.86 -40.94 85.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.887 -1.133 . . . . 0.0 109.86 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.1 p -150.06 154.89 38.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.903 -1.123 . . . . 0.0 110.019 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 87.6 mt -65.33 -37.36 79.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.343 -0.848 . . . . 0.0 109.857 179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.7 ttp180 -60.93 -40.43 93.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 110.164 -179.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -59.58 -41.85 91.19 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.999 -1.063 . . . . 0.0 109.695 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.518 HG23 ' NE2' ' A' ' 65' ' ' HIS . 87.2 mt -67.43 -39.96 83.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.258 -0.901 . . . . 0.0 110.005 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.455 ' HA ' HD11 ' A' ' 7' ' ' ILE . 52.5 t0 -59.16 -40.79 86.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 110.188 -179.405 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.53 -42.71 98.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.129 -0.982 . . . . 0.0 109.586 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.0 t80 -63.74 -45.34 90.34 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.247 -0.908 . . . . 0.0 109.336 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.7 t -63.75 -45.36 97.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.355 -0.841 . . . . 0.0 109.915 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.0 t -60.97 -40.09 84.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 O-C-N 121.125 -0.984 . . . . 0.0 109.637 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.76 -32.25 65.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.15 -50.17 3.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.084 -1.245 . . . . 0.0 110.403 -179.353 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.743 HG21 ' CE2' ' A' ' 52' ' ' PHE . 8.4 t -146.22 155.61 42.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.171 -0.956 . . . . 0.0 110.021 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.317 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.39 11.84 3.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.334 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.75 -33.24 71.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.347 -0.846 . . . . 0.0 109.918 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.35 -35.3 77.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.097 -1.002 . . . . 0.0 109.552 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.26 -37.83 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.184 -0.947 . . . . 0.0 109.167 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 11' ' ' VAL . 87.3 mt -63.55 -43.27 98.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.067 -1.021 . . . . 0.0 110.089 -179.84 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.655 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.22 -50.67 67.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.789 -179.178 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.5 -36.93 74.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.958 -1.088 . . . . 0.0 110.065 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -59.4 -51.3 70.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.844 -1.16 . . . . 0.0 110.082 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.589 HG22 ' O ' ' A' ' 7' ' ' ILE . 20.4 m -74.3 -40.64 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.142 -0.973 . . . . 0.0 110.32 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.7 t -62.49 -39.38 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.257 -0.902 . . . . 0.0 110.502 -179.255 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -61.86 -32.56 72.92 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.128 -0.982 . . . . 0.0 110.02 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.37 -33.24 75.28 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.869 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 11' ' ' VAL . 62.3 m-85 -93.1 -63.86 1.16 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.162 -0.961 . . . . 0.0 110.451 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.289 -0.882 . . . . 0.0 110.594 -178.707 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.578 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.487 1.4 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -64.84 -27.61 59.24 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 121.54 1.493 . . . . 0.0 111.924 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.56 -14.84 62.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.443 -0.786 . . . . 0.0 109.213 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.578 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.1 m-20 -83.3 4.13 28.48 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.42 -0.8 . . . . 0.0 109.18 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.5 t -102.09 136.88 32.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.45 -0.781 . . . . 0.0 108.906 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' A' ' 27' ' ' ASP . 47.6 p30 -67.48 84.36 0.17 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.225 -0.922 . . . . 0.0 109.734 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -60.4 0.23 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.263 179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -88.25 3.75 48.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 108.87 179.504 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.92 139.82 30.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.524 -0.735 . . . . 0.0 109.45 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -60.93 121.73 13.11 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 179.338 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -66.23 1.41 1.56 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.146 -0.971 . . . . 0.0 109.927 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.7 -39.16 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.038 -1.038 . . . . 0.0 108.29 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.458 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.93 -34.94 72.3 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.107 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.61 ' O ' ' N ' ' A' ' 35' ' ' VAL . 4.8 m-20 -84.11 16.5 2.9 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.54 -15.12 0.02 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.01 -36.44 15.89 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.922 -1.34 . . . . 0.0 108.769 179.751 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.588 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.0 tt -70.54 -19.53 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.469 -0.769 . . . . 0.0 109.774 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -55.94 -31.73 63.19 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.324 -0.86 . . . . 0.0 111.228 -178.422 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.9 m -118.89 -64.71 1.25 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.099 -1.0 . . . . 0.0 111.334 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -61.68 -52.18 65.39 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.76 -1.213 . . . . 0.0 109.891 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.68 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.44 -38.27 62.27 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.588 ' N ' ' O ' ' A' ' 36' ' ' ILE . 30.5 tp -58.54 -44.2 89.52 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.343 -1.093 . . . . 0.0 109.979 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.445 HD23 ' HA ' ' A' ' 42' ' ' LEU . 86.1 mt -61.71 -43.82 98.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.117 -0.989 . . . . 0.0 109.287 179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -62.65 -34.91 78.03 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.239 -0.913 . . . . 0.0 108.916 179.206 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.0 t -62.74 -39.8 86.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.529 -0.732 . . . . 0.0 110.136 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.581 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 33.7 mm -58.6 -50.3 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.008 -1.057 . . . . 0.0 109.734 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.15 -37.64 84.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.722 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.0 t90 -70.48 -44.6 67.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.962 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.405 HD12 ' CD1' ' A' ' 52' ' ' PHE . 12.3 tp -58.34 -47.12 84.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 109.63 -179.186 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.413 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -66.82 -37.39 84.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -0.929 . . . . 0.0 109.11 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.13 -42.13 84.95 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 110.668 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.3 ttt-85 -87.37 -58.48 2.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.257 -0.902 . . . . 0.0 111.809 -178.294 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.405 ' CD1' HD12 ' A' ' 48' ' ' LEU . 88.8 m-85 -79.85 -19.46 48.29 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 111.599 -177.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 33.05 41.11 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.413 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.1 mt -102.8 141.87 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.375 -1.074 . . . . 0.0 109.374 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.88 145.01 54.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.254 -0.904 . . . . 0.0 109.854 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.581 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.538 -0.726 . . . . 0.0 109.876 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.74 -25.64 74.95 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.68 2.253 . . . . 0.0 112.235 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.36 -31.46 71.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 109.727 -179.69 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 48.6 t-80 -68.63 -25.93 65.09 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.446 -0.784 . . . . 0.0 111.127 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -95.6 5.86 50.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.743 -1.223 . . . . 0.0 110.92 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 -60.21 -37.53 80.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.895 -1.128 . . . . 0.0 110.353 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.3 p -133.38 147.44 51.79 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.076 -1.015 . . . . 0.0 110.07 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.437 HG23 ' CG2' ' A' ' 7' ' ' ILE . 78.1 mt -66.38 -36.71 78.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 O-C-N 121.432 -0.793 . . . . 0.0 109.797 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 92.3 mtm-85 -60.97 -37.97 84.28 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.346 -0.846 . . . . 0.0 110.099 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.3 p -61.72 -35.92 79.45 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.107 -0.996 . . . . 0.0 109.458 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.566 ' HB ' HD13 ' A' ' 7' ' ' ILE . 61.8 mt -66.71 -39.02 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.238 -0.914 . . . . 0.0 109.174 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.532 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.8 t0 -59.1 -39.44 82.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.333 -0.855 . . . . 0.0 109.779 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.27 -44.2 92.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.1 -1.0 . . . . 0.0 109.654 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -63.42 -46.17 87.57 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.242 -0.911 . . . . 0.0 109.387 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -64.43 -43.36 96.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.346 -0.846 . . . . 0.0 109.739 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 73' ' ' ASP . 51.1 t -60.35 -40.83 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 O-C-N 121.24 -0.913 . . . . 0.0 109.659 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.31 -32.56 72.57 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.88 -50.41 3.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.063 -1.257 . . . . 0.0 110.719 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.4 p -131.79 157.9 42.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.283 -0.885 . . . . 0.0 109.827 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.408 0 O-C-N 121.182 -0.949 . . . . 0.0 109.434 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.577 ' NE2' HG21 ' A' ' 77' ' ' VAL . 96.0 mt-30 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.352 -0.611 . . . . 0.0 109.352 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 30.9 m80 60.94 43.42 11.69 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.025 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.521 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -55.68 -34.86 65.41 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.471 -0.768 . . . . 0.0 109.658 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -58.89 -39.35 81.18 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.229 -0.919 . . . . 0.0 109.01 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.0 t -67.78 -39.25 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.401 -0.812 . . . . 0.0 109.004 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 4' ' ' ALA . 90.9 mt -58.95 -50.05 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.479 -0.763 . . . . 0.0 109.634 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.62 -45.75 88.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.353 -0.842 . . . . 0.0 109.668 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.43 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -69.03 -33.75 74.12 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.365 -0.834 . . . . 0.0 109.694 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.565 ' CE1' ' CZ2' ' A' ' 47' ' ' TRP . 61.7 t80 -64.96 -51.49 61.5 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.091 -1.005 . . . . 0.0 109.694 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.494 HG23 ' N ' ' A' ' 12' ' ' VAL . 15.8 m -74.49 -40.39 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.308 -0.87 . . . . 0.0 110.098 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 8' ' ' ALA . 77.4 t -62.05 -37.8 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.203 -0.936 . . . . 0.0 110.122 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -56.75 -36.7 70.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.33 -0.856 . . . . 0.0 109.752 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -68.16 -35.87 78.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 110.681 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -89.78 -63.01 1.34 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.025 -1.047 . . . . 0.0 110.618 -178.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mt . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.302 -0.874 . . . . 0.0 110.113 -179.285 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.621 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.73 -30.5 59.36 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.612 1.541 . . . . 0.0 112.052 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.75 -14.73 62.55 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.374 -0.829 . . . . 0.0 109.001 179.416 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.621 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -86.53 4.73 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.547 -0.72 . . . . 0.0 109.116 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -98.74 135.59 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -70.37 83.26 0.56 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.19 -0.944 . . . . 0.0 109.651 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -63.47 -0.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 109.117 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 50.6 p30 -100.39 9.83 42.08 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.248 -0.907 . . . . 0.0 109.195 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.7 tp -92.02 145.39 24.57 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.481 -0.762 . . . . 0.0 109.434 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -60.02 121.4 11.75 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.606 HD11 ' CG1' ' A' ' 69' ' ' ILE . 76.4 mt -61.81 -11.73 13.89 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.436 -0.79 . . . . 0.0 109.97 -178.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' ' 67' ' ' ARG . 22.8 t -50.53 -45.33 26.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.801 -1.187 . . . . 0.0 108.678 -179.593 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -57.61 -35.34 70.33 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.382 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.602 ' O ' ' N ' ' A' ' 35' ' ' VAL . 10.6 m120 -86.9 19.04 3.17 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.05 -18.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.276 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.602 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.5 t -52.8 -38.85 29.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.234 -1.157 . . . . 0.0 108.505 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -70.4 -24.05 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.555 -0.716 . . . . 0.0 109.375 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -56.3 -33.01 65.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.513 -0.742 . . . . 0.0 110.919 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -113.78 -64.47 1.31 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.159 -0.963 . . . . 0.0 111.098 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.537 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.6 mp -64.01 -50.44 68.5 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.955 -1.091 . . . . 0.0 110.188 -178.759 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.511 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.53 -40.55 67.39 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.73 -40.55 84.1 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.45 -1.029 . . . . 0.0 109.505 -179.552 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.3 tp -65.92 -44.24 85.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -65.22 -37.47 87.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.263 -0.898 . . . . 0.0 110.005 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.4 t -62.28 -43.26 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.351 -0.843 . . . . 0.0 110.073 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.401 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.5 mp -62.87 -50.42 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.244 -0.91 . . . . 0.0 109.911 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.01 -34.91 78.76 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.267 -0.895 . . . . 0.0 110.16 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.565 ' CZ2' ' CE1' ' A' ' 10' ' ' PHE . 3.8 t90 -66.99 -44.39 80.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 0.0 109.946 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.7 tp -57.51 -43.98 84.67 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.406 -0.809 . . . . 0.0 109.716 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -66.31 -38.54 87.96 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.221 -0.924 . . . . 0.0 109.401 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.86 -41.06 95.98 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.147 -0.97 . . . . 0.0 110.648 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -87.17 -58.37 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.104 -0.998 . . . . 0.0 111.644 -178.442 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -79.73 -19.99 47.49 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.1 -1.0 . . . . 0.0 111.587 -177.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 30.23 50.97 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -179.54 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.43 142.39 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.412 -1.052 . . . . 0.0 109.421 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.36 154.03 25.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.189 -0.944 . . . . 0.0 109.217 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.449 0 O-C-N 121.233 -0.917 . . . . 0.0 109.542 -179.328 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.155 0.503 . . . . 0.0 109.739 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -60.17 -22.98 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.926 2.417 . . . . 0.0 112.168 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.5 -31.14 71.84 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 110.028 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -67.76 -26.71 66.26 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.47 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 28.2 m-85 -97.07 2.66 51.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.193 -0.942 . . . . 0.0 109.281 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.577 ' HG3' HG23 ' A' ' 31' ' ' VAL . 56.0 ttp180 -56.15 -39.62 72.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.476 -0.765 . . . . 0.0 110.524 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 91.2 p -119.66 148.91 42.8 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.415 -0.803 . . . . 0.0 110.463 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.606 ' CG1' HD11 ' A' ' 30' ' ' LEU . 79.7 mt -65.89 -36.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.679 -0.638 . . . . 0.0 109.981 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -61.5 -39.21 90.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 110.231 -179.312 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 19.7 m -60.74 -44.14 97.05 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.018 -1.051 . . . . 0.0 109.529 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.647 ' O ' HG23 ' A' ' 76' ' ' VAL . 79.0 mt -67.13 -39.61 83.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.338 -0.852 . . . . 0.0 109.237 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.863 ' O ' HG23 ' A' ' 77' ' ' VAL . 38.6 t0 -57.5 -38.18 74.18 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.541 -0.724 . . . . 0.0 109.617 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.72 -46.24 89.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.954 -1.091 . . . . 0.0 109.434 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -67.06 -47.47 71.2 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.159 -0.963 . . . . 0.0 108.861 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.721 HG12 ' OG1' ' A' ' 81' ' ' THR . 34.1 t -63.17 -40.11 87.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.863 HG23 ' O ' ' A' ' 73' ' ' ASP . 38.0 t -55.63 -42.42 68.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 O-C-N 121.292 -0.88 . . . . 0.0 108.876 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.54 69.14 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.79 -1.724 . . . . 0.0 108.79 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.63 ' C ' HG22 ' A' ' 80' ' ' THR . . . -67.9 -47.55 68.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -1.098 . . . . 0.0 110.213 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.63 HG22 ' C ' ' A' ' 79' ' ' ALA . 0.0 OUTLIER 172.49 2.59 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.045 -1.034 . . . . 0.0 111.328 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.721 ' OG1' HG12 ' A' ' 76' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.665 -1.272 . . . . 0.0 108.439 179.638 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.451 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.9 mt-30 . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.451 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.9 m170 42.86 38.7 1.46 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.185 -0.947 . . . . 0.0 109.014 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.498 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.94 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 109.722 -179.59 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.7 p -61.42 -37.52 83.8 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.065 -1.022 . . . . 0.0 109.325 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.5 t -68.5 -38.71 79.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.19 -0.944 . . . . 0.0 108.83 179.104 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.498 HD12 ' HA ' ' A' ' 4' ' ' ALA . 86.4 mt -60.27 -51.72 69.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.35 -0.844 . . . . 0.0 109.274 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.589 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -65.33 -47.16 77.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.38 -0.825 . . . . 0.0 109.591 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.7 -44.2 94.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.572 -0.705 . . . . 0.0 109.451 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.401 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.9 t80 -62.15 -48.24 80.98 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.53 -0.731 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 7' ' ' ILE . 85.3 t -69.71 -44.5 79.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.461 -0.774 . . . . 0.0 109.696 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.2 t -66.86 -39.5 83.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.428 -0.795 . . . . 0.0 110.183 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -53.68 -28.92 36.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.184 -0.947 . . . . 0.0 109.957 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.24 -30.43 71.31 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.533 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.575 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.5 p90 -146.73 44.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.832 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.078 -1.014 . . . . 0.0 109.978 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.45 ' O ' HG12 ' A' ' 24' ' ' VAL . 34.8 Cg_exo -49.66 -31.91 26.67 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 121.911 1.741 . . . . 0.0 112.042 179.479 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.6 -23.91 66.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.345 -0.847 . . . . 0.0 109.714 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.28 8.53 44.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.351 -0.843 . . . . 0.0 109.32 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.45 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.5 OUTLIER -88.86 142.52 12.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.327 -0.858 . . . . 0.0 108.814 179.813 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -70.09 84.83 0.53 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.168 -0.958 . . . . 0.0 109.487 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.6 m -64.5 -0.26 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.258 -0.901 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.421 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -98.45 11.17 39.03 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.34 -0.85 . . . . 0.0 108.969 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -88.08 136.5 32.94 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.475 -0.766 . . . . 0.0 109.562 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -61.93 122.02 14.41 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.5 mt -56.21 -16.1 4.82 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.423 -0.798 . . . . 0.0 109.542 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.2 t -50.9 -43.05 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.064 -1.023 . . . . 0.0 109.125 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.24 -37.97 70.46 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.4 m-20 -91.18 22.33 3.85 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.195 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.72 -15.5 0.02 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.5 p -53.89 -33.81 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.013 -1.286 . . . . 0.0 108.891 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.591 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.9 tt -70.99 -19.04 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.51 -0.744 . . . . 0.0 109.673 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 82.1 m-20 -58.05 -31.32 66.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.434 -0.791 . . . . 0.0 111.451 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.7 m -116.39 -64.91 1.25 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.985 -1.072 . . . . 0.0 111.327 -178.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -64.0 -50.72 67.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 110.06 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.434 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.85 -40.1 64.37 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.591 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.8 tp -58.77 -40.88 85.24 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.469 -1.018 . . . . 0.0 109.671 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.91 -44.31 96.44 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.75 -40.22 88.2 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.273 -0.892 . . . . 0.0 109.981 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.9 t -65.1 -42.01 93.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.345 -0.847 . . . . 0.0 110.199 -179.377 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.437 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -60.79 -50.61 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.219 -0.926 . . . . 0.0 109.837 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.437 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.52 -30.83 71.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.188 -0.945 . . . . 0.0 109.365 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.732 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 55.4 t90 -73.13 -47.09 47.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.395 -0.815 . . . . 0.0 110.118 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.83 -45.29 94.44 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -67.13 -36.62 82.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.272 -0.892 . . . . 0.0 109.803 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -62.12 -44.08 97.42 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.703 -179.369 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.732 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 82.1 mtt180 -87.04 -51.43 6.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.05 -1.031 . . . . 0.0 111.52 -178.758 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.416 ' CE2' HG21 ' A' ' 80' ' ' THR . 96.6 m-85 -80.11 -24.58 40.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.005 -1.059 . . . . 0.0 111.223 -178.306 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.09 26.71 59.52 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.7 mt -104.87 143.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -1.121 . . . . 0.0 109.354 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.98 156.54 17.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.185 -0.947 . . . . 0.0 109.692 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.4 -0.813 . . . . 0.0 109.526 -179.488 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.226 0.536 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.1 -25.25 79.34 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.942 2.428 . . . . 0.0 112.237 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.43 -31.45 72.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -67.92 -26.21 65.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -0.842 . . . . 0.0 109.939 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -94.16 16.45 14.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.365 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 tpt180 -53.41 -39.16 64.1 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.334 -0.854 . . . . 0.0 110.018 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.0 p -150.85 165.9 32.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.923 -1.111 . . . . 0.0 110.271 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 95.0 mt -59.31 -36.51 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.378 -0.826 . . . . 0.0 110.078 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.6 mtm180 -60.49 -39.2 86.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 110.077 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.3 m -61.43 -42.89 99.45 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.994 -1.066 . . . . 0.0 109.428 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.4 mt -64.91 -38.41 82.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.249 -0.907 . . . . 0.0 109.32 179.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.807 ' O ' HG23 ' A' ' 77' ' ' VAL . 92.4 m-20 -56.06 -37.45 69.29 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.286 -0.884 . . . . 0.0 109.219 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.15 -43.73 98.19 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.26 -0.9 . . . . 0.0 109.061 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -63.91 -47.5 80.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.154 179.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.7 t -64.4 -40.44 89.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.389 -0.82 . . . . 0.0 109.288 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.807 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.4 t -58.32 -44.02 87.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.333 -0.854 . . . . 0.0 109.615 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -64.77 -41.49 97.57 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.52 -49.53 16.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.135 -1.215 . . . . 0.0 109.645 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.416 HG21 ' CE2' ' A' ' 52' ' ' PHE . 22.1 p -128.32 157.31 41.31 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.302 -1.472 0 O-C-N 121.058 -1.026 . . . . 0.0 110.261 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 32.0 m80 50.49 36.09 12.7 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.142 -0.974 . . . . 0.0 109.027 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.446 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.56 -35.58 76.39 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.39 -0.819 . . . . 0.0 109.78 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 t -59.53 -40.57 87.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.722 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.39 -40.02 87.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 0.0 109.165 179.584 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.469 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 91.8 mt -59.66 -50.15 81.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.36 -0.837 . . . . 0.0 109.512 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.707 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.91 -45.19 90.43 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 108.904 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.4 -39.65 92.44 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.533 -0.729 . . . . 0.0 109.651 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 61.0 t80 -60.66 -52.04 66.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.446 -0.784 . . . . 0.0 110.029 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.474 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.8 p -74.08 -40.56 51.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.902 . . . . 0.0 109.844 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.707 HG23 ' O ' ' A' ' 8' ' ' ALA . 94.2 t -66.69 -40.0 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.395 -0.816 . . . . 0.0 110.315 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -56.17 -27.63 55.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.228 -0.92 . . . . 0.0 109.574 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -65.04 -32.09 73.64 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.342 -0.849 . . . . 0.0 109.724 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -144.2 44.46 1.43 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.066 -1.021 . . . . 0.0 109.92 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.833 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.085 -1.009 . . . . 0.0 110.048 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD3' HD12 ' A' ' 16' ' ' LEU . 47.2 Cg_exo -48.49 -32.12 19.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.969 1.78 . . . . 0.0 111.814 179.428 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.78 -25.97 67.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.419 -0.801 . . . . 0.0 109.447 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -97.69 4.75 49.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.361 -0.837 . . . . 0.0 109.386 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -103.55 137.41 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.52 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -63.78 95.9 0.12 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.404 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.3 m -59.57 0.48 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.168 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.52 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.6 m-20 -87.99 11.24 16.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.362 -0.836 . . . . 0.0 108.939 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 35.2 tp -82.59 134.12 35.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 109.395 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -67.07 121.85 16.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.342 -0.849 . . . . 0.0 108.871 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.642 HD11 HG12 ' A' ' 69' ' ' ILE . 82.6 mt -59.28 -14.1 10.14 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.303 -0.873 . . . . 0.0 109.198 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.412 ' O ' ' N ' ' A' ' 34' ' ' GLY . 42.1 t -50.44 -42.34 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 O-C-N 121.179 -0.951 . . . . 0.0 108.89 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.62 -35.32 65.74 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 178.568 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.608 ' O ' ' N ' ' A' ' 35' ' ' VAL . 8.5 m120 -86.27 21.55 2.03 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.0 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.162 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.608 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.0 t -53.05 -40.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.766 -1.432 . . . . 0.0 108.228 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.653 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.2 tt -71.15 -24.11 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.575 -0.703 . . . . 0.0 109.924 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -62.11 -27.54 69.0 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.957 -1.09 . . . . 0.0 110.975 -178.525 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.18 -65.73 1.05 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.801 -1.187 . . . . 0.0 111.055 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -73.73 -51.24 17.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.951 -1.093 . . . . 0.0 110.61 -178.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.75 -36.32 92.11 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.1 tt -57.95 -43.14 86.2 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.208 -1.172 . . . . 0.0 109.2 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.9 mt -60.96 -44.1 97.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.094 -1.004 . . . . 0.0 108.694 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -69.97 -35.45 74.46 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.423 -0.798 . . . . 0.0 109.84 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.732 HG23 ' O ' ' A' ' 40' ' ' GLY . 81.1 t -64.78 -49.85 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.339 -0.851 . . . . 0.0 110.849 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -60.41 -47.82 90.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 120.944 -1.097 . . . . 0.0 109.51 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.46 -32.95 74.64 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.179 -0.951 . . . . 0.0 109.232 179.7 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 39.4 t90 -71.67 -47.46 54.09 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.24 -0.912 . . . . 0.0 109.927 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 26.5 tp -59.81 -44.98 93.72 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.318 -0.864 . . . . 0.0 109.687 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.478 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 80.3 tt0 -68.62 -34.88 76.51 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 110.057 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.21 -38.49 80.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.008 -1.058 . . . . 0.0 110.028 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.536 ' NE ' ' CZ2' ' A' ' 47' ' ' TRP . 34.2 mtm105 -86.39 -48.52 8.38 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.149 -0.969 . . . . 0.0 111.497 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -90.9 -24.44 20.2 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.8 -1.187 . . . . 0.0 111.219 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 79.35 50.03 5.95 Favored Glycine 0 N--CA 1.496 2.689 0 C-N-CA 119.588 -1.292 . . . . 0.0 110.525 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.478 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 65.2 mt -108.04 140.94 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.199 -1.177 . . . . 0.0 109.21 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.53 141.11 57.95 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.937 -1.102 . . . . 0.0 109.334 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.574 -179.704 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.0 p . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -53.37 -34.31 70.39 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.346 2.031 . . . . 0.0 111.61 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -68.08 -14.32 62.89 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.525 -0.735 . . . . 0.0 109.148 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.604 ' CE1' HG23 ' A' ' 72' ' ' ILE . 21.7 t-80 -66.2 -26.32 67.34 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.432 -0.792 . . . . 0.0 110.062 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.667 ' HA ' HD11 ' A' ' 72' ' ' ILE . 97.4 m-85 -92.45 9.05 35.98 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.006 -1.058 . . . . 0.0 109.597 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.4 tpt180 -54.7 -35.98 64.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.8 p -150.82 149.39 29.65 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.215 -0.928 . . . . 0.0 110.023 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.642 HG12 HD11 ' A' ' 30' ' ' LEU . 81.6 mt -66.56 -39.33 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.425 -0.797 . . . . 0.0 110.264 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.428 HH22 ' HA ' ' A' ' 27' ' ' ASP . 93.0 mtm-85 -61.35 -39.99 92.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -0.906 . . . . 0.0 110.373 -178.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 t -60.63 -45.91 92.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.985 -1.072 . . . . 0.0 109.425 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.667 HD11 ' HA ' ' A' ' 66' ' ' PHE . 79.0 mt -63.91 -38.74 83.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.85 . . . . 0.0 109.709 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.469 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 55.9 t0 -57.54 -42.28 82.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 110.256 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.76 -46.09 76.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 110.502 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -63.36 -45.1 92.71 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.099 -1.0 . . . . 0.0 109.496 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.1 t -68.18 -47.6 77.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.219 -0.926 . . . . 0.0 110.159 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 45.4 t -68.28 -44.22 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.051 -1.031 . . . . 0.0 110.023 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.02 -27.0 68.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.27 -50.12 3.55 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.199 -1.177 . . . . 0.0 111.143 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.529 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.2 m -134.91 140.1 45.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.107 -0.995 . . . . 0.0 110.864 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.79 ' CE1' HG21 ' A' ' 6' ' ' VAL . 73.6 t60 -116.13 8.94 14.58 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.478 -0.764 . . . . 0.0 109.478 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.58 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -61.09 -35.61 77.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.212 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 m -58.8 -40.28 83.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.053 -1.03 . . . . 0.0 109.395 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.79 HG21 ' CE1' ' A' ' 3' ' ' HIS . 72.3 t -66.53 -36.56 77.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.007 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.646 ' O ' HG23 ' A' ' 11' ' ' VAL . 81.8 mt -63.59 -44.18 98.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.397 -0.814 . . . . 0.0 110.31 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.484 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.0 -50.63 67.78 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.175 -0.953 . . . . 0.0 110.521 -178.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.22 -44.3 68.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.122 -0.986 . . . . 0.0 109.673 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.568 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 75.1 t80 -59.52 -45.89 90.44 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.993 -1.067 . . . . 0.0 109.282 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.646 HG23 ' O ' ' A' ' 7' ' ' ILE . 99.7 t -70.03 -46.52 72.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 8' ' ' ALA . 74.9 t -66.51 -37.23 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.337 -0.852 . . . . 0.0 111.086 -179.147 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -60.93 -31.72 71.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.771 -179.058 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -66.16 -32.51 73.99 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.938 -1.102 . . . . 0.0 110.137 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.727 ' O ' HD12 ' A' ' 16' ' ' LEU . 58.6 m-85 -96.63 -61.11 1.47 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.104 -0.997 . . . . 0.0 110.6 -179.082 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.727 HD12 ' O ' ' A' ' 15' ' ' PHE . 3.7 mp . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.29 -0.881 . . . . 0.0 110.663 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.648 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.486 1.334 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.827 ' O ' HG12 ' A' ' 24' ' ' VAL . 21.6 Cg_endo -64.98 -26.75 58.43 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 C-N-CA 121.619 1.546 . . . . 0.0 111.854 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.92 -13.88 60.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.421 -0.799 . . . . 0.0 109.326 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.648 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -85.58 8.03 20.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 109.853 -179.277 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.827 HG12 ' O ' ' A' ' 21' ' ' PRO . 9.9 p -107.58 144.41 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.372 -0.83 . . . . 0.0 109.034 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.493 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.6 m-20 -69.05 86.18 0.36 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.006 -1.059 . . . . 0.0 109.177 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.9 0.06 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.34 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.03 6.04 47.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.321 -0.862 . . . . 0.0 108.77 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -93.58 136.82 33.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.599 -0.688 . . . . 0.0 109.364 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -61.16 121.53 12.75 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.632 ' CD1' HD11 ' A' ' 36' ' ' ILE . 1.5 pp -68.84 0.25 4.61 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.285 -0.885 . . . . 0.0 109.796 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 34' ' ' GLY . 72.7 t -56.16 -35.17 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.21 -0.931 . . . . 0.0 108.946 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' A' ' 34' ' ' GLY . 92.3 m-20 -53.94 -34.83 60.78 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.121 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -83.53 21.89 1.14 Allowed 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.028 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -41.73 -13.99 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.93 -1.268 . . . . 0.0 109.93 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 3.4 p -51.94 -31.12 13.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.085 -1.244 . . . . 0.0 108.479 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.632 HD11 ' CD1' ' A' ' 30' ' ' LEU . 32.6 pt -73.56 -7.14 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.522 -0.736 . . . . 0.0 109.965 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.504 ' HA ' HD12 ' A' ' 41' ' ' LEU . 92.7 m-20 -48.88 -39.95 27.88 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.342 -0.849 . . . . 0.0 110.205 -178.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -122.56 -48.24 2.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 111.348 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.482 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.2 mp -74.71 -52.79 10.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.944 -1.097 . . . . 0.0 111.63 -178.077 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.538 ' H ' ' HA ' ' A' ' 36' ' ' ILE . . . -70.49 -43.21 62.12 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 120.079 -1.058 . . . . 0.0 110.77 -178.665 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.635 ' O ' HD13 ' A' ' 45' ' ' ILE . 16.2 mt -63.42 -40.66 97.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.065 -1.256 . . . . 0.0 110.482 -179.191 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.63 -44.17 96.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.322 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttt -66.96 -41.58 86.64 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.244 -0.91 . . . . 0.0 109.465 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 40' ' ' GLY . 90.1 t -66.95 -41.06 86.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.446 -0.784 . . . . 0.0 109.879 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.635 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.4 mp -58.94 -49.03 84.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.245 -0.91 . . . . 0.0 109.65 -179.56 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.94 -32.29 72.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.604 ' CZ2' ' NH1' ' A' ' 51' ' ' ARG . 9.3 t90 -68.51 -44.81 73.84 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.37 -0.831 . . . . 0.0 109.508 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -62.53 -44.98 95.02 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 109.605 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 53' ' ' GLY . 81.6 tt0 -67.2 -34.51 77.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.909 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -58.75 -39.3 80.54 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.89 -1.131 . . . . 0.0 109.759 -179.561 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.604 ' NH1' ' CZ2' ' A' ' 47' ' ' TRP . 51.7 mtm180 -86.97 -53.86 4.66 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.135 -0.978 . . . . 0.0 110.931 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.42 -25.02 39.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 111.367 -178.289 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 76.46 39.2 31.11 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.334 -1.412 . . . . 0.0 109.627 -179.676 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.427 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 66.1 mt -103.03 138.73 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.197 -1.178 . . . . 0.0 109.331 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.05 141.08 57.66 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.737 -1.227 . . . . 0.0 109.303 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.338 -179.55 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 -27.54 69.48 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.862 1.708 . . . . 0.0 112.324 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.88 -28.12 69.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.892 . . . . 0.0 109.711 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.417 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 11.6 t-160 -67.8 -26.74 66.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.296 -0.878 . . . . 0.0 110.02 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.543 ' CE1' HD21 ' A' ' 41' ' ' LEU . 58.4 m-85 -102.27 13.65 34.06 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.955 . . . . 0.0 109.97 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.535 ' HD2' HG21 ' A' ' 31' ' ' VAL . 25.6 tpt180 -53.19 -36.88 61.42 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 108.959 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t -143.46 146.91 33.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -0.887 . . . . 0.0 109.479 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.78 -38.44 76.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.285 -0.885 . . . . 0.0 109.91 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 ptt85 -61.81 -40.23 94.51 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.8 p -61.69 -36.68 81.58 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.097 -1.002 . . . . 0.0 110.043 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.433 HD11 ' CD1' ' A' ' 66' ' ' PHE . 76.1 mt -65.12 -40.81 90.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 121.095 -1.003 . . . . 0.0 109.807 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 55.6 t0 -58.75 -38.05 77.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.713 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.85 -41.69 99.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.178 -0.951 . . . . 0.0 109.598 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.417 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 65.6 t80 -63.8 -47.44 80.88 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.283 -0.886 . . . . 0.0 109.366 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.5 t -64.15 -42.72 96.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.288 -0.882 . . . . 0.0 109.551 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 73' ' ' ASP . 46.6 t -58.98 -41.07 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.288 -0.883 . . . . 0.0 109.532 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.18 -32.56 76.71 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.85 -50.45 3.53 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.026 -1.279 . . . . 0.0 110.746 -179.132 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 76' ' ' VAL . 16.6 p -129.14 156.65 43.57 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.333 -0.854 . . . . 0.0 109.519 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.39 0 O-C-N 121.184 -0.947 . . . . 0.0 109.499 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.406 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 63.8 mtt . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -58.93 -36.18 74.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.166 -0.959 . . . . 0.0 109.388 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.792 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -153.2 29.48 0.5 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.337 -0.852 . . . . 0.0 109.04 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.406 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -61.09 -32.97 72.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.311 -0.868 . . . . 0.0 109.883 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -61.01 -35.72 77.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.058 -1.026 . . . . 0.0 109.58 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.792 HG21 ' CE1' ' A' ' 3' ' ' HIS . 72.4 t -67.29 -38.41 80.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.028 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.456 ' O ' HG23 ' A' ' 11' ' ' VAL . 89.2 mt -61.73 -50.45 80.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.1 -45.52 88.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.197 -0.939 . . . . 0.0 109.096 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.99 -44.32 89.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.477 -0.764 . . . . 0.0 109.266 179.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.671 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -65.15 -46.97 78.72 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.648 -0.658 . . . . 0.0 109.915 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.683 HG13 HD12 ' A' ' 36' ' ' ILE . 75.7 t -67.65 -47.31 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.378 -0.826 . . . . 0.0 110.124 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.3 t -65.84 -34.47 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.364 -0.835 . . . . 0.0 110.613 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.53 -36.61 55.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.117 -0.99 . . . . 0.0 110.013 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.15 -34.07 76.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 110.662 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.615 ' O ' HD12 ' A' ' 16' ' ' LEU . 66.5 m-85 -94.83 -64.24 1.09 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.927 -1.108 . . . . 0.0 110.784 -178.68 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.615 HD12 ' O ' ' A' ' 15' ' ' PHE . 6.1 mp -123.64 83.04 53.86 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.31 -0.869 . . . . 0.0 110.155 -179.073 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -83.48 -21.73 4.19 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.973 2.449 . . . . 0.0 112.168 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -76.84 -4.09 41.86 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.239 -0.913 . . . . 0.0 109.19 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -113.32 140.76 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.84 117.74 31.76 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.971 -1.081 . . . . 0.0 108.61 -179.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -65.28 -30.01 54.57 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.637 1.558 . . . . 0.0 111.869 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.98 61.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.182 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.0 m-20 -87.96 6.35 36.22 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.341 -0.849 . . . . 0.0 109.387 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -100.64 137.53 27.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.394 -0.816 . . . . 0.0 108.824 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -62.69 88.07 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.185 -0.947 . . . . 0.0 109.434 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.45 HG21 ' HE2' ' A' ' 87' ' ' LYS . 17.1 m -62.15 0.08 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.397 -0.814 . . . . 0.0 109.281 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -90.88 6.82 42.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.295 -0.878 . . . . 0.0 108.949 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 tp -94.29 137.04 33.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.53 -0.731 . . . . 0.0 109.499 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -60.94 121.77 13.22 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.188 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -73.16 4.57 4.28 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.192 -0.943 . . . . 0.0 109.959 -179.021 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.4 p -51.17 -38.61 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.08 -1.012 . . . . 0.0 108.423 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.442 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.12 -35.43 69.44 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.7 m-20 -84.45 17.03 2.79 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -43.22 -14.04 0.02 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.05 -35.94 15.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.261 -1.141 . . . . 0.0 108.971 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.683 HD12 HG13 ' A' ' 11' ' ' VAL . 1.5 tt -70.01 -23.31 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.356 -0.84 . . . . 0.0 109.889 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.595 ' OD2' ' CD1' ' A' ' 66' ' ' PHE . 77.0 m-20 -56.33 -34.17 66.32 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.384 -0.823 . . . . 0.0 110.622 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.552 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.6 OUTLIER -112.57 -64.45 1.3 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 111.092 -178.522 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 50.9 tp -64.25 -51.96 61.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.71 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -36.5 69.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.1 tt -58.37 -41.82 85.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.224 -1.163 . . . . 0.0 109.685 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 42' ' ' LEU . 92.8 mt -67.08 -44.14 80.81 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.137 -0.977 . . . . 0.0 109.391 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.5 mttm -67.09 -41.65 85.96 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.26 -0.9 . . . . 0.0 109.843 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.524 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 88.6 t -66.68 -43.2 90.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.307 -0.871 . . . . 0.0 109.956 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.446 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.73 -50.53 79.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.263 -0.898 . . . . 0.0 109.569 -179.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.446 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -66.6 -38.46 87.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.182 -0.949 . . . . 0.0 109.413 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.671 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -68.48 -41.43 80.11 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.302 -0.874 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.503 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 13.8 tp -56.97 -47.42 80.81 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.403 -0.811 . . . . 0.0 109.644 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.514 ' OE2' ' O ' ' A' ' 54' ' ' ILE . 28.0 tp10 -69.26 -35.71 76.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.182 -0.949 . . . . 0.0 109.287 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -63.98 -46.07 86.21 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.077 -1.014 . . . . 0.0 110.552 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 22.4 ttm180 -88.15 -58.22 2.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 111.926 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -79.38 -24.4 42.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.0 -1.062 . . . . 0.0 111.751 -177.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.26 32.82 41.96 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.187 -1.483 . . . . 0.0 109.417 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.514 ' O ' ' OE2' ' A' ' 49' ' ' GLU . 68.8 mt -104.44 143.94 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.274 -1.133 . . . . 0.0 109.189 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.53 146.92 43.25 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.155 -0.966 . . . . 0.0 109.478 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.82 -33.69 68.87 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.39 -0.819 . . . . 0.0 109.604 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 54.11 44.22 29.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.326 -0.859 . . . . 0.0 109.532 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.444 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.2 p30 -95.09 12.21 29.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.641 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.63 -43.04 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.119 -0.988 . . . . 0.0 109.736 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -115.95 135.05 54.34 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.508 -0.745 . . . . 0.0 109.53 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 20.7 mt -108.25 140.09 42.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.379 -0.825 . . . . 0.0 109.301 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.4 ' H ' ' C6 ' ' A' ' 101' ' ' 7V9 . 0.4 OUTLIER -130.72 84.18 59.47 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.355 -0.84 . . . . 0.0 109.7 -179.821 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -54.13 -28.47 51.36 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.549 2.166 . . . . 0.0 111.953 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -68.39 -15.9 63.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.413 -0.805 . . . . 0.0 109.482 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 7.4 t-160 -66.7 -25.39 66.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.536 -0.727 . . . . 0.0 110.143 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.595 ' CD1' ' OD2' ' A' ' 37' ' ' ASP . 62.3 m-85 -87.68 2.91 49.78 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.019 -1.051 . . . . 0.0 109.99 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -57.25 -39.82 76.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.944 -1.097 . . . . 0.0 110.293 -179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.422 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 86.0 p -143.31 153.21 42.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.834 -1.166 . . . . 0.0 110.264 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -65.96 -36.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.456 -0.778 . . . . 0.0 109.67 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.2 mtm180 -60.94 -37.18 81.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.789 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.422 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 19.6 m -59.36 -41.98 90.51 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.068 -1.02 . . . . 0.0 109.083 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.62 -38.18 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.321 -0.862 . . . . 0.0 109.431 179.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.484 ' O ' HG23 ' A' ' 77' ' ' VAL . 74.5 m-20 -57.06 -39.61 75.24 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.342 -0.849 . . . . 0.0 109.704 -179.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.91 -39.11 90.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.247 -0.908 . . . . 0.0 109.904 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.25 -47.51 85.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.743 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.3 t -65.37 -41.06 90.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.149 -0.969 . . . . 0.0 109.777 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.7 t -61.51 -44.6 98.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.204 -0.935 . . . . 0.0 109.936 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -65.14 -40.54 96.93 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.81 -49.67 12.59 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.147 -1.207 . . . . 0.0 109.766 -179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.471 ' O ' ' O ' ' A' ' 76' ' ' VAL . 19.3 p -130.46 156.89 44.02 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -140.09 87.55 12.3 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.171 -0.955 . . . . 0.0 109.78 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.444 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.1 Cg_exo -66.03 -175.91 0.56 Allowed 'Trans proline' 0 N--CA 1.493 1.496 0 C-N-CA 122.83 2.353 . . . . 0.0 111.865 179.332 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 24.2 Cg_exo -60.37 150.94 77.84 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.483 2.122 . . . . 0.0 111.52 179.585 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 84' ' ' VAL . 13.0 p -92.12 127.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.133 -0.979 . . . . 0.0 109.833 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -134.31 158.53 43.54 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.429 -0.794 . . . . 0.0 109.079 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.62 123.26 25.22 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 109.247 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.45 ' HE2' HG21 ' A' ' 26' ' ' VAL . 51.2 tttp -59.89 -37.14 78.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.508 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.6 tp -98.77 130.58 45.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.477 -179.99 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.561 ' O8 ' HD11 ' A' ' 41' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.833 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 84.4 mtp . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.819 ' O ' HG22 ' A' ' 84' ' ' VAL . 93.2 mt-30 -60.17 -38.21 82.52 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.91 . . . . 0.0 109.631 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.585 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 40.1 m80 -139.52 6.47 2.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.271 -0.893 . . . . 0.0 109.762 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.833 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -59.26 -33.87 71.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.075 -1.016 . . . . 0.0 109.761 -179.482 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.441 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 22.2 t -59.22 -45.01 92.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.067 -1.021 . . . . 0.0 109.59 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.9 -36.59 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.268 -0.895 . . . . 0.0 108.656 179.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.496 HD12 ' HA ' ' A' ' 4' ' ' ALA . 91.8 mt -66.75 -42.16 89.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.609 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.24 -50.39 70.38 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.047 -1.033 . . . . 0.0 110.241 -179.021 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.31 -42.97 71.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.291 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.513 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 67.9 t80 -62.56 -48.72 78.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.366 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.797 HG13 HD12 ' A' ' 36' ' ' ILE . 64.4 t -65.49 -45.07 93.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 0.0 109.333 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.609 HG23 ' O ' ' A' ' 8' ' ' ALA . 69.4 t -65.85 -37.12 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.439 -0.788 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -52.86 -30.78 35.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.38 -0.825 . . . . 0.0 109.811 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.54 -31.26 72.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.66 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.551 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 34.4 p90 -143.93 44.24 1.46 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.185 -0.947 . . . . 0.0 109.601 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.797 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.68 130.47 64.21 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.155 -0.966 . . . . 0.0 110.305 -179.822 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.79 -151.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 122.111 1.874 . . . . 0.0 110.542 178.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -79.44 17.27 0.87 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.898 -1.126 . . . . 0.0 108.965 179.258 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.2 t -113.2 135.77 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.402 -0.811 . . . . 0.0 109.81 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.4 141.71 80.6 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.164 -0.96 . . . . 0.0 109.243 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -49.38 -29.66 18.42 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 121.881 1.721 . . . . 0.0 111.813 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.6 -25.99 68.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.315 -0.866 . . . . 0.0 109.528 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -95.38 6.42 49.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.319 -0.863 . . . . 0.0 109.209 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.3 t -104.07 136.37 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.528 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.4 m-20 -69.7 88.89 0.54 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.202 -0.936 . . . . 0.0 109.529 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.2 m -59.91 0.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.196 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.528 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.91 9.97 33.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 108.884 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -90.34 137.37 32.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.533 -0.729 . . . . 0.0 109.507 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.455 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.89 121.82 14.43 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.12 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.441 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -69.62 10.86 0.31 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.144 -0.972 . . . . 0.0 109.932 -178.977 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.455 ' H ' ' C ' ' A' ' 29' ' ' ASP . 75.7 t -54.68 -44.22 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.002 -1.061 . . . . 0.0 108.627 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.72 -36.64 67.44 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 179.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.5 m-20 -86.21 18.24 3.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 178.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.92 -14.99 0.02 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.9 t -52.05 -37.13 21.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.117 -1.225 . . . . 0.0 108.677 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.797 HD12 HG13 ' A' ' 11' ' ' VAL . 1.4 tt -70.59 -22.5 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.533 -0.73 . . . . 0.0 110.323 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.407 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 88.1 m-20 -54.14 -32.62 55.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.313 -0.867 . . . . 0.0 111.284 -178.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.534 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.4 OUTLIER -117.34 -64.23 1.33 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.912 -1.117 . . . . 0.0 111.165 -178.782 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.3 -52.5 63.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.9 -1.125 . . . . 0.0 110.343 -178.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.664 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.53 -37.1 62.34 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 36' ' ' ILE . 16.2 tp -58.51 -43.53 89.16 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.38 -1.07 . . . . 0.0 109.931 -178.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HA ' HD23 ' A' ' 42' ' ' LEU . 92.9 mt -65.6 -43.56 89.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.556 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -63.08 -34.43 77.57 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.259 -0.9 . . . . 0.0 109.366 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 40' ' ' GLY . 68.4 t -60.52 -41.43 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.914 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.612 HD11 ' S12' ' A' ' 101' ' ' 7V9 . 35.8 mm -58.94 -50.16 80.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.983 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.24 -35.6 79.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.801 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.513 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 44.2 t90 -66.49 -41.74 88.48 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.269 -0.894 . . . . 0.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -61.24 -43.35 99.01 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 109.918 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.412 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 87.5 tt0 -67.51 -37.16 82.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -60.3 -44.79 95.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.049 -1.032 . . . . 0.0 110.555 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -87.49 -53.02 5.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.136 -0.977 . . . . 0.0 111.585 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -80.16 -24.75 40.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.041 -1.037 . . . . 0.0 111.59 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.67 31.05 51.29 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.412 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.6 mt -103.41 147.51 9.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.393 -1.063 . . . . 0.0 109.556 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.04 157.6 15.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.188 -0.945 . . . . 0.0 109.309 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.505 ' HB1' HG21 ' A' ' 45' ' ' ILE . . . -52.95 -39.16 62.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.24 -0.912 . . . . 0.0 109.773 -179.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 51.89 50.69 18.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.114 -0.991 . . . . 0.0 109.092 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -71.19 116.98 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.929 -179.121 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.414 HG23 HD21 ' A' ' 61' ' ' LEU . 29.5 m -130.24 162.17 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -89.28 122.62 32.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.998 -1.064 . . . . 0.0 110.085 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.414 HD21 HG23 ' A' ' 59' ' ' VAL . 30.8 mt -115.97 144.81 43.57 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.25 153.13 95.43 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.166 -0.959 . . . . 0.0 109.276 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.79 -27.05 84.04 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.618 2.212 . . . . 0.0 111.886 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.56 -24.49 67.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.403 -0.81 . . . . 0.0 109.945 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -67.13 -26.61 66.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.155 -0.965 . . . . 0.0 110.234 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -97.71 6.68 47.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.074 -1.016 . . . . 0.0 109.001 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 -56.49 -37.8 70.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.452 -0.78 . . . . 0.0 109.977 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.8 p -137.03 153.25 50.68 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.096 -1.003 . . . . 0.0 110.121 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.6 mt -64.59 -36.45 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.478 -0.763 . . . . 0.0 110.251 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -60.87 -37.02 80.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.133 -0.979 . . . . 0.0 110.217 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 92.6 p -61.59 -36.15 79.87 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.014 -1.054 . . . . 0.0 109.66 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -64.93 -40.63 89.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.232 -0.918 . . . . 0.0 109.453 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.552 ' OD2' HG23 ' A' ' 77' ' ' VAL . 53.9 t0 -59.12 -36.93 76.04 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.305 -0.872 . . . . 0.0 109.634 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.88 -40.71 94.04 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.326 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -64.16 -48.7 75.0 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.305 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.5 t -64.89 -43.45 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.317 -0.864 . . . . 0.0 109.671 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.552 HG23 ' OD2' ' A' ' 73' ' ' ASP . 55.7 t -59.87 -41.06 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.225 -0.922 . . . . 0.0 109.627 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.33 -31.83 70.82 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.1 -50.63 3.32 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.021 -1.282 . . . . 0.0 110.844 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 21.8 p -131.28 159.43 37.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.225 -0.922 . . . . 0.0 109.854 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.96 88.17 15.96 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.189 -0.944 . . . . 0.0 109.449 179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.585 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 10.7 Cg_exo -66.38 -178.01 1.04 Allowed 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.551 2.167 . . . . 0.0 112.146 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.417 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.0 Cg_exo -61.34 150.26 85.72 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.423 2.082 . . . . 0.0 111.779 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.819 HG22 ' O ' ' A' ' 2' ' ' GLN . 44.5 t -109.32 129.69 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.562 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -137.71 155.45 49.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.382 -0.824 . . . . 0.0 109.459 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -102.59 140.21 37.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.34 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.441 ' NZ ' ' O ' ' A' ' 5' ' ' SER . 30.4 mttm -59.23 -34.77 72.59 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.152 -0.967 . . . . 0.0 109.539 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.8 tp -99.62 130.31 45.84 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.337 -0.852 . . . . 0.0 109.462 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.442 -179.923 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.612 ' S12' HD11 ' A' ' 45' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.613 ' HB3' HG21 ' A' ' 77' ' ' VAL . 83.3 mmm . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.556 ' OE1' HG21 ' A' ' 81' ' ' THR . 91.8 mt-30 -108.5 138.05 45.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.328 -0.857 . . . . 0.0 109.153 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.4 m80 47.46 38.44 7.71 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.118 -0.988 . . . . 0.0 109.298 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.12 -34.26 73.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.288 -0.883 . . . . 0.0 109.629 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -59.14 -36.64 75.59 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 109.618 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.8 t -62.88 -40.96 90.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.287 -0.883 . . . . 0.0 109.516 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.498 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 85.5 mt -59.69 -43.95 92.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.356 -0.84 . . . . 0.0 109.839 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.4 77.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.429 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.42 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -69.08 -33.66 73.89 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.414 -0.804 . . . . 0.0 109.624 179.826 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.407 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 63.1 t80 -62.64 -52.08 64.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.001 . . . . 0.0 109.977 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 12' ' ' VAL . 6.3 p -74.91 -44.32 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.357 -0.839 . . . . 0.0 110.855 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.538 ' N ' HG13 ' A' ' 11' ' ' VAL . 76.9 t -65.32 -40.09 87.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.183 -0.948 . . . . 0.0 111.031 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -58.22 -28.69 65.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.045 -1.034 . . . . 0.0 109.791 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.8 -38.69 89.64 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.276 -0.89 . . . . 0.0 110.425 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.498 ' HE1' HG22 ' A' ' 11' ' ' VAL . 5.4 m-85 -96.68 -45.11 6.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.04 -1.038 . . . . 0.0 110.489 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.416 HD22 HG21 ' A' ' 19' ' ' VAL . 1.5 mt -126.93 82.46 67.85 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.284 -0.885 . . . . 0.0 110.273 -179.147 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -83.01 -24.81 3.07 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.104 2.536 . . . . 0.0 112.149 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -81.01 -3.73 52.73 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.195 -0.94 . . . . 0.0 109.622 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.416 HG21 HD22 ' A' ' 16' ' ' LEU . 39.6 t -113.48 141.07 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.87 117.92 33.58 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.026 -1.046 . . . . 0.0 108.669 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -64.69 -30.36 59.79 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 C-N-CA 121.585 1.524 . . . . 0.0 111.966 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.86 -19.05 63.46 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.064 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -89.18 1.74 55.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.361 -0.837 . . . . 0.0 108.99 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.1 t -102.28 139.0 24.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.515 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.2 t0 -67.97 94.14 0.46 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 109.438 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -59.99 0.56 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.429 -0.794 . . . . 0.0 109.229 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.1 m-20 -88.16 9.8 21.55 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.019 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.4 tp -86.33 134.17 33.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.541 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -62.94 122.07 15.1 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.742 HD11 HG12 ' A' ' 69' ' ' ILE . 74.1 mt -59.72 -12.14 6.48 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.3 p -49.97 -37.28 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 119.32 -0.952 . . . . 0.0 108.647 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.13 -36.01 70.18 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.3 m-20 -86.13 21.07 2.1 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.3 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.48 -40.32 24.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 120.979 -1.307 . . . . 0.0 108.54 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.637 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.2 tt -71.77 -24.41 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.509 -0.744 . . . . 0.0 110.418 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 91.9 m-20 -59.25 -28.13 66.42 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.931 -1.105 . . . . 0.0 110.962 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.562 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 1.3 m -113.3 -64.32 1.32 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.026 -1.046 . . . . 0.0 111.167 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.487 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.88 -51.31 41.58 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.904 -1.123 . . . . 0.0 110.472 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.02 -35.89 72.12 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.747 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.0 tt -57.99 -45.24 87.11 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.421 -1.046 . . . . 0.0 110.145 -179.083 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.8 mt -61.83 -44.18 97.37 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.001 -1.062 . . . . 0.0 109.191 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -71.64 -35.54 70.44 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.351 -0.843 . . . . 0.0 110.303 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 40' ' ' GLY . 66.0 t -64.56 -49.41 80.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.284 -0.885 . . . . 0.0 111.277 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.2 mm -58.78 -49.46 82.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 120.566 -1.334 . . . . 0.0 109.644 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.34 -35.6 79.73 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.012 -1.055 . . . . 0.0 109.68 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.511 ' CZ3' ' NZ ' ' A' ' 87' ' ' LYS . 19.2 t90 -76.84 -51.07 11.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.272 -0.892 . . . . 0.0 111.398 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.476 ' CD2' ' CE3' ' A' ' 47' ' ' TRP . 3.8 mm? -65.72 -39.32 91.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.062 -1.024 . . . . 0.0 110.616 -179.181 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 17.8 pt-20 -65.73 -35.01 79.53 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.979 -1.076 . . . . 0.0 109.596 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -65.45 -43.52 90.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.173 -0.954 . . . . 0.0 110.051 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -67.68 -43.13 80.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.252 -0.905 . . . . 0.0 111.165 -179.251 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -98.34 -12.73 21.19 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.9 -1.125 . . . . 0.0 110.47 -178.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.05 42.16 96.82 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.5 mt -104.79 129.21 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 109.531 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.95 144.39 57.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 109.451 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.2 -33.76 75.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.271 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -58.08 -34.09 69.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.408 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.48 -33.33 44.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.241 -0.912 . . . . 0.0 109.745 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.06 151.57 24.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.417 -0.802 . . . . 0.0 109.652 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -111.9 148.8 32.92 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.451 -0.781 . . . . 0.0 109.524 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.8 mt -84.22 140.52 31.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.48 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.0 OUTLIER -155.98 109.25 2.12 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.301 -0.874 . . . . 0.0 109.174 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -49.95 -36.12 42.92 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 121.814 1.676 . . . . 0.0 112.107 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.92 -27.73 66.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.257 -0.902 . . . . 0.0 109.677 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 36.6 t-80 -68.22 -27.13 66.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 110.211 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.653 ' CE2' ' C8 ' ' A' ' 101' ' ' 7V9 . 88.7 m-85 -100.72 9.14 42.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.485 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 35.9 tpt85 -55.52 -36.21 66.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.479 -0.763 . . . . 0.0 109.369 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.1 p -143.56 158.34 43.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.18 -0.95 . . . . 0.0 110.017 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.742 HG12 HD11 ' A' ' 30' ' ' LEU . 75.7 mt -64.15 -36.54 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.387 -0.821 . . . . 0.0 110.35 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.6 mtm180 -60.72 -38.82 86.4 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.098 -1.001 . . . . 0.0 110.068 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.0 t -61.45 -44.09 97.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.042 -1.036 . . . . 0.0 109.539 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 84.3 mt -67.72 -40.08 83.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.288 -0.882 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 59.8 t0 -58.99 -41.59 88.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.867 . . . . 0.0 110.391 -179.256 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.39 -43.78 84.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.034 -1.041 . . . . 0.0 110.248 -179.265 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -62.67 -47.27 84.39 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.748 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.517 HG12 ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.92 -44.36 96.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.613 HG21 ' HB3' ' A' ' 1' ' ' MET . 48.1 t -61.06 -39.74 83.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.11 -0.994 . . . . 0.0 109.459 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.85 -33.17 67.46 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.02 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.054 -1.263 . . . . 0.0 110.489 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.517 ' O ' HG12 ' A' ' 76' ' ' VAL . 8.3 t -158.41 152.69 24.19 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.064 -1.023 . . . . 0.0 110.204 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.556 HG21 ' OE1' ' A' ' 2' ' ' GLN . 0.8 OUTLIER -130.09 88.66 47.69 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 108.937 179.463 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -93.91 107.05 0.15 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.345 2.697 . . . . 0.0 113.132 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -80.65 138.85 12.23 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 C-N-CA 122.307 2.004 . . . . 0.0 111.996 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.489 HG22 ' H ' ' A' ' 86' ' ' ALA . 10.9 p -134.13 140.97 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.155 -0.966 . . . . 0.0 109.422 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.54 -35.2 79.69 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.588 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.489 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -149.23 155.92 41.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.511 ' NZ ' ' CZ3' ' A' ' 47' ' ' TRP . 19.8 tttm -57.75 -36.98 72.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.482 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.1 mt -92.17 142.06 27.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.441 -179.962 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.653 ' C8 ' ' CE2' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.559 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 11.9 ptp . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.348 0.594 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 -60.16 -42.76 95.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.385 -0.822 . . . . 0.0 110.247 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 90.6 m-70 -149.0 3.45 0.61 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.965 -1.085 . . . . 0.0 110.603 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.586 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -63.34 -32.4 73.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.778 -1.201 . . . . 0.0 109.866 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.508 ' OG ' ' CG2' ' A' ' 84' ' ' VAL . 83.7 p -59.04 -35.3 73.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.069 -1.02 . . . . 0.0 109.372 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 1.04 HG23 HG23 ' A' ' 84' ' ' VAL . 77.8 t -66.34 -37.74 80.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.264 -0.898 . . . . 0.0 109.2 179.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.615 ' O ' HG23 ' A' ' 11' ' ' VAL . 30.8 mm -62.16 -47.12 94.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.419 -0.8 . . . . 0.0 110.176 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.81 -49.74 71.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.206 -0.933 . . . . 0.0 110.445 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.436 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.71 -42.75 73.62 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.154 -0.967 . . . . 0.0 109.858 -179.571 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 9' ' ' GLN . 69.9 t80 -61.63 -46.66 88.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.147 -0.971 . . . . 0.0 109.512 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.733 HG13 HD12 ' A' ' 36' ' ' ILE . 91.4 t -67.5 -47.61 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.375 -0.828 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 78.7 t -66.44 -34.74 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.416 -0.802 . . . . 0.0 110.423 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.77 -36.46 58.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -0.93 . . . . 0.0 109.897 -179.068 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.76 -35.12 78.14 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.273 -0.892 . . . . 0.0 110.708 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.619 ' O ' HD12 ' A' ' 16' ' ' LEU . 65.9 m-85 -92.91 -63.47 1.22 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.919 -1.113 . . . . 0.0 110.767 -178.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.619 HD12 ' O ' ' A' ' 15' ' ' PHE . 5.7 mp -125.19 83.05 61.3 Favored Pre-proline 0 N--CA 1.495 1.794 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.018 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -82.6 -21.39 5.15 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.845 2.363 . . . . 0.0 112.11 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.91 -3.8 40.55 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.238 -0.914 . . . . 0.0 109.127 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.8 t -113.26 142.05 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.418 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . -61.68 118.96 43.09 Favored Pre-proline 0 C--N 1.304 -1.4 0 O-C-N 120.909 -1.119 . . . . 0.0 108.785 -179.529 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -64.62 -23.91 63.28 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 121.628 1.552 . . . . 0.0 111.828 -179.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.49 -14.89 62.27 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.446 -0.784 . . . . 0.0 109.272 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.418 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 90.5 m-20 -82.9 3.24 30.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.383 -0.823 . . . . 0.0 109.158 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.54 136.97 30.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.451 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.12 88.13 0.07 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.136 -0.977 . . . . 0.0 109.271 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -63.61 0.04 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.273 -0.892 . . . . 0.0 109.309 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.451 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -93.44 4.65 53.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 108.969 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.8 tt -98.36 137.65 36.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.461 -0.775 . . . . 0.0 109.541 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.63 ' O ' HD23 ' A' ' 28' ' ' LEU . 89.4 m-20 -60.56 121.57 12.48 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.231 -0.918 . . . . 0.0 108.625 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.426 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.6 OUTLIER -64.94 6.08 0.27 Allowed 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.255 -0.903 . . . . 0.0 110.047 -178.975 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.471 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.0 p -51.55 -38.23 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.053 -1.029 . . . . 0.0 108.634 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.83 -35.68 71.21 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.641 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.4 m-20 -86.18 20.14 2.44 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.176 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.84 -14.69 0.02 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.641 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.52 -35.62 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.264 -1.139 . . . . 0.0 108.802 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.733 HD12 HG13 ' A' ' 11' ' ' VAL . 1.1 tt -69.99 -22.16 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.567 -0.708 . . . . 0.0 110.067 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -55.02 -32.51 61.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.302 -0.874 . . . . 0.0 110.845 -178.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.7 m -118.0 -63.79 1.38 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.22 -0.925 . . . . 0.0 111.168 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.5 tp -62.01 -52.55 63.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.961 -1.087 . . . . 0.0 110.276 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -38.17 66.1 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.561 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -59.57 -40.66 88.11 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.419 -1.048 . . . . 0.0 109.15 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.99 -44.12 97.4 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.217 -0.927 . . . . 0.0 108.947 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.4 mttm -65.73 -37.42 86.33 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.316 -0.865 . . . . 0.0 109.483 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.5 t -62.84 -39.97 87.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.399 -0.813 . . . . 0.0 109.875 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.457 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.87 -51.41 73.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.11 -0.994 . . . . 0.0 109.664 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.59 -39.28 84.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -0.908 . . . . 0.0 109.627 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.706 ' HE1' ' CZ ' ' A' ' 51' ' ' ARG . 76.2 t90 -68.89 -43.04 76.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.41 -0.806 . . . . 0.0 109.962 -179.788 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.54 HD13 ' C19' ' A' ' 101' ' ' 7V9 . 12.0 tp -63.15 -46.83 85.38 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.353 -0.842 . . . . 0.0 109.962 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -68.23 -36.0 78.81 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.88 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.56 -45.48 93.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.066 -1.022 . . . . 0.0 110.68 -179.293 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.706 ' CZ ' ' HE1' ' A' ' 47' ' ' TRP . 85.0 mtt180 -87.2 -50.25 6.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.078 -1.013 . . . . 0.0 111.45 -178.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -80.1 -24.78 40.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.0 -1.062 . . . . 0.0 111.271 -178.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.21 30.07 57.59 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -105.95 144.13 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.288 -1.125 . . . . 0.0 109.478 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.89 152.1 28.35 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.2 -0.938 . . . . 0.0 109.479 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.31 -33.15 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.417 -0.802 . . . . 0.0 109.704 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 54.28 46.19 25.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.192 -0.943 . . . . 0.0 109.402 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.53 11.34 24.45 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.328 -0.858 . . . . 0.0 109.76 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 78.2 t -56.9 -41.5 76.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.541 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.582 ' C ' HD23 ' A' ' 61' ' ' LEU . 96.0 mt-10 -116.07 138.34 51.32 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.505 -0.747 . . . . 0.0 109.197 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.582 HD23 ' C ' ' A' ' 60' ' ' GLU . 0.4 OUTLIER -106.54 138.02 43.48 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.369 -0.832 . . . . 0.0 109.255 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p -132.83 73.92 75.14 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.874 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.48 -29.96 90.2 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.704 2.269 . . . . 0.0 111.931 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.54 -26.77 68.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.393 -0.817 . . . . 0.0 109.614 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 12.5 t-80 -67.81 -25.89 65.8 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 110.691 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -88.69 7.52 33.22 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.031 -1.043 . . . . 0.0 110.606 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.3 mmt85 -59.73 -36.93 77.57 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.985 -1.072 . . . . 0.0 110.547 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.453 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 93.5 p -132.94 150.53 52.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.995 -1.066 . . . . 0.0 110.345 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.403 HG23 ' CG2' ' A' ' 7' ' ' ILE . 88.9 mt -65.9 -37.67 80.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 O-C-N 121.49 -0.756 . . . . 0.0 109.854 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 93.8 mtm-85 -61.2 -38.29 86.03 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.091 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.453 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 22.2 m -60.07 -40.7 90.44 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.137 -0.977 . . . . 0.0 109.404 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -65.66 -42.33 92.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.267 -0.895 . . . . 0.0 109.836 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.586 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 53.2 t0 -60.05 -38.74 83.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.335 -0.853 . . . . 0.0 110.062 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.12 -40.64 98.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.182 -0.949 . . . . 0.0 109.747 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -62.7 -46.94 85.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -64.44 -44.02 97.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.24 -0.913 . . . . 0.0 109.757 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 73' ' ' ASP . 58.2 t -60.54 -40.66 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.34 -0.85 . . . . 0.0 109.625 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.46 -31.97 71.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.73 -50.44 3.41 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.113 -1.228 . . . . 0.0 110.807 -179.116 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.0 p -131.43 157.62 42.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 109.805 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.24 88.43 17.31 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.213 -0.93 . . . . 0.0 109.255 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 72.9 Cg_endo -82.94 160.28 15.89 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.758 2.305 . . . . 0.0 112.561 -179.721 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.94 150.88 84.49 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.91 2.407 . . . . 0.0 111.962 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 1.04 HG23 HG23 ' A' ' 6' ' ' VAL . 14.5 p -126.77 139.17 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.39 -0.819 . . . . 0.0 109.71 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -116.79 141.86 47.67 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.92 137.47 58.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.114 -0.991 . . . . 0.0 109.298 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 26.9 mttp -59.99 -34.74 73.72 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.338 -0.851 . . . . 0.0 109.482 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.1 tp -57.16 -37.6 72.34 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.457 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.482 179.952 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.54 ' C19' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.9 mmm . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -60.12 -35.89 76.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.35 -0.844 . . . . 0.0 109.703 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.822 ' NE2' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -155.18 28.44 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.129 -0.982 . . . . 0.0 109.541 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.43 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.63 -33.39 73.85 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.57 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 84.8 p -61.59 -36.56 81.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.197 -0.939 . . . . 0.0 109.497 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.822 HG21 ' NE2' ' A' ' 3' ' ' HIS . 69.8 t -67.83 -37.85 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.209 -0.932 . . . . 0.0 109.0 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.576 ' O ' HG23 ' A' ' 11' ' ' VAL . 84.4 mt -60.47 -50.92 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.268 -0.895 . . . . 0.0 109.219 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.68 -47.53 78.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.303 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -44.4 96.02 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.486 -0.759 . . . . 0.0 109.19 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.57 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.7 t80 -65.05 -46.48 81.04 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.538 0.685 . . . . 0.0 109.607 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.783 HG13 HD12 ' A' ' 36' ' ' ILE . 97.7 t -69.73 -47.42 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.529 -0.732 . . . . 0.0 110.293 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.8 t -64.57 -34.81 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.397 -0.814 . . . . 0.0 110.729 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.68 -36.11 56.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.072 -1.018 . . . . 0.0 109.982 -179.02 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.71 -35.06 78.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 110.676 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -92.82 -63.79 1.18 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.932 -1.105 . . . . 0.0 110.682 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.423 HD22 HG23 ' A' ' 19' ' ' VAL . 5.4 mt -124.86 83.03 60.04 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.334 -0.854 . . . . 0.0 110.196 -178.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -82.83 -21.29 4.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.928 2.419 . . . . 0.0 112.21 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.94 -4.2 42.7 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.152 -0.968 . . . . 0.0 109.263 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.423 HG23 HD22 ' A' ' 16' ' ' LEU . 43.7 t -113.32 141.64 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.51 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.456 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . -61.9 117.82 32.7 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 120.933 -1.104 . . . . 0.0 108.574 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.88 -25.63 59.92 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 C-N-CA 121.586 1.524 . . . . 0.0 111.877 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.47 -14.95 62.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -0.862 . . . . 0.0 109.136 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 91.3 m-20 -84.05 2.99 36.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.313 -0.867 . . . . 0.0 109.024 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.66 136.64 32.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 27' ' ' ASP . 87.4 m-20 -68.05 87.96 0.27 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.148 -0.97 . . . . 0.0 109.478 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -64.06 -0.15 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.34 -0.85 . . . . 0.0 109.594 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.473 ' OD2' ' C ' ' A' ' 27' ' ' ASP . 49.3 p30 -88.83 7.57 33.49 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.203 -0.936 . . . . 0.0 108.954 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -97.15 141.75 29.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.618 -0.676 . . . . 0.0 109.486 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.52 121.76 12.96 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.36 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.4 pp -68.77 4.92 1.24 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.166 -0.959 . . . . 0.0 109.975 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.445 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.87 -38.34 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.034 -1.041 . . . . 0.0 108.53 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -58.44 -35.7 72.52 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 34.8 m120 -84.55 16.33 3.24 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.042 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.03 -14.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.7 t -51.3 -36.61 17.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.119 -1.224 . . . . 0.0 108.891 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.783 HD12 HG13 ' A' ' 11' ' ' VAL . 1.3 tt -70.56 -21.84 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 110.091 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -55.22 -31.88 61.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 111.083 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.15 -64.59 1.29 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.066 -1.021 . . . . 0.0 111.518 -178.353 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.2 tp -65.12 -52.08 57.45 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.814 -1.179 . . . . 0.0 110.581 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.524 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.9 -35.69 79.92 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.576 HD21 ' C10' ' A' ' 101' ' ' 7V9 . 15.0 tp -58.14 -41.59 84.04 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -1.138 . . . . 0.0 109.282 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 42' ' ' LEU . 87.6 mt -62.61 -44.07 97.23 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.138 -0.976 . . . . 0.0 108.823 179.223 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.2 mttp -63.56 -36.71 84.7 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.8 t -64.12 -38.31 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.774 -0.579 . . . . 0.0 109.749 179.58 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.532 HG13 ' HB1' ' A' ' 56' ' ' ALA . 1.3 mp -56.91 -51.03 73.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 109.958 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.42 -39.15 85.48 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.055 -1.028 . . . . 0.0 109.7 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.57 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 52.4 t90 -67.51 -44.39 78.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.301 -0.874 . . . . 0.0 111.08 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.593 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.4 OUTLIER -62.13 -49.1 77.21 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.133 -0.979 . . . . 0.0 109.978 -178.068 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -68.83 -39.22 80.1 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.957 -1.089 . . . . 0.0 109.391 179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -64.65 -42.62 95.29 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.119 -0.988 . . . . 0.0 111.135 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.692 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 54.7 ttt-85 -72.2 -48.23 44.66 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.216 -0.927 . . . . 0.0 112.036 -177.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.73 ' CE2' HG21 ' A' ' 80' ' ' THR . 90.9 m-85 -104.23 -6.21 21.15 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 111.733 -178.143 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.56 30.79 66.09 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 59.9 mt -106.04 142.27 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.255 -1.144 . . . . 0.0 109.34 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.628 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -61.18 122.66 15.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.955 -1.091 . . . . 0.0 108.958 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.532 ' HB1' HG13 ' A' ' 45' ' ' ILE . . . -67.87 -32.74 73.46 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.46 -0.775 . . . . 0.0 110.142 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -92.26 8.65 37.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.35 -0.844 . . . . 0.0 110.284 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.3 t0 -54.08 -40.34 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.996 -1.065 . . . . 0.0 109.308 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.7 p -138.89 143.88 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.352 -0.843 . . . . 0.0 109.363 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -100.91 138.11 38.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.104 -0.998 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.8 mt -104.67 143.48 33.02 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.409 -0.807 . . . . 0.0 109.713 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -83.96 159.22 60.56 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.217 -0.927 . . . . 0.0 109.251 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -57.7 -31.93 93.31 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.675 2.25 . . . . 0.0 111.962 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.88 -24.8 66.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 179.623 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.9 t60 -67.28 -26.4 66.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.287 -0.883 . . . . 0.0 109.955 -179.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -95.05 6.23 49.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.107 -0.995 . . . . 0.0 109.426 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -56.33 -39.6 73.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.917 . . . . 0.0 109.7 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -135.25 153.5 51.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.094 -1.004 . . . . 0.0 109.924 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.4 ' N ' HD23 ' A' ' 30' ' ' LEU . 83.6 mt -63.88 -36.31 76.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 O-C-N 121.4 -0.813 . . . . 0.0 109.818 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.5 mtm180 -60.73 -37.68 82.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.823 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 t -59.76 -43.94 94.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.064 -1.023 . . . . 0.0 109.346 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.3 mt -64.39 -38.54 82.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.28 -0.888 . . . . 0.0 109.455 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.622 ' O ' HG23 ' A' ' 77' ' ' VAL . 21.8 t70 -56.16 -38.14 70.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.351 -0.843 . . . . 0.0 109.511 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.16 95.31 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.305 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -64.05 -46.69 83.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.493 179.407 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 58.3 t -64.18 -41.63 93.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.439 -0.788 . . . . 0.0 109.708 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.8 t -62.82 -43.5 98.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.216 -0.928 . . . . 0.0 109.96 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.82 -37.92 95.12 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -88.78 -49.64 6.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.111 -1.229 . . . . 0.0 110.185 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.73 HG21 ' CE2' ' A' ' 52' ' ' PHE . 28.0 m -128.86 138.75 52.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.68 88.41 51.98 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.441 -0.787 . . . . 0.0 109.566 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -66.08 160.33 45.14 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.533 2.155 . . . . 0.0 111.872 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -61.23 150.31 85.21 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.705 2.27 . . . . 0.0 111.949 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.5 t -107.99 135.2 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.389 -0.819 . . . . 0.0 109.504 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -151.84 -18.81 0.19 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -140.35 158.46 43.98 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.248 -0.907 . . . . 0.0 109.62 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 32.7 tttm 60.91 54.6 3.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.4 -0.812 . . . . 0.0 109.361 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.6 tp -99.0 130.45 45.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.189 -0.945 . . . . 0.0 109.357 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.484 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.576 ' C10' HD21 ' A' ' 41' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.9 mmm . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.649 ' HA ' HG22 ' A' ' 84' ' ' VAL . 94.1 mt-30 -58.85 -34.94 72.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.919 . . . . 0.0 109.384 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.654 ' CE1' HD11 ' A' ' 7' ' ' ILE . 5.4 p80 -160.33 23.14 0.16 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.372 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.4 -38.64 87.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.91 -34.12 77.25 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.357 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.68 -38.1 80.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.285 -0.885 . . . . 0.0 109.356 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.875 ' O ' HG12 ' A' ' 11' ' ' VAL . 88.4 mt -60.43 -50.39 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.526 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.795 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -64.0 -44.09 93.7 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.301 -0.874 . . . . 0.0 109.024 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.47 -40.8 89.54 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.529 -0.732 . . . . 0.0 109.647 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -66.39 -49.47 66.73 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.535 -0.728 . . . . 0.0 111.272 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.875 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.4 p -69.95 -44.81 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.126 -0.984 . . . . 0.0 111.258 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.795 HG22 ' O ' ' A' ' 8' ' ' ALA . 15.9 m -67.48 -33.87 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.026 -1.046 . . . . 0.0 110.733 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.408 ' N ' HG23 ' A' ' 12' ' ' VAL . 82.8 tt0 -52.2 -36.34 51.68 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.107 -0.996 . . . . 0.0 109.832 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -33.36 75.41 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.176 -0.952 . . . . 0.0 110.568 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.67 ' O ' HD12 ' A' ' 16' ' ' LEU . 64.5 m-85 -95.94 -63.72 1.12 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.016 -1.053 . . . . 0.0 110.98 -178.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.67 HD12 ' O ' ' A' ' 15' ' ' PHE . 5.1 mp -124.32 83.09 57.27 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 110.62 -178.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -84.12 -18.27 5.26 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.024 2.482 . . . . 0.0 112.048 179.027 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.97 -3.4 38.73 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.279 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.3 t -109.09 144.21 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.17 117.59 27.87 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 120.864 -1.148 . . . . 0.0 108.465 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -65.24 -28.82 55.57 Favored 'Trans proline' 0 N--CA 1.49 1.271 0 C-N-CA 121.596 1.531 . . . . 0.0 112.041 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.71 -14.85 61.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.377 -0.827 . . . . 0.0 109.297 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -90.68 8.17 35.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.364 -0.835 . . . . 0.0 109.34 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.2 t -98.3 137.15 26.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.352 -0.842 . . . . 0.0 108.79 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.521 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -65.57 85.01 0.07 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.168 -0.958 . . . . 0.0 109.466 -179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.511 HG21 ' CE ' ' A' ' 87' ' ' LYS . 19.1 m -59.89 -0.06 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.312 -0.868 . . . . 0.0 109.266 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.45 7.14 44.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 108.954 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -94.23 136.01 35.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -63.51 121.71 14.52 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.128 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.468 HD11 ' O ' ' A' ' 66' ' ' PHE . 0.5 OUTLIER -68.78 5.24 1.15 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.87 -178.97 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.1 p -52.81 -38.87 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.03 -1.044 . . . . 0.0 108.547 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.446 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.9 t0 -57.77 -35.47 70.81 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.415 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.8 m-20 -86.06 19.52 2.6 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -14.51 0.01 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.4 t -51.44 -36.35 17.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 108.558 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.549 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.3 OUTLIER -69.98 -20.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.455 -0.778 . . . . 0.0 110.054 179.967 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -51.35 -35.57 38.94 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.216 -0.928 . . . . 0.0 110.98 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -119.1 -61.9 1.58 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.131 -0.981 . . . . 0.0 111.51 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.9 -52.39 64.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.925 -1.11 . . . . 0.0 110.14 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.583 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.35 -41.1 59.58 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.8 -41.86 87.75 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.386 -1.067 . . . . 0.0 109.491 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -59.32 -44.31 92.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.184 -0.947 . . . . 0.0 108.949 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -65.35 -34.64 78.8 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.272 -0.892 . . . . 0.0 109.007 179.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 40' ' ' GLY . 70.2 t -62.67 -41.59 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.784 . . . . 0.0 110.424 -179.373 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.2 mm -59.32 -49.59 82.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 120.931 -1.106 . . . . 0.0 109.635 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -65.84 -40.98 92.28 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -0.97 . . . . 0.0 109.338 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ2' ' HD3' ' A' ' 51' ' ' ARG . 69.3 t90 -66.89 -41.63 86.88 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.446 -0.784 . . . . 0.0 109.289 179.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.702 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 12.8 tp -60.07 -46.91 88.01 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.421 -0.8 . . . . 0.0 109.168 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.432 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -67.89 -34.18 76.15 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.314 -0.866 . . . . 0.0 109.207 178.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 92.4 m-20 -59.19 -46.62 87.94 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.233 -0.917 . . . . 0.0 110.291 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.401 ' HD3' ' CZ2' ' A' ' 47' ' ' TRP . 42.2 mtp180 -88.46 -51.77 5.54 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.075 -1.016 . . . . 0.0 111.616 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -80.23 -25.3 39.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.984 -1.072 . . . . 0.0 111.633 -177.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.34 31.16 52.52 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.248 -1.453 . . . . 0.0 109.712 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.432 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.9 mt -97.86 145.3 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.276 -1.132 . . . . 0.0 109.409 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.657 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -61.17 145.52 50.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.09 -1.006 . . . . 0.0 109.71 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.49 -36.47 80.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.463 -0.773 . . . . 0.0 109.933 -179.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -97.81 8.54 44.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.273 -0.892 . . . . 0.0 109.964 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.657 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.6 t0 -55.79 -40.54 72.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.71 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -135.15 153.58 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 109.666 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.563 ' C ' HD22 ' A' ' 61' ' ' LEU . 95.4 mt-10 -134.98 118.25 16.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.264 -0.898 . . . . 0.0 109.296 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.914 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.4 mm? -110.33 139.31 45.66 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.83 . . . . 0.0 109.704 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -77.91 162.07 68.9 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.257 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.406 ' HA ' ' CD1' ' A' ' 66' ' ' PHE . 10.0 Cg_endo -56.41 -27.41 67.84 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.664 2.243 . . . . 0.0 111.955 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.54 -27.46 69.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.249 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 33.5 t-80 -67.14 -26.25 66.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.434 -0.791 . . . . 0.0 109.697 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 0.9 OUTLIER -91.64 7.77 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.2 -0.937 . . . . 0.0 109.188 -179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.6 tpt180 -55.63 -39.44 70.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.971 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 91.6 p -137.25 152.57 49.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.047 -1.033 . . . . 0.0 110.214 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.479 HG23 ' CG2' ' A' ' 7' ' ' ILE . 89.5 mt -65.25 -36.67 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.308 -0.87 . . . . 0.0 110.027 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.1 ptt85 -61.2 -40.5 94.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 110.07 -179.219 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -59.21 -40.51 86.02 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.108 -0.995 . . . . 0.0 109.402 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -65.97 -39.74 85.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.338 -0.851 . . . . 0.0 109.728 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.691 ' O ' HG23 ' A' ' 77' ' ' VAL . 60.7 t0 -58.51 -38.64 78.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.315 -0.866 . . . . 0.0 109.918 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.52 -42.17 95.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 109.92 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -63.58 -48.53 77.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.07 -1.019 . . . . 0.0 109.606 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -65.49 -41.6 91.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.295 -0.878 . . . . 0.0 109.761 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.691 HG23 ' O ' ' A' ' 73' ' ' ASP . 62.6 t -61.33 -41.39 89.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.311 -0.868 . . . . 0.0 109.788 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.86 -31.72 76.96 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.49 -50.26 3.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.042 -1.27 . . . . 0.0 110.618 -178.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.1 p -129.86 157.52 42.01 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.399 -0.813 . . . . 0.0 109.613 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.31 88.36 17.24 Favored Pre-proline 0 C--N 1.304 -1.385 0 O-C-N 121.206 -0.933 . . . . 0.0 109.393 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.458 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.5 Cg_exo -63.13 -176.23 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.688 2.259 . . . . 0.0 112.178 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.458 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.6 Cg_exo -60.84 151.07 79.89 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.674 2.249 . . . . 0.0 111.907 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.649 HG22 ' HA ' ' A' ' 2' ' ' GLN . 26.0 t -99.39 129.41 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -136.0 158.86 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.317 -0.864 . . . . 0.0 109.366 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -98.55 137.91 36.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.511 ' CE ' HG21 ' A' ' 26' ' ' VAL . 17.9 mttp -59.15 -35.38 73.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.46 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.2 tp -101.46 129.84 47.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 117.982 -1.008 . . . . 0.0 109.448 179.995 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.702 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.2 mtm . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -59.38 -37.43 77.94 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.541 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.606 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 81.9 m-70 -139.61 28.35 2.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.456 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -60.62 -34.35 74.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.281 -0.887 . . . . 0.0 110.151 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m -58.87 -40.16 83.5 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.018 -1.051 . . . . 0.0 109.666 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 1.133 HG23 HG23 ' A' ' 84' ' ' VAL . 69.3 t -64.5 -36.59 77.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.88 . . . . 0.0 109.066 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.44 ' O ' HG12 ' A' ' 11' ' ' VAL . 27.7 mm -64.76 -44.31 96.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.433 -0.792 . . . . 0.0 110.323 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.688 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.73 -50.44 69.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.113 -0.992 . . . . 0.0 110.734 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.86 -39.49 76.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.016 -1.052 . . . . 0.0 109.566 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 68.3 t80 -65.75 -51.29 60.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.346 -0.846 . . . . 0.0 109.94 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -67.93 -40.76 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 109.763 -179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.688 HG23 ' O ' ' A' ' 8' ' ' ALA . 71.1 t -65.93 -40.55 87.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.216 -0.927 . . . . 0.0 109.571 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -52.74 -30.54 33.15 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.438 -0.789 . . . . 0.0 109.827 -179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -65.37 -30.46 71.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.939 . . . . 0.0 109.412 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.9 p90 -145.41 44.12 1.3 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.4 pt? -80.63 130.79 63.12 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.054 -1.029 . . . . 0.0 110.082 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -76.62 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.362 0 C-N-CA 121.83 1.687 . . . . 0.0 110.625 178.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.63 16.62 0.81 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.958 -1.089 . . . . 0.0 108.916 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.0 t -113.57 135.62 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.416 -0.802 . . . . 0.0 109.786 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.61 141.43 76.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -49.04 -31.54 21.1 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.817 1.678 . . . . 0.0 111.993 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.96 -22.28 66.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.419 -0.8 . . . . 0.0 109.446 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -95.88 2.06 53.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.429 -0.795 . . . . 0.0 108.928 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.6 t -104.88 136.46 38.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.518 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.5 t0 -71.19 97.03 1.46 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.051 -1.031 . . . . 0.0 109.312 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.6 m -59.5 0.14 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.195 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.518 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -91.96 7.82 40.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.325 -0.859 . . . . 0.0 108.779 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.8 tp -91.22 133.83 35.06 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.478 -0.764 . . . . 0.0 109.376 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -66.33 121.31 14.96 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.049 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -74.74 9.6 1.77 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.219 -0.925 . . . . 0.0 109.825 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.5 p -52.25 -38.91 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.156 -0.965 . . . . 0.0 108.642 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.454 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.1 m-20 -57.33 -35.73 70.25 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 178.49 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.2 m-20 -84.94 18.25 2.54 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.011 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.92 -13.69 0.01 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -50.72 -35.24 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.072 -1.251 . . . . 0.0 108.945 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.578 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -70.01 -23.48 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.418 ' OD2' ' CG ' ' A' ' 66' ' ' PHE . 84.2 m-20 -54.93 -32.42 61.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 110.714 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.51 -64.09 1.36 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.149 -0.969 . . . . 0.0 111.174 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 15.5 mt -62.67 -52.52 62.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.002 -1.061 . . . . 0.0 110.2 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.48 -37.19 69.18 Favored Glycine 0 N--CA 1.486 1.97 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.73 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.4 tt -58.86 -41.46 87.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.266 -1.138 . . . . 0.0 109.149 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -61.51 -44.22 97.45 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.348 -0.845 . . . . 0.0 108.894 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -67.92 -40.79 83.32 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.301 -0.875 . . . . 0.0 110.007 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.524 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 74.8 t -65.68 -42.86 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.277 -0.889 . . . . 0.0 110.131 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -58.87 -50.47 79.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.186 -0.946 . . . . 0.0 109.65 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.424 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.72 -37.18 85.7 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.94 . . . . 0.0 109.436 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.517 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -69.32 -43.7 73.2 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.281 -0.887 . . . . 0.0 109.715 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.494 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 12.1 tp -57.34 -48.0 80.12 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.323 -0.86 . . . . 0.0 109.402 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -68.73 -37.71 79.66 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.301 -0.874 . . . . 0.0 109.122 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.5 t0 -63.77 -41.73 97.91 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.297 -0.877 . . . . 0.0 110.593 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.7 ttt180 -87.1 -55.26 3.9 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.231 -0.918 . . . . 0.0 111.454 -178.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -79.49 -22.34 44.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.987 -1.071 . . . . 0.0 111.383 -178.181 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 25.84 60.69 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.1 mt -106.07 144.91 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.471 -1.017 . . . . 0.0 109.416 -179.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 152.41 29.01 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.283 -0.886 . . . . 0.0 109.54 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.78 -28.56 61.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.368 -0.833 . . . . 0.0 109.688 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 54.86 46.23 24.89 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.262 -0.899 . . . . 0.0 109.278 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.447 ' C ' ' OD2' ' A' ' 58' ' ' ASP . 53.3 p30 -88.42 13.11 12.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.39 -0.819 . . . . 0.0 109.621 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 55.8 t -53.85 -42.52 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.238 -0.914 . . . . 0.0 109.607 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -121.68 136.34 54.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.464 -0.772 . . . . 0.0 109.75 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 20.1 mt -104.84 140.47 38.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.32 -0.863 . . . . 0.0 108.975 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.449 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.8 OUTLIER -130.27 80.57 70.37 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.197 -0.939 . . . . 0.0 110.228 -179.516 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -58.08 -25.99 73.49 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 C-N-CA 122.578 2.186 . . . . 0.0 111.664 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.72 -23.54 65.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.56 -0.713 . . . . 0.0 110.198 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.413 ' O ' HD11 ' A' ' 72' ' ' ILE . 0.2 OUTLIER -67.76 -26.63 66.22 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.59 -178.923 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.418 ' CG ' ' OD2' ' A' ' 37' ' ' ASP . 68.4 m-85 -80.17 -3.67 49.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.883 -1.136 . . . . 0.0 110.144 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 83.1 mmt-85 -60.47 -36.18 77.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.892 -1.13 . . . . 0.0 109.745 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.458 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 93.7 p -139.92 150.94 45.17 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.014 -1.054 . . . . 0.0 109.749 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 80.2 mt -65.13 -36.65 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -60.63 -38.41 84.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 110.197 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.458 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 24.6 m -57.81 -40.63 80.4 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.018 -1.051 . . . . 0.0 109.53 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.413 HD11 ' O ' ' A' ' 65' ' ' HIS . 17.0 mm -65.36 -38.97 83.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.154 -0.966 . . . . 0.0 109.17 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.536 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.4 t0 -57.23 -38.35 73.65 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.288 -0.882 . . . . 0.0 109.594 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.44 99.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.307 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -63.75 -46.56 84.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.357 -0.839 . . . . 0.0 109.432 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.8 t -64.68 -41.63 92.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.333 -0.854 . . . . 0.0 109.663 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 73' ' ' ASP . 52.9 t -61.59 -40.94 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.269 -0.894 . . . . 0.0 109.634 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.17 76.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.28 -50.01 5.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.096 -1.237 . . . . 0.0 109.961 -179.546 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.4 t -144.97 153.21 41.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.55 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.606 ' HG1' ' HE2' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -133.11 89.07 34.54 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.213 -0.929 . . . . 0.0 109.552 -179.901 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.5 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 61.4 Cg_endo -82.51 161.38 17.0 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.715 2.277 . . . . 0.0 112.494 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.39 150.83 83.26 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.868 2.379 . . . . 0.0 112.022 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 1.133 HG23 HG23 ' A' ' 6' ' ' VAL . 13.4 p -128.13 141.03 47.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.38 -0.825 . . . . 0.0 109.859 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.16 151.5 39.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.565 -0.71 . . . . 0.0 109.096 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.54 142.54 58.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -0.901 . . . . 0.0 109.432 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 61.4 mttp -58.88 -36.39 74.57 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.356 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.9 tp -104.38 130.12 52.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.901 . . . . 0.0 109.435 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.489 1.517 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.451 -179.957 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.524 ' C18' ' CG1' ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.8 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.387 0.613 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.468 ' OE1' HG13 ' A' ' 77' ' ' VAL . 61.4 tt0 -55.39 -38.92 69.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.191 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.587 ' ND1' ' OG1' ' A' ' 81' ' ' THR . 45.2 m80 -152.92 28.89 0.52 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.417 -0.802 . . . . 0.0 109.19 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.436 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.27 -33.02 71.73 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.412 -0.805 . . . . 0.0 109.658 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -58.97 -38.95 80.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.173 -0.954 . . . . 0.0 109.613 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -65.14 -39.06 84.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.15 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.436 HD12 ' HA ' ' A' ' 4' ' ' ALA . 89.1 mt -60.58 -50.62 79.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.276 -0.89 . . . . 0.0 109.459 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.737 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.96 -44.62 92.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 109.064 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.37 -44.17 88.48 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.74 0.781 . . . . 0.0 109.227 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -61.61 -47.79 83.86 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.525 -0.735 . . . . 0.0 109.331 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.476 HG12 ' HE1' ' A' ' 15' ' ' PHE . 96.6 t -73.16 -41.49 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.446 -0.784 . . . . 0.0 110.139 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 8' ' ' ALA . 78.4 t -63.96 -41.27 91.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -0.882 . . . . 0.0 111.022 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -57.01 -28.25 62.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 109.907 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.44 -30.09 70.84 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.21 -0.931 . . . . 0.0 109.359 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.603 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.8 p90 -146.8 45.68 1.19 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.161 -0.962 . . . . 0.0 109.775 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.819 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.93 63.18 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.965 -1.084 . . . . 0.0 110.369 -179.725 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.55 -149.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 122.021 1.814 . . . . 0.0 110.311 178.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.6 p30 -80.73 15.77 1.63 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.764 -1.21 . . . . 0.0 109.146 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.459 HG23 ' OD1' ' A' ' 18' ' ' ASP . 39.4 t -113.33 136.05 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.443 -0.786 . . . . 0.0 109.778 -179.611 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.55 142.06 85.95 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.212 -0.93 . . . . 0.0 109.386 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -49.25 -33.8 29.46 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.878 1.719 . . . . 0.0 111.697 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.03 -21.87 65.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.489 -0.757 . . . . 0.0 109.331 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.4 5.21 50.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.55 -0.719 . . . . 0.0 109.17 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.4 t -102.54 136.49 34.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.516 ' C ' ' H ' ' A' ' 27' ' ' ASP . 84.5 m-20 -67.42 94.35 0.39 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.137 -0.977 . . . . 0.0 109.418 -179.399 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.5 m -59.24 0.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.39 -0.819 . . . . 0.0 109.423 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.516 ' H ' ' C ' ' A' ' 25' ' ' ASP . 48.2 p30 -84.26 9.79 12.08 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.227 -0.921 . . . . 0.0 109.078 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.8 tp -86.34 134.95 33.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.6 -0.687 . . . . 0.0 109.366 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -65.43 121.83 15.78 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 108.733 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.694 HD11 HG12 ' A' ' 69' ' ' ILE . 82.3 mt -56.87 -16.66 7.14 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 108.931 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' A' ' 34' ' ' GLY . 41.7 t -50.64 -40.94 19.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.237 -0.914 . . . . 0.0 108.914 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.67 -36.17 66.81 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 178.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' A' ' 35' ' ' VAL . 9.7 m120 -85.02 20.44 1.88 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.11 -15.35 0.02 OUTLIER Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.346 -1.101 . . . . 0.0 110.346 -179.079 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.597 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.4 t -51.91 -40.17 27.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.604 -1.527 . . . . 0.0 108.585 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.4 tt -71.91 -22.25 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.577 -0.702 . . . . 0.0 110.883 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.408 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 93.0 m-20 -52.51 -34.8 51.36 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.154 -0.966 . . . . 0.0 111.784 -177.73 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.554 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.5 OUTLIER -119.02 -60.59 1.74 Allowed 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.957 -1.09 . . . . 0.0 111.224 -178.692 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.96 -52.18 65.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.145 . . . . 0.0 109.598 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.441 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.91 -36.98 65.29 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.635 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.85 HD12 ' N9 ' ' A' ' 101' ' ' 7V9 . 5.7 tt -58.02 -41.02 82.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.358 -1.083 . . . . 0.0 109.294 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 30.4 mt -60.31 -44.43 95.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 108.667 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -67.75 -38.74 83.89 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.406 -0.809 . . . . 0.0 109.576 179.281 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.724 HG21 ' S12' ' A' ' 101' ' ' 7V9 . 79.5 t -65.09 -39.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.448 -0.783 . . . . 0.0 110.351 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -58.11 -50.6 77.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.033 -1.042 . . . . 0.0 109.642 -179.262 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.463 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.16 -39.14 86.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.089 -1.007 . . . . 0.0 109.702 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.5 t90 -70.38 -42.14 72.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.131 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.7 tp -61.43 -47.2 86.81 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.383 -0.823 . . . . 0.0 110.029 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.584 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -64.72 -43.7 92.59 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.116 -0.99 . . . . 0.0 108.613 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -66.45 -39.93 89.15 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.335 -0.853 . . . . 0.0 110.232 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 27.2 tpt85 -63.02 -45.06 94.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.499 -0.751 . . . . 0.0 111.547 -178.201 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.405 ' CZ ' ' CB ' ' A' ' 82' ' ' PRO . 54.8 m-85 -126.24 2.27 7.1 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.912 -1.118 . . . . 0.0 111.858 -178.26 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.7 33.79 54.91 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.5 ' CG2' ' OD1' ' A' ' 58' ' ' ASP . 70.6 mt -95.85 135.87 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.183 -1.186 . . . . 0.0 109.146 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.732 ' HB3' ' HB3' ' A' ' 58' ' ' ASP . . . -61.54 140.7 58.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.087 -1.008 . . . . 0.0 109.678 -179.214 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.89 -35.74 81.65 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.468 -0.77 . . . . 0.0 109.786 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -99.75 14.3 30.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.331 -0.856 . . . . 0.0 110.118 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.732 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 28.5 p-10 -57.68 -35.51 70.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.096 -1.003 . . . . 0.0 109.458 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.577 ' N ' ' OD2' ' A' ' 58' ' ' ASP . 21.7 m -130.98 158.67 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.472 -0.767 . . . . 0.0 109.436 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.558 ' C ' HD12 ' A' ' 61' ' ' LEU . 95.4 mt-10 -95.19 137.67 33.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.177 -0.952 . . . . 0.0 109.241 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.86 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.1 mp -106.34 139.02 41.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.861 -179.742 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.61 155.54 75.17 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.349 -0.844 . . . . 0.0 108.967 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -59.39 -35.13 97.22 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.511 2.141 . . . . 0.0 112.184 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.91 -28.73 68.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.398 -0.814 . . . . 0.0 109.796 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -67.81 -27.03 66.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.289 -0.882 . . . . 0.0 110.231 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.603 ' CD1' ' O8 ' ' A' ' 101' ' ' 7V9 . 56.0 m-85 -101.68 13.84 33.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.133 -0.98 . . . . 0.0 110.06 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -53.03 -32.96 49.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.094 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.7 t -151.29 151.76 32.25 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 109.973 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.694 HG12 HD11 ' A' ' 30' ' ' LEU . 81.8 mt -60.97 -36.87 75.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 O-C-N 121.262 -0.898 . . . . 0.0 110.11 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -60.63 -40.82 93.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.224 -0.922 . . . . 0.0 110.214 -179.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.2 m -60.66 -41.8 95.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.037 -1.04 . . . . 0.0 109.936 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.523 HD11 ' CD1' ' A' ' 66' ' ' PHE . 77.3 mt -66.95 -40.83 86.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.245 -0.909 . . . . 0.0 110.156 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.407 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.1 t0 -59.12 -40.72 86.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 110.405 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.17 -41.9 89.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.124 -0.985 . . . . 0.0 110.09 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.7 t80 -62.06 -49.65 75.15 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.164 -0.96 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 80' ' ' THR . 53.6 t -65.55 -47.05 87.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.219 -0.926 . . . . 0.0 109.562 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.468 HG13 ' OE1' ' A' ' 2' ' ' GLN . 45.8 t -58.93 -38.84 75.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.112 -0.992 . . . . 0.0 109.455 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.73 -33.06 66.6 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.46 -51.24 3.14 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -1.224 . . . . 0.0 110.397 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.624 ' O ' HG12 ' A' ' 76' ' ' VAL . 7.2 t -153.87 152.41 30.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.728 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.587 ' OG1' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -123.7 88.66 51.89 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.236 -0.915 . . . . 0.0 109.22 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.405 ' CB ' ' CZ ' ' A' ' 52' ' ' PHE . 97.2 Cg_endo -92.57 108.44 0.22 Allowed 'Trans proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.184 2.59 . . . . 0.0 112.973 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -80.11 136.1 11.38 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.103 1.869 . . . . 0.0 111.698 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.467 HG13 ' O ' ' A' ' 89' ' ' GLN . 40.1 t -124.15 129.14 74.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.359 -0.838 . . . . 0.0 109.647 -179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.99 -37.31 81.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.928 . . . . 0.0 109.471 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -155.29 153.01 29.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.282 -0.886 . . . . 0.0 109.542 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -58.54 -37.72 76.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.191 -0.943 . . . . 0.0 109.461 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.0 mt -59.52 -35.27 73.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.222 -0.924 . . . . 0.0 109.513 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.467 ' O ' HG13 ' A' ' 84' ' ' VAL . 59.8 tt0 . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.517 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.85 ' N9 ' HD12 ' A' ' 41' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.312 0.577 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.504 ' O ' HG22 ' A' ' 84' ' ' VAL . 93.2 mt-30 -59.49 -36.63 76.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.874 . . . . 0.0 109.458 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 83' ' ' PRO . 2.9 m-70 -137.03 18.69 3.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.352 -0.843 . . . . 0.0 109.702 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.415 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -57.64 -38.98 75.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.166 -0.959 . . . . 0.0 109.599 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.6 p -65.24 -37.29 86.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.098 -1.001 . . . . 0.0 109.624 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.434 HG21 ' ND1' ' A' ' 3' ' ' HIS . 76.2 t -68.13 -37.81 78.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.287 -0.883 . . . . 0.0 109.261 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.554 HD11 ' HA ' ' A' ' 73' ' ' ASP . 97.2 mt -60.02 -49.79 82.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.75 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.71 -47.17 82.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.184 -0.947 . . . . 0.0 109.098 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -44.16 94.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.445 -0.785 . . . . 0.0 109.252 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.696 ' CZ ' ' CZ3' ' A' ' 47' ' ' TRP . 70.2 t80 -68.39 -48.32 65.01 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.512 0.673 . . . . 0.0 109.48 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.54 HG13 ' CD1' ' A' ' 36' ' ' ILE . 97.5 t -68.67 -44.22 82.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.667 -0.645 . . . . 0.0 110.014 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.728 HG23 ' O ' ' A' ' 8' ' ' ALA . 96.9 t -64.22 -36.71 77.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -52.37 -32.8 40.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.316 -0.865 . . . . 0.0 109.729 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.594 ' OE1' ' CZ3' ' A' ' 47' ' ' TRP . 76.8 mm-40 -66.0 -31.79 72.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.206 -0.934 . . . . 0.0 109.804 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.548 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 34.4 p90 -140.06 42.94 1.94 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.103 -0.998 . . . . 0.0 109.835 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.82 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.63 130.56 64.02 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.05 -1.031 . . . . 0.0 110.015 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.413 ' C ' ' H ' ' A' ' 19' ' ' VAL . 73.4 Cg_endo -76.86 -152.18 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 121.962 1.774 . . . . 0.0 110.667 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.55 15.53 0.79 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.934 -1.104 . . . . 0.0 108.966 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.413 ' H ' ' C ' ' A' ' 17' ' ' PRO . 42.8 t -113.42 135.22 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.516 -0.74 . . . . 0.0 109.736 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.22 140.91 80.26 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.208 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.437 ' HB2' ' HZ1' ' A' ' 87' ' ' LYS . 35.1 Cg_exo -49.76 -31.45 25.92 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 121.842 1.695 . . . . 0.0 111.924 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.38 -22.77 66.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.537 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -92.77 4.29 54.06 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.448 -0.782 . . . . 0.0 109.225 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -105.35 136.48 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.522 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -69.23 91.24 0.52 Allowed 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -59.83 0.08 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.349 -0.844 . . . . 0.0 109.186 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.522 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -93.44 8.19 41.57 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.339 -0.851 . . . . 0.0 108.886 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.7 tp -92.34 136.86 32.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.432 -0.793 . . . . 0.0 109.519 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' A' ' 31' ' ' VAL . 33.6 p30 -62.61 114.4 3.55 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.141 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -63.74 8.7 0.08 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.112 -0.993 . . . . 0.0 109.926 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.539 ' H ' ' C ' ' A' ' 29' ' ' ASP . 6.3 p -54.98 -38.25 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.059 -1.025 . . . . 0.0 109.172 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.433 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.3 t0 -56.85 -37.21 70.98 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.596 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.5 m-80 -87.3 16.92 4.76 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.43 -17.4 0.03 OUTLIER Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.749 -1.341 . . . . 0.0 109.749 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.596 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.13 -34.19 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 O-C-N 120.969 -1.312 . . . . 0.0 108.453 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.593 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.9 OUTLIER -71.08 -21.32 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.512 -0.743 . . . . 0.0 110.042 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -55.06 -33.6 62.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.29 -0.881 . . . . 0.0 111.388 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 31.6 m -114.02 -64.52 1.3 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.055 -1.028 . . . . 0.0 111.522 -178.351 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.536 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.7 mp -65.45 -51.68 58.45 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.0 -1.062 . . . . 0.0 110.573 -178.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.613 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.5 -37.64 69.08 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 120.016 -1.088 . . . . 0.0 110.426 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.605 ' O ' HD13 ' A' ' 45' ' ' ILE . 6.9 tt -58.75 -41.49 86.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.176 -1.191 . . . . 0.0 109.796 -179.193 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.9 tp -66.76 -44.66 80.85 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.299 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -67.89 -37.95 82.39 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.1 t -63.59 -40.94 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.412 -0.805 . . . . 0.0 110.303 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.605 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.3 mp -58.88 -51.09 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.113 -0.992 . . . . 0.0 109.832 -179.189 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.441 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.14 -37.46 83.84 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.11 -0.994 . . . . 0.0 109.217 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.696 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 25.9 t90 -66.25 -39.61 89.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.445 -0.784 . . . . 0.0 109.538 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.604 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 11.0 tp -59.53 -41.92 91.09 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.511 -0.743 . . . . 0.0 109.84 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.461 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 4.1 tm-20 -65.77 -39.11 90.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.183 -0.948 . . . . 0.0 109.925 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -60.09 -39.09 84.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.617 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.6 mtp85 -86.02 -54.18 4.64 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 111.247 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -80.4 -22.89 40.79 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.054 -1.028 . . . . 0.0 110.984 -178.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 27.47 57.76 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.461 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 68.3 mt -104.85 148.7 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.343 -1.092 . . . . 0.0 109.424 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.38 155.21 22.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.33 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.411 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -55.25 -37.98 67.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.325 -0.859 . . . . 0.0 109.809 -179.261 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 51.92 50.52 18.42 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.057 -1.027 . . . . 0.0 108.9 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -71.86 116.36 12.15 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 110.055 -179.09 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.454 ' O ' ' O8 ' ' A' ' 101' ' ' 7V9 . 22.8 m -130.36 161.59 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.401 ' O ' HD23 ' A' ' 61' ' ' LEU . 89.0 tt0 -88.17 117.16 26.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.904 -1.122 . . . . 0.0 110.233 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.522 ' H ' ' C6 ' ' A' ' 101' ' ' 7V9 . 32.8 mt -116.03 145.15 43.22 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -68.16 153.84 94.86 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.149 -0.97 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -60.93 -27.12 84.3 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.649 2.232 . . . . 0.0 112.096 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.69 -25.45 67.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.384 -0.823 . . . . 0.0 109.947 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 52.6 t-80 -67.16 -26.64 66.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.173 -0.955 . . . . 0.0 110.202 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -96.78 3.14 52.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.095 -1.003 . . . . 0.0 109.387 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -56.67 -41.01 76.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.806 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -130.26 147.2 51.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.224 -0.922 . . . . 0.0 109.926 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.75 HD13 ' HB2' ' A' ' 8' ' ' ALA . 82.8 mt -63.12 -35.85 73.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 O-C-N 121.372 -0.83 . . . . 0.0 109.977 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.5 mtm180 -60.35 -37.35 80.4 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.202 -0.936 . . . . 0.0 110.108 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.3 t -58.67 -39.77 81.62 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.035 -1.041 . . . . 0.0 108.821 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.5 mt -62.65 -38.19 80.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.4 -0.812 . . . . 0.0 108.985 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.576 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.3 t0 -54.31 -38.73 66.29 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.409 -0.807 . . . . 0.0 109.275 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.15 93.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.927 . . . . 0.0 109.246 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -65.4 -46.35 80.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.244 -0.91 . . . . 0.0 109.374 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.2 t -65.38 -41.99 92.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.383 -0.823 . . . . 0.0 110.123 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.4 t -62.8 -42.92 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.085 -1.009 . . . . 0.0 109.864 -179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.95 -36.41 92.13 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.47 -49.79 5.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 110.532 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 37.9 m -129.22 139.68 51.77 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.835 . . . . 0.0 109.95 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.19 88.0 55.18 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.38 -0.825 . . . . 0.0 109.284 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.543 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 56.7 Cg_endo -82.07 161.34 18.11 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.666 2.244 . . . . 0.0 112.452 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 18.7 Cg_endo -61.39 148.91 91.73 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.817 2.345 . . . . 0.0 111.7 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 2' ' ' GLN . 46.2 t -98.08 131.52 44.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.115 -0.991 . . . . 0.0 109.97 -179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.12 163.5 23.68 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.24 141.41 35.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.186 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.437 ' HZ1' ' HB2' ' A' ' 21' ' ' PRO . 43.7 tttm -58.7 -36.19 73.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.266 -0.896 . . . . 0.0 109.518 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.5 mt -58.7 -35.35 72.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.438 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.436 -179.996 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.604 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.788 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 93.3 mmm . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 68.1 tp60 -56.98 -41.36 78.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.233 -0.917 . . . . 0.0 109.643 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.563 ' NE2' ' OG1' ' A' ' 81' ' ' THR . 95.9 m-70 -139.98 8.82 2.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.182 -0.949 . . . . 0.0 109.78 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.788 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -59.83 -37.49 79.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.163 -0.961 . . . . 0.0 109.394 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -59.76 -36.53 76.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.216 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.98 HG22 HG23 ' A' ' 84' ' ' VAL . 82.5 t -64.91 -37.25 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.388 -0.82 . . . . 0.0 109.45 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.54 ' CG2' HG23 ' A' ' 69' ' ' ILE . 89.6 mt -59.54 -48.53 86.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.567 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.612 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.25 -45.25 92.4 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.092 -1.005 . . . . 0.0 108.628 179.288 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.445 ' NE2' ' O ' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -65.65 -38.22 88.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.512 0.672 . . . . 0.0 109.398 179.276 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.553 ' CE2' ' NZ ' ' A' ' 87' ' ' LYS . 68.6 t80 -64.51 -51.69 61.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.567 -0.708 . . . . 0.0 110.003 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.524 ' HB ' HD12 ' A' ' 36' ' ' ILE . 16.2 m -74.42 -41.53 49.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 110.457 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 8' ' ' ALA . 73.9 t -62.85 -36.22 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.16 -0.963 . . . . 0.0 110.403 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.661 ' OE1' ' HB1' ' A' ' 86' ' ' ALA . 83.3 tt0 -57.36 -36.91 71.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.316 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -67.38 -36.85 82.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 110.504 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -90.58 -61.61 1.64 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.028 -1.045 . . . . 0.0 110.721 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.1 mt -125.7 82.83 63.23 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.304 -0.873 . . . . 0.0 110.134 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -83.02 -20.58 5.14 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.819 2.346 . . . . 0.0 112.204 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.88 -4.31 43.07 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.184 -0.948 . . . . 0.0 108.905 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.3 t -113.56 140.09 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.5 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.83 118.52 39.37 Favored Pre-proline 0 C--N 1.303 -1.431 0 O-C-N 120.96 -1.088 . . . . 0.0 108.726 -179.689 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.87 -27.51 59.05 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.528 1.485 . . . . 0.0 111.808 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.28 -17.07 63.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.198 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.5 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.9 m-20 -82.95 -1.26 51.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.385 -0.822 . . . . 0.0 108.787 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -102.5 138.65 25.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.505 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.4 t0 -67.93 94.36 0.47 Allowed 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.125 -0.984 . . . . 0.0 109.4 -179.399 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.5 m -60.87 0.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.363 -0.835 . . . . 0.0 109.319 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.505 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.1 m-20 -87.57 9.58 20.68 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.007 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -87.38 134.59 33.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.47 -0.769 . . . . 0.0 109.516 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.481 ' OD1' ' O ' ' A' ' 67' ' ' ARG . 86.1 m-20 -62.27 122.29 15.26 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 108.776 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.733 HD11 HG12 ' A' ' 69' ' ' ILE . 76.3 mt -58.13 -10.82 2.1 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.176 -0.952 . . . . 0.0 109.311 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 89.0 t -50.55 -45.35 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.116 -0.99 . . . . 0.0 108.691 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -55.94 -36.54 67.88 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.2 m-20 -90.13 22.91 3.05 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.13 -15.13 0.01 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.434 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -52.61 -37.2 23.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.308 . . . . 0.0 108.542 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.524 HD12 ' HB ' ' A' ' 11' ' ' VAL . 2.8 tt -70.48 -19.42 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.514 -0.741 . . . . 0.0 110.167 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.589 ' OD1' ' CE1' ' A' ' 66' ' ' PHE . 77.2 m-20 -56.71 -35.57 68.66 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.234 -0.916 . . . . 0.0 111.461 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.533 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.6 OUTLIER -113.08 -64.56 1.29 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.086 -1.009 . . . . 0.0 111.268 -178.322 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.41 -48.93 77.52 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.066 -1.021 . . . . 0.0 110.02 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.08 -43.52 56.6 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.559 HD13 ' C4 ' ' A' ' 101' ' ' 7V9 . 8.0 tt -58.8 -39.66 81.76 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -1.097 . . . . 0.0 109.371 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.77 -44.24 93.96 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.171 -0.956 . . . . 0.0 108.772 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -68.42 -39.95 81.41 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.323 -0.861 . . . . 0.0 109.602 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.439 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 70.4 t -65.84 -44.09 92.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.4 -0.812 . . . . 0.0 110.123 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.413 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.2 mp -61.63 -50.5 80.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.127 -0.983 . . . . 0.0 109.481 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.413 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -66.85 -38.25 86.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.311 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 44.7 t90 -68.97 -43.57 74.68 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.328 -0.858 . . . . 0.0 109.6 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.625 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 11.7 tp -60.2 -43.68 95.76 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.434 -0.792 . . . . 0.0 109.485 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.429 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 85.4 tt0 -67.71 -36.3 80.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.298 -0.876 . . . . 0.0 109.874 179.655 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -59.42 -39.24 82.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.838 -1.164 . . . . 0.0 110.119 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 36.3 mtp180 -87.04 -58.22 2.67 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.184 -0.947 . . . . 0.0 111.522 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -80.58 -23.16 40.06 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.951 -1.093 . . . . 0.0 111.733 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.71 35.01 33.15 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.319 -1.42 . . . . 0.0 109.709 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.546 HG23 ' OD2' ' A' ' 58' ' ' ASP . 69.2 mt -97.63 138.5 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.247 -1.149 . . . . 0.0 108.878 179.636 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.93 142.72 56.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.891 -1.131 . . . . 0.0 109.487 -179.403 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.05 -34.42 73.39 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.356 -0.84 . . . . 0.0 109.335 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -94.58 11.07 32.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.87 . . . . 0.0 109.419 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' OD2' HG23 ' A' ' 54' ' ' ILE . 53.9 t0 -52.91 -33.33 49.88 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.318 -0.864 . . . . 0.0 109.847 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.1 m -124.59 159.67 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.393 -0.817 . . . . 0.0 109.745 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -83.56 152.72 24.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.836 . . . . 0.0 109.449 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.427 HD22 ' O4 ' ' A' ' 101' ' ' 7V9 . 36.6 mt -72.52 136.28 45.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 109.398 -179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.84 87.45 19.73 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.621 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_exo -51.67 -23.55 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.283 1.989 . . . . 0.0 111.971 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.5 -20.87 61.51 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 109.564 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -67.43 -26.94 66.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.309 -0.869 . . . . 0.0 110.383 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.589 ' CE1' ' OD1' ' A' ' 37' ' ' ASP . 51.7 m-85 -72.91 -14.14 61.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.009 -1.057 . . . . 0.0 109.555 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.481 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 25.1 mmt180 -56.79 -35.94 69.3 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.299 -0.875 . . . . 0.0 110.194 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.9 p -157.52 143.77 17.75 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.86 -1.15 . . . . 0.0 110.463 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.733 HG12 HD11 ' A' ' 30' ' ' LEU . 84.9 mt -66.99 -36.6 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 O-C-N 121.562 -0.711 . . . . 0.0 110.172 179.521 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -60.27 -41.89 94.25 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -0.829 . . . . 0.0 110.629 -178.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -57.49 -42.12 82.06 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.134 -0.978 . . . . 0.0 109.774 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.14 -38.66 80.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.133 -0.979 . . . . 0.0 109.928 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 77' ' ' VAL . 40.4 t0 -57.72 -40.54 79.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 -179.347 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.9 85.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.142 -0.974 . . . . 0.0 109.745 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -62.97 -48.88 76.95 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.228 -0.92 . . . . 0.0 109.398 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.55 -45.47 88.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.242 -0.911 . . . . 0.0 109.725 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 73' ' ' ASP . 49.2 t -60.91 -41.84 90.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 O-C-N 121.069 -1.02 . . . . 0.0 109.592 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.96 -28.42 63.56 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.32 -50.67 3.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.139 -1.212 . . . . 0.0 110.678 -179.163 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.1 t -149.17 156.58 42.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.068 -1.02 . . . . 0.0 109.997 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.563 ' OG1' ' NE2' ' A' ' 3' ' ' HIS . 0.2 OUTLIER -129.07 89.19 49.21 Favored Pre-proline 0 C--N 1.302 -1.466 0 O-C-N 121.454 -0.779 . . . . 0.0 108.918 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -60.86 157.04 40.14 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.665 2.243 . . . . 0.0 112.891 -178.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.42 151.92 83.56 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 123.034 2.489 . . . . 0.0 112.153 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.98 HG23 HG22 ' A' ' 6' ' ' VAL . 7.2 p -89.57 130.22 39.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.172 -0.955 . . . . 0.0 109.458 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.445 ' O ' ' NE2' ' A' ' 9' ' ' GLN . 73.6 tt0 -171.47 -119.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.32 -0.862 . . . . 0.0 109.187 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.661 ' HB1' ' OE1' ' A' ' 13' ' ' GLU . . . -159.26 165.24 33.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 109.581 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.553 ' NZ ' ' CE2' ' A' ' 10' ' ' PHE . 26.2 mttm -71.29 143.72 50.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.921 . . . . 0.0 109.302 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 70.0 mt -59.3 -35.09 73.15 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.911 . . . . 0.0 109.435 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.496 -179.967 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.625 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.8 mtt . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.315 0.579 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.594 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 93.4 mt-30 -104.93 140.34 38.31 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.594 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 22.0 p-80 40.28 24.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.412 -0.805 . . . . 0.0 109.164 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.553 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -61.53 -37.58 84.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.488 -0.757 . . . . 0.0 109.652 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 m -59.56 -38.1 80.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -0.943 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' CB ' ' A' ' 10' ' ' PHE . 71.6 t -64.28 -37.53 80.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.255 -0.903 . . . . 0.0 109.07 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.474 HD11 ' NE2' ' A' ' 3' ' ' HIS . 77.9 mt -64.19 -46.82 92.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.283 -0.886 . . . . 0.0 109.961 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.683 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.21 -49.98 69.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.293 -0.879 . . . . 0.0 110.593 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.72 -40.93 75.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.014 -1.054 . . . . 0.0 109.866 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.404 ' CB ' ' O ' ' A' ' 6' ' ' VAL . 74.4 t80 -63.69 -51.32 65.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -0.973 . . . . 0.0 110.159 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.47 HG12 ' O ' ' A' ' 7' ' ' ILE . 5.0 p -68.51 -40.38 81.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.703 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 8' ' ' ALA . 72.4 t -66.95 -37.8 80.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.311 -0.868 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -52.41 -29.67 25.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.378 -0.827 . . . . 0.0 109.992 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.51 -30.42 71.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.222 -0.924 . . . . 0.0 109.679 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.724 ' CE1' ' ND2' ' A' ' 33' ' ' ASN . 38.6 p90 -142.56 38.52 1.52 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.068 -1.02 . . . . 0.0 109.963 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.832 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.66 130.92 62.5 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.827 -1.17 . . . . 0.0 110.053 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.401 ' C ' ' H ' ' A' ' 19' ' ' VAL . 67.7 Cg_endo -76.07 -152.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 122.015 1.81 . . . . 0.0 110.784 179.017 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -77.75 16.26 0.71 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.98 -1.075 . . . . 0.0 109.117 179.531 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.401 ' H ' ' C ' ' A' ' 17' ' ' PRO . 43.4 t -113.19 136.29 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 109.674 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.6 141.9 93.5 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.511 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.496 ' HD3' HD12 ' A' ' 16' ' ' LEU . 35.2 Cg_exo -50.02 -31.09 26.51 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 C-N-CA 121.943 1.762 . . . . 0.0 112.104 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.3 -25.44 68.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.64 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -96.74 8.62 43.86 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.237 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.46 137.18 28.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.356 -0.84 . . . . 0.0 108.818 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.53 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.87 85.89 0.33 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.216 -0.927 . . . . 0.0 109.642 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.8 m -59.97 0.08 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.387 -0.82 . . . . 0.0 109.086 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.53 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.64 7.69 40.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.345 -0.847 . . . . 0.0 108.87 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.9 tp -90.81 138.0 31.92 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.45 -0.781 . . . . 0.0 109.454 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.36 121.54 15.07 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.415 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -72.53 3.34 5.0 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.944 -178.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.2 p -52.46 -39.22 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.007 -1.058 . . . . 0.0 108.635 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -58.11 -34.74 70.53 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.397 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.724 ' ND2' ' CE1' ' A' ' 15' ' ' PHE . 4.4 m-20 -84.42 16.97 2.81 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 179.093 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.17 -17.37 0.03 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.295 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.79 -35.81 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.038 -1.272 . . . . 0.0 108.51 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.4 tt -70.22 -16.07 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.571 -0.706 . . . . 0.0 109.768 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -55.87 -32.94 64.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 111.392 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 73.9 m -119.43 -64.69 1.24 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.008 -1.057 . . . . 0.0 111.601 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.482 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.5 mp -62.51 -48.14 80.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 110.612 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -42.56 60.99 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.534 ' O ' HD13 ' A' ' 45' ' ' ILE . 2.5 mt -62.39 -38.92 91.5 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.272 -1.134 . . . . 0.0 109.675 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.8 tp -59.12 -44.03 91.99 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.143 -0.973 . . . . 0.0 108.676 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -66.16 -38.25 87.62 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.291 -0.881 . . . . 0.0 109.017 178.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.2 t -64.93 -39.6 86.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.527 -0.733 . . . . 0.0 110.054 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.534 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.4 mp -58.1 -50.27 78.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.221 -0.925 . . . . 0.0 109.679 -179.318 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.54 -38.16 90.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.14 -0.975 . . . . 0.0 109.171 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.741 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 51.6 t90 -66.84 -40.15 87.86 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.392 -0.817 . . . . 0.0 109.474 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.585 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 8.6 tp -61.01 -43.53 98.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.462 -0.774 . . . . 0.0 109.735 -179.694 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.403 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 85.4 tt0 -66.3 -36.4 82.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 110.001 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -62.3 -46.24 89.65 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.045 -1.034 . . . . 0.0 110.837 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.741 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt180 -87.4 -51.14 6.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.074 -1.016 . . . . 0.0 111.798 -178.529 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.785 ' CE2' HG21 ' A' ' 80' ' ' THR . 95.3 m-85 -79.88 -24.1 41.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.966 -1.084 . . . . 0.0 111.13 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.47 31.54 45.55 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.44 -1.362 . . . . 0.0 109.739 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.403 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 68.1 mt -100.21 136.31 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.167 -1.196 . . . . 0.0 108.656 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.925 -1.11 . . . . 0.0 109.765 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.462 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -65.79 -32.57 74.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.522 -0.736 . . . . 0.0 109.405 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -58.91 -33.45 70.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.453 -0.78 . . . . 0.0 110.463 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -73.68 109.45 7.19 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.017 -1.052 . . . . 0.0 109.996 -179.181 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 m -133.94 157.77 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.44 -0.788 . . . . 0.0 109.242 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.587 ' C ' HD12 ' A' ' 61' ' ' LEU . 63.1 tt0 -169.44 23.29 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.127 -0.983 . . . . 0.0 109.021 179.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.8 ' N ' HD12 ' A' ' 61' ' ' LEU . 5.8 mp -104.65 143.34 33.21 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.168 -0.958 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.74 162.34 21.07 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.479 -0.763 . . . . 0.0 109.316 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -57.69 -30.67 89.75 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.757 2.304 . . . . 0.0 112.11 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.54 -31.83 73.21 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.264 -0.897 . . . . 0.0 109.509 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.479 ' CE1' ' O ' ' A' ' 71' ' ' SER . 83.7 t60 -68.59 -26.19 65.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 110.653 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.491 ' CZ ' HD11 ' A' ' 41' ' ' LEU . 97.1 m-85 -88.79 7.35 34.5 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.996 -1.065 . . . . 0.0 110.489 -178.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 24.0 mmt85 -58.07 -36.33 72.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.07 -1.019 . . . . 0.0 109.968 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 90.9 p -133.68 150.04 51.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.208 -0.932 . . . . 0.0 109.834 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.9 mt -66.05 -36.45 77.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.313 -0.867 . . . . 0.0 109.875 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -60.93 -37.61 82.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.171 -0.955 . . . . 0.0 109.916 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.479 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 88.4 p -61.37 -35.73 78.25 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.07 -1.019 . . . . 0.0 109.274 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.3 mt -61.41 -39.06 81.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.25 -0.907 . . . . 0.0 109.015 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.725 ' O ' HG23 ' A' ' 77' ' ' VAL . 51.3 t0 -59.24 -37.32 77.27 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.515 -0.741 . . . . 0.0 109.68 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.19 -46.67 82.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.188 -0.945 . . . . 0.0 109.872 -179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 68.9 t80 -66.12 -44.85 83.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.053 -1.029 . . . . 0.0 109.079 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -62.63 -41.83 93.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.471 -0.768 . . . . 0.0 109.549 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.6 t -61.92 -41.73 91.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 O-C-N 121.264 -0.898 . . . . 0.0 109.661 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.65 -36.33 85.29 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -90.57 -49.82 6.28 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.11 -1.23 . . . . 0.0 110.079 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.785 HG21 ' CE2' ' A' ' 52' ' ' PHE . 12.4 t -145.1 153.35 41.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -0.888 . . . . 0.0 109.577 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -134.69 88.5 28.24 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.667 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.44 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.0 Cg_exo -65.27 -176.47 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.655 2.237 . . . . 0.0 111.985 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.44 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.5 Cg_exo -60.59 150.9 79.4 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.574 2.182 . . . . 0.0 111.714 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.492 ' HA ' ' H ' ' A' ' 3' ' ' HIS . 43.7 t -100.43 131.82 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 109.735 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -125.42 157.7 36.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.498 -0.751 . . . . 0.0 109.364 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -103.47 149.79 24.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.447 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -78.72 146.6 33.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.949 . . . . 0.0 109.373 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.0 mt -58.79 -34.99 72.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.901 . . . . 0.0 109.412 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.451 179.983 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.585 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.542 ' SD ' ' CD ' ' A' ' 70' ' ' ARG . 67.0 mtm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.444 0.64 . . . . 0.0 109.943 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.1 mt-30 -100.75 127.01 47.34 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.403 -0.811 . . . . 0.0 108.87 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.668 ' CD2' HG12 ' A' ' 84' ' ' VAL . 6.4 m80 61.79 20.09 11.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -0.988 . . . . 0.0 109.139 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -63.43 -38.24 90.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.6 m -60.79 -39.12 87.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.97 . . . . 0.0 110.065 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.5 t -64.81 -38.09 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.103 -0.998 . . . . 0.0 109.554 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.674 ' O ' HG22 ' A' ' 11' ' ' VAL . 83.2 mt -59.81 -50.8 78.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.25 -0.906 . . . . 0.0 109.631 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.718 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.21 -46.36 84.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 109.139 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.36 -39.98 94.95 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.4 -0.813 . . . . 0.0 109.648 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.64 -51.21 61.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.431 -0.793 . . . . 0.0 110.493 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.674 HG22 ' O ' ' A' ' 7' ' ' ILE . 22.9 m -73.74 -39.28 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.24 -0.913 . . . . 0.0 110.367 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.718 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.3 t -65.13 -39.03 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.065 -1.022 . . . . 0.0 109.773 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -53.12 -35.87 60.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 109.8 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.62 -31.88 72.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.27 -0.894 . . . . 0.0 109.918 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.88 39.86 3.12 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 110.047 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.834 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.54 130.39 64.97 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 120.93 -1.106 . . . . 0.0 110.024 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.84 -149.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 122.01 1.807 . . . . 0.0 110.346 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.553 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.5 p30 -77.91 13.3 1.42 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.719 -1.238 . . . . 0.0 108.871 179.167 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.553 HG23 ' OD2' ' A' ' 18' ' ' ASP . 42.3 t -113.51 136.13 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.575 -0.703 . . . . 0.0 109.62 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.93 141.49 81.84 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.311 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -49.52 -30.28 20.91 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.929 1.753 . . . . 0.0 112.052 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.04 -22.86 67.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.307 -0.87 . . . . 0.0 109.643 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -96.11 7.13 47.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.333 -0.854 . . . . 0.0 109.132 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.58 136.52 34.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.535 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.1 89.61 0.44 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.175 -0.953 . . . . 0.0 109.605 -179.34 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -59.63 0.11 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.261 -0.899 . . . . 0.0 109.146 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.535 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -92.21 8.22 39.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.352 -0.842 . . . . 0.0 108.786 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.0 tp -90.96 139.06 31.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.427 -0.796 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.416 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.9 m-20 -60.82 121.58 12.69 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -69.86 7.13 0.97 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.254 -0.904 . . . . 0.0 109.847 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -53.46 -38.61 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.113 -0.992 . . . . 0.0 109.123 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.92 -36.45 72.5 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.15 19.55 3.09 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -15.01 0.02 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.63 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -53.43 -36.49 27.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.125 -1.221 . . . . 0.0 108.862 179.53 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.5 tt -70.38 -22.48 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.538 -0.726 . . . . 0.0 110.245 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.3 m-20 -55.42 -33.22 63.36 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 110.932 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -116.17 -63.75 1.41 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.123 -0.985 . . . . 0.0 111.24 -178.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.54 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.4 mm? -62.41 -52.18 64.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.047 -1.033 . . . . 0.0 110.096 -178.78 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.6 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.79 -40.19 64.87 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.7 tt -58.7 -41.04 85.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -1.094 . . . . 0.0 109.552 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 24.9 tp -62.76 -44.4 96.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.935 . . . . 0.0 109.024 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -66.24 -35.12 79.6 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.349 -0.844 . . . . 0.0 109.592 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 40' ' ' GLY . 64.2 t -60.86 -42.99 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 110.24 -179.366 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -59.64 -50.54 79.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.105 -0.997 . . . . 0.0 109.632 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.91 -36.65 82.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 34.3 t90 -67.79 -43.33 79.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 109.633 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.577 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 10.9 tp -58.01 -46.3 85.48 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.477 -179.284 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -67.84 -38.05 82.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.35 -0.844 . . . . 0.0 109.067 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.8 t0 -65.47 -41.48 93.32 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 110.64 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 74.5 ttt-85 -87.12 -58.14 2.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.171 -0.956 . . . . 0.0 111.662 -178.385 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -79.73 -19.47 48.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.02 -1.05 . . . . 0.0 111.559 -177.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 28.19 56.26 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -104.47 142.58 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.405 -1.056 . . . . 0.0 109.348 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.47 154.73 23.69 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.237 -0.914 . . . . 0.0 109.143 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -53.12 -39.34 63.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.259 -0.901 . . . . 0.0 109.405 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 52.0 48.19 23.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.193 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.84 133.61 56.25 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.252 -0.905 . . . . 0.0 109.747 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.605 HG23 HD13 ' A' ' 61' ' ' LEU . 31.3 m -132.23 160.9 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.492 -0.755 . . . . 0.0 109.203 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.772 ' O ' HD12 ' A' ' 61' ' ' LEU . 86.4 tt0 -91.99 120.64 32.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.059 -1.026 . . . . 0.0 109.81 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.772 HD12 ' O ' ' A' ' 60' ' ' GLU . 5.5 mp -134.31 -166.98 1.89 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 109.091 179.742 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.77 160.95 64.07 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.476 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.19 -21.47 59.91 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.892 2.395 . . . . 0.0 111.866 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.43 -32.32 70.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.402 -0.811 . . . . 0.0 110.091 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.44 ' O ' ' OG ' ' A' ' 71' ' ' SER . 44.9 t-80 -70.23 -26.27 63.77 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.319 -0.863 . . . . 0.0 111.404 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -95.11 8.0 44.37 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.799 -1.188 . . . . 0.0 110.817 -178.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -60.91 -38.44 85.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.998 -1.064 . . . . 0.0 110.671 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.4 m -126.66 147.58 49.91 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.222 -0.924 . . . . 0.0 110.483 -179.149 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.2 -36.09 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 O-C-N 121.434 -0.791 . . . . 0.0 109.802 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.542 ' CD ' ' SD ' ' A' ' 1' ' ' MET . 80.5 mtm180 -60.42 -37.7 81.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 110.157 -178.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 97.6 p -61.44 -36.85 81.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.08 -1.013 . . . . 0.0 109.282 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.6 -38.62 82.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.373 -0.83 . . . . 0.0 109.117 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 53.5 t0 -56.52 -38.74 72.24 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.43 -0.794 . . . . 0.0 109.655 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.84 -42.04 97.7 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.132 -0.98 . . . . 0.0 109.405 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -64.35 -45.66 86.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.863 . . . . 0.0 109.563 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.6 t -65.0 -42.42 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.348 -0.845 . . . . 0.0 110.05 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.2 t -63.18 -42.37 96.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.155 -0.966 . . . . 0.0 109.892 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.9 -30.07 72.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -97.69 -49.54 4.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.958 -1.319 . . . . 0.0 110.307 -179.228 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 76' ' ' VAL . 11.0 t -139.19 155.54 47.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.554 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 89.48 32.76 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.448 -0.783 . . . . 0.0 109.514 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.594 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 55.1 Cg_endo -79.86 162.22 23.92 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.737 2.291 . . . . 0.0 112.519 -179.512 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -61.26 150.81 83.0 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.785 2.323 . . . . 0.0 112.04 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.668 HG12 ' CD2' ' A' ' 3' ' ' HIS . 17.1 m -89.69 131.72 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.708 -179.668 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.82 143.39 51.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.512 -0.743 . . . . 0.0 109.236 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.05 144.66 42.9 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -0.963 . . . . 0.0 109.498 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 47.3 mttp -58.06 -33.51 69.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.948 . . . . 0.0 109.274 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 50.7 mt -90.21 142.46 27.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 50.4 tt0 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.888 -1.053 . . . . 0.0 109.515 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.577 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.8 mmm . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' O ' ' O ' ' A' ' 83' ' ' PRO . 94.4 mt-30 -58.71 -35.17 72.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.726 ' CD2' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -163.88 25.0 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.155 -0.966 . . . . 0.0 109.385 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.641 ' HB2' ' OD1' ' A' ' 73' ' ' ASP . . . -61.87 -34.83 76.71 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.231 -0.918 . . . . 0.0 109.563 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 t -59.11 -39.6 82.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.159 -0.963 . . . . 0.0 109.543 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.726 HG21 ' CD2' ' A' ' 3' ' ' HIS . 78.3 t -65.13 -39.29 85.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.2 179.63 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.5 ' O ' HG23 ' A' ' 11' ' ' VAL . 88.1 mt -59.86 -48.0 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.444 -0.785 . . . . 0.0 109.657 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.487 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.66 -46.37 85.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.318 -0.864 . . . . 0.0 109.656 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.434 ' HG3' ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.52 -36.54 76.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.547 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.3 t80 -68.57 -48.23 64.76 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.389 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.527 HG13 HD12 ' A' ' 36' ' ' ILE . 73.7 t -69.12 -46.3 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 110.104 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 8' ' ' ALA . 76.6 t -63.53 -35.2 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.39 -0.819 . . . . 0.0 110.676 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.95 -36.8 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.125 -0.985 . . . . 0.0 109.86 -179.105 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.72 -35.39 78.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 110.685 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -91.99 -63.6 1.22 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.022 -1.049 . . . . 0.0 110.731 -178.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.9 mt -125.66 83.03 62.79 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.255 -0.903 . . . . 0.0 110.19 -179.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -82.78 -19.53 5.98 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.299 179.387 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.873 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.3 p30 -78.15 -3.41 42.33 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.176 -0.953 . . . . 0.0 109.216 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.873 HG23 ' OD1' ' A' ' 18' ' ' ASP . 57.7 t -113.81 140.33 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.16 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.652 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . -61.91 117.82 32.74 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.936 -1.103 . . . . 0.0 108.552 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.0 -28.6 57.6 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.574 1.516 . . . . 0.0 111.813 -179.186 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.62 -14.75 62.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.391 -0.818 . . . . 0.0 109.174 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.652 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 90.0 m-20 -82.94 -0.16 47.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.377 -0.827 . . . . 0.0 108.917 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -98.94 137.74 25.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.525 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -67.41 92.75 0.3 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.087 -1.008 . . . . 0.0 109.437 -179.277 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.655 HG21 ' HE3' ' A' ' 87' ' ' LYS . 19.9 m -59.77 0.01 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.421 -0.799 . . . . 0.0 109.206 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -88.98 5.69 43.05 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.8 tp -92.67 136.42 33.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.612 -0.68 . . . . 0.0 109.399 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.45 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.2 m-20 -60.93 121.58 12.74 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.1 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.518 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -67.02 6.53 0.51 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.126 -0.983 . . . . 0.0 109.72 -178.938 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.513 HG21 ' NH2' ' A' ' 67' ' ' ARG . 5.1 p -54.78 -37.57 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 108.933 179.741 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.432 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.25 -36.31 70.8 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.1 m-20 -84.96 17.92 2.69 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.44 ' O ' ' CG ' ' A' ' 37' ' ' ASP . . . -42.87 -14.26 0.01 OUTLIER Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.6 t -51.34 -37.93 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 108.855 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.527 HD12 HG13 ' A' ' 11' ' ' VAL . 0.9 OUTLIER -70.9 -11.82 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.47 -0.769 . . . . 0.0 109.757 179.92 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.44 ' CG ' ' O ' ' A' ' 34' ' ' GLY . 85.3 m-20 -51.64 -42.31 61.96 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 111.376 -177.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.47 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.4 OUTLIER -120.91 -58.66 1.8 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.109 -0.995 . . . . 0.0 111.975 -178.381 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.567 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.6 mp -61.27 -52.15 65.95 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.825 -1.172 . . . . 0.0 110.135 -178.313 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.625 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.56 -36.06 68.08 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.756 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.98 -43.23 86.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -1.083 . . . . 0.0 109.548 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.65 -43.91 95.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.076 -1.015 . . . . 0.0 109.205 179.577 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -65.27 -38.05 89.1 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 40' ' ' GLY . 80.0 t -65.31 -39.93 86.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.381 -0.825 . . . . 0.0 110.067 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.442 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -58.45 -50.1 79.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.155 -0.966 . . . . 0.0 109.905 -179.333 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.442 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -60.98 -36.7 80.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.971 -1.081 . . . . 0.0 109.94 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.547 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -76.58 -41.92 44.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.143 -0.973 . . . . 0.0 110.126 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.7 tt -60.84 -43.12 98.74 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.411 -0.805 . . . . 0.0 110.801 -178.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.714 ' OE1' ' HB2' ' A' ' 56' ' ' ALA . 54.8 mt-10 -65.78 -39.64 91.2 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.946 -1.096 . . . . 0.0 109.217 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -67.84 -49.21 63.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.419 -0.8 . . . . 0.0 110.932 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.615 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 67.4 ttt-85 -62.07 -41.3 98.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 97.5 m-85 -101.58 -9.62 20.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.953 -1.092 . . . . 0.0 110.559 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.21 35.78 88.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -105.88 143.94 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.302 -1.117 . . . . 0.0 109.869 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.76 152.85 34.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.365 -0.835 . . . . 0.0 109.082 179.523 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.714 ' HB2' ' OE1' ' A' ' 49' ' ' GLU . . . -58.98 -38.78 79.92 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 110.206 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.931 ' O ' HG13 ' A' ' 59' ' ' VAL . 85.4 m-20 52.92 48.8 21.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.052 -1.03 . . . . 0.0 108.495 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.446 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.3 m-20 -39.49 110.72 0.15 Allowed 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 121.563 0.697 . . . . 0.0 110.336 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.98 HG23 HD21 ' A' ' 61' ' ' LEU . 33.8 m -132.97 160.14 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.563 ' C ' HD22 ' A' ' 61' ' ' LEU . 95.7 mt-10 -96.41 117.05 30.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.011 -1.056 . . . . 0.0 109.753 -179.734 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.98 HD21 HG23 ' A' ' 59' ' ' VAL . 1.6 mm? -108.98 140.92 41.83 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.467 -0.77 . . . . 0.0 109.224 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.51 150.51 70.37 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.333 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.43 -28.06 77.78 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.532 2.154 . . . . 0.0 111.943 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -60.95 -28.3 68.88 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.418 -0.801 . . . . 0.0 109.993 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.402 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 78.4 t60 -67.78 -26.54 66.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.15 -0.969 . . . . 0.0 110.188 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.694 ' CD1' ' N9 ' ' A' ' 101' ' ' 7V9 . 71.5 m-85 -100.75 8.12 43.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.767 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.513 ' NH2' HG21 ' A' ' 31' ' ' VAL . 20.5 tpt180 -54.86 -40.06 69.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.356 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -127.69 148.6 50.4 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.319 -0.863 . . . . 0.0 109.69 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.3 mt -60.72 -36.59 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.299 -0.876 . . . . 0.0 109.891 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -60.55 -39.26 87.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.271 -0.893 . . . . 0.0 110.25 -179.195 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 m -58.25 -41.25 83.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.983 -1.073 . . . . 0.0 109.521 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.2 -38.62 83.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.839 ' O ' HG23 ' A' ' 77' ' ' VAL . 91.9 m-20 -56.31 -38.14 70.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.461 -0.774 . . . . 0.0 109.609 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.88 -45.99 86.92 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.402 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.6 t80 -65.69 -46.67 78.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.181 179.572 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.3 t -64.35 -40.73 90.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.422 -0.799 . . . . 0.0 109.681 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.839 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.1 t -60.33 -43.34 93.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.16 -0.963 . . . . 0.0 109.91 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.46 -37.38 94.71 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -87.62 -50.15 6.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.999 -1.295 . . . . 0.0 110.331 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.9 p -130.8 156.24 45.34 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.409 -0.807 . . . . 0.0 109.199 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.23 88.53 11.42 Favored Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.219 -0.926 . . . . 0.0 109.609 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.425 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.0 Cg_exo -63.94 -177.68 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.528 2.152 . . . . 0.0 111.911 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 2' ' ' GLN . 22.1 Cg_exo -60.73 150.55 82.04 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.463 2.108 . . . . 0.0 111.819 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.434 HG13 ' HA ' ' A' ' 2' ' ' GLN . 42.3 t -105.56 129.13 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.294 -0.879 . . . . 0.0 109.718 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -138.88 156.0 47.64 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.366 -0.834 . . . . 0.0 109.218 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.88 140.74 58.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.068 -1.02 . . . . 0.0 109.188 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.655 ' HE3' HG21 ' A' ' 26' ' ' VAL . 48.0 tttm -88.73 143.11 27.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.434 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.1 mt -56.91 -32.15 65.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.306 -0.871 . . . . 0.0 109.879 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 19.9 mm100 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.944 -1.026 . . . . 0.0 109.384 -179.667 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.694 ' N9 ' ' CD1' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.343 0.592 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -58.98 -35.91 74.0 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.35 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -152.04 57.42 0.84 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.905 . . . . 0.0 109.107 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.565 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.36 -35.41 75.61 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.265 -0.897 . . . . 0.0 109.97 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -59.46 -40.8 88.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.055 -1.028 . . . . 0.0 109.545 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.2 t -67.01 -37.85 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.239 -0.913 . . . . 0.0 109.182 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.565 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.8 mt -59.73 -40.03 81.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.496 -0.753 . . . . 0.0 110.101 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 1.018 ' HB1' HG11 ' A' ' 26' ' ' VAL . . . -63.18 -50.0 72.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.023 -1.048 . . . . 0.0 109.294 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.488 ' OE1' ' OE1' ' A' ' 13' ' ' GLU . 1.2 pp0? -69.94 -33.94 72.79 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.338 -0.851 . . . . 0.0 109.439 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.595 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 65.0 t80 -66.35 -51.96 51.84 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.043 -1.035 . . . . 0.0 109.942 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 5.5 p -70.57 -38.7 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.233 -0.917 . . . . 0.0 110.111 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.735 HG23 ' O ' ' A' ' 8' ' ' ALA . 88.6 t -65.25 -42.1 93.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.211 -0.93 . . . . 0.0 110.639 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' OE1' ' OE1' ' A' ' 9' ' ' GLN . 76.6 mt-10 -55.18 -27.38 45.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.021 -1.049 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.759 ' CD ' HD11 ' A' ' 36' ' ' ILE . 85.7 tt0 -65.38 -27.75 68.79 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 109.101 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.586 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.0 p90 -149.83 41.64 0.85 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.219 -0.926 . . . . 0.0 109.852 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.67 131.21 61.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 120.948 -1.095 . . . . 0.0 110.196 -179.817 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -75.94 -151.31 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 C-N-CA 122.061 1.841 . . . . 0.0 110.671 178.658 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -79.3 17.01 0.87 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.86 -1.15 . . . . 0.0 109.345 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.6 t -113.37 136.83 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.368 -0.832 . . . . 0.0 109.586 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.06 142.17 97.02 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.192 -0.942 . . . . 0.0 109.496 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.464 ' HD3' HD12 ' A' ' 16' ' ' LEU . 31.7 Cg_exo -49.94 -32.55 30.85 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.936 1.757 . . . . 0.0 111.938 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.33 -24.84 67.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.453 -0.779 . . . . 0.0 109.64 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -98.47 7.12 46.58 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -0.863 . . . . 0.0 109.453 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.4 t -103.8 135.16 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.315 -0.866 . . . . 0.0 108.879 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.429 ' C ' ' H ' ' A' ' 27' ' ' ASP . 88.0 m-20 -72.17 86.06 1.06 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.219 -0.925 . . . . 0.0 109.315 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.018 HG11 ' HB1' ' A' ' 8' ' ' ALA . 19.7 m -63.11 -0.3 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.233 -0.917 . . . . 0.0 109.627 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.475 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 48.0 p30 -90.7 8.52 34.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.141 -0.974 . . . . 0.0 108.787 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 18.8 tp -93.93 136.37 34.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 109.447 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -60.95 122.48 15.02 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.754 HD11 ' CG2' ' A' ' 69' ' ' ILE . 56.6 mt -66.89 -0.86 3.35 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.258 -0.901 . . . . 0.0 109.87 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.9 t -52.61 -42.47 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.089 -1.007 . . . . 0.0 108.911 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.46 -36.33 66.46 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.619 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.6 m120 -86.55 20.29 2.53 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.46 -15.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.619 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -53.33 -38.81 32.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.884 -1.363 . . . . 0.0 108.277 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.759 HD11 ' CD ' ' A' ' 14' ' ' GLU . 5.4 tt -70.87 -24.2 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.599 -0.688 . . . . 0.0 109.95 179.724 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -62.54 -22.51 66.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.181 -0.949 . . . . 0.0 110.697 -178.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -117.47 -64.87 1.24 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.081 -1.012 . . . . 0.0 111.013 -178.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.516 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -67.41 -50.2 60.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.034 -1.041 . . . . 0.0 110.171 -178.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.562 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.74 -41.24 64.13 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tt -61.1 -40.05 92.26 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.494 -1.003 . . . . 0.0 109.617 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.6 tp -58.63 -44.31 89.96 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.189 -0.944 . . . . 0.0 108.569 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.0 mtpt -65.06 -34.2 77.86 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.2 t -64.49 -39.77 86.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.495 -0.753 . . . . 0.0 110.511 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.9 mm -59.22 -50.74 78.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.637 -1.29 . . . . 0.0 109.525 -179.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.87 -41.31 83.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.292 -0.88 . . . . 0.0 109.793 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 16.8 t90 -69.77 -42.81 73.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 110.233 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 33.2 tp -59.36 -41.93 90.43 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.329 -0.857 . . . . 0.0 109.712 -179.384 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.567 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.5 tt0 -64.06 -38.12 89.92 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.238 -0.914 . . . . 0.0 109.753 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -60.07 -37.08 78.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.951 -1.093 . . . . 0.0 110.064 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -75.09 -48.68 22.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.245 -0.91 . . . . 0.0 111.958 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.509 ' CZ ' HG21 ' A' ' 80' ' ' THR . 24.7 m-85 -114.66 -3.12 12.91 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.012 -1.055 . . . . 0.0 111.855 -178.311 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 30.48 61.22 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.874 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.427 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.8 mt -78.19 138.78 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -1.217 . . . . 0.0 108.977 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 131.21 49.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.827 -1.17 . . . . 0.0 109.736 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.82 -28.5 68.41 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.448 -0.782 . . . . 0.0 109.258 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.81 -31.96 63.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.444 -0.785 . . . . 0.0 110.247 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -49.04 139.15 10.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.062 -1.024 . . . . 0.0 109.758 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.789 ' O ' HG22 ' A' ' 59' ' ' VAL . 7.7 p -157.8 29.02 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.417 -0.802 . . . . 0.0 109.207 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.03 -26.75 68.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.346 -0.847 . . . . 0.0 109.719 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.749 ' N ' HD12 ' A' ' 61' ' ' LEU . 5.6 mp -75.97 146.07 39.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.289 -0.882 . . . . 0.0 109.725 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 173.17 6.16 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.465 -0.772 . . . . 0.0 109.226 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -50.7 -31.45 32.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.222 1.948 . . . . 0.0 111.69 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.05 -30.72 71.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.423 -0.798 . . . . 0.0 109.074 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.472 ' CE1' HD23 ' A' ' 61' ' ' LEU . 46.7 t-80 -67.65 -26.55 66.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.474 -0.767 . . . . 0.0 109.802 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -91.9 10.22 29.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.181 -0.949 . . . . 0.0 109.449 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -53.61 -36.55 62.11 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.294 -0.879 . . . . 0.0 109.463 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.9 t -150.3 152.61 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.273 -0.892 . . . . 0.0 109.846 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.754 ' CG2' HD11 ' A' ' 30' ' ' LEU . 0.9 OUTLIER -64.31 -36.16 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 179.854 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -60.7 -38.07 83.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.111 -0.993 . . . . 0.0 110.107 -179.241 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.01 -37.03 85.55 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.073 -1.017 . . . . 0.0 109.16 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.5 mt -66.36 -38.43 81.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.329 -0.857 . . . . 0.0 109.29 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.1 t0 -56.25 -41.05 75.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.491 -0.756 . . . . 0.0 109.88 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.63 -45.33 79.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.205 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.699 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 65.6 t80 -63.08 -48.61 77.88 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -0.966 . . . . 0.0 109.751 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.637 HG12 ' O ' ' A' ' 80' ' ' THR . 71.9 t -66.48 -42.83 90.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.251 -0.906 . . . . 0.0 109.836 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' ' 73' ' ' ASP . 44.5 t -61.96 -40.55 87.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 120.969 -1.082 . . . . 0.0 109.693 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.84 -34.36 71.06 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.36 -50.65 3.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.133 -1.216 . . . . 0.0 110.79 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.637 ' O ' HG12 ' A' ' 76' ' ' VAL . 56.0 m -153.96 140.41 18.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.995 -1.066 . . . . 0.0 110.267 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.99 87.77 50.89 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.282 -0.886 . . . . 0.0 109.239 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -95.87 105.69 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 123.542 2.828 . . . . 0.0 112.894 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -80.36 128.36 7.06 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.098 1.865 . . . . 0.0 111.953 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.04 132.4 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.617 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.23 -38.86 92.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.266 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -162.46 150.89 14.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.304 -0.873 . . . . 0.0 109.419 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.595 ' NZ ' ' O ' ' A' ' 10' ' ' PHE . 16.6 mttm -59.76 -33.76 72.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.121 -0.987 . . . . 0.0 109.627 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 33.4 tp -95.85 130.28 42.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.474 -179.964 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.407 ' C11' HD22 ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.6 mtt . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -60.04 -37.49 79.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.935 . . . . 0.0 109.266 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.684 ' NE2' HG11 ' A' ' 6' ' ' VAL . 57.1 t-80 -148.33 8.06 0.8 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.34 -0.85 . . . . 0.0 109.724 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.63 -39.81 95.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.055 -1.028 . . . . 0.0 109.769 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.3 t -61.52 -40.08 93.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.924 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.684 HG11 ' NE2' ' A' ' 3' ' ' HIS . 78.1 t -63.27 -39.71 86.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.257 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.634 ' O ' HG23 ' A' ' 11' ' ' VAL . 92.0 mt -62.4 -46.45 96.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.346 -0.846 . . . . 0.0 110.01 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.45 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.88 -49.93 70.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 110.411 -179.327 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.436 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.91 -42.07 73.83 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.182 -0.949 . . . . 0.0 109.894 -179.677 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 9' ' ' GLN . 71.4 t80 -60.49 -46.47 90.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 7' ' ' ILE . 67.2 t -69.63 -47.01 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.44 -0.787 . . . . 0.0 109.92 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 8' ' ' ALA . 75.5 t -65.51 -35.18 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.404 -0.81 . . . . 0.0 110.453 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -53.52 -36.66 62.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.214 -0.928 . . . . 0.0 109.992 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.96 -35.57 78.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 110.771 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.662 ' O ' HD12 ' A' ' 16' ' ' LEU . 69.9 m-85 -91.74 -63.6 1.23 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.963 -1.085 . . . . 0.0 110.657 -178.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.662 HD12 ' O ' ' A' ' 15' ' ' PHE . 6.2 mp -125.66 83.06 62.76 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.331 -0.855 . . . . 0.0 110.119 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.64 -18.96 7.76 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.853 2.369 . . . . 0.0 112.202 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.866 ' OD2' HG23 ' A' ' 19' ' ' VAL . 54.4 p30 -80.11 -1.25 39.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.211 -0.931 . . . . 0.0 109.119 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.866 HG23 ' OD2' ' A' ' 18' ' ' ASP . 48.4 t -113.59 142.09 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.332 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.544 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.72 117.44 28.35 Favored Pre-proline 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 108.531 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.642 ' C ' ' HZ1' ' A' ' 87' ' ' LYS . 17.9 Cg_endo -64.9 -25.57 59.81 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.524 1.483 . . . . 0.0 111.723 -179.268 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.571 ' N ' ' NZ ' ' A' ' 87' ' ' LYS . . . -70.49 -14.87 62.7 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.31 -0.869 . . . . 0.0 109.232 179.419 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.544 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -82.87 2.91 31.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.255 -0.903 . . . . 0.0 108.929 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.13 137.27 32.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.466 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.4 89.17 0.14 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.147 -0.971 . . . . 0.0 109.377 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.7 m -62.31 -0.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.307 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -93.85 7.07 46.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 108.979 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.9 tp -95.7 137.87 34.15 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.483 -0.761 . . . . 0.0 109.6 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -61.71 121.81 13.75 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.453 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.5 OUTLIER -67.97 2.87 1.79 Allowed 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.266 -0.896 . . . . 0.0 109.932 -178.811 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.456 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -51.28 -39.19 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.08 -1.012 . . . . 0.0 108.395 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.42 -35.78 70.5 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.7 m-20 -87.09 22.14 2.14 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.009 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -14.27 0.01 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -51.26 -35.31 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.104 -1.233 . . . . 0.0 108.612 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.624 HD12 HG13 ' A' ' 11' ' ' VAL . 1.1 tt -70.07 -19.94 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.517 -0.739 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.418 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -55.53 -33.18 63.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -0.87 . . . . 0.0 111.046 -178.51 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.486 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.5 OUTLIER -116.78 -64.13 1.35 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.115 -0.991 . . . . 0.0 111.356 -178.571 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.531 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.5 mp -62.88 -52.08 64.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.99 -1.068 . . . . 0.0 110.093 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.67 -38.92 67.39 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.723 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.2 tt -58.45 -43.08 88.7 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.401 -1.058 . . . . 0.0 109.725 -179.75 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 tp -60.23 -44.32 95.31 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 108.956 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -69.72 -40.1 76.46 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.373 -0.829 . . . . 0.0 109.967 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.8 t -66.03 -45.01 91.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 110.391 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.2 mp -59.45 -50.24 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.084 -1.01 . . . . 0.0 109.513 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.401 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.62 -32.2 73.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 29.6 t90 -74.46 -45.83 43.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.878 . . . . 0.0 110.246 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.501 HD22 ' C19' ' A' ' 101' ' ' 7V9 . 9.8 tp -57.41 -45.31 84.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.362 -0.836 . . . . 0.0 110.009 -178.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.414 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 8.4 pt-20 -71.23 -36.42 71.82 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.098 -1.001 . . . . 0.0 109.056 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.9 t0 -64.78 -41.45 95.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.322 -0.861 . . . . 0.0 110.639 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.4 ttt180 -83.78 -51.56 7.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 110.95 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.743 ' CE2' HG21 ' A' ' 80' ' ' THR . 92.7 m-85 -79.85 -24.55 41.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.05 -1.031 . . . . 0.0 110.842 -178.706 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.41 31.44 54.54 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 53.9 mt -109.4 134.28 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -1.085 . . . . 0.0 109.582 -179.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.93 143.39 57.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.352 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.79 73.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -56.96 -35.52 69.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.252 -0.905 . . . . 0.0 109.74 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -53.84 -33.74 57.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.767 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.785 HG11 ' O13' ' A' ' 101' ' ' 7V9 . 45.6 t -97.49 137.32 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.144 -0.973 . . . . 0.0 109.758 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -78.66 142.83 36.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.573 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 33.0 mt -95.08 137.36 34.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.399 -0.813 . . . . 0.0 109.654 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 178.56 145.66 0.34 Allowed Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.973 . . . . 0.0 109.665 179.514 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.89 -26.88 74.53 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.481 2.121 . . . . 0.0 112.281 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -57.65 -27.42 62.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.843 . . . . 0.0 109.654 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.518 ' NE2' HG23 ' A' ' 72' ' ' ILE . 85.9 t60 -67.13 -26.92 66.91 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.941 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -101.1 4.25 42.01 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.028 -1.045 . . . . 0.0 110.373 -179.46 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -58.86 -40.94 85.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.887 -1.133 . . . . 0.0 109.86 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.1 p -150.06 154.89 38.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.903 -1.123 . . . . 0.0 110.019 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 87.6 mt -65.33 -37.36 79.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.343 -0.848 . . . . 0.0 109.857 179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.7 ttp180 -60.93 -40.43 93.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 110.164 -179.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -59.58 -41.85 91.19 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.999 -1.063 . . . . 0.0 109.695 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.518 HG23 ' NE2' ' A' ' 65' ' ' HIS . 87.2 mt -67.43 -39.96 83.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.258 -0.901 . . . . 0.0 110.005 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.455 ' HA ' HD11 ' A' ' 7' ' ' ILE . 52.5 t0 -59.16 -40.79 86.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 110.188 -179.405 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.53 -42.71 98.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.129 -0.982 . . . . 0.0 109.586 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.689 ' CZ ' HG13 ' A' ' 59' ' ' VAL . 66.0 t80 -63.74 -45.34 90.34 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.247 -0.908 . . . . 0.0 109.336 179.736 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.7 t -63.75 -45.36 97.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.355 -0.841 . . . . 0.0 109.915 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.0 t -60.97 -40.09 84.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 O-C-N 121.125 -0.984 . . . . 0.0 109.637 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.76 -32.25 65.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.15 -50.17 3.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.084 -1.245 . . . . 0.0 110.403 -179.353 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.743 HG21 ' CE2' ' A' ' 52' ' ' PHE . 8.4 t -146.22 155.61 42.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.171 -0.956 . . . . 0.0 110.021 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -133.21 88.55 35.54 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.317 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -67.18 159.4 52.32 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.588 2.192 . . . . 0.0 112.239 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.76 150.82 84.28 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.915 2.41 . . . . 0.0 112.165 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.1 141.05 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.382 -0.824 . . . . 0.0 109.427 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.404 ' H ' ' H ' ' A' ' 86' ' ' ALA . 80.1 tt0 -173.59 -7.54 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.335 -0.853 . . . . 0.0 109.105 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.404 ' H ' ' H ' ' A' ' 85' ' ' GLU . . . -58.71 -39.18 80.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.015 -1.053 . . . . 0.0 109.815 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.642 ' HZ1' ' C ' ' A' ' 21' ' ' PRO . 49.3 mttm -106.65 146.74 30.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 109.41 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.462 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 69.7 mt -59.43 -35.8 74.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.238 -0.914 . . . . 0.0 109.822 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.462 ' OXT' ' O ' ' A' ' 88' ' ' LEU . 30.2 mm100 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.465 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.785 ' O13' HG11 ' A' ' 59' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtt . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.313 0.578 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.496 ' O ' HG22 ' A' ' 84' ' ' VAL . 93.4 mt-30 -59.43 -38.34 80.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.381 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.583 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 49.4 m80 -136.39 11.84 3.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.334 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.75 -33.24 71.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.347 -0.846 . . . . 0.0 109.918 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.35 -35.3 77.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.097 -1.002 . . . . 0.0 109.552 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.26 -37.83 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.184 -0.947 . . . . 0.0 109.167 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 11' ' ' VAL . 87.3 mt -63.55 -43.27 98.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.067 -1.021 . . . . 0.0 110.089 -179.84 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.655 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.22 -50.67 67.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.789 -179.178 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.5 -36.93 74.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.958 -1.088 . . . . 0.0 110.065 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -59.4 -51.3 70.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.844 -1.16 . . . . 0.0 110.082 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.589 HG22 ' O ' ' A' ' 7' ' ' ILE . 20.4 m -74.3 -40.64 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.142 -0.973 . . . . 0.0 110.32 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.7 t -62.49 -39.38 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.257 -0.902 . . . . 0.0 110.502 -179.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -61.86 -32.56 72.92 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.128 -0.982 . . . . 0.0 110.02 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.37 -33.24 75.28 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.869 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 11' ' ' VAL . 62.3 m-85 -93.1 -63.86 1.16 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.162 -0.961 . . . . 0.0 110.451 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.8 mt -129.52 83.47 64.74 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.289 -0.882 . . . . 0.0 110.594 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.22 -13.88 13.6 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.613 2.209 . . . . 0.0 112.169 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.69 -4.46 43.32 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.136 -0.978 . . . . 0.0 108.869 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.89 141.02 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.578 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.81 119.69 50.16 Favored Pre-proline 0 C--N 1.304 -1.404 0 O-C-N 120.905 -1.122 . . . . 0.0 108.74 -179.684 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -64.84 -27.61 59.24 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 121.54 1.493 . . . . 0.0 111.924 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . . . -70.56 -14.84 62.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.443 -0.786 . . . . 0.0 109.213 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.578 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.1 m-20 -83.3 4.13 28.48 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.42 -0.8 . . . . 0.0 109.18 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.5 t -102.09 136.88 32.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.45 -0.781 . . . . 0.0 108.906 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' A' ' 27' ' ' ASP . 47.6 p30 -67.48 84.36 0.17 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.225 -0.922 . . . . 0.0 109.734 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.414 HG22 ' HE3' ' A' ' 87' ' ' LYS . 13.7 m -60.4 0.23 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.263 179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -88.25 3.75 48.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 108.87 179.504 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.92 139.82 30.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.524 -0.735 . . . . 0.0 109.45 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -60.93 121.73 13.11 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 179.338 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -66.23 1.41 1.56 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.146 -0.971 . . . . 0.0 109.927 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.7 -39.16 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.038 -1.038 . . . . 0.0 108.29 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.458 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.93 -34.94 72.3 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.107 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.61 ' O ' ' N ' ' A' ' 35' ' ' VAL . 4.8 m-20 -84.11 16.5 2.9 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.54 -15.12 0.02 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.01 -36.44 15.89 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.922 -1.34 . . . . 0.0 108.769 179.751 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.588 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.0 tt -70.54 -19.53 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.469 -0.769 . . . . 0.0 109.774 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -55.94 -31.73 63.19 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.324 -0.86 . . . . 0.0 111.228 -178.422 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.9 m -118.89 -64.71 1.25 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.099 -1.0 . . . . 0.0 111.334 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -61.68 -52.18 65.39 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.76 -1.213 . . . . 0.0 109.891 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.68 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.44 -38.27 62.27 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.588 ' N ' ' O ' ' A' ' 36' ' ' ILE . 30.5 tp -58.54 -44.2 89.52 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.343 -1.093 . . . . 0.0 109.979 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.445 HD23 ' HA ' ' A' ' 42' ' ' LEU . 86.1 mt -61.71 -43.82 98.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.117 -0.989 . . . . 0.0 109.287 179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -62.65 -34.91 78.03 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.239 -0.913 . . . . 0.0 108.916 179.206 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.0 t -62.74 -39.8 86.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.529 -0.732 . . . . 0.0 110.136 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.581 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 33.7 mm -58.6 -50.3 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.008 -1.057 . . . . 0.0 109.734 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.15 -37.64 84.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.722 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.0 t90 -70.48 -44.6 67.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.962 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.672 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 12.3 tp -58.34 -47.12 84.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 109.63 -179.186 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.413 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -66.82 -37.39 84.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -0.929 . . . . 0.0 109.11 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.13 -42.13 84.95 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 110.668 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.3 ttt-85 -87.37 -58.48 2.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.257 -0.902 . . . . 0.0 111.809 -178.294 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.405 ' CD1' HD12 ' A' ' 48' ' ' LEU . 88.8 m-85 -79.85 -19.46 48.29 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 111.599 -177.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 33.05 41.11 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.413 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.1 mt -102.8 141.87 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.375 -1.074 . . . . 0.0 109.374 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.88 145.01 54.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.254 -0.904 . . . . 0.0 109.854 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.581 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -65.9 -19.27 65.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.538 -0.726 . . . . 0.0 109.876 -179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.485 ' O ' ' O ' ' A' ' 58' ' ' ASP . 92.2 m-20 -52.85 -37.27 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.17 -0.956 . . . . 0.0 109.371 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.485 ' O ' ' O ' ' A' ' 57' ' ' ASP . 94.1 m-20 52.42 172.44 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.274 -0.891 . . . . 0.0 109.231 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.1 p -136.67 142.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.266 -0.896 . . . . 0.0 110.161 -179.493 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.625 ' C ' HD23 ' A' ' 61' ' ' LEU . 84.7 tt0 52.92 77.52 0.16 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.43 -0.794 . . . . 0.0 110.187 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.84 HD23 ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -104.23 127.13 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.302 -0.874 . . . . 0.0 109.168 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.17 148.01 17.23 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 120.962 -1.086 . . . . 0.0 109.712 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.74 -25.64 74.95 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.68 2.253 . . . . 0.0 112.235 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.36 -31.46 71.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 109.727 -179.69 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 48.6 t-80 -68.63 -25.93 65.09 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.446 -0.784 . . . . 0.0 111.127 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -95.6 5.86 50.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.743 -1.223 . . . . 0.0 110.92 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 -60.21 -37.53 80.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.895 -1.128 . . . . 0.0 110.353 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.3 p -133.38 147.44 51.79 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.076 -1.015 . . . . 0.0 110.07 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.437 HG23 ' CG2' ' A' ' 7' ' ' ILE . 78.1 mt -66.38 -36.71 78.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 O-C-N 121.432 -0.793 . . . . 0.0 109.797 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 92.3 mtm-85 -60.97 -37.97 84.28 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.346 -0.846 . . . . 0.0 110.099 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.3 p -61.72 -35.92 79.45 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.107 -0.996 . . . . 0.0 109.458 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.566 ' HB ' HD13 ' A' ' 7' ' ' ILE . 61.8 mt -66.71 -39.02 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.238 -0.914 . . . . 0.0 109.174 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.532 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.8 t0 -59.1 -39.44 82.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.333 -0.855 . . . . 0.0 109.779 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.27 -44.2 92.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.1 -1.0 . . . . 0.0 109.654 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -63.42 -46.17 87.57 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.242 -0.911 . . . . 0.0 109.387 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -64.43 -43.36 96.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.346 -0.846 . . . . 0.0 109.739 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 73' ' ' ASP . 51.1 t -60.35 -40.83 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 O-C-N 121.24 -0.913 . . . . 0.0 109.659 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.31 -32.56 72.57 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.88 -50.41 3.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.063 -1.257 . . . . 0.0 110.719 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.4 p -131.79 157.9 42.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.283 -0.885 . . . . 0.0 109.827 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.82 87.99 16.43 Favored Pre-proline 0 C--N 1.304 -1.408 0 O-C-N 121.182 -0.949 . . . . 0.0 109.434 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.583 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 14.4 Cg_exo -65.03 -177.96 0.69 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.553 2.169 . . . . 0.0 112.008 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.421 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.2 Cg_exo -61.1 148.57 92.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.499 2.133 . . . . 0.0 111.845 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.496 HG22 ' O ' ' A' ' 2' ' ' GLN . 43.4 t -111.97 130.83 64.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.345 -0.847 . . . . 0.0 109.571 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.41 156.78 47.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.453 -0.779 . . . . 0.0 109.364 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.8 144.61 54.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -0.934 . . . . 0.0 109.303 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.421 ' NZ ' ' O ' ' A' ' 22' ' ' ALA . 63.8 tttm -57.95 -37.19 73.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.47 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.3 mt -93.89 141.82 28.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.457 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.672 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.642 ' NE2' ' OD1' ' A' ' 73' ' ' ASP . 28.1 mt-30 -83.71 21.79 1.2 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 109.352 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.439 ' H ' ' HG2' ' A' ' 1' ' ' MET . 30.9 m80 60.94 43.42 11.69 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.025 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.521 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -55.68 -34.86 65.41 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.471 -0.768 . . . . 0.0 109.658 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -58.89 -39.35 81.18 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.229 -0.919 . . . . 0.0 109.01 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.0 t -67.78 -39.25 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.401 -0.812 . . . . 0.0 109.004 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 4' ' ' ALA . 90.9 mt -58.95 -50.05 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.479 -0.763 . . . . 0.0 109.634 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.62 -45.75 88.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.353 -0.842 . . . . 0.0 109.668 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.43 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -69.03 -33.75 74.12 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.365 -0.834 . . . . 0.0 109.694 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.565 ' CE1' ' CZ2' ' A' ' 47' ' ' TRP . 61.7 t80 -64.96 -51.49 61.5 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.091 -1.005 . . . . 0.0 109.694 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.494 HG23 ' N ' ' A' ' 12' ' ' VAL . 15.8 m -74.49 -40.39 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.308 -0.87 . . . . 0.0 110.098 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 8' ' ' ALA . 77.4 t -62.05 -37.8 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.203 -0.936 . . . . 0.0 110.122 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -56.75 -36.7 70.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.33 -0.856 . . . . 0.0 109.752 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -68.16 -35.87 78.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 110.681 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -89.78 -63.01 1.34 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.025 -1.047 . . . . 0.0 110.618 -178.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mt -127.36 82.91 67.35 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.302 -0.874 . . . . 0.0 110.113 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -81.01 -18.7 8.72 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.699 2.266 . . . . 0.0 112.125 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.83 -4.14 42.05 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.226 -0.921 . . . . 0.0 109.017 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.57 141.6 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.621 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.71 119.1 44.48 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.0 -1.063 . . . . 0.0 108.599 -179.566 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.73 -30.5 59.36 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.612 1.541 . . . . 0.0 112.052 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.75 -14.73 62.55 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.374 -0.829 . . . . 0.0 109.001 179.416 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.621 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -86.53 4.73 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.547 -0.72 . . . . 0.0 109.116 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -98.74 135.59 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -70.37 83.26 0.56 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.19 -0.944 . . . . 0.0 109.651 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -63.47 -0.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 109.117 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 50.6 p30 -100.39 9.83 42.08 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.248 -0.907 . . . . 0.0 109.195 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.7 tp -92.02 145.39 24.57 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.481 -0.762 . . . . 0.0 109.434 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -60.02 121.4 11.75 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.606 HD11 ' CG1' ' A' ' 69' ' ' ILE . 76.4 mt -61.81 -11.73 13.89 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.436 -0.79 . . . . 0.0 109.97 -178.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' ' 67' ' ' ARG . 22.8 t -50.53 -45.33 26.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.801 -1.187 . . . . 0.0 108.678 -179.593 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -57.61 -35.34 70.33 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.382 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.602 ' O ' ' N ' ' A' ' 35' ' ' VAL . 10.6 m120 -86.9 19.04 3.17 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.05 -18.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.276 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.602 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.5 t -52.8 -38.85 29.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.234 -1.157 . . . . 0.0 108.505 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -70.4 -24.05 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.555 -0.716 . . . . 0.0 109.375 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -56.3 -33.01 65.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.513 -0.742 . . . . 0.0 110.919 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -113.78 -64.47 1.31 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.159 -0.963 . . . . 0.0 111.098 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.537 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.6 mp -64.01 -50.44 68.5 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.955 -1.091 . . . . 0.0 110.188 -178.759 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.511 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.53 -40.55 67.39 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.73 -40.55 84.1 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.45 -1.029 . . . . 0.0 109.505 -179.552 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.3 tp -65.92 -44.24 85.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -65.22 -37.47 87.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.263 -0.898 . . . . 0.0 110.005 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.59 HG12 ' C18' ' A' ' 101' ' ' 7V9 . 73.4 t -62.28 -43.26 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.351 -0.843 . . . . 0.0 110.073 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.401 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.5 mp -62.87 -50.42 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.244 -0.91 . . . . 0.0 109.911 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.01 -34.91 78.76 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.267 -0.895 . . . . 0.0 110.16 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.565 ' CZ2' ' CE1' ' A' ' 10' ' ' PHE . 3.8 t90 -66.99 -44.39 80.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 0.0 109.946 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.7 tp -57.51 -43.98 84.67 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.406 -0.809 . . . . 0.0 109.716 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -66.31 -38.54 87.96 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.221 -0.924 . . . . 0.0 109.401 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.86 -41.06 95.98 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.147 -0.97 . . . . 0.0 110.648 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -87.17 -58.37 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.104 -0.998 . . . . 0.0 111.644 -178.442 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -79.73 -19.99 47.49 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.1 -1.0 . . . . 0.0 111.587 -177.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 30.23 50.97 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -179.54 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.43 142.39 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.412 -1.052 . . . . 0.0 109.421 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.36 154.03 25.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.189 -0.944 . . . . 0.0 109.217 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.12 -40.15 67.08 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.233 -0.917 . . . . 0.0 109.542 -179.328 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.413 ' O ' HG23 ' A' ' 59' ' ' VAL . 86.1 m-20 51.45 47.84 24.06 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.173 -0.955 . . . . 0.0 109.311 179.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -59.87 133.78 56.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.202 -0.936 . . . . 0.0 109.717 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 57' ' ' ASP . 39.2 t -126.85 139.81 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.52 -0.737 . . . . 0.0 109.279 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -68.29 88.59 0.31 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.976 . . . . 0.0 109.74 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.6 mt -111.98 142.28 44.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.535 -0.728 . . . . 0.0 109.43 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.15 159.24 80.77 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.302 -0.874 . . . . 0.0 109.739 -179.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -60.17 -22.98 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.926 2.417 . . . . 0.0 112.168 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.5 -31.14 71.84 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 110.028 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -67.76 -26.71 66.26 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.47 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 28.2 m-85 -97.07 2.66 51.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.193 -0.942 . . . . 0.0 109.281 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.577 ' HG3' HG23 ' A' ' 31' ' ' VAL . 56.0 ttp180 -56.15 -39.62 72.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.476 -0.765 . . . . 0.0 110.524 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 91.2 p -119.66 148.91 42.8 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.415 -0.803 . . . . 0.0 110.463 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.606 ' CG1' HD11 ' A' ' 30' ' ' LEU . 79.7 mt -65.89 -36.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.679 -0.638 . . . . 0.0 109.981 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -61.5 -39.21 90.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 110.231 -179.312 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 19.7 m -60.74 -44.14 97.05 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.018 -1.051 . . . . 0.0 109.529 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.647 ' O ' HG23 ' A' ' 76' ' ' VAL . 79.0 mt -67.13 -39.61 83.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.338 -0.852 . . . . 0.0 109.237 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.863 ' O ' HG23 ' A' ' 77' ' ' VAL . 38.6 t0 -57.5 -38.18 74.18 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.541 -0.724 . . . . 0.0 109.617 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.72 -46.24 89.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.954 -1.091 . . . . 0.0 109.434 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -67.06 -47.47 71.2 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.159 -0.963 . . . . 0.0 108.861 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.721 HG12 ' OG1' ' A' ' 81' ' ' THR . 34.1 t -63.17 -40.11 87.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.863 HG23 ' O ' ' A' ' 73' ' ' ASP . 38.0 t -55.63 -42.42 68.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 O-C-N 121.292 -0.88 . . . . 0.0 108.876 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.54 69.14 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.79 -1.724 . . . . 0.0 108.79 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.63 ' C ' HG22 ' A' ' 80' ' ' THR . . . -67.9 -47.55 68.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -1.098 . . . . 0.0 110.213 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.63 HG22 ' C ' ' A' ' 79' ' ' ALA . 0.0 OUTLIER 172.49 2.59 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.045 -1.034 . . . . 0.0 111.328 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.721 ' OG1' HG12 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -75.04 142.88 76.61 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 120.665 -1.272 . . . . 0.0 108.439 179.638 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.459 ' C ' ' O ' ' A' ' 81' ' ' THR . 89.3 Cg_exo -26.65 125.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.318 -1.078 0 C-N-CA 123.024 2.483 . . . . 0.0 112.802 -178.793 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -76.43 150.64 32.43 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 122.572 2.182 . . . . 0.0 113.312 -179.361 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.485 HG22 ' H ' ' A' ' 86' ' ' ALA . 12.7 p -133.35 142.03 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.448 -0.782 . . . . 0.0 109.139 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -58.8 -36.02 73.78 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -0.945 . . . . 0.0 109.669 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.485 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -153.0 153.38 32.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.063 -1.023 . . . . 0.0 109.72 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -58.74 -38.28 78.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.862 . . . . 0.0 109.392 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.432 ' O ' ' C ' ' A' ' 89' ' ' GLN . 54.0 mt -96.74 142.2 29.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.399 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.432 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.426 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.59 ' C18' HG12 ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ptp . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.416 -0.586 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.672 ' CG ' HG12 ' A' ' 84' ' ' VAL . 91.9 mt-30 55.92 43.31 27.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.367 -0.833 . . . . 0.0 109.437 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.451 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.9 m170 42.86 38.7 1.46 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.185 -0.947 . . . . 0.0 109.014 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.498 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.94 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 109.722 -179.59 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.7 p -61.42 -37.52 83.8 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.065 -1.022 . . . . 0.0 109.325 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.5 t -68.5 -38.71 79.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.19 -0.944 . . . . 0.0 108.83 179.104 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.498 HD12 ' HA ' ' A' ' 4' ' ' ALA . 86.4 mt -60.27 -51.72 69.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.35 -0.844 . . . . 0.0 109.274 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.589 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -65.33 -47.16 77.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.38 -0.825 . . . . 0.0 109.591 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.7 -44.2 94.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.572 -0.705 . . . . 0.0 109.451 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.401 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.9 t80 -62.15 -48.24 80.98 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.53 -0.731 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 7' ' ' ILE . 85.3 t -69.71 -44.5 79.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.461 -0.774 . . . . 0.0 109.696 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.2 t -66.86 -39.5 83.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.428 -0.795 . . . . 0.0 110.183 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -53.68 -28.92 36.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.184 -0.947 . . . . 0.0 109.957 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.24 -30.43 71.31 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.533 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.575 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.5 p90 -146.73 44.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.832 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.67 130.78 63.04 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.078 -1.014 . . . . 0.0 109.978 -179.94 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 70.7 Cg_endo -76.66 -152.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 121.975 1.783 . . . . 0.0 110.626 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -78.37 16.99 0.7 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.924 -1.11 . . . . 0.0 108.997 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.402 ' H ' ' C ' ' A' ' 17' ' ' PRO . 42.5 t -113.27 137.0 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.493 -0.755 . . . . 0.0 109.755 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.63 141.53 95.29 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.435 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.45 ' O ' HG12 ' A' ' 24' ' ' VAL . 34.8 Cg_exo -49.66 -31.91 26.67 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 121.911 1.741 . . . . 0.0 112.042 179.479 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.6 -23.91 66.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.345 -0.847 . . . . 0.0 109.714 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.28 8.53 44.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.351 -0.843 . . . . 0.0 109.32 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.45 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.5 OUTLIER -88.86 142.52 12.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.327 -0.858 . . . . 0.0 108.814 179.813 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -70.09 84.83 0.53 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.168 -0.958 . . . . 0.0 109.487 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.6 m -64.5 -0.26 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.258 -0.901 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.421 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -98.45 11.17 39.03 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.34 -0.85 . . . . 0.0 108.969 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -88.08 136.5 32.94 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.475 -0.766 . . . . 0.0 109.562 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -61.93 122.02 14.41 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.5 mt -56.21 -16.1 4.82 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.423 -0.798 . . . . 0.0 109.542 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.2 t -50.9 -43.05 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.064 -1.023 . . . . 0.0 109.125 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.24 -37.97 70.46 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.4 m-20 -91.18 22.33 3.85 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.195 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.72 -15.5 0.02 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.5 p -53.89 -33.81 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.013 -1.286 . . . . 0.0 108.891 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.591 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.9 tt -70.99 -19.04 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.51 -0.744 . . . . 0.0 109.673 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 82.1 m-20 -58.05 -31.32 66.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.434 -0.791 . . . . 0.0 111.451 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.7 m -116.39 -64.91 1.25 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.985 -1.072 . . . . 0.0 111.327 -178.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -64.0 -50.72 67.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 110.06 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.434 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.85 -40.1 64.37 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.591 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.8 tp -58.77 -40.88 85.24 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.469 -1.018 . . . . 0.0 109.671 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.91 -44.31 96.44 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.75 -40.22 88.2 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.273 -0.892 . . . . 0.0 109.981 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.9 t -65.1 -42.01 93.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.345 -0.847 . . . . 0.0 110.199 -179.377 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.643 HD11 ' S12' ' A' ' 101' ' ' 7V9 . 1.1 mp -60.79 -50.61 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.219 -0.926 . . . . 0.0 109.837 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.437 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.52 -30.83 71.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.188 -0.945 . . . . 0.0 109.365 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.732 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 55.4 t90 -73.13 -47.09 47.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.395 -0.815 . . . . 0.0 110.118 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.83 -45.29 94.44 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -67.13 -36.62 82.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.272 -0.892 . . . . 0.0 109.803 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -62.12 -44.08 97.42 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.703 -179.369 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.732 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 82.1 mtt180 -87.04 -51.43 6.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.05 -1.031 . . . . 0.0 111.52 -178.758 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.416 ' CE2' HG21 ' A' ' 80' ' ' THR . 96.6 m-85 -80.11 -24.58 40.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.005 -1.059 . . . . 0.0 111.223 -178.306 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.09 26.71 59.52 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.7 mt -104.87 143.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -1.121 . . . . 0.0 109.354 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.98 156.54 17.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.185 -0.947 . . . . 0.0 109.692 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.14 -20.14 6.2 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.4 -0.813 . . . . 0.0 109.526 -179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 56.9 46.56 19.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.491 -0.756 . . . . 0.0 109.91 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.433 ' CG ' ' O8 ' ' A' ' 101' ' ' 7V9 . 88.1 m-20 -96.96 19.4 12.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -0.803 . . . . 0.0 109.088 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.9 t -55.35 -41.56 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 110.613 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.497 ' C ' HD22 ' A' ' 61' ' ' LEU . 80.4 tt0 -159.08 64.08 0.4 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.858 -1.151 . . . . 0.0 110.219 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.497 HD22 ' C ' ' A' ' 60' ' ' GLU . 3.5 mm? -104.04 141.46 36.17 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.097 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.84 162.25 50.69 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.384 -0.823 . . . . 0.0 109.81 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.1 -25.25 79.34 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.942 2.428 . . . . 0.0 112.237 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.43 -31.45 72.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -67.92 -26.21 65.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -0.842 . . . . 0.0 109.939 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -94.16 16.45 14.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.365 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 tpt180 -53.41 -39.16 64.1 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.334 -0.854 . . . . 0.0 110.018 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.0 p -150.85 165.9 32.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.923 -1.111 . . . . 0.0 110.271 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 95.0 mt -59.31 -36.51 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.378 -0.826 . . . . 0.0 110.078 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.6 mtm180 -60.49 -39.2 86.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 110.077 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.3 m -61.43 -42.89 99.45 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.994 -1.066 . . . . 0.0 109.428 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.4 mt -64.91 -38.41 82.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.249 -0.907 . . . . 0.0 109.32 179.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.807 ' O ' HG23 ' A' ' 77' ' ' VAL . 92.4 m-20 -56.06 -37.45 69.29 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.286 -0.884 . . . . 0.0 109.219 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.15 -43.73 98.19 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.26 -0.9 . . . . 0.0 109.061 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -63.91 -47.5 80.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.154 179.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.7 t -64.4 -40.44 89.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.389 -0.82 . . . . 0.0 109.288 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.807 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.4 t -58.32 -44.02 87.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.333 -0.854 . . . . 0.0 109.615 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -64.77 -41.49 97.57 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.52 -49.53 16.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.135 -1.215 . . . . 0.0 109.645 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.416 HG21 ' CE2' ' A' ' 52' ' ' PHE . 22.1 p -128.32 157.31 41.31 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.33 87.84 11.73 Favored Pre-proline 0 C--N 1.302 -1.472 0 O-C-N 121.058 -1.026 . . . . 0.0 110.261 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -68.72 -178.2 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.486 2.124 . . . . 0.0 111.26 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.562 ' O ' ' N ' ' A' ' 2' ' ' GLN . 23.2 Cg_exo -60.19 148.49 89.55 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.2 1.933 . . . . 0.0 111.429 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.672 HG12 ' CG ' ' A' ' 2' ' ' GLN . 16.7 m -125.16 141.72 44.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.262 -0.899 . . . . 0.0 109.921 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.733 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 78.1 mm-40 -142.23 -40.41 0.35 Allowed 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.353 -0.842 . . . . 0.0 109.201 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.733 ' HB2' ' O ' ' A' ' 85' ' ' GLU . . . 160.28 95.23 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.423 -0.798 . . . . 0.0 109.368 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -57.72 -38.39 75.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.121 -0.987 . . . . 0.0 109.358 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 31.0 tp -102.92 130.34 49.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.387 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.496 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.643 ' S12' HD11 ' A' ' 45' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.481 0.657 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.58 119.09 36.7 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.48 -0.763 . . . . 0.0 108.985 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 32.0 m80 50.49 36.09 12.7 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.142 -0.974 . . . . 0.0 109.027 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.446 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.56 -35.58 76.39 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.39 -0.819 . . . . 0.0 109.78 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 t -59.53 -40.57 87.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.722 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.39 -40.02 87.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 0.0 109.165 179.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.469 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 91.8 mt -59.66 -50.15 81.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.36 -0.837 . . . . 0.0 109.512 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.707 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.91 -45.19 90.43 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 108.904 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.4 -39.65 92.44 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.533 -0.729 . . . . 0.0 109.651 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 61.0 t80 -60.66 -52.04 66.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.446 -0.784 . . . . 0.0 110.029 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.474 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.8 p -74.08 -40.56 51.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.902 . . . . 0.0 109.844 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.707 HG23 ' O ' ' A' ' 8' ' ' ALA . 94.2 t -66.69 -40.0 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.395 -0.816 . . . . 0.0 110.315 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -56.17 -27.63 55.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.228 -0.92 . . . . 0.0 109.574 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -65.04 -32.09 73.64 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.342 -0.849 . . . . 0.0 109.724 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -144.2 44.46 1.43 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.066 -1.021 . . . . 0.0 109.92 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.833 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.46 131.46 61.54 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.085 -1.009 . . . . 0.0 110.048 -179.981 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.46 -150.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.314 -1.277 0 C-N-CA 121.954 1.769 . . . . 0.0 110.655 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.562 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.6 p30 -78.36 13.04 1.67 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.133 . . . . 0.0 109.324 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.562 HG23 ' OD1' ' A' ' 18' ' ' ASP . 42.2 t -113.53 135.48 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.483 -0.761 . . . . 0.0 109.612 -179.796 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.09 142.43 87.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.312 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD3' HD12 ' A' ' 16' ' ' LEU . 47.2 Cg_exo -48.49 -32.12 19.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.969 1.78 . . . . 0.0 111.814 179.428 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.78 -25.97 67.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.419 -0.801 . . . . 0.0 109.447 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -97.69 4.75 49.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.361 -0.837 . . . . 0.0 109.386 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -103.55 137.41 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.52 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -63.78 95.9 0.12 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.404 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.3 m -59.57 0.48 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.168 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.52 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.6 m-20 -87.99 11.24 16.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.362 -0.836 . . . . 0.0 108.939 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 35.2 tp -82.59 134.12 35.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 109.395 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -67.07 121.85 16.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.342 -0.849 . . . . 0.0 108.871 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.642 HD11 HG12 ' A' ' 69' ' ' ILE . 82.6 mt -59.28 -14.1 10.14 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.303 -0.873 . . . . 0.0 109.198 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.412 ' O ' ' N ' ' A' ' 34' ' ' GLY . 42.1 t -50.44 -42.34 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 O-C-N 121.179 -0.951 . . . . 0.0 108.89 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.62 -35.32 65.74 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 178.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.608 ' O ' ' N ' ' A' ' 35' ' ' VAL . 8.5 m120 -86.27 21.55 2.03 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.0 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.162 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.608 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.0 t -53.05 -40.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.766 -1.432 . . . . 0.0 108.228 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.653 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.2 tt -71.15 -24.11 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.575 -0.703 . . . . 0.0 109.924 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 83.5 m-20 -62.11 -27.54 69.0 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.957 -1.09 . . . . 0.0 110.975 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.546 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.3 OUTLIER -106.18 -65.73 1.05 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.801 -1.187 . . . . 0.0 111.055 -178.766 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -73.73 -51.24 17.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.951 -1.093 . . . . 0.0 110.61 -178.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.75 -36.32 92.11 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.655 HD11 ' C10' ' A' ' 101' ' ' 7V9 . 8.1 tt -57.95 -43.14 86.2 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.208 -1.172 . . . . 0.0 109.2 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.9 mt -60.96 -44.1 97.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.094 -1.004 . . . . 0.0 108.694 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -69.97 -35.45 74.46 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.423 -0.798 . . . . 0.0 109.84 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.732 HG23 ' O ' ' A' ' 40' ' ' GLY . 81.1 t -64.78 -49.85 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.339 -0.851 . . . . 0.0 110.849 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -60.41 -47.82 90.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 120.944 -1.097 . . . . 0.0 109.51 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.46 -32.95 74.64 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.179 -0.951 . . . . 0.0 109.232 179.7 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 39.4 t90 -71.67 -47.46 54.09 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.24 -0.912 . . . . 0.0 109.927 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.525 HD22 ' C18' ' A' ' 101' ' ' 7V9 . 26.5 tp -59.81 -44.98 93.72 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.318 -0.864 . . . . 0.0 109.687 -179.328 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.478 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 80.3 tt0 -68.62 -34.88 76.51 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 110.057 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.21 -38.49 80.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.008 -1.058 . . . . 0.0 110.028 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.536 ' NE ' ' CZ2' ' A' ' 47' ' ' TRP . 34.2 mtm105 -86.39 -48.52 8.38 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.149 -0.969 . . . . 0.0 111.497 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -90.9 -24.44 20.2 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.8 -1.187 . . . . 0.0 111.219 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 79.35 50.03 5.95 Favored Glycine 0 N--CA 1.496 2.689 0 C-N-CA 119.588 -1.292 . . . . 0.0 110.525 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.478 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 65.2 mt -108.04 140.94 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.199 -1.177 . . . . 0.0 109.21 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.53 141.11 57.95 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.937 -1.102 . . . . 0.0 109.334 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.51 -29.25 70.42 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.574 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -82.89 1.02 41.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.339 -0.85 . . . . 0.0 109.826 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.2 -31.53 61.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.615 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.5 m -122.47 159.73 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.502 -0.749 . . . . 0.0 109.403 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -99.12 169.4 9.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.399 -0.813 . . . . 0.0 109.954 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.865 HD23 ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -76.83 125.56 29.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.455 -0.778 . . . . 0.0 109.222 -179.499 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.712 ' H ' ' C8 ' ' A' ' 101' ' ' 7V9 . 4.0 p -142.77 87.34 9.04 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.16 -0.963 . . . . 0.0 109.955 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -53.37 -34.31 70.39 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.346 2.031 . . . . 0.0 111.61 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -68.08 -14.32 62.89 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.525 -0.735 . . . . 0.0 109.148 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.604 ' CE1' HG23 ' A' ' 72' ' ' ILE . 21.7 t-80 -66.2 -26.32 67.34 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.432 -0.792 . . . . 0.0 110.062 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.667 ' HA ' HD11 ' A' ' 72' ' ' ILE . 97.4 m-85 -92.45 9.05 35.98 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.006 -1.058 . . . . 0.0 109.597 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.4 tpt180 -54.7 -35.98 64.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.8 p -150.82 149.39 29.65 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.215 -0.928 . . . . 0.0 110.023 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.642 HG12 HD11 ' A' ' 30' ' ' LEU . 81.6 mt -66.56 -39.33 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.425 -0.797 . . . . 0.0 110.264 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.428 HH22 ' HA ' ' A' ' 27' ' ' ASP . 93.0 mtm-85 -61.35 -39.99 92.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -0.906 . . . . 0.0 110.373 -178.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 t -60.63 -45.91 92.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.985 -1.072 . . . . 0.0 109.425 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.667 HD11 ' HA ' ' A' ' 66' ' ' PHE . 79.0 mt -63.91 -38.74 83.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.85 . . . . 0.0 109.709 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.469 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 55.9 t0 -57.54 -42.28 82.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 110.256 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.76 -46.09 76.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 110.502 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -63.36 -45.1 92.71 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.099 -1.0 . . . . 0.0 109.496 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.1 t -68.18 -47.6 77.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.219 -0.926 . . . . 0.0 110.159 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 45.4 t -68.28 -44.22 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.051 -1.031 . . . . 0.0 110.023 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.02 -27.0 68.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.27 -50.12 3.55 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.199 -1.177 . . . . 0.0 111.143 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.529 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.2 m -134.91 140.1 45.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.107 -0.995 . . . . 0.0 110.864 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.34 88.4 53.07 Favored Pre-proline 0 N--CA 1.488 1.445 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -81.97 159.97 18.36 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.714 2.276 . . . . 0.0 113.344 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -64.56 152.42 81.82 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.27 2.647 . . . . 0.0 111.767 179.408 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.6 t -89.04 127.38 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.081 -1.012 . . . . 0.0 109.565 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -143.18 152.45 41.78 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.439 -0.788 . . . . 0.0 109.238 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.76 143.89 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.17 -0.956 . . . . 0.0 109.375 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.6 tttm -77.95 134.71 37.81 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.9 mt -58.89 -35.52 73.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.527 179.93 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.712 ' C8 ' ' H ' ' A' ' 62' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.463 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 71.9 mtm . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.372 0.606 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -60.11 -37.03 78.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 109.494 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.79 ' CE1' HG21 ' A' ' 6' ' ' VAL . 73.6 t60 -116.13 8.94 14.58 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.478 -0.764 . . . . 0.0 109.478 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.58 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -61.09 -35.61 77.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.212 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 m -58.8 -40.28 83.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.053 -1.03 . . . . 0.0 109.395 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.79 HG21 ' CE1' ' A' ' 3' ' ' HIS . 72.3 t -66.53 -36.56 77.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.007 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.646 ' O ' HG23 ' A' ' 11' ' ' VAL . 81.8 mt -63.59 -44.18 98.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.397 -0.814 . . . . 0.0 110.31 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.484 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.0 -50.63 67.78 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.175 -0.953 . . . . 0.0 110.521 -178.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.22 -44.3 68.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.122 -0.986 . . . . 0.0 109.673 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.568 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 75.1 t80 -59.52 -45.89 90.44 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.993 -1.067 . . . . 0.0 109.282 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.646 HG23 ' O ' ' A' ' 7' ' ' ILE . 99.7 t -70.03 -46.52 72.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 8' ' ' ALA . 74.9 t -66.51 -37.23 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.337 -0.852 . . . . 0.0 111.086 -179.147 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -60.93 -31.72 71.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.771 -179.058 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -66.16 -32.51 73.99 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.938 -1.102 . . . . 0.0 110.137 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.727 ' O ' HD12 ' A' ' 16' ' ' LEU . 58.6 m-85 -96.63 -61.11 1.47 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.104 -0.997 . . . . 0.0 110.6 -179.082 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.727 HD12 ' O ' ' A' ' 15' ' ' PHE . 3.7 mp -129.16 83.24 66.4 Favored Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 121.29 -0.881 . . . . 0.0 110.663 -178.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -80.75 -13.29 11.88 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.841 2.361 . . . . 0.0 112.102 178.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.56 -4.3 42.08 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.138 -0.976 . . . . 0.0 108.974 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.59 140.62 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.386 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.648 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . -61.86 117.87 33.04 Favored Pre-proline 0 C--N 1.305 -1.353 0 O-C-N 120.882 -1.136 . . . . 0.0 108.779 -179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.827 ' O ' HG12 ' A' ' 24' ' ' VAL . 21.6 Cg_endo -64.98 -26.75 58.43 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 C-N-CA 121.619 1.546 . . . . 0.0 111.854 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.92 -13.88 60.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.421 -0.799 . . . . 0.0 109.326 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.648 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -85.58 8.03 20.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 109.853 -179.277 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.827 HG12 ' O ' ' A' ' 21' ' ' PRO . 9.9 p -107.58 144.41 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.372 -0.83 . . . . 0.0 109.034 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.493 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.6 m-20 -69.05 86.18 0.36 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.006 -1.059 . . . . 0.0 109.177 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.517 HG11 ' HE3' ' A' ' 87' ' ' LYS . 26.8 m -60.9 0.06 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.34 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.03 6.04 47.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.321 -0.862 . . . . 0.0 108.77 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -93.58 136.82 33.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.599 -0.688 . . . . 0.0 109.364 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -61.16 121.53 12.75 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.632 ' CD1' HD11 ' A' ' 36' ' ' ILE . 1.5 pp -68.84 0.25 4.61 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.285 -0.885 . . . . 0.0 109.796 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 34' ' ' GLY . 72.7 t -56.16 -35.17 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.21 -0.931 . . . . 0.0 108.946 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' A' ' 34' ' ' GLY . 92.3 m-20 -53.94 -34.83 60.78 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.121 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -83.53 21.89 1.14 Allowed 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.028 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -41.73 -13.99 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.93 -1.268 . . . . 0.0 109.93 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 3.4 p -51.94 -31.12 13.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.085 -1.244 . . . . 0.0 108.479 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.632 HD11 ' CD1' ' A' ' 30' ' ' LEU . 32.6 pt -73.56 -7.14 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.522 -0.736 . . . . 0.0 109.965 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.504 ' HA ' HD12 ' A' ' 41' ' ' LEU . 92.7 m-20 -48.88 -39.95 27.88 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.342 -0.849 . . . . 0.0 110.205 -178.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -122.56 -48.24 2.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 111.348 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.482 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.2 mp -74.71 -52.79 10.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.944 -1.097 . . . . 0.0 111.63 -178.077 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.538 ' H ' ' HA ' ' A' ' 36' ' ' ILE . . . -70.49 -43.21 62.12 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 120.079 -1.058 . . . . 0.0 110.77 -178.665 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.635 ' O ' HD13 ' A' ' 45' ' ' ILE . 16.2 mt -63.42 -40.66 97.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.065 -1.256 . . . . 0.0 110.482 -179.191 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.63 -44.17 96.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.322 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttt -66.96 -41.58 86.64 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.244 -0.91 . . . . 0.0 109.465 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 40' ' ' GLY . 90.1 t -66.95 -41.06 86.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.446 -0.784 . . . . 0.0 109.879 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.635 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.4 mp -58.94 -49.03 84.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.245 -0.91 . . . . 0.0 109.65 -179.56 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.94 -32.29 72.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.604 ' CZ2' ' NH1' ' A' ' 51' ' ' ARG . 9.3 t90 -68.51 -44.81 73.84 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.37 -0.831 . . . . 0.0 109.508 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.426 HD22 ' C17' ' A' ' 101' ' ' 7V9 . 7.8 tp -62.53 -44.98 95.02 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 109.605 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 53' ' ' GLY . 81.6 tt0 -67.2 -34.51 77.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.909 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -58.75 -39.3 80.54 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.89 -1.131 . . . . 0.0 109.759 -179.561 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.604 ' NH1' ' CZ2' ' A' ' 47' ' ' TRP . 51.7 mtm180 -86.97 -53.86 4.66 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.135 -0.978 . . . . 0.0 110.931 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.42 -25.02 39.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 111.367 -178.289 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 76.46 39.2 31.11 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.334 -1.412 . . . . 0.0 109.627 -179.676 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.427 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 66.1 mt -103.03 138.73 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.197 -1.178 . . . . 0.0 109.331 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.05 141.08 57.66 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.737 -1.227 . . . . 0.0 109.303 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.48 -34.1 73.55 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.338 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -95.98 12.41 30.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.405 -0.809 . . . . 0.0 109.468 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -52.32 -34.66 48.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.923 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.3 m -126.45 158.84 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.356 -0.84 . . . . 0.0 109.668 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -68.73 143.64 54.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.343 -0.848 . . . . 0.0 109.448 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 12.9 mt -92.4 139.97 30.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.25 -0.906 . . . . 0.0 109.144 -179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -154.41 129.8 5.18 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.973 -1.079 . . . . 0.0 109.41 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 -27.54 69.48 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.862 1.708 . . . . 0.0 112.324 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.88 -28.12 69.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.892 . . . . 0.0 109.711 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.417 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 11.6 t-160 -67.8 -26.74 66.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.296 -0.878 . . . . 0.0 110.02 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.543 ' CE1' HD21 ' A' ' 41' ' ' LEU . 58.4 m-85 -102.27 13.65 34.06 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.955 . . . . 0.0 109.97 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.535 ' HD2' HG21 ' A' ' 31' ' ' VAL . 25.6 tpt180 -53.19 -36.88 61.42 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 108.959 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t -143.46 146.91 33.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -0.887 . . . . 0.0 109.479 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.78 -38.44 76.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.285 -0.885 . . . . 0.0 109.91 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 ptt85 -61.81 -40.23 94.51 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.8 p -61.69 -36.68 81.58 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.097 -1.002 . . . . 0.0 110.043 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.433 HD11 ' CD1' ' A' ' 66' ' ' PHE . 76.1 mt -65.12 -40.81 90.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 121.095 -1.003 . . . . 0.0 109.807 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 55.6 t0 -58.75 -38.05 77.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.713 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.85 -41.69 99.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.178 -0.951 . . . . 0.0 109.598 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.417 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 65.6 t80 -63.8 -47.44 80.88 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.283 -0.886 . . . . 0.0 109.366 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.5 t -64.15 -42.72 96.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.288 -0.882 . . . . 0.0 109.551 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 73' ' ' ASP . 46.6 t -58.98 -41.07 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.288 -0.883 . . . . 0.0 109.532 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.18 -32.56 76.71 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.85 -50.45 3.53 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.026 -1.279 . . . . 0.0 110.746 -179.132 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 76' ' ' VAL . 16.6 p -129.14 156.65 43.57 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.333 -0.854 . . . . 0.0 109.519 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.01 88.77 21.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 O-C-N 121.184 -0.947 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -81.32 159.65 20.02 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.539 2.159 . . . . 0.0 112.365 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.84 148.57 92.8 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.755 2.303 . . . . 0.0 111.98 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.493 HG23 HG23 ' A' ' 6' ' ' VAL . 13.8 p -130.09 141.31 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.403 -0.81 . . . . 0.0 109.669 -179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -110.04 164.04 13.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.514 -0.741 . . . . 0.0 109.177 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -51.03 141.74 13.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.296 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.517 ' HE3' HG11 ' A' ' 26' ' ' VAL . 18.8 tttt -58.61 -37.07 75.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.263 -0.898 . . . . 0.0 109.469 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.5 tp -100.6 130.55 46.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 109.507 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 60.7 tp60 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.433 -179.974 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 101' ' ' 7V9 . . . . . 0.426 ' C17' HD22 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.792 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -153.2 29.48 0.5 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.337 -0.852 . . . . 0.0 109.04 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.09 -32.97 72.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.311 -0.868 . . . . 0.0 109.883 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -61.01 -35.72 77.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.058 -1.026 . . . . 0.0 109.58 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.792 HG21 ' CE1' ' A' ' 3' ' ' HIS . 72.4 t -67.29 -38.41 80.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.028 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.456 ' O ' HG23 ' A' ' 11' ' ' VAL . 89.2 mt -61.73 -50.45 80.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.1 -45.52 88.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.197 -0.939 . . . . 0.0 109.096 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.99 -44.32 89.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.477 -0.764 . . . . 0.0 109.266 179.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.671 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -65.15 -46.97 78.72 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.648 -0.658 . . . . 0.0 109.915 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.683 HG13 HD12 ' A' ' 36' ' ' ILE . 75.7 t -67.65 -47.31 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.378 -0.826 . . . . 0.0 110.124 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.3 t -65.84 -34.47 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.364 -0.835 . . . . 0.0 110.613 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.53 -36.61 55.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.117 -0.99 . . . . 0.0 110.013 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.15 -34.07 76.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 110.662 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.615 ' O ' HD12 ' A' ' 16' ' ' LEU . 66.5 m-85 -94.83 -64.24 1.09 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.927 -1.108 . . . . 0.0 110.784 -178.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.615 HD12 ' O ' ' A' ' 15' ' ' PHE . 6.1 mp . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.31 -0.869 . . . . 0.0 110.155 -179.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -65.28 -30.01 54.57 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.637 1.558 . . . . 0.0 111.869 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.98 61.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.182 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.0 m-20 -87.96 6.35 36.22 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.341 -0.849 . . . . 0.0 109.387 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -100.64 137.53 27.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.394 -0.816 . . . . 0.0 108.824 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -62.69 88.07 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.185 -0.947 . . . . 0.0 109.434 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.1 m -62.15 0.08 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.397 -0.814 . . . . 0.0 109.281 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -90.88 6.82 42.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.295 -0.878 . . . . 0.0 108.949 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 tp -94.29 137.04 33.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.53 -0.731 . . . . 0.0 109.499 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -60.94 121.77 13.22 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -73.16 4.57 4.28 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.192 -0.943 . . . . 0.0 109.959 -179.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.4 p -51.17 -38.61 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.08 -1.012 . . . . 0.0 108.423 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.442 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.12 -35.43 69.44 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.7 m-20 -84.45 17.03 2.79 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -43.22 -14.04 0.02 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.05 -35.94 15.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.261 -1.141 . . . . 0.0 108.971 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.683 HD12 HG13 ' A' ' 11' ' ' VAL . 1.5 tt -70.01 -23.31 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.356 -0.84 . . . . 0.0 109.889 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.595 ' OD2' ' CD1' ' A' ' 66' ' ' PHE . 77.0 m-20 -56.33 -34.17 66.32 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.384 -0.823 . . . . 0.0 110.622 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -112.57 -64.45 1.3 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 111.092 -178.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 50.9 tp -64.25 -51.96 61.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.71 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -36.5 69.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.1 tt -58.37 -41.82 85.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.224 -1.163 . . . . 0.0 109.685 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 42' ' ' LEU . 92.8 mt -67.08 -44.14 80.81 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.137 -0.977 . . . . 0.0 109.391 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.5 mttm -67.09 -41.65 85.96 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.26 -0.9 . . . . 0.0 109.843 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 40' ' ' GLY . 88.6 t -66.68 -43.2 90.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.307 -0.871 . . . . 0.0 109.956 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.446 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.73 -50.53 79.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.263 -0.898 . . . . 0.0 109.569 -179.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.446 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -66.6 -38.46 87.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.182 -0.949 . . . . 0.0 109.413 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.671 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -68.48 -41.43 80.11 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.302 -0.874 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 13.8 tp -56.97 -47.42 80.81 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.403 -0.811 . . . . 0.0 109.644 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.514 ' OE2' ' O ' ' A' ' 54' ' ' ILE . 28.0 tp10 -69.26 -35.71 76.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.182 -0.949 . . . . 0.0 109.287 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -63.98 -46.07 86.21 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.077 -1.014 . . . . 0.0 110.552 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 22.4 ttm180 -88.15 -58.22 2.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 111.926 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -79.38 -24.4 42.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.0 -1.062 . . . . 0.0 111.751 -177.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.26 32.82 41.96 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.187 -1.483 . . . . 0.0 109.417 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.514 ' O ' ' OE2' ' A' ' 49' ' ' GLU . 68.8 mt -104.44 143.94 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.274 -1.133 . . . . 0.0 109.189 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.53 146.92 43.25 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.155 -0.966 . . . . 0.0 109.478 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.39 -0.819 . . . . 0.0 109.604 -179.391 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -54.13 -28.47 51.36 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.549 2.166 . . . . 0.0 111.953 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -68.39 -15.9 63.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.413 -0.805 . . . . 0.0 109.482 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 7.4 t-160 -66.7 -25.39 66.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.536 -0.727 . . . . 0.0 110.143 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.595 ' CD1' ' OD2' ' A' ' 37' ' ' ASP . 62.3 m-85 -87.68 2.91 49.78 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.019 -1.051 . . . . 0.0 109.99 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -57.25 -39.82 76.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.944 -1.097 . . . . 0.0 110.293 -179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.422 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 86.0 p -143.31 153.21 42.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.834 -1.166 . . . . 0.0 110.264 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -65.96 -36.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.456 -0.778 . . . . 0.0 109.67 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.2 mtm180 -60.94 -37.18 81.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.789 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.422 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 19.6 m -59.36 -41.98 90.51 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.068 -1.02 . . . . 0.0 109.083 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.62 -38.18 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.321 -0.862 . . . . 0.0 109.431 179.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.484 ' O ' HG23 ' A' ' 77' ' ' VAL . 74.5 m-20 -57.06 -39.61 75.24 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.342 -0.849 . . . . 0.0 109.704 -179.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.91 -39.11 90.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.247 -0.908 . . . . 0.0 109.904 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.25 -47.51 85.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.743 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.3 t -65.37 -41.06 90.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.149 -0.969 . . . . 0.0 109.777 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.7 t -61.51 -44.6 98.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.204 -0.935 . . . . 0.0 109.936 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -65.14 -40.54 96.93 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.81 -49.67 12.59 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.147 -1.207 . . . . 0.0 109.766 -179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.471 ' O ' ' O ' ' A' ' 76' ' ' VAL . 19.3 p -130.46 156.89 44.02 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.301 -1.504 0 O-C-N 121.171 -0.955 . . . . 0.0 109.78 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.2 0.524 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 40.1 m80 -139.52 6.47 2.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.271 -0.893 . . . . 0.0 109.762 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.496 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.26 -33.87 71.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.075 -1.016 . . . . 0.0 109.761 -179.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.22 -45.01 92.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.067 -1.021 . . . . 0.0 109.59 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.9 -36.59 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.268 -0.895 . . . . 0.0 108.656 179.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.496 HD12 ' HA ' ' A' ' 4' ' ' ALA . 91.8 mt -66.75 -42.16 89.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.609 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.24 -50.39 70.38 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.047 -1.033 . . . . 0.0 110.241 -179.021 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.677 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.31 -42.97 71.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.291 179.749 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.677 ' N ' HE21 ' A' ' 9' ' ' GLN . 67.9 t80 -62.56 -48.72 78.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.366 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.797 HG13 HD12 ' A' ' 36' ' ' ILE . 64.4 t -65.49 -45.07 93.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 0.0 109.333 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.609 HG23 ' O ' ' A' ' 8' ' ' ALA . 69.4 t -65.85 -37.12 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.439 -0.788 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -52.86 -30.78 35.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.38 -0.825 . . . . 0.0 109.811 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.54 -31.26 72.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.66 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.551 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 34.4 p90 -143.93 44.24 1.46 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.185 -0.947 . . . . 0.0 109.601 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.797 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.155 -0.966 . . . . 0.0 110.305 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -49.38 -29.66 18.42 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 121.881 1.721 . . . . 0.0 111.813 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.6 -25.99 68.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.315 -0.866 . . . . 0.0 109.528 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -95.38 6.42 49.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.319 -0.863 . . . . 0.0 109.209 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.3 t -104.07 136.37 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.528 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.4 m-20 -69.7 88.89 0.54 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.202 -0.936 . . . . 0.0 109.529 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.2 m -59.91 0.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.196 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.528 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.91 9.97 33.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 108.884 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -90.34 137.37 32.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.533 -0.729 . . . . 0.0 109.507 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.455 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.89 121.82 14.43 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.12 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.441 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -69.62 10.86 0.31 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.144 -0.972 . . . . 0.0 109.932 -178.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.455 ' H ' ' C ' ' A' ' 29' ' ' ASP . 75.7 t -54.68 -44.22 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.002 -1.061 . . . . 0.0 108.627 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.72 -36.64 67.44 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 179.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.5 m-20 -86.21 18.24 3.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 178.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.92 -14.99 0.02 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.9 t -52.05 -37.13 21.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.117 -1.225 . . . . 0.0 108.677 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.797 HD12 HG13 ' A' ' 11' ' ' VAL . 1.4 tt -70.59 -22.5 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.533 -0.73 . . . . 0.0 110.323 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -54.14 -32.62 55.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.313 -0.867 . . . . 0.0 111.284 -178.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -117.34 -64.23 1.33 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.912 -1.117 . . . . 0.0 111.165 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.3 -52.5 63.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.9 -1.125 . . . . 0.0 110.343 -178.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.664 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.53 -37.1 62.34 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 36' ' ' ILE . 16.2 tp -58.51 -43.53 89.16 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.38 -1.07 . . . . 0.0 109.931 -178.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HA ' HD23 ' A' ' 42' ' ' LEU . 92.9 mt -65.6 -43.56 89.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.556 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -63.08 -34.43 77.57 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.259 -0.9 . . . . 0.0 109.366 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 40' ' ' GLY . 68.4 t -60.52 -41.43 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.914 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.505 HG21 ' HB1' ' A' ' 56' ' ' ALA . 35.8 mm -58.94 -50.16 80.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.983 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.24 -35.6 79.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.801 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.513 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 44.2 t90 -66.49 -41.74 88.48 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.269 -0.894 . . . . 0.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -61.24 -43.35 99.01 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 109.918 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.412 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 87.5 tt0 -67.51 -37.16 82.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -60.3 -44.79 95.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.049 -1.032 . . . . 0.0 110.555 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -87.49 -53.02 5.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.136 -0.977 . . . . 0.0 111.585 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -80.16 -24.75 40.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.041 -1.037 . . . . 0.0 111.59 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.67 31.05 51.29 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.412 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.6 mt -103.41 147.51 9.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.393 -1.063 . . . . 0.0 109.556 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.04 157.6 15.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.188 -0.945 . . . . 0.0 109.309 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.505 ' HB1' HG21 ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.456 0 O-C-N 121.24 -0.912 . . . . 0.0 109.773 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.79 -27.05 84.04 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.618 2.212 . . . . 0.0 111.886 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.56 -24.49 67.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.403 -0.81 . . . . 0.0 109.945 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -67.13 -26.61 66.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.155 -0.965 . . . . 0.0 110.234 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -97.71 6.68 47.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.074 -1.016 . . . . 0.0 109.001 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 -56.49 -37.8 70.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.452 -0.78 . . . . 0.0 109.977 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.8 p -137.03 153.25 50.68 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.096 -1.003 . . . . 0.0 110.121 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.6 mt -64.59 -36.45 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.478 -0.763 . . . . 0.0 110.251 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -60.87 -37.02 80.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.133 -0.979 . . . . 0.0 110.217 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 92.6 p -61.59 -36.15 79.87 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.014 -1.054 . . . . 0.0 109.66 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -64.93 -40.63 89.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.232 -0.918 . . . . 0.0 109.453 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.552 ' OD2' HG23 ' A' ' 77' ' ' VAL . 53.9 t0 -59.12 -36.93 76.04 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.305 -0.872 . . . . 0.0 109.634 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.88 -40.71 94.04 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.326 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -64.16 -48.7 75.0 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.305 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.5 t -64.89 -43.45 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.317 -0.864 . . . . 0.0 109.671 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.552 HG23 ' OD2' ' A' ' 73' ' ' ASP . 55.7 t -59.87 -41.06 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.225 -0.922 . . . . 0.0 109.627 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.33 -31.83 70.82 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.1 -50.63 3.32 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.021 -1.282 . . . . 0.0 110.844 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 21.8 p -131.28 159.43 37.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.225 -0.922 . . . . 0.0 109.854 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.389 0 O-C-N 121.189 -0.944 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.556 ' OE1' HG21 ' A' ' 81' ' ' THR . 91.8 mt-30 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.4 m80 47.46 38.44 7.71 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.118 -0.988 . . . . 0.0 109.298 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.12 -34.26 73.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.288 -0.883 . . . . 0.0 109.629 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -59.14 -36.64 75.59 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 109.618 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.8 t -62.88 -40.96 90.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.287 -0.883 . . . . 0.0 109.516 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.498 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 85.5 mt -59.69 -43.95 92.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.356 -0.84 . . . . 0.0 109.839 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.4 77.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.429 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.42 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.08 -33.66 73.89 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.414 -0.804 . . . . 0.0 109.624 179.826 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.407 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 63.1 t80 -62.64 -52.08 64.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.001 . . . . 0.0 109.977 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 12' ' ' VAL . 6.3 p -74.91 -44.32 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.357 -0.839 . . . . 0.0 110.855 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.538 ' N ' HG13 ' A' ' 11' ' ' VAL . 76.9 t -65.32 -40.09 87.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.183 -0.948 . . . . 0.0 111.031 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -58.22 -28.69 65.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.045 -1.034 . . . . 0.0 109.791 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.8 -38.69 89.64 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.276 -0.89 . . . . 0.0 110.425 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.498 ' HE1' HG22 ' A' ' 11' ' ' VAL . 5.4 m-85 -96.68 -45.11 6.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.04 -1.038 . . . . 0.0 110.489 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.5 mt . . . . . 0 N--CA 1.493 1.719 0 O-C-N 121.284 -0.885 . . . . 0.0 110.273 -179.147 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -64.69 -30.36 59.79 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 C-N-CA 121.585 1.524 . . . . 0.0 111.966 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.86 -19.05 63.46 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.064 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -89.18 1.74 55.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.361 -0.837 . . . . 0.0 108.99 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.1 t -102.28 139.0 24.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.515 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.2 t0 -67.97 94.14 0.46 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 109.438 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -59.99 0.56 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.429 -0.794 . . . . 0.0 109.229 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.1 m-20 -88.16 9.8 21.55 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.019 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.4 tp -86.33 134.17 33.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.541 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -62.94 122.07 15.1 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.742 HD11 HG12 ' A' ' 69' ' ' ILE . 74.1 mt -59.72 -12.14 6.48 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.3 p -49.97 -37.28 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 119.32 -0.952 . . . . 0.0 108.647 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.13 -36.01 70.18 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.3 m-20 -86.13 21.07 2.1 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.3 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.48 -40.32 24.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 120.979 -1.307 . . . . 0.0 108.54 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.637 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.2 tt -71.77 -24.41 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.509 -0.744 . . . . 0.0 110.418 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 91.9 m-20 -59.25 -28.13 66.42 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.931 -1.105 . . . . 0.0 110.962 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.3 m -113.3 -64.32 1.32 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.026 -1.046 . . . . 0.0 111.167 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.487 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.88 -51.31 41.58 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.904 -1.123 . . . . 0.0 110.472 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.02 -35.89 72.12 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.747 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.0 tt -57.99 -45.24 87.11 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.421 -1.046 . . . . 0.0 110.145 -179.083 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.8 mt -61.83 -44.18 97.37 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.001 -1.062 . . . . 0.0 109.191 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -71.64 -35.54 70.44 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.351 -0.843 . . . . 0.0 110.303 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 40' ' ' GLY . 66.0 t -64.56 -49.41 80.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.284 -0.885 . . . . 0.0 111.277 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.2 mm -58.78 -49.46 82.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 120.566 -1.334 . . . . 0.0 109.644 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.34 -35.6 79.73 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.012 -1.055 . . . . 0.0 109.68 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.476 ' CE3' ' CD2' ' A' ' 48' ' ' LEU . 19.2 t90 -76.84 -51.07 11.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.272 -0.892 . . . . 0.0 111.398 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.476 ' CD2' ' CE3' ' A' ' 47' ' ' TRP . 3.8 mm? -65.72 -39.32 91.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.062 -1.024 . . . . 0.0 110.616 -179.181 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 17.8 pt-20 -65.73 -35.01 79.53 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.979 -1.076 . . . . 0.0 109.596 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -65.45 -43.52 90.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.173 -0.954 . . . . 0.0 110.051 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -67.68 -43.13 80.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.252 -0.905 . . . . 0.0 111.165 -179.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -98.34 -12.73 21.19 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.9 -1.125 . . . . 0.0 110.47 -178.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.05 42.16 96.82 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.5 mt -104.79 129.21 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 109.531 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.95 144.39 57.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 109.451 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.271 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -49.95 -36.12 42.92 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 121.814 1.676 . . . . 0.0 112.107 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.92 -27.73 66.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.257 -0.902 . . . . 0.0 109.677 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 36.6 t-80 -68.22 -27.13 66.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 110.211 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -100.72 9.14 42.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.485 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 35.9 tpt85 -55.52 -36.21 66.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.479 -0.763 . . . . 0.0 109.369 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.1 p -143.56 158.34 43.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.18 -0.95 . . . . 0.0 110.017 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.742 HG12 HD11 ' A' ' 30' ' ' LEU . 75.7 mt -64.15 -36.54 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.387 -0.821 . . . . 0.0 110.35 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.6 mtm180 -60.72 -38.82 86.4 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.098 -1.001 . . . . 0.0 110.068 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.0 t -61.45 -44.09 97.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.042 -1.036 . . . . 0.0 109.539 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 84.3 mt -67.72 -40.08 83.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.288 -0.882 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 59.8 t0 -58.99 -41.59 88.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.867 . . . . 0.0 110.391 -179.256 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.39 -43.78 84.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.034 -1.041 . . . . 0.0 110.248 -179.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -62.67 -47.27 84.39 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.748 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.517 HG12 ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.92 -44.36 96.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 73' ' ' ASP . 48.1 t -61.06 -39.74 83.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.11 -0.994 . . . . 0.0 109.459 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.85 -33.17 67.46 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.02 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.054 -1.263 . . . . 0.0 110.489 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.517 ' O ' HG12 ' A' ' 76' ' ' VAL . 8.3 t -158.41 152.69 24.19 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.064 -1.023 . . . . 0.0 110.204 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.556 HG21 ' OE1' ' A' ' 2' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 108.937 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 120.905 0.383 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.6 m-70 -149.0 3.45 0.61 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.965 -1.085 . . . . 0.0 110.603 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.586 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -63.34 -32.4 73.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.778 -1.201 . . . . 0.0 109.866 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.7 p -59.04 -35.3 73.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.069 -1.02 . . . . 0.0 109.372 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.34 -37.74 80.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.264 -0.898 . . . . 0.0 109.2 179.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.615 ' O ' HG23 ' A' ' 11' ' ' VAL . 30.8 mm -62.16 -47.12 94.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.419 -0.8 . . . . 0.0 110.176 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.81 -49.74 71.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.206 -0.933 . . . . 0.0 110.445 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.466 ' NE2' ' CA ' ' A' ' 10' ' ' PHE . 4.2 pp0? -69.71 -42.75 73.62 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.154 -0.967 . . . . 0.0 109.858 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CA ' ' NE2' ' A' ' 9' ' ' GLN . 69.9 t80 -61.63 -46.66 88.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.147 -0.971 . . . . 0.0 109.512 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.733 HG13 HD12 ' A' ' 36' ' ' ILE . 91.4 t -67.5 -47.61 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.375 -0.828 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 78.7 t -66.44 -34.74 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.416 -0.802 . . . . 0.0 110.423 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.77 -36.46 58.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -0.93 . . . . 0.0 109.897 -179.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.76 -35.12 78.14 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.273 -0.892 . . . . 0.0 110.708 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.619 ' O ' HD12 ' A' ' 16' ' ' LEU . 65.9 m-85 -92.91 -63.47 1.22 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.919 -1.113 . . . . 0.0 110.767 -178.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.619 HD12 ' O ' ' A' ' 15' ' ' PHE . 5.7 mp . . . . . 0 N--CA 1.495 1.794 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.418 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -64.62 -23.91 63.28 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 121.628 1.552 . . . . 0.0 111.828 -179.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.49 -14.89 62.27 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.446 -0.784 . . . . 0.0 109.272 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.418 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 90.5 m-20 -82.9 3.24 30.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.383 -0.823 . . . . 0.0 109.158 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.54 136.97 30.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.451 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.12 88.13 0.07 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.136 -0.977 . . . . 0.0 109.271 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -63.61 0.04 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.273 -0.892 . . . . 0.0 109.309 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.451 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -93.44 4.65 53.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 108.969 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.8 tt -98.36 137.65 36.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.461 -0.775 . . . . 0.0 109.541 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.63 ' O ' HD23 ' A' ' 28' ' ' LEU . 89.4 m-20 -60.56 121.57 12.48 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.231 -0.918 . . . . 0.0 108.625 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.426 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.6 OUTLIER -64.94 6.08 0.27 Allowed 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.255 -0.903 . . . . 0.0 110.047 -178.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.471 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.0 p -51.55 -38.23 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.053 -1.029 . . . . 0.0 108.634 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.83 -35.68 71.21 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.641 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.4 m-20 -86.18 20.14 2.44 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.84 -14.69 0.02 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.641 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.52 -35.62 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.264 -1.139 . . . . 0.0 108.802 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.733 HD12 HG13 ' A' ' 11' ' ' VAL . 1.1 tt -69.99 -22.16 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.567 -0.708 . . . . 0.0 110.067 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -55.02 -32.51 61.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.302 -0.874 . . . . 0.0 110.845 -178.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.7 m -118.0 -63.79 1.38 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.22 -0.925 . . . . 0.0 111.168 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.5 tp -62.01 -52.55 63.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.961 -1.087 . . . . 0.0 110.276 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -38.17 66.1 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.561 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -59.57 -40.66 88.11 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.419 -1.048 . . . . 0.0 109.15 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.99 -44.12 97.4 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.217 -0.927 . . . . 0.0 108.947 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.4 mttm -65.73 -37.42 86.33 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.316 -0.865 . . . . 0.0 109.483 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.5 t -62.84 -39.97 87.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.399 -0.813 . . . . 0.0 109.875 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.457 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.87 -51.41 73.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.11 -0.994 . . . . 0.0 109.664 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.59 -39.28 84.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -0.908 . . . . 0.0 109.627 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.706 ' HE1' ' CZ ' ' A' ' 51' ' ' ARG . 76.2 t90 -68.89 -43.04 76.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.41 -0.806 . . . . 0.0 109.962 -179.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.0 tp -63.15 -46.83 85.38 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.353 -0.842 . . . . 0.0 109.962 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -68.23 -36.0 78.81 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.88 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.56 -45.48 93.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.066 -1.022 . . . . 0.0 110.68 -179.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.706 ' CZ ' ' HE1' ' A' ' 47' ' ' TRP . 85.0 mtt180 -87.2 -50.25 6.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.078 -1.013 . . . . 0.0 111.45 -178.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -80.1 -24.78 40.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.0 -1.062 . . . . 0.0 111.271 -178.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.21 30.07 57.59 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -105.95 144.13 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.288 -1.125 . . . . 0.0 109.478 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.89 152.1 28.35 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.2 -0.938 . . . . 0.0 109.479 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.417 -0.802 . . . . 0.0 109.704 -179.295 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.06 0.457 . . . . 0.0 109.874 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.48 -29.96 90.2 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.704 2.269 . . . . 0.0 111.931 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.54 -26.77 68.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.393 -0.817 . . . . 0.0 109.614 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 12.5 t-80 -67.81 -25.89 65.8 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 110.691 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -88.69 7.52 33.22 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.031 -1.043 . . . . 0.0 110.606 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.3 mmt85 -59.73 -36.93 77.57 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.985 -1.072 . . . . 0.0 110.547 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.453 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 93.5 p -132.94 150.53 52.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.995 -1.066 . . . . 0.0 110.345 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.403 HG23 ' CG2' ' A' ' 7' ' ' ILE . 88.9 mt -65.9 -37.67 80.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 O-C-N 121.49 -0.756 . . . . 0.0 109.854 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 93.8 mtm-85 -61.2 -38.29 86.03 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.091 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.453 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 22.2 m -60.07 -40.7 90.44 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.137 -0.977 . . . . 0.0 109.404 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -65.66 -42.33 92.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.267 -0.895 . . . . 0.0 109.836 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.586 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 53.2 t0 -60.05 -38.74 83.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.335 -0.853 . . . . 0.0 110.062 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.12 -40.64 98.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.182 -0.949 . . . . 0.0 109.747 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -62.7 -46.94 85.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -64.44 -44.02 97.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.24 -0.913 . . . . 0.0 109.757 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 73' ' ' ASP . 58.2 t -60.54 -40.66 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.34 -0.85 . . . . 0.0 109.625 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.46 -31.97 71.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.73 -50.44 3.41 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.113 -1.228 . . . . 0.0 110.807 -179.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.0 p -131.43 157.62 42.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 109.805 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.408 0 O-C-N 121.213 -0.93 . . . . 0.0 109.255 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.272 0.558 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.822 ' NE2' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -155.18 28.44 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.129 -0.982 . . . . 0.0 109.541 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.43 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.63 -33.39 73.85 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.57 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 84.8 p -61.59 -36.56 81.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.197 -0.939 . . . . 0.0 109.497 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.822 HG21 ' NE2' ' A' ' 3' ' ' HIS . 69.8 t -67.83 -37.85 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.209 -0.932 . . . . 0.0 109.0 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.576 ' O ' HG23 ' A' ' 11' ' ' VAL . 84.4 mt -60.47 -50.92 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.268 -0.895 . . . . 0.0 109.219 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.68 -47.53 78.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.303 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -44.4 96.02 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.486 -0.759 . . . . 0.0 109.19 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.57 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.7 t80 -65.05 -46.48 81.04 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.538 0.685 . . . . 0.0 109.607 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.783 HG13 HD12 ' A' ' 36' ' ' ILE . 97.7 t -69.73 -47.42 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.529 -0.732 . . . . 0.0 110.293 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.8 t -64.57 -34.81 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.397 -0.814 . . . . 0.0 110.729 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.68 -36.11 56.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.072 -1.018 . . . . 0.0 109.982 -179.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.71 -35.06 78.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 110.676 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -92.82 -63.79 1.18 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.932 -1.105 . . . . 0.0 110.682 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.4 mt . . . . . 0 N--CA 1.494 1.742 0 O-C-N 121.334 -0.854 . . . . 0.0 110.196 -178.98 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.456 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.485 1.308 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.88 -25.63 59.92 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 C-N-CA 121.586 1.524 . . . . 0.0 111.877 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.47 -14.95 62.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -0.862 . . . . 0.0 109.136 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 91.3 m-20 -84.05 2.99 36.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.313 -0.867 . . . . 0.0 109.024 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.66 136.64 32.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 27' ' ' ASP . 87.4 m-20 -68.05 87.96 0.27 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.148 -0.97 . . . . 0.0 109.478 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -64.06 -0.15 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.34 -0.85 . . . . 0.0 109.594 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.473 ' OD2' ' C ' ' A' ' 27' ' ' ASP . 49.3 p30 -88.83 7.57 33.49 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.203 -0.936 . . . . 0.0 108.954 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -97.15 141.75 29.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.618 -0.676 . . . . 0.0 109.486 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.52 121.76 12.96 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.4 pp -68.77 4.92 1.24 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.166 -0.959 . . . . 0.0 109.975 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.445 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.87 -38.34 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.034 -1.041 . . . . 0.0 108.53 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -58.44 -35.7 72.52 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 66.9 m-80 -84.55 16.33 3.24 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.042 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.03 -14.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.7 t -51.3 -36.61 17.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.119 -1.224 . . . . 0.0 108.891 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.783 HD12 HG13 ' A' ' 11' ' ' VAL . 1.3 tt -70.56 -21.84 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 110.091 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -55.22 -31.88 61.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 111.083 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.15 -64.59 1.29 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.066 -1.021 . . . . 0.0 111.518 -178.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.2 tp -65.12 -52.08 57.45 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.814 -1.179 . . . . 0.0 110.581 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.524 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.9 -35.69 79.92 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.0 tp -58.14 -41.59 84.04 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -1.138 . . . . 0.0 109.282 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 42' ' ' LEU . 87.6 mt -62.61 -44.07 97.23 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.138 -0.976 . . . . 0.0 108.823 179.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.2 mttp -63.56 -36.71 84.7 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.8 t -64.12 -38.31 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.774 -0.579 . . . . 0.0 109.749 179.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.532 HG13 ' HB1' ' A' ' 56' ' ' ALA . 1.3 mp -56.91 -51.03 73.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 109.958 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.459 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.42 -39.15 85.48 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.055 -1.028 . . . . 0.0 109.7 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.57 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 52.4 t90 -67.51 -44.39 78.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.301 -0.874 . . . . 0.0 111.08 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.593 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.4 OUTLIER -62.13 -49.1 77.21 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.133 -0.979 . . . . 0.0 109.978 -178.068 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -68.83 -39.22 80.1 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.957 -1.089 . . . . 0.0 109.391 179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -64.65 -42.62 95.29 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.119 -0.988 . . . . 0.0 111.135 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.692 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 54.7 ttt-85 -72.2 -48.23 44.66 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.216 -0.927 . . . . 0.0 112.036 -177.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.73 ' CE2' HG21 ' A' ' 80' ' ' THR . 90.9 m-85 -104.23 -6.21 21.15 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 111.733 -178.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.56 30.79 66.09 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 59.9 mt -106.04 142.27 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.255 -1.144 . . . . 0.0 109.34 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.18 122.66 15.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.955 -1.091 . . . . 0.0 108.958 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.532 ' HB1' HG13 ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.46 -0.775 . . . . 0.0 110.142 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -57.7 -31.93 93.31 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.675 2.25 . . . . 0.0 111.962 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.88 -24.8 66.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 179.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.9 t60 -67.28 -26.4 66.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.287 -0.883 . . . . 0.0 109.955 -179.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -95.05 6.23 49.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.107 -0.995 . . . . 0.0 109.426 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -56.33 -39.6 73.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.917 . . . . 0.0 109.7 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -135.25 153.5 51.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.094 -1.004 . . . . 0.0 109.924 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.4 ' N ' HD23 ' A' ' 30' ' ' LEU . 83.6 mt -63.88 -36.31 76.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 O-C-N 121.4 -0.813 . . . . 0.0 109.818 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.5 mtm180 -60.73 -37.68 82.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.823 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 t -59.76 -43.94 94.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.064 -1.023 . . . . 0.0 109.346 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.3 mt -64.39 -38.54 82.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.28 -0.888 . . . . 0.0 109.455 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.622 ' O ' HG23 ' A' ' 77' ' ' VAL . 21.8 t70 -56.16 -38.14 70.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.351 -0.843 . . . . 0.0 109.511 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.16 95.31 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.305 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -64.05 -46.69 83.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.493 179.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 58.3 t -64.18 -41.63 93.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.439 -0.788 . . . . 0.0 109.708 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.8 t -62.82 -43.5 98.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.216 -0.928 . . . . 0.0 109.96 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.82 -37.92 95.12 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -88.78 -49.64 6.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.111 -1.229 . . . . 0.0 110.185 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.73 HG21 ' CE2' ' A' ' 52' ' ' PHE . 28.0 m -128.86 138.75 52.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.519 0 O-C-N 121.441 -0.787 . . . . 0.0 109.566 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.604 ' OE1' HG13 ' A' ' 77' ' ' VAL . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.654 ' CE1' HD11 ' A' ' 7' ' ' ILE . 5.4 p80 -160.33 23.14 0.16 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.372 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.4 -38.64 87.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.91 -34.12 77.25 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.357 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.68 -38.1 80.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.285 -0.885 . . . . 0.0 109.356 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.875 ' O ' HG12 ' A' ' 11' ' ' VAL . 88.4 mt -60.43 -50.39 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.526 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.795 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -64.0 -44.09 93.7 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.301 -0.874 . . . . 0.0 109.024 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.47 -40.8 89.54 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.529 -0.732 . . . . 0.0 109.647 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -66.39 -49.47 66.73 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.535 -0.728 . . . . 0.0 111.272 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.875 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.4 p -69.95 -44.81 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.126 -0.984 . . . . 0.0 111.258 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.795 HG22 ' O ' ' A' ' 8' ' ' ALA . 15.9 m -67.48 -33.87 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.026 -1.046 . . . . 0.0 110.733 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.408 ' N ' HG23 ' A' ' 12' ' ' VAL . 82.8 tt0 -52.2 -36.34 51.68 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.107 -0.996 . . . . 0.0 109.832 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -33.36 75.41 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.176 -0.952 . . . . 0.0 110.568 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.67 ' O ' HD12 ' A' ' 16' ' ' LEU . 64.5 m-85 -95.94 -63.72 1.12 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.016 -1.053 . . . . 0.0 110.98 -178.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.67 HD12 ' O ' ' A' ' 15' ' ' PHE . 5.1 mp . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 110.62 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.362 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -65.24 -28.82 55.57 Favored 'Trans proline' 0 N--CA 1.49 1.271 0 C-N-CA 121.596 1.531 . . . . 0.0 112.041 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.71 -14.85 61.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.377 -0.827 . . . . 0.0 109.297 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -90.68 8.17 35.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.364 -0.835 . . . . 0.0 109.34 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.2 t -98.3 137.15 26.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.352 -0.842 . . . . 0.0 108.79 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.521 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -65.57 85.01 0.07 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.168 -0.958 . . . . 0.0 109.466 -179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.1 m -59.89 -0.06 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.312 -0.868 . . . . 0.0 109.266 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.45 7.14 44.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 108.954 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -94.23 136.01 35.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -63.51 121.71 14.52 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.468 HD11 ' O ' ' A' ' 66' ' ' PHE . 0.5 OUTLIER -68.78 5.24 1.15 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.87 -178.97 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.1 p -52.81 -38.87 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.03 -1.044 . . . . 0.0 108.547 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.446 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.9 t0 -57.77 -35.47 70.81 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.8 m-20 -86.06 19.52 2.6 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -14.51 0.01 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.4 t -51.44 -36.35 17.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 108.558 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.549 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.3 OUTLIER -69.98 -20.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.455 -0.778 . . . . 0.0 110.054 179.967 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -51.35 -35.57 38.94 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.216 -0.928 . . . . 0.0 110.98 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -119.1 -61.9 1.58 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.131 -0.981 . . . . 0.0 111.51 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.9 -52.39 64.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.925 -1.11 . . . . 0.0 110.14 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.583 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.35 -41.1 59.58 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.8 -41.86 87.75 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.386 -1.067 . . . . 0.0 109.491 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -59.32 -44.31 92.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.184 -0.947 . . . . 0.0 108.949 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -65.35 -34.64 78.8 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.272 -0.892 . . . . 0.0 109.007 179.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 40' ' ' GLY . 70.2 t -62.67 -41.59 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.784 . . . . 0.0 110.424 -179.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.2 mm -59.32 -49.59 82.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 120.931 -1.106 . . . . 0.0 109.635 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -65.84 -40.98 92.28 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -0.97 . . . . 0.0 109.338 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ2' ' HD3' ' A' ' 51' ' ' ARG . 69.3 t90 -66.89 -41.63 86.88 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.446 -0.784 . . . . 0.0 109.289 179.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.8 tp -60.07 -46.91 88.01 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.421 -0.8 . . . . 0.0 109.168 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.432 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -67.89 -34.18 76.15 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.314 -0.866 . . . . 0.0 109.207 178.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 92.4 m-20 -59.19 -46.62 87.94 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.233 -0.917 . . . . 0.0 110.291 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.401 ' HD3' ' CZ2' ' A' ' 47' ' ' TRP . 42.2 mtp180 -88.46 -51.77 5.54 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.075 -1.016 . . . . 0.0 111.616 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -80.23 -25.3 39.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.984 -1.072 . . . . 0.0 111.633 -177.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.34 31.16 52.52 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.248 -1.453 . . . . 0.0 109.712 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.432 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.9 mt -97.86 145.3 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.276 -1.132 . . . . 0.0 109.409 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.17 145.52 50.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.09 -1.006 . . . . 0.0 109.71 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.463 -0.773 . . . . 0.0 109.933 -179.594 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.406 ' HA ' ' CD1' ' A' ' 66' ' ' PHE . 10.0 Cg_endo -56.41 -27.41 67.84 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.664 2.243 . . . . 0.0 111.955 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.54 -27.46 69.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.249 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 33.5 t-80 -67.14 -26.25 66.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.434 -0.791 . . . . 0.0 109.697 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 0.9 OUTLIER -91.64 7.77 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.2 -0.937 . . . . 0.0 109.188 -179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.6 tpt180 -55.63 -39.44 70.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.971 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 91.6 p -137.25 152.57 49.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.047 -1.033 . . . . 0.0 110.214 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.479 HG23 ' CG2' ' A' ' 7' ' ' ILE . 89.5 mt -65.25 -36.67 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.308 -0.87 . . . . 0.0 110.027 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.1 ptt85 -61.2 -40.5 94.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 110.07 -179.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -59.21 -40.51 86.02 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.108 -0.995 . . . . 0.0 109.402 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -65.97 -39.74 85.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.338 -0.851 . . . . 0.0 109.728 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.691 ' O ' HG23 ' A' ' 77' ' ' VAL . 60.7 t0 -58.51 -38.64 78.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.315 -0.866 . . . . 0.0 109.918 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.52 -42.17 95.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 109.92 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -63.58 -48.53 77.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.07 -1.019 . . . . 0.0 109.606 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -65.49 -41.6 91.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.295 -0.878 . . . . 0.0 109.761 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.691 HG23 ' O ' ' A' ' 73' ' ' ASP . 62.6 t -61.33 -41.39 89.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.311 -0.868 . . . . 0.0 109.788 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.86 -31.72 76.96 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.49 -50.26 3.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.042 -1.27 . . . . 0.0 110.618 -178.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.1 p -129.86 157.52 42.01 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.399 -0.813 . . . . 0.0 109.613 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.385 0 O-C-N 121.206 -0.933 . . . . 0.0 109.393 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.606 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 81.9 m-70 -139.61 28.35 2.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.456 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -60.62 -34.35 74.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.281 -0.887 . . . . 0.0 110.151 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m -58.87 -40.16 83.5 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.018 -1.051 . . . . 0.0 109.666 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.3 t -64.5 -36.59 77.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.88 . . . . 0.0 109.066 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.44 ' O ' HG12 ' A' ' 11' ' ' VAL . 27.7 mm -64.76 -44.31 96.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.433 -0.792 . . . . 0.0 110.323 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.688 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.73 -50.44 69.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.113 -0.992 . . . . 0.0 110.734 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.54 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.86 -39.49 76.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.016 -1.052 . . . . 0.0 109.566 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.54 ' N ' HE21 ' A' ' 9' ' ' GLN . 68.3 t80 -65.75 -51.29 60.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.346 -0.846 . . . . 0.0 109.94 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -67.93 -40.76 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 109.763 -179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.688 HG23 ' O ' ' A' ' 8' ' ' ALA . 71.1 t -65.93 -40.55 87.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.216 -0.927 . . . . 0.0 109.571 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -52.74 -30.54 33.15 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.438 -0.789 . . . . 0.0 109.827 -179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -65.37 -30.46 71.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.939 . . . . 0.0 109.412 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.9 p90 -145.41 44.12 1.3 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.4 pt? . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.054 -1.029 . . . . 0.0 110.082 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -49.04 -31.54 21.1 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.817 1.678 . . . . 0.0 111.993 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.96 -22.28 66.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.419 -0.8 . . . . 0.0 109.446 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -95.88 2.06 53.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.429 -0.795 . . . . 0.0 108.928 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.6 t -104.88 136.46 38.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.518 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.5 t0 -71.19 97.03 1.46 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.051 -1.031 . . . . 0.0 109.312 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.6 m -59.5 0.14 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.195 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.518 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -91.96 7.82 40.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.325 -0.859 . . . . 0.0 108.779 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.8 tp -91.22 133.83 35.06 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.478 -0.764 . . . . 0.0 109.376 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -66.33 121.31 14.96 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -74.74 9.6 1.77 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.219 -0.925 . . . . 0.0 109.825 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.5 p -52.25 -38.91 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.156 -0.965 . . . . 0.0 108.642 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.454 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.1 m-20 -57.33 -35.73 70.25 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 178.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.2 m-20 -84.94 18.25 2.54 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.011 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.92 -13.69 0.01 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -50.72 -35.24 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.072 -1.251 . . . . 0.0 108.945 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.578 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -70.01 -23.48 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.418 ' OD2' ' CG ' ' A' ' 66' ' ' PHE . 84.2 m-20 -54.93 -32.42 61.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 110.714 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.51 -64.09 1.36 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.149 -0.969 . . . . 0.0 111.174 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 15.5 mt -62.67 -52.52 62.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.002 -1.061 . . . . 0.0 110.2 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.48 -37.19 69.18 Favored Glycine 0 N--CA 1.486 1.97 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.73 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.4 tt -58.86 -41.46 87.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.266 -1.138 . . . . 0.0 109.149 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -61.51 -44.22 97.45 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.348 -0.845 . . . . 0.0 108.894 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -67.92 -40.79 83.32 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.301 -0.875 . . . . 0.0 110.007 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.8 t -65.68 -42.86 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.277 -0.889 . . . . 0.0 110.131 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -58.87 -50.47 79.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.186 -0.946 . . . . 0.0 109.65 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.424 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.72 -37.18 85.7 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.94 . . . . 0.0 109.436 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.517 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -69.32 -43.7 73.2 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.281 -0.887 . . . . 0.0 109.715 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.1 tp -57.34 -48.0 80.12 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.323 -0.86 . . . . 0.0 109.402 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -68.73 -37.71 79.66 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.301 -0.874 . . . . 0.0 109.122 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.5 t0 -63.77 -41.73 97.91 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.297 -0.877 . . . . 0.0 110.593 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.7 ttt180 -87.1 -55.26 3.9 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.231 -0.918 . . . . 0.0 111.454 -178.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -79.49 -22.34 44.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.987 -1.071 . . . . 0.0 111.383 -178.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 25.84 60.69 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.1 mt -106.07 144.91 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.471 -1.017 . . . . 0.0 109.416 -179.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 152.41 29.01 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.283 -0.886 . . . . 0.0 109.54 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.368 -0.833 . . . . 0.0 109.688 -179.571 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.449 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.218 0.532 . . . . 0.0 110.228 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -58.08 -25.99 73.49 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 C-N-CA 122.578 2.186 . . . . 0.0 111.664 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.72 -23.54 65.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.56 -0.713 . . . . 0.0 110.198 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.413 ' O ' HD11 ' A' ' 72' ' ' ILE . 0.2 OUTLIER -67.76 -26.63 66.22 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.59 -178.923 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.418 ' CG ' ' OD2' ' A' ' 37' ' ' ASP . 68.4 m-85 -80.17 -3.67 49.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.883 -1.136 . . . . 0.0 110.144 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 83.1 mmt-85 -60.47 -36.18 77.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.892 -1.13 . . . . 0.0 109.745 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.458 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 93.7 p -139.92 150.94 45.17 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.014 -1.054 . . . . 0.0 109.749 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 80.2 mt -65.13 -36.65 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -60.63 -38.41 84.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 110.197 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.458 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 24.6 m -57.81 -40.63 80.4 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.018 -1.051 . . . . 0.0 109.53 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.413 HD11 ' O ' ' A' ' 65' ' ' HIS . 17.0 mm -65.36 -38.97 83.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.154 -0.966 . . . . 0.0 109.17 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.536 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.4 t0 -57.23 -38.35 73.65 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.288 -0.882 . . . . 0.0 109.594 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.44 99.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.307 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -63.75 -46.56 84.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.357 -0.839 . . . . 0.0 109.432 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.8 t -64.68 -41.63 92.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.333 -0.854 . . . . 0.0 109.663 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 73' ' ' ASP . 52.9 t -61.59 -40.94 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.269 -0.894 . . . . 0.0 109.634 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.17 76.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.28 -50.01 5.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.096 -1.237 . . . . 0.0 109.961 -179.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.4 t -144.97 153.21 41.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.55 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.606 ' HG1' ' HE2' ' A' ' 3' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.213 -0.929 . . . . 0.0 109.552 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.468 ' OE1' HG13 ' A' ' 77' ' ' VAL . 61.4 tt0 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.587 ' ND1' ' OG1' ' A' ' 81' ' ' THR . 45.2 m80 -152.92 28.89 0.52 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.417 -0.802 . . . . 0.0 109.19 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.436 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.27 -33.02 71.73 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.412 -0.805 . . . . 0.0 109.658 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -58.97 -38.95 80.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.173 -0.954 . . . . 0.0 109.613 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -65.14 -39.06 84.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.15 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.436 HD12 ' HA ' ' A' ' 4' ' ' ALA . 89.1 mt -60.58 -50.62 79.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.276 -0.89 . . . . 0.0 109.459 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.737 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.96 -44.62 92.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 109.064 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.37 -44.17 88.48 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.74 0.781 . . . . 0.0 109.227 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -61.61 -47.79 83.86 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.525 -0.735 . . . . 0.0 109.331 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.476 HG12 ' HE1' ' A' ' 15' ' ' PHE . 96.6 t -73.16 -41.49 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.446 -0.784 . . . . 0.0 110.139 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 8' ' ' ALA . 78.4 t -63.96 -41.27 91.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -0.882 . . . . 0.0 111.022 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -57.01 -28.25 62.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 109.907 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.44 -30.09 70.84 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.21 -0.931 . . . . 0.0 109.359 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.603 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.8 p90 -146.8 45.68 1.19 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.161 -0.962 . . . . 0.0 109.775 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.819 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 120.965 -1.084 . . . . 0.0 110.369 -179.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -49.25 -33.8 29.46 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.878 1.719 . . . . 0.0 111.697 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.03 -21.87 65.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.489 -0.757 . . . . 0.0 109.331 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.4 5.21 50.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.55 -0.719 . . . . 0.0 109.17 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.4 t -102.54 136.49 34.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.516 ' C ' ' H ' ' A' ' 27' ' ' ASP . 84.5 m-20 -67.42 94.35 0.39 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.137 -0.977 . . . . 0.0 109.418 -179.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.5 m -59.24 0.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.39 -0.819 . . . . 0.0 109.423 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.516 ' H ' ' C ' ' A' ' 25' ' ' ASP . 48.2 p30 -84.26 9.79 12.08 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.227 -0.921 . . . . 0.0 109.078 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.8 tp -86.34 134.95 33.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.6 -0.687 . . . . 0.0 109.366 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -65.43 121.83 15.78 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 108.733 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.694 HD11 HG12 ' A' ' 69' ' ' ILE . 82.3 mt -56.87 -16.66 7.14 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 108.931 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' A' ' 34' ' ' GLY . 41.7 t -50.64 -40.94 19.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.237 -0.914 . . . . 0.0 108.914 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.67 -36.17 66.81 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 178.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' A' ' 35' ' ' VAL . 9.7 m120 -85.02 20.44 1.88 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.11 -15.35 0.02 OUTLIER Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.346 -1.101 . . . . 0.0 110.346 -179.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.597 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.4 t -51.91 -40.17 27.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.604 -1.527 . . . . 0.0 108.585 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.4 tt -71.91 -22.25 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.577 -0.702 . . . . 0.0 110.883 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.401 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 93.0 m-20 -52.51 -34.8 51.36 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.154 -0.966 . . . . 0.0 111.784 -177.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -119.02 -60.59 1.74 Allowed 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.957 -1.09 . . . . 0.0 111.224 -178.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.96 -52.18 65.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.145 . . . . 0.0 109.598 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.441 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.91 -36.98 65.29 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.7 tt -58.02 -41.02 82.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.358 -1.083 . . . . 0.0 109.294 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 30.4 mt -60.31 -44.43 95.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 108.667 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -67.75 -38.74 83.89 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.406 -0.809 . . . . 0.0 109.576 179.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.5 t -65.09 -39.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.448 -0.783 . . . . 0.0 110.351 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -58.11 -50.6 77.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.033 -1.042 . . . . 0.0 109.642 -179.262 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.463 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.16 -39.14 86.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.089 -1.007 . . . . 0.0 109.702 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.5 t90 -70.38 -42.14 72.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.131 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.7 tp -61.43 -47.2 86.81 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.383 -0.823 . . . . 0.0 110.029 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.584 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -64.72 -43.7 92.59 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.116 -0.99 . . . . 0.0 108.613 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -66.45 -39.93 89.15 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.335 -0.853 . . . . 0.0 110.232 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 27.2 tpt85 -63.02 -45.06 94.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.499 -0.751 . . . . 0.0 111.547 -178.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 54.8 m-85 -126.24 2.27 7.1 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.912 -1.118 . . . . 0.0 111.858 -178.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.7 33.79 54.91 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.6 mt -95.85 135.87 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.183 -1.186 . . . . 0.0 109.146 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.54 140.7 58.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.087 -1.008 . . . . 0.0 109.678 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.452 0 O-C-N 121.468 -0.77 . . . . 0.0 109.786 -179.756 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -59.39 -35.13 97.22 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.511 2.141 . . . . 0.0 112.184 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.91 -28.73 68.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.398 -0.814 . . . . 0.0 109.796 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -67.81 -27.03 66.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.289 -0.882 . . . . 0.0 110.231 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.523 ' CD1' HD11 ' A' ' 72' ' ' ILE . 56.0 m-85 -101.68 13.84 33.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.133 -0.98 . . . . 0.0 110.06 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -53.03 -32.96 49.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.094 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.7 t -151.29 151.76 32.25 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 109.973 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.694 HG12 HD11 ' A' ' 30' ' ' LEU . 81.8 mt -60.97 -36.87 75.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 O-C-N 121.262 -0.898 . . . . 0.0 110.11 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -60.63 -40.82 93.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.224 -0.922 . . . . 0.0 110.214 -179.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.2 m -60.66 -41.8 95.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.037 -1.04 . . . . 0.0 109.936 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.523 HD11 ' CD1' ' A' ' 66' ' ' PHE . 77.3 mt -66.95 -40.83 86.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.245 -0.909 . . . . 0.0 110.156 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.407 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.1 t0 -59.12 -40.72 86.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 110.405 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.17 -41.9 89.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.124 -0.985 . . . . 0.0 110.09 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.7 t80 -62.06 -49.65 75.15 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.164 -0.96 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 80' ' ' THR . 53.6 t -65.55 -47.05 87.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.219 -0.926 . . . . 0.0 109.562 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.468 HG13 ' OE1' ' A' ' 2' ' ' GLN . 45.8 t -58.93 -38.84 75.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.112 -0.992 . . . . 0.0 109.455 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.73 -33.06 66.6 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.46 -51.24 3.14 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -1.224 . . . . 0.0 110.397 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.624 ' O ' HG12 ' A' ' 76' ' ' VAL . 7.2 t -153.87 152.41 30.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.728 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.587 ' OG1' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.469 0 O-C-N 121.236 -0.915 . . . . 0.0 109.22 179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.434 ' ND1' HG21 ' A' ' 6' ' ' VAL . 2.9 m-70 -137.03 18.69 3.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.352 -0.843 . . . . 0.0 109.702 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.415 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -57.64 -38.98 75.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.166 -0.959 . . . . 0.0 109.599 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.6 p -65.24 -37.29 86.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.098 -1.001 . . . . 0.0 109.624 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.434 HG21 ' ND1' ' A' ' 3' ' ' HIS . 76.2 t -68.13 -37.81 78.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.287 -0.883 . . . . 0.0 109.261 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.554 HD11 ' HA ' ' A' ' 73' ' ' ASP . 97.2 mt -60.02 -49.79 82.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.75 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.71 -47.17 82.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.184 -0.947 . . . . 0.0 109.098 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -44.16 94.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.445 -0.785 . . . . 0.0 109.252 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.696 ' CZ ' ' CZ3' ' A' ' 47' ' ' TRP . 70.2 t80 -68.39 -48.32 65.01 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.512 0.673 . . . . 0.0 109.48 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.54 HG13 ' CD1' ' A' ' 36' ' ' ILE . 97.5 t -68.67 -44.22 82.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.667 -0.645 . . . . 0.0 110.014 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.728 HG23 ' O ' ' A' ' 8' ' ' ALA . 96.9 t -64.22 -36.71 77.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -52.37 -32.8 40.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.316 -0.865 . . . . 0.0 109.729 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.594 ' OE1' ' CZ3' ' A' ' 47' ' ' TRP . 76.8 mm-40 -66.0 -31.79 72.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.206 -0.934 . . . . 0.0 109.804 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.548 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 34.4 p90 -140.06 42.94 1.94 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.103 -0.998 . . . . 0.0 109.835 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.82 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.05 -1.031 . . . . 0.0 110.015 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -49.76 -31.45 25.92 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 121.842 1.695 . . . . 0.0 111.924 179.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.38 -22.77 66.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.537 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -92.77 4.29 54.06 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.448 -0.782 . . . . 0.0 109.225 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -105.35 136.48 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.522 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -69.23 91.24 0.52 Allowed 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -59.83 0.08 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.349 -0.844 . . . . 0.0 109.186 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.522 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -93.44 8.19 41.57 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.339 -0.851 . . . . 0.0 108.886 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.7 tp -92.34 136.86 32.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.432 -0.793 . . . . 0.0 109.519 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' A' ' 31' ' ' VAL . 33.6 p30 -62.61 114.4 3.55 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.141 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -63.74 8.7 0.08 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.112 -0.993 . . . . 0.0 109.926 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.539 ' H ' ' C ' ' A' ' 29' ' ' ASP . 6.3 p -54.98 -38.25 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.059 -1.025 . . . . 0.0 109.172 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.433 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.3 t0 -56.85 -37.21 70.98 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.596 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.5 m-80 -87.3 16.92 4.76 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.43 -17.4 0.03 OUTLIER Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.749 -1.341 . . . . 0.0 109.749 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.596 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.13 -34.19 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 O-C-N 120.969 -1.312 . . . . 0.0 108.453 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.593 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.9 OUTLIER -71.08 -21.32 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.512 -0.743 . . . . 0.0 110.042 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -55.06 -33.6 62.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.29 -0.881 . . . . 0.0 111.388 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 31.6 m -114.02 -64.52 1.3 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.055 -1.028 . . . . 0.0 111.522 -178.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.536 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.7 mp -65.45 -51.68 58.45 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.0 -1.062 . . . . 0.0 110.573 -178.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.613 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.5 -37.64 69.08 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 120.016 -1.088 . . . . 0.0 110.426 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.605 ' O ' HD13 ' A' ' 45' ' ' ILE . 6.9 tt -58.75 -41.49 86.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.176 -1.191 . . . . 0.0 109.796 -179.193 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.9 tp -66.76 -44.66 80.85 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.299 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -67.89 -37.95 82.39 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.1 t -63.59 -40.94 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.412 -0.805 . . . . 0.0 110.303 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.605 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.3 mp -58.88 -51.09 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.113 -0.992 . . . . 0.0 109.832 -179.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.441 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.14 -37.46 83.84 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.11 -0.994 . . . . 0.0 109.217 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.696 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 25.9 t90 -66.25 -39.61 89.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.445 -0.784 . . . . 0.0 109.538 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -59.53 -41.92 91.09 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.511 -0.743 . . . . 0.0 109.84 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.461 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 4.1 tm-20 -65.77 -39.11 90.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.183 -0.948 . . . . 0.0 109.925 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -60.09 -39.09 84.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.617 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.6 mtp85 -86.02 -54.18 4.64 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 111.247 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -80.4 -22.89 40.79 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.054 -1.028 . . . . 0.0 110.984 -178.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 27.47 57.76 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.461 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 68.3 mt -104.85 148.7 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.343 -1.092 . . . . 0.0 109.424 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.38 155.21 22.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.33 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.411 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.325 -0.859 . . . . 0.0 109.809 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -60.93 -27.12 84.3 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.649 2.232 . . . . 0.0 112.096 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.69 -25.45 67.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.384 -0.823 . . . . 0.0 109.947 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 52.6 t-80 -67.16 -26.64 66.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.173 -0.955 . . . . 0.0 110.202 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -96.78 3.14 52.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.095 -1.003 . . . . 0.0 109.387 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -56.67 -41.01 76.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.806 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -130.26 147.2 51.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.224 -0.922 . . . . 0.0 109.926 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.75 HD13 ' HB2' ' A' ' 8' ' ' ALA . 82.8 mt -63.12 -35.85 73.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 O-C-N 121.372 -0.83 . . . . 0.0 109.977 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.5 mtm180 -60.35 -37.35 80.4 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.202 -0.936 . . . . 0.0 110.108 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.3 t -58.67 -39.77 81.62 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.035 -1.041 . . . . 0.0 108.821 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.5 mt -62.65 -38.19 80.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.4 -0.812 . . . . 0.0 108.985 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.576 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.3 t0 -54.31 -38.73 66.29 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.409 -0.807 . . . . 0.0 109.275 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.15 93.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.927 . . . . 0.0 109.246 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -65.4 -46.35 80.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.244 -0.91 . . . . 0.0 109.374 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.2 t -65.38 -41.99 92.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.383 -0.823 . . . . 0.0 110.123 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.4 t -62.8 -42.92 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.085 -1.009 . . . . 0.0 109.864 -179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.95 -36.41 92.13 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.47 -49.79 5.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 110.532 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 37.9 m -129.22 139.68 51.77 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.835 . . . . 0.0 109.95 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.38 -0.825 . . . . 0.0 109.284 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 68.1 tp60 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.229 0.538 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.563 ' NE2' ' OG1' ' A' ' 81' ' ' THR . 95.9 m-70 -139.98 8.82 2.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.182 -0.949 . . . . 0.0 109.78 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.449 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.83 -37.49 79.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.163 -0.961 . . . . 0.0 109.394 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -59.76 -36.53 76.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.216 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 82.5 t -64.91 -37.25 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.388 -0.82 . . . . 0.0 109.45 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.54 ' CG2' HG23 ' A' ' 69' ' ' ILE . 89.6 mt -59.54 -48.53 86.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.567 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.612 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.25 -45.25 92.4 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.092 -1.005 . . . . 0.0 108.628 179.288 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -38.22 88.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.512 0.672 . . . . 0.0 109.398 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.433 ' N ' ' O ' ' A' ' 6' ' ' VAL . 68.6 t80 -64.51 -51.69 61.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.567 -0.708 . . . . 0.0 110.003 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.524 ' HB ' HD12 ' A' ' 36' ' ' ILE . 16.2 m -74.42 -41.53 49.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 110.457 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 8' ' ' ALA . 73.9 t -62.85 -36.22 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.16 -0.963 . . . . 0.0 110.403 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -57.36 -36.91 71.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -67.38 -36.85 82.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 110.504 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -90.58 -61.61 1.64 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.028 -1.045 . . . . 0.0 110.721 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.1 mt . . . . . 0 N--CA 1.493 1.691 0 O-C-N 121.304 -0.873 . . . . 0.0 110.134 -179.118 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.5 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.87 -27.51 59.05 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.528 1.485 . . . . 0.0 111.808 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.28 -17.07 63.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.198 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.5 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.9 m-20 -82.95 -1.26 51.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.385 -0.822 . . . . 0.0 108.787 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -102.5 138.65 25.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.505 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.4 t0 -67.93 94.36 0.47 Allowed 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.125 -0.984 . . . . 0.0 109.4 -179.399 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.5 m -60.87 0.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.363 -0.835 . . . . 0.0 109.319 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.505 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.1 m-20 -87.57 9.58 20.68 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.007 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -87.38 134.59 33.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.47 -0.769 . . . . 0.0 109.516 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.481 ' OD1' ' O ' ' A' ' 67' ' ' ARG . 86.1 m-20 -62.27 122.29 15.26 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 108.776 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.733 HD11 HG12 ' A' ' 69' ' ' ILE . 76.3 mt -58.13 -10.82 2.1 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.176 -0.952 . . . . 0.0 109.311 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 89.0 t -50.55 -45.35 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.116 -0.99 . . . . 0.0 108.691 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -55.94 -36.54 67.88 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.2 m-20 -90.13 22.91 3.05 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.13 -15.13 0.01 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -52.61 -37.2 23.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.308 . . . . 0.0 108.542 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.524 HD12 ' HB ' ' A' ' 11' ' ' VAL . 2.8 tt -70.48 -19.42 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.514 -0.741 . . . . 0.0 110.167 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.589 ' OD1' ' CE1' ' A' ' 66' ' ' PHE . 77.2 m-20 -56.71 -35.57 68.66 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.234 -0.916 . . . . 0.0 111.461 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -113.08 -64.56 1.29 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.086 -1.009 . . . . 0.0 111.268 -178.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.41 -48.93 77.52 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.066 -1.021 . . . . 0.0 110.02 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.08 -43.52 56.6 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -58.8 -39.66 81.76 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -1.097 . . . . 0.0 109.371 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.77 -44.24 93.96 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.171 -0.956 . . . . 0.0 108.772 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -68.42 -39.95 81.41 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.323 -0.861 . . . . 0.0 109.602 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.4 t -65.84 -44.09 92.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.4 -0.812 . . . . 0.0 110.123 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.413 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.2 mp -61.63 -50.5 80.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.127 -0.983 . . . . 0.0 109.481 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.413 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -66.85 -38.25 86.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.311 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 44.7 t90 -68.97 -43.57 74.68 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.328 -0.858 . . . . 0.0 109.6 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.7 tp -60.2 -43.68 95.76 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.434 -0.792 . . . . 0.0 109.485 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.429 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 85.4 tt0 -67.71 -36.3 80.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.298 -0.876 . . . . 0.0 109.874 179.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -59.42 -39.24 82.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.838 -1.164 . . . . 0.0 110.119 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 36.3 mtp180 -87.04 -58.22 2.67 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.184 -0.947 . . . . 0.0 111.522 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -80.58 -23.16 40.06 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.951 -1.093 . . . . 0.0 111.733 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.71 35.01 33.15 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.319 -1.42 . . . . 0.0 109.709 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.429 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.2 mt -97.63 138.5 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.247 -1.149 . . . . 0.0 108.878 179.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.93 142.72 56.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.891 -1.131 . . . . 0.0 109.487 -179.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.356 -0.84 . . . . 0.0 109.335 -179.715 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_exo -51.67 -23.55 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.283 1.989 . . . . 0.0 111.971 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.5 -20.87 61.51 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 109.564 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -67.43 -26.94 66.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.309 -0.869 . . . . 0.0 110.383 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.589 ' CE1' ' OD1' ' A' ' 37' ' ' ASP . 51.7 m-85 -72.91 -14.14 61.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.009 -1.057 . . . . 0.0 109.555 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.481 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 25.1 mmt180 -56.79 -35.94 69.3 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.299 -0.875 . . . . 0.0 110.194 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.9 p -157.52 143.77 17.75 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.86 -1.15 . . . . 0.0 110.463 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.733 HG12 HD11 ' A' ' 30' ' ' LEU . 84.9 mt -66.99 -36.6 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 O-C-N 121.562 -0.711 . . . . 0.0 110.172 179.521 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -60.27 -41.89 94.25 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -0.829 . . . . 0.0 110.629 -178.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -57.49 -42.12 82.06 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.134 -0.978 . . . . 0.0 109.774 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.14 -38.66 80.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.133 -0.979 . . . . 0.0 109.928 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 77' ' ' VAL . 40.4 t0 -57.72 -40.54 79.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 -179.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.9 85.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.142 -0.974 . . . . 0.0 109.745 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -62.97 -48.88 76.95 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.228 -0.92 . . . . 0.0 109.398 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.55 -45.47 88.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.242 -0.911 . . . . 0.0 109.725 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 73' ' ' ASP . 49.2 t -60.91 -41.84 90.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 O-C-N 121.069 -1.02 . . . . 0.0 109.592 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.96 -28.42 63.56 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.32 -50.67 3.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.139 -1.212 . . . . 0.0 110.678 -179.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.1 t -149.17 156.58 42.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.068 -1.02 . . . . 0.0 109.997 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.563 ' OG1' ' NE2' ' A' ' 3' ' ' HIS . 0.2 OUTLIER . . . . . 0 C--N 1.302 -1.466 0 O-C-N 121.454 -0.779 . . . . 0.0 108.918 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.594 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 93.4 mt-30 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.594 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 22.0 p-80 40.28 24.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.412 -0.805 . . . . 0.0 109.164 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.553 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -61.53 -37.58 84.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.488 -0.757 . . . . 0.0 109.652 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 m -59.56 -38.1 80.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -0.943 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' CB ' ' A' ' 10' ' ' PHE . 71.6 t -64.28 -37.53 80.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.255 -0.903 . . . . 0.0 109.07 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.474 HD11 ' NE2' ' A' ' 3' ' ' HIS . 77.9 mt -64.19 -46.82 92.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.283 -0.886 . . . . 0.0 109.961 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.683 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.21 -49.98 69.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.293 -0.879 . . . . 0.0 110.593 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.751 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.72 -40.93 75.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.014 -1.054 . . . . 0.0 109.866 -179.661 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.751 ' N ' HE21 ' A' ' 9' ' ' GLN . 74.4 t80 -63.69 -51.32 65.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -0.973 . . . . 0.0 110.159 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.47 HG12 ' O ' ' A' ' 7' ' ' ILE . 5.0 p -68.51 -40.38 81.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.703 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 8' ' ' ALA . 72.4 t -66.95 -37.8 80.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.311 -0.868 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -52.41 -29.67 25.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.378 -0.827 . . . . 0.0 109.992 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.51 -30.42 71.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.222 -0.924 . . . . 0.0 109.679 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.574 ' CE1' ' OD1' ' A' ' 33' ' ' ASN . 38.6 p90 -142.56 38.52 1.52 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.068 -1.02 . . . . 0.0 109.963 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.832 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.459 0 O-C-N 120.827 -1.17 . . . . 0.0 110.053 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.496 ' HD3' HD12 ' A' ' 16' ' ' LEU . 35.2 Cg_exo -50.02 -31.09 26.51 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 C-N-CA 121.943 1.762 . . . . 0.0 112.104 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.3 -25.44 68.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.64 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -96.74 8.62 43.86 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.237 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.46 137.18 28.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.356 -0.84 . . . . 0.0 108.818 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.53 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.87 85.89 0.33 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.216 -0.927 . . . . 0.0 109.642 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.8 m -59.97 0.08 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.387 -0.82 . . . . 0.0 109.086 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.53 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.64 7.69 40.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.345 -0.847 . . . . 0.0 108.87 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.9 tp -90.81 138.0 31.92 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.45 -0.781 . . . . 0.0 109.454 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.36 121.54 15.07 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.415 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -72.53 3.34 5.0 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.944 -178.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.2 p -52.46 -39.22 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.007 -1.058 . . . . 0.0 108.635 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -58.11 -34.74 70.53 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.736 ' N ' HD22 ' A' ' 33' ' ' ASN . 0.9 OUTLIER -84.42 16.97 2.81 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 179.093 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.17 -17.37 0.03 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.79 -35.81 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.038 -1.272 . . . . 0.0 108.51 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.4 tt -70.22 -16.07 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.571 -0.706 . . . . 0.0 109.768 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -55.87 -32.94 64.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 111.392 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 73.9 m -119.43 -64.69 1.24 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.008 -1.057 . . . . 0.0 111.601 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.482 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.5 mp -62.51 -48.14 80.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 110.612 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -42.56 60.99 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.534 ' O ' HD13 ' A' ' 45' ' ' ILE . 2.5 mt -62.39 -38.92 91.5 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.272 -1.134 . . . . 0.0 109.675 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.8 tp -59.12 -44.03 91.99 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.143 -0.973 . . . . 0.0 108.676 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -66.16 -38.25 87.62 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.291 -0.881 . . . . 0.0 109.017 178.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.2 t -64.93 -39.6 86.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.527 -0.733 . . . . 0.0 110.054 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.534 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.4 mp -58.1 -50.27 78.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.221 -0.925 . . . . 0.0 109.679 -179.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.54 -38.16 90.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.14 -0.975 . . . . 0.0 109.171 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.741 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 51.6 t90 -66.84 -40.15 87.86 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.392 -0.817 . . . . 0.0 109.474 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.6 tp -61.01 -43.53 98.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.462 -0.774 . . . . 0.0 109.735 -179.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.403 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 85.4 tt0 -66.3 -36.4 82.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 110.001 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -62.3 -46.24 89.65 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.045 -1.034 . . . . 0.0 110.837 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.741 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt180 -87.4 -51.14 6.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.074 -1.016 . . . . 0.0 111.798 -178.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.785 ' CE2' HG21 ' A' ' 80' ' ' THR . 95.3 m-85 -79.88 -24.1 41.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.966 -1.084 . . . . 0.0 111.13 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.47 31.54 45.55 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.44 -1.362 . . . . 0.0 109.739 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.403 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 68.1 mt -100.21 136.31 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.167 -1.196 . . . . 0.0 108.656 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.925 -1.11 . . . . 0.0 109.765 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.462 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.512 0 O-C-N 121.522 -0.736 . . . . 0.0 109.405 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -57.69 -30.67 89.75 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.757 2.304 . . . . 0.0 112.11 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.54 -31.83 73.21 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.264 -0.897 . . . . 0.0 109.509 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.479 ' CE1' ' O ' ' A' ' 71' ' ' SER . 83.7 t60 -68.59 -26.19 65.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 110.653 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.491 ' CZ ' HD11 ' A' ' 41' ' ' LEU . 97.1 m-85 -88.79 7.35 34.5 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.996 -1.065 . . . . 0.0 110.489 -178.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 24.0 mmt85 -58.07 -36.33 72.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.07 -1.019 . . . . 0.0 109.968 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 90.9 p -133.68 150.04 51.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.208 -0.932 . . . . 0.0 109.834 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.9 mt -66.05 -36.45 77.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.313 -0.867 . . . . 0.0 109.875 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -60.93 -37.61 82.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.171 -0.955 . . . . 0.0 109.916 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.479 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 88.4 p -61.37 -35.73 78.25 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.07 -1.019 . . . . 0.0 109.274 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.3 mt -61.41 -39.06 81.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.25 -0.907 . . . . 0.0 109.015 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.725 ' O ' HG23 ' A' ' 77' ' ' VAL . 51.3 t0 -59.24 -37.32 77.27 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.515 -0.741 . . . . 0.0 109.68 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.19 -46.67 82.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.188 -0.945 . . . . 0.0 109.872 -179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.414 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 68.9 t80 -66.12 -44.85 83.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.053 -1.029 . . . . 0.0 109.079 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -62.63 -41.83 93.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.471 -0.768 . . . . 0.0 109.549 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.6 t -61.92 -41.73 91.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 O-C-N 121.264 -0.898 . . . . 0.0 109.661 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.65 -36.33 85.29 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -90.57 -49.82 6.28 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.11 -1.23 . . . . 0.0 110.079 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.785 HG21 ' CE2' ' A' ' 52' ' ' PHE . 12.4 t -145.1 153.35 41.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -0.888 . . . . 0.0 109.577 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.667 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.1 mt-30 . . . . . 0 N--CA 1.488 1.447 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.4 m80 61.79 20.09 11.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -0.988 . . . . 0.0 109.139 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -63.43 -38.24 90.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.6 m -60.79 -39.12 87.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.97 . . . . 0.0 110.065 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.5 t -64.81 -38.09 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.103 -0.998 . . . . 0.0 109.554 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.674 ' O ' HG22 ' A' ' 11' ' ' VAL . 83.2 mt -59.81 -50.8 78.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.25 -0.906 . . . . 0.0 109.631 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.718 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.21 -46.36 84.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 109.139 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.36 -39.98 94.95 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.4 -0.813 . . . . 0.0 109.648 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.64 -51.21 61.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.431 -0.793 . . . . 0.0 110.493 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.674 HG22 ' O ' ' A' ' 7' ' ' ILE . 22.9 m -73.74 -39.28 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.24 -0.913 . . . . 0.0 110.367 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.718 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.3 t -65.13 -39.03 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.065 -1.022 . . . . 0.0 109.773 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -53.12 -35.87 60.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 109.8 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.62 -31.88 72.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.27 -0.894 . . . . 0.0 109.918 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.88 39.86 3.12 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 110.047 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.834 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.93 -1.106 . . . . 0.0 110.024 -179.73 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -49.52 -30.28 20.91 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.929 1.753 . . . . 0.0 112.052 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.04 -22.86 67.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.307 -0.87 . . . . 0.0 109.643 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -96.11 7.13 47.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.333 -0.854 . . . . 0.0 109.132 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.58 136.52 34.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.535 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.1 89.61 0.44 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.175 -0.953 . . . . 0.0 109.605 -179.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -59.63 0.11 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.261 -0.899 . . . . 0.0 109.146 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.535 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -92.21 8.22 39.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.352 -0.842 . . . . 0.0 108.786 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.0 tp -90.96 139.06 31.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.427 -0.796 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.416 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.9 m-20 -60.82 121.58 12.69 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -69.86 7.13 0.97 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.254 -0.904 . . . . 0.0 109.847 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -53.46 -38.61 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.113 -0.992 . . . . 0.0 109.123 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.92 -36.45 72.5 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.15 19.55 3.09 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -15.01 0.02 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.63 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -53.43 -36.49 27.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.125 -1.221 . . . . 0.0 108.862 179.53 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.5 tt -70.38 -22.48 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.538 -0.726 . . . . 0.0 110.245 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.3 m-20 -55.42 -33.22 63.36 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 110.932 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -116.17 -63.75 1.41 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.123 -0.985 . . . . 0.0 111.24 -178.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.54 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.4 mm? -62.41 -52.18 64.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.047 -1.033 . . . . 0.0 110.096 -178.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.6 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.79 -40.19 64.87 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.7 tt -58.7 -41.04 85.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -1.094 . . . . 0.0 109.552 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 24.9 tp -62.76 -44.4 96.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.935 . . . . 0.0 109.024 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -66.24 -35.12 79.6 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.349 -0.844 . . . . 0.0 109.592 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 40' ' ' GLY . 64.2 t -60.86 -42.99 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 110.24 -179.366 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -59.64 -50.54 79.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.105 -0.997 . . . . 0.0 109.632 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.91 -36.65 82.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 34.3 t90 -67.79 -43.33 79.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 109.633 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.01 -46.3 85.48 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.477 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -67.84 -38.05 82.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.35 -0.844 . . . . 0.0 109.067 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.8 t0 -65.47 -41.48 93.32 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 110.64 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 74.5 ttt-85 -87.12 -58.14 2.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.171 -0.956 . . . . 0.0 111.662 -178.385 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -79.73 -19.47 48.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.02 -1.05 . . . . 0.0 111.559 -177.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 28.19 56.26 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -104.47 142.58 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.405 -1.056 . . . . 0.0 109.348 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.47 154.73 23.69 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.237 -0.914 . . . . 0.0 109.143 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.494 0 O-C-N 121.259 -0.901 . . . . 0.0 109.405 -179.354 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.476 -0.565 . . . . 0.0 109.476 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.19 -21.47 59.91 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.892 2.395 . . . . 0.0 111.866 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.43 -32.32 70.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.402 -0.811 . . . . 0.0 110.091 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.44 ' O ' ' OG ' ' A' ' 71' ' ' SER . 44.9 t-80 -70.23 -26.27 63.77 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.319 -0.863 . . . . 0.0 111.404 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -95.11 8.0 44.37 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.799 -1.188 . . . . 0.0 110.817 -178.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -60.91 -38.44 85.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.998 -1.064 . . . . 0.0 110.671 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.4 m -126.66 147.58 49.91 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.222 -0.924 . . . . 0.0 110.483 -179.149 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.2 -36.09 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 O-C-N 121.434 -0.791 . . . . 0.0 109.802 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -60.42 -37.7 81.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 110.157 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 97.6 p -61.44 -36.85 81.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.08 -1.013 . . . . 0.0 109.282 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.6 -38.62 82.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.373 -0.83 . . . . 0.0 109.117 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 53.5 t0 -56.52 -38.74 72.24 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.43 -0.794 . . . . 0.0 109.655 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.84 -42.04 97.7 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.132 -0.98 . . . . 0.0 109.405 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -64.35 -45.66 86.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.863 . . . . 0.0 109.563 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.6 t -65.0 -42.42 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.348 -0.845 . . . . 0.0 110.05 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.2 t -63.18 -42.37 96.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.155 -0.966 . . . . 0.0 109.892 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.9 -30.07 72.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -97.69 -49.54 4.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.958 -1.319 . . . . 0.0 110.307 -179.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 76' ' ' VAL . 11.0 t -139.19 155.54 47.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.554 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.488 1.467 0 O-C-N 121.448 -0.783 . . . . 0.0 109.514 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.335 0.588 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.726 ' CD2' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -163.88 25.0 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.155 -0.966 . . . . 0.0 109.385 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.641 ' HB2' ' OD1' ' A' ' 73' ' ' ASP . . . -61.87 -34.83 76.71 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.231 -0.918 . . . . 0.0 109.563 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 t -59.11 -39.6 82.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.159 -0.963 . . . . 0.0 109.543 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.726 HG21 ' CD2' ' A' ' 3' ' ' HIS . 78.3 t -65.13 -39.29 85.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.2 179.63 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.5 ' O ' HG23 ' A' ' 11' ' ' VAL . 88.1 mt -59.86 -48.0 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.444 -0.785 . . . . 0.0 109.657 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.487 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.66 -46.37 85.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.318 -0.864 . . . . 0.0 109.656 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.434 ' HG3' ' N ' ' A' ' 10' ' ' PHE . 0.9 OUTLIER -69.52 -36.54 76.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.547 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.3 t80 -68.57 -48.23 64.76 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.389 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.527 HG13 HD12 ' A' ' 36' ' ' ILE . 73.7 t -69.12 -46.3 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 110.104 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 8' ' ' ALA . 76.6 t -63.53 -35.2 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.39 -0.819 . . . . 0.0 110.676 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.95 -36.8 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.125 -0.985 . . . . 0.0 109.86 -179.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.72 -35.39 78.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 110.685 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -91.99 -63.6 1.22 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.022 -1.049 . . . . 0.0 110.731 -178.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.9 mt . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.255 -0.903 . . . . 0.0 110.19 -179.024 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.652 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.487 1.403 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.0 -28.6 57.6 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.574 1.516 . . . . 0.0 111.813 -179.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.62 -14.75 62.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.391 -0.818 . . . . 0.0 109.174 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.652 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 90.0 m-20 -82.94 -0.16 47.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.377 -0.827 . . . . 0.0 108.917 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -98.94 137.74 25.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.525 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -67.41 92.75 0.3 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.087 -1.008 . . . . 0.0 109.437 -179.277 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.9 m -59.77 0.01 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.421 -0.799 . . . . 0.0 109.206 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -88.98 5.69 43.05 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.8 tp -92.67 136.42 33.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.612 -0.68 . . . . 0.0 109.399 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.45 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.2 m-20 -60.93 121.58 12.74 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.1 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.518 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -67.02 6.53 0.51 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.126 -0.983 . . . . 0.0 109.72 -178.938 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.513 HG21 ' NH2' ' A' ' 67' ' ' ARG . 5.1 p -54.78 -37.57 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 108.933 179.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.432 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.25 -36.31 70.8 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.1 m-20 -84.96 17.92 2.69 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.44 ' O ' ' CG ' ' A' ' 37' ' ' ASP . . . -42.87 -14.26 0.01 OUTLIER Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.6 t -51.34 -37.93 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 108.855 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.527 HD12 HG13 ' A' ' 11' ' ' VAL . 0.9 OUTLIER -70.9 -11.82 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.47 -0.769 . . . . 0.0 109.757 179.92 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.44 ' CG ' ' O ' ' A' ' 34' ' ' GLY . 85.3 m-20 -51.64 -42.31 61.96 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 111.376 -177.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -120.91 -58.66 1.8 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.109 -0.995 . . . . 0.0 111.975 -178.381 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.567 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.6 mp -61.27 -52.15 65.95 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.825 -1.172 . . . . 0.0 110.135 -178.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.625 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.56 -36.06 68.08 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.756 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.98 -43.23 86.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -1.083 . . . . 0.0 109.548 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.65 -43.91 95.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.076 -1.015 . . . . 0.0 109.205 179.577 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -65.27 -38.05 89.1 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 40' ' ' GLY . 80.0 t -65.31 -39.93 86.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.381 -0.825 . . . . 0.0 110.067 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.442 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -58.45 -50.1 79.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.155 -0.966 . . . . 0.0 109.905 -179.333 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.442 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -60.98 -36.7 80.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.971 -1.081 . . . . 0.0 109.94 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.547 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -76.58 -41.92 44.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.143 -0.973 . . . . 0.0 110.126 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.7 tt -60.84 -43.12 98.74 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.411 -0.805 . . . . 0.0 110.801 -178.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.714 ' OE1' ' HB2' ' A' ' 56' ' ' ALA . 54.8 mt-10 -65.78 -39.64 91.2 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.946 -1.096 . . . . 0.0 109.217 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -67.84 -49.21 63.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.419 -0.8 . . . . 0.0 110.932 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.615 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 67.4 ttt-85 -62.07 -41.3 98.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 97.5 m-85 -101.58 -9.62 20.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.953 -1.092 . . . . 0.0 110.559 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.21 35.78 88.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -105.88 143.94 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.302 -1.117 . . . . 0.0 109.869 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.76 152.85 34.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.365 -0.835 . . . . 0.0 109.082 179.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.714 ' HB2' ' OE1' ' A' ' 49' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 110.206 -179.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.43 -28.06 77.78 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.532 2.154 . . . . 0.0 111.943 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -60.95 -28.3 68.88 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.418 -0.801 . . . . 0.0 109.993 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.402 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 78.4 t60 -67.78 -26.54 66.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.15 -0.969 . . . . 0.0 110.188 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -100.75 8.12 43.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.767 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.513 ' NH2' HG21 ' A' ' 31' ' ' VAL . 20.5 tpt180 -54.86 -40.06 69.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.356 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -127.69 148.6 50.4 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.319 -0.863 . . . . 0.0 109.69 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.3 mt -60.72 -36.59 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.299 -0.876 . . . . 0.0 109.891 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -60.55 -39.26 87.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.271 -0.893 . . . . 0.0 110.25 -179.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 m -58.25 -41.25 83.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.983 -1.073 . . . . 0.0 109.521 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.2 -38.62 83.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.839 ' O ' HG23 ' A' ' 77' ' ' VAL . 91.9 m-20 -56.31 -38.14 70.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.461 -0.774 . . . . 0.0 109.609 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.88 -45.99 86.92 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.402 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.6 t80 -65.69 -46.67 78.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.181 179.572 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.3 t -64.35 -40.73 90.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.422 -0.799 . . . . 0.0 109.681 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.839 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.1 t -60.33 -43.34 93.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.16 -0.963 . . . . 0.0 109.91 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.46 -37.38 94.71 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -87.62 -50.15 6.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.999 -1.295 . . . . 0.0 110.331 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.9 p -130.8 156.24 45.34 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.409 -0.807 . . . . 0.0 109.199 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.302 -1.474 0 O-C-N 121.219 -0.926 . . . . 0.0 109.609 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -152.04 57.42 0.84 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.905 . . . . 0.0 109.107 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.565 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.36 -35.41 75.61 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.265 -0.897 . . . . 0.0 109.97 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -59.46 -40.8 88.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.055 -1.028 . . . . 0.0 109.545 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.2 t -67.01 -37.85 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.239 -0.913 . . . . 0.0 109.182 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.565 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.8 mt -59.73 -40.03 81.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.496 -0.753 . . . . 0.0 110.101 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 1.018 ' HB1' HG11 ' A' ' 26' ' ' VAL . . . -63.18 -50.0 72.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.023 -1.048 . . . . 0.0 109.294 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.488 ' OE1' ' OE1' ' A' ' 13' ' ' GLU . 1.2 pp0? -69.94 -33.94 72.79 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.338 -0.851 . . . . 0.0 109.439 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.414 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 65.0 t80 -66.35 -51.96 51.84 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.043 -1.035 . . . . 0.0 109.942 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 5.5 p -70.57 -38.7 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.233 -0.917 . . . . 0.0 110.111 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.735 HG23 ' O ' ' A' ' 8' ' ' ALA . 88.6 t -65.25 -42.1 93.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.211 -0.93 . . . . 0.0 110.639 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.488 ' OE1' ' OE1' ' A' ' 9' ' ' GLN . 76.6 mt-10 -55.18 -27.38 45.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.021 -1.049 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.759 ' CD ' HD11 ' A' ' 36' ' ' ILE . 85.7 tt0 -65.38 -27.75 68.79 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 109.101 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.586 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.0 p90 -149.83 41.64 0.85 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.219 -0.926 . . . . 0.0 109.852 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 O-C-N 120.948 -1.095 . . . . 0.0 110.196 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.464 ' HD3' HD12 ' A' ' 16' ' ' LEU . 31.7 Cg_exo -49.94 -32.55 30.85 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.936 1.757 . . . . 0.0 111.938 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.33 -24.84 67.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.453 -0.779 . . . . 0.0 109.64 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -98.47 7.12 46.58 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -0.863 . . . . 0.0 109.453 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.4 t -103.8 135.16 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.315 -0.866 . . . . 0.0 108.879 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.429 ' C ' ' H ' ' A' ' 27' ' ' ASP . 88.0 m-20 -72.17 86.06 1.06 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.219 -0.925 . . . . 0.0 109.315 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.018 HG11 ' HB1' ' A' ' 8' ' ' ALA . 19.7 m -63.11 -0.3 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.233 -0.917 . . . . 0.0 109.627 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.475 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 48.0 p30 -90.7 8.52 34.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.141 -0.974 . . . . 0.0 108.787 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 18.8 tp -93.93 136.37 34.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 109.447 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -60.95 122.48 15.02 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.754 HD11 ' CG2' ' A' ' 69' ' ' ILE . 56.6 mt -66.89 -0.86 3.35 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.258 -0.901 . . . . 0.0 109.87 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.9 t -52.61 -42.47 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.089 -1.007 . . . . 0.0 108.911 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.46 -36.33 66.46 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.619 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.8 m-80 -86.55 20.29 2.53 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.46 -15.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.619 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -53.33 -38.81 32.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.884 -1.363 . . . . 0.0 108.277 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.759 HD11 ' CD ' ' A' ' 14' ' ' GLU . 5.4 tt -70.87 -24.2 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.599 -0.688 . . . . 0.0 109.95 179.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -62.54 -22.51 66.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.181 -0.949 . . . . 0.0 110.697 -178.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -117.47 -64.87 1.24 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.081 -1.012 . . . . 0.0 111.013 -178.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.516 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -67.41 -50.2 60.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.034 -1.041 . . . . 0.0 110.171 -178.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.562 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.74 -41.24 64.13 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tt -61.1 -40.05 92.26 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.494 -1.003 . . . . 0.0 109.617 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.6 tp -58.63 -44.31 89.96 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.189 -0.944 . . . . 0.0 108.569 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.0 mtpt -65.06 -34.2 77.86 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.2 t -64.49 -39.77 86.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.495 -0.753 . . . . 0.0 110.511 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.9 mm -59.22 -50.74 78.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.637 -1.29 . . . . 0.0 109.525 -179.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.87 -41.31 83.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.292 -0.88 . . . . 0.0 109.793 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 16.8 t90 -69.77 -42.81 73.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 110.233 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 33.2 tp -59.36 -41.93 90.43 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.329 -0.857 . . . . 0.0 109.712 -179.384 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.567 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.5 tt0 -64.06 -38.12 89.92 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.238 -0.914 . . . . 0.0 109.753 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -60.07 -37.08 78.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.951 -1.093 . . . . 0.0 110.064 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -75.09 -48.68 22.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.245 -0.91 . . . . 0.0 111.958 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.509 ' CZ ' HG21 ' A' ' 80' ' ' THR . 24.7 m-85 -114.66 -3.12 12.91 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.012 -1.055 . . . . 0.0 111.855 -178.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 30.48 61.22 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.874 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.427 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.8 mt -78.19 138.78 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -1.217 . . . . 0.0 108.977 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 131.21 49.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.827 -1.17 . . . . 0.0 109.736 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.448 -0.782 . . . . 0.0 109.258 179.848 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -50.7 -31.45 32.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.222 1.948 . . . . 0.0 111.69 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.05 -30.72 71.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.423 -0.798 . . . . 0.0 109.074 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -67.65 -26.55 66.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.474 -0.767 . . . . 0.0 109.802 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -91.9 10.22 29.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.181 -0.949 . . . . 0.0 109.449 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -53.61 -36.55 62.11 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.294 -0.879 . . . . 0.0 109.463 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.9 t -150.3 152.61 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.273 -0.892 . . . . 0.0 109.846 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.754 ' CG2' HD11 ' A' ' 30' ' ' LEU . 0.9 OUTLIER -64.31 -36.16 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 179.854 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -60.7 -38.07 83.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.111 -0.993 . . . . 0.0 110.107 -179.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.01 -37.03 85.55 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.073 -1.017 . . . . 0.0 109.16 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.5 mt -66.36 -38.43 81.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.329 -0.857 . . . . 0.0 109.29 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.1 t0 -56.25 -41.05 75.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.491 -0.756 . . . . 0.0 109.88 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.63 -45.33 79.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.205 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.6 t80 -63.08 -48.61 77.88 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -0.966 . . . . 0.0 109.751 -179.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.637 HG12 ' O ' ' A' ' 80' ' ' THR . 71.9 t -66.48 -42.83 90.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.251 -0.906 . . . . 0.0 109.836 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' ' 73' ' ' ASP . 44.5 t -61.96 -40.55 87.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 120.969 -1.082 . . . . 0.0 109.693 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.84 -34.36 71.06 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.36 -50.65 3.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.133 -1.216 . . . . 0.0 110.79 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.637 ' O ' HG12 ' A' ' 76' ' ' VAL . 56.0 m -153.96 140.41 18.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.995 -1.066 . . . . 0.0 110.267 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.282 -0.886 . . . . 0.0 109.239 179.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.684 ' NE2' HG11 ' A' ' 6' ' ' VAL . 57.1 t-80 -148.33 8.06 0.8 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.34 -0.85 . . . . 0.0 109.724 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.63 -39.81 95.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.055 -1.028 . . . . 0.0 109.769 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.3 t -61.52 -40.08 93.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.924 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.684 HG11 ' NE2' ' A' ' 3' ' ' HIS . 78.1 t -63.27 -39.71 86.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.257 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.634 ' O ' HG23 ' A' ' 11' ' ' VAL . 92.0 mt -62.4 -46.45 96.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.346 -0.846 . . . . 0.0 110.01 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.45 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.88 -49.93 70.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 110.411 -179.327 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.436 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 4.2 pp0? -69.91 -42.07 73.83 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.182 -0.949 . . . . 0.0 109.894 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 9' ' ' GLN . 71.4 t80 -60.49 -46.47 90.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 7' ' ' ILE . 67.2 t -69.63 -47.01 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.44 -0.787 . . . . 0.0 109.92 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 8' ' ' ALA . 75.5 t -65.51 -35.18 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.404 -0.81 . . . . 0.0 110.453 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -53.52 -36.66 62.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.214 -0.928 . . . . 0.0 109.992 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.96 -35.57 78.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 110.771 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.662 ' O ' HD12 ' A' ' 16' ' ' LEU . 69.9 m-85 -91.74 -63.6 1.23 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.963 -1.085 . . . . 0.0 110.657 -178.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.662 HD12 ' O ' ' A' ' 15' ' ' PHE . 6.2 mp . . . . . 0 N--CA 1.493 1.718 0 O-C-N 121.331 -0.855 . . . . 0.0 110.119 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.544 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.486 1.354 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.9 -25.57 59.81 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.524 1.483 . . . . 0.0 111.723 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.49 -14.87 62.7 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.31 -0.869 . . . . 0.0 109.232 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.544 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -82.87 2.91 31.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.255 -0.903 . . . . 0.0 108.929 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.13 137.27 32.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.466 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.4 89.17 0.14 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.147 -0.971 . . . . 0.0 109.377 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.7 m -62.31 -0.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.307 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -93.85 7.07 46.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 108.979 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.9 tp -95.7 137.87 34.15 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.483 -0.761 . . . . 0.0 109.6 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -61.71 121.81 13.75 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.453 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.5 OUTLIER -67.97 2.87 1.79 Allowed 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.266 -0.896 . . . . 0.0 109.932 -178.811 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.456 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -51.28 -39.19 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.08 -1.012 . . . . 0.0 108.395 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.42 -35.78 70.5 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.7 m-20 -87.09 22.14 2.14 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.009 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -14.27 0.01 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -51.26 -35.31 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.104 -1.233 . . . . 0.0 108.612 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.624 HD12 HG13 ' A' ' 11' ' ' VAL . 1.1 tt -70.07 -19.94 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.517 -0.739 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.418 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -55.53 -33.18 63.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -0.87 . . . . 0.0 111.046 -178.51 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -116.78 -64.13 1.35 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.115 -0.991 . . . . 0.0 111.356 -178.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.531 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.5 mp -62.88 -52.08 64.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.99 -1.068 . . . . 0.0 110.093 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.67 -38.92 67.39 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.723 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.2 tt -58.45 -43.08 88.7 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.401 -1.058 . . . . 0.0 109.725 -179.75 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 tp -60.23 -44.32 95.31 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 108.956 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -69.72 -40.1 76.46 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.373 -0.829 . . . . 0.0 109.967 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.8 t -66.03 -45.01 91.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 110.391 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.2 mp -59.45 -50.24 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.084 -1.01 . . . . 0.0 109.513 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.401 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.62 -32.2 73.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 29.6 t90 -74.46 -45.83 43.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.878 . . . . 0.0 110.246 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -57.41 -45.31 84.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.362 -0.836 . . . . 0.0 110.009 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.414 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 8.4 pt-20 -71.23 -36.42 71.82 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.098 -1.001 . . . . 0.0 109.056 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.9 t0 -64.78 -41.45 95.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.322 -0.861 . . . . 0.0 110.639 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.4 ttt180 -83.78 -51.56 7.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 110.95 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.743 ' CE2' HG21 ' A' ' 80' ' ' THR . 92.7 m-85 -79.85 -24.55 41.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.05 -1.031 . . . . 0.0 110.842 -178.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.41 31.44 54.54 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 53.9 mt -109.4 134.28 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -1.085 . . . . 0.0 109.582 -179.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.93 143.39 57.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.352 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 -179.84 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.89 -26.88 74.53 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.481 2.121 . . . . 0.0 112.281 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -57.65 -27.42 62.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.843 . . . . 0.0 109.654 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.518 ' NE2' HG23 ' A' ' 72' ' ' ILE . 85.9 t60 -67.13 -26.92 66.91 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.941 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -101.1 4.25 42.01 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.028 -1.045 . . . . 0.0 110.373 -179.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -58.86 -40.94 85.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.887 -1.133 . . . . 0.0 109.86 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.1 p -150.06 154.89 38.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.903 -1.123 . . . . 0.0 110.019 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 87.6 mt -65.33 -37.36 79.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.343 -0.848 . . . . 0.0 109.857 179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.7 ttp180 -60.93 -40.43 93.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 110.164 -179.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -59.58 -41.85 91.19 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.999 -1.063 . . . . 0.0 109.695 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.518 HG23 ' NE2' ' A' ' 65' ' ' HIS . 87.2 mt -67.43 -39.96 83.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.258 -0.901 . . . . 0.0 110.005 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.455 ' HA ' HD11 ' A' ' 7' ' ' ILE . 52.5 t0 -59.16 -40.79 86.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 110.188 -179.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.53 -42.71 98.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.129 -0.982 . . . . 0.0 109.586 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.0 t80 -63.74 -45.34 90.34 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.247 -0.908 . . . . 0.0 109.336 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.7 t -63.75 -45.36 97.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.355 -0.841 . . . . 0.0 109.915 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.0 t -60.97 -40.09 84.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 O-C-N 121.125 -0.984 . . . . 0.0 109.637 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.76 -32.25 65.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.15 -50.17 3.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.084 -1.245 . . . . 0.0 110.403 -179.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.743 HG21 ' CE2' ' A' ' 52' ' ' PHE . 8.4 t -146.22 155.61 42.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.171 -0.956 . . . . 0.0 110.021 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.317 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -136.39 11.84 3.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.334 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.75 -33.24 71.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.347 -0.846 . . . . 0.0 109.918 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.35 -35.3 77.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.097 -1.002 . . . . 0.0 109.552 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.26 -37.83 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.184 -0.947 . . . . 0.0 109.167 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 11' ' ' VAL . 87.3 mt -63.55 -43.27 98.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.067 -1.021 . . . . 0.0 110.089 -179.84 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.655 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.22 -50.67 67.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.789 -179.178 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.5 -36.93 74.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.958 -1.088 . . . . 0.0 110.065 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -59.4 -51.3 70.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.844 -1.16 . . . . 0.0 110.082 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.589 HG22 ' O ' ' A' ' 7' ' ' ILE . 20.4 m -74.3 -40.64 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.142 -0.973 . . . . 0.0 110.32 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.7 t -62.49 -39.38 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.257 -0.902 . . . . 0.0 110.502 -179.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -61.86 -32.56 72.92 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.128 -0.982 . . . . 0.0 110.02 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.37 -33.24 75.28 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.869 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 11' ' ' VAL . 62.3 m-85 -93.1 -63.86 1.16 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.162 -0.961 . . . . 0.0 110.451 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.289 -0.882 . . . . 0.0 110.594 -178.707 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.578 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.487 1.4 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -64.84 -27.61 59.24 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 121.54 1.493 . . . . 0.0 111.924 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.56 -14.84 62.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.443 -0.786 . . . . 0.0 109.213 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.578 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.1 m-20 -83.3 4.13 28.48 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.42 -0.8 . . . . 0.0 109.18 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.5 t -102.09 136.88 32.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.45 -0.781 . . . . 0.0 108.906 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' A' ' 27' ' ' ASP . 47.6 p30 -67.48 84.36 0.17 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.225 -0.922 . . . . 0.0 109.734 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -60.4 0.23 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.263 179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -88.25 3.75 48.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 108.87 179.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.92 139.82 30.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.524 -0.735 . . . . 0.0 109.45 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -60.93 121.73 13.11 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 179.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -66.23 1.41 1.56 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.146 -0.971 . . . . 0.0 109.927 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.7 -39.16 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.038 -1.038 . . . . 0.0 108.29 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.458 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.93 -34.94 72.3 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.107 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.725 ' N ' HD22 ' A' ' 33' ' ' ASN . 1.0 OUTLIER -84.11 16.5 2.9 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.54 -15.12 0.02 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.01 -36.44 15.89 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.922 -1.34 . . . . 0.0 108.769 179.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.588 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.0 tt -70.54 -19.53 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.469 -0.769 . . . . 0.0 109.774 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -55.94 -31.73 63.19 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.324 -0.86 . . . . 0.0 111.228 -178.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.9 m -118.89 -64.71 1.25 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.099 -1.0 . . . . 0.0 111.334 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -61.68 -52.18 65.39 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.76 -1.213 . . . . 0.0 109.891 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.68 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.44 -38.27 62.27 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.588 ' N ' ' O ' ' A' ' 36' ' ' ILE . 30.5 tp -58.54 -44.2 89.52 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.343 -1.093 . . . . 0.0 109.979 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.445 HD23 ' HA ' ' A' ' 42' ' ' LEU . 86.1 mt -61.71 -43.82 98.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.117 -0.989 . . . . 0.0 109.287 179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -62.65 -34.91 78.03 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.239 -0.913 . . . . 0.0 108.916 179.206 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.0 t -62.74 -39.8 86.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.529 -0.732 . . . . 0.0 110.136 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.581 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 33.7 mm -58.6 -50.3 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.008 -1.057 . . . . 0.0 109.734 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.15 -37.64 84.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.722 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.0 t90 -70.48 -44.6 67.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.962 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.405 HD12 ' CD1' ' A' ' 52' ' ' PHE . 12.3 tp -58.34 -47.12 84.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 109.63 -179.186 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.413 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -66.82 -37.39 84.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -0.929 . . . . 0.0 109.11 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.13 -42.13 84.95 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 110.668 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.3 ttt-85 -87.37 -58.48 2.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.257 -0.902 . . . . 0.0 111.809 -178.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.405 ' CD1' HD12 ' A' ' 48' ' ' LEU . 88.8 m-85 -79.85 -19.46 48.29 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 111.599 -177.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 33.05 41.11 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.413 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.1 mt -102.8 141.87 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.375 -1.074 . . . . 0.0 109.374 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.88 145.01 54.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.254 -0.904 . . . . 0.0 109.854 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.581 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.538 -0.726 . . . . 0.0 109.876 -179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.74 -25.64 74.95 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.68 2.253 . . . . 0.0 112.235 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.36 -31.46 71.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 109.727 -179.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 48.6 t-80 -68.63 -25.93 65.09 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.446 -0.784 . . . . 0.0 111.127 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -95.6 5.86 50.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.743 -1.223 . . . . 0.0 110.92 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 -60.21 -37.53 80.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.895 -1.128 . . . . 0.0 110.353 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.3 p -133.38 147.44 51.79 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.076 -1.015 . . . . 0.0 110.07 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.437 HG23 ' CG2' ' A' ' 7' ' ' ILE . 78.1 mt -66.38 -36.71 78.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 O-C-N 121.432 -0.793 . . . . 0.0 109.797 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 92.3 mtm-85 -60.97 -37.97 84.28 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.346 -0.846 . . . . 0.0 110.099 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.3 p -61.72 -35.92 79.45 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.107 -0.996 . . . . 0.0 109.458 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.566 ' HB ' HD13 ' A' ' 7' ' ' ILE . 61.8 mt -66.71 -39.02 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.238 -0.914 . . . . 0.0 109.174 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.532 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.8 t0 -59.1 -39.44 82.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.333 -0.855 . . . . 0.0 109.779 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.27 -44.2 92.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.1 -1.0 . . . . 0.0 109.654 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -63.42 -46.17 87.57 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.242 -0.911 . . . . 0.0 109.387 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -64.43 -43.36 96.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.346 -0.846 . . . . 0.0 109.739 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 73' ' ' ASP . 51.1 t -60.35 -40.83 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 O-C-N 121.24 -0.913 . . . . 0.0 109.659 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.31 -32.56 72.57 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.88 -50.41 3.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.063 -1.257 . . . . 0.0 110.719 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.4 p -131.79 157.9 42.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.283 -0.885 . . . . 0.0 109.827 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.408 0 O-C-N 121.182 -0.949 . . . . 0.0 109.434 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.577 ' NE2' HG21 ' A' ' 77' ' ' VAL . 96.0 mt-30 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.352 -0.611 . . . . 0.0 109.352 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 30.9 m80 60.94 43.42 11.69 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.025 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.521 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -55.68 -34.86 65.41 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.471 -0.768 . . . . 0.0 109.658 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -58.89 -39.35 81.18 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.229 -0.919 . . . . 0.0 109.01 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.0 t -67.78 -39.25 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.401 -0.812 . . . . 0.0 109.004 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 4' ' ' ALA . 90.9 mt -58.95 -50.05 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.479 -0.763 . . . . 0.0 109.634 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.62 -45.75 88.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.353 -0.842 . . . . 0.0 109.668 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.43 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.03 -33.75 74.12 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.365 -0.834 . . . . 0.0 109.694 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.565 ' CE1' ' CZ2' ' A' ' 47' ' ' TRP . 61.7 t80 -64.96 -51.49 61.5 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.091 -1.005 . . . . 0.0 109.694 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.494 HG23 ' N ' ' A' ' 12' ' ' VAL . 15.8 m -74.49 -40.39 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.308 -0.87 . . . . 0.0 110.098 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 8' ' ' ALA . 77.4 t -62.05 -37.8 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.203 -0.936 . . . . 0.0 110.122 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -56.75 -36.7 70.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.33 -0.856 . . . . 0.0 109.752 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -68.16 -35.87 78.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 110.681 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -89.78 -63.01 1.34 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.025 -1.047 . . . . 0.0 110.618 -178.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mt . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.302 -0.874 . . . . 0.0 110.113 -179.285 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.621 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.73 -30.5 59.36 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.612 1.541 . . . . 0.0 112.052 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.75 -14.73 62.55 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.374 -0.829 . . . . 0.0 109.001 179.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.621 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -86.53 4.73 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.547 -0.72 . . . . 0.0 109.116 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -98.74 135.59 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -70.37 83.26 0.56 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.19 -0.944 . . . . 0.0 109.651 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -63.47 -0.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 109.117 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 50.6 p30 -100.39 9.83 42.08 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.248 -0.907 . . . . 0.0 109.195 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.7 tp -92.02 145.39 24.57 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.481 -0.762 . . . . 0.0 109.434 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -60.02 121.4 11.75 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.606 HD11 ' CG1' ' A' ' 69' ' ' ILE . 76.4 mt -61.81 -11.73 13.89 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.436 -0.79 . . . . 0.0 109.97 -178.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' ' 67' ' ' ARG . 22.8 t -50.53 -45.33 26.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.801 -1.187 . . . . 0.0 108.678 -179.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -57.61 -35.34 70.33 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.602 ' O ' ' N ' ' A' ' 35' ' ' VAL . 10.6 m120 -86.9 19.04 3.17 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.05 -18.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.276 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.602 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.5 t -52.8 -38.85 29.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.234 -1.157 . . . . 0.0 108.505 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -70.4 -24.05 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.555 -0.716 . . . . 0.0 109.375 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -56.3 -33.01 65.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.513 -0.742 . . . . 0.0 110.919 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -113.78 -64.47 1.31 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.159 -0.963 . . . . 0.0 111.098 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.537 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.6 mp -64.01 -50.44 68.5 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.955 -1.091 . . . . 0.0 110.188 -178.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.511 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.53 -40.55 67.39 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.73 -40.55 84.1 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.45 -1.029 . . . . 0.0 109.505 -179.552 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.3 tp -65.92 -44.24 85.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -65.22 -37.47 87.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.263 -0.898 . . . . 0.0 110.005 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.4 t -62.28 -43.26 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.351 -0.843 . . . . 0.0 110.073 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.401 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.5 mp -62.87 -50.42 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.244 -0.91 . . . . 0.0 109.911 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.01 -34.91 78.76 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.267 -0.895 . . . . 0.0 110.16 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.565 ' CZ2' ' CE1' ' A' ' 10' ' ' PHE . 3.8 t90 -66.99 -44.39 80.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 0.0 109.946 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.7 tp -57.51 -43.98 84.67 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.406 -0.809 . . . . 0.0 109.716 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -66.31 -38.54 87.96 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.221 -0.924 . . . . 0.0 109.401 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.86 -41.06 95.98 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.147 -0.97 . . . . 0.0 110.648 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -87.17 -58.37 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.104 -0.998 . . . . 0.0 111.644 -178.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -79.73 -19.99 47.49 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.1 -1.0 . . . . 0.0 111.587 -177.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 30.23 50.97 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -179.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.43 142.39 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.412 -1.052 . . . . 0.0 109.421 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.36 154.03 25.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.189 -0.944 . . . . 0.0 109.217 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.449 0 O-C-N 121.233 -0.917 . . . . 0.0 109.542 -179.328 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.155 0.503 . . . . 0.0 109.739 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -60.17 -22.98 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.926 2.417 . . . . 0.0 112.168 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.5 -31.14 71.84 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 110.028 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -67.76 -26.71 66.26 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.47 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 28.2 m-85 -97.07 2.66 51.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.193 -0.942 . . . . 0.0 109.281 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.577 ' HG3' HG23 ' A' ' 31' ' ' VAL . 56.0 ttp180 -56.15 -39.62 72.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.476 -0.765 . . . . 0.0 110.524 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 91.2 p -119.66 148.91 42.8 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.415 -0.803 . . . . 0.0 110.463 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.606 ' CG1' HD11 ' A' ' 30' ' ' LEU . 79.7 mt -65.89 -36.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.679 -0.638 . . . . 0.0 109.981 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -61.5 -39.21 90.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 110.231 -179.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 19.7 m -60.74 -44.14 97.05 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.018 -1.051 . . . . 0.0 109.529 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.647 ' O ' HG23 ' A' ' 76' ' ' VAL . 79.0 mt -67.13 -39.61 83.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.338 -0.852 . . . . 0.0 109.237 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.863 ' O ' HG23 ' A' ' 77' ' ' VAL . 38.6 t0 -57.5 -38.18 74.18 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.541 -0.724 . . . . 0.0 109.617 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.72 -46.24 89.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.954 -1.091 . . . . 0.0 109.434 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -67.06 -47.47 71.2 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.159 -0.963 . . . . 0.0 108.861 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.721 HG12 ' OG1' ' A' ' 81' ' ' THR . 34.1 t -63.17 -40.11 87.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.863 HG23 ' O ' ' A' ' 73' ' ' ASP . 38.0 t -55.63 -42.42 68.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 O-C-N 121.292 -0.88 . . . . 0.0 108.876 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.54 69.14 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.79 -1.724 . . . . 0.0 108.79 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.63 ' C ' HG22 ' A' ' 80' ' ' THR . . . -67.9 -47.55 68.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -1.098 . . . . 0.0 110.213 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.63 HG22 ' C ' ' A' ' 79' ' ' ALA . 0.0 OUTLIER 172.49 2.59 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.045 -1.034 . . . . 0.0 111.328 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.721 ' OG1' HG12 ' A' ' 76' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.665 -1.272 . . . . 0.0 108.439 179.638 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.451 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.9 mt-30 . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.451 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.9 m170 42.86 38.7 1.46 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.185 -0.947 . . . . 0.0 109.014 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.498 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.94 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 109.722 -179.59 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.7 p -61.42 -37.52 83.8 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.065 -1.022 . . . . 0.0 109.325 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.5 t -68.5 -38.71 79.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.19 -0.944 . . . . 0.0 108.83 179.104 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.498 HD12 ' HA ' ' A' ' 4' ' ' ALA . 86.4 mt -60.27 -51.72 69.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.35 -0.844 . . . . 0.0 109.274 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.589 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -65.33 -47.16 77.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.38 -0.825 . . . . 0.0 109.591 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.7 -44.2 94.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.572 -0.705 . . . . 0.0 109.451 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.401 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.9 t80 -62.15 -48.24 80.98 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.53 -0.731 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 7' ' ' ILE . 85.3 t -69.71 -44.5 79.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.461 -0.774 . . . . 0.0 109.696 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.2 t -66.86 -39.5 83.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.428 -0.795 . . . . 0.0 110.183 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -53.68 -28.92 36.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.184 -0.947 . . . . 0.0 109.957 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.24 -30.43 71.31 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.533 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.575 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.5 p90 -146.73 44.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.832 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 O-C-N 121.078 -1.014 . . . . 0.0 109.978 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.45 ' O ' HG12 ' A' ' 24' ' ' VAL . 34.8 Cg_exo -49.66 -31.91 26.67 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 121.911 1.741 . . . . 0.0 112.042 179.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.6 -23.91 66.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.345 -0.847 . . . . 0.0 109.714 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.28 8.53 44.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.351 -0.843 . . . . 0.0 109.32 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.45 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.5 OUTLIER -88.86 142.52 12.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.327 -0.858 . . . . 0.0 108.814 179.813 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -70.09 84.83 0.53 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.168 -0.958 . . . . 0.0 109.487 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.6 m -64.5 -0.26 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.258 -0.901 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.421 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -98.45 11.17 39.03 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.34 -0.85 . . . . 0.0 108.969 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -88.08 136.5 32.94 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.475 -0.766 . . . . 0.0 109.562 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -61.93 122.02 14.41 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.5 mt -56.21 -16.1 4.82 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.423 -0.798 . . . . 0.0 109.542 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.2 t -50.9 -43.05 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.064 -1.023 . . . . 0.0 109.125 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.24 -37.97 70.46 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.4 m-20 -91.18 22.33 3.85 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.72 -15.5 0.02 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.5 p -53.89 -33.81 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.013 -1.286 . . . . 0.0 108.891 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.591 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.9 tt -70.99 -19.04 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.51 -0.744 . . . . 0.0 109.673 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 82.1 m-20 -58.05 -31.32 66.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.434 -0.791 . . . . 0.0 111.451 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.7 m -116.39 -64.91 1.25 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.985 -1.072 . . . . 0.0 111.327 -178.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -64.0 -50.72 67.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 110.06 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.434 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.85 -40.1 64.37 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.591 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.8 tp -58.77 -40.88 85.24 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.469 -1.018 . . . . 0.0 109.671 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.91 -44.31 96.44 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.75 -40.22 88.2 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.273 -0.892 . . . . 0.0 109.981 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.9 t -65.1 -42.01 93.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.345 -0.847 . . . . 0.0 110.199 -179.377 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.437 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -60.79 -50.61 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.219 -0.926 . . . . 0.0 109.837 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.437 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.52 -30.83 71.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.188 -0.945 . . . . 0.0 109.365 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.732 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 55.4 t90 -73.13 -47.09 47.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.395 -0.815 . . . . 0.0 110.118 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.83 -45.29 94.44 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -67.13 -36.62 82.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.272 -0.892 . . . . 0.0 109.803 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -62.12 -44.08 97.42 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.703 -179.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.732 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 82.1 mtt180 -87.04 -51.43 6.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.05 -1.031 . . . . 0.0 111.52 -178.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.416 ' CE2' HG21 ' A' ' 80' ' ' THR . 96.6 m-85 -80.11 -24.58 40.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.005 -1.059 . . . . 0.0 111.223 -178.306 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.09 26.71 59.52 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.7 mt -104.87 143.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -1.121 . . . . 0.0 109.354 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.98 156.54 17.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.185 -0.947 . . . . 0.0 109.692 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.56 0 O-C-N 121.4 -0.813 . . . . 0.0 109.526 -179.488 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.226 0.536 . . . . 0.0 109.81 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.1 -25.25 79.34 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.942 2.428 . . . . 0.0 112.237 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.43 -31.45 72.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -67.92 -26.21 65.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -0.842 . . . . 0.0 109.939 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -94.16 16.45 14.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.365 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 tpt180 -53.41 -39.16 64.1 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.334 -0.854 . . . . 0.0 110.018 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.0 p -150.85 165.9 32.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.923 -1.111 . . . . 0.0 110.271 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 95.0 mt -59.31 -36.51 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.378 -0.826 . . . . 0.0 110.078 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.6 mtm180 -60.49 -39.2 86.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 110.077 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.3 m -61.43 -42.89 99.45 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.994 -1.066 . . . . 0.0 109.428 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.4 mt -64.91 -38.41 82.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.249 -0.907 . . . . 0.0 109.32 179.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.807 ' O ' HG23 ' A' ' 77' ' ' VAL . 92.4 m-20 -56.06 -37.45 69.29 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.286 -0.884 . . . . 0.0 109.219 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.15 -43.73 98.19 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.26 -0.9 . . . . 0.0 109.061 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -63.91 -47.5 80.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.154 179.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.7 t -64.4 -40.44 89.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.389 -0.82 . . . . 0.0 109.288 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.807 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.4 t -58.32 -44.02 87.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.333 -0.854 . . . . 0.0 109.615 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -64.77 -41.49 97.57 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.52 -49.53 16.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.135 -1.215 . . . . 0.0 109.645 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.416 HG21 ' CE2' ' A' ' 52' ' ' PHE . 22.1 p -128.32 157.31 41.31 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.302 -1.472 0 O-C-N 121.058 -1.026 . . . . 0.0 110.261 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 50.49 36.09 12.7 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.142 -0.974 . . . . 0.0 109.027 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.446 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.56 -35.58 76.39 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.39 -0.819 . . . . 0.0 109.78 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 t -59.53 -40.57 87.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.722 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.39 -40.02 87.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 0.0 109.165 179.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.469 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 91.8 mt -59.66 -50.15 81.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.36 -0.837 . . . . 0.0 109.512 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.707 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.91 -45.19 90.43 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 108.904 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.4 -39.65 92.44 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.533 -0.729 . . . . 0.0 109.651 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 61.0 t80 -60.66 -52.04 66.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.446 -0.784 . . . . 0.0 110.029 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.474 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.8 p -74.08 -40.56 51.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.902 . . . . 0.0 109.844 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.707 HG23 ' O ' ' A' ' 8' ' ' ALA . 94.2 t -66.69 -40.0 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.395 -0.816 . . . . 0.0 110.315 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -56.17 -27.63 55.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.228 -0.92 . . . . 0.0 109.574 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -65.04 -32.09 73.64 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.342 -0.849 . . . . 0.0 109.724 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -144.2 44.46 1.43 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.066 -1.021 . . . . 0.0 109.92 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.833 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.085 -1.009 . . . . 0.0 110.048 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD3' HD12 ' A' ' 16' ' ' LEU . 47.2 Cg_exo -48.49 -32.12 19.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.969 1.78 . . . . 0.0 111.814 179.428 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.78 -25.97 67.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.419 -0.801 . . . . 0.0 109.447 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -97.69 4.75 49.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.361 -0.837 . . . . 0.0 109.386 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -103.55 137.41 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.52 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -63.78 95.9 0.12 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.404 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.3 m -59.57 0.48 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.168 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.52 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.6 m-20 -87.99 11.24 16.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.362 -0.836 . . . . 0.0 108.939 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 35.2 tp -82.59 134.12 35.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 109.395 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -67.07 121.85 16.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.342 -0.849 . . . . 0.0 108.871 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.642 HD11 HG12 ' A' ' 69' ' ' ILE . 82.6 mt -59.28 -14.1 10.14 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.303 -0.873 . . . . 0.0 109.198 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.412 ' O ' ' N ' ' A' ' 34' ' ' GLY . 42.1 t -50.44 -42.34 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 O-C-N 121.179 -0.951 . . . . 0.0 108.89 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.62 -35.32 65.74 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 178.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.608 ' O ' ' N ' ' A' ' 35' ' ' VAL . 8.5 m120 -86.27 21.55 2.03 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.0 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.162 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.608 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.0 t -53.05 -40.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.766 -1.432 . . . . 0.0 108.228 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.653 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.2 tt -71.15 -24.11 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.575 -0.703 . . . . 0.0 109.924 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -62.11 -27.54 69.0 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.957 -1.09 . . . . 0.0 110.975 -178.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -106.18 -65.73 1.05 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.801 -1.187 . . . . 0.0 111.055 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -73.73 -51.24 17.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.951 -1.093 . . . . 0.0 110.61 -178.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.75 -36.32 92.11 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.1 tt -57.95 -43.14 86.2 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.208 -1.172 . . . . 0.0 109.2 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.9 mt -60.96 -44.1 97.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.094 -1.004 . . . . 0.0 108.694 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -69.97 -35.45 74.46 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.423 -0.798 . . . . 0.0 109.84 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.732 HG23 ' O ' ' A' ' 40' ' ' GLY . 81.1 t -64.78 -49.85 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.339 -0.851 . . . . 0.0 110.849 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -60.41 -47.82 90.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 120.944 -1.097 . . . . 0.0 109.51 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.46 -32.95 74.64 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.179 -0.951 . . . . 0.0 109.232 179.7 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 39.4 t90 -71.67 -47.46 54.09 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.24 -0.912 . . . . 0.0 109.927 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 26.5 tp -59.81 -44.98 93.72 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.318 -0.864 . . . . 0.0 109.687 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.478 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 80.3 tt0 -68.62 -34.88 76.51 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 110.057 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.21 -38.49 80.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.008 -1.058 . . . . 0.0 110.028 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.536 ' NE ' ' CZ2' ' A' ' 47' ' ' TRP . 34.2 mtm105 -86.39 -48.52 8.38 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.149 -0.969 . . . . 0.0 111.497 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -90.9 -24.44 20.2 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.8 -1.187 . . . . 0.0 111.219 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 79.35 50.03 5.95 Favored Glycine 0 N--CA 1.496 2.689 0 C-N-CA 119.588 -1.292 . . . . 0.0 110.525 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.478 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 65.2 mt -108.04 140.94 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.199 -1.177 . . . . 0.0 109.21 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.53 141.11 57.95 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.937 -1.102 . . . . 0.0 109.334 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.574 -179.704 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.0 p . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -53.37 -34.31 70.39 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.346 2.031 . . . . 0.0 111.61 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -68.08 -14.32 62.89 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.525 -0.735 . . . . 0.0 109.148 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.604 ' CE1' HG23 ' A' ' 72' ' ' ILE . 21.7 t-80 -66.2 -26.32 67.34 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.432 -0.792 . . . . 0.0 110.062 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.667 ' HA ' HD11 ' A' ' 72' ' ' ILE . 97.4 m-85 -92.45 9.05 35.98 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.006 -1.058 . . . . 0.0 109.597 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.4 tpt180 -54.7 -35.98 64.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.8 p -150.82 149.39 29.65 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.215 -0.928 . . . . 0.0 110.023 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.642 HG12 HD11 ' A' ' 30' ' ' LEU . 81.6 mt -66.56 -39.33 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.425 -0.797 . . . . 0.0 110.264 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.428 HH22 ' HA ' ' A' ' 27' ' ' ASP . 93.0 mtm-85 -61.35 -39.99 92.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -0.906 . . . . 0.0 110.373 -178.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 t -60.63 -45.91 92.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.985 -1.072 . . . . 0.0 109.425 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.667 HD11 ' HA ' ' A' ' 66' ' ' PHE . 79.0 mt -63.91 -38.74 83.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.85 . . . . 0.0 109.709 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.469 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 55.9 t0 -57.54 -42.28 82.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 110.256 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.76 -46.09 76.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 110.502 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -63.36 -45.1 92.71 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.099 -1.0 . . . . 0.0 109.496 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.1 t -68.18 -47.6 77.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.219 -0.926 . . . . 0.0 110.159 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 45.4 t -68.28 -44.22 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.051 -1.031 . . . . 0.0 110.023 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.02 -27.0 68.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.27 -50.12 3.55 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.199 -1.177 . . . . 0.0 111.143 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.529 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.2 m -134.91 140.1 45.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.107 -0.995 . . . . 0.0 110.864 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.79 ' CE1' HG21 ' A' ' 6' ' ' VAL . 73.6 t60 -116.13 8.94 14.58 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.478 -0.764 . . . . 0.0 109.478 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.58 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -61.09 -35.61 77.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.212 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 m -58.8 -40.28 83.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.053 -1.03 . . . . 0.0 109.395 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.79 HG21 ' CE1' ' A' ' 3' ' ' HIS . 72.3 t -66.53 -36.56 77.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.007 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.646 ' O ' HG23 ' A' ' 11' ' ' VAL . 81.8 mt -63.59 -44.18 98.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.397 -0.814 . . . . 0.0 110.31 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.484 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.0 -50.63 67.78 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.175 -0.953 . . . . 0.0 110.521 -178.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.444 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.22 -44.3 68.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.122 -0.986 . . . . 0.0 109.673 -179.844 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.568 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 75.1 t80 -59.52 -45.89 90.44 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.993 -1.067 . . . . 0.0 109.282 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.646 HG23 ' O ' ' A' ' 7' ' ' ILE . 99.7 t -70.03 -46.52 72.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 8' ' ' ALA . 74.9 t -66.51 -37.23 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.337 -0.852 . . . . 0.0 111.086 -179.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -60.93 -31.72 71.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.771 -179.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -66.16 -32.51 73.99 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.938 -1.102 . . . . 0.0 110.137 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.727 ' O ' HD12 ' A' ' 16' ' ' LEU . 58.6 m-85 -96.63 -61.11 1.47 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.104 -0.997 . . . . 0.0 110.6 -179.082 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.727 HD12 ' O ' ' A' ' 15' ' ' PHE . 3.7 mp . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.29 -0.881 . . . . 0.0 110.663 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.648 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . . . . . . 0 N--CA 1.486 1.334 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.827 ' O ' HG12 ' A' ' 24' ' ' VAL . 21.6 Cg_endo -64.98 -26.75 58.43 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 C-N-CA 121.619 1.546 . . . . 0.0 111.854 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.92 -13.88 60.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.421 -0.799 . . . . 0.0 109.326 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.648 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -85.58 8.03 20.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 109.853 -179.277 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.827 HG12 ' O ' ' A' ' 21' ' ' PRO . 9.9 p -107.58 144.41 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.372 -0.83 . . . . 0.0 109.034 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.493 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.6 m-20 -69.05 86.18 0.36 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.006 -1.059 . . . . 0.0 109.177 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.9 0.06 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.34 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.03 6.04 47.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.321 -0.862 . . . . 0.0 108.77 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -93.58 136.82 33.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.599 -0.688 . . . . 0.0 109.364 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -61.16 121.53 12.75 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.632 ' CD1' HD11 ' A' ' 36' ' ' ILE . 1.5 pp -68.84 0.25 4.61 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.285 -0.885 . . . . 0.0 109.796 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 34' ' ' GLY . 72.7 t -56.16 -35.17 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.21 -0.931 . . . . 0.0 108.946 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' A' ' 34' ' ' GLY . 92.3 m-20 -53.94 -34.83 60.78 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -83.53 21.89 1.14 Allowed 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.028 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -41.73 -13.99 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.93 -1.268 . . . . 0.0 109.93 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 3.4 p -51.94 -31.12 13.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.085 -1.244 . . . . 0.0 108.479 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.632 HD11 ' CD1' ' A' ' 30' ' ' LEU . 32.6 pt -73.56 -7.14 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.522 -0.736 . . . . 0.0 109.965 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.504 ' HA ' HD12 ' A' ' 41' ' ' LEU . 92.7 m-20 -48.88 -39.95 27.88 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.342 -0.849 . . . . 0.0 110.205 -178.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -122.56 -48.24 2.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 111.348 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.482 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.2 mp -74.71 -52.79 10.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.944 -1.097 . . . . 0.0 111.63 -178.077 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.538 ' H ' ' HA ' ' A' ' 36' ' ' ILE . . . -70.49 -43.21 62.12 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 120.079 -1.058 . . . . 0.0 110.77 -178.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.635 ' O ' HD13 ' A' ' 45' ' ' ILE . 16.2 mt -63.42 -40.66 97.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.065 -1.256 . . . . 0.0 110.482 -179.191 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.63 -44.17 96.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.322 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttt -66.96 -41.58 86.64 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.244 -0.91 . . . . 0.0 109.465 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 40' ' ' GLY . 90.1 t -66.95 -41.06 86.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.446 -0.784 . . . . 0.0 109.879 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.635 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.4 mp -58.94 -49.03 84.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.245 -0.91 . . . . 0.0 109.65 -179.56 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.94 -32.29 72.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.604 ' CZ2' ' NH1' ' A' ' 51' ' ' ARG . 9.3 t90 -68.51 -44.81 73.84 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.37 -0.831 . . . . 0.0 109.508 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.8 tp -62.53 -44.98 95.02 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 109.605 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 53' ' ' GLY . 81.6 tt0 -67.2 -34.51 77.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.909 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -58.75 -39.3 80.54 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.89 -1.131 . . . . 0.0 109.759 -179.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.604 ' NH1' ' CZ2' ' A' ' 47' ' ' TRP . 51.7 mtm180 -86.97 -53.86 4.66 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.135 -0.978 . . . . 0.0 110.931 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.42 -25.02 39.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 111.367 -178.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 76.46 39.2 31.11 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.334 -1.412 . . . . 0.0 109.627 -179.676 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.427 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 66.1 mt -103.03 138.73 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.197 -1.178 . . . . 0.0 109.331 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.05 141.08 57.66 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.737 -1.227 . . . . 0.0 109.303 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.338 -179.55 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 -27.54 69.48 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.862 1.708 . . . . 0.0 112.324 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.88 -28.12 69.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.892 . . . . 0.0 109.711 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.417 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 11.6 t-160 -67.8 -26.74 66.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.296 -0.878 . . . . 0.0 110.02 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.543 ' CE1' HD21 ' A' ' 41' ' ' LEU . 58.4 m-85 -102.27 13.65 34.06 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.955 . . . . 0.0 109.97 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.535 ' HD2' HG21 ' A' ' 31' ' ' VAL . 25.6 tpt180 -53.19 -36.88 61.42 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 108.959 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t -143.46 146.91 33.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -0.887 . . . . 0.0 109.479 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.78 -38.44 76.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.285 -0.885 . . . . 0.0 109.91 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 ptt85 -61.81 -40.23 94.51 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.8 p -61.69 -36.68 81.58 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.097 -1.002 . . . . 0.0 110.043 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.433 HD11 ' CD1' ' A' ' 66' ' ' PHE . 76.1 mt -65.12 -40.81 90.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 121.095 -1.003 . . . . 0.0 109.807 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 55.6 t0 -58.75 -38.05 77.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.713 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.85 -41.69 99.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.178 -0.951 . . . . 0.0 109.598 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.417 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 65.6 t80 -63.8 -47.44 80.88 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.283 -0.886 . . . . 0.0 109.366 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.5 t -64.15 -42.72 96.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.288 -0.882 . . . . 0.0 109.551 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 73' ' ' ASP . 46.6 t -58.98 -41.07 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.288 -0.883 . . . . 0.0 109.532 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.18 -32.56 76.71 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.85 -50.45 3.53 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.026 -1.279 . . . . 0.0 110.746 -179.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 76' ' ' VAL . 16.6 p -129.14 156.65 43.57 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.333 -0.854 . . . . 0.0 109.519 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.304 -1.39 0 O-C-N 121.184 -0.947 . . . . 0.0 109.499 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.406 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 63.8 mtt . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -58.93 -36.18 74.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.166 -0.959 . . . . 0.0 109.388 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.792 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -153.2 29.48 0.5 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.337 -0.852 . . . . 0.0 109.04 179.926 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.406 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -61.09 -32.97 72.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.311 -0.868 . . . . 0.0 109.883 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -61.01 -35.72 77.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.058 -1.026 . . . . 0.0 109.58 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.792 HG21 ' CE1' ' A' ' 3' ' ' HIS . 72.4 t -67.29 -38.41 80.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.028 179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.456 ' O ' HG23 ' A' ' 11' ' ' VAL . 89.2 mt -61.73 -50.45 80.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.1 -45.52 88.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.197 -0.939 . . . . 0.0 109.096 179.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.99 -44.32 89.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.477 -0.764 . . . . 0.0 109.266 179.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.671 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -65.15 -46.97 78.72 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.648 -0.658 . . . . 0.0 109.915 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.683 HG13 HD12 ' A' ' 36' ' ' ILE . 75.7 t -67.65 -47.31 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.378 -0.826 . . . . 0.0 110.124 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.3 t -65.84 -34.47 70.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.364 -0.835 . . . . 0.0 110.613 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.53 -36.61 55.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.117 -0.99 . . . . 0.0 110.013 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.15 -34.07 76.77 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 110.662 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.615 ' O ' HD12 ' A' ' 16' ' ' LEU . 66.5 m-85 -94.83 -64.24 1.09 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.927 -1.108 . . . . 0.0 110.784 -178.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.615 HD12 ' O ' ' A' ' 15' ' ' PHE . 6.1 mp -123.64 83.04 53.86 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.31 -0.869 . . . . 0.0 110.155 -179.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -83.48 -21.73 4.19 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.973 2.449 . . . . 0.0 112.168 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -76.84 -4.09 41.86 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.239 -0.913 . . . . 0.0 109.19 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -113.32 140.76 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.84 117.74 31.76 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.971 -1.081 . . . . 0.0 108.61 -179.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -65.28 -30.01 54.57 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 C-N-CA 121.637 1.558 . . . . 0.0 111.869 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.13 -14.98 61.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.337 -0.852 . . . . 0.0 109.182 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.0 m-20 -87.96 6.35 36.22 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.341 -0.849 . . . . 0.0 109.387 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -100.64 137.53 27.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.394 -0.816 . . . . 0.0 108.824 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -62.69 88.07 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.185 -0.947 . . . . 0.0 109.434 -179.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.45 HG21 ' HE2' ' A' ' 87' ' ' LYS . 17.1 m -62.15 0.08 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.397 -0.814 . . . . 0.0 109.281 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -90.88 6.82 42.92 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.295 -0.878 . . . . 0.0 108.949 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 tp -94.29 137.04 33.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.53 -0.731 . . . . 0.0 109.499 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -60.94 121.77 13.22 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 179.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -73.16 4.57 4.28 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.192 -0.943 . . . . 0.0 109.959 -179.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.4 p -51.17 -38.61 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.08 -1.012 . . . . 0.0 108.423 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.442 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.12 -35.43 69.44 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.7 m-20 -84.45 17.03 2.79 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.129 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -43.22 -14.04 0.02 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.05 -35.94 15.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.261 -1.141 . . . . 0.0 108.971 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.683 HD12 HG13 ' A' ' 11' ' ' VAL . 1.5 tt -70.01 -23.31 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.356 -0.84 . . . . 0.0 109.889 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.595 ' OD2' ' CD1' ' A' ' 66' ' ' PHE . 77.0 m-20 -56.33 -34.17 66.32 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.384 -0.823 . . . . 0.0 110.622 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.552 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.6 OUTLIER -112.57 -64.45 1.3 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 111.092 -178.522 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 50.9 tp -64.25 -51.96 61.04 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.71 -178.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.38 -36.5 69.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.082 -1.207 . . . . 0.0 110.082 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.1 tt -58.37 -41.82 85.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.224 -1.163 . . . . 0.0 109.685 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 42' ' ' LEU . 92.8 mt -67.08 -44.14 80.81 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.137 -0.977 . . . . 0.0 109.391 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.5 mttm -67.09 -41.65 85.96 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.26 -0.9 . . . . 0.0 109.843 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.524 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 88.6 t -66.68 -43.2 90.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.307 -0.871 . . . . 0.0 109.956 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.446 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.73 -50.53 79.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.263 -0.898 . . . . 0.0 109.569 -179.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.446 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -66.6 -38.46 87.06 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.182 -0.949 . . . . 0.0 109.413 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.671 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -68.48 -41.43 80.11 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.302 -0.874 . . . . 0.0 109.806 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.503 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 13.8 tp -56.97 -47.42 80.81 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.403 -0.811 . . . . 0.0 109.644 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.514 ' OE2' ' O ' ' A' ' 54' ' ' ILE . 28.0 tp10 -69.26 -35.71 76.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.182 -0.949 . . . . 0.0 109.287 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -63.98 -46.07 86.21 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.077 -1.014 . . . . 0.0 110.552 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 22.4 ttm180 -88.15 -58.22 2.64 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.207 -0.933 . . . . 0.0 111.926 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -79.38 -24.4 42.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.0 -1.062 . . . . 0.0 111.751 -177.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.26 32.82 41.96 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.187 -1.483 . . . . 0.0 109.417 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.514 ' O ' ' OE2' ' A' ' 49' ' ' GLU . 68.8 mt -104.44 143.94 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.274 -1.133 . . . . 0.0 109.189 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.53 146.92 43.25 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.155 -0.966 . . . . 0.0 109.478 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.82 -33.69 68.87 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.39 -0.819 . . . . 0.0 109.604 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 54.11 44.22 29.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.326 -0.859 . . . . 0.0 109.532 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.444 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.2 p30 -95.09 12.21 29.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.641 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.63 -43.04 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.119 -0.988 . . . . 0.0 109.736 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -115.95 135.05 54.34 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.508 -0.745 . . . . 0.0 109.53 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 20.7 mt -108.25 140.09 42.0 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.379 -0.825 . . . . 0.0 109.301 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.4 ' H ' ' C6 ' ' A' ' 101' ' ' 7V9 . 0.4 OUTLIER -130.72 84.18 59.47 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.355 -0.84 . . . . 0.0 109.7 -179.821 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -54.13 -28.47 51.36 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.549 2.166 . . . . 0.0 111.953 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -68.39 -15.9 63.72 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.413 -0.805 . . . . 0.0 109.482 179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 7.4 t-160 -66.7 -25.39 66.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.536 -0.727 . . . . 0.0 110.143 -179.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.595 ' CD1' ' OD2' ' A' ' 37' ' ' ASP . 62.3 m-85 -87.68 2.91 49.78 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.019 -1.051 . . . . 0.0 109.99 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.3 tpt180 -57.25 -39.82 76.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.944 -1.097 . . . . 0.0 110.293 -179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.422 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 86.0 p -143.31 153.21 42.53 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.834 -1.166 . . . . 0.0 110.264 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -65.96 -36.59 77.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.456 -0.778 . . . . 0.0 109.67 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.2 mtm180 -60.94 -37.18 81.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.245 -0.909 . . . . 0.0 109.789 -179.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.422 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 19.6 m -59.36 -41.98 90.51 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.068 -1.02 . . . . 0.0 109.083 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.62 -38.18 80.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.321 -0.862 . . . . 0.0 109.431 179.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.484 ' O ' HG23 ' A' ' 77' ' ' VAL . 74.5 m-20 -57.06 -39.61 75.24 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.342 -0.849 . . . . 0.0 109.704 -179.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.91 -39.11 90.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.247 -0.908 . . . . 0.0 109.904 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -61.25 -47.51 85.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.743 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.3 t -65.37 -41.06 90.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.149 -0.969 . . . . 0.0 109.777 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.7 t -61.51 -44.6 98.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 O-C-N 121.204 -0.935 . . . . 0.0 109.936 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -65.14 -40.54 96.93 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -78.81 -49.67 12.59 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.147 -1.207 . . . . 0.0 109.766 -179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.471 ' O ' ' O ' ' A' ' 76' ' ' VAL . 19.3 p -130.46 156.89 44.02 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -140.09 87.55 12.3 Favored Pre-proline 0 C--N 1.301 -1.504 0 O-C-N 121.171 -0.955 . . . . 0.0 109.78 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.444 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.1 Cg_exo -66.03 -175.91 0.56 Allowed 'Trans proline' 0 N--CA 1.493 1.496 0 C-N-CA 122.83 2.353 . . . . 0.0 111.865 179.332 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.444 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 24.2 Cg_exo -60.37 150.94 77.84 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.483 2.122 . . . . 0.0 111.52 179.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 84' ' ' VAL . 13.0 p -92.12 127.79 44.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.133 -0.979 . . . . 0.0 109.833 -179.359 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -134.31 158.53 43.54 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.429 -0.794 . . . . 0.0 109.079 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.62 123.26 25.22 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 109.247 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.45 ' HE2' HG21 ' A' ' 26' ' ' VAL . 51.2 tttp -59.89 -37.14 78.53 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.508 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.6 tp -98.77 130.58 45.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.477 -179.99 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.561 ' O8 ' HD11 ' A' ' 41' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.833 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 84.4 mtp . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.819 ' O ' HG22 ' A' ' 84' ' ' VAL . 93.2 mt-30 -60.17 -38.21 82.52 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.91 . . . . 0.0 109.631 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.585 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 40.1 m80 -139.52 6.47 2.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.271 -0.893 . . . . 0.0 109.762 -179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.833 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -59.26 -33.87 71.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.075 -1.016 . . . . 0.0 109.761 -179.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.441 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 22.2 t -59.22 -45.01 92.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.067 -1.021 . . . . 0.0 109.59 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.9 -36.59 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.268 -0.895 . . . . 0.0 108.656 179.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.496 HD12 ' HA ' ' A' ' 4' ' ' ALA . 91.8 mt -66.75 -42.16 89.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.609 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.24 -50.39 70.38 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.047 -1.033 . . . . 0.0 110.241 -179.021 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.677 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.31 -42.97 71.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.291 179.749 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.677 ' N ' HE21 ' A' ' 9' ' ' GLN . 67.9 t80 -62.56 -48.72 78.26 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.336 -0.853 . . . . 0.0 109.366 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.797 HG13 HD12 ' A' ' 36' ' ' ILE . 64.4 t -65.49 -45.07 93.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 0.0 109.333 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.609 HG23 ' O ' ' A' ' 8' ' ' ALA . 69.4 t -65.85 -37.12 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.439 -0.788 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -52.86 -30.78 35.77 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.38 -0.825 . . . . 0.0 109.811 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.54 -31.26 72.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 0.0 109.66 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.551 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 34.4 p90 -143.93 44.24 1.46 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.185 -0.947 . . . . 0.0 109.601 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.797 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.68 130.47 64.21 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.155 -0.966 . . . . 0.0 110.305 -179.822 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.79 -151.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 122.111 1.874 . . . . 0.0 110.542 178.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -79.44 17.27 0.87 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.898 -1.126 . . . . 0.0 108.965 179.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.2 t -113.2 135.77 51.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.402 -0.811 . . . . 0.0 109.81 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.4 141.71 80.6 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.164 -0.96 . . . . 0.0 109.243 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -49.38 -29.66 18.42 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 121.881 1.721 . . . . 0.0 111.813 179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.6 -25.99 68.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.315 -0.866 . . . . 0.0 109.528 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -95.38 6.42 49.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.319 -0.863 . . . . 0.0 109.209 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.3 t -104.07 136.37 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.528 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.4 m-20 -69.7 88.89 0.54 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.202 -0.936 . . . . 0.0 109.529 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.2 m -59.91 0.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 109.196 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.528 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -92.91 9.97 33.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 108.884 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 tp -90.34 137.37 32.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.533 -0.729 . . . . 0.0 109.507 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.455 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.6 m-20 -62.89 121.82 14.43 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.12 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.441 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -69.62 10.86 0.31 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.144 -0.972 . . . . 0.0 109.932 -178.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.455 ' H ' ' C ' ' A' ' 29' ' ' ASP . 75.7 t -54.68 -44.22 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.002 -1.061 . . . . 0.0 108.627 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.72 -36.64 67.44 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 179.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.5 m-20 -86.21 18.24 3.24 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 178.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.92 -14.99 0.02 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.9 t -52.05 -37.13 21.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.117 -1.225 . . . . 0.0 108.677 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.797 HD12 HG13 ' A' ' 11' ' ' VAL . 1.4 tt -70.59 -22.5 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.533 -0.73 . . . . 0.0 110.323 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.407 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 88.1 m-20 -54.14 -32.62 55.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.313 -0.867 . . . . 0.0 111.284 -178.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.534 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.4 OUTLIER -117.34 -64.23 1.33 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.912 -1.117 . . . . 0.0 111.165 -178.782 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.3 -52.5 63.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.9 -1.125 . . . . 0.0 110.343 -178.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.664 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.53 -37.1 62.34 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.579 ' N ' ' O ' ' A' ' 36' ' ' ILE . 16.2 tp -58.51 -43.53 89.16 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.38 -1.07 . . . . 0.0 109.931 -178.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.436 ' HA ' HD23 ' A' ' 42' ' ' LEU . 92.9 mt -65.6 -43.56 89.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.14 -0.975 . . . . 0.0 109.556 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -63.08 -34.43 77.57 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.259 -0.9 . . . . 0.0 109.366 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 40' ' ' GLY . 68.4 t -60.52 -41.43 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.338 -0.851 . . . . 0.0 109.914 -179.681 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.612 HD11 ' S12' ' A' ' 101' ' ' 7V9 . 35.8 mm -58.94 -50.16 80.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.983 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.24 -35.6 79.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.801 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.513 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 44.2 t90 -66.49 -41.74 88.48 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.269 -0.894 . . . . 0.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.8 tp -61.24 -43.35 99.01 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 109.918 -179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.412 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 87.5 tt0 -67.51 -37.16 82.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -60.3 -44.79 95.09 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.049 -1.032 . . . . 0.0 110.555 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.6 mtp85 -87.49 -53.02 5.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.136 -0.977 . . . . 0.0 111.585 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -80.16 -24.75 40.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.041 -1.037 . . . . 0.0 111.59 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.67 31.05 51.29 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.412 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.6 mt -103.41 147.51 9.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.393 -1.063 . . . . 0.0 109.556 -179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.04 157.6 15.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.188 -0.945 . . . . 0.0 109.309 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.505 ' HB1' HG21 ' A' ' 45' ' ' ILE . . . -52.95 -39.16 62.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.24 -0.912 . . . . 0.0 109.773 -179.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 51.89 50.69 18.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.114 -0.991 . . . . 0.0 109.092 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -71.19 116.98 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.929 -179.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.414 HG23 HD21 ' A' ' 61' ' ' LEU . 29.5 m -130.24 162.17 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -89.28 122.62 32.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.998 -1.064 . . . . 0.0 110.085 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.414 HD21 HG23 ' A' ' 59' ' ' VAL . 30.8 mt -115.97 144.81 43.57 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.25 153.13 95.43 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.166 -0.959 . . . . 0.0 109.276 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.79 -27.05 84.04 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.618 2.212 . . . . 0.0 111.886 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.56 -24.49 67.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.403 -0.81 . . . . 0.0 109.945 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -67.13 -26.61 66.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.155 -0.965 . . . . 0.0 110.234 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -97.71 6.68 47.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.074 -1.016 . . . . 0.0 109.001 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 -56.49 -37.8 70.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.452 -0.78 . . . . 0.0 109.977 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.8 p -137.03 153.25 50.68 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.096 -1.003 . . . . 0.0 110.121 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.6 mt -64.59 -36.45 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.478 -0.763 . . . . 0.0 110.251 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -60.87 -37.02 80.69 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.133 -0.979 . . . . 0.0 110.217 -178.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 92.6 p -61.59 -36.15 79.87 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.014 -1.054 . . . . 0.0 109.66 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -64.93 -40.63 89.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.232 -0.918 . . . . 0.0 109.453 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.552 ' OD2' HG23 ' A' ' 77' ' ' VAL . 53.9 t0 -59.12 -36.93 76.04 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.305 -0.872 . . . . 0.0 109.634 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.88 -40.71 94.04 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.326 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -64.16 -48.7 75.0 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.28 -0.888 . . . . 0.0 109.305 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.5 t -64.89 -43.45 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.317 -0.864 . . . . 0.0 109.671 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.552 HG23 ' OD2' ' A' ' 73' ' ' ASP . 55.7 t -59.87 -41.06 84.55 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.225 -0.922 . . . . 0.0 109.627 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.33 -31.83 70.82 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.1 -50.63 3.32 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.021 -1.282 . . . . 0.0 110.844 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 21.8 p -131.28 159.43 37.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.225 -0.922 . . . . 0.0 109.854 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.96 88.17 15.96 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.189 -0.944 . . . . 0.0 109.449 179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.585 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 10.7 Cg_exo -66.38 -178.01 1.04 Allowed 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.551 2.167 . . . . 0.0 112.146 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.417 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.0 Cg_exo -61.34 150.26 85.72 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.423 2.082 . . . . 0.0 111.779 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.819 HG22 ' O ' ' A' ' 2' ' ' GLN . 44.5 t -109.32 129.69 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.562 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -137.71 155.45 49.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.382 -0.824 . . . . 0.0 109.459 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -102.59 140.21 37.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.34 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.441 ' NZ ' ' O ' ' A' ' 5' ' ' SER . 30.4 mttm -59.23 -34.77 72.59 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.152 -0.967 . . . . 0.0 109.539 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.8 tp -99.62 130.31 45.84 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.337 -0.852 . . . . 0.0 109.462 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.442 -179.923 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.612 ' S12' HD11 ' A' ' 45' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.613 ' HB3' HG21 ' A' ' 77' ' ' VAL . 83.3 mmm . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.556 ' OE1' HG21 ' A' ' 81' ' ' THR . 91.8 mt-30 -108.5 138.05 45.44 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.328 -0.857 . . . . 0.0 109.153 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 69.4 m80 47.46 38.44 7.71 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.118 -0.988 . . . . 0.0 109.298 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.12 -34.26 73.28 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.288 -0.883 . . . . 0.0 109.629 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -59.14 -36.64 75.59 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 109.618 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.8 t -62.88 -40.96 90.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.287 -0.883 . . . . 0.0 109.516 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.498 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 85.5 mt -59.69 -43.95 92.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.356 -0.84 . . . . 0.0 109.839 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.53 -48.4 77.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.429 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.42 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.08 -33.66 73.89 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.414 -0.804 . . . . 0.0 109.624 179.826 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.407 ' N ' ' HG3' ' A' ' 9' ' ' GLN . 63.1 t80 -62.64 -52.08 64.75 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.099 -1.001 . . . . 0.0 109.977 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 12' ' ' VAL . 6.3 p -74.91 -44.32 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.357 -0.839 . . . . 0.0 110.855 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.538 ' N ' HG13 ' A' ' 11' ' ' VAL . 76.9 t -65.32 -40.09 87.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.183 -0.948 . . . . 0.0 111.031 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -58.22 -28.69 65.08 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.045 -1.034 . . . . 0.0 109.791 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.8 -38.69 89.64 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.276 -0.89 . . . . 0.0 110.425 -179.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.498 ' HE1' HG22 ' A' ' 11' ' ' VAL . 5.4 m-85 -96.68 -45.11 6.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.04 -1.038 . . . . 0.0 110.489 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.416 HD22 HG21 ' A' ' 19' ' ' VAL . 1.5 mt -126.93 82.46 67.85 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.284 -0.885 . . . . 0.0 110.273 -179.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -83.01 -24.81 3.07 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.104 2.536 . . . . 0.0 112.149 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -81.01 -3.73 52.73 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.195 -0.94 . . . . 0.0 109.622 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.416 HG21 HD22 ' A' ' 16' ' ' LEU . 39.6 t -113.48 141.07 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.87 117.92 33.58 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.026 -1.046 . . . . 0.0 108.669 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -64.69 -30.36 59.79 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 C-N-CA 121.585 1.524 . . . . 0.0 111.966 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.86 -19.05 63.46 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.064 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -89.18 1.74 55.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.361 -0.837 . . . . 0.0 108.99 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.1 t -102.28 139.0 24.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.515 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.2 t0 -67.97 94.14 0.46 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.09 -1.006 . . . . 0.0 109.438 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 m -59.99 0.56 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.429 -0.794 . . . . 0.0 109.229 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.1 m-20 -88.16 9.8 21.55 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.019 179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.4 tp -86.33 134.17 33.75 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.541 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -62.94 122.07 15.1 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.742 HD11 HG12 ' A' ' 69' ' ' ILE . 74.1 mt -59.72 -12.14 6.48 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.3 p -49.97 -37.28 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 119.32 -0.952 . . . . 0.0 108.647 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.13 -36.01 70.18 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.3 m-20 -86.13 21.07 2.1 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.71 -14.3 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.9 t -51.48 -40.32 24.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 120.979 -1.307 . . . . 0.0 108.54 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.637 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.2 tt -71.77 -24.41 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.509 -0.744 . . . . 0.0 110.418 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 91.9 m-20 -59.25 -28.13 66.42 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.931 -1.105 . . . . 0.0 110.962 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.562 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 1.3 m -113.3 -64.32 1.32 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.026 -1.046 . . . . 0.0 111.167 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.487 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -68.88 -51.31 41.58 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.904 -1.123 . . . . 0.0 110.472 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.02 -35.89 72.12 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.747 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.0 tt -57.99 -45.24 87.11 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.421 -1.046 . . . . 0.0 110.145 -179.083 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.8 mt -61.83 -44.18 97.37 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.001 -1.062 . . . . 0.0 109.191 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -71.64 -35.54 70.44 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.351 -0.843 . . . . 0.0 110.303 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 40' ' ' GLY . 66.0 t -64.56 -49.41 80.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.284 -0.885 . . . . 0.0 111.277 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.2 mm -58.78 -49.46 82.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 120.566 -1.334 . . . . 0.0 109.644 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.34 -35.6 79.73 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.012 -1.055 . . . . 0.0 109.68 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.511 ' CZ3' ' NZ ' ' A' ' 87' ' ' LYS . 19.2 t90 -76.84 -51.07 11.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.272 -0.892 . . . . 0.0 111.398 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.476 ' CD2' ' CE3' ' A' ' 47' ' ' TRP . 3.8 mm? -65.72 -39.32 91.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.062 -1.024 . . . . 0.0 110.616 -179.181 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' ' N ' ' A' ' 53' ' ' GLY . 17.8 pt-20 -65.73 -35.01 79.53 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.979 -1.076 . . . . 0.0 109.596 -179.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.1 t0 -65.45 -43.52 90.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.173 -0.954 . . . . 0.0 110.051 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -67.68 -43.13 80.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.252 -0.905 . . . . 0.0 111.165 -179.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -98.34 -12.73 21.19 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.9 -1.125 . . . . 0.0 110.47 -178.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 65.05 42.16 96.82 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.5 mt -104.79 129.21 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -1.162 . . . . 0.0 109.531 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.95 144.39 57.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 109.451 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.2 -33.76 75.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.19 -0.944 . . . . 0.0 109.271 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -58.08 -34.09 69.78 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.408 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.48 -33.33 44.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.241 -0.912 . . . . 0.0 109.745 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.06 151.57 24.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.417 -0.802 . . . . 0.0 109.652 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -111.9 148.8 32.92 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.451 -0.781 . . . . 0.0 109.524 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.8 mt -84.22 140.52 31.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.48 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.0 OUTLIER -155.98 109.25 2.12 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.301 -0.874 . . . . 0.0 109.174 -179.962 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -49.95 -36.12 42.92 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 121.814 1.676 . . . . 0.0 112.107 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.92 -27.73 66.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.257 -0.902 . . . . 0.0 109.677 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 36.6 t-80 -68.22 -27.13 66.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 110.211 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.653 ' CE2' ' C8 ' ' A' ' 101' ' ' 7V9 . 88.7 m-85 -100.72 9.14 42.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.171 -0.956 . . . . 0.0 109.485 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 35.9 tpt85 -55.52 -36.21 66.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.479 -0.763 . . . . 0.0 109.369 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.1 p -143.56 158.34 43.73 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.18 -0.95 . . . . 0.0 110.017 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.742 HG12 HD11 ' A' ' 30' ' ' LEU . 75.7 mt -64.15 -36.54 77.28 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.387 -0.821 . . . . 0.0 110.35 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.6 mtm180 -60.72 -38.82 86.4 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.098 -1.001 . . . . 0.0 110.068 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.0 t -61.45 -44.09 97.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.042 -1.036 . . . . 0.0 109.539 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 84.3 mt -67.72 -40.08 83.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.288 -0.882 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.498 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 59.8 t0 -58.99 -41.59 88.01 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.312 -0.867 . . . . 0.0 110.391 -179.256 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.39 -43.78 84.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.034 -1.041 . . . . 0.0 110.248 -179.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.4 t80 -62.67 -47.27 84.39 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.748 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.517 HG12 ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.92 -44.36 96.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.162 -0.961 . . . . 0.0 109.675 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.613 HG21 ' HB3' ' A' ' 1' ' ' MET . 48.1 t -61.06 -39.74 83.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 O-C-N 121.11 -0.994 . . . . 0.0 109.459 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.85 -33.17 67.46 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.02 3.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.054 -1.263 . . . . 0.0 110.489 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.517 ' O ' HG12 ' A' ' 76' ' ' VAL . 8.3 t -158.41 152.69 24.19 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.064 -1.023 . . . . 0.0 110.204 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.556 HG21 ' OE1' ' A' ' 2' ' ' GLN . 0.8 OUTLIER -130.09 88.66 47.69 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 108.937 179.463 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -93.91 107.05 0.15 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.345 2.697 . . . . 0.0 113.132 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -80.65 138.85 12.23 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 C-N-CA 122.307 2.004 . . . . 0.0 111.996 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.489 HG22 ' H ' ' A' ' 86' ' ' ALA . 10.9 p -134.13 140.97 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.155 -0.966 . . . . 0.0 109.422 179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.54 -35.2 79.69 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.588 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.489 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -149.23 155.92 41.33 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.511 ' NZ ' ' CZ3' ' A' ' 47' ' ' TRP . 19.8 tttm -57.75 -36.98 72.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.482 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.1 mt -92.17 142.06 27.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.458 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.441 -179.962 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.653 ' C8 ' ' CE2' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.559 ' HB2' ' HB3' ' A' ' 4' ' ' ALA . 11.9 ptp . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.348 0.594 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 -60.16 -42.76 95.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.385 -0.822 . . . . 0.0 110.247 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 90.6 m-70 -149.0 3.45 0.61 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.965 -1.085 . . . . 0.0 110.603 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.586 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -63.34 -32.4 73.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.778 -1.201 . . . . 0.0 109.866 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.508 ' OG ' ' CG2' ' A' ' 84' ' ' VAL . 83.7 p -59.04 -35.3 73.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.069 -1.02 . . . . 0.0 109.372 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 1.04 HG23 HG23 ' A' ' 84' ' ' VAL . 77.8 t -66.34 -37.74 80.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.264 -0.898 . . . . 0.0 109.2 179.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.615 ' O ' HG23 ' A' ' 11' ' ' VAL . 30.8 mm -62.16 -47.12 94.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.419 -0.8 . . . . 0.0 110.176 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.81 -49.74 71.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.206 -0.933 . . . . 0.0 110.445 -179.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.466 ' NE2' ' CA ' ' A' ' 10' ' ' PHE . 4.2 pp0? -69.71 -42.75 73.62 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.154 -0.967 . . . . 0.0 109.858 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CA ' ' NE2' ' A' ' 9' ' ' GLN . 69.9 t80 -61.63 -46.66 88.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.147 -0.971 . . . . 0.0 109.512 179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.733 HG13 HD12 ' A' ' 36' ' ' ILE . 91.4 t -67.5 -47.61 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.375 -0.828 . . . . 0.0 109.966 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 78.7 t -66.44 -34.74 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.416 -0.802 . . . . 0.0 110.423 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -52.77 -36.46 58.05 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -0.93 . . . . 0.0 109.897 -179.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.76 -35.12 78.14 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.273 -0.892 . . . . 0.0 110.708 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.619 ' O ' HD12 ' A' ' 16' ' ' LEU . 65.9 m-85 -92.91 -63.47 1.22 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.919 -1.113 . . . . 0.0 110.767 -178.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.619 HD12 ' O ' ' A' ' 15' ' ' PHE . 5.7 mp -125.19 83.05 61.3 Favored Pre-proline 0 N--CA 1.495 1.794 0 O-C-N 121.37 -0.831 . . . . 0.0 110.234 -179.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -82.6 -21.39 5.15 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.845 2.363 . . . . 0.0 112.11 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.91 -3.8 40.55 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.238 -0.914 . . . . 0.0 109.127 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.8 t -113.26 142.05 26.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.418 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . -61.68 118.96 43.09 Favored Pre-proline 0 C--N 1.304 -1.4 0 O-C-N 120.909 -1.119 . . . . 0.0 108.785 -179.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -64.62 -23.91 63.28 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 121.628 1.552 . . . . 0.0 111.828 -179.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.49 -14.89 62.27 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.446 -0.784 . . . . 0.0 109.272 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.418 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 90.5 m-20 -82.9 3.24 30.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.383 -0.823 . . . . 0.0 109.158 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.54 136.97 30.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.451 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -65.12 88.13 0.07 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.136 -0.977 . . . . 0.0 109.271 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 13.7 m -63.61 0.04 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.273 -0.892 . . . . 0.0 109.309 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.451 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -93.44 4.65 53.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 108.969 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.8 tt -98.36 137.65 36.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.461 -0.775 . . . . 0.0 109.541 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.63 ' O ' HD23 ' A' ' 28' ' ' LEU . 89.4 m-20 -60.56 121.57 12.48 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.231 -0.918 . . . . 0.0 108.625 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.426 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.6 OUTLIER -64.94 6.08 0.27 Allowed 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.255 -0.903 . . . . 0.0 110.047 -178.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.471 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.0 p -51.55 -38.23 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.053 -1.029 . . . . 0.0 108.634 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.83 -35.68 71.21 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.641 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.4 m-20 -86.18 20.14 2.44 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.424 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.84 -14.69 0.02 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.641 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.52 -35.62 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.264 -1.139 . . . . 0.0 108.802 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.733 HD12 HG13 ' A' ' 11' ' ' VAL . 1.1 tt -69.99 -22.16 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.567 -0.708 . . . . 0.0 110.067 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -55.02 -32.51 61.87 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.302 -0.874 . . . . 0.0 110.845 -178.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.7 m -118.0 -63.79 1.38 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.22 -0.925 . . . . 0.0 111.168 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.5 tp -62.01 -52.55 63.53 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.961 -1.087 . . . . 0.0 110.276 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -38.17 66.1 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.561 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tt -59.57 -40.66 88.11 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.419 -1.048 . . . . 0.0 109.15 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 41.2 tp -61.99 -44.12 97.4 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.217 -0.927 . . . . 0.0 108.947 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.4 mttm -65.73 -37.42 86.33 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.316 -0.865 . . . . 0.0 109.483 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.5 t -62.84 -39.97 87.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.399 -0.813 . . . . 0.0 109.875 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.457 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -59.87 -51.41 73.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.11 -0.994 . . . . 0.0 109.664 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.457 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.59 -39.28 84.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.247 -0.908 . . . . 0.0 109.627 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.706 ' HE1' ' CZ ' ' A' ' 51' ' ' ARG . 76.2 t90 -68.89 -43.04 76.09 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.41 -0.806 . . . . 0.0 109.962 -179.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.54 HD13 ' C19' ' A' ' 101' ' ' 7V9 . 12.0 tp -63.15 -46.83 85.38 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.353 -0.842 . . . . 0.0 109.962 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -68.23 -36.0 78.81 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.238 -0.914 . . . . 0.0 109.88 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.56 -45.48 93.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.066 -1.022 . . . . 0.0 110.68 -179.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.706 ' CZ ' ' HE1' ' A' ' 47' ' ' TRP . 85.0 mtt180 -87.2 -50.25 6.73 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.078 -1.013 . . . . 0.0 111.45 -178.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -80.1 -24.78 40.32 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.0 -1.062 . . . . 0.0 111.271 -178.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.21 30.07 57.59 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -105.95 144.13 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.288 -1.125 . . . . 0.0 109.478 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.89 152.1 28.35 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.2 -0.938 . . . . 0.0 109.479 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.31 -33.15 65.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.417 -0.802 . . . . 0.0 109.704 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 54.28 46.19 25.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.192 -0.943 . . . . 0.0 109.402 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -91.53 11.34 24.45 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.328 -0.858 . . . . 0.0 109.76 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 78.2 t -56.9 -41.5 76.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.541 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.582 ' C ' HD23 ' A' ' 61' ' ' LEU . 96.0 mt-10 -116.07 138.34 51.32 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.505 -0.747 . . . . 0.0 109.197 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.582 HD23 ' C ' ' A' ' 60' ' ' GLU . 0.4 OUTLIER -106.54 138.02 43.48 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.369 -0.832 . . . . 0.0 109.255 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p -132.83 73.92 75.14 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.874 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_exo -58.48 -29.96 90.2 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.704 2.269 . . . . 0.0 111.931 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.54 -26.77 68.56 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.393 -0.817 . . . . 0.0 109.614 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 12.5 t-80 -67.81 -25.89 65.8 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 110.691 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -88.69 7.52 33.22 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.031 -1.043 . . . . 0.0 110.606 -179.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.3 mmt85 -59.73 -36.93 77.57 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.985 -1.072 . . . . 0.0 110.547 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.453 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 93.5 p -132.94 150.53 52.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.995 -1.066 . . . . 0.0 110.345 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.403 HG23 ' CG2' ' A' ' 7' ' ' ILE . 88.9 mt -65.9 -37.67 80.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 O-C-N 121.49 -0.756 . . . . 0.0 109.854 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 93.8 mtm-85 -61.2 -38.29 86.03 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.314 -0.866 . . . . 0.0 110.091 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.453 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 22.2 m -60.07 -40.7 90.44 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.137 -0.977 . . . . 0.0 109.404 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -65.66 -42.33 92.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.267 -0.895 . . . . 0.0 109.836 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.586 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 53.2 t0 -60.05 -38.74 83.69 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.335 -0.853 . . . . 0.0 110.062 -179.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.12 -40.64 98.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.182 -0.949 . . . . 0.0 109.747 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -62.7 -46.94 85.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -64.44 -44.02 97.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 121.24 -0.913 . . . . 0.0 109.757 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 73' ' ' ASP . 58.2 t -60.54 -40.66 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.34 -0.85 . . . . 0.0 109.625 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.46 -31.97 71.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.73 -50.44 3.41 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.113 -1.228 . . . . 0.0 110.807 -179.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.0 p -131.43 157.62 42.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 109.805 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.24 88.43 17.31 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.213 -0.93 . . . . 0.0 109.255 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 72.9 Cg_endo -82.94 160.28 15.89 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.758 2.305 . . . . 0.0 112.561 -179.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.94 150.88 84.49 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.91 2.407 . . . . 0.0 111.962 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 1.04 HG23 HG23 ' A' ' 6' ' ' VAL . 14.5 p -126.77 139.17 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.39 -0.819 . . . . 0.0 109.71 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -116.79 141.86 47.67 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.92 137.47 58.06 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.114 -0.991 . . . . 0.0 109.298 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 26.9 mttp -59.99 -34.74 73.72 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.338 -0.851 . . . . 0.0 109.482 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.1 tp -57.16 -37.6 72.34 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.236 -0.915 . . . . 0.0 109.457 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.482 179.952 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.54 ' C19' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.9 mmm . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -60.12 -35.89 76.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.35 -0.844 . . . . 0.0 109.703 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.822 ' NE2' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -155.18 28.44 0.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.129 -0.982 . . . . 0.0 109.541 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.43 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.63 -33.39 73.85 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.207 -0.933 . . . . 0.0 109.57 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 84.8 p -61.59 -36.56 81.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.197 -0.939 . . . . 0.0 109.497 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.822 HG21 ' NE2' ' A' ' 3' ' ' HIS . 69.8 t -67.83 -37.85 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.209 -0.932 . . . . 0.0 109.0 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.576 ' O ' HG23 ' A' ' 11' ' ' VAL . 84.4 mt -60.47 -50.92 78.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.268 -0.895 . . . . 0.0 109.219 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.68 -47.53 78.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -0.888 . . . . 0.0 109.303 179.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.04 -44.4 96.02 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.486 -0.759 . . . . 0.0 109.19 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.57 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.7 t80 -65.05 -46.48 81.04 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.538 0.685 . . . . 0.0 109.607 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.783 HG13 HD12 ' A' ' 36' ' ' ILE . 97.7 t -69.73 -47.42 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.529 -0.732 . . . . 0.0 110.293 -179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.8 t -64.57 -34.81 72.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.397 -0.814 . . . . 0.0 110.729 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.68 -36.11 56.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.072 -1.018 . . . . 0.0 109.982 -179.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.71 -35.06 78.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 0.0 110.676 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -92.82 -63.79 1.18 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.932 -1.105 . . . . 0.0 110.682 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.423 HD22 HG23 ' A' ' 19' ' ' VAL . 5.4 mt -124.86 83.03 60.04 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.334 -0.854 . . . . 0.0 110.196 -178.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -82.83 -21.29 4.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.928 2.419 . . . . 0.0 112.21 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.94 -4.2 42.7 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.152 -0.968 . . . . 0.0 109.263 179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.423 HG23 HD22 ' A' ' 16' ' ' LEU . 43.7 t -113.32 141.64 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.51 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.456 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . -61.9 117.82 32.7 Favored Pre-proline 0 C--N 1.303 -1.421 0 O-C-N 120.933 -1.104 . . . . 0.0 108.574 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.88 -25.63 59.92 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 C-N-CA 121.586 1.524 . . . . 0.0 111.877 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.47 -14.95 62.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -0.862 . . . . 0.0 109.136 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 91.3 m-20 -84.05 2.99 36.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.313 -0.867 . . . . 0.0 109.024 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.7 t -101.66 136.64 32.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.403 ' C ' ' H ' ' A' ' 27' ' ' ASP . 87.4 m-20 -68.05 87.96 0.27 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.148 -0.97 . . . . 0.0 109.478 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -64.06 -0.15 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.34 -0.85 . . . . 0.0 109.594 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.473 ' OD2' ' C ' ' A' ' 27' ' ' ASP . 49.3 p30 -88.83 7.57 33.49 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.203 -0.936 . . . . 0.0 108.954 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -97.15 141.75 29.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.618 -0.676 . . . . 0.0 109.486 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -60.52 121.76 12.96 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 179.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.4 pp -68.77 4.92 1.24 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.166 -0.959 . . . . 0.0 109.975 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.445 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.87 -38.34 17.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.034 -1.041 . . . . 0.0 108.53 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.3 m-20 -58.44 -35.7 72.52 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.626 ' O ' ' N ' ' A' ' 35' ' ' VAL . 66.9 m-80 -84.55 16.33 3.24 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.042 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -43.03 -14.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.626 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.7 t -51.3 -36.61 17.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.119 -1.224 . . . . 0.0 108.891 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.783 HD12 HG13 ' A' ' 11' ' ' VAL . 1.3 tt -70.56 -21.84 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 110.091 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -55.22 -31.88 61.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.261 -0.899 . . . . 0.0 111.083 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.15 -64.59 1.29 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.066 -1.021 . . . . 0.0 111.518 -178.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 55.2 tp -65.12 -52.08 57.45 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.814 -1.179 . . . . 0.0 110.581 -178.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.524 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.9 -35.69 79.92 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.576 HD21 ' C10' ' A' ' 101' ' ' 7V9 . 15.0 tp -58.14 -41.59 84.04 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -1.138 . . . . 0.0 109.282 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 42' ' ' LEU . 87.6 mt -62.61 -44.07 97.23 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.138 -0.976 . . . . 0.0 108.823 179.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.2 mttp -63.56 -36.71 84.7 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.8 t -64.12 -38.31 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.774 -0.579 . . . . 0.0 109.749 179.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.532 HG13 ' HB1' ' A' ' 56' ' ' ALA . 1.3 mp -56.91 -51.03 73.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 109.958 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.42 -39.15 85.48 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.055 -1.028 . . . . 0.0 109.7 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.57 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 52.4 t90 -67.51 -44.39 78.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.301 -0.874 . . . . 0.0 111.08 -179.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.593 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.4 OUTLIER -62.13 -49.1 77.21 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.133 -0.979 . . . . 0.0 109.978 -178.068 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -68.83 -39.22 80.1 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.957 -1.089 . . . . 0.0 109.391 179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -64.65 -42.62 95.29 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.119 -0.988 . . . . 0.0 111.135 -179.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.692 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 54.7 ttt-85 -72.2 -48.23 44.66 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.216 -0.927 . . . . 0.0 112.036 -177.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.73 ' CE2' HG21 ' A' ' 80' ' ' THR . 90.9 m-85 -104.23 -6.21 21.15 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 111.733 -178.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 71.56 30.79 66.09 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 59.9 mt -106.04 142.27 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.255 -1.144 . . . . 0.0 109.34 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.628 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -61.18 122.66 15.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.955 -1.091 . . . . 0.0 108.958 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.532 ' HB1' HG13 ' A' ' 45' ' ' ILE . . . -67.87 -32.74 73.46 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.46 -0.775 . . . . 0.0 110.142 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -92.26 8.65 37.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.35 -0.844 . . . . 0.0 110.284 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.3 t0 -54.08 -40.34 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.996 -1.065 . . . . 0.0 109.308 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.7 p -138.89 143.88 30.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.352 -0.843 . . . . 0.0 109.363 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -100.91 138.11 38.39 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.104 -0.998 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 23.8 mt -104.67 143.48 33.02 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.409 -0.807 . . . . 0.0 109.713 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -83.96 159.22 60.56 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.217 -0.927 . . . . 0.0 109.251 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -57.7 -31.93 93.31 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.675 2.25 . . . . 0.0 111.962 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.88 -24.8 66.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 179.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.9 t60 -67.28 -26.4 66.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.287 -0.883 . . . . 0.0 109.955 -179.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -95.05 6.23 49.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.107 -0.995 . . . . 0.0 109.426 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -56.33 -39.6 73.07 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.917 . . . . 0.0 109.7 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -135.25 153.5 51.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.094 -1.004 . . . . 0.0 109.924 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.4 ' N ' HD23 ' A' ' 30' ' ' LEU . 83.6 mt -63.88 -36.31 76.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 O-C-N 121.4 -0.813 . . . . 0.0 109.818 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 74.5 mtm180 -60.73 -37.68 82.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.325 -0.859 . . . . 0.0 109.823 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 t -59.76 -43.94 94.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.064 -1.023 . . . . 0.0 109.346 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.3 mt -64.39 -38.54 82.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.28 -0.888 . . . . 0.0 109.455 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.622 ' O ' HG23 ' A' ' 77' ' ' VAL . 21.8 t70 -56.16 -38.14 70.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.351 -0.843 . . . . 0.0 109.511 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.16 95.31 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.305 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -64.05 -46.69 83.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.493 179.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 58.3 t -64.18 -41.63 93.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.439 -0.788 . . . . 0.0 109.708 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.8 t -62.82 -43.5 98.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.216 -0.928 . . . . 0.0 109.96 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.82 -37.92 95.12 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.482 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -88.78 -49.64 6.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.111 -1.229 . . . . 0.0 110.185 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.73 HG21 ' CE2' ' A' ' 52' ' ' PHE . 28.0 m -128.86 138.75 52.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.492 -0.755 . . . . 0.0 109.316 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.68 88.41 51.98 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.441 -0.787 . . . . 0.0 109.566 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -66.08 160.33 45.14 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.533 2.155 . . . . 0.0 111.872 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -61.23 150.31 85.21 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.705 2.27 . . . . 0.0 111.949 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.5 t -107.99 135.2 47.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.389 -0.819 . . . . 0.0 109.504 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -151.84 -18.81 0.19 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 109.513 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -140.35 158.46 43.98 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.248 -0.907 . . . . 0.0 109.62 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 32.7 tttm 60.91 54.6 3.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.4 -0.812 . . . . 0.0 109.361 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.6 tp -99.0 130.45 45.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.189 -0.945 . . . . 0.0 109.357 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.484 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.576 ' C10' HD21 ' A' ' 41' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.9 mmm . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.649 ' HA ' HG22 ' A' ' 84' ' ' VAL . 94.1 mt-30 -58.85 -34.94 72.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.919 . . . . 0.0 109.384 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.654 ' CE1' HD11 ' A' ' 7' ' ' ILE . 5.4 p80 -160.33 23.14 0.16 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.372 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.4 -38.64 87.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.91 -34.12 77.25 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.357 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.68 -38.1 80.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.285 -0.885 . . . . 0.0 109.356 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.875 ' O ' HG12 ' A' ' 11' ' ' VAL . 88.4 mt -60.43 -50.39 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.526 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.795 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -64.0 -44.09 93.7 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.301 -0.874 . . . . 0.0 109.024 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.47 -40.8 89.54 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.529 -0.732 . . . . 0.0 109.647 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -66.39 -49.47 66.73 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.535 -0.728 . . . . 0.0 111.272 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.875 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.4 p -69.95 -44.81 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.126 -0.984 . . . . 0.0 111.258 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.795 HG22 ' O ' ' A' ' 8' ' ' ALA . 15.9 m -67.48 -33.87 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.026 -1.046 . . . . 0.0 110.733 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.408 ' N ' HG23 ' A' ' 12' ' ' VAL . 82.8 tt0 -52.2 -36.34 51.68 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.107 -0.996 . . . . 0.0 109.832 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -33.36 75.41 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.176 -0.952 . . . . 0.0 110.568 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.67 ' O ' HD12 ' A' ' 16' ' ' LEU . 64.5 m-85 -95.94 -63.72 1.12 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.016 -1.053 . . . . 0.0 110.98 -178.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.67 HD12 ' O ' ' A' ' 15' ' ' PHE . 5.1 mp -124.32 83.09 57.27 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 110.62 -178.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -84.12 -18.27 5.26 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.024 2.482 . . . . 0.0 112.048 179.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.97 -3.4 38.73 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.279 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.3 t -109.09 144.21 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.17 117.59 27.87 Favored Pre-proline 0 C--N 1.304 -1.396 0 O-C-N 120.864 -1.148 . . . . 0.0 108.465 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -65.24 -28.82 55.57 Favored 'Trans proline' 0 N--CA 1.49 1.271 0 C-N-CA 121.596 1.531 . . . . 0.0 112.041 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.71 -14.85 61.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.377 -0.827 . . . . 0.0 109.297 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -90.68 8.17 35.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.364 -0.835 . . . . 0.0 109.34 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.2 t -98.3 137.15 26.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.352 -0.842 . . . . 0.0 108.79 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.521 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -65.57 85.01 0.07 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.168 -0.958 . . . . 0.0 109.466 -179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.511 HG21 ' CE ' ' A' ' 87' ' ' LYS . 19.1 m -59.89 -0.06 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.312 -0.868 . . . . 0.0 109.266 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.45 7.14 44.37 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 108.954 179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.7 tp -94.23 136.01 35.0 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.494 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -63.51 121.71 14.52 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 179.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.468 HD11 ' O ' ' A' ' 66' ' ' PHE . 0.5 OUTLIER -68.78 5.24 1.15 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.262 -0.899 . . . . 0.0 109.87 -178.97 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.1 p -52.81 -38.87 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.03 -1.044 . . . . 0.0 108.547 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.446 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.9 t0 -57.77 -35.47 70.81 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 178.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.8 m-20 -86.06 19.52 2.6 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -14.51 0.01 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.4 t -51.44 -36.35 17.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 108.558 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.549 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.3 OUTLIER -69.98 -20.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.455 -0.778 . . . . 0.0 110.054 179.967 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -51.35 -35.57 38.94 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.216 -0.928 . . . . 0.0 110.98 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -119.1 -61.9 1.58 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.131 -0.981 . . . . 0.0 111.51 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -61.9 -52.39 64.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.925 -1.11 . . . . 0.0 110.14 -178.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.583 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.35 -41.1 59.58 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.8 -41.86 87.75 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.386 -1.067 . . . . 0.0 109.491 -179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -59.32 -44.31 92.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.184 -0.947 . . . . 0.0 108.949 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -65.35 -34.64 78.8 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.272 -0.892 . . . . 0.0 109.007 179.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 40' ' ' GLY . 70.2 t -62.67 -41.59 92.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.445 -0.784 . . . . 0.0 110.424 -179.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.2 mm -59.32 -49.59 82.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 120.931 -1.106 . . . . 0.0 109.635 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -65.84 -40.98 92.28 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -0.97 . . . . 0.0 109.338 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ2' ' HD3' ' A' ' 51' ' ' ARG . 69.3 t90 -66.89 -41.63 86.88 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.446 -0.784 . . . . 0.0 109.289 179.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.702 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 12.8 tp -60.07 -46.91 88.01 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.421 -0.8 . . . . 0.0 109.168 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.432 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -67.89 -34.18 76.15 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.314 -0.866 . . . . 0.0 109.207 178.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 92.4 m-20 -59.19 -46.62 87.94 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.233 -0.917 . . . . 0.0 110.291 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.401 ' HD3' ' CZ2' ' A' ' 47' ' ' TRP . 42.2 mtp180 -88.46 -51.77 5.54 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.075 -1.016 . . . . 0.0 111.616 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -80.23 -25.3 39.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.984 -1.072 . . . . 0.0 111.633 -177.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.34 31.16 52.52 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 119.248 -1.453 . . . . 0.0 109.712 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.432 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.9 mt -97.86 145.3 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.276 -1.132 . . . . 0.0 109.409 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.657 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -61.17 145.52 50.81 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.09 -1.006 . . . . 0.0 109.71 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.49 -36.47 80.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.463 -0.773 . . . . 0.0 109.933 -179.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -97.81 8.54 44.54 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.273 -0.892 . . . . 0.0 109.964 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.657 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 54.6 t0 -55.79 -40.54 72.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.232 -0.918 . . . . 0.0 109.71 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.9 m -135.15 153.58 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 109.666 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.563 ' C ' HD22 ' A' ' 61' ' ' LEU . 95.4 mt-10 -134.98 118.25 16.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.264 -0.898 . . . . 0.0 109.296 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.914 ' N ' HD22 ' A' ' 61' ' ' LEU . 1.4 mm? -110.33 139.31 45.66 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.83 . . . . 0.0 109.704 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -77.91 162.07 68.9 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.257 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.406 ' HA ' ' CD1' ' A' ' 66' ' ' PHE . 10.0 Cg_endo -56.41 -27.41 67.84 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.664 2.243 . . . . 0.0 111.955 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.54 -27.46 69.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.249 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 33.5 t-80 -67.14 -26.25 66.58 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.434 -0.791 . . . . 0.0 109.697 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 0.9 OUTLIER -91.64 7.77 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.2 -0.937 . . . . 0.0 109.188 -179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.6 tpt180 -55.63 -39.44 70.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.971 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 91.6 p -137.25 152.57 49.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.047 -1.033 . . . . 0.0 110.214 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.479 HG23 ' CG2' ' A' ' 7' ' ' ILE . 89.5 mt -65.25 -36.67 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.308 -0.87 . . . . 0.0 110.027 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 39.1 ptt85 -61.2 -40.5 94.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 110.07 -179.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -59.21 -40.51 86.02 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.108 -0.995 . . . . 0.0 109.402 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -65.97 -39.74 85.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.338 -0.851 . . . . 0.0 109.728 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.691 ' O ' HG23 ' A' ' 77' ' ' VAL . 60.7 t0 -58.51 -38.64 78.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.315 -0.866 . . . . 0.0 109.918 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.52 -42.17 95.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.193 -0.942 . . . . 0.0 109.92 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -63.58 -48.53 77.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.07 -1.019 . . . . 0.0 109.606 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -65.49 -41.6 91.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.295 -0.878 . . . . 0.0 109.761 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.691 HG23 ' O ' ' A' ' 73' ' ' ASP . 62.6 t -61.33 -41.39 89.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.311 -0.868 . . . . 0.0 109.788 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.86 -31.72 76.96 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.49 -50.26 3.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.042 -1.27 . . . . 0.0 110.618 -178.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.1 p -129.86 157.52 42.01 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.399 -0.813 . . . . 0.0 109.613 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.31 88.36 17.24 Favored Pre-proline 0 C--N 1.304 -1.385 0 O-C-N 121.206 -0.933 . . . . 0.0 109.393 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.458 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.5 Cg_exo -63.13 -176.23 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.688 2.259 . . . . 0.0 112.178 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.458 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.6 Cg_exo -60.84 151.07 79.89 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.674 2.249 . . . . 0.0 111.907 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.649 HG22 ' HA ' ' A' ' 2' ' ' GLN . 26.0 t -99.39 129.41 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.166 -0.959 . . . . 0.0 109.564 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -136.0 158.86 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.317 -0.864 . . . . 0.0 109.366 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -98.55 137.91 36.52 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.511 ' CE ' HG21 ' A' ' 26' ' ' VAL . 17.9 mttp -59.15 -35.38 73.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.46 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.2 tp -101.46 129.84 47.59 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.489 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 117.982 -1.008 . . . . 0.0 109.448 179.995 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.702 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.2 mtm . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -59.38 -37.43 77.94 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.541 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.606 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 81.9 m-70 -139.61 28.35 2.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.22 -0.925 . . . . 0.0 109.462 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.456 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -60.62 -34.35 74.12 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.281 -0.887 . . . . 0.0 110.151 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m -58.87 -40.16 83.5 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.018 -1.051 . . . . 0.0 109.666 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 1.133 HG23 HG23 ' A' ' 84' ' ' VAL . 69.3 t -64.5 -36.59 77.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.291 -0.88 . . . . 0.0 109.066 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.44 ' O ' HG12 ' A' ' 11' ' ' VAL . 27.7 mm -64.76 -44.31 96.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.433 -0.792 . . . . 0.0 110.323 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.688 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.73 -50.44 69.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.113 -0.992 . . . . 0.0 110.734 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.54 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.86 -39.49 76.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.016 -1.052 . . . . 0.0 109.566 -179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.54 ' N ' HE21 ' A' ' 9' ' ' GLN . 68.3 t80 -65.75 -51.29 60.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.346 -0.846 . . . . 0.0 109.94 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -67.93 -40.76 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 109.763 -179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.688 HG23 ' O ' ' A' ' 8' ' ' ALA . 71.1 t -65.93 -40.55 87.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.216 -0.927 . . . . 0.0 109.571 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -52.74 -30.54 33.15 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.438 -0.789 . . . . 0.0 109.827 -179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -65.37 -30.46 71.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.198 -0.939 . . . . 0.0 109.412 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.9 p90 -145.41 44.12 1.3 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.291 -0.881 . . . . 0.0 109.513 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.461 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.4 pt? -80.63 130.79 63.12 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.054 -1.029 . . . . 0.0 110.082 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -76.62 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.362 0 C-N-CA 121.83 1.687 . . . . 0.0 110.625 178.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.63 16.62 0.81 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.958 -1.089 . . . . 0.0 108.916 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.0 t -113.57 135.62 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.416 -0.802 . . . . 0.0 109.786 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.61 141.43 76.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.2 -0.938 . . . . 0.0 109.22 179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -49.04 -31.54 21.1 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.817 1.678 . . . . 0.0 111.993 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.96 -22.28 66.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.419 -0.8 . . . . 0.0 109.446 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -95.88 2.06 53.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.429 -0.795 . . . . 0.0 108.928 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.6 t -104.88 136.46 38.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.518 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.5 t0 -71.19 97.03 1.46 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.051 -1.031 . . . . 0.0 109.312 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.6 m -59.5 0.14 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.321 -0.862 . . . . 0.0 109.195 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.518 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -91.96 7.82 40.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.325 -0.859 . . . . 0.0 108.779 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.8 tp -91.22 133.83 35.06 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.478 -0.764 . . . . 0.0 109.376 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -66.33 121.31 14.96 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -74.74 9.6 1.77 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.219 -0.925 . . . . 0.0 109.825 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.5 p -52.25 -38.91 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.156 -0.965 . . . . 0.0 108.642 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.454 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.1 m-20 -57.33 -35.73 70.25 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 178.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.2 m-20 -84.94 18.25 2.54 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.011 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.92 -13.69 0.01 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -50.72 -35.24 13.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.072 -1.251 . . . . 0.0 108.945 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.578 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.1 tt -70.01 -23.48 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.308 -0.87 . . . . 0.0 110.042 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.418 ' OD2' ' CG ' ' A' ' 66' ' ' PHE . 84.2 m-20 -54.93 -32.42 61.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.194 -0.941 . . . . 0.0 110.714 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -116.51 -64.09 1.36 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.149 -0.969 . . . . 0.0 111.174 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 15.5 mt -62.67 -52.52 62.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.002 -1.061 . . . . 0.0 110.2 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.48 -37.19 69.18 Favored Glycine 0 N--CA 1.486 1.97 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.73 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.4 tt -58.86 -41.46 87.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.266 -1.138 . . . . 0.0 109.149 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -61.51 -44.22 97.45 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.348 -0.845 . . . . 0.0 108.894 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 48.7 mttt -67.92 -40.79 83.32 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.301 -0.875 . . . . 0.0 110.007 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.524 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 74.8 t -65.68 -42.86 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.277 -0.889 . . . . 0.0 110.131 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.1 mp -58.87 -50.47 79.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.186 -0.946 . . . . 0.0 109.65 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.424 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.72 -37.18 85.7 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.94 . . . . 0.0 109.436 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.517 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 35.4 t90 -69.32 -43.7 73.2 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.281 -0.887 . . . . 0.0 109.715 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.494 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 12.1 tp -57.34 -48.0 80.12 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.323 -0.86 . . . . 0.0 109.402 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -68.73 -37.71 79.66 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.301 -0.874 . . . . 0.0 109.122 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.5 t0 -63.77 -41.73 97.91 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.297 -0.877 . . . . 0.0 110.593 -179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.7 ttt180 -87.1 -55.26 3.9 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.231 -0.918 . . . . 0.0 111.454 -178.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -79.49 -22.34 44.16 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.987 -1.071 . . . . 0.0 111.383 -178.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 25.84 60.69 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 -179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.1 mt -106.07 144.91 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.471 -1.017 . . . . 0.0 109.416 -179.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 152.41 29.01 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.283 -0.886 . . . . 0.0 109.54 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.78 -28.56 61.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.368 -0.833 . . . . 0.0 109.688 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 54.86 46.23 24.89 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.262 -0.899 . . . . 0.0 109.278 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.447 ' C ' ' OD2' ' A' ' 58' ' ' ASP . 53.3 p30 -88.42 13.11 12.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.39 -0.819 . . . . 0.0 109.621 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 55.8 t -53.85 -42.52 53.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.238 -0.914 . . . . 0.0 109.607 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -121.68 136.34 54.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.464 -0.772 . . . . 0.0 109.75 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 20.1 mt -104.84 140.47 38.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.32 -0.863 . . . . 0.0 108.975 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.449 ' O ' ' OG ' ' A' ' 62' ' ' SER . 0.8 OUTLIER -130.27 80.57 70.37 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.197 -0.939 . . . . 0.0 110.228 -179.516 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -58.08 -25.99 73.49 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 C-N-CA 122.578 2.186 . . . . 0.0 111.664 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -67.72 -23.54 65.28 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.56 -0.713 . . . . 0.0 110.198 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.413 ' O ' HD11 ' A' ' 72' ' ' ILE . 0.2 OUTLIER -67.76 -26.63 66.22 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.59 -178.923 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.418 ' CG ' ' OD2' ' A' ' 37' ' ' ASP . 68.4 m-85 -80.17 -3.67 49.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.883 -1.136 . . . . 0.0 110.144 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 83.1 mmt-85 -60.47 -36.18 77.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.892 -1.13 . . . . 0.0 109.745 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.458 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 93.7 p -139.92 150.94 45.17 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.014 -1.054 . . . . 0.0 109.749 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 80.2 mt -65.13 -36.65 78.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 O-C-N 121.265 -0.897 . . . . 0.0 109.806 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -60.63 -38.41 84.68 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 110.197 -179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.458 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 24.6 m -57.81 -40.63 80.4 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.018 -1.051 . . . . 0.0 109.53 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.413 HD11 ' O ' ' A' ' 65' ' ' HIS . 17.0 mm -65.36 -38.97 83.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.154 -0.966 . . . . 0.0 109.17 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.536 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.4 t0 -57.23 -38.35 73.65 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.288 -0.882 . . . . 0.0 109.594 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.44 99.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.307 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -63.75 -46.56 84.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.357 -0.839 . . . . 0.0 109.432 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.8 t -64.68 -41.63 92.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 O-C-N 121.333 -0.854 . . . . 0.0 109.663 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 73' ' ' ASP . 52.9 t -61.59 -40.94 88.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.269 -0.894 . . . . 0.0 109.634 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.17 76.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.28 -50.01 5.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.096 -1.237 . . . . 0.0 109.961 -179.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.4 t -144.97 153.21 41.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 109.55 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.606 ' HG1' ' HE2' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -133.11 89.07 34.54 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.213 -0.929 . . . . 0.0 109.552 -179.901 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.5 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 61.4 Cg_endo -82.51 161.38 17.0 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.715 2.277 . . . . 0.0 112.494 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.39 150.83 83.26 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.868 2.379 . . . . 0.0 112.022 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 1.133 HG23 HG23 ' A' ' 6' ' ' VAL . 13.4 p -128.13 141.03 47.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.38 -0.825 . . . . 0.0 109.859 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.16 151.5 39.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.565 -0.71 . . . . 0.0 109.096 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.54 142.54 58.39 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -0.901 . . . . 0.0 109.432 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 61.4 mttp -58.88 -36.39 74.57 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.186 -0.946 . . . . 0.0 109.356 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 37.9 tp -104.38 130.12 52.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.901 . . . . 0.0 109.435 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.489 1.517 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.451 -179.957 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.524 ' C18' ' CG1' ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.8 mtt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.387 0.613 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.468 ' OE1' HG13 ' A' ' 77' ' ' VAL . 61.4 tt0 -55.39 -38.92 69.52 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.191 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.587 ' ND1' ' OG1' ' A' ' 81' ' ' THR . 45.2 m80 -152.92 28.89 0.52 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.417 -0.802 . . . . 0.0 109.19 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.436 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.27 -33.02 71.73 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.412 -0.805 . . . . 0.0 109.658 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.9 m -58.97 -38.95 80.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.173 -0.954 . . . . 0.0 109.613 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -65.14 -39.06 84.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.15 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.436 HD12 ' HA ' ' A' ' 4' ' ' ALA . 89.1 mt -60.58 -50.62 79.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.276 -0.89 . . . . 0.0 109.459 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.737 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.96 -44.62 92.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 109.064 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.37 -44.17 88.48 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-O 121.74 0.781 . . . . 0.0 109.227 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -61.61 -47.79 83.86 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.525 -0.735 . . . . 0.0 109.331 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.476 HG12 ' HE1' ' A' ' 15' ' ' PHE . 96.6 t -73.16 -41.49 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.446 -0.784 . . . . 0.0 110.139 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 8' ' ' ALA . 78.4 t -63.96 -41.27 91.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.289 -0.882 . . . . 0.0 111.022 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -57.01 -28.25 62.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.065 -1.022 . . . . 0.0 109.907 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.44 -30.09 70.84 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.21 -0.931 . . . . 0.0 109.359 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.603 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.8 p90 -146.8 45.68 1.19 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.161 -0.962 . . . . 0.0 109.775 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.819 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.45 130.93 63.18 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.965 -1.084 . . . . 0.0 110.369 -179.725 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.55 -149.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 122.021 1.814 . . . . 0.0 110.311 178.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.6 p30 -80.73 15.77 1.63 Allowed 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.764 -1.21 . . . . 0.0 109.146 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.459 HG23 ' OD1' ' A' ' 18' ' ' ASP . 39.4 t -113.33 136.05 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.443 -0.786 . . . . 0.0 109.778 -179.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.55 142.06 85.95 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.212 -0.93 . . . . 0.0 109.386 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -49.25 -33.8 29.46 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.878 1.719 . . . . 0.0 111.697 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.03 -21.87 65.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.489 -0.757 . . . . 0.0 109.331 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -97.4 5.21 50.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.55 -0.719 . . . . 0.0 109.17 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.4 t -102.54 136.49 34.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.516 ' C ' ' H ' ' A' ' 27' ' ' ASP . 84.5 m-20 -67.42 94.35 0.39 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.137 -0.977 . . . . 0.0 109.418 -179.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.5 m -59.24 0.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.39 -0.819 . . . . 0.0 109.423 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.516 ' H ' ' C ' ' A' ' 25' ' ' ASP . 48.2 p30 -84.26 9.79 12.08 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.227 -0.921 . . . . 0.0 109.078 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.8 tp -86.34 134.95 33.69 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.6 -0.687 . . . . 0.0 109.366 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -65.43 121.83 15.78 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 108.733 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.694 HD11 HG12 ' A' ' 69' ' ' ILE . 82.3 mt -56.87 -16.66 7.14 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.213 -0.929 . . . . 0.0 108.931 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' A' ' 34' ' ' GLY . 41.7 t -50.64 -40.94 19.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.237 -0.914 . . . . 0.0 108.914 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.67 -36.17 66.81 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 178.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' A' ' 35' ' ' VAL . 9.7 m120 -85.02 20.44 1.88 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.11 -15.35 0.02 OUTLIER Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.346 -1.101 . . . . 0.0 110.346 -179.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.597 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.4 t -51.91 -40.17 27.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.604 -1.527 . . . . 0.0 108.585 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.4 tt -71.91 -22.25 21.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.577 -0.702 . . . . 0.0 110.883 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.408 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 93.0 m-20 -52.51 -34.8 51.36 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.154 -0.966 . . . . 0.0 111.784 -177.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.554 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.5 OUTLIER -119.02 -60.59 1.74 Allowed 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.957 -1.09 . . . . 0.0 111.224 -178.692 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -61.96 -52.18 65.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.868 -1.145 . . . . 0.0 109.598 -179.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.441 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.91 -36.98 65.29 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.85 HD12 ' N9 ' ' A' ' 101' ' ' 7V9 . 5.7 tt -58.02 -41.02 82.26 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.358 -1.083 . . . . 0.0 109.294 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 30.4 mt -60.31 -44.43 95.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 108.667 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.0 mttm -67.75 -38.74 83.89 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.406 -0.809 . . . . 0.0 109.576 179.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.724 HG21 ' S12' ' A' ' 101' ' ' 7V9 . 79.5 t -65.09 -39.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.448 -0.783 . . . . 0.0 110.351 -179.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -58.11 -50.6 77.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.033 -1.042 . . . . 0.0 109.642 -179.262 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.463 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.16 -39.14 86.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.089 -1.007 . . . . 0.0 109.702 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.5 t90 -70.38 -42.14 72.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.131 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.7 tp -61.43 -47.2 86.81 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.383 -0.823 . . . . 0.0 110.029 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.584 ' O ' ' N ' ' A' ' 53' ' ' GLY . 82.5 tt0 -64.72 -43.7 92.59 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.116 -0.99 . . . . 0.0 108.613 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -66.45 -39.93 89.15 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.335 -0.853 . . . . 0.0 110.232 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 27.2 tpt85 -63.02 -45.06 94.13 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.499 -0.751 . . . . 0.0 111.547 -178.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.405 ' CZ ' ' CB ' ' A' ' 82' ' ' PRO . 54.8 m-85 -126.24 2.27 7.1 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.912 -1.118 . . . . 0.0 111.858 -178.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.7 33.79 54.91 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.5 ' CG2' ' OD1' ' A' ' 58' ' ' ASP . 70.6 mt -95.85 135.87 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.183 -1.186 . . . . 0.0 109.146 -179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.732 ' HB3' ' HB3' ' A' ' 58' ' ' ASP . . . -61.54 140.7 58.07 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.087 -1.008 . . . . 0.0 109.678 -179.214 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.89 -35.74 81.65 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.468 -0.77 . . . . 0.0 109.786 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -99.75 14.3 30.7 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.331 -0.856 . . . . 0.0 110.118 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.732 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 28.5 p-10 -57.68 -35.51 70.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.096 -1.003 . . . . 0.0 109.458 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.577 ' N ' ' OD2' ' A' ' 58' ' ' ASP . 21.7 m -130.98 158.67 43.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.472 -0.767 . . . . 0.0 109.436 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.558 ' C ' HD12 ' A' ' 61' ' ' LEU . 95.4 mt-10 -95.19 137.67 33.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.177 -0.952 . . . . 0.0 109.241 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.86 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.1 mp -106.34 139.02 41.48 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.861 -179.742 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.61 155.54 75.17 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.349 -0.844 . . . . 0.0 108.967 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -59.39 -35.13 97.22 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.511 2.141 . . . . 0.0 112.184 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.91 -28.73 68.55 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.398 -0.814 . . . . 0.0 109.796 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -67.81 -27.03 66.38 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.289 -0.882 . . . . 0.0 110.231 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.603 ' CD1' ' O8 ' ' A' ' 101' ' ' 7V9 . 56.0 m-85 -101.68 13.84 33.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.133 -0.98 . . . . 0.0 110.06 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.2 tpt180 -53.03 -32.96 49.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.333 -0.855 . . . . 0.0 109.094 179.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.7 t -151.29 151.76 32.25 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 109.973 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.694 HG12 HD11 ' A' ' 30' ' ' LEU . 81.8 mt -60.97 -36.87 75.27 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.32 0 O-C-N 121.262 -0.898 . . . . 0.0 110.11 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -60.63 -40.82 93.38 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.224 -0.922 . . . . 0.0 110.214 -179.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.2 m -60.66 -41.8 95.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.037 -1.04 . . . . 0.0 109.936 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.523 HD11 ' CD1' ' A' ' 66' ' ' PHE . 77.3 mt -66.95 -40.83 86.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 O-C-N 121.245 -0.909 . . . . 0.0 110.156 -179.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.407 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.1 t0 -59.12 -40.72 86.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.273 -0.892 . . . . 0.0 110.405 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.17 -41.9 89.7 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.124 -0.985 . . . . 0.0 110.09 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.7 t80 -62.06 -49.65 75.15 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.164 -0.96 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 80' ' ' THR . 53.6 t -65.55 -47.05 87.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.219 -0.926 . . . . 0.0 109.562 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.468 HG13 ' OE1' ' A' ' 2' ' ' GLN . 45.8 t -58.93 -38.84 75.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.112 -0.992 . . . . 0.0 109.455 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.73 -33.06 66.6 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.46 -51.24 3.14 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.119 -1.224 . . . . 0.0 110.397 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.624 ' O ' HG12 ' A' ' 76' ' ' VAL . 7.2 t -153.87 152.41 30.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 0.0 109.728 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.587 ' OG1' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -123.7 88.66 51.89 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.236 -0.915 . . . . 0.0 109.22 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.405 ' CB ' ' CZ ' ' A' ' 52' ' ' PHE . 97.2 Cg_endo -92.57 108.44 0.22 Allowed 'Trans proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.184 2.59 . . . . 0.0 112.973 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -80.11 136.1 11.38 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.103 1.869 . . . . 0.0 111.698 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.467 HG13 ' O ' ' A' ' 89' ' ' GLN . 40.1 t -124.15 129.14 74.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.359 -0.838 . . . . 0.0 109.647 -179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.99 -37.31 81.32 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.928 . . . . 0.0 109.471 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -155.29 153.01 29.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.282 -0.886 . . . . 0.0 109.542 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -58.54 -37.72 76.28 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.191 -0.943 . . . . 0.0 109.461 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.0 mt -59.52 -35.27 73.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.222 -0.924 . . . . 0.0 109.513 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.467 ' O ' HG13 ' A' ' 84' ' ' VAL . 7.2 tt0 . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.517 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.85 ' N9 ' HD12 ' A' ' 41' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.312 0.577 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.504 ' O ' HG22 ' A' ' 84' ' ' VAL . 93.2 mt-30 -59.49 -36.63 76.39 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.301 -0.874 . . . . 0.0 109.458 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 83' ' ' PRO . 2.9 m-70 -137.03 18.69 3.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.352 -0.843 . . . . 0.0 109.702 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.415 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -57.64 -38.98 75.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.166 -0.959 . . . . 0.0 109.599 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.6 p -65.24 -37.29 86.79 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.098 -1.001 . . . . 0.0 109.624 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.434 HG21 ' ND1' ' A' ' 3' ' ' HIS . 76.2 t -68.13 -37.81 78.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.287 -0.883 . . . . 0.0 109.261 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.554 HD11 ' HA ' ' A' ' 73' ' ' ASP . 97.2 mt -60.02 -49.79 82.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.241 -0.912 . . . . 0.0 109.454 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.75 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.71 -47.17 82.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.184 -0.947 . . . . 0.0 109.098 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -44.16 94.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.445 -0.785 . . . . 0.0 109.252 179.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.696 ' CZ ' ' CZ3' ' A' ' 47' ' ' TRP . 70.2 t80 -68.39 -48.32 65.01 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.512 0.673 . . . . 0.0 109.48 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.54 HG13 ' CD1' ' A' ' 36' ' ' ILE . 97.5 t -68.67 -44.22 82.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.667 -0.645 . . . . 0.0 110.014 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.728 HG23 ' O ' ' A' ' 8' ' ' ALA . 96.9 t -64.22 -36.71 77.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -52.37 -32.8 40.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.316 -0.865 . . . . 0.0 109.729 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.594 ' OE1' ' CZ3' ' A' ' 47' ' ' TRP . 76.8 mm-40 -66.0 -31.79 72.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.206 -0.934 . . . . 0.0 109.804 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.548 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 34.4 p90 -140.06 42.94 1.94 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.103 -0.998 . . . . 0.0 109.835 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.82 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.63 130.56 64.02 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.05 -1.031 . . . . 0.0 110.015 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.413 ' C ' ' H ' ' A' ' 19' ' ' VAL . 73.4 Cg_endo -76.86 -152.18 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 121.962 1.774 . . . . 0.0 110.667 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -77.55 15.53 0.79 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.934 -1.104 . . . . 0.0 108.966 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.413 ' H ' ' C ' ' A' ' 17' ' ' PRO . 42.8 t -113.42 135.22 53.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.516 -0.74 . . . . 0.0 109.736 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.22 140.91 80.26 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.22 -0.925 . . . . 0.0 109.208 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.437 ' HB2' ' HZ1' ' A' ' 87' ' ' LYS . 35.1 Cg_exo -49.76 -31.45 25.92 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 121.842 1.695 . . . . 0.0 111.924 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.38 -22.77 66.83 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.537 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -92.77 4.29 54.06 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.448 -0.782 . . . . 0.0 109.225 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.3 t -105.35 136.48 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.522 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -69.23 91.24 0.52 Allowed 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.213 -0.93 . . . . 0.0 109.516 -179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -59.83 0.08 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.349 -0.844 . . . . 0.0 109.186 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.522 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -93.44 8.19 41.57 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.339 -0.851 . . . . 0.0 108.886 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.7 tp -92.34 136.86 32.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.432 -0.793 . . . . 0.0 109.519 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' A' ' 31' ' ' VAL . 33.6 p30 -62.61 114.4 3.55 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.141 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -63.74 8.7 0.08 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.112 -0.993 . . . . 0.0 109.926 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.539 ' H ' ' C ' ' A' ' 29' ' ' ASP . 6.3 p -54.98 -38.25 44.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.059 -1.025 . . . . 0.0 109.172 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.433 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.3 t0 -56.85 -37.21 70.98 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.596 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.5 m-80 -87.3 16.92 4.76 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.43 -17.4 0.03 OUTLIER Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.749 -1.341 . . . . 0.0 109.749 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.596 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.13 -34.19 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 O-C-N 120.969 -1.312 . . . . 0.0 108.453 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.593 ' O ' ' N ' ' A' ' 41' ' ' LEU . 0.9 OUTLIER -71.08 -21.32 22.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.512 -0.743 . . . . 0.0 110.042 179.896 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -55.06 -33.6 62.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.29 -0.881 . . . . 0.0 111.388 -178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 31.6 m -114.02 -64.52 1.3 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.055 -1.028 . . . . 0.0 111.522 -178.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.536 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.7 mp -65.45 -51.68 58.45 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.0 -1.062 . . . . 0.0 110.573 -178.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.613 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.5 -37.64 69.08 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 120.016 -1.088 . . . . 0.0 110.426 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.605 ' O ' HD13 ' A' ' 45' ' ' ILE . 6.9 tt -58.75 -41.49 86.65 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.176 -1.191 . . . . 0.0 109.796 -179.193 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.9 tp -66.76 -44.66 80.85 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.241 -0.912 . . . . 0.0 109.299 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -67.89 -37.95 82.39 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 40' ' ' GLY . 61.1 t -63.59 -40.94 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.412 -0.805 . . . . 0.0 110.303 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.605 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.3 mp -58.88 -51.09 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.113 -0.992 . . . . 0.0 109.832 -179.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.441 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.14 -37.46 83.84 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.11 -0.994 . . . . 0.0 109.217 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.696 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 25.9 t90 -66.25 -39.61 89.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.445 -0.784 . . . . 0.0 109.538 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.604 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 11.0 tp -59.53 -41.92 91.09 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.511 -0.743 . . . . 0.0 109.84 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.461 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 4.1 tm-20 -65.77 -39.11 90.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.183 -0.948 . . . . 0.0 109.925 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -60.09 -39.09 84.91 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.617 -179.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 79.6 mtp85 -86.02 -54.18 4.64 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 111.247 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -80.4 -22.89 40.79 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.054 -1.028 . . . . 0.0 110.984 -178.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 27.47 57.76 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.12 -1.592 . . . . 0.0 109.12 -179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.461 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 68.3 mt -104.85 148.7 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.343 -1.092 . . . . 0.0 109.424 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.38 155.21 22.06 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.266 -0.896 . . . . 0.0 109.33 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.411 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -55.25 -37.98 67.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.325 -0.859 . . . . 0.0 109.809 -179.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 51.92 50.52 18.42 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.057 -1.027 . . . . 0.0 108.9 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -71.86 116.36 12.15 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 110.055 -179.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.454 ' O ' ' O8 ' ' A' ' 101' ' ' 7V9 . 22.8 m -130.36 161.59 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.401 ' O ' HD23 ' A' ' 61' ' ' LEU . 89.0 tt0 -88.17 117.16 26.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.904 -1.122 . . . . 0.0 110.233 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.522 ' H ' ' C6 ' ' A' ' 101' ' ' 7V9 . 32.8 mt -116.03 145.15 43.22 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -68.16 153.84 94.86 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.149 -0.97 . . . . 0.0 109.453 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -60.93 -27.12 84.3 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.649 2.232 . . . . 0.0 112.096 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.69 -25.45 67.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.384 -0.823 . . . . 0.0 109.947 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 52.6 t-80 -67.16 -26.64 66.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.173 -0.955 . . . . 0.0 110.202 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -96.78 3.14 52.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.095 -1.003 . . . . 0.0 109.387 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -56.67 -41.01 76.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.806 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -130.26 147.2 51.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.224 -0.922 . . . . 0.0 109.926 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.75 HD13 ' HB2' ' A' ' 8' ' ' ALA . 82.8 mt -63.12 -35.85 73.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 O-C-N 121.372 -0.83 . . . . 0.0 109.977 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 69.5 mtm180 -60.35 -37.35 80.4 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.202 -0.936 . . . . 0.0 110.108 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.3 t -58.67 -39.77 81.62 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.035 -1.041 . . . . 0.0 108.821 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.5 mt -62.65 -38.19 80.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.4 -0.812 . . . . 0.0 108.985 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.576 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.3 t0 -54.31 -38.73 66.29 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.409 -0.807 . . . . 0.0 109.275 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.15 93.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.927 . . . . 0.0 109.246 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -65.4 -46.35 80.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.244 -0.91 . . . . 0.0 109.374 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' A' ' 80' ' ' THR . 55.2 t -65.38 -41.99 92.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.383 -0.823 . . . . 0.0 110.123 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.4 t -62.8 -42.92 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 121.085 -1.009 . . . . 0.0 109.864 -179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.95 -36.41 92.13 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 -179.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -93.47 -49.79 5.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.105 -1.232 . . . . 0.0 110.532 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.498 ' O ' ' O ' ' A' ' 76' ' ' VAL . 37.9 m -129.22 139.68 51.77 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.835 . . . . 0.0 109.95 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.19 88.0 55.18 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.38 -0.825 . . . . 0.0 109.284 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.543 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 56.7 Cg_endo -82.07 161.34 18.11 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.666 2.244 . . . . 0.0 112.452 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 18.7 Cg_endo -61.39 148.91 91.73 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.817 2.345 . . . . 0.0 111.7 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 2' ' ' GLN . 46.2 t -98.08 131.52 44.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.115 -0.991 . . . . 0.0 109.97 -179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.12 163.5 23.68 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.24 141.41 35.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.186 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.437 ' HZ1' ' HB2' ' A' ' 21' ' ' PRO . 43.7 tttm -58.7 -36.19 73.84 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.266 -0.896 . . . . 0.0 109.518 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.5 mt -58.7 -35.35 72.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.438 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.436 -179.996 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.604 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.788 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 93.3 mmm . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 68.1 tp60 -56.98 -41.36 78.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.233 -0.917 . . . . 0.0 109.643 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.563 ' NE2' ' OG1' ' A' ' 81' ' ' THR . 95.9 m-70 -139.98 8.82 2.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.182 -0.949 . . . . 0.0 109.78 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.788 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -59.83 -37.49 79.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.163 -0.961 . . . . 0.0 109.394 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -59.76 -36.53 76.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.216 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.98 HG22 HG23 ' A' ' 84' ' ' VAL . 82.5 t -64.91 -37.25 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.388 -0.82 . . . . 0.0 109.45 179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.54 ' CG2' HG23 ' A' ' 69' ' ' ILE . 89.6 mt -59.54 -48.53 86.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.242 -0.911 . . . . 0.0 109.567 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.612 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.25 -45.25 92.4 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.092 -1.005 . . . . 0.0 108.628 179.288 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.445 ' NE2' ' O ' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -65.65 -38.22 88.72 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 121.512 0.672 . . . . 0.0 109.398 179.276 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.553 ' CE2' ' NZ ' ' A' ' 87' ' ' LYS . 68.6 t80 -64.51 -51.69 61.66 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.567 -0.708 . . . . 0.0 110.003 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.524 ' HB ' HD12 ' A' ' 36' ' ' ILE . 16.2 m -74.42 -41.53 49.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.25 -0.906 . . . . 0.0 110.457 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 8' ' ' ALA . 73.9 t -62.85 -36.22 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.16 -0.963 . . . . 0.0 110.403 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.661 ' OE1' ' HB1' ' A' ' 86' ' ' ALA . 83.3 tt0 -57.36 -36.91 71.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.464 -179.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -67.38 -36.85 82.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 110.504 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 60.4 m-85 -90.58 -61.61 1.64 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.028 -1.045 . . . . 0.0 110.721 -178.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.1 mt -125.7 82.83 63.23 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.304 -0.873 . . . . 0.0 110.134 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -83.02 -20.58 5.14 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.819 2.346 . . . . 0.0 112.204 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.88 -4.31 43.07 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.184 -0.948 . . . . 0.0 108.905 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.3 t -113.56 140.09 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.5 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.83 118.52 39.37 Favored Pre-proline 0 C--N 1.303 -1.431 0 O-C-N 120.96 -1.088 . . . . 0.0 108.726 -179.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -64.87 -27.51 59.05 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.528 1.485 . . . . 0.0 111.808 -179.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.28 -17.07 63.09 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.287 -0.883 . . . . 0.0 109.198 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.5 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.9 m-20 -82.95 -1.26 51.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.385 -0.822 . . . . 0.0 108.787 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -102.5 138.65 25.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.505 ' C ' ' H ' ' A' ' 27' ' ' ASP . 53.4 t0 -67.93 94.36 0.47 Allowed 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.125 -0.984 . . . . 0.0 109.4 -179.399 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.5 m -60.87 0.51 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.363 -0.835 . . . . 0.0 109.319 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.505 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.1 m-20 -87.57 9.58 20.68 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.007 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -87.38 134.59 33.56 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.47 -0.769 . . . . 0.0 109.516 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.481 ' OD1' ' O ' ' A' ' 67' ' ' ARG . 86.1 m-20 -62.27 122.29 15.26 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.338 -0.851 . . . . 0.0 108.776 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.733 HD11 HG12 ' A' ' 69' ' ' ILE . 76.3 mt -58.13 -10.82 2.1 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.176 -0.952 . . . . 0.0 109.311 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 89.0 t -50.55 -45.35 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.116 -0.99 . . . . 0.0 108.691 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -55.94 -36.54 67.88 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.2 m-20 -90.13 22.91 3.05 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.13 -15.13 0.01 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 56.0 t -52.61 -37.2 23.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.308 . . . . 0.0 108.542 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.524 HD12 ' HB ' ' A' ' 11' ' ' VAL . 2.8 tt -70.48 -19.42 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.514 -0.741 . . . . 0.0 110.167 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.589 ' OD1' ' CE1' ' A' ' 66' ' ' PHE . 77.2 m-20 -56.71 -35.57 68.66 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.234 -0.916 . . . . 0.0 111.461 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.533 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.6 OUTLIER -113.08 -64.56 1.29 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.086 -1.009 . . . . 0.0 111.268 -178.322 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.41 -48.93 77.52 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.066 -1.021 . . . . 0.0 110.02 -178.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.08 -43.52 56.6 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.559 HD13 ' C4 ' ' A' ' 101' ' ' 7V9 . 8.0 tt -58.8 -39.66 81.76 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -1.097 . . . . 0.0 109.371 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.77 -44.24 93.96 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.171 -0.956 . . . . 0.0 108.772 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.2 mttp -68.42 -39.95 81.41 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.323 -0.861 . . . . 0.0 109.602 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.439 ' CG1' ' C18' ' A' ' 101' ' ' 7V9 . 70.4 t -65.84 -44.09 92.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.4 -0.812 . . . . 0.0 110.123 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.413 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.2 mp -61.63 -50.5 80.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.127 -0.983 . . . . 0.0 109.481 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.413 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -66.85 -38.25 86.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.311 179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.401 ' CZ3' ' CZ ' ' A' ' 10' ' ' PHE . 44.7 t90 -68.97 -43.57 74.68 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.328 -0.858 . . . . 0.0 109.6 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.625 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 11.7 tp -60.2 -43.68 95.76 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.434 -0.792 . . . . 0.0 109.485 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.429 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 85.4 tt0 -67.71 -36.3 80.36 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.298 -0.876 . . . . 0.0 109.874 179.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -59.42 -39.24 82.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.838 -1.164 . . . . 0.0 110.119 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 36.3 mtp180 -87.04 -58.22 2.67 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.184 -0.947 . . . . 0.0 111.522 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -80.58 -23.16 40.06 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.951 -1.093 . . . . 0.0 111.733 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.71 35.01 33.15 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.319 -1.42 . . . . 0.0 109.709 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.546 HG23 ' OD2' ' A' ' 58' ' ' ASP . 69.2 mt -97.63 138.5 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.247 -1.149 . . . . 0.0 108.878 179.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.93 142.72 56.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.891 -1.131 . . . . 0.0 109.487 -179.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.05 -34.42 73.39 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.356 -0.84 . . . . 0.0 109.335 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -94.58 11.07 32.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.309 -0.87 . . . . 0.0 109.419 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' OD2' HG23 ' A' ' 54' ' ' ILE . 53.9 t0 -52.91 -33.33 49.88 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.318 -0.864 . . . . 0.0 109.847 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.1 m -124.59 159.67 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.393 -0.817 . . . . 0.0 109.745 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -83.56 152.72 24.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.362 -0.836 . . . . 0.0 109.449 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.427 HD22 ' O4 ' ' A' ' 101' ' ' 7V9 . 36.6 mt -72.52 136.28 45.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.194 -0.941 . . . . 0.0 109.398 -179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.84 87.45 19.73 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.354 -0.841 . . . . 0.0 109.621 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_exo -51.67 -23.55 15.57 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.283 1.989 . . . . 0.0 111.971 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.5 -20.87 61.51 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.415 -0.803 . . . . 0.0 109.564 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -67.43 -26.94 66.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.309 -0.869 . . . . 0.0 110.383 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.589 ' CE1' ' OD1' ' A' ' 37' ' ' ASP . 51.7 m-85 -72.91 -14.14 61.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.009 -1.057 . . . . 0.0 109.555 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.481 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 25.1 mmt180 -56.79 -35.94 69.3 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.299 -0.875 . . . . 0.0 110.194 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.9 p -157.52 143.77 17.75 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.86 -1.15 . . . . 0.0 110.463 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.733 HG12 HD11 ' A' ' 30' ' ' LEU . 84.9 mt -66.99 -36.6 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 O-C-N 121.562 -0.711 . . . . 0.0 110.172 179.521 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 13.4 ttm180 -60.27 -41.89 94.25 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.373 -0.829 . . . . 0.0 110.629 -178.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -57.49 -42.12 82.06 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.134 -0.978 . . . . 0.0 109.774 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.14 -38.66 80.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.133 -0.979 . . . . 0.0 109.928 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 77' ' ' VAL . 40.4 t0 -57.72 -40.54 79.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 -179.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.9 85.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.142 -0.974 . . . . 0.0 109.745 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -62.97 -48.88 76.95 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.228 -0.92 . . . . 0.0 109.398 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.514 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.5 t -66.55 -45.47 88.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.242 -0.911 . . . . 0.0 109.725 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 73' ' ' ASP . 49.2 t -60.91 -41.84 90.41 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 O-C-N 121.069 -1.02 . . . . 0.0 109.592 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.96 -28.42 63.56 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.32 -50.67 3.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.139 -1.212 . . . . 0.0 110.678 -179.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.514 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.1 t -149.17 156.58 42.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.068 -1.02 . . . . 0.0 109.997 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.563 ' OG1' ' NE2' ' A' ' 3' ' ' HIS . 0.2 OUTLIER -129.07 89.19 49.21 Favored Pre-proline 0 C--N 1.302 -1.466 0 O-C-N 121.454 -0.779 . . . . 0.0 108.918 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -60.86 157.04 40.14 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.665 2.243 . . . . 0.0 112.891 -178.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -65.42 151.92 83.56 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 123.034 2.489 . . . . 0.0 112.153 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.98 HG23 HG22 ' A' ' 6' ' ' VAL . 7.2 p -89.57 130.22 39.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.172 -0.955 . . . . 0.0 109.458 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.445 ' O ' ' NE2' ' A' ' 9' ' ' GLN . 73.6 tt0 -171.47 -119.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.32 -0.862 . . . . 0.0 109.187 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.661 ' HB1' ' OE1' ' A' ' 13' ' ' GLU . . . -159.26 165.24 33.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.169 -0.957 . . . . 0.0 109.581 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.553 ' NZ ' ' CE2' ' A' ' 10' ' ' PHE . 26.2 mttm -71.29 143.72 50.24 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.921 . . . . 0.0 109.302 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 70.0 mt -59.3 -35.09 73.15 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.243 -0.911 . . . . 0.0 109.435 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.914 -1.041 . . . . 0.0 109.496 -179.967 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.625 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.8 mtt . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.315 0.579 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.594 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 93.4 mt-30 -104.93 140.34 38.31 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.594 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 22.0 p-80 40.28 24.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.412 -0.805 . . . . 0.0 109.164 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.553 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -61.53 -37.58 84.27 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.488 -0.757 . . . . 0.0 109.652 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.1 m -59.56 -38.1 80.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -0.943 . . . . 0.0 109.543 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.404 ' O ' ' CB ' ' A' ' 10' ' ' PHE . 71.6 t -64.28 -37.53 80.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.255 -0.903 . . . . 0.0 109.07 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.474 HD11 ' NE2' ' A' ' 3' ' ' HIS . 77.9 mt -64.19 -46.82 92.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.283 -0.886 . . . . 0.0 109.961 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.683 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.21 -49.98 69.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.293 -0.879 . . . . 0.0 110.593 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.751 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -69.72 -40.93 75.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.014 -1.054 . . . . 0.0 109.866 -179.661 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.751 ' N ' HE21 ' A' ' 9' ' ' GLN . 74.4 t80 -63.69 -51.32 65.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -0.973 . . . . 0.0 110.159 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.47 HG12 ' O ' ' A' ' 7' ' ' ILE . 5.0 p -68.51 -40.38 81.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -0.914 . . . . 0.0 109.703 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 8' ' ' ALA . 72.4 t -66.95 -37.8 80.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.311 -0.868 . . . . 0.0 109.795 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -52.41 -29.67 25.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.378 -0.827 . . . . 0.0 109.992 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.51 -30.42 71.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.222 -0.924 . . . . 0.0 109.679 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.574 ' CE1' ' OD1' ' A' ' 33' ' ' ASN . 38.6 p90 -142.56 38.52 1.52 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.068 -1.02 . . . . 0.0 109.963 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.832 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.66 130.92 62.5 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.827 -1.17 . . . . 0.0 110.053 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.401 ' C ' ' H ' ' A' ' 19' ' ' VAL . 67.7 Cg_endo -76.07 -152.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 122.015 1.81 . . . . 0.0 110.784 179.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -77.75 16.26 0.71 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.98 -1.075 . . . . 0.0 109.117 179.531 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.401 ' H ' ' C ' ' A' ' 17' ' ' PRO . 43.4 t -113.19 136.29 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 109.674 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -68.6 141.9 93.5 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.19 -0.944 . . . . 0.0 109.511 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.496 ' HD3' HD12 ' A' ' 16' ' ' LEU . 35.2 Cg_exo -50.02 -31.09 26.51 Favored 'Trans proline' 0 N--CA 1.491 1.379 0 C-N-CA 121.943 1.762 . . . . 0.0 112.104 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.3 -25.44 68.05 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.64 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -96.74 8.62 43.86 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.333 -0.855 . . . . 0.0 109.237 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.46 137.18 28.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.356 -0.84 . . . . 0.0 108.818 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.53 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.87 85.89 0.33 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.216 -0.927 . . . . 0.0 109.642 -179.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.8 m -59.97 0.08 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.387 -0.82 . . . . 0.0 109.086 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.53 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -91.64 7.69 40.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.345 -0.847 . . . . 0.0 108.87 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.9 tp -90.81 138.0 31.92 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.45 -0.781 . . . . 0.0 109.454 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.36 121.54 15.07 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.415 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -72.53 3.34 5.0 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.944 -178.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.2 p -52.46 -39.22 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.007 -1.058 . . . . 0.0 108.635 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -58.11 -34.74 70.53 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.736 ' N ' HD22 ' A' ' 33' ' ' ASN . 0.9 OUTLIER -84.42 16.97 2.81 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 179.093 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.17 -17.37 0.03 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.79 -35.81 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.038 -1.272 . . . . 0.0 108.51 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.4 tt -70.22 -16.07 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.571 -0.706 . . . . 0.0 109.768 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -55.87 -32.94 64.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 111.392 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 73.9 m -119.43 -64.69 1.24 Allowed 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.008 -1.057 . . . . 0.0 111.601 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.482 ' H ' HD12 ' A' ' 39' ' ' LEU . 3.5 mp -62.51 -48.14 80.86 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 110.612 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.8 -42.56 60.99 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.534 ' O ' HD13 ' A' ' 45' ' ' ILE . 2.5 mt -62.39 -38.92 91.5 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.272 -1.134 . . . . 0.0 109.675 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.8 tp -59.12 -44.03 91.99 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.143 -0.973 . . . . 0.0 108.676 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -66.16 -38.25 87.62 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.291 -0.881 . . . . 0.0 109.017 178.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.2 t -64.93 -39.6 86.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.527 -0.733 . . . . 0.0 110.054 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.534 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.4 mp -58.1 -50.27 78.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.221 -0.925 . . . . 0.0 109.679 -179.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.54 -38.16 90.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.14 -0.975 . . . . 0.0 109.171 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.741 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 51.6 t90 -66.84 -40.15 87.86 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.392 -0.817 . . . . 0.0 109.474 179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.585 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 8.6 tp -61.01 -43.53 98.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.462 -0.774 . . . . 0.0 109.735 -179.694 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.403 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 85.4 tt0 -66.3 -36.4 82.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.284 -0.885 . . . . 0.0 110.001 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -62.3 -46.24 89.65 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.045 -1.034 . . . . 0.0 110.837 -179.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.741 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt180 -87.4 -51.14 6.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.074 -1.016 . . . . 0.0 111.798 -178.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.785 ' CE2' HG21 ' A' ' 80' ' ' THR . 95.3 m-85 -79.88 -24.1 41.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.966 -1.084 . . . . 0.0 111.13 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.47 31.54 45.55 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.44 -1.362 . . . . 0.0 109.739 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.403 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 68.1 mt -100.21 136.31 32.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.167 -1.196 . . . . 0.0 108.656 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.925 -1.11 . . . . 0.0 109.765 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.462 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -65.79 -32.57 74.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.522 -0.736 . . . . 0.0 109.405 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -58.91 -33.45 70.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.453 -0.78 . . . . 0.0 110.463 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -73.68 109.45 7.19 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.017 -1.052 . . . . 0.0 109.996 -179.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 23.2 m -133.94 157.77 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.44 -0.788 . . . . 0.0 109.242 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.587 ' C ' HD12 ' A' ' 61' ' ' LEU . 63.1 tt0 -169.44 23.29 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.127 -0.983 . . . . 0.0 109.021 179.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.8 ' N ' HD12 ' A' ' 61' ' ' LEU . 5.8 mp -104.65 143.34 33.21 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.168 -0.958 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.74 162.34 21.07 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.479 -0.763 . . . . 0.0 109.316 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -57.69 -30.67 89.75 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.757 2.304 . . . . 0.0 112.11 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.54 -31.83 73.21 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.264 -0.897 . . . . 0.0 109.509 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.479 ' CE1' ' O ' ' A' ' 71' ' ' SER . 83.7 t60 -68.59 -26.19 65.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 110.653 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.491 ' CZ ' HD11 ' A' ' 41' ' ' LEU . 97.1 m-85 -88.79 7.35 34.5 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.996 -1.065 . . . . 0.0 110.489 -178.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 24.0 mmt85 -58.07 -36.33 72.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.07 -1.019 . . . . 0.0 109.968 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 90.9 p -133.68 150.04 51.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.208 -0.932 . . . . 0.0 109.834 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.9 mt -66.05 -36.45 77.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.313 -0.867 . . . . 0.0 109.875 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -60.93 -37.61 82.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.171 -0.955 . . . . 0.0 109.916 -179.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.479 ' O ' ' CE1' ' A' ' 65' ' ' HIS . 88.4 p -61.37 -35.73 78.25 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.07 -1.019 . . . . 0.0 109.274 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.3 mt -61.41 -39.06 81.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.25 -0.907 . . . . 0.0 109.015 179.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.725 ' O ' HG23 ' A' ' 77' ' ' VAL . 51.3 t0 -59.24 -37.32 77.27 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.515 -0.741 . . . . 0.0 109.68 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.19 -46.67 82.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.188 -0.945 . . . . 0.0 109.872 -179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 68.9 t80 -66.12 -44.85 83.09 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.053 -1.029 . . . . 0.0 109.079 179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -62.63 -41.83 93.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.471 -0.768 . . . . 0.0 109.549 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 73' ' ' ASP . 53.6 t -61.92 -41.73 91.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.284 0 O-C-N 121.264 -0.898 . . . . 0.0 109.661 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.65 -36.33 85.29 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -90.57 -49.82 6.28 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.11 -1.23 . . . . 0.0 110.079 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.785 HG21 ' CE2' ' A' ' 52' ' ' PHE . 12.4 t -145.1 153.35 41.33 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -0.888 . . . . 0.0 109.577 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -134.69 88.5 28.24 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.667 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.44 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.0 Cg_exo -65.27 -176.47 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.5 0 C-N-CA 122.655 2.237 . . . . 0.0 111.985 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.44 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 23.5 Cg_exo -60.59 150.9 79.4 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.574 2.182 . . . . 0.0 111.714 179.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.492 ' HA ' ' H ' ' A' ' 3' ' ' HIS . 43.7 t -100.43 131.82 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 109.735 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -125.42 157.7 36.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.498 -0.751 . . . . 0.0 109.364 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -103.47 149.79 24.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.447 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 51.9 mttp -78.72 146.6 33.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.181 -0.949 . . . . 0.0 109.373 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.0 mt -58.79 -34.99 72.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.901 . . . . 0.0 109.412 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.451 179.983 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.585 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.542 ' SD ' ' CD ' ' A' ' 70' ' ' ARG . 67.0 mtm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.444 0.64 . . . . 0.0 109.943 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.1 mt-30 -100.75 127.01 47.34 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.403 -0.811 . . . . 0.0 108.87 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.668 ' CD2' HG12 ' A' ' 84' ' ' VAL . 6.4 m80 61.79 20.09 11.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -0.988 . . . . 0.0 109.139 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -63.43 -38.24 90.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.6 m -60.79 -39.12 87.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.97 . . . . 0.0 110.065 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.5 t -64.81 -38.09 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.103 -0.998 . . . . 0.0 109.554 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.674 ' O ' HG22 ' A' ' 11' ' ' VAL . 83.2 mt -59.81 -50.8 78.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.25 -0.906 . . . . 0.0 109.631 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.718 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.21 -46.36 84.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 109.139 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.36 -39.98 94.95 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.4 -0.813 . . . . 0.0 109.648 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.64 -51.21 61.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.431 -0.793 . . . . 0.0 110.493 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.674 HG22 ' O ' ' A' ' 7' ' ' ILE . 22.9 m -73.74 -39.28 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.24 -0.913 . . . . 0.0 110.367 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.718 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.3 t -65.13 -39.03 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.065 -1.022 . . . . 0.0 109.773 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -53.12 -35.87 60.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 109.8 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.62 -31.88 72.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.27 -0.894 . . . . 0.0 109.918 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.88 39.86 3.12 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 110.047 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.834 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.54 130.39 64.97 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 120.93 -1.106 . . . . 0.0 110.024 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.84 -149.72 0.04 OUTLIER 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 122.01 1.807 . . . . 0.0 110.346 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.553 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.5 p30 -77.91 13.3 1.42 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.719 -1.238 . . . . 0.0 108.871 179.167 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.553 HG23 ' OD2' ' A' ' 18' ' ' ASP . 42.3 t -113.51 136.13 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.575 -0.703 . . . . 0.0 109.62 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.93 141.49 81.84 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.244 -0.91 . . . . 0.0 109.311 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -49.52 -30.28 20.91 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.929 1.753 . . . . 0.0 112.052 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.04 -22.86 67.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.307 -0.87 . . . . 0.0 109.643 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -96.11 7.13 47.22 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.333 -0.854 . . . . 0.0 109.132 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.0 t -102.58 136.52 34.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.535 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -69.1 89.61 0.44 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.175 -0.953 . . . . 0.0 109.605 -179.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -59.63 0.11 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.261 -0.899 . . . . 0.0 109.146 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.535 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -92.21 8.22 39.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.352 -0.842 . . . . 0.0 108.786 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.0 tp -90.96 139.06 31.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.427 -0.796 . . . . 0.0 109.45 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.416 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.9 m-20 -60.82 121.58 12.69 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -69.86 7.13 0.97 Allowed 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.254 -0.904 . . . . 0.0 109.847 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -53.46 -38.61 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.113 -0.992 . . . . 0.0 109.123 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.0 m-20 -57.92 -36.45 72.5 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -87.15 19.55 3.09 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.79 -15.01 0.02 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.63 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -53.43 -36.49 27.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.125 -1.221 . . . . 0.0 108.862 179.53 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.5 tt -70.38 -22.48 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.538 -0.726 . . . . 0.0 110.245 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.3 m-20 -55.42 -33.22 63.36 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.278 -0.889 . . . . 0.0 110.932 -178.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -116.17 -63.75 1.41 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.123 -0.985 . . . . 0.0 111.24 -178.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.54 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.4 mm? -62.41 -52.18 64.58 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.047 -1.033 . . . . 0.0 110.096 -178.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.6 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.79 -40.19 64.87 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.7 tt -58.7 -41.04 85.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.341 -1.094 . . . . 0.0 109.552 -179.454 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 24.9 tp -62.76 -44.4 96.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.935 . . . . 0.0 109.024 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.1 mttt -66.24 -35.12 79.6 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.349 -0.844 . . . . 0.0 109.592 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 40' ' ' GLY . 64.2 t -60.86 -42.99 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.319 -0.863 . . . . 0.0 110.24 -179.366 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -59.64 -50.54 79.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.105 -0.997 . . . . 0.0 109.632 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.91 -36.65 82.74 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 34.3 t90 -67.79 -43.33 79.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.273 -0.892 . . . . 0.0 109.633 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.577 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 10.9 tp -58.01 -46.3 85.48 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.477 -179.284 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -67.84 -38.05 82.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.35 -0.844 . . . . 0.0 109.067 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 61.8 t0 -65.47 -41.48 93.32 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 110.64 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 74.5 ttt-85 -87.12 -58.14 2.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.171 -0.956 . . . . 0.0 111.662 -178.385 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 m-85 -79.73 -19.47 48.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.02 -1.05 . . . . 0.0 111.559 -177.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.3 28.19 56.26 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.1 mt -104.47 142.58 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.405 -1.056 . . . . 0.0 109.348 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.47 154.73 23.69 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.237 -0.914 . . . . 0.0 109.143 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -53.12 -39.34 63.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.259 -0.901 . . . . 0.0 109.405 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 52.0 48.19 23.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 109.193 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.84 133.61 56.25 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.252 -0.905 . . . . 0.0 109.747 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.605 HG23 HD13 ' A' ' 61' ' ' LEU . 31.3 m -132.23 160.9 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.492 -0.755 . . . . 0.0 109.203 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.772 ' O ' HD12 ' A' ' 61' ' ' LEU . 86.4 tt0 -91.99 120.64 32.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.059 -1.026 . . . . 0.0 109.81 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.772 HD12 ' O ' ' A' ' 60' ' ' GLU . 5.5 mp -134.31 -166.98 1.89 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.424 -0.797 . . . . 0.0 109.091 179.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.77 160.95 64.07 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.476 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.19 -21.47 59.91 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.892 2.395 . . . . 0.0 111.866 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -59.43 -32.32 70.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.402 -0.811 . . . . 0.0 110.091 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.44 ' O ' ' OG ' ' A' ' 71' ' ' SER . 44.9 t-80 -70.23 -26.27 63.77 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.319 -0.863 . . . . 0.0 111.404 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -95.11 8.0 44.37 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.799 -1.188 . . . . 0.0 110.817 -178.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -60.91 -38.44 85.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.998 -1.064 . . . . 0.0 110.671 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.4 m -126.66 147.58 49.91 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.222 -0.924 . . . . 0.0 110.483 -179.149 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.2 -36.09 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 O-C-N 121.434 -0.791 . . . . 0.0 109.802 179.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.542 ' CD ' ' SD ' ' A' ' 1' ' ' MET . 80.5 mtm180 -60.42 -37.7 81.69 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.254 -0.904 . . . . 0.0 110.157 -178.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 97.6 p -61.44 -36.85 81.53 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.08 -1.013 . . . . 0.0 109.282 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.6 -38.62 82.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.373 -0.83 . . . . 0.0 109.117 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 53.5 t0 -56.52 -38.74 72.24 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.43 -0.794 . . . . 0.0 109.655 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.84 -42.04 97.7 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.132 -0.98 . . . . 0.0 109.405 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -64.35 -45.66 86.81 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.32 -0.863 . . . . 0.0 109.563 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.6 t -65.0 -42.42 94.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.348 -0.845 . . . . 0.0 110.05 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.2 t -63.18 -42.37 96.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.155 -0.966 . . . . 0.0 109.892 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.9 -30.07 72.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -97.69 -49.54 4.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.958 -1.319 . . . . 0.0 110.307 -179.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 76' ' ' VAL . 11.0 t -139.19 155.54 47.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.554 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 89.48 32.76 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.448 -0.783 . . . . 0.0 109.514 -179.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.594 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 55.1 Cg_endo -79.86 162.22 23.92 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.737 2.291 . . . . 0.0 112.519 -179.512 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -61.26 150.81 83.0 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.785 2.323 . . . . 0.0 112.04 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.668 HG12 ' CD2' ' A' ' 3' ' ' HIS . 17.1 m -89.69 131.72 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.708 -179.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.82 143.39 51.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.512 -0.743 . . . . 0.0 109.236 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.05 144.66 42.9 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.159 -0.963 . . . . 0.0 109.498 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 47.3 mttp -58.06 -33.51 69.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.184 -0.948 . . . . 0.0 109.274 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 50.7 mt -90.21 142.46 27.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.896 . . . . 0.0 109.387 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 50.4 tt0 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.888 -1.053 . . . . 0.0 109.515 -179.99 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.577 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.8 mmm . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' O ' ' O ' ' A' ' 83' ' ' PRO . 94.4 mt-30 -58.71 -35.17 72.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.269 -0.895 . . . . 0.0 109.457 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.726 ' CD2' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -163.88 25.0 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.155 -0.966 . . . . 0.0 109.385 179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.641 ' HB2' ' OD1' ' A' ' 73' ' ' ASP . . . -61.87 -34.83 76.71 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.231 -0.918 . . . . 0.0 109.563 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 t -59.11 -39.6 82.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.159 -0.963 . . . . 0.0 109.543 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.726 HG21 ' CD2' ' A' ' 3' ' ' HIS . 78.3 t -65.13 -39.29 85.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.2 179.63 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.5 ' O ' HG23 ' A' ' 11' ' ' VAL . 88.1 mt -59.86 -48.0 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.444 -0.785 . . . . 0.0 109.657 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.487 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.66 -46.37 85.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.318 -0.864 . . . . 0.0 109.656 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.434 ' HG3' ' N ' ' A' ' 10' ' ' PHE . 0.9 OUTLIER -69.52 -36.54 76.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.547 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.3 t80 -68.57 -48.23 64.76 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.389 179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.527 HG13 HD12 ' A' ' 36' ' ' ILE . 73.7 t -69.12 -46.3 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.482 -0.761 . . . . 0.0 110.104 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 8' ' ' ALA . 76.6 t -63.53 -35.2 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.39 -0.819 . . . . 0.0 110.676 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -52.95 -36.8 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.125 -0.985 . . . . 0.0 109.86 -179.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.72 -35.39 78.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 110.685 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 -91.99 -63.6 1.22 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.022 -1.049 . . . . 0.0 110.731 -178.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.9 mt -125.66 83.03 62.79 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.255 -0.903 . . . . 0.0 110.19 -179.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -82.78 -19.53 5.98 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.299 179.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.873 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.3 p30 -78.15 -3.41 42.33 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.176 -0.953 . . . . 0.0 109.216 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.873 HG23 ' OD1' ' A' ' 18' ' ' ASP . 57.7 t -113.81 140.33 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.16 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.652 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . -61.91 117.82 32.74 Favored Pre-proline 0 C--N 1.304 -1.41 0 O-C-N 120.936 -1.103 . . . . 0.0 108.552 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.0 -28.6 57.6 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.574 1.516 . . . . 0.0 111.813 -179.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.62 -14.75 62.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.391 -0.818 . . . . 0.0 109.174 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.652 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 90.0 m-20 -82.94 -0.16 47.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.377 -0.827 . . . . 0.0 108.917 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -98.94 137.74 25.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.525 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.2 t0 -67.41 92.75 0.3 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.087 -1.008 . . . . 0.0 109.437 -179.277 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.655 HG21 ' HE3' ' A' ' 87' ' ' LYS . 19.9 m -59.77 0.01 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.421 -0.799 . . . . 0.0 109.206 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.9 t0 -88.98 5.69 43.05 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.8 tp -92.67 136.42 33.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.612 -0.68 . . . . 0.0 109.399 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.45 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.2 m-20 -60.93 121.58 12.74 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.1 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.518 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -67.02 6.53 0.51 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.126 -0.983 . . . . 0.0 109.72 -178.938 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.513 HG21 ' NH2' ' A' ' 67' ' ' ARG . 5.1 p -54.78 -37.57 40.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 108.933 179.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.432 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.8 m-20 -57.25 -36.31 70.8 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.1 m-20 -84.96 17.92 2.69 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.44 ' O ' ' CG ' ' A' ' 37' ' ' ASP . . . -42.87 -14.26 0.01 OUTLIER Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.6 t -51.34 -37.93 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.223 -1.163 . . . . 0.0 108.855 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.527 HD12 HG13 ' A' ' 11' ' ' VAL . 0.9 OUTLIER -70.9 -11.82 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.47 -0.769 . . . . 0.0 109.757 179.92 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.44 ' CG ' ' O ' ' A' ' 34' ' ' GLY . 85.3 m-20 -51.64 -42.31 61.96 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 111.376 -177.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.47 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.4 OUTLIER -120.91 -58.66 1.8 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.109 -0.995 . . . . 0.0 111.975 -178.381 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.567 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.6 mp -61.27 -52.15 65.95 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.825 -1.172 . . . . 0.0 110.135 -178.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.625 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.56 -36.06 68.08 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.756 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.98 -43.23 86.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -1.083 . . . . 0.0 109.548 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 91.8 mt -63.65 -43.91 95.38 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.076 -1.015 . . . . 0.0 109.205 179.577 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.8 mttt -65.27 -38.05 89.1 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.285 -0.884 . . . . 0.0 109.501 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 40' ' ' GLY . 80.0 t -65.31 -39.93 86.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.381 -0.825 . . . . 0.0 110.067 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.442 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.0 OUTLIER -58.45 -50.1 79.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.155 -0.966 . . . . 0.0 109.905 -179.333 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.442 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -60.98 -36.7 80.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.971 -1.081 . . . . 0.0 109.94 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.547 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -76.58 -41.92 44.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.143 -0.973 . . . . 0.0 110.126 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 6.7 tt -60.84 -43.12 98.74 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.411 -0.805 . . . . 0.0 110.801 -178.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.714 ' OE1' ' HB2' ' A' ' 56' ' ' ALA . 54.8 mt-10 -65.78 -39.64 91.2 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.946 -1.096 . . . . 0.0 109.217 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -67.84 -49.21 63.45 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.419 -0.8 . . . . 0.0 110.932 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.615 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 67.4 ttt-85 -62.07 -41.3 98.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 97.5 m-85 -101.58 -9.62 20.81 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.953 -1.092 . . . . 0.0 110.559 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.21 35.78 88.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -105.88 143.94 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.302 -1.117 . . . . 0.0 109.869 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.76 152.85 34.58 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.365 -0.835 . . . . 0.0 109.082 179.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.714 ' HB2' ' OE1' ' A' ' 49' ' ' GLU . . . -58.98 -38.78 79.92 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 110.206 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.931 ' O ' HG13 ' A' ' 59' ' ' VAL . 85.4 m-20 52.92 48.8 21.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.052 -1.03 . . . . 0.0 108.495 -179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.446 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.3 m-20 -39.49 110.72 0.15 Allowed 'General case' 0 N--CA 1.489 1.514 0 CA-C-O 121.563 0.697 . . . . 0.0 110.336 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.98 HG23 HD21 ' A' ' 61' ' ' LEU . 33.8 m -132.97 160.14 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.563 ' C ' HD22 ' A' ' 61' ' ' LEU . 95.7 mt-10 -96.41 117.05 30.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.011 -1.056 . . . . 0.0 109.753 -179.734 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.98 HD21 HG23 ' A' ' 59' ' ' VAL . 1.6 mm? -108.98 140.92 41.83 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.467 -0.77 . . . . 0.0 109.224 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.51 150.51 70.37 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.333 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.43 -28.06 77.78 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.532 2.154 . . . . 0.0 111.943 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -60.95 -28.3 68.88 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.418 -0.801 . . . . 0.0 109.993 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.402 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 78.4 t60 -67.78 -26.54 66.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.15 -0.969 . . . . 0.0 110.188 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.694 ' CD1' ' N9 ' ' A' ' 101' ' ' 7V9 . 71.5 m-85 -100.75 8.12 43.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.151 -0.968 . . . . 0.0 109.767 -179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.513 ' NH2' HG21 ' A' ' 31' ' ' VAL . 20.5 tpt180 -54.86 -40.06 69.3 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.356 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -127.69 148.6 50.4 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.319 -0.863 . . . . 0.0 109.69 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 81.3 mt -60.72 -36.59 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.299 -0.876 . . . . 0.0 109.891 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -60.55 -39.26 87.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.271 -0.893 . . . . 0.0 110.25 -179.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.7 m -58.25 -41.25 83.79 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.983 -1.073 . . . . 0.0 109.521 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.2 -38.62 83.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.839 ' O ' HG23 ' A' ' 77' ' ' VAL . 91.9 m-20 -56.31 -38.14 70.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.461 -0.774 . . . . 0.0 109.609 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.88 -45.99 86.92 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.402 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.6 t80 -65.69 -46.67 78.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.181 179.572 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 80' ' ' THR . 56.3 t -64.35 -40.73 90.09 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.422 -0.799 . . . . 0.0 109.681 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.839 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.1 t -60.33 -43.34 93.48 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.16 -0.963 . . . . 0.0 109.91 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.46 -37.38 94.71 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -87.62 -50.15 6.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.999 -1.295 . . . . 0.0 110.331 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.9 p -130.8 156.24 45.34 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.409 -0.807 . . . . 0.0 109.199 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.23 88.53 11.42 Favored Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.219 -0.926 . . . . 0.0 109.609 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.425 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.0 Cg_exo -63.94 -177.68 0.48 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.528 2.152 . . . . 0.0 111.911 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 2' ' ' GLN . 22.1 Cg_exo -60.73 150.55 82.04 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.463 2.108 . . . . 0.0 111.819 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.434 HG13 ' HA ' ' A' ' 2' ' ' GLN . 42.3 t -105.56 129.13 58.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.294 -0.879 . . . . 0.0 109.718 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -138.88 156.0 47.64 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.366 -0.834 . . . . 0.0 109.218 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.88 140.74 58.84 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.068 -1.02 . . . . 0.0 109.188 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.655 ' HE3' HG21 ' A' ' 26' ' ' VAL . 48.0 tttm -88.73 143.11 27.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.434 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.1 mt -56.91 -32.15 65.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.306 -0.871 . . . . 0.0 109.879 -179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.452 HE21 ' HB3' ' A' ' 87' ' ' LYS . 92.3 mm-40 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.944 -1.026 . . . . 0.0 109.384 -179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.694 ' N9 ' ' CD1' ' A' ' 66' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.343 0.592 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -58.98 -35.91 74.0 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.343 -0.848 . . . . 0.0 109.35 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -152.04 57.42 0.84 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.251 -0.905 . . . . 0.0 109.107 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.565 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.36 -35.41 75.61 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.265 -0.897 . . . . 0.0 109.97 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -59.46 -40.8 88.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.055 -1.028 . . . . 0.0 109.545 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 71.2 t -67.01 -37.85 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.239 -0.913 . . . . 0.0 109.182 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.565 HD12 ' HA ' ' A' ' 4' ' ' ALA . 87.8 mt -59.73 -40.03 81.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.496 -0.753 . . . . 0.0 110.101 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 1.018 ' HB1' HG11 ' A' ' 26' ' ' VAL . . . -63.18 -50.0 72.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.023 -1.048 . . . . 0.0 109.294 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.488 ' OE1' ' OE1' ' A' ' 13' ' ' GLU . 1.2 pp0? -69.94 -33.94 72.79 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.338 -0.851 . . . . 0.0 109.439 179.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.595 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 65.0 t80 -66.35 -51.96 51.84 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.043 -1.035 . . . . 0.0 109.942 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 5.5 p -70.57 -38.7 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.233 -0.917 . . . . 0.0 110.111 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.735 HG23 ' O ' ' A' ' 8' ' ' ALA . 88.6 t -65.25 -42.1 93.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.211 -0.93 . . . . 0.0 110.639 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.488 ' OE1' ' OE1' ' A' ' 9' ' ' GLN . 76.6 mt-10 -55.18 -27.38 45.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.021 -1.049 . . . . 0.0 109.845 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.759 ' CD ' HD11 ' A' ' 36' ' ' ILE . 85.7 tt0 -65.38 -27.75 68.79 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 109.101 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.586 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.0 p90 -149.83 41.64 0.85 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.219 -0.926 . . . . 0.0 109.852 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.67 131.21 61.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 120.948 -1.095 . . . . 0.0 110.196 -179.817 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -75.94 -151.31 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.298 0 C-N-CA 122.061 1.841 . . . . 0.0 110.671 178.658 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -79.3 17.01 0.87 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.86 -1.15 . . . . 0.0 109.345 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.6 t -113.37 136.83 48.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.368 -0.832 . . . . 0.0 109.586 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.06 142.17 97.02 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.192 -0.942 . . . . 0.0 109.496 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.464 ' HD3' HD12 ' A' ' 16' ' ' LEU . 31.7 Cg_exo -49.94 -32.55 30.85 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 121.936 1.757 . . . . 0.0 111.938 179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.33 -24.84 67.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.453 -0.779 . . . . 0.0 109.64 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -98.47 7.12 46.58 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -0.863 . . . . 0.0 109.453 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.4 t -103.8 135.16 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.315 -0.866 . . . . 0.0 108.879 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.429 ' C ' ' H ' ' A' ' 27' ' ' ASP . 88.0 m-20 -72.17 86.06 1.06 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.219 -0.925 . . . . 0.0 109.315 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.018 HG11 ' HB1' ' A' ' 8' ' ' ALA . 19.7 m -63.11 -0.3 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.233 -0.917 . . . . 0.0 109.627 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.475 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 48.0 p30 -90.7 8.52 34.06 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.141 -0.974 . . . . 0.0 108.787 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 18.8 tp -93.93 136.37 34.29 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.599 -0.688 . . . . 0.0 109.447 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -60.95 122.48 15.02 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.754 HD11 ' CG2' ' A' ' 69' ' ' ILE . 56.6 mt -66.89 -0.86 3.35 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.258 -0.901 . . . . 0.0 109.87 -179.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.9 t -52.61 -42.47 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.089 -1.007 . . . . 0.0 108.911 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.46 -36.33 66.46 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 178.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.619 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.8 m-80 -86.55 20.29 2.53 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.46 -15.87 0.02 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.619 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.0 t -53.33 -38.81 32.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.884 -1.363 . . . . 0.0 108.277 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.759 HD11 ' CD ' ' A' ' 14' ' ' GLU . 5.4 tt -70.87 -24.2 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.599 -0.688 . . . . 0.0 109.95 179.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -62.54 -22.51 66.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.181 -0.949 . . . . 0.0 110.697 -178.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 m -117.47 -64.87 1.24 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.081 -1.012 . . . . 0.0 111.013 -178.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.516 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.2 mp -67.41 -50.2 60.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.034 -1.041 . . . . 0.0 110.171 -178.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.562 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.74 -41.24 64.13 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tt -61.1 -40.05 92.26 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.494 -1.003 . . . . 0.0 109.617 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.6 tp -58.63 -44.31 89.96 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.189 -0.944 . . . . 0.0 108.569 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.0 mtpt -65.06 -34.2 77.86 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 40' ' ' GLY . 76.2 t -64.49 -39.77 86.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.495 -0.753 . . . . 0.0 110.511 -179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.9 mm -59.22 -50.74 78.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.637 -1.29 . . . . 0.0 109.525 -179.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.87 -41.31 83.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.292 -0.88 . . . . 0.0 109.793 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 16.8 t90 -69.77 -42.81 73.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 110.233 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 33.2 tp -59.36 -41.93 90.43 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.329 -0.857 . . . . 0.0 109.712 -179.384 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.567 ' O ' ' N ' ' A' ' 53' ' ' GLY . 84.5 tt0 -64.06 -38.12 89.92 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.238 -0.914 . . . . 0.0 109.753 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.0 t0 -60.07 -37.08 78.83 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.951 -1.093 . . . . 0.0 110.064 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -75.09 -48.68 22.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.245 -0.91 . . . . 0.0 111.958 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.509 ' CZ ' HG21 ' A' ' 80' ' ' THR . 24.7 m-85 -114.66 -3.12 12.91 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.012 -1.055 . . . . 0.0 111.855 -178.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 30.48 61.22 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.874 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.427 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 75.8 mt -78.19 138.78 19.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -1.217 . . . . 0.0 108.977 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 131.21 49.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.827 -1.17 . . . . 0.0 109.736 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.82 -28.5 68.41 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.448 -0.782 . . . . 0.0 109.258 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.81 -31.96 63.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.444 -0.785 . . . . 0.0 110.247 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -49.04 139.15 10.85 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.062 -1.024 . . . . 0.0 109.758 -179.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.789 ' O ' HG22 ' A' ' 59' ' ' VAL . 7.7 p -157.8 29.02 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.417 -0.802 . . . . 0.0 109.207 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.03 -26.75 68.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.346 -0.847 . . . . 0.0 109.719 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.749 ' N ' HD12 ' A' ' 61' ' ' LEU . 5.6 mp -75.97 146.07 39.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.289 -0.882 . . . . 0.0 109.725 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -130.75 173.17 6.16 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.465 -0.772 . . . . 0.0 109.226 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_exo -50.7 -31.45 32.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.222 1.948 . . . . 0.0 111.69 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.05 -30.72 71.3 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.423 -0.798 . . . . 0.0 109.074 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.472 ' CE1' HD23 ' A' ' 61' ' ' LEU . 46.7 t-80 -67.65 -26.55 66.27 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.474 -0.767 . . . . 0.0 109.802 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -91.9 10.22 29.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.181 -0.949 . . . . 0.0 109.449 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -53.61 -36.55 62.11 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.294 -0.879 . . . . 0.0 109.463 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 27.9 t -150.3 152.61 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.273 -0.892 . . . . 0.0 109.846 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.754 ' CG2' HD11 ' A' ' 30' ' ' LEU . 0.9 OUTLIER -64.31 -36.16 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 179.854 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -60.7 -38.07 83.79 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.111 -0.993 . . . . 0.0 110.107 -179.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -63.01 -37.03 85.55 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.073 -1.017 . . . . 0.0 109.16 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.5 mt -66.36 -38.43 81.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.329 -0.857 . . . . 0.0 109.29 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.1 t0 -56.25 -41.05 75.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.491 -0.756 . . . . 0.0 109.88 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.63 -45.33 79.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.137 -0.977 . . . . 0.0 110.205 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.699 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 65.6 t80 -63.08 -48.61 77.88 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.154 -0.966 . . . . 0.0 109.751 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.637 HG12 ' O ' ' A' ' 80' ' ' THR . 71.9 t -66.48 -42.83 90.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.251 -0.906 . . . . 0.0 109.836 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' ' 73' ' ' ASP . 44.5 t -61.96 -40.55 87.61 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 120.969 -1.082 . . . . 0.0 109.693 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.84 -34.36 71.06 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.36 -50.65 3.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.133 -1.216 . . . . 0.0 110.79 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.637 ' O ' HG12 ' A' ' 76' ' ' VAL . 56.0 m -153.96 140.41 18.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.995 -1.066 . . . . 0.0 110.267 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -122.99 87.77 50.89 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.282 -0.886 . . . . 0.0 109.239 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -95.87 105.69 0.1 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 123.542 2.828 . . . . 0.0 112.894 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -80.36 128.36 7.06 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.098 1.865 . . . . 0.0 111.953 179.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.0 t -134.04 132.4 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.617 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.23 -38.86 92.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.266 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -162.46 150.89 14.6 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.304 -0.873 . . . . 0.0 109.419 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.595 ' NZ ' ' O ' ' A' ' 10' ' ' PHE . 16.6 mttm -59.76 -33.76 72.1 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.121 -0.987 . . . . 0.0 109.627 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 33.4 tp -95.85 130.28 42.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.24 -0.912 . . . . 0.0 109.48 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.474 -179.964 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.407 ' C11' HD22 ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.6 mtt . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -60.04 -37.49 79.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.935 . . . . 0.0 109.266 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.684 ' NE2' HG11 ' A' ' 6' ' ' VAL . 57.1 t-80 -148.33 8.06 0.8 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.34 -0.85 . . . . 0.0 109.724 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.63 -39.81 95.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.055 -1.028 . . . . 0.0 109.769 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.3 t -61.52 -40.08 93.36 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.278 -0.889 . . . . 0.0 109.924 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.684 HG11 ' NE2' ' A' ' 3' ' ' HIS . 78.1 t -63.27 -39.71 86.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.212 -0.93 . . . . 0.0 109.257 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.634 ' O ' HG23 ' A' ' 11' ' ' VAL . 92.0 mt -62.4 -46.45 96.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.346 -0.846 . . . . 0.0 110.01 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.45 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.88 -49.93 70.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 110.411 -179.327 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.436 ' CG ' ' N ' ' A' ' 10' ' ' PHE . 4.2 pp0? -69.91 -42.07 73.83 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.182 -0.949 . . . . 0.0 109.894 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 9' ' ' GLN . 71.4 t80 -60.49 -46.47 90.0 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.954 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 7' ' ' ILE . 67.2 t -69.63 -47.01 73.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.44 -0.787 . . . . 0.0 109.92 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 8' ' ' ALA . 75.5 t -65.51 -35.18 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.404 -0.81 . . . . 0.0 110.453 -179.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -53.52 -36.66 62.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.214 -0.928 . . . . 0.0 109.992 -179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.96 -35.57 78.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 110.771 -179.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.662 ' O ' HD12 ' A' ' 16' ' ' LEU . 69.9 m-85 -91.74 -63.6 1.23 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.963 -1.085 . . . . 0.0 110.657 -178.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.662 HD12 ' O ' ' A' ' 15' ' ' PHE . 6.2 mp -125.66 83.06 62.76 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.331 -0.855 . . . . 0.0 110.119 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.64 -18.96 7.76 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.853 2.369 . . . . 0.0 112.202 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.866 ' OD2' HG23 ' A' ' 19' ' ' VAL . 54.4 p30 -80.11 -1.25 39.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.211 -0.931 . . . . 0.0 109.119 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.866 HG23 ' OD2' ' A' ' 18' ' ' ASP . 48.4 t -113.59 142.09 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.332 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.544 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.72 117.44 28.35 Favored Pre-proline 0 C--N 1.304 -1.407 0 O-C-N 120.862 -1.149 . . . . 0.0 108.531 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.642 ' C ' ' HZ1' ' A' ' 87' ' ' LYS . 17.9 Cg_endo -64.9 -25.57 59.81 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.524 1.483 . . . . 0.0 111.723 -179.268 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.571 ' N ' ' NZ ' ' A' ' 87' ' ' LYS . . . -70.49 -14.87 62.7 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.31 -0.869 . . . . 0.0 109.232 179.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.544 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -82.87 2.91 31.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.255 -0.903 . . . . 0.0 108.929 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.13 137.27 32.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.466 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.4 89.17 0.14 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.147 -0.971 . . . . 0.0 109.377 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.7 m -62.31 -0.01 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.307 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -93.85 7.07 46.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 108.979 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.9 tp -95.7 137.87 34.15 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.483 -0.761 . . . . 0.0 109.6 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -61.71 121.81 13.75 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.453 ' O ' ' N ' ' A' ' 33' ' ' ASN . 0.5 OUTLIER -67.97 2.87 1.79 Allowed 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.266 -0.896 . . . . 0.0 109.932 -178.811 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.456 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.7 p -51.28 -39.19 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.08 -1.012 . . . . 0.0 108.395 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.5 m-20 -57.42 -35.78 70.5 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 80.7 m-20 -87.09 22.14 2.14 Favored 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.009 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -14.27 0.01 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.6 t -51.26 -35.31 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.104 -1.233 . . . . 0.0 108.612 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.624 HD12 HG13 ' A' ' 11' ' ' VAL . 1.1 tt -70.07 -19.94 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.517 -0.739 . . . . 0.0 109.903 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.418 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.1 m-20 -55.53 -33.18 63.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -0.87 . . . . 0.0 111.046 -178.51 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.486 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.5 OUTLIER -116.78 -64.13 1.35 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.115 -0.991 . . . . 0.0 111.356 -178.571 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.531 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.5 mp -62.88 -52.08 64.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.99 -1.068 . . . . 0.0 110.093 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.67 -38.92 67.39 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.723 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.2 tt -58.45 -43.08 88.7 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.401 -1.058 . . . . 0.0 109.725 -179.75 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.7 tp -60.23 -44.32 95.31 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 108.956 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -69.72 -40.1 76.46 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.373 -0.829 . . . . 0.0 109.967 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.8 t -66.03 -45.01 91.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.346 -0.846 . . . . 0.0 110.391 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 46' ' ' ALA . 1.2 mp -59.45 -50.24 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.084 -1.01 . . . . 0.0 109.513 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.401 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.62 -32.2 73.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.54 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 29.6 t90 -74.46 -45.83 43.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.878 . . . . 0.0 110.246 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.501 HD22 ' C19' ' A' ' 101' ' ' 7V9 . 9.8 tp -57.41 -45.31 84.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.362 -0.836 . . . . 0.0 110.009 -178.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.414 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 8.4 pt-20 -71.23 -36.42 71.82 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.098 -1.001 . . . . 0.0 109.056 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.414 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.9 t0 -64.78 -41.45 95.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.322 -0.861 . . . . 0.0 110.639 -179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.4 ttt180 -83.78 -51.56 7.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 110.95 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.743 ' CE2' HG21 ' A' ' 80' ' ' THR . 92.7 m-85 -79.85 -24.55 41.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.05 -1.031 . . . . 0.0 110.842 -178.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.41 31.44 54.54 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 53.9 mt -109.4 134.28 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -1.085 . . . . 0.0 109.582 -179.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.93 143.39 57.73 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.352 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.79 73.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.301 -0.874 . . . . 0.0 109.545 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -56.96 -35.52 69.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.252 -0.905 . . . . 0.0 109.74 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -53.84 -33.74 57.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.767 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.785 HG11 ' O13' ' A' ' 101' ' ' 7V9 . 45.6 t -97.49 137.32 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.144 -0.973 . . . . 0.0 109.758 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -78.66 142.83 36.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.573 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 33.0 mt -95.08 137.36 34.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.399 -0.813 . . . . 0.0 109.654 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 178.56 145.66 0.34 Allowed Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.144 -0.973 . . . . 0.0 109.665 179.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.89 -26.88 74.53 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.481 2.121 . . . . 0.0 112.281 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -57.65 -27.42 62.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.843 . . . . 0.0 109.654 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.518 ' NE2' HG23 ' A' ' 72' ' ' ILE . 85.9 t60 -67.13 -26.92 66.91 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.274 -0.891 . . . . 0.0 109.941 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -101.1 4.25 42.01 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.028 -1.045 . . . . 0.0 110.373 -179.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -58.86 -40.94 85.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.887 -1.133 . . . . 0.0 109.86 -179.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.1 p -150.06 154.89 38.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.903 -1.123 . . . . 0.0 110.019 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 87.6 mt -65.33 -37.36 79.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.343 -0.848 . . . . 0.0 109.857 179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 54.7 ttp180 -60.93 -40.43 93.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.287 -0.883 . . . . 0.0 110.164 -179.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -59.58 -41.85 91.19 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.999 -1.063 . . . . 0.0 109.695 -179.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.518 HG23 ' NE2' ' A' ' 65' ' ' HIS . 87.2 mt -67.43 -39.96 83.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.258 -0.901 . . . . 0.0 110.005 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.455 ' HA ' HD11 ' A' ' 7' ' ' ILE . 52.5 t0 -59.16 -40.79 86.67 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 110.188 -179.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.53 -42.71 98.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.129 -0.982 . . . . 0.0 109.586 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.689 ' CZ ' HG13 ' A' ' 59' ' ' VAL . 66.0 t80 -63.74 -45.34 90.34 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.247 -0.908 . . . . 0.0 109.336 179.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.7 t -63.75 -45.36 97.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.355 -0.841 . . . . 0.0 109.915 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.0 t -60.97 -40.09 84.35 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 O-C-N 121.125 -0.984 . . . . 0.0 109.637 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.76 -32.25 65.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.15 -50.17 3.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.084 -1.245 . . . . 0.0 110.403 -179.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.743 HG21 ' CE2' ' A' ' 52' ' ' PHE . 8.4 t -146.22 155.61 42.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.171 -0.956 . . . . 0.0 110.021 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -133.21 88.55 35.54 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.317 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -67.18 159.4 52.32 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.588 2.192 . . . . 0.0 112.239 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.76 150.82 84.28 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.915 2.41 . . . . 0.0 112.165 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.1 141.05 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.382 -0.824 . . . . 0.0 109.427 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.404 ' H ' ' H ' ' A' ' 86' ' ' ALA . 80.1 tt0 -173.59 -7.54 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.335 -0.853 . . . . 0.0 109.105 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.404 ' H ' ' H ' ' A' ' 85' ' ' GLU . . . -58.71 -39.18 80.07 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.015 -1.053 . . . . 0.0 109.815 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.642 ' HZ1' ' C ' ' A' ' 21' ' ' PRO . 49.3 mttm -106.65 146.74 30.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 109.41 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.462 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 69.7 mt -59.43 -35.8 74.7 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.238 -0.914 . . . . 0.0 109.822 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.606 HE21 ' CB ' ' A' ' 87' ' ' LYS . 99.3 mm-40 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.465 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.785 ' O13' HG11 ' A' ' 59' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtt . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.313 0.578 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.496 ' O ' HG22 ' A' ' 84' ' ' VAL . 93.4 mt-30 -59.43 -38.34 80.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.381 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.583 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 49.4 m80 -136.39 11.84 3.25 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.273 -0.892 . . . . 0.0 109.334 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.75 -33.24 71.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.347 -0.846 . . . . 0.0 109.918 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -61.35 -35.3 77.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.097 -1.002 . . . . 0.0 109.552 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.3 t -66.26 -37.83 80.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.184 -0.947 . . . . 0.0 109.167 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.589 ' O ' HG22 ' A' ' 11' ' ' VAL . 87.3 mt -63.55 -43.27 98.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.067 -1.021 . . . . 0.0 110.089 -179.84 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.655 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.22 -50.67 67.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.789 -179.178 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.5 -36.93 74.07 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.958 -1.088 . . . . 0.0 110.065 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -59.4 -51.3 70.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.844 -1.16 . . . . 0.0 110.082 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.589 HG22 ' O ' ' A' ' 7' ' ' ILE . 20.4 m -74.3 -40.64 50.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.142 -0.973 . . . . 0.0 110.32 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.7 t -62.49 -39.38 84.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.257 -0.902 . . . . 0.0 110.502 -179.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -61.86 -32.56 72.92 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.128 -0.982 . . . . 0.0 110.02 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.37 -33.24 75.28 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.869 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 11' ' ' VAL . 62.3 m-85 -93.1 -63.86 1.16 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.162 -0.961 . . . . 0.0 110.451 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.8 mt -129.52 83.47 64.74 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.289 -0.882 . . . . 0.0 110.594 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.22 -13.88 13.6 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.613 2.209 . . . . 0.0 112.169 179.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -76.69 -4.46 43.32 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.136 -0.978 . . . . 0.0 108.869 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.89 141.02 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.578 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.81 119.69 50.16 Favored Pre-proline 0 C--N 1.304 -1.404 0 O-C-N 120.905 -1.122 . . . . 0.0 108.74 -179.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -64.84 -27.61 59.24 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 121.54 1.493 . . . . 0.0 111.924 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . . . -70.56 -14.84 62.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.443 -0.786 . . . . 0.0 109.213 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.578 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.1 m-20 -83.3 4.13 28.48 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.42 -0.8 . . . . 0.0 109.18 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.5 t -102.09 136.88 32.14 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.45 -0.781 . . . . 0.0 108.906 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' A' ' 27' ' ' ASP . 47.6 p30 -67.48 84.36 0.17 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.225 -0.922 . . . . 0.0 109.734 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.414 HG22 ' HE3' ' A' ' 87' ' ' LYS . 13.7 m -60.4 0.23 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.263 179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -88.25 3.75 48.35 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 108.87 179.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.92 139.82 30.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.524 -0.735 . . . . 0.0 109.45 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -60.93 121.73 13.11 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 179.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.491 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.5 pp -66.23 1.41 1.56 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.146 -0.971 . . . . 0.0 109.927 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.458 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.7 -39.16 17.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.038 -1.038 . . . . 0.0 108.29 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.458 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -58.93 -34.94 72.3 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.107 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.725 ' N ' HD22 ' A' ' 33' ' ' ASN . 1.0 OUTLIER -84.11 16.5 2.9 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -42.54 -15.12 0.02 OUTLIER Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -179.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.5 t -51.01 -36.44 15.89 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 120.922 -1.34 . . . . 0.0 108.769 179.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.588 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.0 tt -70.54 -19.53 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.469 -0.769 . . . . 0.0 109.774 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -55.94 -31.73 63.19 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.324 -0.86 . . . . 0.0 111.228 -178.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.9 m -118.89 -64.71 1.25 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.099 -1.0 . . . . 0.0 111.334 -178.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.5 tt -61.68 -52.18 65.39 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.76 -1.213 . . . . 0.0 109.891 -178.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.68 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -71.44 -38.27 62.27 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.588 ' N ' ' O ' ' A' ' 36' ' ' ILE . 30.5 tp -58.54 -44.2 89.52 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.343 -1.093 . . . . 0.0 109.979 -179.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.445 HD23 ' HA ' ' A' ' 42' ' ' LEU . 86.1 mt -61.71 -43.82 98.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.117 -0.989 . . . . 0.0 109.287 179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -62.65 -34.91 78.03 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.239 -0.913 . . . . 0.0 108.916 179.206 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.0 t -62.74 -39.8 86.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.529 -0.732 . . . . 0.0 110.136 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.581 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 33.7 mm -58.6 -50.3 79.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.008 -1.057 . . . . 0.0 109.734 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.15 -37.64 84.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.722 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.0 t90 -70.48 -44.6 67.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.962 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.672 HD13 ' C18' ' A' ' 101' ' ' 7V9 . 12.3 tp -58.34 -47.12 84.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 109.63 -179.186 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.413 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 86.6 tt0 -66.82 -37.39 84.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -0.929 . . . . 0.0 109.11 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.13 -42.13 84.95 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 110.668 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.3 ttt-85 -87.37 -58.48 2.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.257 -0.902 . . . . 0.0 111.809 -178.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.405 ' CD1' HD12 ' A' ' 48' ' ' LEU . 88.8 m-85 -79.85 -19.46 48.29 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 111.599 -177.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 33.05 41.11 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.413 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 69.1 mt -102.8 141.87 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.375 -1.074 . . . . 0.0 109.374 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.88 145.01 54.06 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.254 -0.904 . . . . 0.0 109.854 -179.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.581 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -65.9 -19.27 65.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.538 -0.726 . . . . 0.0 109.876 -179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.485 ' O ' ' O ' ' A' ' 58' ' ' ASP . 92.2 m-20 -52.85 -37.27 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.17 -0.956 . . . . 0.0 109.371 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.485 ' O ' ' O ' ' A' ' 57' ' ' ASP . 94.1 m-20 52.42 172.44 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.274 -0.891 . . . . 0.0 109.231 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.1 p -136.67 142.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.266 -0.896 . . . . 0.0 110.161 -179.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.625 ' C ' HD23 ' A' ' 61' ' ' LEU . 84.7 tt0 52.92 77.52 0.16 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.43 -0.794 . . . . 0.0 110.187 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.84 HD23 ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -104.23 127.13 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.302 -0.874 . . . . 0.0 109.168 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.17 148.01 17.23 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 120.962 -1.086 . . . . 0.0 109.712 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.74 -25.64 74.95 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.68 2.253 . . . . 0.0 112.235 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.36 -31.46 71.35 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 109.727 -179.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 48.6 t-80 -68.63 -25.93 65.09 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.446 -0.784 . . . . 0.0 111.127 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -95.6 5.86 50.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.743 -1.223 . . . . 0.0 110.92 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 -60.21 -37.53 80.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.895 -1.128 . . . . 0.0 110.353 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.3 p -133.38 147.44 51.79 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.076 -1.015 . . . . 0.0 110.07 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.437 HG23 ' CG2' ' A' ' 7' ' ' ILE . 78.1 mt -66.38 -36.71 78.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 O-C-N 121.432 -0.793 . . . . 0.0 109.797 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 92.3 mtm-85 -60.97 -37.97 84.28 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.346 -0.846 . . . . 0.0 110.099 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.3 p -61.72 -35.92 79.45 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.107 -0.996 . . . . 0.0 109.458 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.566 ' HB ' HD13 ' A' ' 7' ' ' ILE . 61.8 mt -66.71 -39.02 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.238 -0.914 . . . . 0.0 109.174 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.532 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.8 t0 -59.1 -39.44 82.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.333 -0.855 . . . . 0.0 109.779 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.27 -44.2 92.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.1 -1.0 . . . . 0.0 109.654 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -63.42 -46.17 87.57 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.242 -0.911 . . . . 0.0 109.387 179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -64.43 -43.36 96.97 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.346 -0.846 . . . . 0.0 109.739 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 73' ' ' ASP . 51.1 t -60.35 -40.83 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 O-C-N 121.24 -0.913 . . . . 0.0 109.659 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.31 -32.56 72.57 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.88 -50.41 3.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.063 -1.257 . . . . 0.0 110.719 -179.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.4 p -131.79 157.9 42.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.283 -0.885 . . . . 0.0 109.827 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -137.82 87.99 16.43 Favored Pre-proline 0 C--N 1.304 -1.408 0 O-C-N 121.182 -0.949 . . . . 0.0 109.434 179.694 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.583 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 14.4 Cg_exo -65.03 -177.96 0.69 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.553 2.169 . . . . 0.0 112.008 179.748 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.421 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 21.2 Cg_exo -61.1 148.57 92.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.499 2.133 . . . . 0.0 111.845 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.496 HG22 ' O ' ' A' ' 2' ' ' GLN . 43.4 t -111.97 130.83 64.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.345 -0.847 . . . . 0.0 109.571 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -133.41 156.78 47.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.453 -0.779 . . . . 0.0 109.364 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.8 144.61 54.51 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -0.934 . . . . 0.0 109.303 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.421 ' NZ ' ' O ' ' A' ' 22' ' ' ALA . 63.8 tttm -57.95 -37.19 73.69 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.152 -0.968 . . . . 0.0 109.47 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.3 mt -93.89 141.82 28.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.209 -0.932 . . . . 0.0 109.448 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.457 -179.992 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.672 ' C18' HD13 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.579 ' NE2' ' CG1' ' A' ' 84' ' ' VAL . 96.0 mt-30 -83.71 21.79 1.2 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.41 -0.806 . . . . 0.0 109.352 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.439 ' H ' ' HG2' ' A' ' 1' ' ' MET . 30.9 m80 60.94 43.42 11.69 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.025 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.521 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -55.68 -34.86 65.41 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.471 -0.768 . . . . 0.0 109.658 -179.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -58.89 -39.35 81.18 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.229 -0.919 . . . . 0.0 109.01 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.0 t -67.78 -39.25 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.401 -0.812 . . . . 0.0 109.004 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 4' ' ' ALA . 90.9 mt -58.95 -50.05 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.479 -0.763 . . . . 0.0 109.634 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.62 -45.75 88.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.353 -0.842 . . . . 0.0 109.668 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.43 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.6 OUTLIER -69.03 -33.75 74.12 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.365 -0.834 . . . . 0.0 109.694 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.565 ' CE1' ' CZ2' ' A' ' 47' ' ' TRP . 61.7 t80 -64.96 -51.49 61.5 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.091 -1.005 . . . . 0.0 109.694 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.494 HG23 ' N ' ' A' ' 12' ' ' VAL . 15.8 m -74.49 -40.39 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.308 -0.87 . . . . 0.0 110.098 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 8' ' ' ALA . 77.4 t -62.05 -37.8 79.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.203 -0.936 . . . . 0.0 110.122 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -56.75 -36.7 70.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.33 -0.856 . . . . 0.0 109.752 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 77.6 mm-40 -68.16 -35.87 78.74 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 110.681 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -89.78 -63.01 1.34 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.025 -1.047 . . . . 0.0 110.618 -178.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 mt -127.36 82.91 67.35 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.302 -0.874 . . . . 0.0 110.113 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -81.01 -18.7 8.72 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.699 2.266 . . . . 0.0 112.125 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -76.83 -4.14 42.05 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.226 -0.921 . . . . 0.0 109.017 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.57 141.6 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.621 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.71 119.1 44.48 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.0 -1.063 . . . . 0.0 108.599 -179.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -64.73 -30.5 59.36 Favored 'Trans proline' 0 N--CA 1.49 1.286 0 C-N-CA 121.612 1.541 . . . . 0.0 112.052 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.75 -14.73 62.55 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.374 -0.829 . . . . 0.0 109.001 179.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.621 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -86.53 4.73 38.74 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.547 -0.72 . . . . 0.0 109.116 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.3 t -98.74 135.59 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 179.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.438 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -70.37 83.26 0.56 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.19 -0.944 . . . . 0.0 109.651 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.3 m -63.47 -0.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 109.117 179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 50.6 p30 -100.39 9.83 42.08 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 121.248 -0.907 . . . . 0.0 109.195 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.7 tp -92.02 145.39 24.57 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.481 -0.762 . . . . 0.0 109.434 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -60.02 121.4 11.75 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.606 HD11 ' CG1' ' A' ' 69' ' ' ILE . 76.4 mt -61.81 -11.73 13.89 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.436 -0.79 . . . . 0.0 109.97 -178.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.577 HG23 ' HG3' ' A' ' 67' ' ' ARG . 22.8 t -50.53 -45.33 26.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.801 -1.187 . . . . 0.0 108.678 -179.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -57.61 -35.34 70.33 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.602 ' O ' ' N ' ' A' ' 35' ' ' VAL . 10.6 m120 -86.9 19.04 3.17 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 179.084 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.05 -18.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.276 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.602 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.5 t -52.8 -38.85 29.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.234 -1.157 . . . . 0.0 108.505 179.196 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.7 tt -70.4 -24.05 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.555 -0.716 . . . . 0.0 109.375 179.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -56.3 -33.01 65.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.513 -0.742 . . . . 0.0 110.919 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -113.78 -64.47 1.31 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.159 -0.963 . . . . 0.0 111.098 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.537 ' H ' HD12 ' A' ' 39' ' ' LEU . 6.6 mp -64.01 -50.44 68.5 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.955 -1.091 . . . . 0.0 110.188 -178.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.511 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.53 -40.55 67.39 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tt -58.73 -40.55 84.1 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.45 -1.029 . . . . 0.0 109.505 -179.552 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.3 tp -65.92 -44.24 85.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -65.22 -37.47 87.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.263 -0.898 . . . . 0.0 110.005 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.59 HG12 ' C18' ' A' ' 101' ' ' 7V9 . 73.4 t -62.28 -43.26 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.351 -0.843 . . . . 0.0 110.073 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.401 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.5 mp -62.87 -50.42 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.244 -0.91 . . . . 0.0 109.911 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.01 -34.91 78.76 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.267 -0.895 . . . . 0.0 110.16 -179.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.565 ' CZ2' ' CE1' ' A' ' 10' ' ' PHE . 3.8 t90 -66.99 -44.39 80.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 0.0 109.946 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.7 tp -57.51 -43.98 84.67 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.406 -0.809 . . . . 0.0 109.716 -179.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -66.31 -38.54 87.96 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.221 -0.924 . . . . 0.0 109.401 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -64.86 -41.06 95.98 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.147 -0.97 . . . . 0.0 110.648 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -87.17 -58.37 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.104 -0.998 . . . . 0.0 111.644 -178.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -79.73 -19.99 47.49 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.1 -1.0 . . . . 0.0 111.587 -177.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 30.23 50.97 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -179.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.43 142.39 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.412 -1.052 . . . . 0.0 109.421 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.36 154.03 25.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.189 -0.944 . . . . 0.0 109.217 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.12 -40.15 67.08 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.233 -0.917 . . . . 0.0 109.542 -179.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.413 ' O ' HG23 ' A' ' 59' ' ' VAL . 86.1 m-20 51.45 47.84 24.06 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.173 -0.955 . . . . 0.0 109.311 179.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -59.87 133.78 56.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.202 -0.936 . . . . 0.0 109.717 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 57' ' ' ASP . 39.2 t -126.85 139.81 50.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.52 -0.737 . . . . 0.0 109.279 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 89.2 tt0 -68.29 88.59 0.31 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.976 . . . . 0.0 109.74 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.6 mt -111.98 142.28 44.59 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.535 -0.728 . . . . 0.0 109.43 179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -76.15 159.24 80.77 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.302 -0.874 . . . . 0.0 109.739 -179.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -60.17 -22.98 72.27 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.926 2.417 . . . . 0.0 112.168 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.5 -31.14 71.84 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.359 -0.838 . . . . 0.0 110.028 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -67.76 -26.71 66.26 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.47 ' CD2' ' N ' ' A' ' 66' ' ' PHE . 28.2 m-85 -97.07 2.66 51.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.193 -0.942 . . . . 0.0 109.281 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.577 ' HG3' HG23 ' A' ' 31' ' ' VAL . 56.0 ttp180 -56.15 -39.62 72.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.476 -0.765 . . . . 0.0 110.524 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 91.2 p -119.66 148.91 42.8 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.415 -0.803 . . . . 0.0 110.463 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.606 ' CG1' HD11 ' A' ' 30' ' ' LEU . 79.7 mt -65.89 -36.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.679 -0.638 . . . . 0.0 109.981 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -61.5 -39.21 90.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.147 -0.971 . . . . 0.0 110.231 -179.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.44 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 19.7 m -60.74 -44.14 97.05 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.018 -1.051 . . . . 0.0 109.529 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.647 ' O ' HG23 ' A' ' 76' ' ' VAL . 79.0 mt -67.13 -39.61 83.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.338 -0.852 . . . . 0.0 109.237 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.863 ' O ' HG23 ' A' ' 77' ' ' VAL . 38.6 t0 -57.5 -38.18 74.18 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.541 -0.724 . . . . 0.0 109.617 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.72 -46.24 89.01 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.954 -1.091 . . . . 0.0 109.434 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -67.06 -47.47 71.2 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.159 -0.963 . . . . 0.0 108.861 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.721 HG12 ' OG1' ' A' ' 81' ' ' THR . 34.1 t -63.17 -40.11 87.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.422 -0.799 . . . . 0.0 109.065 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.863 HG23 ' O ' ' A' ' 73' ' ' ASP . 38.0 t -55.63 -42.42 68.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 O-C-N 121.292 -0.88 . . . . 0.0 108.876 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.54 69.14 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.79 -1.724 . . . . 0.0 108.79 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.63 ' C ' HG22 ' A' ' 80' ' ' THR . . . -67.9 -47.55 68.49 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.334 -1.098 . . . . 0.0 110.213 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.63 HG22 ' C ' ' A' ' 79' ' ' ALA . 0.0 OUTLIER 172.49 2.59 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.045 -1.034 . . . . 0.0 111.328 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.721 ' OG1' HG12 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -75.04 142.88 76.61 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 120.665 -1.272 . . . . 0.0 108.439 179.638 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.459 ' C ' ' O ' ' A' ' 81' ' ' THR . 89.3 Cg_exo -26.65 125.98 0.03 OUTLIER 'Trans proline' 0 C--N 1.318 -1.078 0 C-N-CA 123.024 2.483 . . . . 0.0 112.802 -178.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -76.43 150.64 32.43 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 122.572 2.182 . . . . 0.0 113.312 -179.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.579 ' CG1' ' NE2' ' A' ' 2' ' ' GLN . 12.7 p -133.35 142.03 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.448 -0.782 . . . . 0.0 109.139 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -58.8 -36.02 73.78 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.187 -0.945 . . . . 0.0 109.669 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.485 ' H ' HG22 ' A' ' 84' ' ' VAL . . . -153.0 153.38 32.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.063 -1.023 . . . . 0.0 109.72 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -58.74 -38.28 78.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.862 . . . . 0.0 109.392 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.432 ' O ' ' C ' ' A' ' 89' ' ' GLN . 54.0 mt -96.74 142.2 29.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.399 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.432 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.426 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.59 ' C18' HG12 ' A' ' 44' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.5 ptp . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.416 -0.586 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.672 ' CG ' HG12 ' A' ' 84' ' ' VAL . 91.9 mt-30 55.92 43.31 27.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.367 -0.833 . . . . 0.0 109.437 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.451 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.9 m170 42.86 38.7 1.46 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.185 -0.947 . . . . 0.0 109.014 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.498 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.94 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.392 -0.817 . . . . 0.0 109.722 -179.59 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.7 p -61.42 -37.52 83.8 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.065 -1.022 . . . . 0.0 109.325 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.5 t -68.5 -38.71 79.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.19 -0.944 . . . . 0.0 108.83 179.104 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.498 HD12 ' HA ' ' A' ' 4' ' ' ALA . 86.4 mt -60.27 -51.72 69.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.35 -0.844 . . . . 0.0 109.274 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.589 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -65.33 -47.16 77.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.38 -0.825 . . . . 0.0 109.591 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.7 -44.2 94.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.572 -0.705 . . . . 0.0 109.451 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.401 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 73.9 t80 -62.15 -48.24 80.98 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.53 -0.731 . . . . 0.0 109.484 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 7' ' ' ILE . 85.3 t -69.71 -44.5 79.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.461 -0.774 . . . . 0.0 109.696 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.2 t -66.86 -39.5 83.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.428 -0.795 . . . . 0.0 110.183 -179.454 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -53.68 -28.92 36.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.184 -0.947 . . . . 0.0 109.957 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -65.24 -30.43 71.31 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.203 -0.936 . . . . 0.0 109.533 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.575 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 33.5 p90 -146.73 44.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.832 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.67 130.78 63.04 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.078 -1.014 . . . . 0.0 109.978 -179.94 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 19' ' ' VAL . 70.7 Cg_endo -76.66 -152.54 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.309 0 C-N-CA 121.975 1.783 . . . . 0.0 110.626 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -78.37 16.99 0.7 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.924 -1.11 . . . . 0.0 108.997 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.402 ' H ' ' C ' ' A' ' 17' ' ' PRO . 42.5 t -113.27 137.0 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.493 -0.755 . . . . 0.0 109.755 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -67.63 141.53 95.29 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.278 -0.889 . . . . 0.0 109.435 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.45 ' O ' HG12 ' A' ' 24' ' ' VAL . 34.8 Cg_exo -49.66 -31.91 26.67 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 121.911 1.741 . . . . 0.0 112.042 179.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.6 -23.91 66.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.345 -0.847 . . . . 0.0 109.714 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.28 8.53 44.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.351 -0.843 . . . . 0.0 109.32 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.45 HG12 ' O ' ' A' ' 21' ' ' PRO . 0.5 OUTLIER -88.86 142.52 12.77 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.327 -0.858 . . . . 0.0 108.814 179.813 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.421 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -70.09 84.83 0.53 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.168 -0.958 . . . . 0.0 109.487 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.6 m -64.5 -0.26 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.258 -0.901 . . . . 0.0 109.233 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.421 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.3 m-20 -98.45 11.17 39.03 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.34 -0.85 . . . . 0.0 108.969 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.2 tp -88.08 136.5 32.94 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.475 -0.766 . . . . 0.0 109.562 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -61.93 122.02 14.41 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.5 mt -56.21 -16.1 4.82 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.423 -0.798 . . . . 0.0 109.542 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.2 t -50.9 -43.05 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.064 -1.023 . . . . 0.0 109.125 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.24 -37.97 70.46 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.628 ' O ' ' N ' ' A' ' 35' ' ' VAL . 84.4 m-20 -91.18 22.33 3.85 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.72 -15.5 0.02 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.628 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.5 p -53.89 -33.81 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.013 -1.286 . . . . 0.0 108.891 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.591 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.9 tt -70.99 -19.04 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.51 -0.744 . . . . 0.0 109.673 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.426 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 82.1 m-20 -58.05 -31.32 66.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.434 -0.791 . . . . 0.0 111.451 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.7 m -116.39 -64.91 1.25 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.985 -1.072 . . . . 0.0 111.327 -178.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.1 tt -64.0 -50.72 67.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.055 -1.028 . . . . 0.0 110.06 -178.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.434 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.85 -40.1 64.37 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.591 ' N ' ' O ' ' A' ' 36' ' ' ILE . 15.8 tp -58.77 -40.88 85.24 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.469 -1.018 . . . . 0.0 109.671 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.5 tp -62.91 -44.31 96.44 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -66.75 -40.22 88.2 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.273 -0.892 . . . . 0.0 109.981 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.9 t -65.1 -42.01 93.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.345 -0.847 . . . . 0.0 110.199 -179.377 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.643 HD11 ' S12' ' A' ' 101' ' ' 7V9 . 1.1 mp -60.79 -50.61 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.219 -0.926 . . . . 0.0 109.837 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.437 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -65.52 -30.83 71.64 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.188 -0.945 . . . . 0.0 109.365 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.732 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 55.4 t90 -73.13 -47.09 47.11 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.395 -0.815 . . . . 0.0 110.118 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.5 tp -61.83 -45.29 94.44 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -67.13 -36.62 82.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.272 -0.892 . . . . 0.0 109.803 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -62.12 -44.08 97.42 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.703 -179.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.732 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 82.1 mtt180 -87.04 -51.43 6.02 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.05 -1.031 . . . . 0.0 111.52 -178.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.416 ' CE2' HG21 ' A' ' 80' ' ' THR . 96.6 m-85 -80.11 -24.58 40.44 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.005 -1.059 . . . . 0.0 111.223 -178.306 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.09 26.71 59.52 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 -179.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.7 mt -104.87 143.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -1.121 . . . . 0.0 109.354 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.98 156.54 17.45 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.185 -0.947 . . . . 0.0 109.692 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -54.14 -20.14 6.2 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.4 -0.813 . . . . 0.0 109.526 -179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 56.9 46.56 19.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.491 -0.756 . . . . 0.0 109.91 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.433 ' CG ' ' O8 ' ' A' ' 101' ' ' 7V9 . 88.1 m-20 -96.96 19.4 12.82 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -0.803 . . . . 0.0 109.088 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.9 t -55.35 -41.56 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 110.613 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.497 ' C ' HD22 ' A' ' 61' ' ' LEU . 80.4 tt0 -159.08 64.08 0.4 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.858 -1.151 . . . . 0.0 110.219 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.497 HD22 ' C ' ' A' ' 60' ' ' GLU . 3.5 mm? -104.04 141.46 36.17 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.097 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -127.84 162.25 50.69 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.384 -0.823 . . . . 0.0 109.81 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -60.1 -25.25 79.34 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.942 2.428 . . . . 0.0 112.237 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.43 -31.45 72.15 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -0.92 . . . . 0.0 109.598 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -67.92 -26.21 65.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -0.842 . . . . 0.0 109.939 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -94.16 16.45 14.72 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.365 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 tpt180 -53.41 -39.16 64.1 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.334 -0.854 . . . . 0.0 110.018 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.0 p -150.85 165.9 32.18 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.923 -1.111 . . . . 0.0 110.271 -179.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 95.0 mt -59.31 -36.51 64.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.378 -0.826 . . . . 0.0 110.078 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 83.6 mtm180 -60.49 -39.2 86.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 110.077 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.3 m -61.43 -42.89 99.45 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.994 -1.066 . . . . 0.0 109.428 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.4 mt -64.91 -38.41 82.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.249 -0.907 . . . . 0.0 109.32 179.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.807 ' O ' HG23 ' A' ' 77' ' ' VAL . 92.4 m-20 -56.06 -37.45 69.29 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.286 -0.884 . . . . 0.0 109.219 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.15 -43.73 98.19 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.26 -0.9 . . . . 0.0 109.061 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -63.91 -47.5 80.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.154 179.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 56.7 t -64.4 -40.44 89.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.389 -0.82 . . . . 0.0 109.288 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.807 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.4 t -58.32 -44.02 87.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.333 -0.854 . . . . 0.0 109.615 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -64.77 -41.49 97.57 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -76.52 -49.53 16.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.135 -1.215 . . . . 0.0 109.645 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.416 HG21 ' CE2' ' A' ' 52' ' ' PHE . 22.1 p -128.32 157.31 41.31 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -140.33 87.84 11.73 Favored Pre-proline 0 C--N 1.302 -1.472 0 O-C-N 121.058 -1.026 . . . . 0.0 110.261 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -68.72 -178.2 1.86 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.486 2.124 . . . . 0.0 111.26 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.562 ' O ' ' N ' ' A' ' 2' ' ' GLN . 23.2 Cg_exo -60.19 148.49 89.55 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.2 1.933 . . . . 0.0 111.429 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.672 HG12 ' CG ' ' A' ' 2' ' ' GLN . 16.7 m -125.16 141.72 44.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.262 -0.899 . . . . 0.0 109.921 -179.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.733 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 78.1 mm-40 -142.23 -40.41 0.35 Allowed 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.353 -0.842 . . . . 0.0 109.201 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.733 ' HB2' ' O ' ' A' ' 85' ' ' GLU . . . 160.28 95.23 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.423 -0.798 . . . . 0.0 109.368 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -57.72 -38.39 75.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.121 -0.987 . . . . 0.0 109.358 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 31.0 tp -102.92 130.34 49.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.276 -0.89 . . . . 0.0 109.387 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.496 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.643 ' S12' HD11 ' A' ' 45' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.9 mtm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 121.481 0.657 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.58 119.09 36.7 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.48 -0.763 . . . . 0.0 108.985 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 50.49 36.09 12.7 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.142 -0.974 . . . . 0.0 109.027 -179.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.446 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.56 -35.58 76.39 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.39 -0.819 . . . . 0.0 109.78 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 t -59.53 -40.57 87.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.722 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.1 t -64.39 -40.02 87.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 0.0 109.165 179.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.469 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 91.8 mt -59.66 -50.15 81.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.36 -0.837 . . . . 0.0 109.512 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.707 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.91 -45.19 90.43 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.29 -0.881 . . . . 0.0 108.904 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.4 -39.65 92.44 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.533 -0.729 . . . . 0.0 109.651 179.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 61.0 t80 -60.66 -52.04 66.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.446 -0.784 . . . . 0.0 110.029 -179.097 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.474 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 3.8 p -74.08 -40.56 51.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.902 . . . . 0.0 109.844 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.707 HG23 ' O ' ' A' ' 8' ' ' ALA . 94.2 t -66.69 -40.0 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.395 -0.816 . . . . 0.0 110.315 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -56.17 -27.63 55.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.228 -0.92 . . . . 0.0 109.574 -179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -65.04 -32.09 73.64 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.342 -0.849 . . . . 0.0 109.724 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 13.5 p90 -144.2 44.46 1.43 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.066 -1.021 . . . . 0.0 109.92 179.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.833 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -80.46 131.46 61.54 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.085 -1.009 . . . . 0.0 110.048 -179.981 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -74.46 -150.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.314 -1.277 0 C-N-CA 121.954 1.769 . . . . 0.0 110.655 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.562 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.6 p30 -78.36 13.04 1.67 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.133 . . . . 0.0 109.324 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.562 HG23 ' OD1' ' A' ' 18' ' ' ASP . 42.2 t -113.53 135.48 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.483 -0.761 . . . . 0.0 109.612 -179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.09 142.43 87.47 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.312 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD3' HD12 ' A' ' 16' ' ' LEU . 47.2 Cg_exo -48.49 -32.12 19.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 121.969 1.78 . . . . 0.0 111.814 179.428 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.78 -25.97 67.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.419 -0.801 . . . . 0.0 109.447 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -97.69 4.75 49.95 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.361 -0.837 . . . . 0.0 109.386 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -103.55 137.41 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.52 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -63.78 95.9 0.12 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.404 -179.531 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.3 m -59.57 0.48 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.168 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.52 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.6 m-20 -87.99 11.24 16.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.362 -0.836 . . . . 0.0 108.939 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 35.2 tp -82.59 134.12 35.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 109.395 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -67.07 121.85 16.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.342 -0.849 . . . . 0.0 108.871 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.642 HD11 HG12 ' A' ' 69' ' ' ILE . 82.6 mt -59.28 -14.1 10.14 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.303 -0.873 . . . . 0.0 109.198 -179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.412 ' O ' ' N ' ' A' ' 34' ' ' GLY . 42.1 t -50.44 -42.34 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 O-C-N 121.179 -0.951 . . . . 0.0 108.89 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -55.62 -35.32 65.74 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 178.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.608 ' O ' ' N ' ' A' ' 35' ' ' VAL . 8.5 m120 -86.27 21.55 2.03 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.0 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 -179.162 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.608 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.0 t -53.05 -40.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.766 -1.432 . . . . 0.0 108.228 179.221 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.653 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.2 tt -71.15 -24.11 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.575 -0.703 . . . . 0.0 109.924 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' C ' ' O2P' ' A' ' 101' ' ' 7V9 . 83.5 m-20 -62.11 -27.54 69.0 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.957 -1.09 . . . . 0.0 110.975 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.546 ' N ' ' O2P' ' A' ' 101' ' ' 7V9 . 0.3 OUTLIER -106.18 -65.73 1.05 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.801 -1.187 . . . . 0.0 111.055 -178.766 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -73.73 -51.24 17.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.951 -1.093 . . . . 0.0 110.61 -178.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.75 -36.32 92.11 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.655 HD11 ' C10' ' A' ' 101' ' ' 7V9 . 8.1 tt -57.95 -43.14 86.2 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.208 -1.172 . . . . 0.0 109.2 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.9 mt -60.96 -44.1 97.8 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.094 -1.004 . . . . 0.0 108.694 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -69.97 -35.45 74.46 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.423 -0.798 . . . . 0.0 109.84 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.732 HG23 ' O ' ' A' ' 40' ' ' GLY . 81.1 t -64.78 -49.85 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.339 -0.851 . . . . 0.0 110.849 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.5 mm -60.41 -47.82 90.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 120.944 -1.097 . . . . 0.0 109.51 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.46 -32.95 74.64 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.179 -0.951 . . . . 0.0 109.232 179.7 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 39.4 t90 -71.67 -47.46 54.09 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.24 -0.912 . . . . 0.0 109.927 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.525 HD22 ' C18' ' A' ' 101' ' ' 7V9 . 26.5 tp -59.81 -44.98 93.72 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.318 -0.864 . . . . 0.0 109.687 -179.328 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.478 ' HA ' ' H ' ' A' ' 54' ' ' ILE . 80.3 tt0 -68.62 -34.88 76.51 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 110.057 179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -59.21 -38.49 80.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.008 -1.058 . . . . 0.0 110.028 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.536 ' NE ' ' CZ2' ' A' ' 47' ' ' TRP . 34.2 mtm105 -86.39 -48.52 8.38 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.149 -0.969 . . . . 0.0 111.497 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -90.9 -24.44 20.2 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.8 -1.187 . . . . 0.0 111.219 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 79.35 50.03 5.95 Favored Glycine 0 N--CA 1.496 2.689 0 C-N-CA 119.588 -1.292 . . . . 0.0 110.525 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.478 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 65.2 mt -108.04 140.94 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.199 -1.177 . . . . 0.0 109.21 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.53 141.11 57.95 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.937 -1.102 . . . . 0.0 109.334 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.51 -29.25 70.42 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.574 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -82.89 1.02 41.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.339 -0.85 . . . . 0.0 109.826 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -55.2 -31.53 61.51 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.615 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.5 m -122.47 159.73 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.502 -0.749 . . . . 0.0 109.403 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -99.12 169.4 9.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.399 -0.813 . . . . 0.0 109.954 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.865 HD23 ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -76.83 125.56 29.49 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.455 -0.778 . . . . 0.0 109.222 -179.499 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.712 ' H ' ' C8 ' ' A' ' 101' ' ' 7V9 . 4.0 p -142.77 87.34 9.04 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.16 -0.963 . . . . 0.0 109.955 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -53.37 -34.31 70.39 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.346 2.031 . . . . 0.0 111.61 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -68.08 -14.32 62.89 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.525 -0.735 . . . . 0.0 109.148 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.604 ' CE1' HG23 ' A' ' 72' ' ' ILE . 21.7 t-80 -66.2 -26.32 67.34 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.432 -0.792 . . . . 0.0 110.062 -178.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.667 ' HA ' HD11 ' A' ' 72' ' ' ILE . 97.4 m-85 -92.45 9.05 35.98 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.006 -1.058 . . . . 0.0 109.597 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 23.4 tpt180 -54.7 -35.98 64.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.327 -0.858 . . . . 0.0 109.454 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.8 p -150.82 149.39 29.65 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.215 -0.928 . . . . 0.0 110.023 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.642 HG12 HD11 ' A' ' 30' ' ' LEU . 81.6 mt -66.56 -39.33 83.64 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.425 -0.797 . . . . 0.0 110.264 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.428 HH22 ' HA ' ' A' ' 27' ' ' ASP . 93.0 mtm-85 -61.35 -39.99 92.6 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.25 -0.906 . . . . 0.0 110.373 -178.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.9 t -60.63 -45.91 92.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.985 -1.072 . . . . 0.0 109.425 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.667 HD11 ' HA ' ' A' ' 66' ' ' PHE . 79.0 mt -63.91 -38.74 83.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.339 -0.85 . . . . 0.0 109.709 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.469 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 55.9 t0 -57.54 -42.28 82.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 110.256 -179.263 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.76 -46.09 76.45 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.089 -1.007 . . . . 0.0 110.502 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 58.4 m-85 -63.36 -45.1 92.71 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.099 -1.0 . . . . 0.0 109.496 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.529 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.1 t -68.18 -47.6 77.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.219 -0.926 . . . . 0.0 110.159 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 45.4 t -68.28 -44.22 84.01 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.051 -1.031 . . . . 0.0 110.023 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.02 -27.0 68.08 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -103.27 -50.12 3.55 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.199 -1.177 . . . . 0.0 111.143 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.529 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.2 m -134.91 140.1 45.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.107 -0.995 . . . . 0.0 110.864 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.34 88.4 53.07 Favored Pre-proline 0 N--CA 1.488 1.445 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -81.97 159.97 18.36 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.714 2.276 . . . . 0.0 113.344 -178.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -64.56 152.42 81.82 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 123.27 2.647 . . . . 0.0 111.767 179.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 90.6 t -89.04 127.38 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.081 -1.012 . . . . 0.0 109.565 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -143.18 152.45 41.78 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.439 -0.788 . . . . 0.0 109.238 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.76 143.89 34.95 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.17 -0.956 . . . . 0.0 109.375 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.6 tttm -77.95 134.71 37.81 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.9 mt -58.89 -35.52 73.15 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.527 179.93 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.712 ' C8 ' ' H ' ' A' ' 62' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.463 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 71.9 mtm . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.372 0.606 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -60.11 -37.03 78.79 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.425 -0.797 . . . . 0.0 109.494 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.79 ' CE1' HG21 ' A' ' 6' ' ' VAL . 73.6 t60 -116.13 8.94 14.58 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.478 -0.764 . . . . 0.0 109.478 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.58 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -61.09 -35.61 77.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.212 -179.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.6 m -58.8 -40.28 83.58 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.053 -1.03 . . . . 0.0 109.395 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.79 HG21 ' CE1' ' A' ' 3' ' ' HIS . 72.3 t -66.53 -36.56 77.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.278 -0.889 . . . . 0.0 109.007 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.646 ' O ' HG23 ' A' ' 11' ' ' VAL . 81.8 mt -63.59 -44.18 98.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.397 -0.814 . . . . 0.0 110.31 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.484 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.0 -50.63 67.78 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.175 -0.953 . . . . 0.0 110.521 -178.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.444 HE21 ' N ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.22 -44.3 68.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.122 -0.986 . . . . 0.0 109.673 -179.844 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.568 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 75.1 t80 -59.52 -45.89 90.44 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.993 -1.067 . . . . 0.0 109.282 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.646 HG23 ' O ' ' A' ' 7' ' ' ILE . 99.7 t -70.03 -46.52 72.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.417 -0.802 . . . . 0.0 110.135 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 8' ' ' ALA . 74.9 t -66.51 -37.23 79.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.337 -0.852 . . . . 0.0 111.086 -179.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -60.93 -31.72 71.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.771 -179.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -66.16 -32.51 73.99 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.938 -1.102 . . . . 0.0 110.137 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.727 ' O ' HD12 ' A' ' 16' ' ' LEU . 58.6 m-85 -96.63 -61.11 1.47 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.104 -0.997 . . . . 0.0 110.6 -179.082 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.727 HD12 ' O ' ' A' ' 15' ' ' PHE . 3.7 mp -129.16 83.24 66.4 Favored Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 121.29 -0.881 . . . . 0.0 110.663 -178.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -80.75 -13.29 11.88 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.841 2.361 . . . . 0.0 112.102 178.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.56 -4.3 42.08 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.138 -0.976 . . . . 0.0 108.974 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.59 140.62 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.648 ' HB3' ' OD1' ' A' ' 23' ' ' ASP . . . -61.86 117.87 33.04 Favored Pre-proline 0 C--N 1.305 -1.353 0 O-C-N 120.882 -1.136 . . . . 0.0 108.779 -179.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.827 ' O ' HG12 ' A' ' 24' ' ' VAL . 21.6 Cg_endo -64.98 -26.75 58.43 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 C-N-CA 121.619 1.546 . . . . 0.0 111.854 -179.176 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.92 -13.88 60.97 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.421 -0.799 . . . . 0.0 109.326 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.648 ' OD1' ' HB3' ' A' ' 20' ' ' ALA . 89.4 m-20 -85.58 8.03 20.91 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 109.853 -179.277 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.827 HG12 ' O ' ' A' ' 21' ' ' PRO . 9.9 p -107.58 144.41 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.372 -0.83 . . . . 0.0 109.034 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.493 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.6 m-20 -69.05 86.18 0.36 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.006 -1.059 . . . . 0.0 109.177 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.517 HG11 ' HE3' ' A' ' 87' ' ' LYS . 26.8 m -60.9 0.06 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.34 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.493 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.03 6.04 47.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.321 -0.862 . . . . 0.0 108.77 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -93.58 136.82 33.48 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.599 -0.688 . . . . 0.0 109.364 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -61.16 121.53 12.75 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.632 ' CD1' HD11 ' A' ' 36' ' ' ILE . 1.5 pp -68.84 0.25 4.61 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.285 -0.885 . . . . 0.0 109.796 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 34' ' ' GLY . 72.7 t -56.16 -35.17 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.21 -0.931 . . . . 0.0 108.946 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' A' ' 34' ' ' GLY . 92.3 m-20 -53.94 -34.83 60.78 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 179.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' A' ' 35' ' ' VAL . 79.0 m-20 -83.53 21.89 1.14 Allowed 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.028 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -41.73 -13.99 0.01 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.93 -1.268 . . . . 0.0 109.93 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.64 ' N ' ' O ' ' A' ' 33' ' ' ASN . 3.4 p -51.94 -31.12 13.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.085 -1.244 . . . . 0.0 108.479 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.632 HD11 ' CD1' ' A' ' 30' ' ' LEU . 32.6 pt -73.56 -7.14 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.522 -0.736 . . . . 0.0 109.965 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.504 ' HA ' HD12 ' A' ' 41' ' ' LEU . 92.7 m-20 -48.88 -39.95 27.88 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.342 -0.849 . . . . 0.0 110.205 -178.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 m -122.56 -48.24 2.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 111.348 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.482 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.2 mp -74.71 -52.79 10.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.944 -1.097 . . . . 0.0 111.63 -178.077 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.538 ' H ' ' HA ' ' A' ' 36' ' ' ILE . . . -70.49 -43.21 62.12 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 120.079 -1.058 . . . . 0.0 110.77 -178.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.635 ' O ' HD13 ' A' ' 45' ' ' ILE . 16.2 mt -63.42 -40.66 97.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.065 -1.256 . . . . 0.0 110.482 -179.191 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.63 -44.17 96.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.322 -179.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.3 mttt -66.96 -41.58 86.64 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.244 -0.91 . . . . 0.0 109.465 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 40' ' ' GLY . 90.1 t -66.95 -41.06 86.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.446 -0.784 . . . . 0.0 109.879 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.635 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.4 mp -58.94 -49.03 84.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.245 -0.91 . . . . 0.0 109.65 -179.56 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.94 -32.29 72.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.604 ' CZ2' ' NH1' ' A' ' 51' ' ' ARG . 9.3 t90 -68.51 -44.81 73.84 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.37 -0.831 . . . . 0.0 109.508 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.426 HD22 ' C17' ' A' ' 101' ' ' 7V9 . 7.8 tp -62.53 -44.98 95.02 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 109.605 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 53' ' ' GLY . 81.6 tt0 -67.2 -34.51 77.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.263 -0.898 . . . . 0.0 109.909 179.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -58.75 -39.3 80.54 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.89 -1.131 . . . . 0.0 109.759 -179.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.604 ' NH1' ' CZ2' ' A' ' 47' ' ' TRP . 51.7 mtm180 -86.97 -53.86 4.66 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.135 -0.978 . . . . 0.0 110.931 -179.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.42 -25.02 39.23 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.114 -0.992 . . . . 0.0 111.367 -178.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 76.46 39.2 31.11 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.334 -1.412 . . . . 0.0 109.627 -179.676 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.427 ' H ' ' HA ' ' A' ' 49' ' ' GLU . 66.1 mt -103.03 138.73 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.197 -1.178 . . . . 0.0 109.331 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.05 141.08 57.66 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.737 -1.227 . . . . 0.0 109.303 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.48 -34.1 73.55 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.282 -0.886 . . . . 0.0 109.338 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -95.98 12.41 30.52 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.405 -0.809 . . . . 0.0 109.468 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -52.32 -34.66 48.04 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.923 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.3 m -126.45 158.84 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.356 -0.84 . . . . 0.0 109.668 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -68.73 143.64 54.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.343 -0.848 . . . . 0.0 109.448 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 12.9 mt -92.4 139.97 30.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.25 -0.906 . . . . 0.0 109.144 -179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -154.41 129.8 5.18 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.973 -1.079 . . . . 0.0 109.41 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 -27.54 69.48 Favored 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 121.862 1.708 . . . . 0.0 112.324 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.88 -28.12 69.82 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.892 . . . . 0.0 109.711 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.417 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 11.6 t-160 -67.8 -26.74 66.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.296 -0.878 . . . . 0.0 110.02 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.543 ' CE1' HD21 ' A' ' 41' ' ' LEU . 58.4 m-85 -102.27 13.65 34.06 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.955 . . . . 0.0 109.97 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.535 ' HD2' HG21 ' A' ' 31' ' ' VAL . 25.6 tpt180 -53.19 -36.88 61.42 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 108.959 179.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.2 t -143.46 146.91 33.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -0.887 . . . . 0.0 109.479 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.78 -38.44 76.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.285 -0.885 . . . . 0.0 109.91 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 40.4 ptt85 -61.81 -40.23 94.51 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.8 p -61.69 -36.68 81.58 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.097 -1.002 . . . . 0.0 110.043 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.433 HD11 ' CD1' ' A' ' 66' ' ' PHE . 76.1 mt -65.12 -40.81 90.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 121.095 -1.003 . . . . 0.0 109.807 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 55.6 t0 -58.75 -38.05 77.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 109.713 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.85 -41.69 99.45 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.178 -0.951 . . . . 0.0 109.598 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.417 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 65.6 t80 -63.8 -47.44 80.88 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.283 -0.886 . . . . 0.0 109.366 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.5 t -64.15 -42.72 96.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 O-C-N 121.288 -0.882 . . . . 0.0 109.551 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 73' ' ' ASP . 46.6 t -58.98 -41.07 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.288 -0.883 . . . . 0.0 109.532 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.18 -32.56 76.71 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.85 -50.45 3.53 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.026 -1.279 . . . . 0.0 110.746 -179.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 76' ' ' VAL . 16.6 p -129.14 156.65 43.57 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.333 -0.854 . . . . 0.0 109.519 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -136.01 88.77 21.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 O-C-N 121.184 -0.947 . . . . 0.0 109.499 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -81.32 159.65 20.02 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.539 2.159 . . . . 0.0 112.365 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.84 148.57 92.8 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.755 2.303 . . . . 0.0 111.98 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.493 HG23 HG23 ' A' ' 6' ' ' VAL . 13.8 p -130.09 141.31 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.403 -0.81 . . . . 0.0 109.669 -179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -110.04 164.04 13.0 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.514 -0.741 . . . . 0.0 109.177 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -51.03 141.74 13.35 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.296 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.517 ' HE3' HG11 ' A' ' 26' ' ' VAL . 18.8 tttt -58.61 -37.07 75.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.263 -0.898 . . . . 0.0 109.469 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.5 tp -100.6 130.55 46.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 109.507 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 60.7 tp60 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.433 -179.974 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' 7V9 . . . . . 0.426 ' C17' HD22 ' A' ' 48' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_